<SEC-DOCUMENT>0001493152-26-010625.txt : 20260317
<SEC-HEADER>0001493152-26-010625.hdr.sgml : 20260317
<ACCEPTANCE-DATETIME>20260317172820
ACCESSION NUMBER:		0001493152-26-010625
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		66
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260317
DATE AS OF CHANGE:		20260317

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Telomir Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001971532
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				872606031
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41952
		FILM NUMBER:		26763646

	BUSINESS ADDRESS:	
		STREET 1:		100 SE 2ND ST
		STREET 2:		SUITE 2000 #1009
		CITY:			MIAMI
		STATE:			FL
		ZIP:			33131
		BUSINESS PHONE:		786-396-6723

	MAIL ADDRESS:	
		STREET 1:		100 SE 2ND ST
		STREET 2:		SUITE 2000 #1009
		CITY:			MIAMI
		STATE:			FL
		ZIP:			33131
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:TELO="http://telomirpharma.com/20251231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2025%2D(with%2DECD%2Dand%2DCYD) -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_TELO_telomirpharma.com_20251231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04E_20250101_20251231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0001971532 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_Segment_0_Segment -->
<!-- Field: Set; Name: xdx; ID: xdx_07B_SO_form10%2Dk.xdxs -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000004" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000005" name="dei:EntityCentralIndexKey">0001971532</ix:nonNumeric>
  <ix:nonFraction name="TELO:DueToOfficer" contextRef="AsOf2024-12-31" id="xdx2ixbrl0096" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TELO:AccruedCompensation" contextRef="AsOf2024-12-31" id="xdx2ixbrl0099" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-12-31" id="xdx2ixbrl0113" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31" id="xdx2ixbrl0114" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-12-31" id="xdx2ixbrl0132" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="xdx2ixbrl0133" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0163" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0164" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TravelAndEntertainmentExpense" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0172" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0184" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0206" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0213" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0215" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TELO:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0220" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TELO:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0222" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0227" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0229" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0232" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0233" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0237" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0244" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0251" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0253" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0258" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0260" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0265" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0272" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0274" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0277" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0282" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0309" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProvisionForOtherCreditLosses" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0314" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToOtherRelatedParties" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TELO:IncreaseDecreaseInAccruedCompensation" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0338" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0341" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TELO:ProceedsFromRepaymentsOfOfficer" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0347" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TELO:ProceedsFromSaleOfCommonStockRelatedParty" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TELO:DeferredOfferingCostsChargedToAdditionalPaidinCapital" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0380" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TravelAndEntertainmentExpense" contextRef="From2025-01-012025-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0509" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2025-01-012025-12-31_custom_MiralogxLLCMember" id="xdx2ixbrl0527" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0535" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0538" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0541" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="xdx2ixbrl0610" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="xdx2ixbrl0628" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember17385953" id="xdx2ixbrl0630" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember17385953" id="xdx2ixbrl0632" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2025-12-31_us-gaap_WarrantMember" id="xdx2ixbrl0640" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="xdx2ixbrl0702" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-12-31" id="xdx2ixbrl0762" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2025-12-31" id="xdx2ixbrl0782" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="AsOf2025-12-31" id="xdx2ixbrl0790" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="AsOf2025-12-31" id="xdx2ixbrl0798" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2025-12-31" id="xdx2ixbrl0843" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl0844" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2025-12-31" id="xdx2ixbrl0846" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2024-12-31" id="xdx2ixbrl0847" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2025-12-31" id="xdx2ixbrl0849" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl0850" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0858" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0861" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0863" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0864" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0866" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0867" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0895" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="telo-20251231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2025-01-01to2025-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-122024-02-13_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-12</xbrli:startDate>
        <xbrli:endDate>2024-02-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-13_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-11-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-11-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_MiralogxLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">TELO:MiralogxLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-11_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-262025-05-27">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-26</xbrli:startDate>
        <xbrli:endDate>2025-05-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-272025-05-27">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-27</xbrli:startDate>
        <xbrli:endDate>2025-05-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-182025-05-19">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-18</xbrli:startDate>
        <xbrli:endDate>2025-05-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-19">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-19_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-202025-05-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-20</xbrli:startDate>
        <xbrli:endDate>2025-05-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-07-31_custom_BayshorefinancingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:BayshorefinancingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-15_custom_BayShoreTrustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:BayShoreTrustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-24_custom_StarwoodTrustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:StarwoodTrustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-092024-12-09_custom_StarwoodTrustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:StarwoodTrustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-09</xbrli:startDate>
        <xbrli:endDate>2024-12-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-09_custom_StarwoodTrustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:StarwoodTrustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-092024-12-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-09</xbrli:startDate>
        <xbrli:endDate>2024-12-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-02-04_custom_TeliPharmaceuticalsIncMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">TELO:TeliPharmaceuticalsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-02-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-02-042026-02-04_custom_LicenseAgreementMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TELO:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-02-04</xbrli:startDate>
        <xbrli:endDate>2026-02-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-02-042026-02-04_custom_TeliPharmaceuticalsIncMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">TELO:TeliPharmaceuticalsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-02-04</xbrli:startDate>
        <xbrli:endDate>2026-02-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-02-042026-02-04_custom_TelomirOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">TELO:TelomirOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-02-04</xbrli:startDate>
        <xbrli:endDate>2026-02-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-02-042026-02-04_custom_PhaseOneByTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">TELO:PhaseOneByTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-02-04</xbrli:startDate>
        <xbrli:endDate>2026-02-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_MiralogxLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:MiralogxLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_MiralogxLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:MiralogxLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TampaFloridaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">TELO:TampaFloridaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-132024-02-13_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-13</xbrli:startDate>
        <xbrli:endDate>2024-02-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-142025-02-14_custom_AtTheMarketOfferingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TELO:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-14</xbrli:startDate>
        <xbrli:endDate>2025-02-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_AtTheMarketOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">TELO:AtTheMarketOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_AtTheMarketOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">TELO:AtTheMarketOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-192025-05-19">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-19</xbrli:startDate>
        <xbrli:endDate>2025-05-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-242025-07-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-24</xbrli:startDate>
        <xbrli:endDate>2025-07-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PlacementAgentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TELO:PlacementAgentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-22_custom_BayShoreTrustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:BayShoreTrustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_BayShoreTrustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:BayShoreTrustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-012024-12-31_custom_BayShoreTrustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:BayShoreTrustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-29_us-gaap_IPOMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-29_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TwoThousandTwentyThreeOmnibusIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TELO:TwoThousandTwentyThreeOmnibusIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_CommonStockMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_UnderwriterWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">TELO:UnderwriterWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember17385937">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_WarrantMember17385953">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_BayShoreTrustWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TELO:BayShoreTrustWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_TwoThousandTwentyThreePrivatePlacementWarrantsMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TELO:TwoThousandTwentyThreePrivatePlacementWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_BayShoreTrustWarrantsMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TELO:BayShoreTrustWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_UnderwriterWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TELO:UnderwriterWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">TELO:UnderwriterWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">TELO:UnderwriterWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-29_custom_UnderwriterWarrantMember_custom_MeasurementInputFairMarketValueUnderlyingCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">TELO:UnderwriterWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">TELO:MeasurementInputFairMarketValueUnderlyingCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">TELO:UnderwriterWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">TELO:UnderwriterWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_MayThirteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">TELO:MayThirteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_MayThirteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">TELO:MayThirteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_MayTwentySevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">TELO:MayTwentySevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_MayTwentySevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">TELO:MayTwentySevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_OctoberFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">TELO:OctoberFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_OctoberFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">TELO:OctoberFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Segment">
      <xbrli:measure>TELO:Segment</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000608" toRefs="Footnote000641"/>
  <ix:relationship fromRefs="Fact000626" toRefs="Footnote000648"/>
  <ix:relationship fromRefs="Fact000638" toRefs="Footnote000648"/>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 18pt"><b>UNITED STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 18pt"><b>SECURITIES AND
EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>Washington, D.C.
20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 18pt"><b>Form <span id="xdx_90F_edei--DocumentType_c20250101__20251231_zygLLz8wjhW5"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000013" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_edei--DocumentAnnualReport_db_c20250101__20251231_zQaId80EwKX8"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000014" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></span></td><td style="text-align: justify"><b>ANNUAL
                                            REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>For the fiscal year ended
<span id="xdx_90D_edei--DocumentPeriodEndDate_c20250101__20251231_zKZKTVUkZ6F1"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:datemonthdayyearen" id="Fact000015" name="dei:DocumentPeriodEndDate"><span id="xdx_908_edei--CurrentFiscalYearEndDate_c20250101__20251231_zSMP6qXv9Q24"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:datemonthdayen" id="Fact000016" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, <span id="xdx_90C_edei--DocumentFiscalYearFocus_c20250101__20251231_zbT2IAludl3c"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000017" name="dei:DocumentFiscalYearFocus">2025</ix:nonNumeric></span></ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_edei--DocumentTransitionReport_c20250101__20251231_z7u1QaBKYC4j"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000018" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>For the transition period from ________to_________</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Commission file number
<span id="xdx_90E_edei--EntityFileNumber_c20250101__20251231_zxPHTmeeKyJi"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000019" name="dei:EntityFileNumber">001-41952</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 18pt"><b><span id="xdx_901_edei--EntityRegistrantName_c20250101__20251231_z3i5tIjcSSl8"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000020" name="dei:EntityRegistrantName">Telomir
Pharmaceuticals, Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(Exact name of registrant
as specified in its charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="height: 10.1pt; vertical-align: bottom">
    <td style="width: 49%; height: 10.1pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20250101__20251231_znxLg9NIGRVe"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:stateprovnameen" id="Fact000021" name="dei:EntityIncorporationStateCountryCode">Florida</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="width: 49%; height: 10.1pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90E_edei--EntityTaxIdentificationNumber_c20250101__20251231_zkEqgKGRTBKb"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000022" name="dei:EntityTaxIdentificationNumber">85-3354547</ix:nonNumeric></span></b></span></td></tr>
  <tr style="height: 10.1pt; vertical-align: bottom">
    <td style="height: 10.1pt; text-align: center"><span style="font-size: 10pt"><b>(State or other jurisdiction of</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="height: 10.1pt; text-align: center"><span style="font-size: 10pt"><b>(I.R.S. Employer</b></span></td></tr>
  <tr style="height: 11.1pt; vertical-align: bottom">
    <td style="height: 11.1pt; text-align: center"><span style="font-size: 10pt"><b>incorporation or organization)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="height: 11.1pt; text-align: center"><span style="font-size: 10pt"><b>Identification No.)</b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="height: 0pt; vertical-align: bottom">
    <td style="height: 0pt; text-align: center; width: 49%"><span style="font-size: 10pt"><b><span id="xdx_90F_edei--EntityAddressAddressLine1_c20250101__20251231_zjszgquYdJDb"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000023" name="dei:EntityAddressAddressLine1">100 SE 2nd St</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressAddressLine2_c20250101__20251231_zBuEnCE6NsGh"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000024" name="dei:EntityAddressAddressLine2">Suite 200 #1009</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressCityOrTown_c20250101__20251231_z1UyNAseEpc3"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000025" name="dei:EntityAddressCityOrTown">Miami</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressStateOrProvince_c20250101__20251231_zMyYw4FlPDHi"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:stateprovnameen" id="Fact000026" name="dei:EntityAddressStateOrProvince">Florida</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="height: 0pt; text-align: center; width: 49%"><span style="font-size: 10pt"><b><span id="xdx_908_edei--EntityAddressPostalZipCode_c20250101__20251231_zcjq97vtqrk4"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000027" name="dei:EntityAddressPostalZipCode">33131</ix:nonNumeric></span></b></span></td></tr>
  <tr style="height: 11.1pt; vertical-align: bottom">
    <td style="height: 11.1pt; text-align: center"><span style="font-size: 10pt"><b>(Address of principal executive offices)</b></span></td>
    <td>&#160;</td>
    <td style="height: 11.1pt; text-align: center"><span style="font-size: 10pt"><b>(Zip Code)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt"><b>Registrant&#8217;s
telephone number, including area code: <span id="xdx_909_edei--CityAreaCode_c20250101__20251231_zwZa152tnqif"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000028" name="dei:CityAreaCode">786</ix:nonNumeric></span>-<span id="xdx_901_edei--LocalPhoneNumber_c20250101__20251231_zjhxZkURRril"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000029" name="dei:LocalPhoneNumber">396-6723</ix:nonNumeric></span></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>Securities registered pursuant
to Section 12(b) of the Act:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="height: 0pt; vertical-align: bottom">
    <td style="height: 0pt; text-align: center"><span style="font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="height: 0pt; text-align: center"><span style="font-size: 10pt">Trading Symbol(s)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="height: 0pt; text-align: center"><span style="font-size: 10pt"><b>Name of exchange on which registered</b></span></td></tr>
  <tr style="height: 11.1pt; vertical-align: bottom">
    <td style="border-top: Black 1pt solid; width: 38%; height: 11.1pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_904_edei--Security12bTitle_c20250101__20251231_zGFEgrqDXVn9"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000030" name="dei:Security12bTitle">Common stock,
    no par value</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-top: Black 1pt solid; width: 20%; height: 11.1pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_908_edei--TradingSymbol_c20250101__20251231_z3j6CJjJ0si7"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000031" name="dei:TradingSymbol">TELO</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-top: Black 1pt solid; width: 38%; height: 11.1pt; text-align: center"><span style="font-size: 10pt"><b><span>The <span id="xdx_909_edei--SecurityExchangeName_c20250101__20251231_zb7dMiyn2Upa"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:exchnameen" id="Fact000032" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    Capital Market</span></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Securities
                                            registered pursuant to Section 12(g) of the Act: None</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is a well-known seasoned
issuer, as defined in Rule 405 of the Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>
<span id="xdx_90F_edei--EntityWellKnownSeasonedIssuer_c20250101__20251231_zaOC2uqztIOl"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000033" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is not required to file reports
pursuant to Section 13 or Section 15(d) of the Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>
<span id="xdx_908_edei--EntityVoluntaryFilers_c20250101__20251231_zWSP88llbWE3"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000034" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15.15pt">Indicate by check mark
whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject
to such filing requirements for the past 90 days.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 15.15pt"><span id="xdx_90A_edei--EntityCurrentReportingStatus_c20250101__20251231_zjzOlFVu9Pyb"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000035" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span> No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15.15pt">Indicate by check mark
whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit
such files).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span id="xdx_901_edei--EntityInteractiveDataCurrent_c20250101__20251231_zOkIB9K7fYo4"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000036" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span>
No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging
growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221;
and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="height: 10.3pt; vertical-align: bottom">
    <td style="width: 25%; height: 10.3pt"><span style="font-size: 10pt">Large accelerated filer</span></td>
    <td style="text-align: right; width: 20%; height: 10.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 25%; height: 10.3pt"><span style="font-size: 10pt">Accelerated filer</span></td>
    <td style="text-align: right; width: 20%; height: 10.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="width: 5%">&#160;</td></tr>
  <tr style="height: 10.1pt; vertical-align: bottom">
    <td style="height: 10.1pt"><span style="font-size: 10pt"><span id="xdx_90F_edei--EntityFilerCategory_c20250101__20251231_zYytybl31Z8f"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000037" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span></span></td>
    <td style="text-align: right; height: 10.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td>&#160;</td>
    <td style="height: 10.1pt"><span style="font-size: 10pt">Smaller reporting company</span></td>
    <td style="text-align: right; height: 10.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--EntitySmallBusiness_db_c20250101__20251231_z4F5zVKGvLOi"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000038" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td>
    <td>&#160;</td></tr>
  <tr style="height: 14.1pt; vertical-align: bottom">
    <td style="height: 14.1pt">&#160;</td>
    <td style="text-align: right; height: 14.1pt">&#160;</td>
    <td>&#160;</td>
    <td style="height: 14.1pt"><span style="font-size: 10pt">Emerging growth company</span></td>
    <td style="text-align: right; height: 14.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--EntityEmergingGrowthCompany_db_c20250101__20251231_z1F2Q8LUaoX7"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000039" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15.15pt">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_edei--EntityExTransitionPeriod_c20250101__20251231_zSp4BtbqDmBb"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000040" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15.15pt">Indicate by check mark
whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal
control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting
firm that prepared or issued its audit report. <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_edei--IcfrAuditorAttestationFlag_c20250101__20251231_zkUbGQUSMfwf" title="ICFR Auditor Attestation Flag"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000042" name="dei:IcfrAuditorAttestationFlag">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15.15pt">If securities are registered
pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant in the filing reflect
the correction of an error to previously issued financial statements. <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_edei--DocumentFinStmtErrorCorrectionFlag_c20250101__20251231_z0lnopyuayI6" title="Document Financial Statement Error Correction [Flag]"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000044" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15.15pt">Indicate by check mark
whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by
any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15.15pt">Indicate by check mark
whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <span style="font-family: Times New Roman, Times, Serif"><span title="Entity Shell Company">&#9744;</span></span>
<span>No</span> <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_edei--EntityShellCompany_dbF_c20250101__20251231_zHpps2y3yLCb" title="Entity Shell Company"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000046" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">The aggregate market value
of the voting and non-voting common equity held by non-affiliates as of June 30, 2025, was $<span id="xdx_90F_edei--EntityPublicFloat_iI_pn5n6_c20250630_zi2V5D0fQphh" title="Entity Public Float"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2025-06-30" id="Fact000048" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">18.1</ix:nonFraction></span> million based on the closing sale price
of the company&#8217;s common stock on such date of $1.25 per share, as reported by the NASDAQ Capital Market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of March 12, 2026, there were <span id="xdx_905_edei--EntityCommonStockSharesOutstanding_iI_c20260312_zGsPuZTIVhzj" title="Entity Common Stock, Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2026-03-12" id="Fact000050" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">34,380,971</ix:nonFraction></span> shares of common stock
issued and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Telomir Pharmaceuticals, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Annual Report on Form 10-K</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the fiscal year ended December 31, 2025</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="background-color: white">
    <td style="width: 0.6in">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE OF CONTENTS</b></span></td>
    <td style="width: 0.6in; text-align: center">&#160;</td></tr>
  <tr style="background-color: white">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td colspan="2"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cautionary Note on Forward-Looking Statements</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="background-color: white">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART I</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td></tr>
  <tr style="background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</span></td>
    <td><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Business</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A.</span></td>
    <td><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</span></td></tr>
  <tr style="background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1B.</span></td>
    <td><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unresolved Staff Comments</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1C.</span></td>
    <td><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cybersecurity</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td></tr>
  <tr style="background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</span></td>
    <td><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Property</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</span></td>
    <td><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td></tr>
  <tr style="background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</span></td>
    <td><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosure</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART II</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td></tr>
  <tr style="background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5.</span></td>
    <td><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market for Common Equity and Related Stockholder Matters</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6.</span></td>
    <td><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved]</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td></tr>
  <tr style="background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7.</span></td>
    <td><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7A.</span></td>
    <td><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 8.</span></td>
    <td><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9.</span></td>
    <td><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes In and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9A.</span></td>
    <td><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</span></a></td>
    <td style="text-align: center">57</td></tr>
  <tr style="background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9B.</span></td>
    <td><a href="#a_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>Other Information</span></span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9C.</span></td>
    <td><a href="#a_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td><a href="#a_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART III</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr>
  <tr style="background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 10.</span></td>
    <td><a href="#a_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors, Executive Officers and Corporate Governance</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 11.</span></td>
    <td><a href="#a_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Compensation</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr>
  <tr style="background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 12</span></td>
    <td><a href="#a_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 13.</span></td>
    <td><a href="#a_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Relationships and Related Transactions, and Director Independence</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr>
  <tr style="background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 14.</span></td>
    <td><a href="#a_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accountant Fees and Services</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td><a href="#a_026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART IV</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
  <tr style="background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 15.</span></td>
    <td><a href="#a_027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits, Financial Statement Schedules</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td><a href="#a_028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signatures</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless we have indicated otherwise, or the context
otherwise requires, references in this Annual Report to &#8220;TELO,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221;
and &#8220;our&#8221; or similar terms refer to Telomir Pharmaceuticals, Inc., a Florida corporation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, we may use our website, our
Facebook page at https://www.facebook.com/people/Telomir-Pharmaceuticals-Inc/100087267737318/#, our Twitter at https://x.com/TelomirPharma,
and on our LinkedIn account at <span style="text-decoration: underline">https://www.linkedin.com/company/telomir-pharmaceuticals-inc/posts/?feedView=all </span>to distribute
material information. Our financial and other material information is routinely posted to and accessible on the Investors section of
our website, available at <b>www.telomirpharma.com</b>. Investors are encouraged to review the Investors section of our website because
we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed
through our website, our Facebook page, our Twitter posts and our LinkedIn posts are not incorporated into, and does not form a part
of, this Annual Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_001"></span>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Annual Report on Form 10-K contains forward-looking
statements (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended (the &#8220;Exchange Act&#8221;) that reflect our current expectations and views of future events. In some cases, you can
identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221;
&#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221;
&#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221;, or &#8220;continue&#8221;
or the negative of these terms or other similar expressions. In particular, statements about the markets in which we operate, including
expectations regarding our studies, growth of our various markets, and our expectations, beliefs, plans, strategies, objectives, prospects,
assumptions, or future events or performance contained in this Annual Report under the headings &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Business&#8221; are forward-looking statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have based these forward-looking statements
on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates, and
projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties,
many of which are beyond our control. These and other important factors, including those discussed in this Annual Report under the headings
&#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;
and &#8220;Business,&#8221; may cause our actual results, performance, or achievements to differ materially from any future results,
performance or achievements expressed or implied by these forward-looking statements, or could affect our share price. Important factors
that could cause actual results or events to differ materially and adversely from those expressed in forward-looking statements include,
but are not limited to, the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in">&#9679;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain and maintain regulatory approval
    of our product candidates;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#9679;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to successfully commercialize and market
    our product candidates, if approved by the FDA; </span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#9679;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to contract with third-party suppliers,
    manufacturers and other service providers and their ability to perform adequately;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#9679;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential market size, opportunity, and growth
    potential for our product candidates, if approved by the FDA;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="background-color: white">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify">&#9679;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain additional
    funding for our operations and development activities;</span></td></tr>
  <tr style="background-color: white">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the accuracy of our estimates
    regarding expenses, capital requirements and needs for additional financing;</span></td></tr>
  <tr style="background-color: white">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the initiation, timing,
    progress and results of our pre-clinical studies and clinical trials, and our research and development programs;</span></td></tr>
  <tr style="background-color: white">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing of anticipated
    regulatory filings;</span></td></tr>
  <tr style="background-color: white">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our future expenses, capital
    requirements and need for additional financing;</span></td></tr>
  <tr style="background-color: white">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to retain the
    continued service of our key professionals and to identify, hire and retain additional qualified professionals;</span></td></tr>
  <tr style="background-color: white">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to advance
    product candidates into, and successfully complete, clinical trials;</span></td></tr>
  <tr style="background-color: white">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to recruit
    and enroll suitable patients in our clinical trials;</span></td></tr>
  <tr style="background-color: white">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing or likelihood
    of the accomplishment of various scientific, clinical, regulatory, and other product development objectives;</span></td></tr>
  <tr style="background-color: white">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the pricing and reimbursement
    of our product candidates, if approved by the FDA;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="background-color: white; text-align: justify">&#160;</td>
    <td style="background-color: white; text-align: justify">&#9679;</td>
    <td style="background-color: white; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    implementation of our business model and strategic plans for our business, product candidates, and technology;</span></td>
    </tr>
  <tr>
    <td style="background-color: white; text-align: justify">&#160;</td>
    <td style="background-color: white; text-align: justify">&#160;</td>
    <td style="background-color: white; text-align: justify">&#160;</td>
    </tr>
  <tr>
    <td style="background-color: white; text-align: justify">&#160;</td>
    <td style="background-color: white; text-align: justify">&#9679;</td>
    <td style="background-color: white; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;</span></td>
    </tr>
  <tr>
    <td style="background-color: white; text-align: justify">&#160;</td>
    <td style="background-color: white; text-align: justify">&#160;</td>
    <td style="background-color: white; text-align: justify">&#160;</td>
    </tr>
  <tr>
    <td style="background-color: white; text-align: justify">&#160;</td>
    <td style="background-color: white; text-align: justify">&#9679;</td>
    <td style="background-color: white; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    relating to our competitors and our industry;</span></td>
    </tr>
  <tr>
    <td style="background-color: white; text-align: justify">&#160;</td>
    <td style="background-color: white; text-align: justify">&#160;</td>
    <td style="background-color: white; text-align: justify">&#160;</td>
    </tr>
  <tr style="height: 0pt">
    <td style="background-color: white; height: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; background-color: white; height: 0pt; text-align: left">&#9679;</td>
    <td style="background-color: white; height: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    development of major public health concerns, including the novel coronavirus outbreak or other pandemics arising globally, and the
    future impact of such events on our business operations and funding requirements;</span></td>
    </tr>
  <tr style="height: 0pt">
    <td style="background-color: white; height: 0pt; text-align: justify">&#160;</td>
    <td style="background-color: white; height: 0pt; text-align: justify">&#160;</td>
    <td style="background-color: white; height: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="width: 0.25in; background-color: white; text-align: justify">&#160;</td>
    <td style="width: 0.25in; background-color: white"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>&#9679;</td>
    <td style="background-color: white; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to successfully integrate and utilize the assets, licenses and businesses we acquire; and</span></td>
    </tr>
  <tr>
    <td style="background-color: white; text-align: justify">&#160;</td>
    <td style="background-color: white">&#160;</td>
    <td style="background-color: white; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="background-color: white; text-align: justify">&#160;</td>
    <td style="background-color: white; text-align: justify">&#9679;</td>
    <td style="background-color: white; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    risks and factors listed under &#8220;Risk Factors&#8221; and elsewhere in this Annual Report.</span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Given the risks and uncertainties set forth in
this Annual Report, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements
contained in this Annual Report are not guarantees of future performance and our actual results of operations, financial condition, and
liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained
in this Annual Report. In addition, even if our results of operations, financial condition and liquidity, and events in the industry
in which we operate are consistent with the forward-looking statements contained in this Annual Report, they may not be predictive of
results or developments in future periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any forward-looking statement that we make in
this Annual Report speaks only as of the date of such statement. Except as required by federal securities laws, we do not undertake any
obligation to update or revise, or to publicly announce any update or revision to, any of the forward-looking statements, whether as
a result of new information, future events or otherwise, after the date of this Annual Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business is subject to numerous risks and
uncertainties that you should consider before investing in our company. You should carefully consider all of the risks described more
fully in the section titled &#8220;Risk Factors&#8221; in this Annual Report on page 22, before deciding to invest in our common stock.
If any of these risks actually occurs, our business, financial condition and results of operations would likely be materially adversely
affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Important factors that could cause actual results
or events to differ materially, but are not limited to, the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Intellectual Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We depend on rights to Telomir-1 that are or
will be licensed to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may not be able to adequately protect our
product candidates or our proprietary technology in the marketplace.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If third parties claim that our intellectual
property, products, processes, or anything else used by us infringes upon their intellectual property, our operating profits could be
adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have been granted a license to the right to
develop Telomir-1 in the United States in human and pet application, but we have not been granted a license to the rights to patents
covering Telomir-1 in foreign jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Operations and Financial
Condition</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an early development-stage company with
no revenues and our financial condition raises substantial doubt as to our ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because we have a limited operating history,
you may not be able to accurately evaluate our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will need to raise additional financing for
the continuation of our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our operating results may fluctuate, which could
have a negative impact on our ability to grow our client base, establish sustainable revenues and succeed overall.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have yet to achieve a profit and will not
achieve a profit in the near future, if at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain of our executive officers are not be
employed by us on a full-time basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Conflicts of interest may arise between us and
MIRALOGX.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Relating to Our Business and Our Industry</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our future success will largely depend on the
success of Telomir-1 and any future product candidates, which development will require significant capital resources and years of clinical
development effort.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are dependent on our current and future product
candidates, some of which may not receive regulatory approval or be successfully commercialized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Results of pre-clinical studies and earlier clinical
trials are not necessarily predictive indicators of future results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have limited marketing experience, and we
do not anticipate at this time establishing a sales force or distribution and reimbursement capabilities, and we may not be able to successfully
commercialize any of our product candidates if they are approved in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will need to further increase the size and
complexity of our organization in the future, and we may experience difficulties in managing our growth and executing our growth strategy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect to face intense competition, often
from companies with greater resources and experience than we have.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have significant and increasing liquidity
needs and may require additional funding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Development and Regulatory
Approval of Our Product Candidates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical trials for our product candidates are
expensive, time-consuming, uncertain, and susceptible to change, delay or termination. The results of clinical trials are open to differing
interpretations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any failure by us to comply with existing regulations
could harm our reputation and operating results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The regulatory approval processes with the FDA
are lengthy and inherently unpredictable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is a high rate of failure for drug candidates
proceeding through clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Reliance Upon Third Parties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely on, and expect to continue to rely on,
third parties to conduct clinical trials for our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our existing collaboration arrangements and any
that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our
product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Relating to the Ownership of Our Common
Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because of the speculative nature of an investment
in our company, you may lose your entire investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Certain of our founding
stockholders, plus our existing officers and directors, control a substantial interest in us and thus may influence certain actions requiring
stockholder vote.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Relating to Our Proposed Merger with
TELI Pharmaceuticals, Inc. (&#8220;TELI&#8221;)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i></i>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because TELI has a limited operating history,
you may not be able to accurately evaluate TELI&#8217;s operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TELI has significant and increasing liquidity
needs and will require additional funding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TELI has yet to generate revenues or achieve
a profit and may not generate revenue or achieve a profit for many years, if at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TELI does not own rights to Telomir-1</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TELI&#8217;s product candidates, if approved,
may not achieve the expected market acceptance and, consequently, limit TELI&#8217;s ability to generate revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are several conflicts of interests inherent
in the Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_002"></span>PART I</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_003"></span>ITEM 1. Description of Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Overview</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Telomir Pharmaceuticals, Inc. is a preclinical-stage
biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging
and age-related diseases rather than treating symptoms alone. Our research strategy targets fundamental cellular processes associated
with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial
dysfunction, and telomere integrity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #EE0000"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Telomir&#8217;s lead investigational compound,
Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance&#8212;particularly
iron, copper, calcium, and zinc&#8212;through a regulated exchange mechanism rather than broad chelation. Our preclinical research has
evaluated Telomir-1 across multiple in vitro and in vivo model systems to characterize biological activity, safety profile, and potential
relevance across a range of disease pathways.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not yet conducted clinical trials in
humans. All findings described in this Business section are derived from preclinical studies and may not be predictive of clinical outcomes.
We plan to submit an IND application in 2026 and, if the IND becomes effective and other conditions are satisfied, to commence a Phase
1/2 clinical trial thereafter. The timing of these activities is subject to change and may be delayed due to regulatory, technical, manufacturing,
financing, or other factors</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #EE0000">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TELI Pharmaceuticals, Inc., a private related party company incorporated
under the laws of Delaware (&#8220;TELI&#8221;) and we entered into an Agreement and Plan of Merger and Reorganization, dated November
20, 2025, and as amended on February 4, 2026 (collectively, the &#8220;Merger Agreement&#8221;), pursuant to which a wholly owned subsidiary
of Telomir will merge with and into TELI, with TELI surviving as a wholly owned subsidiary of Telomir (the &#8220;Merger&#8221;), subject
to shareholder approval. At the effective time of the Merger (the &#8220;Effective Time&#8221;), each outstanding share of common stock
of TELI, $0.0001 par value per share (&#8220;TELI Common Stock&#8221;), will be converted into the right to receive such number of Telomir
Common Stock as is calculated based on the exchange ratio of the shares for the Merger (the &#8220;Exchange Ratio&#8221;). The Exchange
Ratio is calculated using the relative company valuations of each of TELO and TELI, as determined by Moore (as further described herein).
It is expected that shareholders of TELI will receive one share of Telomir Common Stock for each share of TELI Common Stock held (the
&#8220;Merger Share Consideration&#8221;). The Telomir Common Stock issued as the consideration will not be registered for trading under
the Securities Act. The Merger will result in an alignment of U.S. and non-U.S. rights to Telomir-1 within a single public company structure,
thereby simplifying global development and partnership efforts. As a result of the Merger, Telomir will own the entire worldwide intellectual
property portfolio and development programs related to Telomir-1</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Scientific Rationale</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Scientific research supports the role of reactive
metal accumulation and oxidative stress as contributors to progressive cellular dysfunction associated with aging and age-related diseases.
Iron and copper are essential for normal physiology; however, with aging and in certain disease states, regulation can weaken, contributing
to intracellular accumulation of reactive metal species.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Excess ferrous iron and reactive copper catalyze
the formation of reactive oxygen species, which can damage DNA, proteins, lipids, and mitochondria. Calcium dysregulation further contributes
to mitochondrial instability and activation of stress-related signaling pathways. Together, these processes contribute to genomic instability,
cellular senescence, and disease progression.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our research premise is that restoring intracellular
balance across these pathways may support improved cellular function in preclinical systems relevant to aging and disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Telomir-1: Investigational Candidate and Mechanistic
Profile</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Telomir-1 has been evaluated in preclinical model
systems for its potential effects on cellular homeostasis. In nonclinical studies conducted to date, Telomir-1 has demonstrated activity
consistent with modulation of oxidative stress pathways, redox balance under metal-induced stress conditions, mitochondrial structure
and function, intracellular calcium dynamics, and epigenetic regulatory processes. Observed findings also suggest potential interaction
with iron-dependent enzymatic pathways, including histone demethylases. These effects have been observed in controlled preclinical settings
and may reflect interconnected biological mechanisms; however, their relevance to human disease has not been established.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Epigenetic Regulation and DNA Methylation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Epigenetic regulation, including changes in DNA
methylation and histone methylation, plays a central role in gene expression, cellular identity, and disease biology. Abnormal epigenetic
patterns can contribute to inappropriate gene silencing, loss of genomic stability, and impaired stress responses. In disclosed preclinical
cancer and aging models, Telomir-1 has demonstrated the ability to influence DNA methylation patterns and inhibit iron-dependent histone
demethylases, including members of the KDM2, KDM5, and KDM6 families. These enzymes require ferrous iron as a cofactor and play key roles
in regulating chromatin structure and transcriptional programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Telomere Integrity and Genomic Stability</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Telomeres are protective DNA-protein structures
located at the ends of chromosomes that shorten with age and under conditions of oxidative stress and cellular damage. Accelerated telomere
shortening is associated with cellular senescence, impaired regenerative capacity, and age-related disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In disclosed preclinical experimental systems
evaluating genomic stability and cellular aging, Telomir-1 has been associated with preservation of telomere integrity and observed telomere
elongation in certain model systems, together with normalization of accelerated aging phenotypes. These observations were made in controlled
preclinical models and do not represent evidence of clinical benefit in humans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Preclinical Aging and Healthspan Observations</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Across multiple preclinical studies, Telomir-1
has demonstrated biological activity relevant to aging and age-related decline, including reduction of oxidative stress and reactive
oxygen species, preservation of mitochondrial function, protection against stress-induced cell death, normalization of functional decline
in aging and progeria models, and improvements in mobility, survival, and healthspan parameters in model organisms<span style="color: #EE0000"><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #EE0000">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Oncology Research</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #EE0000"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cancer cells frequently rely on dysregulated
metal metabolism, oxidative stress, and epigenetic silencing to support uncontrolled proliferation and treatment resistance. Telomir-1
has been evaluated in multiple preclinical oncology models, including prostate cancer, triple-negative breast cancer, pancreatic cancer,
and leukemia. In these models, Telomir-1 has been associated with reduced tumor growth, altered metabolic activity, reversal of abnormal
DNA methylation, and modulation of pathways related to cancer cell survival. Telomir-1 has demonstrated anti-tumor activity rather than
tumor promotion in preclinical systems evaluating telomere biology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #EE0000">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>IND-Enabling GLP Safety and Toxicology</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #EE0000"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We disclosed favorable results from IND-enabling
Good Laboratory Practice toxicology and safety pharmacology studies for Telomir-1. These studies evaluated cardiovascular safety, respiratory
safety, phototoxicity, and repeat-dose toxicology in animal models. Telomir-1 was reported to be well tolerated across completed GLP
safety studies, without treatment-related adverse or dose-limiting toxicities observed. Cardiovascular assessments demonstrated no test-article-related
changes in blood pressure, heart rate, electrocardiogram parameters, or body temperature, and no concerning cardiac safety signals. Repeated-dose
studies in rats and dogs were reported to be well tolerated, with findings described as limited, reversible, and non-adverse. No clinically
meaningful respiratory effects or phototoxicity were reported. Across oral administration studies, Telomir-1 demonstrated consistent
systemic exposure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Development Strategy and Outlook</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Telomir-1 remains in preclinical development.
We continue to advance regulatory preparation and development activities in support of a potential Investigational New Drug (&#8220;IND&#8221;)
application. We are targeting IND submission in 2026 and, subject to regulatory review, completion of required preclinical and manufacturing
activities, and availability of resources, plans to initiate a Phase 1/2 clinical trial thereafter. The timing of these activities is
subject to change and may be delayed due to regulatory, technical, operational, or financial factors. There can be no assurance that
preclinical findings will translate into safety, efficacy, disease modification, or therapeutic benefit in humans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, we have completed multiple preclinical
studies on Telomir-1, including those demonstrating that Telomir-1 is non-mutagenic and possesses strong biological and metal-binding
properties (Graphic 1). Using advanced &#8220;in silico modeling,&#8221; driven by artificial intelligence to predict a compound&#8217;s
therapeutic potential, chemical and biological activity, and toxicity, we continue to uncover evidence supporting Telomir-1&#8217;s potential
to address metal-overload conditions. Additionally, recent independent in vitro studies have confirmed that Telomir-1 exhibits strong
binding affinities for copper and iron, with reduced binding affinity for zinc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><img src="form10-k_001.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Graphic 1: Telomir-1 is capable of binding
to several metal ions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We collaborate with third-party organizations
to conduct research and advance development efforts. One such partner, InSilico Trials, utilizes in silico digital simulations to support
drug development through computational modeling. These techniques allow us to efficiently predict the safety and efficacy of potential
compounds, reducing the need for extensive clinical trials. Additionally, we work with Recipharm and Smart Assays to assess Telomir-1&#8217;s
binding properties and investigate ion competition and exchange under varying conditions, further refining its therapeutic potential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An example of these findings is illustrated in
the Graphic 2 below, created in collaboration with Smart Assays Biotechnologies Ltd. The figure depicts the concentration of free iron
(Fe&#178;&#8314;) in the presence of Telomir-1 (T1) and various ions. When Telomir-1 is introduced, the concentration of free iron decreases
(indicated by the shift from the blue point to the orange point). This is direct evidence for the binding of iron to T1, reducing its
free ion concertation in the solution. However, the addition of copper (Cu&#178;&#8314;) at varying concentrations leads to an exchange
between bound iron and copper, resulting in the release of previously bound iron and restoration of free iron levels in solution. This
is evidenced by an increase in free iron concentration, corresponding to the amount of copper added. In contrast, zinc does not induce
an exchange effect on the binding of iron to Telomir-1, indicating a lower affinity of Zinc to Telomir-1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><img src="form10-k_002.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Graphic 2: Ionic exchange between iron and
copper or zinc</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Wilson&#8217;s disease </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Wilson&#8217;s disease is a rare genetic disorder
affecting approximately 1 in 30,000 individuals worldwide. It is caused by mutations in the ATP7B gene, which disrupt the body&#8217;s
ability to regulate copper metabolism. This results in toxic copper accumulation, particularly in the liver and brain, leading to severe
complications such as liver failure, neurological damage, and psychiatric disorders. Without treatment, Wilson&#8217;s disease is fatal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Current treatments, including chelating agents
(e.g., penicillamine and trientine) and zinc therapy, focus on reducing copper levels but have notable limitations:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="width: 0.25in; padding-bottom: 0pt">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Chelating
    agents</b> can cause significant side effects, such as kidney damage, bone marrow suppression, and gastrointestinal issues, and require
    lifelong adherence, which can be burdensome for patients.</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Zinc
    therapy</b> reduces copper absorption in the gut but may lead to side effects such as anemia, gastrointestinal discomfort, and diminished
    effectiveness over time.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These challenges highlight the urgent need for
novel therapies that address the root cause of Wilson&#8217;s disease while minimizing adverse effects. Telomir-1, with its targeted
copper-binding properties, has the potential to provide a safer, more effective treatment by directly addressing the underlying mechanisms
of the disease. Furthermore, Wilson&#8217;s disease qualifies as a candidate for orphan drug designation due to its rarity and life-threatening
nature, offering opportunities for accelerated development and additional regulatory and financial incentives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are actively investigating Telomir-1&#8217;s
potential in treating Wilson&#8217;s disease by studying its effects on copper toxicity through in vitro experiments and a mouse model
of the disease. These studies are currently ongoing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Type 2 Diabetic (NIDDM)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In collaboration with the India-based research
organization Pentagrit, in 2024 Telomir conducted preclinical studies evaluating two forms of Telomir-1, administered orally at three
different doses, in zebrafish models of Type 2 diabetes mellitus induced by a high-calorie diet. The study assessed key metabolic indicators,
including fasting glucose levels, Oral Glucose Tolerance Test (OGTT) results, insulin concentrations, and HOMA-IR. The findings revealed:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reversal
of Hyperglycemia and Insulin Resistance:</b> Telomir-1 demonstrated dose-dependent efficacy in normalizing blood glucose and reducing
insulin levels, restoring glucose homeostasis.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr>
    <td style="width: 0.25in; padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; width: 0.25in; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significantly
    Reduced HOMA-IR Values:</b> Telomir-1 showed a substantial improvement in insulin sensitivity to near pre-diabetes values, underscoring
    its potential to mitigate insulin resistance.</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Enhanced
    Glucose Clearance:</b> Significant improvements in OGTT results highlighted Telomir-1&#8217;s impact on glucose metabolism.</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Increased
    Survival Rates:</b> Treated models exhibited improved survival compared to controls, showcasing Telomir-1&#8217;s comprehensive therapeutic
    potential.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A Novel Mechanism of Action</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Telomir-1 introduces a novel mechanism of action
by addressing the cellular role of iron metabolism in chronic diseases such as Type 2 diabetes. Excess iron contributes to oxidative
stress, beta-cell damage, and insulin resistance. Telomir-1 is designed to normalize iron homeostasis, reducing oxidative stress and
enhancing insulin sensitivity. This differentiates it from current diabetes drugs that primarily treat symptoms without targeting the
underlying causes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The study demonstrated significant reductions
in fasting plasma glucose to basal levels, improvements in glucose tolerance, and a reversal of insulin resistance to near pre-diabetic
levels. These results were accompanied by improved HOMA-IR values, a standard measure of insulin sensitivity and resistance, and increased
survival rates in treated models.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Global Impact of Type 2 Diabetes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the International Diabetes Federation,
over 800 million adults worldwide are affected by Type 2 diabetes (both diagnosed and undiagnosed), with annual healthcare costs exceeding
$966 billion as of 2021. Existing treatments primarily manage blood glucose and symptoms but fail to address the root causes of the disease.
These therapies are often associated with significant limitations, including minimal impact on insulin resistance, gastrointestinal issues,
risk of hypoglycemia, cardiovascular risks, and weight gain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The findings from this zebrafish diabetes model
suggest that Telomir-1 could offer a transformative approach to managing Type 2 diabetes. By targeting the underlying mechanisms of insulin
resistance and oxidative stress through iron metabolism normalization, Telomir-1 represents a potential breakthrough in diabetes treatment.
A key indicator of its success was the significant reduction in HOMA-IR values, highlighting its ability to improve insulin sensitivity
and glucose regulation. The reversal of insulin resistance to near pre-diabetic levels underscores Telomir-1&#8217;s potential as a groundbreaking
therapy (Graphic).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img src="form10-k_003.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Graphic 3: Effects of two forms of Telomir-1
on HOMA-IR, a measure of insulin resistance in Zebrafish</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are currently evaluating the potential in
NIDDM by studying the effect of Telomir-1 on several metabolic parameters in a rat model of NIDDM. These studies are ongoing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Age reversal</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have carried out a preclinical study, conducted
in collaboration with Nagi Bioscience SA, utilized a sophisticated in vivo microfluidic-based assay to assess the effects of Telomir-1
on the nematode Caenorhabditis elegans, a well-established model for aging studies. The microfluidic platform allowed precise, automated
tracking of lifespan, health span, and age-related mobility decline in real-time, enabling the research team to accurately measure the
effects of Telomir-1 on these critical metrics.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Two forms of Telomir-1 were administered in two
concentrations, allowing the study to examine dose-dependent responses in treated subjects. The study found that Telomir-1 significantly
enhanced lifespan and health span parameters in aged microorganism populations. Key findings included:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="width: 0.25in; padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; width: 0.25in; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Enhanced
    Mobility in Older Organisms</b>: Subjects treated with Telomir-1 showed improved motility, particularly in later stages of life,
    compared to untreated controls. This enhanced movement in advanced age suggests a slowing of the aging process, as mobility is a
    key indicator of biological health.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="padding-bottom: 0pt; width: 0.25in">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; width: 0.25in; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reduced
    Biological Aging</b>: The study demonstrated a measurable reversal of biological age markers in subjects treated with Telomir-1.
    This significant finding points to Telomir-1&#8217;s potential to slow down, and in certain aspects, reverse biological aging, making
    it a promising candidate for longevity treatments.</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Increased
    Lifespan</b>: Telomir-1 was associated with a statistically significant increase in lifespan among treated populations. This further
    supports Telomir-1&#8217;s role in promoting longevity</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><img src="form10-k_004.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Graphic 4: Effect of Telomir-1 on c.elegans
life span</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><img src="form10-k_005.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Graphic 5: Effect of two forms of Telomir-1
on several motility parameters</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Progeria Study: Telomir-1 Shows Promising
Age-Reversal Effects</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We recently completed a study evaluating the
effects of Telomir-1 in a nematode model of Progeria (Caenorhabditis elegans). The study focused on nematodes with a mutation in the
wrn-1 gene, the equivalent of the human WRN gene, which is implicated in Werner Syndrome, a form of Progeria. In C. elegans, wrn-1 depletion
is associated with a significantly reduced mean and median lifespan compared to normal (wild-type) organisms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The study demonstrated significant age-reversal
effects in <i>wrn-1</i>-mutated nematodes treated with Telomir-1. Treatment effectively restored longevity levels to those comparable
to wild-type organisms. Additional benefits included an extended healthy lifespan and normalization of physiological parameters such
as movement velocity and tail amplitude.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further studies in a Progeria human cell line
are planned in collaboration with Smart Assays to build on these promising findings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Oxidative Stress Study: Telomir-1 Shows potential to Reverse Oxidative
Stress and Provide Robust Cellular Protection</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oxidative stress is a key driver of aging and
disease progression, contributing to conditions such as Alzheimer&#8217;s, Age-related Macular Degeneration (AMD), cardiovascular diseases,
cancer, and diabetes. It also plays a critical role in the severity of viral infections, including avian influenza (bird flu), by increasing
inflammation, cellular damage, and impairing immune responses. Addressing oxidative stress is essential for mitigating these effects
and improving patient outcomes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Telomir Pharmaceuticals recently conducted preclinical
studies in collaboration with Smart Assays Biotechnologies Ltd. to evaluate Telomir-1&#8217;s ability to combat copper-induced oxidative
stress. The study, performed in human cell lines, demonstrated:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="width: 0.25in; padding-bottom: 0pt">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; padding-bottom: 0pt; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reversal
    of Oxidative Stress</b> &#8211; Telomir-1 fully normalized Reactive Oxygen Species (ROS) levels, effectively reversing oxidative
    damage.</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-size: 10pt"><b>Cellular Protection</b> &#8211; Telomir-1
    provided strong protection against copper-induced toxicity while maintaining cellular integrity.</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-size: 10pt"><b>Regulatory Mechanism</b> &#8211; Telomir-1
    demonstrated effects at doses significantly lower than copper levels, indicating a unique regulatory mechanism beyond copper ion
    chelation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These findings suggest Telomir-1&#8217;s potential
to preserve cellular integrity, combat oxidative damage, and regulate metal ion balance&#8212;critical factors in aging-related diseases
and viral infections. This breakthrough supports further clinical development to assess its full potential in disease intervention.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><img src="form10-k_006.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Graphic 6: Effect of Telomir-1 on Oxidative
Stress</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_007.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Graphic 7: Effect of Telomir-1 on Copper Toxicity</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Expanding Telomir-1&#8217;s Therapeutic Potential</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Building on these findings, the Company continues to evaluate the
broader therapeutic potential of Telomir-1 across multiple disease areas characterized by metal dysregulation and oxidative stress. These
areas of scientific interest include Wilson&#8217;s disease, Type 2 diabetes, age-related macular degeneration, oncology, and epigenetic
regulation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Recent studies have shown that Telomir-1 has potent anti-cancer effects.
In vivo evaluation using zebrafish tumor xenografts revealed heterogeneous antitumor responses. Telomir-Zn significantly reduced primary
tumor size in BT-549 and HCC1806 xenografts and decreased metastatic dissemination in HCC1806. Combination treatment with paclitaxel
produced greater tumor suppression compared with either monotherapy (Graphic 8-9).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: Red"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: Red"><img src="form10-k_008.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>Graphic 8. Antitumor efficacy of paclitaxel (PTX) and Telomir-1
in BT-549 zebrafish xenografts. </b>(A)Primary tumor size and metastatic dissemination were evaluated in BT-549 xenografts after 3 days
of treatment. (B) Representative microscopy images of primary tumors treated with vehicle or Telomir-Zn 1-10 &#181;M throughout the
evaluation time Data are normalized relative to the negative control group and presented as mean &#177; SEM. Statistical</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: Red"><img src="form10-k_009.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>Graphic 9. Antitumor efficacy of paclitaxel (PTX) and Telomir-Zn
in HCC1806 zebrafish xenografts.</b>(A) Primary tumor size and metastatic dissemination were evaluated in HCC1806 xenografts after 3
days of treatment. (B) Representative microscopy images of disseminated tumor cells after 3 days of treatment with vehicle or Telomir-Zn
3 &#181;M.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Data are normalized relative to the negative control group and presented
as mean &#177; SEM.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For metastasis data, statistical analysis was performed using one-way
ANOVA (p = 0.0617), followed by a two-tailed Student&#8217;s <i>t</i>-test. <i>p</i> &lt; 0.05 indicates significance compared with the
vehicle group.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Company is in the process of finalizing the initial clinical development
program for Telomir-1 and expects to provide additional details regarding the planned clinical indication in connection with the anticipated
submission of its Investigational New Drug (IND) application. Future development efforts may also explore additional indications based
on regulatory guidance, emerging scientific data, capital availability, and strategic considerations. There can be no assurance that
the Company will pursue development in any or all of these areas.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Wilson&#8217;s Disease Study:</b>
    Investigating Telomir-1&#8217;s effects on copper regulation in preclinical models.</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#9679;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Type 2 Diabetes Studies:</b> Following success in
    zebrafish studies, ongoing research in rat models aims to confirm Telomir-1&#8217;s efficacy in reversing key metabolic abnormalities.</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#9679;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age-related Macular Degeneration:</b> Assessing
    Telomir-1&#8217;s impact on retinal degeneration and Drusen formation caused by metal accumulation.</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#9679;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Progeria: </b>Examining Telomir-1&#8217;s impact
    on accelerated aging and telomere function.</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#9679;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cancer Research:</b> Exploring anti-cancer applications
    using xenograft studies.</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#9679;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Metal Toxicity:</b> Examining Telomir-1&#8217;s
    capacity to reduce harmful metal accumulation and associated cellular damage.</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#9679;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DNA Methylation Analysis:</b> Studying Telomir-1&#8217;s
    role in modulating DNA methylation to restore healthy gene expression patterns linked to aging and disease</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Future Plans and Milestones</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Telomir-1 has demonstrated significant potential
in reversing age-related and metabolic conditions while targeting underlying disease mechanisms. As the company continues to refine the
molecular understanding of Telomir-1, efforts are underway to identify the most impactful indication for its initial IND application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are optimizing manufacturing processes to
produce GMP-grade Telomir-1 for IND-enabling activities and potential future clinical trials. We have completed the preclinical safety
studies it currently believes are required to support an IND submission. We are targeting IND submission in 2026 and, if the IND becomes
effective and subject to completion of remaining regulatory, manufacturing, and operational activities, plans to initiate a Phase 1/2
clinical trial thereafter. The FDA may require additional studies or information prior to or following IND submission. The timing of
these activities is subject to change and may be delayed due to regulatory, technical, operational, financial, or other factors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Through these initiatives, we are committed to
revolutionizing treatments for age-related and chronic diseases by addressing their root causes and paving the way for transformative
healthcare solutions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Market Potential</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market potential for Telomir-1 is substantial, given its focus on addressing the root causes of age-related diseases and promoting longevity.
Chronic diseases such as diabetes, cancer, Alzheimer&#8217;s, and cardiovascular disorders, which are closely tied to aging, account
for over 75% of healthcare spending in the United States, exceeding $4 trillion annually, according to the CDC. As the global population
ages, the demand for innovative therapies targeting the underlying mechanisms of these conditions is expected to grow significantly.
Furthermore, Verified Market Research reports that the anti-aging drug market was valued at approximately $91.05 billion in 2024 and
is projected to reach $160.24 billion by 2031, growing at a compound annual growth rate (CAGR) of 7.32%. With its novel mechanism of
action that regulates cellular metal imbalances and reduces oxidative stress, Telomir-1 is uniquely positioned to capitalize on these
expanding markets, offering transformative potential to enhance health span, slow disease progression, and redefine longevity treatments.</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Pre-Clinical IND-Enabling Studies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have successfully completed several IND-enabling
studies for Telomir-1, aiming to demonstrate its non-toxic profile. In collaboration with Frontage Laboratories, our research is aimed
at establishing the metabolism and maximum tolerated dose (MTD) of Telomir-1, providing critical data to support its development. Our
preclinical studies were conducted in collaboration with third-party organizations, including Frontage Laboratories, InSilico Trials,
Pharmaseed Ltd, Smart Assay Biotechnologies Ltd., Recipharm, Naji Biosciences, and Pantagrit. These partners played a key role in supporting
the execution and analysis of the research.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Our Clinical Development Plan</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon completion of required preclinical studies
and supporting activities, we intend to submit an Investigational New Drug (&#8220;IND&#8221;) application to the U.S. Food and Drug
Administration (&#8220;FDA&#8221;) for Telomir-1. We have not yet selected a specific initial clinical indication and expects that the
development strategy may evolve based on regulatory guidance and ongoing scientific evaluation. We are targeting IND submission in 2026.
If the IND becomes effective and subject to regulatory feedback and operational readiness, we plan to initiate first-in-human clinical
development thereafter. The scope, design, and timing of any clinical trial will be determined in consultation with regulatory authorities
and may be modified based on FDA input. There can be no assurance that the FDA will permit us to proceed to clinical trials on the anticipated
timeline or at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Market Opportunity</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Telomir-1 is under
investigation for its therapeutic potential across multiple areas, including Progeria, Type 2 Diabetes, Wilson&#8217;s disease, Age-related
Macular Degeneration (AMD), cancer, and other age-related conditions. Additionally, Telomir-1 is being explored for its potential in
mitigating the severity of viral infections such as avian influenza (bird flu) by addressing oxidative stress and immune dysfunction.
These indications are being carefully evaluated to identify the most impactful opportunities for clinical development and market entry</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of the therapeutic areas under evaluation represent established pharmaceutical markets in North America. According to Fortune Business
Insights, the U.S. Type 2 Diabetes market was valued at approximately $30.47 billion in 2022. Allied Market Research has projected that
the global age-related macular degeneration (AMD) market could reach approximately $18 billion by 2030, reflecting anticipated growth
over the forecast period. These estimates are based on third-party reports and are subject to assumptions and uncertainty. There can
be no assurance that Telomir-1, if approved, would address any of these markets or achieve commercial adoption</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The U.S oncology market, covering a broad range
of cancers, was valued at $74.1 billion in 2023, and is projected to reach $180.12 billion by 2033, growing at a CAGR of 9.2% from 2024
to 2033, as per Precedence Research. Meanwhile, the anti-aging and age-reversal market was valued at $91.05 billion in 2024 globally
and is projected to grow to $160.24 billion globally by 2031, with a CAGR of 7.32%, according to Verified Market Research.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rare diseases such as Progeria and Wilson&#8217;s
disease, despite having smaller patient populations, represent highly lucrative opportunities due to significant unmet medical needs
and strong pricing potential. For instance, the annual treatment cost for Progeria exceeds $1 million, based on the price of Zokinvy
(lonafarnib), the FDA-approved drug for the condition. Similarly, treatments for Wilson&#8217;s disease, like Syprine (trientine hydrochloride),
can cost approximately $300,000 per year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The global antiviral drugs market is experiencing
significant growth, driven by the increasing prevalence of viral infections and advancements in treatment options. In 2022, the market
was valued at approximately $49.8 billion and is projected to reach around $71.1 billion by 2032, reflecting a compound annual growth
rate (CAGR) of 3.73% during this period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Specifically focusing on avian influenza (bird
flu), the treatment market was estimated at $22.06 billion in 2023 and is expected to grow at a CAGR of 8.18%, reaching approximately
$38.27 billion by 2030.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These figures highlight the substantial market
opportunity for innovative treatments addressing chronic, age-related, and viral diseases. With increasing demand for therapies targeting
oxidative stress, cellular degeneration, and immune resilience, Telomir-1 is well-positioned to address these critical unmet medical
needs. Its broad therapeutic potential, spanning rare diseases, metabolic disorders, neurodegeneration, and viral infections, represents
a significant market opportunity across North America and beyond, reinforcing its potential as a transformative solution in modern medicine.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intellectual Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We license the U.S. patent rights for the use
of Telomir-1 in human applications from MIRALOGX, LLC (&#8220;MIRALOGX&#8221;), a related party intellectual property development and
holding company. &#160;MIRALOGX has filed a Patent Cooperation Treaty (PCT) application, PCT/US2023/073106 on August 29, 2023. The application
designated the U.S. and will enter U.S. national phase. The application, if granted and subject to payment of patent maintenance fees,
would offer protection extending through at least August 29, 2043 in the U.S. The patent rights for Telomir-1 outside of the United States
are not included in our current patent rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our license from MIRALOGX is set forth in an
Amended and Restated Exclusive License Agreement, dated August 11, 2023, between us and MIRALOGX, pursuant to which we obtained the exclusive
perpetual right and license under the above-described patent rights to make, have made, use, and sell &#8220;Licensed Products&#8221;
in the U.S. for human uses and pre-clinical studies and activities of any kind conducted in furtherance of obtaining regulatory approval
or commercialization for human uses (the &#8220;Initial MIRALOGX License Agreement&#8221;). On November 10, 2023, we and MIRALOGX entered
into the Amendment No. 1 to the Amended and Restated License Agreement, pursuant to which the field of use relating to the license was
amended to include therapeutic treatments and other medical or health uses in animals, in addition to humans, and related preclinical
studies and activities conducted in furtherance of obtaining regulatory approval for and commercialization of veterinary, in addition
to human, therapeutic treatments and uses (together with the &#8220;Initial MIRALOGX License Agreement, the &#8220;MIRALOGX License Agreement&#8221;).
&#8220;Licensed Product&#8221; is defined in the agreement as a drug product containing as an active agent 2,4,6-tris(3,4-dihydro-2H-pyrrol-2-yl)
pyridine or a pharmaceutically acceptable salt, ester, or solvate thereof. We also have the right to grant corresponding sublicenses
under the licensed patent rights. The MIRALOGX License Agreement provides for the payment to MIRALOGX of an 8% royalty (payable quarterly)
on our net sales of Licensed Products by us or our sublicensees and on non-royalty bearing milestone revenue. There are no up-front,
execution, or milestone payments in the license agreement. Further, no payments have been made to date under the agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Government Regulation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA and comparable regulatory authorities
in state and local jurisdictions impose substantial and burdensome requirements upon companies involved in the clinical development,
manufacture, marketing, and distribution of drugs. These agencies and other federal, state, and local entities regulate, among other
things, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping,
approval, advertising and promotion, distribution, post-approval monitoring and reporting, sampling and export and import of our drug
candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States, the FDA regulates drugs
under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The process of obtaining regulatory approvals
and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of
substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development
process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the
FDA&#8217;s refusal to approve pending New Drug Applications (NDAs), withdrawal of an approval, imposition of a clinical hold, issuance
of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines,
refusals of government contracts, restitution, disgorgement or civil or criminal penalties. The process required by the FDA before a
drug may be marketed in the United States generally involves the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="width: 0.25in; padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; width: 0.25in; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
    of pre-clinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#8217;s good laboratory practice
    (&#8220;GLP&#8221;) regulations; </span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="padding-bottom: 0pt; width: 0.25in">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an IND application, which must become effective before human clinical trials may begin;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
    by an independent Institutional Review Board (&#8220;IRB&#8221;), at each clinical site before each trial may be initiated;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="width: 0.25in; padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; width: 0.25in; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of adequate and well-controlled human clinical trials in accordance with good clinical practices (&#8220;GCP&#8221;) requirements
    to establish the safety and efficacy of the proposed drug product for each indication;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">demonstration
    that the API and finished product are manufactured under cGMP conditions and meet all applicable standards of identity, strength,
    quality, and purity;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an NDA;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA advisory committee review, if applicable;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance
    with cGMP requirements and to assure that the facilities, methods, and controls are adequate to preserve the drug&#8217;s identity,
    strength, quality, and purity;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    review and approval of the NDA, including consideration of the views of any FDA advisory committee, prior to commercial marketing
    or sale of the drug in the United States; and</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;)
    or to conduct a post-approval study.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Pre-clinical studies</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before testing any drug or biological product
candidate in humans, the product candidate must undergo rigorous pre-clinical testing. The pre-clinical developmental stage generally
involves laboratory evaluations of drug chemistry, formulation, and stability, as well as studies to evaluate toxicity in animals, to
assess the potential for adverse events (&#8220;AEs&#8221;) and, in some cases, to establish a rationale for therapeutic use. The conduct
of pre-clinical studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies.
An IND sponsor must submit the results of the pre-clinical studies, together with manufacturing information, analytical data, any available
clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An IND is a request for authorization from the
FDA to ship an investigation product and then administer it to humans and must be allowed to proceed by the FDA before human clinical
trials may begin. Some long-term pre-clinical testing, such as animal tests of reproductive AEs and carcinogenicity, may continue after
the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions
before that time related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor
and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result
in the FDA allowing clinical trials to commence.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Clinical trials</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The clinical stage of development involves the
administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, generally
physicians not employed by, or under control of, the trial sponsor, in accordance with GCPs, which include the requirement that all research
patients provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols
detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and
the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol,
must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution
at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized
and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each
clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. There also are requirements
governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Information about most
clinical trials must be submitted within specific timeframes for publication on the www.clinicaltrials.gov website. Information related
to the product, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is
made public as part of the registration of the clinical trial. Sponsors are also obligated to disclose the results of their clinical
trials after completion. Disclosure of the results of these trials can be delayed in some cases for up to two years after the date of
completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress of development
programs. Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="width: 0.25in; padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; width: 0.25in; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    I clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to
    a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism,
    pharmacologic action, side effect tolerability and safety of the drug.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="background-color: white">
    <td style="width: 0.25in; padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; width: 0.25in; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    II clinical trials involve studies in disease-affected patients to determine the dose required to produce the desired benefits. At
    the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety
    risks are identified, and a preliminary evaluation of efficacy is conducted.</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase III clinical trials
    generally involve a larger number of patients at multiple sites and are designed to provide the data necessary to demonstrate the
    effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the
    product and provide an adequate basis for product approval. These trials may include comparisons with placebo and/or other comparator
    treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Post-approval trials, sometimes referred to as
Phase IV clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from
the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow up. In certain instances,
the FDA may mandate the performance of Phase IV clinical trials as a condition of approval of an NDA or a Biologics License Application
(&#8220;BLA&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Progress reports detailing the results of the
clinical trials must be submitted at least annually to the FDA and more frequently if significant adverse events (&#8220;SAEs&#8221;)
occur. The FDA or the sponsor may suspend or terminate a clinical trial at any time, or the FDA may impose other sanctions on various
grounds, including a finding that the research patients are being exposed to an unacceptable health risk. Similarly, an IRB can refuse,
suspend, or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with
the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concurrently with clinical trials, companies
usually complete additional pre-clinical studies and must also develop additional information about the physical characteristics of the
drug or biological product as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP
requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among
other things, the sponsor must develop methods for testing the identity, strength, quality, potency, and purity of the final biological
product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that
the biological product candidate does not undergo unacceptable deterioration over its shelf life.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Marketing Approval</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assuming successful completion of the required
clinical testing, the results of the pre-clinical studies and clinical trials, together with detailed information relating to the product&#8217;s
chemistry, manufacture, controls, and proposed labeling, are submitted to the FDA as part of an NDA requesting approval to market the
product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The review process typically takes twelve months
from the date the NDA is submitted to the FDA. The FDA conducts a preliminary review of all NDAs within the first 60 days after submission
to determine whether they are sufficiently complete to permit substantive review before accepting them for &#8220;filing.&#8221; The
FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with
the additional information and may be subject to an additional application user fee. The resubmitted application is also subject to review
before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The
FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured,
processed, packaged, or held meets standards designed to assure the product&#8217;s continued safety, quality and purity. Under the current
guidelines in effect in the Prescription Drug User Fee Act (PDUFA), the FDA has a goal to review and act on the submission within ten
months from the completion of the preliminary review of a standard NDA for a new molecular entity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA also may require submission of a Risk
Evaluation and Mitigation Strategy (REMS) plan to ensure that the benefits of the drug outweigh its risks. The REMS plan could include
medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution
methods, patient registries, or other risk minimization tools.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA may refer to an application for a novel
drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts,
that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The
FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before approving an NDA, the FDA typically will
inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that
the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to ensure the consistent production
of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial
sites to assure compliance with GCP requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After evaluating the NDA and all related information,
including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial
sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains
a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical
trials or pre-clinical studies in order for FDA to reconsider the application. Even with submission of this additional information, the
FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have
been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing
of the drug with specific prescribing information for specific indications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Post-approval requirements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Drugs manufactured or distributed pursuant to
FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to
recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences
with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject
to prior FDA review and approval. There also are continuing annual user fee requirements for any marketed products and the establishments
at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Employees and Human Capital Resources</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 6, 2026, we have two part-time employees&#8212;the
CEO and CFO. At no time have our employees been represented by a labor union or covered by a collective bargaining agreement. We primarily
utilize contractors and outside consultants to support our operational and development activities include three full-time contractors
who support our executives and manage the day to day operations. We expect to continue to rely on a combination of internal personnel
and external service providers to support our development programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Competition </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The biotechnology and pharmaceutical industries are highly competitive
and characterized by rapid technological advancements, evolving regulatory requirements, and significant investment in research and development.
The Company faces competition from a variety of sources, including large pharmaceutical companies, biotechnology companies, specialty
pharmaceutical firms, academic institutions, and government-sponsored research organizations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Many of these organizations have substantially greater financial resources,
technical expertise, manufacturing capabilities, and commercialization infrastructure than the Company. In addition, many competitors
have significantly more experience in clinical development, regulatory approvals, and the commercialization of pharmaceutical products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Company&#8217;s investigational candidate, Telomir-1, is being
developed for conditions that may also be targeted by therapies currently approved or in development by other companies. These competing
approaches may include small molecules, biologics, gene therapies, and other therapeutic modalities designed to address similar disease
pathways.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Company believes that its approach targeting intracellular metal
homeostasis and related cellular pathways represents a differentiated scientific strategy; however, there can be no assurance that Telomir-1
will demonstrate clinical efficacy or safety or that it will be successfully developed or commercialized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Legal Proceedings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no material proceedings to which any
director or officer, or any associate of any such director or officer, is a party that is adverse to us or any of our subsidiaries or
has a material interest adverse to us or any of our subsidiaries. No director or executive officer has been a director or executive officer
of any business which has filed a bankruptcy petition or had a bankruptcy petition filed against it during the past ten years. No current
director or executive officer has been convicted of a criminal offense or is the subject of a pending criminal proceeding during the
past ten years. No current director or executive officer has been the subject of any order, judgment or decree of any court permanently
or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities
during the past ten years. No current director or officer has been found by a court to have violated a federal or state securities or
commodities law during the past ten years. From time to time, we may be named in claims arising in the ordinary course of business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We anticipate that we will expend significant
financial and managerial resources in the defense of our intellectual property rights in the future if we believe that our rights have
been violated. We also anticipate that we will expend significant financial and managerial resources to defend against claims that our
products and services infringe upon the intellectual property rights of third parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Corporation Information</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were organized as a Florida corporation in
August 2021 for the purpose of pursuing the development and commercialization of Telomir-1 in the United States in human applications.
We were originally incorporated under the name &#8220;Metallo Therapies Inc.&#8221; and changed our name to &#8220;Telomir Pharmaceuticals,
Inc.&#8221; in October 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our corporate headquarters is a virtual office
and our mailing address is 100 SE 2<sup>nd</sup> St., Suite 2000 #1009 Miami, Florida 33131. Our telephone number is (786) 396-6723.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our website address is www.telomirpharma.com.
The information contained on, or that can be accessed through, our website is deemed not to be incorporated in this Annual Report or
to be part of this Annual Report. You should not consider the information contained on our website to be part of this Annual Report</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_004"></span>ITEM 1A. Risk Factors </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>RISK FACTORS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Investing in shares of our common stock
is very speculative and involves a high degree of risk.</i></b><i> You should carefully consider the risks and uncertainties described
below, the section of this Annual Report entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results
of Operations&#8221; and our financial statements and related notes included elsewhere in this Annual Report. The risks and uncertainties
described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe
are not material, may also become important factors that affect us. If any of the following risks occur, our business, operating results
and prospects could be materially harmed. In that event, the price of our common stock could decline, and you could lose part or all
of your investment.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Intellectual Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We depend on rights to Telomir-1 that are
or will be licensed to us. We do not own the intellectual property rights to Telomir-1 and any loss of our rights to it could prevent
us from selling our product.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.85pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Within our present and future pipeline of treatments,
Telomir-1 is in-licensed from MIRALOGX. We do not currently own any intellectual property rights, including the patent application that
underlies this license. Our rights to use Telomir-1 is subject to the negotiation of, continuation of and compliance with the terms of
this license. Thus, the non-provisional patent application is not written by us or our attorneys, and we did not have control over the
drafting and prosecution. The patent owner and our licensor might not have given the same attention to the drafting and prosecution of
these patents and applications as we would have if we had been the owner of the patent application and had control over the drafting.
We cannot be certain that drafting of the licensed patent application, or patent prosecution, by the licensor have been or will be conducted
in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights.
This absence of control over the drafting, prosecution of patent and applications, along with non-compliance with royalty payments and
confidentiality breaches are just some of the ways that may result in the Company&#8217;s&#8217; loss of the license and inability to
continue operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant additional research and development
activity, pre-clinical testing, and/or clinical testing Telomir-1 is required before we will have a chance to achieve a viable product
for licensing or commercialization. Our business currently depends entirely on the successful development, regulatory approval, and licensing
or commercialization of our product candidate, which may never occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Enforcement of our licensed patent application
or defense of any claims asserting invalidity of these patents is often subject to the control or cooperation of our licensor. Legal
action could be initiated against the owners of the intellectual property that we license and an adverse outcome in such legal action
could harm our business because it might prevent such companies or institutions from continuing to license intellectual property that
we may need to operate our business. In addition, such licensor may resolve such litigation in a way that benefits it but adversely affects
our ability to have freedom to operate to develop and commercialize Telomir-1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to adequately protect
our product candidates or our proprietary technology in the marketplace.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our success will depend, in part, on our ability
to obtain patents, protect our trade secrets and operate without infringing on the proprietary rights of others. We may rely upon a combination
of patents, trade secret protection (i.e., know-how), trademarks, licenses, and confidentiality agreements to protect the intellectual
property of our product candidates. The strengths of patents in the pharmaceutical field involve complex legal and scientific questions
and can be uncertain. Where appropriate, we seek patent protection for certain aspects of our products and technology. However, patent
protection for naturally occurring compounds is exceedingly difficult to obtain, defend and enforce. Filing, prosecuting and defending
patents throughout the world would be prohibitively expensive, so our policy is to look to patent technologies with commercial potential
in jurisdictions with significant commercial opportunities. However, patent protection may not be available for some of the products
or technology we are developing. If we must spend significant time and money protecting, defending, or enforcing our patents, designing
around patents held by others or licensing, potentially for large fees, patents or other proprietary rights held by others, our business,
results of operations and financial condition may be harmed. We may not develop additional proprietary products that are patentable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The patent positions of pharmaceutical products
are complex and uncertain. Although we have sought and expect to continue to seek patent protection for our product candidates, their
methods of use, and methods of manufacture, any, or all of them may not be subject to effective patent protection. If any of our products
are approved and marketed for an indication for which we do not have an issued patent, our ability to use our patents to prevent a competitor
from commercializing a non-branded version of our commercial products for that non-patented indication could be significantly impaired
or even eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Publication of information related to our product
candidates by us, or others may prevent us from obtaining or enforcing patents relating to these products and product candidates. Furthermore,
others may independently develop similar products, may duplicate our products, or may design around our patent rights. In addition, any
of our issued patents may be opposed and/or declared invalid or unenforceable. If we fail to adequately protect our intellectual property,
we may face competition from companies who attempt to create a generic product to compete with our product candidates. We may also face
competition from companies who develop a substantially similar product to one of our product candidates that is not covered by any of
our patents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many companies have encountered significant problems
in protecting, defending and enforcing intellectual property rights in foreign jurisdictions. The legal systems of certain countries,
particularly certain developing countries, do not favor the enforcement of patents and other intellectual property rights, particularly
those relating to pharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing
products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result
in substantial cost and divert our efforts and attention from other aspects of our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, we do not own the rights to the intellectual
property and technology that will be used to commercially develop our initial product candidate, Telomir-1. MIRALOGX, which is a separate
intellectual property development company owned by a trust established by the Company&#8217;s founder, holds the patent rights to Telomir-1,
which are currently comprised of a pending non-provisional patent application. Pending the issuance of the non-provisional patent application,
we will have an exclusive, license from MIRALOGX to develop and commercialize Telomir-1 in the U.S. for human and non-human applications.
The term of the license will continue through the date of the expiration of the last-to-expire licensed patent or, if later, the date
of the expiration of the last strategic partnership/sublicensing agreement covering the licensed products. The licensed patent rights
are expected to extend through 2043. We expect additional patent terms may be awarded, including additional patent terms based on the
time for regulatory review of drug products. There are no up-front, execution, or milestone payments required under the license agreement.
Further, no payments have been made to date under the agreement. We are also required to pay an 8% royalty on net sales or revenue in
exchange for an exclusive, worldwide license to patent rights, and we may bring suit in our own name to enforce our patent rights under
the license agreement. In the event we are unable to enforce our rights under the agreement or are unable to detect unauthorized use
of our intellectual property, we may lose the benefit of the licensed rights used to commercially develop Telomir-1. MIRALOGX will control
the prosecution of the patent applications for Telomir-1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If third parties claim that our intellectual
property, products, processes, or anything else used by us infringes upon their intellectual property, our operating profits could be
adversely affected.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is a substantial amount of litigation,
both within and outside the U.S., involving patent and other intellectual property rights in the pharmaceutical industry. We may, from
time to time, be notified of claims that we are infringing upon patents, trademarks, copyrights, or other intellectual property rights
owned by third parties, and we cannot provide assurances that other companies will not, in the future, pursue such infringement claims
against us, our commercial partners or any third-party proprietary technologies we have licensed. If we were found to infringe upon a
patent or other intellectual property right, or if we failed to obtain or renew a license under a patent or other intellectual property
right from a third party, or if a third party that we were licensing technologies from was found to infringe upon a patent or other intellectual
property rights of another third party, we may be required to pay damages, including damages of up to three times the damages found or
assessed, if the infringement is found to be willful, suspend the manufacture of certain products or reengineer or rebrand our products,
if feasible, or we may be unable to enter certain new product markets. Any such claims could also be expensive and time consuming to
defend and divert management&#8217;s attention and resources. Our competitive position could suffer as a result. In addition, if we have
declined or failed to enter into a valid non-disclosure or assignment agreement for any reason, we may not own the invention or our intellectual
property, and our products may not be adequately protected. Thus, we cannot guarantee that our product candidates, or our commercialization
thereof, does not and will not infringe any third party&#8217;s intellectual property.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have been granted a license to the right
to develop Telomir-1 in the United States in human and pet application, but we have not been granted a license to the rights to patents
covering Telomir-1 in foreign jurisdictions.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have been granted a license to the right to
develop Telomir-1 in the United States but not in countries outside the United States, as MIRALOGX has retained all rights outside the
United States and may license such rights to other parties. Accordingly, MIRALOGX potentially could develop a competing product for such
jurisdictions outside of the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Operations and Financial
Condition</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are an early development-stage company
with no revenues.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As an early development-stage enterprise that
is focused on the development of a pre-clinical pharmaceutical product, we have generated no revenue and have an accumulated deficit
of $41.0 million and $30.6 million as of December 31, 2025 and December 31, 2024, respectively. There can be no assurance that sufficient
funds required to pursue our development program will be generated from operations or that funds will be available from external sources,
such as debt or equity financings or other potential sources. The lack of additional capital resulting from the inability to generate
cash flow from operations, or to raise capital from external sources would force us to substantially curtail or cease operations and
would, therefore, have a material adverse effect on business. Furthermore, there can be no assurance that any such required funds, if
available, will be available on attractive terms or that they will not have a significant dilutive effect on our existing stockholders.
It is for these reasons substantial doubt about our ability to continue as a going concern exists and an explanatory paragraph relating
to our ability to continue as a going concern can be found within the report of our independent registered public accounting firm on
our audited financial statements for the fiscal year ended December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We seek to overcome the circumstances that impact
our ability to remain a going concern in the future through the growth of revenues with interim cash flow deficiencies being addressed
through additional equity and debt financing. We anticipate raising additional funds through public or private financing, strategic relationships,
or other arrangements in the near future to support our business operations; however, we may not have commitments from third parties
for a sufficient amount of additional capital. We cannot be certain that any such financing will be available on acceptable terms, or
at all, and our failure to raise capital when needed could limit our ability to continue operations. Our ability to obtain additional
funding will determine our ability to continue as a going concern. Failure to secure additional financing in a timely manner and on favorable
terms would have a material adverse effect on our financial performance, results of operations and stock price and require us to curtail
or cease operations, sell off our assets, seek protection from our creditors through bankruptcy proceedings, or otherwise. Furthermore,
additional equity financing may be dilutive to the holders of our common stock, and debt financing, if available, may involve restrictive
covenants, and strategic relationships, if necessary, to raise additional funds, and may require that we relinquish valuable rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
we have a limited operating history, you may not be able to accurately evaluate our operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have had limited operations to date. Therefore,
we have a limited operating history upon which to evaluate the merits of investing in our company. Our stockholders should be aware of
the difficulties normally encountered by new companies and the high rate of failure of such enterprises. The likelihood of success must
be considered in light of the problems, expenses, difficulties, complications, and delays encountered in connection with the operations
that we plan to undertake. These potential problems include, but are not limited to, unanticipated problems relating to the ability to
generate sufficient cash flow to operate our business, and additional costs and expenses that may exceed current estimates. We expect
to continue to incur significant losses into the foreseeable future. We recognize that if the effectiveness of our business plan is not
forthcoming, we will not be able to continue business operations. There is no history upon which to base any assumption as to the likelihood
that we will prove successful, and it is doubtful that we will generate any operating revenues or ever achieve profitable operations.
If we are unsuccessful in addressing these risks, our business will most likely fail.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will need to raise additional financing
for the continuation of our operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because we have generated no revenues and currently
operate at a loss, we are completely dependent on the continued availability of financing in order to continue our business operations.
There can be no assurance that financing sufficient to enable us to continue our operations will be available to us in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will require additional capital to advance
our development activities and to achieve a sustainable level at which operations could be supported by revenues, if any. Based on our
current operating plan and available cash resources, we believe that our existing capital will be sufficient to fund operations and planned
initial clinical development activities into the first quarter of 2027. We will require additional financing to continue development
beyond that period and to fully implement our business strategy. There can be no assurance that additional financing will be available
when needed or, if available, on terms acceptable to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our failure to obtain future financing or to
produce levels of revenue to meet our financial needs could result in our inability to continue as a going concern and the failure of
our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our operating results may fluctuate, which
could have a negative impact on our ability to grow our client base, establish sustainable revenues and succeed overall.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our results of operations may fluctuate as a
result of a number of factors, some of which are beyond our control including but not limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="background-color: white">
    <td style="width: 0.25in; padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    economic conditions in the geographies and industries where we sell our services and conduct operations; legislative policies where
    we sell our services and conduct operations;</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    budgetary constraints of our customers; </span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">success
    of our strategic growth initiatives;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left; width: 0.25in">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    associated with the launching or integration of new or acquired businesses; timing of new product introductions by us, our suppliers
    and our competitors; product and service mix, availability, utilization and pricing;</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    mix, by state and country, of our revenues, personnel, and assets; movements in interest rates or tax rates;</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in, and application of, accounting rules; changes in the regulations applicable to us; and litigation matters.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>As a result of these factors, we may not
succeed in our business, and we could go out of business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have yet to achieve a profit and will
not achieve a profit in the near future, if at all.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not yet produced any revenues or profit
and will not in the near future, if at all. We cannot be certain that we will be able to realize sufficient revenue to achieve profitability.
Further, many of our competitors have a significantly larger industry presence and revenue stream but have yet to achieve profitability.
Our ability to continue as a going concern in the future is dependent upon raising capital from financing transactions, increasing revenue
and keeping operating expenses below our revenue levels in order to achieve positive cash flows, none of which can be assured.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Certain of our executive officers are not
employed by us on a full-time basis.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Erez Aminov, our Chief Executive Officer and
Chairman of our board of directors, is not employed by our company on a full-time basis. Mr. Aminov is the son-in-law of Jonnie R. Williams,
Sr., the founder of the Company. As intended to be provided in his employment agreement with our company, he works on a part-time and
as-needed basis. Because he does not work full time for our company, instances may occur where he may not be immediately available to
provide solutions to problems or address concerns that arise in the course of us conducting our business and thus adversely affect our
business. In addition, he can become subject to conflicts of interest because he devotes part of his working time to other business endeavors
and may have responsibilities to other entities. Although Mr. Aminov is aware of his duties and accountability to our company and to
applicable laws and policies relating to corporate opportunity and conflicts of interest, such conflicts of interest may include deciding
how much time to devote to our affairs, as well as what business opportunities should be presented to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alan Weichselbaum, our Chief Financial Officer,
is not employed by our company on a full-time basis. He works on a part-time and as-needed basis. Because he does not work full time
for our company, instances may occur where he may not be immediately available to provide solutions to problems or address concerns that
arise in the course of us conducting our business and thus adversely affect our business. In addition, he can become subject to conflicts
of interest because he devotes part of her working time to other business endeavors and may have responsibilities to other entities.
Although Mr. Weichselbaum is aware of his duties and accountability to our company and to applicable laws and policies relating to corporate
opportunity and conflicts of interest, such conflicts of interest may include deciding how much time to devote to our affairs, as well
as what business opportunities should be presented to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Conflicts of interest may arise between
us and MIRALOGX.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">MIRALOGX has a non-provisional patent application
to the rights to Telomir-1. MIRALOGX is a separate intellectual property development company owned by the Bay Shore Trust, which is an
irrevocable trust established by our founder, Jonnie R. Williams, Sr., and in which Brian McNulty is the trustee. The Bay Shore Trust
is also our largest stockholder. We have an exclusive license from MIRALOGX to develop and commercialize Telomir-1 in the U.S. for human
and non-human applications. Although the interests of MIRALOGX are 100% owned by the Bay Shore Trust, and Mr. Williams is not an officer
or director of MIRALOGX and Mr. Williams does not have voting or dispositive power over the shares of our company held by Bay Shore Trust,
our relationship with the Bay Shore Trust, Mr. Williams may create, or may create the appearance of, conflicts of interest when we are
faced with decisions that could have different implications for MIRALOGX than the decisions have for us. Furthermore, in light of the
license agreement that we have with MIRALOGX, if a dispute were to arise between MIRALOGX and us relating to our past or future relationship
with MIRALOGX or with respect to intellectual property matters, these potential conflicts of interest may make it more difficult for
us to favorably resolve such disputes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Relating to Our Business and Our Industry</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our future success will largely depend
on the success of Telomir-1 and any future product candidates, which development will require significant capital resources and years
of clinical development effort.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently have no drug products on the market,
and all of our drug development projects are in a pre-clinical stage of development. Our business depends almost entirely on the successful
pre-clinical and clinical development, FDA regulatory approval, and commercialization of our product candidates, principally Telomir-1.
Our stockholders need to be aware that substantial additional investments including pre-clinical and clinical development and FDA regulatory
submission and approval efforts will be required before we are permitted to undertake clinical studies and market and commercialize our
product candidates, if ever. It may be several years before we can commence clinical trials, if ever. Any clinical trial will be subject
to extensive and rigorous review and regulation by numerous government authorities in the United States and other jurisdictions where
we intend, if approved, to market our product candidates. Before obtaining regulatory approvals for any of our product candidates, we
must demonstrate through pre-clinical testing and clinical trials that the product candidate is safe and effective for its specific application.
This process can take many years and may include post- marketing studies and surveillance, which would require the expenditure of substantial
resources. Of the large number of drugs in development for approval in the United States (and the rest of the world), only a small percentage
will successfully complete the FDA regulatory approval financing to fund our planned research, development, and clinical programs, we
cannot assure you that any of our product candidates will be successfully developed or commercialized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may be unable to formulate or scale up any
or all of our product candidates. There is no guarantee that any of the product candidates will be or are able to be manufactured or
produced in a manner to meet the FDA&#8217;s criteria for product stability, content uniformity and all other criteria necessary for
product approval in the United States and other markets. Any of our product candidates may fail to achieve their specified endpoints
in clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, product candidates may not be approved
even if they achieve their specified endpoints in clinical trials. The FDA may disagree with our trial design and our interpretation
of data from clinical trials or may change the requirements for approval even after it has reviewed and commented on the design for our
clinical trials. The FDA may also approve a drug for fewer or more limited indications than we request or may grant approval contingent
on the performance of costly post-approval clinical trials (i.e., Phase IV trials). In addition, the FDA may not approve the labeling
claims that we believe are necessary or desirable for the successful commercialization of our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are unable to expand our pipeline and obtain
regulatory approval for our product candidates within the timelines we anticipate, we will not be able to execute our business strategy
effectively and our ability to substantially grow our revenues will be limited, which would have a material adverse impact on our long-term
business, results of operations, financial condition, and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are dependent on our current and future
product candidates, some of which may not receive regulatory approval or be successfully commercialized.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our ability to progress our plan will depend
on our ability to clinically develop, gain regulatory approval for and ultimately commercialize our product candidates. Our ability to
successfully commercialize our product candidates will depend on, among other things, our ability to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="background-color: white">
    <td style="width: 0.25in; padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complete
    pre-clinical and other nonclinical studies and clinical trials in a manner that allows us to progress our studies;</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">receive
    IND acceptance and regulatory approvals from the FDA;</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">produce,
    through a validated process, in manufacturing facilities inspected and approved by regulatory authorities, including the FDA, sufficiently
    large quantities of product candidates to permit successful commercialization;</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    reimbursement from payers such as government health care programs and insurance companies and achieve commercially attractive levels
    of pricing;</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">secure
    acceptance of our product candidates from physicians, health care payers, patients, and the medical community;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left; width: 0.25in">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">create
    positive publicity surrounding our product candidates;</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manage
    our spending as costs and expenses increase due to clinical trials and commercialization; and</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    and enforce sufficient intellectual property for our product candidates.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our failure or delay with respect to any of the
factors above could have a material adverse effect on our business, results of operations and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Results of pre-clinical studies and earlier
clinical trials are not necessarily predictive indicators of future results.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any positive results from future pre-clinical
testing of our product candidates and potential future clinical trials may not necessarily be predictive of the results from Phase I,
Phase II or Phase III clinical trials. In addition, our interpretation of results derived from clinical data or our conclusions based
on our pre-clinical data may prove inaccurate. Frequently, pharmaceutical and biotechnology companies have suffered significant setbacks
in clinical trials after achieving positive results in pre-clinical testing and early phase clinical trials, and we cannot be certain
that we will not face similar setbacks. These setbacks may be caused by the fact that pre-clinical and clinical data can be susceptible
to varying interpretations and analyses. Furthermore, certain product candidates may perform satisfactorily in pre-clinical studies and
clinical trials but nonetheless fail to obtain FDA approval or appropriate approvals by the appropriate regulatory authorities in other
countries. If we fail to produce positive results in our clinical trials for our product candidates, the development timeline and regulatory
approval and commercialization prospects for them and as a result our business and financial prospects, would be materially adversely
affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have limited marketing experience, and
we do not anticipate at this time establishing a sales force or distribution and reimbursement capabilities, and we may not be able to
successfully commercialize any of our product candidates if they are approved in the future.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our ability to generate revenues ultimately depends
on our ability to sell our approved products and secure adequate third-party reimbursement. We currently have limited experience in marketing
and selling our products. We currently do not have any products approved for sale in the United States or in any other country.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The commercial success of our product candidates
will not happen for the foreseeable future and will depend on a number of factors beyond our control, including the willingness of physicians
to prescribe our products to patients, payers&#8217; willingness and ability to pay for the drugs, the level of pricing achieved, patients&#8217;
response to our drugs and the ability of our marketing partners to generate sales. There can be no guarantee that we will be able to
establish or maintain the personnel, systems, arrangements and capabilities necessary to successfully commercialize Telomir-1 or any
product candidate approved by the FDA in the future. If we fail to establish or maintain successful marketing, sales and reimbursement
capabilities or fail to enter into successful marketing arrangements with third parties, our product revenues may suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will need to further increase the size
and complexity of our organization in the future, and we may experience difficulties in managing our growth and executing our growth
strategy.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management and personnel, systems, and facilities
currently in place may not be adequate to support our business plan and future growth. As a result, we may need to further expand certain
areas of our organization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our need to effectively manage our operations,
growth and various projects requires that we:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="background-color: white">
    <td style="width: 0.25in; padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
    to improve our operational, financial, management and regulatory compliance controls and reporting systems and procedures;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left; width: 0.25in">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract
    and retain enough talented employees;</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manage
    our clinical trials effectively;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="background-color: white">
    <td style="width: 0.25in; padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manage
    our external manufacturing operations with contract research organizations effectively and in a cost-effective manner;</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manage
    our development efforts effectively while carrying out our contractual obligations to contractors and other third parties; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we may utilize the services of part-time
outside consultants and contractors to perform several tasks for us, including tasks related to compliance programs, clinical trial management,
regulatory affairs, formulation development and other drug development functions. Our growth strategy may entail expanding our use of
consultants and contractors to implement these and other tasks going forward. If we are not able to effectively expand our organization
by hiring new employees and expanding our use of consultants and contractors, we may be unable to successfully implement the tasks necessary
to effectively execute on our planned research, development, manufacturing, and commercialization activities and, accordingly, may not
achieve our research, development and commercialization goals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We expect to face intense competition,
often from companies with greater resources and experience than we have.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The development and commercialization of drugs
and medicines is highly competitive. We compete with a variety of multinational pharmaceutical companies and specialized biotechnology
companies, as well as products and processes being developed by universities and other research institutions. Many of our competitors
have developed, are developing, or will develop drugs and processes which may be competitive with our drug candidates. Competitive products
include those that have already been approved by medicines regulators and accepted by the medical community and any new products that
may enter the market. For some of our drug development programs / areas of interest, other treatment options or products are currently
available, under development, and may become commercially available in the future. If any of our product candidates are approved for
the diseases and conditions we are currently pursuing, they may compete with a range of medicines or therapeutic treatments that are
either in development, will be developed in the future or currently marketed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Established companies may have a competitive
advantage over us due to their size and experiences, financial resources, and institutional networks. Many of our competitors may have
significantly greater financial, technical, and human resources than we do. Due to these factors, our competitors may have an advantage
in marketing their approved drugs and may obtain regulatory approval of their drug candidates before we are able to, which may limit
our ability to develop or commercialize our drug candidates. Our competitors may also develop drugs or medicines that are safer, more
effective, more widely used and less expensive than ours. These advantages could materially impact our ability to develop and, if approved,
commercialize our product candidates successfully. Furthermore, some of these competitors may make acquisitions or establish collaborative
relationships among themselves or with third parties to increase their ability to rapidly gain market share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Business interruptions could delay us in
the process of developing our product candidates and could disrupt our product sales.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our research and development activities are conducted
through outside contractors and manufacturers. Loss of our contracted manufacturing facilities, stored inventory or laboratory facilities
through fire, theft or other causes, or loss of our raw material, could have an adverse effect on our ability to continue product development
activities and to conduct our business. Failure to supply our partners with commercial product may lead to adverse consequences, including
the right of partners to take over responsibility for product supply. We currently do not have insurance coverage to compensate us for
such business interruptions. Our contract manufacturers and suppliers provide that in their separate operations; however, such coverage
may prove insufficient to fully compensate us for the damage to our business resulting from any significant property or casualty loss
to those facilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have significant and increasing liquidity
needs and may require additional funding.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our operations have consumed substantial amounts
of cash since inception. For the year ended December 31, 2025, we reported a net operating cash outflow of $3.7 million and a net cash
inflow from financing activities of $9.7 million. For the year ended December 31, 2024, we reported a net operating cash outflow of $5.1
million and a net cash inflow from financing activities of $6.3 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development, and general and administrative
expenses, and cash used for operations will continue to be significant and may increase substantially in the future in connection with
new research and development initiatives and continued product commercialization efforts. We may need to raise additional capital to
fund our operations, continue to conduct clinical trials to support potential regulatory approval of marketing applications and to fund
commercialization of our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amount and timing of our future funding requirements
will depend on many factors, including, but not limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="width: 0.25in; padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; width: 0.25in; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing of FDA approval, if any, and approvals in international markets of our product candidates, if at all; </span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and amount of revenue from sales of our products, or revenue from grants or other sources;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    rate of progress and cost of our clinical trials and other product development programs; </span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of establishing or outsourcing sales, marketing, and distribution capabilities; </span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    and timing of completion of expanded in-house manufacturing facilities as well as any outsourced commercial manufacturing supply
    arrangements for our product candidates; </span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of filing, prosecuting, defending, and enforcing any patent claims and other intellectual property rights associated with our product
    candidates; </span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effect of competing technological and market developments; </span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">personnel,
    facilities, and equipment requirements; and </span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    terms and timing of any additional collaborative, licensing, co-promotion, or other arrangements that we may establish.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While we expect to fund our future capital requirements
from several sources including existing cash balances, future cash flows from operations and the proceeds from equity offerings, we cannot
assure you that any of these funding sources will be available to us on favorable terms, or at all. Further, even if we can raise funds
from all of the above sources, the amounts raised may not be sufficient to meet our future capital requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Operating results may vary significantly
in future periods.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our expenses and operating results have fluctuated
in the past and our revenues, expenses, and operating results are likely to fluctuate significantly in the future. Our financial results
are unpredictable and may fluctuate, for among other reasons, due to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="background-color: white">
    <td style="width: 0.25in; padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; width: 0.25in; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">commercial
    sales of our products;</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    achievement of product development objectives and milestones;</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    trial enrollment and expenses;</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">research
    and development expenses; and</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and nature of contract manufacturing and contract research payments.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
high portion of our costs are predetermined on an annual basis, due in part to our significant research and development costs. Thus,
small declines in revenue could disproportionately affect financial results in a quarter. Because of these factors, our financial results
in one or more future quarters may fail to meet the expectations of securities analysts or our stockholders, which could cause our share
price to decline.</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We depend upon our key personnel and our
ability to attract and retain employees.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our future growth and success depend on our ability
to recruit, retain, manage, and motivate our employees. The inability to hire or retain experienced management personnel could adversely
affect our ability to execute our business plan and harm our operating results. Due to the specialized scientific and managerial nature
of our business, we rely heavily on our ability to attract and retain qualified scientific, technical, and managerial personnel. The
competition for qualified personnel in the pharmaceutical field is intense. Due to this intense competition, we may be unable to continue
to attract and retain the qualified personnel necessary for the development of our business or to recruit suitable replacement personnel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our proprietary information, or that of
our customers, suppliers, and business partners, may be lost or we may suffer security breaches.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the ordinary course of our business, we will
collect and store sensitive data, including valuable and commercially sensitive intellectual property, clinical trial data, our proprietary
business information and that of our customers, suppliers and business partners, and personally identifiable information of our customers,
clinical trial subjects and employees, and patients, on our networks, and with our third-party cloud service providers. The secure processing,
maintenance and transmission of this information is critical to our operations. Despite our security measures, our information technology
and infrastructure, and that of our third parties, may be vulnerable to attacks by hackers or breached due to employee error, malfeasance,
or other disruptions. Any breach could compromise our networks and the information stored there could be accessed, publicly disclosed,
lost, or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under
laws that protect the privacy of personal information, regulatory penalties, disrupt our operations, damage our reputation, and cause
a loss of confidence in our products and our ability to conduct clinical trials, which could adversely affect our business and reputation
and lead to delays in gaining regulatory approvals for Telomir-1 or other product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure of our information technology systems,
including cybersecurity attacks or other data security incidents, could significantly disrupt the operation of our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business is increasingly dependent on critical,
complex, and interdependent information technology (&#8220;IT&#8221;) systems, including internet-based systems, some of which are managed
or hosted by third parties, to support business processes as well as internal and external communications. The size and complexity of
our IT systems make us potentially vulnerable to IT system breakdowns, malicious intrusion, and computer viruses, which may result in
the impairment of our ability to operate our business effectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are continuously evaluating and, where appropriate,
enhancing our IT systems to address our planned growth, including to support our planned manufacturing operations. There are inherent
costs and risks associated with implementing the enhancements to our IT systems, including potential delays in access to, or errors in,
critical business and financial information, substantial capital expenditures, additional administrative time and operating expenses,
retention of sufficiently skilled personnel to implement and operate the enhanced systems, demands on management time, and costs of delays
or difficulties in transitioning to the enhanced systems, any of which could harm our business and results of operations. In addition,
the implementation of enhancements to our IT systems may not result in productivity improvements to a level that outweighs the costs
of implementation, or at all. In addition, our systems and the systems of our third-party providers and collaborators are potentially
vulnerable to data security breaches which may expose sensitive data to unauthorized persons or to the public. Such data security breaches
could lead to the loss of confidential information, trade secrets or other intellectual property, could lead to the public exposure of
personal information (including personally identifiable information or individually identifiable health information) of our employees,
clinical trial patients, customers, business partners, and others, could lead to potential identity theft, or could lead to reputational
harm. Data security breaches could also result in loss of clinical trial data or damage to the integrity of that data. In addition, the
increased use of social media by our employees and contractors could result in inadvertent disclosure of sensitive data or personal information,
including but not limited to, confidential information, trade secrets and other intellectual property.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
such disruption or security breach, as well as any action by us or our employees or contractors that might be inconsistent with the rapidly
evolving data privacy and security laws and regulations applicable within the United States and elsewhere where we conduct business,
could result in enforcement actions by U.S. states, the U.S. federal government or foreign governments, liability or sanctions under
data privacy laws, including healthcare laws such as HIPAA, that protect certain types of sensitive information, regulatory penalties,
other legal proceedings such as but not limited to private litigation, the incurrence of significant remediation costs, disruptions to
our development programs, business operations and collaborations, diversion of management efforts and damage to our reputation, which
could harm our business and operations. Because of the rapidly moving nature of technology and the increasing sophistication of cybersecurity
threats, our measures to prevent, respond to and minimize such risks may be unsuccessful.</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Security breaches, loss of data and other
disruptions could compromise sensitive information related to our business, prevent us from accessing critical information or expose
us to liability, which could adversely affect our business and our reputation.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the ordinary course of our business, we, our
vendors, and our third-party cloud service providers may collect and store sensitive data, including legally protected patient health
information, credit card information, personally identifiable information about our employees and patients, intellectual property, and
proprietary business information. We manage and maintain our applications and data utilizing cloud-based and on-site systems. These applications
and data encompass a wide variety of business-critical information including research and development information, commercial information
and business and financial information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The secure processing, storage, maintenance,
and transmission of this critical information is vital to our operations and business strategy, and we devote significant resources to
protecting such information. Although we take measures to protect sensitive information from unauthorized access or disclosure, our information
technology and infrastructure may be vulnerable to attacks by hackers, or viruses, breaches, or interruptions due to employee error,
malfeasance or other disruptions, or lapses in compliance with privacy and security mandates. Any such virus, breach or interruption
could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or
stolen. We have measures in place that are designed to prevent, and if necessary to detect and respond to such security incidents, breaches
of privacy, and security mandates. However, in the future, any such access, disclosure or other loss of information could result in legal
claims or proceedings, liability under laws that protect the privacy of personal information, such as HIPAA in the United States and
the General Data Protection Regulation in the European Union, or GDPR, government enforcement actions and regulatory penalties. Unauthorized
access, loss or dissemination could also disrupt our operations, including our ability to process samples, provide test results, share
and monitor safety data, bill payers or patients, provide customer support services, conduct research and development activities, process
and prepare company financial information, manage various general and administrative aspects of our business and may damage our reputation,
any of which could adversely affect our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Geopolitical events and global economic
conditions, such as the Israel-Hamas war may impact the third parties that we engage to supply materials or manufacture any products
for our preclinical tests and clinical trials, which increases the risk of potential delay of development efforts, as applicable.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the third parties that we engage to supply
any materials or manufacture any products for our preclinical tests and clinical trials should cease to continue to do so for any reason,
including due to the effects of global economic conditions, including the Hamas-Israel war, we likely would experience delays in advancing
these tests and trials while we identify and qualify replacement suppliers or manufacturers, as applicable, and we may be unable to obtain
replacement supplies on terms that are favorable to us. In addition, if we are not able to obtain adequate supplies of our product, or
the substances used to manufacture them, it will be more difficult for us to develop our product and compete effectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current and anticipated dependence upon third-party suppliers may adversely affect our ability to develop our product, and product candidates
and could delay our clinical trials and development programs as well as affect our marketing and commercialization efforts. In addition,
such dependence may increase our costs and expenses, and may otherwise harm our operations and financial condition</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Development and Regulatory
Approval of Our Product Candidates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Clinical trials for our product candidates
are expensive, time-consuming, uncertain, and susceptible to change, delay or termination. The results of clinical trials are open to
differing interpretations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical trials are expensive, time consuming
and difficult to design and implement. Regulatory agencies may analyze or interpret the results differently than us. Even if the results
of our clinical trials are favorable, the clinical trials for a number of our product candidates are expected to continue for several
years and may take significantly longer to complete. In addition, we, the FDA, or other regulatory authorities, including state and local
authorities, or an Institutional Review Board, or IRB, with respect to a trial at its institution, may suspend, delay or terminate our
clinical trials at any time, require us to conduct additional clinical trials, require a particular clinical trial to continue for a
longer duration than originally planned, require a change to our development plans such that we conduct clinical trials for a product
candidate in a different order, e.g., in a step-wise fashion rather than running two trials of the same product candidate in parallel.
The suspension, delay or termination could be for various reasons, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="background-color: white">
    <td style="width: 0.25in; padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; width: 0.25in; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack
    of effectiveness of any product candidate during clinical trials;</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discovery
    of serious or unexpected toxicities or side effects experienced by trial participants or other safety issues, such as drug interactions,
    including those which cause confounding changes to the levels of other concomitant medications;</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">slower
    than expected rates of subject recruitment and enrollment rates in clinical trials;</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    in retaining subjects who have initiated a clinical trial but may withdraw at any time due to adverse side effects from the therapy,
    insufficient efficacy, fatigue with the clinical trial process or for any other reason;</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or inability in manufacturing or obtaining sufficient quantities of materials for use in clinical trials due to regulatory and manufacturing
    constraints;</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inadequacy
    of or changes in our manufacturing process or product formulation;</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in obtaining regulatory authorization to commence a trial, including &#8220;clinical holds&#8221; or delays requiring suspension
    or termination of a trial by a regulatory agency, such as the FDA, before or after a trial is commenced;</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in applicable regulatory policies and regulation, including changes to requirements imposed on the extent, nature, or timing of studies;</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or failure in reaching agreement on acceptable terms in clinical trial contracts or protocols with prospective clinical trial sites;</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">uncertainty
    regarding proper dosing;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left; width: 0.25in">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    or failure to supply product for use in clinical trials which conforms to regulatory specification;</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable
    results from ongoing pre-clinical studies and clinical trials;</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of our contract research organizations, or CROs, or other third-party contractors to comply with all contractual requirements or
    to perform their services in a timely or acceptable manner;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="background-color: white">
    <td style="width: 0.25in; padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    by us, our employees, our CROs or their employees to comply with all applicable FDA or other regulatory requirements relating to
    the conduct of clinical trials or the handling, storage, security, and recordkeeping;</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">scheduling
    conflicts with participating clinicians and clinical institutions;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="background-color: white">
    <td style="width: 0.25in; padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to design appropriate clinical trial protocols;</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">insufficient
    data to support regulatory approval;</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    or unwillingness of medical investigators to follow our clinical protocols; or</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    in maintaining contact with patients during or after treatment, which may result in incomplete data.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any of the foregoing could have a material adverse
effect on our business, results of operations and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Any failure by us to comply with existing
regulations could harm our reputation and operating results.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to extensive regulation by U.S.
federal and state governments in each of the markets where we have product candidates progressing through the approval process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We must also adhere to all regulatory requirements
including FDA&#8217;s Good Laboratory Practice, Good Clinical Practice, and current Good Manufacturing Practices requirements (&#8220;cGMP&#8221;)
pharmacovigilance requirements, advertising, and promotion restrictions, reporting and recordkeeping requirements. If we or our suppliers
fail to comply with applicable regulations, including FDA pre-or post-approval cGMP requirements, then FDA could sanction us. Even if
a drug is FDA-approved, regulatory authorities may impose significant restrictions on a product&#8217;s indicated uses or marketing or
impose ongoing requirements for potentially costly post-marketing trials. Telomir-1, and any of our product candidates that may be approved
in the U.S. in the future, will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, distribution,
import, export, advertising, promotion, sampling, recordkeeping and submission of safety and other post-market information, including
both federal and state requirements in the U.S. In addition, manufacturers and manufacturers&#8217; facilities are required to comply
with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to GMP. As such, we, and
our contract manufacturers (in the event contract manufacturers are appointed in the future) are subject to continual review and periodic
inspections to assess compliance with GMP. Accordingly, we and others with whom we work must continue to spend time, money, and effort
in all areas of regulatory compliance, including manufacturing, production, quality control and quality assurance. We will also be required
to report certain adverse reactions and production problems, if any, to the FDA, and to comply with requirements concerning advertising
and promotion for our products. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory
restrictions and must be consistent with the information in the product&#8217;s approved label.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a regulatory agency discovers previously unknown
problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product
is manufactured, or disagrees with the promotion, marketing or labeling of the product, it may impose restrictions on that product or
us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory
agency or enforcement authority may:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="width: 0.25in; padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue
    untitled or warning letters;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    to enjoin our activities;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impose
    civil or criminal penalties;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    regulatory approval;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    any of our ongoing clinical trials;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to approve pending applications or supplements to approved applications submitted by us;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impose
    restrictions on our operations, including by requiring us to enter into a Corporate Integrity Agreement or closing our contract manufacturers&#8217;
    facilities, if any; or</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seize
    or detain products or require a product recall.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, any government investigation of alleged violations of law could require us to expend significant time and resources in response
and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect
our ability to commercialize and generate revenue from our product candidates. If regulatory sanctions are applied or if regulatory approval
is withdrawn, the value of our business and our operating results may be adversely affected.</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any action against us for violation of these
laws, even if we successfully defend against it, could cause us to incur significant legal expenses, divert our management&#8217;s attention
from the operation of our business and damage our reputation. We expend significant resources on compliance efforts and such expenses
are unpredictable and might adversely affect our results. Changing laws, regulations and standards might also create uncertainty, higher
expenses and increase insurance costs. As a result, we intend to invest all reasonably necessary resources to comply with evolving standards,
and this investment might result in increased management and administrative expenses and a diversion of management time and attention
from revenue-generating activities to compliance activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The regulatory approval processes with
the FDA are lengthy and inherently unpredictable.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are not permitted to market our drug candidates
as medicines in the United States or other countries until we receive approval of a New Drug Application (&#8220;NDA&#8221;) from the
FDA or in any foreign countries until we receive the approval from the regulatory authorities of such countries. Prior to submitting
an NDA to the FDA for approval of our drug candidates we will need to have completed our pre-clinical studies and clinical trials and
demonstrate that our products meet all applicable standards of identity, strength, quality, and purity throughout their expiration date.
Successfully completing any clinical program and obtaining approval of an NDA is a complex, lengthy, expensive, and uncertain process,
and the FDA (or other country medicines regulatory body) may delay, limit, or deny approval of product candidates for many reasons, including,
among others, because:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="width: 0.25in; padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    inability to demonstrate that our product candidates are safe and effective in treating patients to the satisfaction of the FDA;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">results
    of clinical trials that may not meet the level of statistical or clinical significance required by the FDA;</span></td></tr>

<tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
<tr>
    <td style="width: 0.25in; padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; width: 0.25in; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disagreements
    with the FDA with respect to the number, design, size, conduct or implementation of clinical trials;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
    by the FDA to conduct additional clinical trials;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disapproval
    by the FDA of certain formulations, labeling or specifications of product candidates;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">findings
    by the FDA that the data from pre-clinical studies and clinical trials are insufficient;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">findings
    by the FDA that our API or finished products do not meet all applicable standards of identity, strength, quality, and purity;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may disagree with the interpretation of data from pre-clinical studies and clinical trials; and</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may change their approval policies or adopt new regulations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these factors, many of which are beyond our control, could increase development time and / or costs or jeopardize our ability to obtain
regulatory approval for our drug candidates.</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>There is a high rate of failure for drug candidates proceeding
through clinical trials.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Generally, there is a high rate of failure for
drug candidates proceeding through clinical trials. We may suffer significant setbacks in our clinical trials similar to the experience
of a number of other companies in the pharmaceutical and biotechnology industries, even after receiving promising results in earlier
trials. Further, even if we view the results of a clinical trial to be positive, FDA may disagree with our interpretation of the data.
In the event that we obtain negative results from clinical trials for product candidates or other problems related to potential chemistry,
manufacturing and control issues or other hurdles occur and our product candidates are not approved, we may not be able to generate sufficient
revenue or obtain financing to continue our operations, our ability to execute on our current business plan may be materially impaired,
our reputation in the industry and in the investment community might be significantly damaged and the price of our common stock could
decrease significantly. In addition, our inability to properly design, commence and complete clinical trials may negatively impact the
timing and results of our clinical trials and ability to seek approvals for our drug candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are found in violation of federal
or state &#8220;fraud and abuse&#8221; laws, we may be required to pay a penalty and/or be suspended from participation in federal or
state health care programs, which may adversely affect our business, financial condition, and results of operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States, we are subject to various
federal and state health care &#8220;fraud and abuse&#8221; laws, including anti-kickback laws, false claims laws and other laws intended
to reduce fraud and abuse in federal and state health care programs, which could affect us particularly upon successful commercialization
of our products in the U.S. The Medicare and Medicaid Patient Protection Act of 1987, or federal Anti-Kickback Statute, makes it illegal
for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive,
offer or pay any remuneration that is intended to induce the referral of business, including the purchase, order or prescription of a
particular drug for which payment may be made under a federal health care program, such as Medicare or Medicaid. Under federal law, some
arrangements, known as safe harbors, are deemed not to violate the federal Anti-Kickback Statute. Although we seek to structure our business
arrangements in compliance with all applicable requirements, it is often difficult to determine precisely how the law will be applied
in specific circumstances. Accordingly, it is possible that our practices may be challenged under the federal Anti-Kickback Statute and
Federal False Claims Act. Violations of fraud and abuse laws may be punishable by criminal and/or civil sanctions, including fines and/or
exclusion or suspension from federal and state health care programs such as Medicare and Medicaid and debarment from contracting with
the U.S. government. In addition, private individuals have the ability to bring actions on behalf of the government under the federal
False Claims Act as well as under the false claims laws of several states.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many states have adopted laws similar to the
federal anti-kickback statute, some of which apply to the referral of patients for health care services reimbursed by any source, not
just governmental payers. There are ambiguities as to what is required to comply with these state requirements and if we fail to comply
with an applicable state law requirement, we could be subject to penalties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither the government nor the courts have provided
definitive guidance on the application of fraud and abuse laws to our business. Law enforcement authorities are increasingly focused
on enforcing these laws, and it is possible that some of our practices may be challenged under these laws. While we believe we have structured
our business arrangements to comply with these laws, it is possible that the government could allege violations of, or convict us of
violating, these laws. If we are found in violation of one of these laws, we could be required to pay a penalty and could be suspended
or excluded from participation in federal or state health care programs, and our business, results of operations and financial condition
may be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Serious adverse events or other safety
risks could require us to abandon development and preclude, delay or limit approval of our product candidates, limit the scope of any
approved label or market acceptance, or cause the recall or loss of marketing approval of products that are already marketed.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of our product candidates prior to or
after any approval for commercial sale, cause serious or unexpected side effects, or are associated with other safety risks such as misuse,
abuse or diversion, a number of potentially significant negative consequences could result, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="width: 0.25in; padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may interrupt, delay or halt clinical trials;</span></td></tr>

<tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
<tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may deny regulatory approval of our product candidates;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>

<tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may require certain labeling statements, such as warnings or contraindications or limitations on the indications for
    use, and/or impose restrictions on distribution in the form of a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) in
    connection with approval or post-approval;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may withdraw their approval, require more onerous labeling statements, impose a more restrictive REMS, or require us
    to recall any product that is approved;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to change the way the product is administered or conduct additional clinical trials;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="padding-bottom: 0pt; text-align: justify; width: 0.25in">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left; width: 0.25in">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    relationships with our collaboration partners may suffer;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    could be sued and held liable for harm caused to patients; or</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reputation may suffer. The reputational risk is heightened with respect to those of our product candidates that are being developed
    for pediatric indications.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may voluntarily suspend or terminate our clinical
trials if at any time we believe that they present an unacceptable risk to participants or if preliminary data demonstrate that our product
candidates are unlikely to receive regulatory approval or unlikely to be successfully commercialized. Following receipt of approval for
commercial sale of a product we may voluntarily withdraw or recall that product from the market if at any time we believe that its use,
or a person&#8217;s exposure to it, may cause adverse health consequences or death. To date we have not withdrawn, recalled, or taken
any other action, voluntary or mandatory, to remove an approved product from the market. In addition, regulatory agencies, IRBs, or data
safety monitoring boards may at any time recommend the temporary or permanent discontinuation of our clinical trials or request that
we cease using investigators in the clinical trials if they believe that the clinical trials are not being conducted in accordance with
applicable regulatory requirements, or that they present an unacceptable safety risk to participants. Although we have never been asked
by a regulatory agency, IRB, or data safety monitoring board to discontinue a clinical trial temporarily or permanently, if we elect
or are forced to suspend or terminate a clinical trial of any of our product candidates, the commercial prospects for that product will
be harmed and our ability to generate product revenue from that product may be delayed or eliminated. Furthermore, any of these events
may result in labeling statements such as warnings or contraindications. In addition, such events or labeling could prevent us or our
partners from achieving or maintaining market acceptance of the affected product and could substantially increase the costs of commercializing
our product candidates and impair our ability to generate revenue from the commercialization of these products either by us or by our
collaboration partners.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Reliance Upon Third Parties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We rely on, and expect to continue to rely
on, third parties to conduct clinical trials for our product candidates. If these third parties do not successfully carry out their contractual
duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing approval for or commercialize
our product candidates, and our business could be substantially harmed.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are dependent on third parties to conduct our clinical trials and preclinical and nonclinical studies. Specifically, we rely on, and
intend to continue to rely on, medical institutions, clinical investigators, contract research organizations, or CROs, and consultants
to conduct nonclinical studies and clinical trials, in each case in accordance with our study protocols and applicable regulatory requirements.
These CROs, investigators and other third parties play a significant role in the conduct and timing of these studies or trials and the
subsequent collection and analysis of data. Though we expect to carefully manage our relationships with our CROs, investigators and other
third parties, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges
will not have a material adverse impact on our business, financial condition and prospects. Further, while we have and will have agreements
governing the activities of our third-party contractors, we have limited influence over their actual performance. Nevertheless, we are
responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol and legal, regulatory
and scientific standards and requirements, and our reliance on our CROs and other third parties does not relieve us of our regulatory
responsibilities. In addition, we and our CROs are required to comply with GLP and GCP requirements, as applicable, which are regulations
and guidelines enforced by the FDA and comparable foreign regulatory authorities related to the conduct of nonclinical studies and clinical
trials, respectively. Regulatory authorities enforce GCPs through periodic inspections of trial sponsors, principal investigators and
trial sites. If we or any of our CROs or trial sites fail to comply with applicable GLP or GCP or other requirements, the collected nonclinical
data or the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities
may require us to perform additional nonclinical studies or clinical trials before approving our marketing applications, if ever. Furthermore,
our clinical trials must be conducted with materials manufactured in accordance with cGMP regulations. Failure to comply with these regulations
may require us to repeat clinical trials, which would delay the regulatory approval process.</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is a risk that our CROs, investigators
or other third parties will be unable to devote adequate time and resources to such trials or studies or perform as contractually required.
If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, or otherwise
perform in a substandard manner, our clinical trials may be extended, delayed or terminated. In addition, many of the third parties with
whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting
clinical trials or other development activities that could harm our competitive position. In addition, principal investigators for our
clinical trials are expected to serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation
in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest,
or the FDA concludes that the financial relationship may have affected the interpretation of the study, the integrity of the data generated
at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could
result in the delay or rejection by the FDA of any NDA we submit. Any such delay or rejection could prevent us from receiving regulatory
approval for, or commercializing, Telomir-1 and any future product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our CROs have the right to terminate their agreements
with us in the event of an uncured material breach and under other specified circumstances. If any of our relationships with these third
parties terminate, we may not be able to enter into arrangements with alternative third parties on commercially reasonable terms, in
a timely manner or at all. Switching or adding CROs, investigators and other third parties involves additional cost and requires our
management&#8217;s time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays
occur, which can materially impact our ability to meet our desired clinical development timelines. Though we work to carefully manage
our relationships with our CROs, investigators and other third parties, there can be no assurance that we will not encounter challenges
or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition
and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We currently rely on a third party for
the manufacture of Telomir-1 for clinical development and expect to continue to rely on third parties for the foreseeable future. This
reliance on third parties increases the risk that supplies of our product may not be manufactured in accordance with specifications or
that we will not have sufficient quantities of Telomir-1 or such quantities at an acceptable cost, which could delay, prevent or impair
our development or potential commercialization efforts.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not own or operate manufacturing facilities
and have no plans to develop our own clinical or commercial-scale manufacturing capabilities. We rely on a third party and expect to
continue to rely on third parties for the manufacture of Telomir-1 and related raw materials for clinical development, as well as for
commercial manufacture if Telomir-1 receives marketing approval. There is a risk that supplies of our product for use in pre-clinical
or clinical testing will not be manufactured in accordance with our specifications, which could render our trial data useless or lead
to the creation of compounds which are novel and for which we do not have intellectual property protection. Based on the terms of our
contracts with our manufacturers, we may have no recourse against them in the case of such errors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the facilities used by third-party manufacturers to manufacture Telomir-1 must be approved by the FDA and any comparable foreign regulatory
authority pursuant to inspections that will be conducted after we submit an NDA to the FDA or make any comparable submission to a foreign
regulatory authority. We do not control the manufacturing process of, and are completely dependent on, third-party manufacturers for
compliance with cGMP requirements for manufacture of products. If these third-party manufacturers cannot successfully manufacture material
that conforms to our specifications and the strict regulatory requirements of the FDA or any comparable foreign regulatory authority,
they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities.</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we have no control over the ability
of third-party manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or any comparable
foreign regulatory authority does not approve these facilities for the manufacture of Telomir-1 or if it withdraws any such approval
in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain
regulatory approval for or market Telomir-1, if approved. Our failure, or the failure of our third-party manufacturers, to comply with
applicable regulations also could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties,
delays, suspension or withdrawal of approvals, seizures or recalls of Telomir-1 or other future products, operating restrictions and
criminal prosecutions, any of which could significantly and adversely affect supplies of our products and our financial position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our or a third party&#8217;s failure to execute
on our manufacturing requirements on commercially reasonable terms, in a timely manner and in compliance with cGMP or other regulatory
requirements could adversely affect our business in a number of ways, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="width: 0.25in; padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; width: 0.25in; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    inability to initiate or complete clinical trials of Telomir-1 or any future product candidates in a timely manner;</span></td></tr>

<tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
<tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    in submitting regulatory applications, or receiving marketing approvals, for Telomir-1 or any future product candidates;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>

<tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subjecting
    third-party manufacturing facilities or our potential future manufacturing facilities to additional inspections by regulatory authorities;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>

<tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
    to cease development or to recall batches of Telomir-1 or any future product candidates; and</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>

<tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the event of approval to market and commercialize Telomir-1 or any future product candidates, an inability to meet commercial demands
    for Telomir-1 or any future product candidates.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we do not have any long-term commitments
or supply agreements with any third-party manufacturers. We may be unable to establish any long-term supply agreements with third-party
manufacturers or to do so on acceptable terms, which increases the risk of failing to timely obtain sufficient quantities of Telomir-1
or such quantities at an acceptable cost. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party
manufacturers entails additional risks, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="width: 0.25in; padding-bottom: 0pt">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of third-party manufacturers to comply with regulatory requirements and maintain quality assurance;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>

<tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">breach
    of the manufacturing agreement by the third party;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>

<tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to manufacture our product candidates according to our specifications;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>

<tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to obtain adequate raw materials and other materials required for manufacturing;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>

<tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to manufacture our product according to our schedule or at all;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>

<tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to successfully scale up manufacturing capacity, if required;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>

<tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">misappropriation
    of our proprietary information, including any potential trade secrets and know-how; and</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>

<tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">termination
    or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any performance failure on the part of our existing
or future manufacturers could delay clinical development or marketing approval or jeopardize our ability to commence or continue commercialization
of Telomir-1 or any future product candidates, and any related remedial measures may be costly or time consuming to implement. We do
not currently have arrangements in place for redundant supply or a second source for all required raw materials used in the manufacture
of our product candidates. If our existing or future third-party manufacturers cannot perform as agreed, we may be required to replace
such manufacturers and we may be unable to replace them on a timely basis or at all. Without additional suppliers of required raw materials,
we may also be unable to meet the commercial needs of a commercial launch of any future product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, our current and anticipated future
dependence upon others for the manufacture of Telomir-1 and any future product candidates may adversely affect our future profit margins
and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our existing collaboration arrangements
and any that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize
our product candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have existing, and will likely continue to
seek additional collaboration arrangements with pharmaceutical or biotechnology companies for the manufacturing, testing, development
or commercialization of our product candidates. We may, with respect to our product candidates, enter into new arrangements on a selective
basis depending on the merits of retaining commercialization rights for ourselves as compared to entering into selective collaboration
arrangements with leading pharmaceutical or biotechnology companies for each product candidate, both in the U.S. and internationally.
To the extent that we decide to enter into collaboration agreements, we will face significant competition in seeking appropriate collaborators
and the terms of any collaboration or other arrangements that we may establish may not be favorable to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
existing or future collaboration entered into may not allow us to achieve our goals for such collaboration on a timely basis or at all.
Our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant
discretion in determining the efforts and resources that they will apply to these collaborations. Disagreements between parties to a
collaboration arrangement regarding development, intellectual property, regulatory or commercialization matters can lead to delays in
the development process or commercialization of the applicable product candidate and, in some cases, termination of the collaboration
arrangement. These disagreements can be difficult to resolve if neither of the parties has final decision-making authority. Any such
termination or expiration could harm our business reputation and may adversely affect us financially.</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Relating to the Ownership of Our Common
Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Future sales of our common stock, or the
perception that future sales may occur, may cause the market price of our common stock to decline, even if our business is doing well.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales of substantial amounts of our common stock
in the public market after our IPO, or the perception that these sales may occur, could materially and adversely affect the price of
our common stock and could impair our ability to raise capital through the sale of additional equity securities. Those shares of common
stock sold in our IPO will be freely tradable, without restriction, in the public market, except for any shares sold to our affiliates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, additional shares of our common
stock may be publicly tradable as a result of exercises of stock options and restricted stock units (RSUs) under the 2023 Omnibus Incentive
Plan. Sales of substantial amounts of our common stock in the public market after the completion of the IPO, or the perception that such
sales could occur, could adversely affect the market price of our common stock and could materially impair our ability to raise capital
through offerings of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Because of the speculative nature of an
investment in our company, you may lose your entire investment.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An investment in our securities carries a high
degree of risk and should be considered as a speculative investment. We have a very limited operating history, are in the pre-clinical
stage of development of our product candidate, have never generated revenues, have not paid dividends, and are unlikely to pay dividends
in the immediate or near future. The likelihood of our being able to achieve our goals and run our business must be considered in light
of the problems, expenses, difficulties, complications and delays frequently encountered in connection with the establishment of early-stage
biotechnology companies. An investment in our securities may result in the loss of the entirety of such investment. Only stockholders
and potential stockholders who are experienced in high-risk investments and who can afford to lose their entire investment should consider
an investment in our securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Certain of our
founding stockholders, plus our existing officers and directors, control a substantial interest in us and thus may influence certain
actions requiring stockholder vote.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our founding stockholders,
which include five trusts for the benefit of the family of our founder Johnnie R. Williams, Sr., as well as MIRALOGX, collectively own
of our issued and outstanding common stock. Brian McNulty acts as the trustee for such trusts. Our officers and directors also own shares
of our common stock. Therefore, these entities and individuals could influence the outcome of matters requiring stockholder approval,
including the election of directors and approval of significant corporate transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sales of a significant number of shares
of our common stock in the public markets, or the perception that such sales could occur, could depress the market price of our common
stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur as a result
of our utilization of a universal shelf registration statement or otherwise could depress the market price of our common stock and impair
our ability to raise capital through the sale of additional equity securities. Notably, a large number of shares of our common stock
held by founding stockholders of our company have been registered for public resale and could be sold on the public market, depressing
our stock price. Moreover, we cannot in general predict the effect that future sales of our common stock or the market perception that
we are permitted to sell a significant number of our securities would have on the market price of our common stock.</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The requirements of being a public company
may strain our resources, divert management&#8217;s attention and affect our ability to attract and retain executive management and qualified
board members.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a reporting issuer, we are subject to the
reporting requirements of applicable securities legislation of the jurisdiction in which it is a reporting issuer, the listing requirements
of Nasdaq and other applicable securities rules and regulations. Compliance with these rules and regulations will increase our legal
and financial compliance costs, make some activities more difficult, time-consuming or costly and increase demand on its systems and
resources. Applicable securities laws will require us to, among other things, file certain annual and quarterly reports with respect
to its business and results of operations. In addition, applicable securities laws require us to, among other things, maintain effective
disclosure controls and procedures and internal control over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to maintain and, if required, improve
its disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and
management oversight are required. Specifically, due to the increasing complexity of its transactions, it is anticipated that we will
improve our disclosure controls and procedures and internal control over financial reporting primarily through the continued development
and implementation of formal policies, improved processes and documentation procedures, as well as the continued sourcing of additional
finance resources. As a result, management&#8217;s attention may be diverted from other business concerns, which could harm our business
and results of operations. To comply with these requirements, we may need to hire more employees in the future or engage outside consultants,
which will increase costs and expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, changing laws, regulations and standards
relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial
compliance costs and making some activities more time consuming. These laws, regulations and standards are subject to varying interpretations,
in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance
is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs
necessitated by ongoing revisions to disclosure and governance practices. We intend to continue to invest resources to comply with evolving
laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s
time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and
standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice,
regulatory authorities may initiate legal proceedings against us, which could adversely affect our business and financial results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a public company subject to these rules and
regulations, we may find it more expensive for it to obtain director and officer liability insurance, and it may be required to accept
reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract
and retain qualified members of our board of directors, particularly to serve on its Audit Committee and Compensation Committee, and
qualified executive officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of disclosure of information in filings required of a public company, our business and financial condition will become more
visible, which may result in threatened or actual litigation, including by competitors and other third parties. If such claims are successful,
our business and results of operations could be harmed, and even if the claims do not result in litigation or are resolved in its favor,
these claims, and the time and resources necessary to resolve them, could divert the resources of our management and harm its business
and results of operations.</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are an &#8220;emerging growth company&#8221;
and any decision on our part to comply only with certain reduced reporting and disclosure requirements applicable to emerging growth
companies could make shares of our common stock less attractive to investors.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an &#8220;emerging growth company,&#8221;
as defined in Section 2(a) of the Securities Act. For as long as we continue to be an emerging growth company, we may choose to take
advantage of exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies,
including, but not limited to, not being required to have our independent registered public accounting firm audit our internal control
over financial reporting under Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation
in our periodic reports and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder
approval of any golden parachute payments not previously approved. We could be an emerging growth company until the fifth anniversary
of the fiscal year end date following the completion of our initial public offering, however, our status would change more quickly if
we have more than US$1.235 billion in annual revenue, if the market value of our shares of common stock held by non-affiliates equals
or exceeds US$700 million as of June 30 of any year, or we issue more than US$1.0 billion of non-convertible debt over a three-year period
before the end of that period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investors could find our shares less attractive
if we choose to rely on these exemptions. If some investors find shares less attractive as a result of any choice to reduce future disclosure,
there may be a less active trading market for our shares and our share price may be more volatile.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For as long as we are an &#8220;emerging growth
company&#8221;, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal
controls over financial reporting pursuant to Section 404. We could be an &#8220;emerging growth company&#8221; until the fifth anniversary
of the fiscal year end date following our initial public offering, which became effective on February 9, 2024. An independent assessment
of the effectiveness of our internal controls could detect problems that our management&#8217;s assessment might not. Undetected material
weaknesses in our internal controls could lead to financial statement restatements and require us to incur the expense of remediation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we identify material weaknesses in our internal
control over financial reporting, or if we are unable to comply with the requirements of Section 404 in a timely manner or assert that
our internal control over financial reporting is effective, or if our independent registered public accounting firm is unable to express
an opinion as to the effectiveness of our internal control over financial reporting when required, investors may lose confidence in the
accuracy and completeness of our financial reports and the market price of our securities could be negatively affected, and we could
become subject to investigations by the stock exchange on which our securities are listed, the SEC, or other regulatory authorities,
which could require additional financial and management resources.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are a &#8220;smaller reporting company&#8221;
and, even if we no longer qualify as an emerging growth company, we may still be subject to reduced reporting requirements.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, we are a &#8220;smaller reporting
company&#8221; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure
obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting
company until the last day of any fiscal year for so long as either: (i) the market value of our shares of common stock held by non-affiliates
does not equal or exceed $250 million as of the prior June 30th; or (ii) our annual revenues did not equal or exceed $100 million during
such completed fiscal year. To the extent we take advantage of such reduced disclosure obligations, it may also make the comparison of
our financial statements with other public companies difficult or impossible.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to maintain compliance with
Nasdaq Listing Rules, our shares may be delisted from Nasdaq, which would result in a limited trading market for our shares and make
obtaining future debt or equity financing more difficult for the Company.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is listed on the Nasdaq Capital
Market under the symbol &#8220;TELO&#8221;. However, there is no assurance that we will be able to continue to maintain our compliance
with the Nasdaq continued listing requirements. If we fail to do so, our securities may be de-listed and cease trading on Nasdaq. As
a result, selling our securities could be more difficult because smaller quantities of shares or warrants would likely be bought and
sold, transactions could be delayed, and security analysts&#8217; coverage of us may be reduced. In addition, in the event our securities
are delisted, broker-dealers would face certain regulatory requirements which may discourage them from effecting transactions in the
securities and further limit the liquidity of the securities. These factors could result in lower prices and larger spreads in the bid
and ask prices for the securities. Such delisting from Nasdaq and continued or further declines in the share price of the securities
could also greatly impair our ability to raise additional necessary capital through equity or debt financing and could significantly
increase the ownership dilution to shareholders caused by our issuing equity in financing or other transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If our shares were to be delisted from
Nasdaq, they may become subject to the SEC&#8217;s &#8220;penny stock&#8221; rules.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Delisting from Nasdaq may cause the securities
of the Company to become subject to the SEC&#8217;s &#8220;penny stock&#8221; rules. The SEC generally defines a penny stock as an equity
security that has a market price of less than $5.00 per share or an exercise price of less than $5.00 per share, and that is not listed
on a national securities exchange, such as Nasdaq subject to certain exemptions. Therefore, if shares of our common stock were to be
delisted from Nasdaq, the securities of the Company could become subject to the SEC&#8217;s &#8220;penny stock&#8221; rules. These rules
require, among other things, that any broker engaging in a purchase or sale of our securities provide its customers with: (i) a risk
disclosure document, (ii) disclosure of market quotations, if any, (iii) disclosure of the compensation of the broker and its salespersons
in the transaction, and (iv) monthly account statements showing the market values of our securities held in the customer&#8217;s accounts.
A broker would be required to provide the bid and offer quotations and compensation information before effecting the transaction. This
information must be contained in the customer&#8217;s confirmation. Generally, brokers are less willing to affect transactions in penny
stocks due to these additional delivery requirements. These requirements may make it more difficult for shareholders to purchase or sell
the shares of our common stock. Since the broker, not us, prepares this information, we would not be able to assure that such information
is accurate, complete or current.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Some provisions
of Florida law and our amended and restated articles of incorporation and amended and restated bylaws may have anti-takeover effects
that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our shareholders and may prevent
attempts by our shareholders to replace or remove our current management.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our status as a Florida
corporation and the anti-takeover provisions of the Florida Business Corporation Act, which we sometimes refer to as the FBCA, may discourage,
delay or prevent a change in control even if a change in control would be beneficial to our shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The control share acquisition statute, Section
607.0902 of the FBCA, generally provides that in the event a person acquires voting shares of the company in excess of 20% of the voting
power of all of our issued and outstanding shares, such acquired shares will not have any voting rights unless such rights are restored
by the holders of a majority of the votes of each class or series entitled to vote separately, excluding shares held by the person acquiring
the control shares or any of our officers or employees who are also directors of the company. Certain acquisitions of shares are exempt
from these rules, such as shares acquired pursuant to the laws of intestate succession or pursuant to a gift or testamentary transfer,
pursuant to a merger or share exchange effected in compliance with the FBCA if we are a party to the agreement, or pursuant to an acquisition
of our shares if the acquisition has been approved by our board of directors before the acquisition. The control share acquisition statute
generally applies to any &#8220;issuing public corporation,&#8221; which means a Florida corporation which has:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; background-color: white; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="width: 0.25in; padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; width: 0.25in; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
    hundred or more shareholders;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Its
    principal place of business, its principal office, or substantial assets within Florida; and</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
    (i) more than 10% of its shareholders are resident in Florida; (ii) more than 10% of its shares are owned by residents of Florida;
    or (iii) one thousand shareholders are resident in Florida.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The affiliated transaction (or so-called &#8220;business
combination&#8221;) statute, Section 607.0901 of the FBCA, provides that we may not engage in certain mergers, consolidations, sales
of assets, issuances of stock, reclassifications, recapitalizations, and other affiliated transactions with any &#8220;interested shareholder&#8221;
for a period of three years following the time that such shareholder became an interested shareholder, unless:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; background-color: white; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="width: 0.25in; padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; width: 0.25in; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
    to the time that such shareholder became an interested shareholder, our board of directors approved either the affiliated transaction
    or the transaction which resulted in the shareholder becoming an interested shareholder; or</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
    consummation of the transaction that resulted in the shareholder becoming an interested shareholder, the interested shareholder owned
    at least 85% of our voting shares outstanding at the time the transaction commenced; or</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    or subsequent to the time that such shareholder became an interested shareholder, the affiliated transaction is approved by our board
    of directors and authorized at an annual or special meeting of shareholders, and not by written consent, by the affirmative vote
    of at least two-thirds of the outstanding voting shares which are not owned by the interested shareholder.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An &#8220;interested shareholder&#8221; is generally
defined as any person who is the beneficial owner of more than 15% of our outstanding voting shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The voting requirements set forth above do not
apply to a particular affiliated transaction if one or more conditions are met, including, but not limited to, the following: if the
affiliated transaction has been approved by a majority of our disinterested directors; if we have not had more than 300 shareholders
of record at any time during the three years preceding the date the affiliated transaction is announced; if the interested shareholder
has been the beneficial owner of at least 80% of our outstanding voting shares for at least three years preceding the date the affiliated
transaction is announced; or if the consideration to be paid to the holders of each class or series of voting shares in the affiliated
transaction meets certain requirements of the statute with respect to form and amount, among other things.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Both the control share acquisition statute and
the affiliated transactions statute may have the effect of discouraging or preventing certain change of control or takeover transactions
involving us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, our amended and restated articles
of incorporation and amended and restated bylaws contain provisions that may make it more difficult for a third party to acquire us or
increase the cost of acquiring us, even if doing so would benefit our shareholders, including transactions in which shareholders might
otherwise receive a premium for their shares. These provisions include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; background-color: white; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="width: 0.25in; padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; width: 0.25in; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">nothing
    in our amended and restated articles of incorporation precludes future issuances without shareholder approval of the authorized but
    unissued shares of our common stock;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advance
    notice procedures apply for shareholders to nominate candidates for election as directors or to bring matters before an annual meeting
    of shareholders;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    special meeting of shareholders can only be called by our chairman of the board of directors, our chief executive officer, our president
    (in the absence of a chief executive officer), a majority of our board of directors or the holders of 10% or more of all of our votes
    entitled to be cast on any issue proposed to be considered at the special meeting of shareholders;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    provision in our amended and restated articles of incorporation or amended and restated bylaws provides for cumulative voting, which
    limits the ability of minority shareholders to elect director candidates; directors will only be able to be removed for cause;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; background-color: white; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="padding-bottom: 0pt; width: 0.25in">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    amended and restated articles of incorporation authorize undesignated preferred stock, the terms of which may be established and
    shares of which may be issued, without the approval of the holders of our capital stock; and</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
    litigation against us can only be brought in Florida.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These provisions could discourage, delay or prevent
a transaction involving a change in control of our company. These provisions could also discourage proxy contests and make it more difficult
for you and other shareholders to elect directors of your choosing and cause us to take corporate actions other than those you desire.
See &#8220;Description of Capital Stock.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Our amended and
restated bylaws designate the state courts located within the state of Florida as the exclusive forum for substantially all disputes
between us and our shareholders and the federal district courts as the exclusive forum for Securities Act claims, which could limit our
shareholders&#8217; ability to obtain a favorable judicial forum for disputes with us.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our amended and restated bylaws provide that,
unless we consent in writing to the selection of an alternative forum, the sole and exclusive forum for (i) any derivative action or
proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our current or former
directors, officers or other employees to us or our shareholders, (iii) any action arising pursuant to any provision of the FBCA, our
amended and restated articles of incorporation or our amended and restated bylaws, or (iv) any other action asserting a claim that is
governed by the internal affairs doctrine shall be a state court located within the state of Florida (or, if a state court located within
the state of Florida does not have jurisdiction, the federal district court for the Middle District of Florida); provided that, the exclusive
forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act, or to any claim for which
the federal courts have exclusive jurisdiction. Our amended and restated bylaws also provide that, unless we consent in writing to the
selection of an alternative forum, the U.S. federal district courts shall be the exclusive forum for the resolution of any claims arising
under the Securities Act. Under the Securities Act, federal and state courts have concurrent jurisdiction over all suits brought to enforce
any duty or liability created by the Securities Act, and our stockholders cannot waive compliance with the federal securities laws and
the rules and regulations thereunder. Accordingly, there is uncertainty as to whether a court would enforce such a forum selection provision
as written in connection with claims arising under the Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">By becoming a shareholder in our company, you
will be deemed to have notice of and have consented to the provisions of our amended and restated bylaws related to choice of forum.
The choice of forum provisions in our amended and restated bylaws may limit our shareholders&#8217; ability to obtain a favorable judicial
forum for disputes with us. Additionally, the enforceability of choice of forum provisions in other companies&#8217; governing documents
has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court
could find the choice of forum provisions contained in our amended and restated bylaws to be inapplicable or unenforceable in such action.
If so, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results
of operations, and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Securities or industry analysts may not
regularly publish reports on us, which could cause the price of our securities or trading volumes to decline.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The trading market for our securities could be
influenced by research and reports that industry and/or securities analysts may publish about us, our business, the market or our competitors.
We do not have any control over these analysts and cannot be assured that such analysts will cover us or provide favorable coverage.
If any of the analysts who may cover our business change their recommendation regarding our securities adversely, or provide more favorable
relative recommendations about our competitors, the price of our securities would likely decline. If any analysts who may cover our business
were to cease coverage or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could
cause the price of our securities or trading volumes to decline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will likely conduct further offerings
of our equity securities in the future, in which case your proportionate interest may become diluted.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will likely be required to conduct equity offerings in the future to finance our current projects or to finance subsequent projects that
we decide to undertake. If our common stock shares are issued in return for additional funds, the price per share could be lower than
that paid by our current shareholders. We anticipate continuing to rely on equity sales of our common stock shares in order to fund our
business operations. If we issue additional common stock shares or securities convertible into shares of our common stock, your percentage
interest in us could become diluted.</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may issue shares of preferred stock
in the future, which could make it difficult for another company to acquire us or could otherwise adversely affect holders of our common
stock, which could depress the price of our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our certificate of incorporation authorizes us
to issue one or more series of preferred stock. Our board of directors will have the authority to determine the preferences, limitations
and relative rights of the shares of preferred stock and to fix the number of shares constituting any series and the designation of such
series, without any further vote or action by our shareholders. Our preferred stock could be issued with voting, liquidation, dividend
and other rights superior to the rights of our common stock. The potential issuance of preferred stock may delay or prevent a change
in control of us, discouraging bids for our common stock at a premium to the market price, and materially adversely affect the market
price and the voting and other rights of the holders of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have never declared or paid any cash
dividends or distributions on our capital stock. We do not anticipate paying any cash dividends on our common stock in the foreseeable
future.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never declared or paid any cash dividends
or distributions on our capital stock. We currently intend to retain our future earnings, if any, to support operations and to finance
expansion and therefore we do not anticipate paying any cash dividends on our common stock in the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The declaration, payment and amount of any future
dividends will be made at the discretion of the board of directors, and will depend upon, among other things, the results of our operations,
cash flows and financial condition, operating and capital requirements, and other factors as the board of directors considers relevant.
There is no assurance that future dividends will be paid, and, if dividends are paid, there is no assurance with respect to the amount
of any such dividend.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to the planned merger with TELI</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Because TELI has a limited operating history,
you may not be able to accurately evaluate TELI&#8217;s operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TELI has had no operations to date, and therefore,
TELI has a limited operating history upon which to evaluate the merits of investing in TELI. Potential investors should be aware of the
difficulties normally encountered by new companies and the high rate of failure of such enterprises. The likelihood of success must be
considered in light of the problems, expenses, difficulties, complications, and delays encountered in connection with the operations
that TELI plans to undertake. These potential problems include, but are not limited to, unanticipated problems relating to the ability
to generate sufficient cash flow to operate TELI&#8217;s business, and additional costs and expenses that may exceed current estimates.
TELI expects to continue to incur significant losses into the foreseeable future. TELI recognizes that if the effectiveness of its business
plan is not forthcoming, it will not be able to continue business operations. There is no history upon which to base any assumption as
to the likelihood that TELI will prove successful, and it is doubtful that TELI will generate any operating revenues or ever achieve
profitable operations. If TELI is unsuccessful in addressing these risks, TELI&#8217;s business will most likely fail.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>TELI is an early development-stage company
with no revenues.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a very early development-stage enterprise
that is focused on the development of a pre-clinical pharmaceutical product, TELI has generated no revenue to date. There can be no assurance
that TELI will be successful in obtaining sufficient funding on terms acceptable to it to fund continuing operations, if at all, identify
and enter into any strategic transactions that will provide the capital that TELI will require or achieve the other strategies to alleviate
the conditions that raise substantial doubt about TELI&#8217;s ability to continue as a going concern. The failure to obtain sufficient
capital on acceptable terms when needed may require TELI to delay, limit, or eliminate the development of business opportunities and
TELI&#8217;s ability to achieve its business objectives. Any of such failures will materially adversely affect TELI&#8217;s competitiveness,
and TELI&#8217;s business, financial condition, and results of operations. In addition, the perception that TELI may not be able to continue
as a going concern may cause others to choose not to deal with it due to concerns about TELI&#8217;s ability to meet TELI&#8217;s contractual
obligations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>TELI has significant and increasing liquidity
needs and will require additional funding.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development, general and administrative
expenses and cash used for operations will continue to be significant and may increase substantially in the future in connection with
new research and development initiatives and continued product commercialization efforts. Following the Merger, the combined company
will need to raise additional capital to fund its operations, continue clinical trials to support potential regulatory approval of marketing
applications and to fund commercialization of its products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Operating results may vary significantly
in future periods.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the Merger, the combined company&#8217;s
operating and financial results are likely to fluctuate significantly in the future. TELI&#8217;s operating and financial results are
unpredictable and may fluctuate, for among other reasons, due to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">TELI&#8217;s
                                            achievement of product development objectives and milestones;</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">clinical
                                            trial enrollment and expenses;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">research
                                            and development expenses; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            timing and nature of contract manufacturing and contract research payments.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, a high portion of TELI&#8217;s costs
are determined on an annual basis, due in part to TELI&#8217;s significant research and development costs. Thus, increases in TELI&#8217;s
costs could disproportionately affect financial results in a quarter. Other factors, including non-cash expenses associated with financing
activity, could also lead to fluctuations in TELI&#8217;s results of operations. Because of these factors, TELI&#8217;s operating and
financial results in one or more future quarters may fail to meet the expectations of securities analysts or investors, which could cause
TELO&#8217;s share price to decline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>TELI has yet to generate revenues or achieve
a profit and may not generate revenue or achieve a profit for many years, if at all.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TELI has not yet produced any revenues or profit
and may not for many years, if at all. TELI&#8217;s ability to generate revenue is dependent on the receipt of regulatory approval of
TELI&#8217;s product candidates, which will take years to achieve and may not be obtained. We therefore cannot assure you TELI will be
able to ever generate sufficient revenue to pay for TELI&#8217;s expenses or achieve profitability. TELI&#8217;s ability to continue
as a going concern in the future is dependent upon raising capital from financing transactions and keeping operating expenses below TELI&#8217;s
revenue levels in order to achieve positive cash flows, none of which can be assured.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>TELI does not own rights to Telomir-1</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of TELI&#8217;s rights in Telomir-1 are granted
to it under a license (&#8220;License&#8221;) from MIRALOGX LLC, a Florida corporation (&#8220;Licensor&#8221;), so TELI does not have
an ownership interest in Telomir-1. The License gives TELI the right to make, use and sell Telomir-1 outside the United States. If TELI breaches the License or if the Licensor goes
bankrupt, TELI could lose its rights to Telomir-1 and all of such rights would revert back to the Licensor. Further, Licensor will control
the process of applying for and obtaining any patents or other intellectual property rights in Telomir-1, all at the expense of TELI.
All of such patents and intellectual rights will be owned by Licensor, subject to TELI&#8217;s rights under the License. Furthermore,
TELI has no control over the patent prosecution strategy, which is fully managed by the Licensor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>TELI&#8217;s rights to Telomir-1 are subject
to royalties.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TELI entered into an exclusive licensing agreement
with MIRALOGX for the licensing by MIRALOGX to TELI the international commercial rights of Telomir-1 (the &#8220;Telomir-1 Licensing
Agreement&#8221;) in the United States, Mexico and Canada. Under the Telomir-1 Licensing Agreement TELI will owe MIRALOGX a royalty of
8% on all revenue it receives from Telomir-1, with a minimum annual royalty of $250,000 that begins in the first year that there is any
revenue from Telomir-1. This $250,000 will be owed even if in any later year there is no revenue from Telomir-1 or if the 8% royalty
rate on actual revenues yields less than $250,000. TELI&#8217;s failure to pay minimum royalties in any year would be a breach of the
Telomir-1 Licensing Agreement and such breach would let the Licensor terminate TELI&#8217;s rights to Telomir-1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Conflicts of interest may arise between
TELI and MIRALOGX.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">MIRALOGX is the licensor of TELI&#8217;s rights
to Telomir-1. MIRALOGX is a separate intellectual property development company owned by the Bayshore Trust. The Bayshore Trust is also
TELI&#8217;s largest stockholder. MIRALOGX is 100% owned by the Bayshore Trust. TELI&#8217;s relationship with MIRALOGX and the Bayshore
Trust may create, or may create the appearance of, conflicts of interest when TELI is faced with decisions that benefit MIRALOGX but
do not benefit other holders of TELO Common Stock. Furthermore, in light of the license agreement that TELI has with MIRALOGX, if a dispute
were to arise between MIRALOGX and TELO relating to TELI&#8217;s past or future relationship with MIRALOGX or with respect to intellectual
property matters, there could be a conflict of interest that may make it more difficult for TELI to resolve such disputes on terms that
are acceptable to TELI.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>TELI&#8217;s product candidates, if approved,
may not achieve the expected market acceptance and, consequently, limit TELI&#8217;s ability to generate revenue.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even when product development is successful and
regulatory approval has been obtained, TELI&#8217;s ability to generate sufficient revenue depends on the acceptance of its products
by physicians and patients. There is no assurance that TELI&#8217;s product candidates will achieve the expected level of market acceptance
and revenue if and when they obtain the requisite regulatory approvals. The market acceptance of any product depends on a number of factors,
including the indication statement and warnings required by regulatory authorities in the product label. Market acceptance can also be
influenced by continued demonstrations of efficacy and safety in commercial use, physicians&#8217; willingness to prescribe the product,
reimbursement from third-party payers such as government health care programs and private third-party payers, the price of the product,
the nature of any post-approval risk management activities mandated by regulatory authorities, competition, and marketing and distribution
support. Further, an ineffective or inefficient distribution model at launch may lead to the inability to fulfill demand, and consequently
a loss of revenue. Any factors preventing or limiting the market acceptance of TELI&#8217;s products could have a material adverse effect
on TELI&#8217;s business, results of operations and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If the price for any future approved products
decreases or if government and other third-party payers do not provide coverage and adequate reimbursement levels, TELI&#8217;s revenue
and prospects for profitability will suffer.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patients who are prescribed medicine for the
treatment of their conditions generally rely on third-party payers to reimburse all or part of the costs associated with their prescription
drugs. Reimbursement systems in international markets vary significantly by country and by region, and reimbursement approvals generally
must be obtained on a country-by-country basis. Coverage and adequate reimbursement from governmental healthcare programs, such as Medicare
and Medicaid, and commercial payers is critical to new product acceptance. Coverage decisions may depend upon clinical and economic standards
that disfavor new drug products when more established or lower-cost therapeutic alternatives are already available or subsequently become
available. Even if TELI obtains coverage for products TELI may market, the resulting reimbursement payment rates may require co-payments
that patients find unacceptably high. Patients may not use TELI&#8217;s products if coverage is not provided, or reimbursement is inadequate
to cover a significant portion of their cost.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the market for TELI&#8217;s products
will depend significantly on access to third-party payers&#8217; drug formularies or lists of medications for which third-party payers
provide coverage and reimbursement. The industry competition to be included in such formularies often leads to downward pricing pressures
on pharmaceutical companies. Also, third-party payers may refuse to include a particular branded drug in their formularies or otherwise
restrict patient access to a branded drug when a less costly generic equivalent or other alternative is available, even if not approved
for the indications for which TELI&#8217;s products are approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Third-party payers or governmental or commercial
entities are developing increasingly sophisticated methods of controlling healthcare costs. The current environment is putting pressure
on companies to price products below what they may feel is appropriate. Selling TELI&#8217;s products at less than an optimized price
could impact its revenues and overall success as a company. It will be difficult to determine the optimized price for TELI&#8217;s products.
In addition, in the U.S., no uniform policy of coverage and reimbursement for drug products exists among third-party payers. Therefore,
coverage and reimbursement for its products may differ significantly from payer to payer. As a result, the coverage determination process
is often a time-consuming and costly process that will require TELI to provide scientific and clinical support for the use of its products
to each payer separately, with no assurance that coverage will be obtained. If TELI is unable to obtain coverage of, and adequate payment
levels for, products we may market to third-party payers, physicians may limit how much or under what circumstances they will prescribe
or administer them, and patients may decline to purchase them. This in turn could affect TELI&#8217;s ability to successfully commercialize
products we may market, and thereby adversely impact TELI&#8217;s profitability, results of operations, financial condition, and future
success.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, where TELI has chosen to collaborate
with a third party on product candidate development and commercialization, TELI&#8217;s partner may elect to reduce the price of its
products in order to increase the likelihood of obtaining reimbursement approvals. In many countries, products cannot be commercially
launched until reimbursement is approved and the negotiation process in some countries can exceed 12 months. In addition, pricing and
reimbursement decisions in certain countries can be affected by decisions taken in other countries, which can lead to mandatory price
reductions and/or additional reimbursement restrictions across a number of other countries, which may thereby adversely affect TELI&#8217;s
sales and profitability. In the event that countries impose prices that are not sufficient to allow TELI or its partners to generate
a profit, TELI&#8217;s partners may refuse to launch the product in such countries or withdraw the product from the market, which would
adversely affect sales and profitability. Events, such as price decreases, government mandated rebates or unfavorable reimbursement decisions,
could affect the pricing and reimbursement of TELI&#8217;s products and its other product candidates and could have a material adverse
effect on TELI&#8217;s business, reputation, results of operations and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>TELI expects to face intense competition,
often from companies with greater resources and experience.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Demand for TELI&#8217;s product candidates will
likely be dependent on a number of social, political, legislative, and economic factors that are beyond its control. While we believe
that there will be a demand for such drugs, and that the demand will grow, there is no assurance that such demand will happen, that we
will benefit from any demand or that its business, in fact, will ever generate revenues from its drug development programs or become
profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The emerging markets for product candidates like
TELI&#8217;s and related medical research and development are and will likely remain competitive. The development and commercialization
of drugs and medicines is highly competitive. TELI competes with a variety of multinational pharmaceutical companies and specialized
biotechnology companies, as well as products and processes being developed by universities and other research institutions. Many of TELI&#8217;s
competitors have developed, are developing, or will develop drugs and processes which may be competitive with TELI&#8217;s drug candidates.
Competitive therapeutic treatments include those that have already been approved by medicines regulators and accepted by the medical
community and any new treatments that may enter the market. For some of TELI&#8217;s drug development programs / areas of therapeutic
interest, other treatment options are currently available, under development, and may become commercially available in the future. If
any of TELI&#8217;s product candidates are approved for the diseases and conditions TELI is currently pursuing, they may compete with
a range of medicines or therapeutic treatments that are either in development, will be developed in the future or currently marketed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Established companies may have a competitive
advantage over TELI due to their size and experience, financial resources, and institutional networks. Many of TELI&#8217;s competitors
may have significantly greater financial, technical, and human resources than TELI does. Due to these factors, TELI&#8217;s competitors
may have an advantage in marketing their approved drugs and may obtain regulatory approval of their drug candidates before TELI is able
to, which may limit its ability to develop or commercialize TELI&#8217;s drug candidates. TELI&#8217;s competitors may also develop drugs
/ medicines that are safer, more effective, more widely used and less expensive than TELI&#8217;s. These advantages could materially
impact TELI&#8217;s ability to develop and, if approved, commercialize TELI&#8217;s product candidates successfully. Furthermore, some
of these competitors may make acquisitions or establish collaborative relationships among themselves or with third parties to increase
their ability to rapidly gain market share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Moreover, as generic versions of drug products
enter the market, the price for such medicines may be expected to decline rapidly and substantially. Even if Telomir-1 is the first to
obtain FDA approval of one of its product candidates, the future potential approval of generics could adversely affect the price TELI
is able to charge, and the profitability of TELI&#8217;s product(s) will likely decline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mergers and acquisitions in the pharmaceutical
and biotechnology industries may result in more resources being concentrated among a smaller number of TELI&#8217;s competitors. Smaller
and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large
and established companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These companies may compete with TELI in recruiting
and retaining qualified scientific, management and commercial personnel, utilizing contract manufacturing facilities or contract research
organizations (CROs), or establishing clinical trial sites and subject registration for clinical trials, as well as in acquiring technologies
complementary to TELI&#8217;s research projects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>There are several conflicts of interests
inherent in the Merger.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Several beneficial owners of TELI, are also related
parties of Telomir. For example, our Chief Executive Officer, Erez Aminov, and owner of 5,369,860 shares of Telomir also holds a beneficial
ownership interest of 7,919,710 shares, or 23%, on a fully diluted basis, of TELI. Furthermore, shares of Telomir are held by several
trusts or individuals, also own shares of TELI. Specifically, (i) Bayshore Trust, holders of 5,406,431 shares of TELO, on a fully diluted
basis, hold 10,798,767 shares of Telomir, or 31.4% on a fully diluted basis, and (ii) the Celeste J Williams Lifetime QTIP Trust holds
of 1,853,659 shares of TELO and 1,000,000, or 2.9% shares of Telomir.&#160;Following the Merger, Mr. Aminov and Bayshore Trust are expected
to each beneficially own 13,289,570 and 16,205,198 shares of Telomir, respectively, or 19.32% and 23.56% shares of Telomir respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, several of the parties in the Merger
are related by marriage. For example, Erez Aminov, CEO of each of TELI and Telomir, is the son-in-law of Jonny Williams Sr., the beneficiary
of the Bayshore Trust, and the largest shareholder of TELO, Telomir and the primary owner of MIRALOGX LLC, the licensor of Telomir-1
to each of TELI and Telomir.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, in connection with the approval
of the Merger, the Board previously adopted an Executive Compensation Plan that provides for certain performance-based compensation arrangements
for executive officers, including Erez Aminov, the Chief Executive Officer of TELO. These arrangements may be tied to the successful
completion and overall value of the Merger.&#160;This would be separate from the shares of TELI Common Stock issued to Mr. Aminov in
connection with the Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Following the Merger, the TELI shareholders
may potentially own a majority of TELO.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the issuance of the Merger Share Consideration,
at the Closing, pre-Merger holders of TELI may potentially own a majority of the post-Merger TELO shares. Accordingly, after the completion
of the Merger, the current stockholders of TELI will own a smaller percentage of the post-Merger combined company than their ownership
of their respective companies prior to the Merger. Immediately after the Merger, TELO securityholders as of immediately prior to the
Merger are currently estimated to own approximately 50% of the outstanding shares of the post-Merger company on a fully-diluted basis
and former TELI securityholders are currently estimated to own approximately 50% of the outstanding shares of the combined post-Merger
company on a fully-diluted basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>There is no assurance when or if the Merger
will be completed.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The completion of the Merger is subject to the
satisfaction or waiver of a number of conditions as set forth in the Merger Agreement, including, among others, the receipt of the TELO
Stockholder Approval. Further, at the time of the completion of the Merger, under the terms of the Merger Agreement, TELI must have cash
and marketable securities valued at $1 million. There can be no assurance that any conditions, consents, clearances or approvals necessary
or advisable to be obtained in connection with the Merger will be obtained in a timely manner or at all, or whether they will be subject
to actions, conditions, limitations or restrictions that may jeopardize or delay the completion of the Transaction, materially reduce
or delay the anticipated benefits of the Merger or allow the parties to terminate the Merger Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Merger Agreement may be terminated in certain
circumstances, including, among others, if the Merger has not been completed by the outside date of June 30, 2026 or if a governmental
entity of competent jurisdiction has issued or granted an order, judgment, decree, ruling or injunction that results in a permanent restraint
that has become final and nonappealable or imposes, as a final and nonappealable condition. See &#8220;<i>The Merger Agreement&#8212;Termination.</i>&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The price of TELO&#8217;s common stock
is subject to fluctuations</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The market price of TELO Common Stock is subject
to general price fluctuations in the market for publicly traded equity securities and has experienced volatility in the past. Stock price
changes may result from a variety of factors, including, among others, general market and economic conditions, changes in the businesses,
operations and prospects of TELI, and an evolving regulatory landscape. Market assessments of the benefits of the Merger and the likelihood
that the Merger will be completed, as well as general and industry specific market and economic conditions, may also impact the market
price of TELI Common Stock. Many of these factors are beyond TELI&#8217;s control. You are encouraged to obtain current market price
quotations for TELO Common Stock before you determine how to vote on the Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 48; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Merger may be time-consuming to complete
and may not be completed in a timely manner, or at all, due to pending or potential litigation or regulatory challenges.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The proposed Merger and related transactions
may be challenged in court by shareholders or other interested parties. While management believes any such claims would be without merit,
we may be subject to various lawsuits or other legal proceedings, including but not limited to shareholder class action lawsuits alleging
breaches of fiduciary duties related to the proposed transaction structure, valuation, conflicts of interest or disclosure. Responding
to and defending against these claims can be time-consuming, expensive, and could divert management&#8217;s attention and resources away
from day-to-day business operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, government agencies, including antitrust
authorities, may seek to block, delay, or impose conditions on the Merger. These regulatory reviews and filings are a common aspect of
mergers and acquisitions and are subject to significant costs, including substantial legal fees and potential judgments or settlements;
transaction delays or the inability to close the merger on the contemplated terms; the imposition of burdensome conditions or restrictions
on the combined company&#8217;s operations; or the termination of the Merger agreement altogether, which could have a material adverse
effect on our business, financial condition, and stock price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_005"></span>Item 1B. Unresolved Staff Comments.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.45pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_98D_ecyd--CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_iB_c20250101__20251231_gBFCRMPFAIAMT-KX_zNu7w899BXEl" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" continuedAt="ConU000054-01" escape="true" id="Fact000054" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"><b><span id="a_006"></span>Item 1C. Cybersecurity.</b></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt"><span id="xdx_C05_gBFCRMPFAIAMT-KX_zdDfLkXxELgc"><ix:continuation continuedAt="ConU000054-02" id="ConU000054-01">&#160;</ix:continuation></span></p>

<div id="xdx_C07_gBFCRMPFAIAMT-KX_zJ41g70RWam3"><ix:continuation continuedAt="ConU000054-03" id="ConU000054-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We recognize the importance of assessing, identifying,
and managing material risks associated with cybersecurity threats, as such term is defined in Item 106(a) of Regulation S-K. These risks
include, among other things: operational risks, intellectual property theft, fraud, extortion, harm to employees and violation of data
privacy or security laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_90D_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_z6pWW8gNJ48d" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000055" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag">Identifying and assessing cybersecurity risk
is integrated into our overall risk management systems and processes.</ix:nonNumeric></span> <span id="xdx_90E_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20250101__20251231_zCY4SzqjJQ56" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000056" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock">Cybersecurity risks related to our business, technical operations,
privacy and compliance issues are identified and addressed through a multi-faceted approach including third party assessments, internal
IT Audit, IT security, governance, risk and compliance reviews. To defend, detect and respond to cybersecurity incidents, we, among other
things: conduct proactive privacy and cybersecurity reviews of systems and applications, audit applicable data, conduct employee training,
monitor emerging laws and regulations related to data protection and information security and implement appropriate changes.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_903_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20250101__20251231_zUUz7GzxCRYh" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000057" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag">Our risk management program also assesses third
party risks, and we perform third-party risk management to identify and mitigate risks from third parties such as vendors, suppliers,
and other business partners associated with our use of third-party service providers.</ix:nonNumeric></span> <span id="xdx_90C_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20250101__20251231_zoG6IEFrmC26" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000058" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">Cybersecurity risks are evaluated when determining
the selection and oversight of applicable third-party service providers and potential fourth-party risks when handling and/or processing
our employee, business or customer data.</ix:nonNumeric></span></p>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_C06_gBFCRMPFAIAMT-KX_z6BctKFYBU3a"><ix:continuation id="ConU000054-03">&#160;</ix:continuation></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_007"></span>Item 2. Description of Property.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our former corporate headquarters was located
in Baltimore, Maryland, which included a lease for office space. This lease began in November 2022 and expired in April 2024. The lease
was not renewed. We moved all corporate related activities in April 2024 to a shared office space in Tampa, Florida, see Note 5. In September
2024, we decided to no longer utilize the shared space and moved to a virtual office model. As of October 1, 2024, we have not had a
physical office space.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_008"></span>Item 3. Legal Proceedings.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_009"></span>Item 4. Mine Safety Disclosures.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.45pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 49; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_010"></span>PART II</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_011"></span>Item 5. Market for Registrant&#8217;s Common
Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify; text-indent: 23.9pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Market Information</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify; text-indent: 23.9pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is listed on The Nasdaq Capital
Market under the symbol &#8220;TELO&#8221; and began trading February 9, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Holders of Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify; text-indent: 23.9pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 9, 2026, we had approximately 58
holders of record of our common stock. No cash dividends have been paid on the common stock to date. A significant number of shares of
our common stock are held in either nominee name or street name brokerage accounts, and consequently, we are unable to determine the
total number of beneficial owners of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Dividends</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not paid any cash dividends on our common
stock to date and do not anticipate paying any cash dividends on our common stock in the foreseeable future. We intend to retain earnings,
if any, for the future operation and expansion of our business. Any determination to pay cash dividends in the future will be at the
discretion of our board of directors and will depend upon our results of operations, cash requirements, financial condition, contractual
restrictions, restrictions imposed by applicable laws and other factors that our board of directors may deem relevant</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Unregistered Sales of Equity Securities
and Use of Proceeds</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.45pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have previously disclosed all sales of securities
without registration under the Securities Act of 1933, as amended.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.45pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Issuer Purchases of Equity Securities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_012"></span>Item 6. [Reserved]</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_013"></span>Item 7.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS
OF</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The following discussion and analysis provide
information which our management believes is relevant to an assessment and understanding of our results of operations and financial condition.
You should read the following discussion and analysis of our results of operations and financial condition together with our financial
statements and related notes and other information included elsewhere in this Annual Report.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>In addition to historical financial information,
this discussion contains forward-looking statements based upon our current expectations that involve risks and uncertainties. Our actual
results could differ materially from such forward-looking statements as a result of various factors, including those set forth under
&#8220;Risk Factors&#8221; and &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; included elsewhere in this Annual Report.
Additionally, our historical results are not necessarily indicative of the results that may be expected for any period in the future.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a preclinical-stage pharmaceutical company
focused on the development of novel small-molecule therapeutics targeting age-related diseases and oncology. Our lead investigational
candidate, Telomir-1, is a small molecule metal ion regulator designed to modulate intracellular metal homeostasis. Dysregulation of
metal ions, including iron, copper, zinc, and calcium, has been implicated in cellular aging processes as well as in tumor cell proliferation,
oxidative stress, and other oncogenic pathways. By influencing intracellular metal balance, Telomir-1 may affect biological mechanisms
relevant to age-related conditions and certain oncology indications. We are conducting ongoing preclinical research in animal and other
model systems to further evaluate these potential applications. There can be no assurance that preclinical findings will translate into
clinical benefit in humans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We had net losses of $10.4 and $16.5 million
for the years ended December 31, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company and TELI Pharmaceuticals, Inc., a
private company incorporated under the laws of Delaware (&#8220;TELI&#8221;) have entered into an Agreement and Plan of Merger and Reorganization,
dated November 20, 2025, and as amended on February 4, 2026 (collectively, the &#8220;Merger Agreement&#8221;), pursuant to which a wholly
owned subsidiary of Telomir will merge with and into TELI, with TELI surviving as a wholly owned subsidiary of Telomir (the &#8220;Merger&#8221;).
At the effective time of the Merger (the &#8220;Effective Time&#8221;), each outstanding share of common stock of TELI, $0.0001 par value
per share (&#8220;TELI Common Stock&#8221;), will be converted into the right to receive such number of Telomir Common Stock as is calculated
based on the exchange ratio of the shares for the Merger (the &#8220;Exchange Ratio&#8221;). The Exchange Ratio is calculated using the
relative company valuations of each of Telomir and TELI. It is expected that shareholders of TELI will receive one share of Telomir Common
Stock for each share of TELI Common Stock held (the &#8220;Merger Share Consideration&#8221;). The Telomir Common Stock issued as the consideration
will not be registered for trading under the Securities Act. The Merger will result in an alignment of U.S. and non-U.S. rights to Telomir-1
within a single public company structure, thereby simplifying global development and partnership efforts. As a result of the Merger,
TELO will own the entire worldwide intellectual property portfolio and development programs related to Telomir-1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a condition to the closing of the Merger,
TELI must hold at least $1 million in either cash, marketable securities or a combination of cash and marketable securities and certain
shareholders of TELI must agree to provide $2 million upon FDA acceptance of an Investigational New Drug (IND) application for Telomir-1,
and $2 million upon initiation of a Phase 1/2 study. The actual payments of such amounts following the milestones are not a condition
to the closing of the Merger. At the Effective Time, Telomir&#8217;s stockholders will continue to own and hold their existing shares
of Telomir Common Stock. Following the Merger, Telomir&#8217;s shares will continue to be listed on the Nasdaq under the symbol &#8220;TELO&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Components of our Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses represent costs
incurred to conduct research and development of our product candidate. We recognize all research and development costs as they are incurred.
Research and development expenses consist primarily of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="width: 0.25in; padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">contracted
    research and manufacturing;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consulting
    arrangements; and</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    expenses incurred to advance the Company&#8217;s research and development activities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our operating expenses have historically been
the cost associated with our initial investment in pre-clinical research and development activities. We expect research and development
expenses to increase in the future as we advance Telomir-1 into and through clinical trials and pursue regulatory approvals, which will
require a significant investment in costs of clinical trials, regulatory support, and contract manufacturing. In addition, we will evaluate
opportunities to acquire or in-license additional product candidates and technologies, which may result in higher research and development
expenses due to license fee and/or milestone payments, as well as added clinical development costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The process of conducting clinical trials necessary
to obtain regulatory approval is costly and time consuming. We may never succeed in timely development and achieving regulatory approval
for our product candidates. The probability of success of our product candidates may be affected by numerous factors, including clinical
data, competition, manufacturing capability and commercial viability. As a result, we are unable to determine the duration and completion
costs of our development projects or when and to what extent we will generate revenue from the commercialization and sale of our product
candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General and Administrative Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses consist of
administrative functions, as well as fees paid for legal consulting fees and facilities costs not otherwise included in research and
development expenses. Legal costs include general corporate legal fees and license costs. We expect to incur additional expenses as a
result of becoming a public company, including expenses related to compliance with the rules and regulations of the SEC and Nasdaq, additional
insurance, investor relations and other administrative expenses and professional services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><b><i>Results
of Operations for years ended December 31, 2025 and 2024</i></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the year ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Revenues   </td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating costs:   </td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left">General and administrative expenses </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">8,103,280</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">9,636,333</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Related party travel costs  </td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">370,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Research and development expenses </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,435,569</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,235,341</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total operating costs </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,538,849</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,242,174</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest income   </td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">125,644</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">48,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Interest expense   </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,338,542</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(10,413,205</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(16,532,716</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General and Administrative Expenses.</i></b>
We incurred general and administrative expenses of $8.1 million and $9.6 million during the years ended December 31, 2025 and 2024, respectively.
General and administrative expenses in the year ended December 31, 2025 consisted of stock-based compensation expense of $5.2 million,
issuance of common stock for services of $840,000, payroll and benefits expense of $0.7 million, executive cash bonus of $0.4 million,
legal expenses of $0.2 million, accounting expenses of $0.1 million, and other expenses of $0.8 million. General and administrative expenses
in the year ended December 31, 2024 consisted of stock compensation expense of $6.7 million for new options granted in 2024, payroll
expense of $1.2 million, accounting and legal expenses of $0.6 million relating to the IPO in 2024, and office and rent expenses of $1.1
million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Related Party Travel Costs. </i></b>We
did not incur related party travel costs in the year ended December 31, 2025. We incurred $0.4 million in related party travel costs
during the year ended December 31, 2024. Related party travel costs consisted of a shared lease and use of an airplane with an entity
under common control. We ceased using the airplane after March 2024 and our obligations related to this lease terminated shortly thereafter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Expenses. </i></b>We
incurred research and development expenses of $2.4 million and $2.2 million during the years ended December 31, 2025 and 2024. The following
categorized various elements of R&amp;D expense in 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 40%; border-collapse: collapse; font-size: 10pt; margin-left: 0.5in">
  <tr>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>R&amp;D Category</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expense</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Toxicology</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">$0.6 million</span></td></tr>
  <tr style="background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Pre-clinical research</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">$1.6 million</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">R&amp;D consultants</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">$0.2 million</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Interest income (expense).</i></b> We recorded
interest income of $0.1 million in the year ended December 31, 2025, compared with $0.05 million in the year ended December 31, 2024.
We incurred $4.4 million in interest expense during the year ended December 31, 2024 in contrast to incurring none for the year ended
December 31, 2025. Interest expense during 2024 was composed of debt issuance costs related to a line of credit financing that expired
upon the completion of the IPO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity and Capital Resources</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sources of Liquidity</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since our inception in August 2021, we have financed
our operations primarily through sales of our common stock. These equity financings included the proceeds from our initial public offering
that occurred in February of 2024, a $1.0 million stock purchase agreement of our Common Stock with Starwood Trust that occurred in the
fourth quarter of 2024, a $3 million stock purchase agreement in 2025 with The Bayshore Trust, and our ATM Financings. We raised $6.5
million from ATM financings in the year ended December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to finance our clinical development
programs and working capital needs from existing cash and potential new sources of debt and equity financing. Further, we plan to conduct
a raise of capital in the near future to assist in financing working capital needs.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 53; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 19, 2025, we entered into an agreement
to raise $3 million in equity financing through a direct investment by The Bayshore Trust, an entity affiliated with our largest shareholder.
The transaction was structured as a straight restricted common stock deal with no warrants. We issued 333,334 restricted shares of its
common stock, no par value (the &#8220;Common Stock&#8221;) at a purchase price of $3.00 per share, representing an 18% premium to the
closing share price of the Common Stock of $2.54 on the date of execution (the &#8220;Bayshore Financing&#8221;). We received the initial
payment of $1 million for the Bayshore Financing on May 20, 2025. In July 2025, an additional $2 million was received, for the issuance
of 666,666 shares.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 24, 2024 we entered into an unsecured
Promissory Note and Loan Agreement with the Starwood Trust, a separate trust which was established by our founder for the benefit of
his family. Under this Promissory Note and Loan Agreement (the &#8220;Starwood Note&#8221;), we have the right to borrow up to an aggregate
of $5 million from the Starwood Trust at any time up until the second anniversary of the note. Our right to borrow funds under the Starwood
Note is subject to the absence of a material adverse change in its assets, operations, or prospects. The Starwood Note, together with
accrued interest, is to become due and payable on the second anniversary of the issuance of the note and provides for prepayment at any
time without penalty. The Starwood Note accrues interest at a rate equal to 7% per annum, simple interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, on December 9, 2024, Starwood Trust
entered into a stock purchase agreement with us to purchase 142,857 shares of unregistered common stock at $7 a share for a total of
$1.0 million in proceeds to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since January 1, 2023, MIRALOGX, an intellectual
property development and holding company owned by Bay Shore Trust, and The Starwood Trust, a separate trust established by our founder,
have advanced funds on behalf of Bay Shore Trust to our company in order to fund operating activities. The total amount advanced and
outstanding as of November 30, 2023, was $1.7 million. These advances were converted into 837,841 shares of our common stock on November
30, 2023 at a conversion rate of $2.05 per share (after giving effect to our 1-for-2.05 reverse stock split that occurred on December
11, 2023) pursuant to a conversion agreement. The total amount advanced and outstanding as of December 31, 2024 was $0.06 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have incurred significant losses and negative
cash flows from operations since inception and expect to incur additional losses until such time that we can generate significant revenue
and profit. We had negative cash flow from operations of approximately $3.7 million for the year ended December 31, 2025 and an accumulated
deficit of approximately $41.0 million as of December 31, 2025. As of December 31, 2025 we had cash and cash equivalents of approximately
$7.3 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently expect that our cash and cash equivalents
will be sufficient to fund our operations, development plans, and capital expenditures through the first quarter of 2027.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We did not have any material non-cancellable
contractual obligations as of December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Cash Flows</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides information regarding
our cash flows for the periods presented:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 70%; margin-right: 0pt; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net cash provided by (used in):</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Operating activities</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(3,688,188</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(5,070,428</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Financing activities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9,708,727</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,335,328</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net change in cash</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,020,539</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,264,900</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Net Cash Used in Operating Activities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2025, operating
activities used $3.7 million of cash, primarily due to a net loss of $10.4 million and a decrease in accounts payable of $0.05 million,
offset by $5.3 million of stock compensation expense, $0.8 million in common stock issued for services, and $0.2 million increase in
due to related parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2024, operating
activities used $5.1 million of cash, primarily due to a net loss of $16.5 million, offset by a $0.11 million change in accounts payable,
accrued and prepaid expenses, $4.4 million in amortization of debt issuance costs and $6.9 million of stock compensation expense. Accounts
payable was composed of research and development payables, and accounting and legal expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 54; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Net Cash Provided by Financing Activities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2025, financing
activities provided $9.7 million of cash, resulting from $6.5 million from the sale of common stock in ATM financings, $3.0 million in
sales of common stock to a related party, and $0.2 million in due to officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2024, financing
activities provided $6.3 million of cash, resulting primarily from $6.8 million from the sale of common stock, offset by $0.5 million
in repayments to a related party.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, we have not generated any revenue from
product sales. We do not expect to generate revenue from product sales unless and until we successfully complete pre-clinical and clinical
development of, receive regulatory approval for, and commercialize a program and we do not know when, or if at all, that will occur.
We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the pre-clinical
activities and studies and initiate clinical trials. In addition, if we obtain regulatory approval for any programs, we expect to incur
significant expenses related to product sales, marketing, and distribution to the extent that such sales, marketing and distribution
are not the responsibility of potential collaborators. The timing and amount of our operating expenditure will depend largely on the
factors set out above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our funding requirements and timing and amount
of our operating expenditure will depend on many factors, including, but not limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="width: 0.25in; padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; width: 0.25in; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    rate of progress in the development of our Telomir-1 program and other development programs&#894;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, progress, results and costs of pre-clinical studies and clinical trials for any other current and future programs&#894;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number and characteristics of programs and technologies that we develop or may in-license&#894;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our
    programs for which we receive marketing approval&#894;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs necessary to obtain regulatory approvals, if any, for any approved products in the United States and other jurisdictions, and
    the costs of post-marketing studies that could be required by regulatory authorities in jurisdictions where approval is obtained&#894;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights
    and defending any intellectual property-related claims&#894;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    continuation of our existing licensing arrangements and entry into new collaborations and licensing arrangements&#894;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs we incur in maintaining business operations&#894;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of hiring additional clinical, quality control, manufacturing and other scientific personnel&#894;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 55; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="padding-bottom: 0pt; width: 0.25in">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs adding operational, financial and management information systems and personnel&#894;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs associated with being a public company&#894;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    revenue, if any, received from commercial sales of our programs for which we receive marketing approval&#894;</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effect of competing technological and market developments&#894; and</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">&#9679;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or collaboration
    arrangements for programs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Identifying potential programs, product candidates,
conducting pre-clinical studies and clinical trials is a time consuming, expensive and uncertain process that takes years to complete,
and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition,
our programs, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products
that we do not expect to be commercially available for many years, if ever. Accordingly, we will need to obtain substantial additional
funds to achieve our business objectives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recently Issued and Adopted Accounting Pronouncements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A description of recently issued and adopted
accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 1 to our
financial statements appearing at the end of this Annual Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Off-Balance Sheet Arrangements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the periods presented, we did not have,
nor do we currently have, any off-balance sheet arrangements as defined under Generally Accepted Accounting Principles (GAAP) and SEC
rules.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Summary of Critical Accounting Policies and
Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and development expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development costs are expensed in
the period in which they are incurred and include the expenses paid to third parties, such as contract research organizations and consultants,
who conduct research and development activities on behalf of the Company. Patent-related costs, including registration costs, documentation
costs and other legal fees associated with the application, are expensed in the period in which they are incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock-based compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for stock-based compensation
under the provisions of FASB ASC 718, &#8220;<i>Compensation - Stock Compensation</i>&#8221;, which requires the measurement and recognition
of compensation expense for all stock-based awards made to employees, directors and consultants based on estimated fair values on the
grant date. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value
of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the
straight-line method. The Company has elected to account for forfeiture of stock-based awards as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 56; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Emerging Growth Company Election</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an &#8220;emerging growth company&#8221;
as defined in Section 2(a) of the Securities Act and have elected to take advantage of the benefits of the extended transition period
for new or revised financial accounting standards. We expect to continue to take advantage of the benefits of the extended transition
period, although we may decide to early adopt such new or revised accounting standards to the extent permitted by such standards. We
expect to use this extended transition period for complying with new or revised accounting standards that have different effective dates
for public and non-public companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively
and irrevocably opt out of the extended transition period provided in the JOBS Act. This may make it difficult or impossible to compare
our financial results with the financial results of another public company that is either not an emerging growth company or is an emerging
growth company that has chosen not to take advantage of the extended transition period exemptions because of the potential differences
in accounting standards used.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we intend to rely on the other exemptions
and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act and compliance with
applicable laws, if, as an emerging growth company, we rely on such exemptions, we are not required to, among other things: (a) provide
an auditor&#8217;s attestation report on our system of internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley
Act of 2002; (b) provide all of the compensation disclosures that may be required of non-emerging growth public companies under the Dodd-Frank
Wall Street Reform and Consumer Protection Act of 2010; (c) comply with any requirement that may be adopted by the Public Company Accounting
Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information
about the audit and the financial statements (auditor discussion and analysis); and (d) disclose certain executive compensation-related
items such as the correlation between executive compensation and performance and comparisons of the Chief Executive Officer&#8217;s compensation
to median employee compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.55pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will remain an emerging growth company under
the JOBS Act until the earliest of (a) December 31, 2027, (b) the last date of our fiscal year in which we had total annual gross revenue
of at least $1.07 billion, (c) the date on which we are deemed to be a &#8220;large accelerated filer&#8221; under the rules of the SEC
or (d) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the previous three years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_014"></span>Item 7A. Quantitative and Qualitative Disclosures
About Market Risk.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify; text-indent: 23.9pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Smaller reporting companies are not required
to provide the information required by this item.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_015"></span>Item 8. Financial Statements and Supplementary
Data.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify; text-indent: 23.9pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Financial Statements and Notes thereto and
the reports of Salberg &amp; Company P.A, our independent registered public accounting firm, for the years ended December 31, 2025 and
2024, are set forth on pages F-1 through F-16 of this Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_016"></span>Item 9. Changes In and Disagreements With
Accountants on Accounting and Financial Disclosure.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify; text-indent: 23.9pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_017"></span>Item 9A. Controls and Procedures.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.55pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Evaluation of Disclosure Controls and Procedures</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify; text-indent: 23.9pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management, our Chief Executive Officer (our
principal executive officer) and our Chief Financial Officer (our principal financial officer) (the &#8220;Certifying Officers&#8221;),
has evaluated the effectiveness of our disclosure controls and procedures (as defined in&#160;Rules 13a-15(e) or&#160;15d-15(e) under
the&#160;Exchange Act) as of December 31, 2025. The term &#8220;disclosure controls and procedures,&#8221; as defined in&#160;Rules 13a-15(e)
and&#160;15d-15(e) under the&#160;Exchange Act, means controls and other procedures of a company that are designed to ensure that information
required to be disclosed by the company in the reports that it files or submits under the&#160;Exchange Act&#160;is recorded, processed,
summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include,
without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports
that it files or submits under the&#160;Exchange Act&#160;is accumulated and communicated to the company&#8217;s management, including
its principal executive and principal accounting officers, or persons performing similar functions, as appropriate to allow timely decisions
regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated,
can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating
the cost-benefit relationship of possible controls and procedures. The Certifying Officers have concluded, based on their evaluation
as of the end of the period covered by this Report, that our disclosure controls and procedures were effective to provide reasonable
assurance that the objectives of our disclosure control system were met.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 57; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Management&#8217;s Annual Report on Internal
Control over Financial Reporting</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management of the Company is responsible for
establishing and maintaining adequate internal control over financial reporting (as defined in Section 13a-15(f) of the&#160;Securities
Exchange Act of 1934, as amended). Internal control over financial reporting is a process designed by, or under the supervision of, the
Company&#8217;s principal financial officer to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of the Company&#8217;s financial statements for external reporting purposes in conformity with U.S. generally accepted accounting
principles and include those policies and procedures that (i) pertain to the maintenance of records that in reasonable detail accurately
and fairly reflect the transactions and disposition of the assets of the company; (ii) provide reasonable assurance that transactions
are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles,
and that receipts and expenditures of the Company are being made only in accordance with authorization of management and directors of
the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition
of the Company&#8217;s assets that could have a material effect on the financial statements. During 2024, we designed and implemented
new and enhanced controls to strengthen our internal controls over financial reporting, including hiring additional experienced accounting
personnel, among other enhancements. Management believes these enhancements were sufficient to remediate previously identified material
weaknesses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2025, management conducted
an assessment of the effectiveness of the Company&#8217;s internal control over financial reporting based on the framework established
in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations (COSO) of the Treadway Commission. Based
on the criteria established by COSO management concluded that the Company&#8217;s internal control over financial reporting was effective
as of December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Report does not include an attestation report
of the Company&#8217;s independent registered public accounting firm regarding internal control over financial reporting as smaller reporting
companies are not required to include such report and emerging growth companies (&#8220;EGC&#8217;s&#8221;) are exempt from this requirement
entirely until they are no longer an&#160;EGC. Management&#8217;s report is not subject to attestation by the Company&#8217;s independent
registered public accounting firm.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes in Internal Control over Financial
Reporting</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no additional changes in our internal
control over financial reporting (as defined in Rule 13(a)-15(f) of the Exchange Act) that occurred during the period covered by this
annual report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify; text-indent: 23.9pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_018"></span>Item 9B. Other Information.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify; text-indent: 23.9pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_905_ecustom--NoInsiderTradingFlag_dbT_c20250101__20251231_zbm96P1DPpmh" title="No insider trading flag" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000060" name="TELO:NoInsiderTradingFlag">None</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.55pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_019"></span>Item 9C. Disclosure Regarding Foreign Jurisdictions
that Prevent Inspections</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify; text-indent: 23.9pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 58; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_020"></span>PART III</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain information required by Part III of this
Annual Report on Form 10-K is omitted from this report because we are incorporating by reference to the definitive Proxy Statement for
our 2025 Annual Meeting of Shareholders, referred to as the Proxy Statement, which was filed with the SEC on February 19, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_021"></span>Item 10. Directors, Executive Officers and
Corporate Governance </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information required by this item is incorporated
herein by reference to the information from the Proxy Statement under the sections entitled &#8220;Election of Directors,&#8221; &#8220;Nomination
of Directors,&#8221; and &#8220;Corporate Governance &#8211; Board Committees,&#8221; except for the information required with respect
to our executive officers, which has been included under the heading &#8220;Executive Officers&#8221; in Item 1, Part I of this Form
10-K, and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_022"></span>Item 11. Executive Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain information required by this item is
incorporated herein by reference to the information from the Proxy Statement under the sections entitled &#8220;Executive Compensation,&#8221;
and &#8220;Director Compensation.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_023"></span>Item 12. Security Ownership of Certain Beneficial
Owners and Management and Related Stockholder Matters </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information required by tis item is incorporated
herein by reference to the information from the Proxy Statement under the sections entitled &#8220;Share Ownership of Certain Beneficial
Owners, Management and Directors&#8221; and &#8220;Equity Compensation Plan Information.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_024"></span>Item 13. Certain Relationships and Related
Transactions and Director Independence</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following is a description
of transactions within the last two fiscal years to which we have been a party, in which the amount involved exceeded or will exceed
$120,000, and in which any of our executive officers, directors or holders of more than 5% of our voting securities, or an immediate
family member thereof, had or will have a direct or indirect material interest. We believe the terms obtained or consideration that we
paid or received, as applicable, in connection with the transactions described below were comparable to terms available or amounts that
would be paid or received, as applicable, in arm&#8217;s-length transactions with unrelated third parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Transactions with MIRALOGX LLC</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since January 1, 2023, MIRALOGX and The Starwood
Trust, a separate Trust established by our founder, have advanced funds on behalf of Bay Shore Trust to our company in order to fund
operating activities. The total amount advanced and outstanding as of November 30, 2023, was $1.7 million. These advances were converted
into 837,841 shares of our common stock on November 30, 2023 at a conversion rate of $2.05 per share (after giving effect to our 1-for-2.05
reverse stock split that occurred on December 11, 2023) pursuant to a conversion agreement that resulted in a loss of $4.1 million for
the year ended December 31, 2023 and a remaining balance as of December 31, 2023 of $0.3 million. As of December 31, 2024, the remaining
balances due to Miralogx and Starwood Trust total $0.055 and $0.037 million respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 11, 2023, we entered into the Initial
MIRALOGX License Agreement with MIRALOGX, which is an intellectual property development and holding company established by our founder
and the inventor of Telomir-1, Jonnie R. Williams, Sr. See &#8220;Business&#8211; Intellectual Property&#8221;. MIRALOGX is wholly owned
by the Bay Shore Trust, and Mr. Williams does not have voting or dispositive power over the shares of the Company held by Bay Shore Trust,
and Mr. Williams is not an officer or director of the Bay Shore Trust. On November 10, 2023, we entered into an amendment to the Initial
MIRALOGX License Agreement, pursuant to which we acquired the license to the non-human applications of the &#8220;Licensed Products.
This amendment was reaffirmed by new management on October 18, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were also a party to an Agreement for Shared
Lease Costs, dated April 1, 2023, with MIRALOGX and MIRA Pharmaceuticals, Inc., under which we have agreed to pay our pro rata share
of the operating usage costs owing by MIRALOGX under an aircraft lease agreement between MIRALOGX and Supera Aviation I LLC (&#8220;Supera
Aviation&#8221;) based on our usage of the leased aircraft each month. No amounts are payable by us under this agreement unless and to
the extent we choose to utilize the leased aircraft, and we may discontinue the use of the aircraft and terminate this agreement at any
time. Supera Aviation is a company owned by Starwood Trust, a trust established by Mr. Williams. For the year ended December 31, 2024,
the Company incurred $0.4 million in expenses under the aircraft lease agreement. The aircraft lease was terminated in April 2024 and
no other costs will be incurred under this agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Starwood Trust Line of Credit</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 24, 2024 the Company entered into
an unsecured Promissory Note and Loan Agreement (&#8220;the Starwood Note&#8221;) with the Starwood Trust, a separate related party trust
established by the Company&#8217;s founder for the benefit of the founder&#8217;s family. Under the Starwood Note, the Company has the
right to borrow up to an aggregate of $5&#160;million from the Starwood Trust at any time up until the second anniversary of the note.
The Company&#8217;s right to borrow funds under the Starwood Note is subject to the absence of a material adverse change in its assets,
operations, or prospects. The Starwood Note, together with accrued interest, is to become due and payable on the second anniversary of
the issuance of the note, provides for prepayment at any time without penalty, and accrues simple interest at a rate equal&#160;7% per
annum. As of December 31, 2024, the Company has not borrowed any amounts under the Starwood Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, on December 9, 2024, Starwood Trust
entered into a stock purchase agreement with the Company to purchase 142,857 shares of unregistered common stock at $7 a share for a
total of $1.0 million in proceeds to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Investment from Largest Shareholder</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 19, 2025, we entered into an agreement
to raise $3 million in equity financing through a direct investment by The Bayshore Trust, an entity affiliated with our largest shareholder.
The transaction was structured as a straight restricted common stock deal with no warrants. We issued 333,334 restricted shares of our
Common Stock at a purchase price of $3.00 per share, representing an 18% premium to the closing share price of the Common Stock of $2.54
on the date of execution (the &#8220;Bayshore Financing&#8221;). We received the initial payment of $1 million for the Bayshore Financing
on May 20, 2025. In July 2025, an additional $2 million was received, for the issuance of 666,666 shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 59; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Review and Approval of Related Party Transactions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors adopted a written policy
regarding the review and approval of related party transactions. Our audit committee charter provides that the audit committee shall
review and approve or disapprove any related party transactions, which are transactions between us and related persons in which the aggregate
amount involved exceeds or may be expected to exceed $120,000 and in which a related person has or will have a direct or indirect material
interest. Our policy regarding transactions between us and related persons will provide that a related person is defined as a director,
executive officer, nominee for director or greater than 5% beneficial owner of our common stock, in each case since the beginning of
the most recently completed year, and any of their immediate family members.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain of the foregoing disclosures are summaries
of certain provisions of our related party agreements and are qualified in their entirety by reference to all of the provisions of such
agreements. Because these descriptions are only summaries of the applicable agreements, they do not necessarily contain all of the information
that you may find useful. Copies of certain of the agreements have been filed as exhibits to the registration statement of which this
Annual Report is a part and are available electronically on the website of the SEC at <i>www.sec.gov</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a matter of corporate governance policy, we
have not and will not make loans to officers or loan guarantees available to &#8220;promoters&#8221; as that term is commonly understood
by the SEC and state securities authorities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All future transactions between us and our officers,
directors or five percent stockholders, and respective affiliates will be on terms no less favorable than could be obtained from unaffiliated
third parties and will be approved by a majority of our independent directors who do not have an interest in the transactions and who
had access, at our expense, to our legal counsel or independent legal counsel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_025"></span>Item 14. Principal Accountant Fees and Services.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Audit Fees.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company appointed Salberg &amp; Company P.A
(&#8220;Salberg&#8221;) as our audit firm effective December 19, 2024. The aggregate fees billed by Salberg for professional services
rendered for the audit of our annual financial statements, and other required filings with the SEC for the years ended December 31, 2025
and totaled $87,000 and $50,000, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate fees billed by our prior audit
firm, Cherry Bekaert LLP, for professional services rendered for the audit of our annual financial statements, review of the financial
information included in our Forms 10-Q (where applicable) for the respective periods and other required filings with the SEC for the
year ended December 31, 2024 totaled $64,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The above amounts include interim procedures
and audit fees, as well as attendance at audit committee meetings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Audit-Related Fees.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate fees billed by Salberg for audit-related
fees for the year ended December 31, 2025, were $18,000. The fees were provided in consideration of services consisting of review and
update procedures associated with registration statements and other SEC filings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate fees billed by Cherry Bekaert LLP
for audit-related fees for the year ended December 31, 2024 were $51,000. The fees were provided in consideration of services consisting
of review and update procedures associated with registration statements and other SEC filings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Tax Fees.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no fees billed by Salberg &amp; Company
P.A for tax services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>All Other Fees. None</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Audit Committee of our board of directors
has established its pre-approval policies and procedures, pursuant to which the Audit Committee approved the foregoing audit and non-audit
services provided by Salberg in 2025 and Cherry Bekaert LLP and Salberg in 2024. Consistent with the Audit Committee&#8217;s responsibility
for engaging our independent auditors, all audit and permitted non-audit services require pre-approval by the Audit Committee. The full
Audit Committee approves proposed services and fee estimates for these services. The Audit Committee chairperson has been designated
by the Audit Committee to approve any audit-related services arising during the year that were not pre-approved by the Audit Committee.
Any non-audit service must be approved by the full Audit Committee. Services approved by the Audit Committee chairperson are communicated
to the full Audit Committee at its next regular meeting and the Audit Committee reviews services and fees for the fiscal year at each
such meeting. Pursuant to these procedures, the Audit Committee approved the foregoing services provided by Salberg &amp; Company P.A
and Cherry Bekaert LLP.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_026"></span>PART IV</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_027"></span>Item 15. Exhibits, Financial Statement Schedules.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.45pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information called for by this Item is incorporated
herein by reference to the Exhibit Index in this Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>INDEX
TO EXHIBITS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="border-bottom: black 1pt solid; text-align: left; width: 0.75in; padding-bottom: 0pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    No.</span></td>
    <td style="width: 0.1in; padding-bottom: 0pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    Description </span></td></tr>
  <tr>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315225006943/ex1-2.htm"><span style="font-size: 10pt">At The Market Offering Agreement, dated February 14, 2025, by and between Telomir Pharmaceuticals, Inc. and Rodman &amp; Renshaw LLC (incorporated by reference to Exhibit 1.2 of the Company&#8217;s Form S-3 filed on February 14, 2025).</span></a></td></tr>
  <tr>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223044902/ex3-1.htm"><span style="font-size: 10pt">Amended and Restated Articles of Incorporation of Telomir Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 to Form 10-K filed on February 4, 2025<span style="font-family: Times New Roman, Times, Serif">)</span></span></a></td></tr>
  <tr>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223044902/ex3-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Bylaws of Telomir Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.2 to Form 10K filed February 4, 2025)</span></a></td></tr>
  <tr>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223045454/ex4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Representative&#8217;s Warrant (incorporated by reference to Exhibit 4.1 to Form S-1/A filed December 19, 2023)</span></a></td></tr>
  <tr>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223044902/ex4-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock Purchase Warrant, dated June 15, 2023, between Telomir Pharmaceuticals, Inc. and Bay Shore Trust (incorporated by reference to Exhibit 4.2 to Form S-1/A filed December 14, 2023)</span></a></td></tr>
  <tr>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223045454/ex4-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Common Stock Purchase Warrant, by and between the Company and certain investors from January 2023 through March 2023 (incorporated by reference to Exhibit 4.3 to Form S-1/A filed December 19, 2023)</span></a></td></tr>
  <tr>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315224012049/ex4-4.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Securities (incorporated by reference to Exhibit 4.4 to Form 10-K filed March 29, 2024)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223044902/ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 to Form S-1/A filed December 14, 2023)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315224031606/ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement between the Company and Erez Aminov, dated August 12, 2024 (incorporated by reference to Exhibit 10.1 to Form 10-Q filed on August 13, 2024)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000164117225011938/ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement dated May 15, 2025, between Telomir Pharmaceuticals, Inc. and Alan Weichselbaum (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed on May 21, 2025)</span></a></td></tr>
  <tr>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223044902/ex10-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Stock Option Award under 2023 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.2 to Form S-1/A filed December 14, 2023)</span></a></td></tr>
  <tr>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223044902/ex10-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.3 to Form S-1/A filed December 14, 2023)</span></a></td></tr>
  <tr>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223040696/ex10-4.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated License Agreement, dated August 11, 2023, by and between Telomir Pharmaceuticals, Inc. and MIRALOGX LLC (incorporated by reference to Exhibit 10.4 to Form S-1 filed November 14, 2023)</span></a></td></tr>
  <tr>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223040696/ex10-5.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to Amended and Restated License Agreement, dated November 10, 2023, by and between Telomir Pharmaceuticals, Inc. and MIRALOGX LLC (incorporated by reference to Exhibit 10.5 to Form S-1 filed November 14, 2023)</span></a></td></tr>
  <tr>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223044902/ex10-8.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promissory Note and Loan Agreement, dated June 15, 2023, by and between Telomir Pharmaceuticals, Inc. and Bay Shore Trust (incorporated by reference to Exhibit 10.8 to Form S-1/A filed December 14, 2023)</span></a></td></tr>
  <tr>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223044902/ex14-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code of Business Conduct and Ethics (incorporated by reference to Exhibit 14.1 to Form S-1/A filed December 14, 2023)</span></a></td></tr>

<tr>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.1</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223044902/ex99-5.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insider Trading Policy (incorporate by reference to Exhibit 99.5 to Form S-1/A filed December 14, 2023)</span></a></td></tr>
  <tr>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223044902/ex21-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of Subsidiaries of Registrant (incorporated by reference to Exhibit 21.1 to Form S-1/A filed December 14, 2023)</span></a></td></tr>

<tr>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top">23.1</td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><a href="ex23-1.htm">Consent <span style="font-family: Times New Roman, Times, Serif">of Salberg &amp; Company, P.A.</span></a></td></tr>
<tr>
    <td style="vertical-align: top; width: 0.75in; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</span></td>
    <td style="width: 0.1in; padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><a href="#a_028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney (included on signature page)</span></a></td></tr>
  <tr>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><a href="ex31-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*</span></a></td></tr>
  <tr>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><a href="ex31-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Financial Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*</span></a></td></tr>
  <tr>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><a href="ex32-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><a href="ex32-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315224012049/ex97-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Policy Relating to Recovery of Erroneously Awarded Compensation (incorporated by reference to Exhibit 97.1 to Form 10-K filed March 29, 2024)</span></a></td></tr>
  <tr>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223044902/ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit Committee Charter (incorporated by reference to Exhibit 99.1 to Form S-1/A filed December 14, 2023)</span></a></td></tr>
  <tr>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223044902/ex99-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nominating and Corporate Governance Committee Charter (incorporated by reference to Exhibit 99.2 to Form S-1/A filed December 14, 2023)</span></a></td></tr>
  <tr>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223044902/ex99-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation Committee Charter (incorporated by reference to Exhibit 99.3 to Form S-1/A filed December 14, 2023)</span></a></td></tr>
  <tr>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.4</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223044902/ex99-4.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate Governance Guidelines (incorporated by reference to Exhibit 99.4 to Form S-1/A filed December 14, 2023)</span></a></td></tr>
  <tr>
    <td style="text-align: left; padding-bottom: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.6</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223044902/ex99-6.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related Person Transaction Policy and Procedures (incorporated by reference to Exhibit 99.6 to Form S-1/A filed December 14, 2023)</span></a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="width: 0.25in; padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x5E;</span></td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously
    filed.</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</span></td>
    <td style="padding-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denotes
    management contract or compensatory plan or arrangement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TELOMIR PHARMACEUTICALS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDEX TO FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="background-color: #CCEEFF">
    <td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_001">Report of Independent Registered Public Accounting Firm</a> (PCAOB Firm ID <span id="xdx_904_edei--AuditorFirmId_c20250101__20251231_zsePwwzKyoq6" title="Auditor Firm ID"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000062" name="dei:AuditorFirmId">106</ix:nonNumeric></span>)</span></td>
    <td style="width: 0.5in; padding-bottom: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: right">&#160;</td></tr>
  <tr style="height: 10.85pt; background-color: #CCEEFF">
    <td style="padding-bottom: 0pt; height: 10.85pt"><a href="#f_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance Sheets as of December 31, 2025 and 2024</span></a></td>
    <td style="padding-bottom: 0pt; height: 10.85pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: right">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="padding-bottom: 0pt"><a href="#f_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements of Operations for the years ended December 31, 2025 and 2024</span></a></td>
    <td style="padding-bottom: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: right">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="padding-bottom: 0pt; text-align: justify"><a href="#f_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statement of Changes in Stockholders&#8217; Equity for the years ended December 31, 2025 and 2024</span></a></td>
    <td style="padding-bottom: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: right">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="padding-bottom: 0pt"><a href="#f_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements of Cash Flows for the years ended December 31, 2025 and 2024</span></a></td>
    <td style="padding-bottom: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="background-color: white">
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: right">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="padding-bottom: 0pt"><a href="#f_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Financial Statements</span></a></td>
    <td style="padding-bottom: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 62; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;<img src="fin_001.jpg" alt="" style="height: 81px; width: 670px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="f_001"></span>Report of Independent Registered Public Accounting
Firm</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Board of Directors and Stockholders</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Telomir Pharmaceuticals, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
on the Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying balance sheets of Telomir Pharmaceuticals, Inc. (the &#8220;Company&#8221;) as of December 31, 2025 and
2024, the related statements of operations, changes in stockholders&#8217; equity and cash flows for each of the two years in the period
ended December 31, 2025, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion,
the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and
2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity
with accounting principles generally accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Going
Concern</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note
2 to the financial statements, the Company used approximately $3.7 million of cash in operations and had a net loss of $10.4 million
during the year ended December 31, 2025. These matters raise substantial doubt about the Company&#8217;s ability to continue as a going
concern. Management&#8217;s Plans in regard to these matters are also described in Note 2. The financial statements do not include any
adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis
for Opinion</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">/s/ <span id="xdx_907_edei--AuditorName_c20250101__20251231_z5NJvfpbnase" title="Auditor Name"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000064" name="dei:AuditorName">SALBERG &amp; COMPANY, P.A.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span>Salberg &amp; Company, P.A.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--AuditorLocation_c20250101__20251231_zNogAobStiyd" title="Auditor Location"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000066" name="dei:AuditorLocation">Boca
Raton, Florida</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
17, 2026</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">2295 NW Corporate Blvd., Suite 240 &#9679; Boca Raton,
FL 33431-7326</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Phone: (561) 995-8270 &#9679; Toll Free: (866) CPA-8500
&#9679; Fax: (561) 995-1920</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">www.salbergco.com &#9679; info@salbergco.com</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><i>Member National Association of Certified Valuation
Analysts &#9679; Registered with the PCAOB</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><i>Member CPAConnect with Affiliated Offices Worldwide
&#9679; Member AICPA Center for Audit Quality</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="f_002"></span>Telomir Pharmaceuticals, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase">BALANCE
SHEETS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_111_zrt9AMmVGSy3" summary="xdx: Statement - Balance Sheets" style="border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-left: 10pt; font-size: 10pt">&#160;</td>
    <td>&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20251231_zibsobuVK5P7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20241231_zdRfkuqddu46" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; font-size: 10pt">&#160;</td>
    <td>&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; font-size: 10pt">&#160;</td>
    <td>&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsAbstract_iB_z4Zh1asVryrl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0in">ASSETS</td>
    <td>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AssetsCurrentAbstract_i01B_zB8FnxHjl9E1" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0in; text-align: left">Current assets:</td>
    <td>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Cash_i02I_maACzmsc_z4crKpthwaM" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 57%">Cash</td>
    <td style="width: 9%">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2025-12-31" id="Fact000074" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,286,670</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-12-31" id="Fact000075" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,266,131</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidExpenseCurrent_i02I_maACzmsc_zdS9zbLEFiNh" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Prepaid expenses</td>
    <td>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2025-12-31" id="Fact000077" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,691</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2024-12-31" id="Fact000078" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,874</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AssetsCurrent_i02TI_mtACzmsc_maAzeqI_zX4hf8i1t6Sk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total current assets</td>
    <td>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2025-12-31" id="Fact000080" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,341,361</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000081" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,324,005</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Assets_i01TI_mtAzeqI_zEmZxMwDONC2" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total assets</td>
    <td>&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-12-31" id="Fact000083" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,341,361</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000084" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,324,005</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zXRNBG9EabW4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0in; text-align: left">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td>
    <td>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesCurrentAbstract_i01B_zREu3zhCgvc8" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0in; text-align: left">Current liabilities:</td>
    <td>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_maLCzf4V_ztiK9T6TWkpg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Trade accounts payable and accrued liabilities</td>
    <td>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2025-12-31" id="Fact000092" format="ixt:numdotdecimal" decimals="0" unitRef="USD">536,769</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000093" format="ixt:numdotdecimal" decimals="0" unitRef="USD">587,536</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DueToOfficer_i02I_maLCzf4V_z0P2sz90qJB5" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Due to officer</td>
    <td>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="TELO:DueToOfficer" contextRef="AsOf2025-12-31" id="Fact000095" format="ixt:numdotdecimal" decimals="0" unitRef="USD">155,518</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0096">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--AccruedCompensation_i02I_maLCzf4V_zkofaVkcmSii" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Accrued compensation - officer</td>
    <td>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="TELO:AccruedCompensation" contextRef="AsOf2025-12-31" id="Fact000098" format="ixt:numdotdecimal" decimals="0" unitRef="USD">417,470</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0099">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherLiabilitiesCurrent_i02I_maLCzf4V_z2c0WNBov0uj" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Due to related parties</td>
    <td>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2025-12-31" id="Fact000101" format="ixt:numdotdecimal" decimals="0" unitRef="USD">318,234</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000102" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,432</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzf4V_maLzNbd_zMnvqAE9nbO5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 20pt; text-align: left">Total current liabilities</td>
    <td>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-12-31" id="Fact000104" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,427,991</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000105" format="ixt:numdotdecimal" decimals="0" unitRef="USD">680,968</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt">&#160;</td>
    <td>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Liabilities_i01TI_mtLzNbd_maLASEzkG8_zxocQUJC1pJg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total liabilities</td>
    <td>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2025-12-31" id="Fact000107" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,427,991</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-12-31" id="Fact000108" format="ixt:numdotdecimal" decimals="0" unitRef="USD">680,968</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt">&#160;</td>
    <td>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockholdersEquityAbstract_i01B_zQJEzM1JkZlg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0in; text-align: left">Stockholders&#8217; Equity</td>
    <td>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PreferredStockValue_i02I_maSEzo1L_z63CzsmC5Pnd" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Preferred Stock, <span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_do_c20251231_zt2WwT7Pv3re" title="Preferred stock, par value"><span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_do_c20241231_zSgQAuIfNCZ1" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31" id="Fact000116" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000118" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares">no</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231_zztT3noaAyKk" title="Preferred stock, shares authorized"><span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231_z1TUUPZmKVEk" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-12-31" id="Fact000120" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000122" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized and <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_dn_c20251231_z6qFhRLsdqCc" title="Preferred stock, shares issued"><span id="xdx_901_eus-gaap--PreferredStockSharesIssued_iI_dn_c20241231_zmgKhiIxTir7" title="Preferred stock, shares issued"><span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20251231_zEA0g7NYSsvf" title="Preferred stock, shares outstanding"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20241231_zb2jK64mtupc" title="Preferred stock, shares outstanding"><span><span><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-12-31" id="Fact000124" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000126" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-12-31" id="Fact000128" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000130" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span></span></span> issued or outstanding.</td>
    <td>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0113">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0114">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CommonStockValue_i02I_maSEzo1L_zjwA4dsnHVHg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Common Stock, <span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_do_c20251231_zLyxFRupCyXf" title="Common stock, par value"><span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_do_c20241231_zD9mtPQC5R99" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31" id="Fact000135" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000137" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares">no</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20251231_zKntHxTNWf5" title="Common stock, shares authorized"><span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zPjiKIxhMqqh" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-12-31" id="Fact000139" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000141" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_pid_c20251231_zDeCScB1Dfkf" title="Common stock, shares issued"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20251231_z4p7BM4JePta" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-12-31" id="Fact000143" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-12-31" id="Fact000145" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">34,380,971</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zTdUfJLod418" title="Common stock, shares outstanding"><span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20241231_zva8wkpdBG9j" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000147" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000149" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29,762,671</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding at December 31, 2025 and 2024, respectively.</td>
    <td>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0132">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0133">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AdditionalPaidInCapital_i02I_maSEzo1L_zy8bsPZeqq3h" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Additional paid-in capital</td>
    <td>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2025-12-31" id="Fact000151" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,923,433</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact000152" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,239,895</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzo1L_zKDI3psIC336" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Accumulated deficit</td>
    <td>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-12-31" id="Fact000154" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">41,010,063</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000155" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,596,858</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--StockholdersEquity_i02TI_mtSEzo1L_maLASEzkG8_zwWg0HSBRe96" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total stockholders&#8217; equity</td>
    <td>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31" id="Fact000157" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,913,370</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000158" format="ixt:numdotdecimal" decimals="0" unitRef="USD">643,037</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesAndStockholdersEquity_i02TI_mtLASEzkG8_zYUZL1OGTqWl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217; equity</td>
    <td>&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-12-31" id="Fact000160" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,341,361</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000161" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,324,005</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes to the financial statements
are an integral part of these statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="f_003"></span>Telomir Pharmaceuticals, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase">STATEMENTS
OF OPERATIONS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_304_113_zd5LFBeW4RB9" summary="xdx: Statement - Statements of Operations" style="border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-left: 10pt; font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20250101__20251231_zJ2GnhVPQERe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20240101__20241231_zJnh8XMLgh7c" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_msOEzFOM_zPeousgzJJnd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0in">Revenues</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0163">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0164">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingExpensesAbstract_iB_zJnsH82OI4Y7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0in; text-align: left">Operating costs:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_i01_maOEzFOM_zpeq4xP2aWYg" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left">General and administrative expenses</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000169" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,103,280</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31" id="Fact000170" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,636,333</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--TravelAndEntertainmentExpense_i01_maOEzFOM_z3WZIgc3mCE" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Related party travel costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0172">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:TravelAndEntertainmentExpense" contextRef="From2024-01-012024-12-31" id="Fact000173" format="ixt:numdotdecimal" decimals="0" unitRef="USD">370,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEzFOM_zXIeE0jHeK79" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Research and development expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000175" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,435,569</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31" id="Fact000176" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,235,341</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingExpenses_i01T_mtOEzFOM_msNILzC28_za6v4KA0Ywdk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Total operating costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-01-01to2025-12-31" id="Fact000178" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,538,849</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-012024-12-31" id="Fact000179" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,242,174</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InvestmentIncomeInterest_maNILzC28_zVzT76MzNBW7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0in; text-align: left">Interest income</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2025-01-01to2025-12-31" id="Fact000181" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,644</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2024-01-012024-12-31" id="Fact000182" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--InterestExpenseNonoperating_iN_di_msNILzC28_zWN8RdCjv3r9" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0in; text-align: left; padding-bottom: 1pt">Interest expense</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0184">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2024-01-012024-12-31" id="Fact000185" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,338,542</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_iT_mtNILzC28_zzM7SjaM1JL6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000187" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,413,205</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000188" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,532,716</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per share</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_c20250101__20251231_zBbbSHHYCkGc" title="Basic loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_c20250101__20251231_zm75OGKTgdH2" title="Diluted loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-01-01to2025-12-31" id="Fact000190" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-01-01to2025-12-31" id="Fact000192" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.33</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20240101__20241231_zK0yWhystIRi" title="Diluted loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_c20240101__20241231_zAexdD0BOjC1" title="Basic loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-012024-12-31" id="Fact000194" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-012024-12-31" id="Fact000196" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.56</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted weighted average common stock shares outstanding</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20251231_zBQGpH2PTfNb" title="Basic weighted average common stock shares outstanding" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20251231_zyVaEeBcdL31" title="Diluted weighted average common stock shares outstanding" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-01-01to2025-12-31" id="Fact000198" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-01-01to2025-12-31" id="Fact000200" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">31,653,094</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_z9DUqri9Ovl4" title="Basic weighted average common stock shares outstanding" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_zkGwh827AoYk" title="Diluted weighted average common stock shares outstanding" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-12-31" id="Fact000202" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-12-31" id="Fact000204" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29,539,219</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes to the financial statements
are an integral part of these statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="f_004"></span>Telomir Pharmaceuticals, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase">Statements
of Changes in stockholders&#8217; EQUITY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase">&#160;</span>&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_303_114_zGqHgO7Y9BS8" summary="xdx: Statement - Statements of Changes in Stockholders' Equity" style="border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z0lnCkQjUBJf" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z9JD9CmXhx72" style="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Paid-In Capital</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_z8xGXrEFWFm" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Deficit</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B1_zXWRIX7m6Aq1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Equity</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Common Stock</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">Additional</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">Accumulated</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">Total Stockholders&#8217;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Paid-In Capital</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Deficit</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Equity</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr id="xdx_432_c20240101__20241231_eus-gaap--StockholdersEquity_iS_zHSrJX1B0PSc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 35%">Balances, December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zn35wwdSKiCj" title="Balance, shares" style="font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000211" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,609,814</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0206">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000207" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,502,346</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000208" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,064,142</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000209" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,438,204</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_z0X8Vjw8cOY9" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Issuance of common stock, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqAepJ4FQGji" title="Issuance of common stock, net, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000218" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,142,857</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0213">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000214" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,832,973</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0215">-</span></p></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31" id="Fact000216" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,832,973</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--StockIssuedDuringPeriodValueWarrantsExercised_zpk9LrB0iGLd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercise of warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEOyP6YIvmNf" title="Exercise of Warrants, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="TELO:StockIssuedDuringPeriodSharesWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000225" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0220">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="TELO:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000221" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,300</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0222">-</span></p></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="TELO:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2024-01-012024-12-31" id="Fact000223" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,300</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zsAz9hDnAtvc" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">-</p></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0227">-</span></p></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000228" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,867,276</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0229">-</span></p></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31" id="Fact000230" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,867,276</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_ziUCSxX7bYRk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net loss</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">-</p></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0232">-</span></p></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0233">-</span></p></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="Fact000234" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,532,716</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000235" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,532,716</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_436_c20250101__20251231_eus-gaap--StockholdersEquity_iS_zoFlHSp5Xqjl" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Balances, December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjD8QK8Sn574" title="Balance, shares" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000242" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29,762,671</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0237">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000238" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,239,895</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000239" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,596,858</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000240" format="ixt:numdotdecimal" decimals="0" unitRef="USD">643,037</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_43E_c20250101__20251231_eus-gaap--StockholdersEquity_iS_z4iUddEncaE7" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Balance</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVs6xP9CYlZk" title="Balance, shares" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000249" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29,762,671</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0244">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000245" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,239,895</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000246" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,596,858</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000247" format="ixt:numdotdecimal" decimals="0" unitRef="USD">643,037</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueNewIssues_z4VenjGMF8ye" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Issuance of common stock for cash in ATM, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIH7wSv5wuF6" title="Issuance of common stock for cash in ATM, net, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000256" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,218,300</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0251">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000252" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,553,209</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0253">-</span></p></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-01to2025-12-31" id="Fact000254" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,553,209</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueOther_zZwZdeAoGAL4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Issuance of common stock for cash, related party</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKiaYuARQKAd" title="Issuance of common stock for cash, Related party, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000263" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0258">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000259" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0260">-</span></p></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-01-01to2025-12-31" id="Fact000261" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_z7IA2Zi16GOb" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Issuance of common stock for services</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKUrEKnzt8Ml" title="Issuance of common stock for services, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000270" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">400,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0265">-</span></p></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000266" format="ixt:numdotdecimal" decimals="0" unitRef="USD">840,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0267">-</span></p></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-01to2025-12-31" id="Fact000268" format="ixt:numdotdecimal" decimals="0" unitRef="USD">840,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zyhFQ2KmHjj7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">-</p></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0272">-</span></p></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000273" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,290,329</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0274">-</span></p></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-01to2025-12-31" id="Fact000275" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,290,329</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_zpqSbzOEqp7a" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net loss</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">-</p></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0277">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="Fact000279" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,413,205</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000280" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,413,205</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_436_c20250101__20251231_eus-gaap--StockholdersEquity_iE_zsiZMD5Cz9h9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balances, December 31, 2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoZBsNxAPIo4" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember" id="Fact000287" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">34,380,971</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0282">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000283" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,923,433</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember" id="Fact000284" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">41,010,063</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31" id="Fact000285" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,913,370</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_437_c20250101__20251231_eus-gaap--StockholdersEquity_iE_zjcXgFYrofhb" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpuz1O11OVGd" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember" id="Fact000294" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">34,380,971</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0289">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000290" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,923,433</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember" id="Fact000291" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">41,010,063</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31" id="Fact000292" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,913,370</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes to the financial statements
are an integral part of these statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="f_005"></span>Telomir Pharmaceuticals, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase">statements
of cash flows</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_112_zthc9hvbgT9a" summary="xdx: Statement - Statements of Cash Flows" style="border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-left: 10pt; font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20250101__20251231_zpEjZtpb78U4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20240101__20241231_zZuJoTw5cgUi" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zU5P697Z7MCh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0in; text-align: left">Cash flows from Operating activities:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_i01_maNCPBUzccc_zVGNX1UfWM5" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000299" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,413,205</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000300" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,532,716</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zcAWl4ZhFwb5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used in operations</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_i02_maNCPBUzccc_zeegneDReB82" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Stock-based compensation expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-01to2025-12-31" id="Fact000305" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,290,329</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31" id="Fact000306" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,867,276</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_i02_maNCPBUzccc_zwGqzh8k6Cel" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Issuance of common stock for services</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2025-01-01to2025-12-31" id="Fact000308" format="ixt:numdotdecimal" decimals="0" unitRef="USD">840,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0309">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProvisionForOtherCreditLosses_i02_maNCPBUzccc_zXbyb8uIRRii" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Credit loss expenses - loan due from related party</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0311">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProvisionForOtherCreditLosses" contextRef="From2024-01-012024-12-31" id="Fact000312" format="ixt:numdotdecimal" decimals="0" unitRef="USD">130,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AmortizationOfFinancingCosts_i02_maNCPBUzccc_zKVvlSP0YtS2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Amortization of debt issuance costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0314">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2024-01-012024-12-31" id="Fact000315" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,338,543</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_zflLtMGzem89" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Change in operating assets and liabilities:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_di_msNCPBUzccc_zVPCmiOPbUPb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Prepaid expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000320" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,183</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2024-01-012024-12-31" id="Fact000321" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,160</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i02_maNCPBUzccc_zqV2DswxzMj5" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Trade accounts payable and accrued liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2025-01-01to2025-12-31" id="Fact000323" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">50,767</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2024-01-012024-12-31" id="Fact000324" format="ixt:numdotdecimal" decimals="0" unitRef="USD">183,629</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInDueToOtherRelatedParties_i02_maNCPBUzccc_zm0v7cklukrh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Due to related parties</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToOtherRelatedParties" contextRef="From2025-01-01to2025-12-31" id="Fact000326" format="ixt:numdotdecimal" decimals="0" unitRef="USD">224,802</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0327">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--IncreaseDecreaseInAccruedCompensation_i02_maNCPBUzccc_zaejlJkNr3W1" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left; padding-bottom: 1pt">Accrued compensation - officer</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="TELO:IncreaseDecreaseInAccruedCompensation" contextRef="From2025-01-01to2025-12-31" id="Fact000329" format="ixt:numdotdecimal" decimals="0" unitRef="USD">417,470</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0330">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUzccc_maCCERCzDc3_zG70bZSDpnob" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Net cash used in operating activities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-01-01to2025-12-31" id="Fact000332" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,688,188</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-012024-12-31" id="Fact000333" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,070,428</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zp77iZlAfsXi" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0in; text-align: left">Cash flows from Financing activities:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RepaymentsOfLinesOfCredit_i01N_di_msNCPBUzRql_msNCPBUz8No_z3j411gCMXB8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Payments under related party line of credit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0338">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="From2024-01-012024-12-31" id="Fact000339" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_i01_maNCPBUz8No_zwEPZlX38bah" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Repayments to related party</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0341">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" contextRef="From2024-01-012024-12-31" id="Fact000342" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">433,945</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_407_ecustom--ProceedsFromRepaymentsOfOfficer_i01_maNCPBUz8No_zxeAcJ8jyB96" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Repayment from officer</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="TELO:ProceedsFromRepaymentsOfOfficer" contextRef="From2025-01-01to2025-12-31" id="Fact000344" format="ixt:numdotdecimal" decimals="0" unitRef="USD">155,518</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0345">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ProceedsFromWarrantExercises_i01_maNCPBUz8No_zEsuik1uM9lb" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Proceeds from warrant exercise</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0347">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-01-012024-12-31" id="Fact000348" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,300</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ProceedsFromSaleOfCommonStockRelatedParty_i01_maNCPBUz8No_zqeEVBKZbEVf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Proceeds from sale of common stock, related party</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="TELO:ProceedsFromSaleOfCommonStockRelatedParty" contextRef="From2025-01-01to2025-12-31" id="Fact000350" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0351">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--ProceedsFromSaleOfCommonStock_i01_maNCPBUz8No_zk2eU2MatVVa" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Net proceeds from sale of common stock</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="TELO:ProceedsFromSaleOfCommonStock" contextRef="From2025-01-01to2025-12-31" id="Fact000353" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,553,209</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="TELO:ProceedsFromSaleOfCommonStock" contextRef="From2024-01-012024-12-31" id="Fact000354" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,832,973</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_pp0p0_maCCERCzDc3_mtNCPBUz8No_zrjU8hqzbIC7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2025-01-01to2025-12-31" id="Fact000356" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,708,727</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-012024-12-31" id="Fact000357" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,335,328</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_pp0p0_mtCCERCzDc3_zs0w1IV9vyzd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0in; text-align: left">Net change in cash</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2025-01-01to2025-12-31" id="Fact000359" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,020,539</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-012024-12-31" id="Fact000360" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,264,900</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_pp0p0_zs7vFTgieNjb" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0in; text-align: left; padding-bottom: 1pt">Cash, beginning of year</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-12-31" id="Fact000362" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,266,131</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000363" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,231</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_pp0p0_zFk8AiSVhTm9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0in; text-align: left; padding-bottom: 2.5pt">Cash, end of year</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2025-12-31" id="Fact000365" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,286,670</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-12-31" id="Fact000366" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,266,131</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--SupplementalCashFlowInformationAbstract_iB_ztsOQAxnbgka" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0in; text-align: left">Supplemental disclosure of cash flow information:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--InterestPaid_i01_zrBzQpvtvlne" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0in; text-align: left">Cash paid for interest</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0371">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0372">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxesPaidNet_i01_zlNCn1DQGKG6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0in; text-align: left">Cash paid for income tax</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0374">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0375">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_i01B_zvrHgScctYck" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0in; text-align: left">Non-cash investing and financing activities:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--DeferredOfferingCostsChargedToAdditionalPaidinCapital_i01_zDhYORFwpWY2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0in; text-align: left">Deferred offering costs charged to additional paid-in capital</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0380">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="TELO:DeferredOfferingCostsChargedToAdditionalPaidinCapital" contextRef="From2024-01-012024-12-31" id="Fact000381" format="ixt:numdotdecimal" decimals="0" unitRef="USD">303,281</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes to the financial statements
are an integral part of these statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="f_006"></span>Telomir Pharmaceuticals, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase">notes
to the financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase">DECEMBER
31, 2025 and 2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000383" name="us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock"><p id="xdx_805_eus-gaap--BusinessDescriptionAndAccountingPoliciesTextBlock_zk8HENW6SSVc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1. <span id="xdx_82B_zhM3PaX6UYEd">Description of business and summary
of significant accounting policies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000385" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zcyNcuoCf5Wk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86C_zEHeuZaF5tl">Overview</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Telomir Pharmaceuticals, Inc.
(&#8220;Telomir&#8221; or the &#8220;Company&#8221;) was formed in August 2021 and is a Florida-incorporated pre-clinical stage
biotechnology company developing therapies designed to target the root epigenetic mechanisms underlying cancer, aging, and
degenerative disease. The Company&#8217;s lead candidate, Telomir-1, has demonstrated activity in preclinical studies involving
modulation of DNA and histone methylation patterns, which may contribute to balanced gene expression, cellular function, and genomic
stability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Telomir-1 is a novel oral small molecule metal
ion regulator designed to extend telomere caps, maintain cellular balance, and combat oxidative stress, a key driver of aging and disease
progression. By modulating essential metal ions such as iron, and copper, Telomir-1 may help protect against age related conditions,
including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson&#8217;s disease (a genetic disorder leading
to toxic copper buildup in the body), and Age-related Macular Degeneration (AMD), as well as Type 2 diabetes, breast cancer, and Alzheimer&#8217;s
disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As used herein, the Company&#8217;s common stock,
no par value per share, is referred to as the &#8220;Common Stock&#8221; and the Company&#8217;s preferred stock, no par value per share,
is referred to as the &#8220;Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000387" name="TELO:InitialPublicOfferingPolicyTextBlock"><p id="xdx_84D_ecustom--InitialPublicOfferingPolicyTextBlock_zBngH3MgXwqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_867_zOe80Bfe0g8l">Initial public offering</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 13, 2024, the Company closed its
initial public offering (the &#8220;IPO&#8221;) consisting of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240212__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zXhzjf4GcOrg" title="IPO units, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-02-122024-02-13_us-gaap_IPOMember" id="Fact000389" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares of Common Stock at a price of $<span id="xdx_908_eus-gaap--SharePrice_iI_c20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zXACQWFfZiP9" title="Initial public offering shares"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-02-13_us-gaap_IPOMember" id="Fact000391" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></span> per share for approximately
$<span id="xdx_904_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20240212__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zwLJpZMWDhe6" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2024-02-122024-02-13_us-gaap_IPOMember" id="Fact000393" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.0</ix:nonFraction></span> million in gross proceeds. After deducting the underwriting commission and other offering expenses totaling $<span id="xdx_90D_eus-gaap--OtherUnderwritingExpense_pn5n6_c20240212__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z7zUzOHXJlkl" title="Underwriting commission and other offering expenses"><ix:nonFraction name="us-gaap:OtherUnderwritingExpense" contextRef="From2024-02-122024-02-13_us-gaap_IPOMember" id="Fact000395" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span> million, the net
proceeds to the Company were $<span id="xdx_904_ecustom--ProceedsFromInitialPublicOfferingNetProceeds_pn5n6_c20240212__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zACg2SryjJub" title="Initial public offering net proceeds"><ix:nonFraction name="TELO:ProceedsFromInitialPublicOfferingNetProceeds" contextRef="From2024-02-122024-02-13_us-gaap_IPOMember" id="Fact000397" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.8</ix:nonFraction></span> million. The Common Stock began trading on The Nasdaq Capital Market on February 9, 2024 under the
symbol &#8220;TELO&#8221; (See Note 7 &#8220;Common Stock&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000399" name="TELO:ProposedMergerPolicyTextBlock"><p id="xdx_84E_ecustom--ProposedMergerPolicyTextBlock_zcv5hFANvy8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86A_zDrtsOS9yay7">Proposed merger</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Company and TELI Pharmaceuticals, Inc., a related party private
company incorporated under the laws of Delaware (&#8220;TELI&#8221;) have entered into an Agreement and Plan of Merger and Reorganization,
dated November 20, 2025, and as amended on February 4, 2026 (collectively, the &#8220;Merger Agreement&#8221;), pursuant to which a wholly
owned subsidiary of Telomir will merge with and into TELI, with TELI surviving as a wholly owned subsidiary of Telomir (the &#8220;Merger&#8221;),
subject to shareholder approval. At the effective time of the Merger (the &#8220;Effective Time&#8221;), each outstanding share of common
stock of TELI, $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251120_zJCp5dWMrgqf" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-11-20" id="Fact000401" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> par value per share (&#8220;TELI Common Stock&#8221;), will be converted into the right to receive such number
of Telomir Common Stock as is calculated based on the exchange ratio of the shares for the Merger (the &#8220;Exchange Ratio&#8221;).
The Exchange Ratio is calculated using the relative company valuations of each of Telomir and TELI, as determined by a third-party valuation
firm (as further described herein). It is expected that shareholders of TELI will receive one share of Telomir Common Stock for each
share of TELI Common Stock held (the &#8220;Merger Share Consideration&#8221;). The Telomir Common Stock issued as the consideration
will not be registered for trading under the Securities Act. The Merger will result in an alignment of U.S. and non-U.S. rights to Telomir-1
within a single public company structure, thereby simplifying global development and partnership efforts. As a result of the Merger,
TELO will own the entire worldwide intellectual property portfolio and development programs related to Telomir-1. See Note 5, <i>Merger
Agreement.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 68; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000403" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zAoI6yYkHcLg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_866_zmlQbeYRYKj2">Revenue recognition</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company currently has no source of revenue.
Miscellaneous income, including interest, is recognized when earned by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000405" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_z8RxvchywP9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_869_zntlUZHp0BVf">Income taxes</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes pursuant
to the provision of Accounting Standards Codification (&#8220;ASC&#8221;) 740-10, &#8220;Accounting for Income Taxes&#8221; (&#8220;ASC
740-10&#8221;), which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and
liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary
differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any
net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows the provision of&#160;ASC
740-10&#160;related to Accounting for Uncertain Income Tax Positions. When tax returns are filed, there may be uncertainty about the
merits of positions taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of&#160;ASC
740-10, the benefit of a tax position is recognized in the consolidated financial statements in the period during which, based on all
available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the
resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions
that meet the more likely than not recognition threshold are measured at the largest amount of tax benefit that is more than&#160;50&#160;percent
likely of being realized upon settlement with the applicable taxing authority. The portion of the benefit associated with tax positions
taken that exceed the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying
balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The
Company believes its tax positions are all more likely than not to be upheld upon examination. As such, the Company has not recorded
a liability for uncertain tax benefits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has adopted&#160;ASC 740-10-25, &#8220;Definition
of Settlement&#8221;, which provides guidance on how an entity should determine whether a tax position is effectively settled for the
purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion
and examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity
would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based
solely on the basis of its technical merits and the statute of limitations remains open. The federal and state income tax returns of
the Company are subject to examination by the IRS and state taxing authorities, generally for three years after they are filed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000407" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_z3CMQ6zURrRb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_861_zIeIdv2Cy7zk">Research and development expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development costs are expensed in
the period in which they are incurred and include the expenses paid to third parties, such as contract research organizations and consultants,
who conduct research and development activities on behalf of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000409" name="us-gaap:UseOfEstimates"><p id="xdx_84A_eus-gaap--UseOfEstimates_zi4qYvdAfKF7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_864_zoZkUJLUcC3k">Use of estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in accordance
with generally accepted accounting principles in the United States of America requires the Company&#8217;s management to make estimates
and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at
the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results may differ from
such estimates and such differences could be material. Significant estimates during the reporting periods include stock-based compensation
and the deferred tax asset valuation allowance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000411" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zhNPo926zCNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_866_zEIO4qLaV7S4">Cash and Cash Equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid debt
instruments and other short-term investments with maturities of three months or less, when purchased, to be cash equivalents. The Company
maintains cash and cash equivalent balances at two financial institutions that are insured by the Federal Deposit Insurance Corporation
(&#8220;FDIC&#8221;). The Company&#8217;s accounts at these institutions are insured by the FDIC up to $<span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_c20251231_zhzTq8QqQ3Ih" title="Cash insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2025-12-31" id="Fact000413" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>. On December 31, 2025
and 2024, the Company had cash in excess of FDIC limits of approximately $<span id="xdx_907_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20251231_zYb8zhGQf1Lg" title="Cash, Uninsured Amount"><ix:nonFraction name="us-gaap:CashUninsuredAmount" contextRef="AsOf2025-12-31" id="Fact000415" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.0</ix:nonFraction></span> million and $<span id="xdx_902_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20241231_z5LbG5jXtJD5" title="Cash, Uninsured Amount"><ix:nonFraction name="us-gaap:CashUninsuredAmount" contextRef="AsOf2024-12-31" id="Fact000417" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million, respectively. To reduce its risk
associated with the failure of such financial institution, the Company evaluates at least annually the rating of the financial institution
in which it holds deposits. Any material loss that the Company may experience in the future could have an adverse effect on its ability
to pay its operational expenses or make other payments and may require the Company to move its cash to other high quality financial institutions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 69; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000419" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zwFZJoo8kq0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_863_z0OyzotJZQx9">Stock-based compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for stock-based compensation
under the provisions of FASB&#160;ASC 718, &#8220;Compensation - Stock Compensation&#8221;, which requires the measurement and recognition
of compensation expense for all stock-based awards made to employees, directors and consultants based on estimated fair values on the
grant date. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value
of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the
straight-line method. The Company has elected to account for forfeitures of stock-based awards as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000421" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_84B_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zdeiGi41SuNj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_862_znF1qK7olRO9">Fair Value Measurements and Financial Instruments</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures the fair value of financial
instruments in accordance with GAAP which defines fair value, establishes a framework for measuring fair value, and expands disclosures
about fair value measurements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">GAAP defines fair value as the exchange price
that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for
the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes a fair value
hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring
fair value. GAAP describes three levels of inputs that may be used to measure fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 1 &#8211; quoted prices
in active markets for identical assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 2 &#8211; quoted prices
for similar assets and liabilities in active markets or inputs that are observable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 3 &#8211; inputs that
are unobservable (for example cash flow modeling inputs based on assumptions).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers the carrying amount of
prepaid assets and all current liabilities to approximate fair value due to the short-term nature of those elements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000423" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zWfpQBLGwnH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_866_zO7MsxX3Q3zd">Earnings per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Earnings (loss) per share is computed in accordance
with ASC Topic 260, &#8220;Earnings per Share&#8221; Basic weighted-average number of shares of common stock outstanding for the year
ended December 31, 2025 and December 31, 2024 include the shares of the Company issued and outstanding during such period, on a weighted
average basis. The basic weighted average number of shares of common stock outstanding excludes common stock equivalents such as stock
options and warrants, while diluted weighted average number of shares outstanding includes such stock options and warrants. As of December
31, 2025 there were <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zY1vFKjEfDHj" title="Antidilutive securities excluded from computation of earnings per share"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember" id="Fact000425" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,814,057</ix:nonFraction></span> common stock warrants and <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zAjoxzE3nv6e" title="Antidilutive securities excluded from computation of earnings per share"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000427" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,187,670</ix:nonFraction></span> common stock options that were not included in the computation of diluted
earnings per share, because to do so would have an antidilutive effect. As of December 31, 2024 there were <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zDJUG8wNt7E6" title="Antidilutive securities excluded from computation of earnings per share"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" id="Fact000429" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,814,057</ix:nonFraction></span> stock warrants and
<span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z6tprkC9Tt49" title="Antidilutive securities excluded from computation of earnings per share"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000431" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,352,670</ix:nonFraction></span> stock options that were not included in the computation of diluted earnings per share, because to do so would have an antidilutive
effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000433" name="TELO:RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock"><p id="xdx_846_ecustom--RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_zBRaUZBi3TX9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_865_zqWhF34cwIFb">Recent accounting pronouncements not yet
adopted</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2023, the FASB issued ASU 2023-09,
<i>Income Taxes (Topic 740) - Improvements to Income Tax Disclosures</i>. The new standard requires a company to expand its existing
income tax disclosures, specifically related to the rate reconciliation and income taxes paid. The standard is effective for the Company
beginning in fiscal year 2025. The Company applied the amendments prospectively for the year ended December 31, 2025, and the impact
of the adoption of the amendments in this update was not material to the Company&#8217;s financial position and results of operations
for the year ended December 31, 2025, since the amendments require only enhancement of existing income tax disclosures in the footnotes
to the Company&#8217;s financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2024, the FASB issued ASU 2024-03,&#160;<i>Income
Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures&#160;</i>(Subtopic 220-40), which requires entities to provide
more detailed disaggregation of expenses in the income statement, focusing on the nature of the expenses rather than their function.
The new disclosures will require entities to separately present expenses for significant line items, including but not limited to, depreciation,
amortization, and employee compensation. Entities will also be required to provide a qualitative description of the amounts remaining
in relevant expense captions that are not separately disaggregated quantitatively, disclose the total amount of selling expenses and,
in annual reporting periods, provide a definition of what constitutes selling expenses. This pronouncement is effective for fiscal years
beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted.
The Company does not expect the adoption of this new guidance to have a material impact on the consolidated financial statements.</p>

</ix:nonNumeric><p id="xdx_857_zsBX1Un9Bvc4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000435" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock"><p id="xdx_802_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zLT3LOnHb4Dc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2. <span><span id="xdx_82B_zKAs4dlBKZTk">Going Concern</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have been
prepared assuming the Company will continue as a going concern which contemplates the realization of assets and settlement of liabilities
and commitments in the normal course of business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the Company had cash of approximately $<span id="xdx_905_eus-gaap--Cash_iI_pn5n6_c20251231_zbwqPtCpZZU4" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2025-12-31" id="Fact000437" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.3</ix:nonFraction></span> million. The Company raised approximately $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250101__20251231_zdUdRSVqKBCb" title="Raised amount"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2025-01-01to2025-12-31" id="Fact000439" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">9.6</ix:nonFraction></span> million in 2025, used
approximately $<span id="xdx_90D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20250101__20251231_zUkOpn2Azphl" title="Cash in operations"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-01-01to2025-12-31" id="Fact000441" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">3.7</ix:nonFraction></span> million of cash in operations during the year ended December 31, 2025, had a net loss of $<span id="xdx_90D_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20250101__20251231_zIMI4waMEKYc" title="Net Loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000443" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">10.4</ix:nonFraction></span> million in 2025 and
had stockholders&#8217; equity of approximately $<span id="xdx_903_eus-gaap--StockholdersEquity_iI_pn5n6_c20251231_zMNVUjpEMC28" title="Stockholders equity"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31" id="Fact000445" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.9</ix:nonFraction></span> million at December 31, 2025, versus stockholders&#8217; equity of approximately
$<span id="xdx_905_eus-gaap--StockholdersEquity_iI_pn5n6_c20241231_zvZDwnTwCI6j" title="Stockholders equity"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000447" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></span> million at December 31, 2024.</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 70; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Historically, the Company has been primarily
engaged in developing Telomir-1. During these activities, the Company sustained substantial losses. The Company&#8217;s ability to fund
ongoing operations and future clinical trials required for FDA approval is dependent on the Company&#8217;s ability to obtain significant
additional external funding in the near term. Since inception, the Company has financed its operations through related party financings-see
Note 4, an initial public offering &#8211; see Note 1, and ATM financings. Additional sources of financing may be sought by the Company.
However, there can be no assurance that any fundraising will be achieved on commercially reasonable terms, if at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of filing this Annual Report,
the Company will continue to generate losses and have insufficient cash and cash equivalents on hand to support its operations for at
least the 12 months following the date the financial statements are issued. These factors raise substantial doubt about the Company&#8217;s
ability to continue as a going concern for a period of twelve months from the issuance date of this report. Management cannot provide
assurance that the Company will ultimately achieve profitable operations or become cash flow positive or raise additional debt and/or
equity capital. The Company is seeking to raise capital through additional debt and/or equity financings to fund our operations in the
future. If the Company is unable to raise additional capital or secure additional lending in the near future, management expects that
the Company will need to curtail its operations. These financial statements do not include any adjustments related to the recoverability
and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to
continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000449" name="TELO:LicenseAgreementRelatedPartyTextBlock"><p id="xdx_80A_ecustom--LicenseAgreementRelatedPartyTextBlock_zuHDf3ShNRIe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 3. <span id="xdx_821_zX0Qk8kWsmkc">License agreement, related party</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company licenses the U.S. patent rights for
the use of Telomir-1 in human applications from MIRALOGX, LLC (&#8220;MIRALOGX&#8221;), an intellectual property development and holding
company owned by a trust established by the Company&#8217;s founder&#8212;a related party to the Company and greater than <span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MiralogxLLCMember_zN1c5biwwgt7" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2025-12-31_custom_MiralogxLLCMember" id="Fact000451" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% shareholder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 11, 2023, (the &#8220;Effective Date&#8221;),
the Company and MIRALOGX entered into an Amended and Restated Exclusive License Agreement, under which the Company has the exclusive
perpetual right and license under the above-described patent rights to make, have made, use, and sell &#8220;Licensed Products&#8221;
in the U.S. for human uses and preclinical studies and activities of any kind conducted in furtherance of obtaining regulatory approval
or commercialization for human uses (the &#8220;MIRALOGX License Agreement&#8221;). On November 10, 2023, the Company and MIRALOGX entered
into the Amendment No. 1 to the Amended and Restated License Agreement, pursuant to which the field of use relating to the license was
amended to include therapeutic treatments and other medical or health uses in animals, in addition to humans, and related preclinical
studies and activities conducted in furtherance of obtaining regulatory approval for and commercialization of veterinary, in addition
to human, therapeutic treatments and uses (together with the &#8220;Initial MIRALOGX License Agreement, the &#8220;MIRALOGX License Agreement&#8221;).
&#8220;Licensed Product&#8221; is defined in the agreement as a drug product containing as an active agent 2,4,6-tris(3,4-dihydro-2H-pyrrol-2-yl)
pyridine or a pharmaceutically acceptable salt, ester, or solvate thereof. The Company also has the right to grant corresponding sublicenses
under the licensed patent rights. The MIRALOGX License Agreement provides for the payment to MIRALOGX of an <span id="xdx_90D_ecustom--PercentageOfRoyaltyPayable_iI_dp_uPure_c20230811__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zmwA0puwMBQ1" title="Percentage of royalty payable"><ix:nonFraction name="TELO:PercentageOfRoyaltyPayable" contextRef="AsOf2023-08-11_us-gaap_RelatedPartyMember" id="Fact000453" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% royalty (payable quarterly)
on the Company&#8217;s net sales of Licensed Products by the Company or its sublicensees and on non-royalty bearing milestone revenue.
There are no up-front, execution, or milestone payments in the license agreement. Further, no payments have been made to date under the
agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The term of the license from MIRALOGX will continue
through the date of the expiration of the last-to-expire licensed patent or, if later, the date of the expiration of the last strategic
partnership/sublicensing agreement covering the licensed products. The patent rights are expected to extend through 2043, and additional
patent terms may be awarded, including additional patent terms based on the time taken for regulatory review of drug products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The agreement also provides that Telomir may
bring suit in its own name to enforce patent rights. MIRALOGX will control the prosecution of the patent applications for Telomir-1.
Telomir is required to be kept informed by MIRALOGX of patent prosecution activities and may select identified countries for patent protection.
Telomir is to reimburse MIRALOGX for patent prosecution and maintenance costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000455" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_80C_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zFCAYHHwfmG9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 4. <span id="xdx_82F_z0B6Wg15XUX9">Related parties balances and transactions</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Due to Officer</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 27, 2025, <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250526__20250527_zxEPbzG6hY5b" title="Issuance of common stock for services, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2025-05-262025-05-27" id="Fact000457" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">400,000</ix:nonFraction></span> fully vested common
shares were granted for services to our Chairman and Chief Executive Officer, Erez Aminov, who is the son-in-law of Jonnie R. Williams
(see below). The shares were valued at $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250527__20250527_zz3hgQpaTP0f" title="Vested common shares service, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-05-272025-05-27" id="Fact000459" format="ixt:numdotdecimal" decimals="0" unitRef="USD">840,000</ix:nonFraction></span> based on the stock quoted trading price at the grant date and were expensed immediately
as compensation expense. In December 2025, Mr. Aminov transferred $<span id="xdx_90F_eus-gaap--DebtInstrumentRepurchaseAmount_iI_c20251231_zijLWuntQxUk" title="Debt Instrument, Repurchase Amount"><ix:nonFraction name="us-gaap:DebtInstrumentRepurchaseAmount" contextRef="AsOf2025-12-31" id="Fact000461" format="ixt:numdotdecimal" decimals="0" unitRef="USD">155,518</ix:nonFraction></span> to the Company, for the Company to use to pay certain payroll
withholding taxes Mr. Aminov owed as a result of this RSU grant. These payroll taxes ultimately were not paid in the Company&#8217;s
payroll processing. Therefore, in January 2026, $<span id="xdx_903_eus-gaap--AccruedPayrollTaxesCurrentAndNoncurrent_iI_c20260131_zWxdXEoGZr1a" title="Payroll taxes"><ix:nonFraction name="us-gaap:AccruedPayrollTaxesCurrentAndNoncurrent" contextRef="AsOf2026-01-31" id="Fact000463" format="ixt:numdotdecimal" decimals="0" unitRef="USD">155,518</ix:nonFraction></span> was paid back to Mr. Aminov so he can remit this amount directly to the IRS.
The company, however, did remit the employer portion of his Medicare taxes totaling $<span id="xdx_909_eus-gaap--TaxesOther_c20250101__20251231_zknPUSYV97d8" title="Medicare taxes"><ix:nonFraction name="us-gaap:TaxesOther" contextRef="From2025-01-01to2025-12-31" id="Fact000465" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,180</ix:nonFraction></span> in 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Due from related parties</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2023, the
Company provided working capital advances to companies under common control. These advances were due on demand and are non-interest bearing.
Amounts due from related parties as of December 31, 2023 were $<span id="xdx_903_eus-gaap--OtherReceivablesNetCurrent_iI_pn4n6_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zto98vd8Jmj5" title="Amounts due from related parties"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact000467" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.13</ix:nonFraction></span>&#160;million. In 2024, the company under common control was dissolved
and therefore the amount due become uncollectable and was written off and reflected as credit loss expense, which is included in general
and administration expenses. As of December 31, 2024, there was&#160;<span id="xdx_90D_eus-gaap--OtherReceivables_iI_do_c20241231_zvqs9AyY7Eu9" title="Amount due from related parties"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2024-12-31" id="Fact000469" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span>&#160;amount due from related parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 71; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Due to related parties</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2024, the
Company received working capital advances from related party companies under common control. These advances are due on demand and are
non-interest bearing. During the year ended December 31, 2025, a related party, MIRALOGX, shipped pharmaceutical chemicals to Telomir&#8217;s
service provider for ongoing research at a cost of approximately $<span id="xdx_907_eus-gaap--CostsAndExpensesRelatedParty_c20250101__20251231_zq3bixHxPxQ8" title="Costs and Expenses, Related Party"><ix:nonFraction name="us-gaap:CostsAndExpensesRelatedParty" contextRef="From2025-01-01to2025-12-31" id="Fact000471" format="ixt:numdotdecimal" decimals="0" unitRef="USD">224,800</ix:nonFraction></span>. As of December 31, 2025 and 2024, the amounts due to related
parties is $<span id="xdx_906_eus-gaap--OtherReceivablesNetCurrent_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zlX3PKC7d4s3" title="Amount due from related parties"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember" id="Fact000473" format="ixt:numdotdecimal" decimals="0" unitRef="USD">318,234</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--OtherReceivablesNetCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zH3M4OpdHLYe" title="Amount due from related parties"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact000475" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,432</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Investment from Largest Shareholder</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 19, 2025, the Company entered into an
agreement to raise $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn6n6_c20250518__20250519_zV85LNB5zcn6" title="Raised amount in equity financing"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="From2025-05-182025-05-19" id="Fact000477" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">3</ix:nonFraction></span> million in equity financing through a direct investment by The Bayshore Trust, an entity affiliated with the Company&#8217;s
largest shareholder, Jonnie R. Williams, Sr. The transaction was structured as a straight restricted common stock deal with no warrants.
The Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20250518__20250519_zF4UueDlZZk2" title="Number of restricted shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2025-05-182025-05-19" id="Fact000479" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">333,334</ix:nonFraction></span> restricted shares of its common stock, no par value (the &#8220;Common Stock&#8221;) at a purchase price of
$<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20250519_zEGG0u3gJf6g" title="Purchase price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2025-05-19" id="Fact000481" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></span> per share, representing an <span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardPriceOfCommonStockPercent_pid_dp_uPure_c20250518__20250519_zWjL1lsVjamd" title="Premium share price percentage"><ix:nonFraction name="TELO:SharebasedCompensationArrangementBySharebasedPaymentAwardPriceOfCommonStockPercent" contextRef="From2025-05-182025-05-19" id="Fact000483" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">18</ix:nonFraction></span>% premium to the closing share price of the Common Stock of $<span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20250519__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNI76Ln9ibDj" title="Purchase price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-05-19_us-gaap_CommonStockMember" id="Fact000485" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.54</ix:nonFraction></span> on the date of execution (the &#8220;Bayshore
Financing&#8221;). The Company received the initial payment of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn6n6_c20250520__20250520_zfPI6521hmyb" title="Initial payment"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2025-05-202025-05-20" id="Fact000487" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">1</ix:nonFraction></span> million for the Bayshore Financing on May 20, 2025. In July 2025, an
additional $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn6n6_c20250701__20250731__dei--LegalEntityAxis__custom--BayshorefinancingMember_zXpPCvPz7jLg" title="Initial payment"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2025-07-012025-07-31_custom_BayshorefinancingMember" id="Fact000489" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">2</ix:nonFraction></span> million was received, for the issuance of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250701__20250731__dei--LegalEntityAxis__custom--BayshorefinancingMember_zc5JH9hKDeke" title="Issuance of common stock for cash in ATM, net, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-07-012025-07-31_custom_BayshorefinancingMember" id="Fact000491" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">666,666</ix:nonFraction></span> shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Bay Shore Trust Line of Credit </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 15, 2023, the Company entered into a
Promissory Note and Loan Agreement with the Bay Shore Trust, a trust established by the Company&#8217;s founder, Jonnie R. Williams,
Sr., and under which various of his family members are beneficiaries. Under this Promissory Note and Loan Agreement (the &#8220;Bay Shore
Note&#8221;), the Company had the right to borrow up to an aggregate of $<span id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zFFmnsa4vjAf" title="Unused line of credit"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2023-06-15_custom_BayShoreTrustMember" id="Fact000493" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span> million from the Bay Shore Trust at any time up to the second
anniversary of the issuance of the Bay Shore Note or, if earlier, upon the completion of the Company&#8217;s IPO. As of December 31,
2025 and 2024, the line of credit is no longer available as the IPO was completed in February 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In consideration of the loan facility provided
by the Bay Shore Trust, the Company issued to the Bay Shore Trust a Common Stock purchase warrant on June 15, 2023 giving the Bay Shore
Trust the right to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zrdGKXcSPqfa" title="Fair value of total warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-06-15_custom_BayShoreTrustMember" id="Fact000495" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,439,025</ix:nonFraction></span> shares of Common Stock at an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zl6v0E13OVr5" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-06-15_custom_BayShoreTrustMember" id="Fact000497" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.73</ix:nonFraction></span> per share (See Note 7).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Starwood Trust Line of Credit and Stock
Purchase Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 24, 2024 the Company entered into
an unsecured Promissory Note and Loan Agreement (&#8220;the Starwood Note&#8221;) with the Starwood Trust, a separate related party trust
established by the Company&#8217;s founder, Jonnie R. Williams, Sr. who is the sole owner of Bay Shore Trust as well as our largest shareholder,
and under which various of his family members are beneficiaries. Under the Starwood Note, the Company has the right to borrow up to an
aggregate of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20240924__dei--LegalEntityAxis__custom--StarwoodTrustMember_ziLnTzY1SvH" title="Aggregate borrowings amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-09-24_custom_StarwoodTrustMember" id="Fact000499" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span>&#160;million from the Starwood Trust at any time up until September 24, 2026, the second anniversary of the note. The
Company&#8217;s right to borrow funds under the Starwood Note is subject to the absence of a material adverse change in its assets, operations,
or prospects The Starwood Note contains default provisions in which in the event of the Company misses payment, makes false representations,
fails to comply in any material respect to covenants, files for bankruptcy, or experiences a material adverse change in is assets or
operations than the Company is considered in default and the entire unpaid principal and accrued interest is due immediately. The Starwood
Note, together with accrued interest, is to become due and payable on the second anniversary of the issuance of the note, provides for
prepayment at any time without penalty, and accrues simple interest at a rate equal&#160;<span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240924__dei--LegalEntityAxis__custom--StarwoodTrustMember_zAYufrXDzly9" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-09-24_custom_StarwoodTrustMember" id="Fact000501" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7</ix:nonFraction></span>% per annum. As of December 31, 2025 and 2024,
the Company has not borrowed any amounts under the Starwood Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, on December 9, 2024, Starwood Trust
entered into a stock purchase agreement with the Company to purchase <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241209__20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_zUI8d2yFppZk" title="Issuance of common stock, net, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-12-092024-12-09_custom_StarwoodTrustMember" id="Fact000503" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">142,857</ix:nonFraction></span> shares of unregistered common stock at $<span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_zCYpV9BNajWd" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-12-09_custom_StarwoodTrustMember" id="Fact000505" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7</ix:nonFraction></span> a share for a
total of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20241209__20241209_zzG7EfP120ib" title="Proceeds from common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-12-092024-12-09" id="Fact000507" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million in proceeds to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>License agreement</i> - </b>See Note 3</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Related Party Travel Costs</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 1, 2023 the Company entered into an
Agreement For Shared Lease Costs (the &#8220;Shared Agreement&#8221;) with MIRALOGX, LLC, a related party under which we have agreed
to pay our pro rata share of the operating usage costs owing by MIRALOGX under an aircraft lease agreement between MIRALOGX and Supera
Aviation I LLC (&#8220;Supera Aviation&#8221;) based on our usage of the leased aircraft each month. No amounts are payable by the Company
under this agreement unless and to the extent the Company chooses to utilize the leased aircraft, and the Company may discontinue the
use of the aircraft and terminate this agreement at any time. Supera Aviation is a company owned by Starwood Trust, a trust established
by Mr. Williams, the Company&#8217;s founder and largest shareholder. For the year ended December 31, 2025 and December 31, 2024, the
Company incurred <span id="xdx_90C_eus-gaap--TravelAndEntertainmentExpense_dxL_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zm7D8mwFSaHg" title="Related party travel costs::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0509">nil</span></span> and $<span id="xdx_906_eus-gaap--TravelAndEntertainmentExpense_pn4n6_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zJQAQorqVN5l" title="Related party travel costs"><ix:nonFraction name="us-gaap:TravelAndEntertainmentExpense" contextRef="From2024-01-012024-12-31_us-gaap_RelatedPartyMember" id="Fact000511" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.37</ix:nonFraction></span> million, respectively, in expenses under the aircraft lease agreement. The aircraft lease was terminated
in April 2024 and no other costs have been incurred under this agreement since the lease termination (See Note 6 Variable lease costs).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 72; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Related Party Rental Agreement</i></b><i>-</i>
see Note 6 for Variable lease costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000513" name="TELO:ProposedMergerAgreementDisclosureTextBlock"><p id="xdx_802_ecustom--ProposedMergerAgreementDisclosureTextBlock_zHCyNwcpprFi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 5. <span id="xdx_824_z4AiPPcQ1D69">Proposed Merger Agreement</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company and TELI Pharmaceuticals, Inc., a
related party private company incorporated under the laws of Delaware (&#8220;TELI&#8221;) have entered into an Agreement and Plan of
Merger and Reorganization, dated November 20, 2025, and as amended on February 4, 2026 (collectively, the &#8220;Merger Agreement&#8221;),
pursuant to which a wholly owned subsidiary of Telomir will merge with and into TELI, with TELI surviving as a wholly owned subsidiary
of Telomir (the &#8220;Merger&#8221;), subject to shareholder approval. At the effective time of the Merger (the &#8220;Effective Time&#8221;),
each outstanding share of common stock of TELI, $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20260204__us-gaap--BusinessAcquisitionAxis__custom--TeliPharmaceuticalsIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zynZBUfk5HZ4" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2026-02-04_custom_TeliPharmaceuticalsIncMember_us-gaap_SubsequentEventMember" id="Fact000515" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> par value per share (&#8220;TELI Common Stock&#8221;), will be converted into
the right to receive such number of Telomir Common Stock as is calculated based on the exchange ratio of the shares for the Merger (the
&#8220;Exchange Ratio&#8221;). The Exchange Ratio is calculated using the relative company valuations of each of Telomir and TELI, as
determined by an independent valuation firm. It is expected that shareholders of TELI will receive one share of Telomir Common Stock
for each share of TELI Common Stock held (the &#8220;Merger Share Consideration&#8221;). The Telomir Common Stock issued as the consideration
will not be registered for trading under the Securities Act. The Merger will result in an alignment of U.S. and non-U.S. rights to Telomir-1
within a single public company structure, thereby simplifying global development and partnership efforts. As a result of the Merger,
Telomir will own the entire worldwide intellectual property portfolio and development programs related to Telomir-1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transaction is expected to be recorded
as an asset acquisition from a related party at acquired cost basis with two assets to be acquired, the license agreement and
$<span id="xdx_903_eus-gaap--PaymentsToAcquireMarketableSecurities_c20260204__20260204__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLImq8MQek" title="Cash or marketable securities"><ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="From2026-02-042026-02-04_custom_LicenseAgreementMember_us-gaap_SubsequentEventMember" id="Fact000517" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span> in cash or marketable securities. TELI is a newly formed legal entity with no revenue, no employees, no facilities, and
no infrastructure. TELI&#8217;s assets as of the Merger Date will consist exclusively of the $<span id="xdx_90D_eus-gaap--PaymentsToAcquireMarketableSecurities_c20260204__20260204__us-gaap--BusinessAcquisitionAxis__custom--TeliPharmaceuticalsIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zEnGKa9sWeca" title="Cash or marketable securities"><ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="From2026-02-042026-02-04_custom_TeliPharmaceuticalsIncMember_us-gaap_SubsequentEventMember" id="Fact000519" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span> in cash or marketable
securities and the Telo-1 license agreement with MIRALOGX. MIRALOGX is the licensor of the Company&#8217;s and TELI&#8217;s rights
to Telomir-1. MIRALOGX is a separate intellectual property development company owned by the Bayshore Trust. The Bayshore Trust, a
related party, is also TELI&#8217;s largest stockholder. The license agreement grants rights to develop and commercialize the
Telomir-1 compound in the United Arab Amirates, Australia, Canada, China, European Union, Israel, India, Japan, South Korea, Mexico,
Argentina, Taiwan and Uruguay. No other tangible or intangible assets, such as equipment, customer relationships, or developed
technologies, will be transferred. The contingent consideration to Telomir in the transaction consists of two possible payments.
Certain shareholders of TELI will agree to provide $<span id="xdx_900_eus-gaap--AssetAcquisitionConsiderationTransferredTransactionCost_pn6n6_c20260204__20260204__us-gaap--AssetAcquisitionAxis__custom--TelomirOneMember_z8MGnuVeLV19" title="Contingent consideration transaction cost"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost" contextRef="From2026-02-042026-02-04_custom_TelomirOneMember" id="Fact000521" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">2</ix:nonFraction></span> million upon FDA acceptance of an Investigational New Drug or IND application
for Telomir-1, and $<span id="xdx_905_eus-gaap--AssetAcquisitionConsiderationTransferredTransactionCost_pn6n6_c20260204__20260204__us-gaap--AssetAcquisitionAxis__custom--PhaseOneByTwoMember_z7u2ANPLaGZc" title="Contingent consideration transaction cost"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost" contextRef="From2026-02-042026-02-04_custom_PhaseOneByTwoMember" id="Fact000523" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">2</ix:nonFraction></span> million upon initiation of a Phase 1/2 study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000525" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_806_eus-gaap--LesseeOperatingLeasesTextBlock_zawm3LcwKda7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 6. <span id="xdx_827_zNYFHJwCCwq9">Leases</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s former corporate headquarters
was located in Baltimore, Maryland, which included a lease for office space. This lease began in November 2022 and expired in April 2024.
The lease was not renewed. To align with the accounting and administrative staff detailed below, the Company moved all remaining corporate
activities in April 2024 to the shared space in Tampa, Florida referenced below within variable lease costs. In September 2024, the Company
decided to no longer utilize the shared space and moved to a virtual office model. The Company has not had a physical office space since
October 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Variable lease costs</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Variable lease costs primarily include utilities,
property taxes, and other operating costs that are passed on from the lessor for the former corporate headquarters in Baltimore, Maryland.
Variable lease costs related to the usage of the MIRALOGX airplane include usage expenses, which includes pilot expenses, jet fuel and
general flight expenses that totaled <span id="xdx_90B_eus-gaap--VariableLeaseCost_pn6n6_dxL_c20250101__20251231__dei--LegalEntityAxis__custom--MiralogxLLCMember_zlvaIoQgaSDf" title="Variable lease, cost::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0527">nil</span></span> and $<span id="xdx_90A_eus-gaap--VariableLeaseCost_pn4n6_c20240101__20241231__dei--LegalEntityAxis__custom--MiralogxLLCMember_za7jS8eni2Ya" title="Variable lease, cost"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2024-01-012024-12-31_custom_MiralogxLLCMember" id="Fact000529" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.32</ix:nonFraction></span> million in 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Beginning August 1, 2023, the Company&#8217;s
accounting and administrative staff began sharing office space with a related party in Tampa, Florida. During the year ended December
31, 2024, this variable least cost related to the Tampa, Florida space totaled $<span id="xdx_90E_eus-gaap--VariableLeaseCost_pn4n6_c20240101__20241231__srt--StatementGeographicalAxis__custom--TampaFloridaMember_zOrri1CkaEWa" title="Variable lease, cost"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2024-01-012024-12-31_custom_TampaFloridaMember" id="Fact000531" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.02</ix:nonFraction></span> million. The Company did not have lease costs during
the year ended December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000533" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_899_eus-gaap--LeaseCostTableTextBlock_zskfffFPOTjb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The components of lease expense were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B9_zK7BPagaSni4" style="display: none">Schedule of Components of Lease Expenses</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20250101__20251231_zwRyEPX32mg1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zCUrlNHyobJc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Lease Costs</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Operating lease cost</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseCost_maLCzhnC_zazPIYT7LTdk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; width: 60%; text-align: left">Operating lease</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0535">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2024-01-012024-12-31" id="Fact000536" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,667</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--VariableLeaseCost_maLCzhnC_zMpYOHkOlHZ2" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Variable lease costs</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0538">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2024-01-012024-12-31" id="Fact000539" format="ixt:numdotdecimal" decimals="0" unitRef="USD">336,656</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LeaseCost_iT_mtLCzhnC_zK7pGGuKPHIj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0541">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2024-01-012024-12-31" id="Fact000542" format="ixt:numdotdecimal" decimals="0" unitRef="USD">392,323</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A3_ziVK133MZsq" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<ix:exclude><!-- Field: Page; Sequence: 73; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000544" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zpCZYr7cerTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 7. <span id="xdx_82F_zzuTRjiR7yRa">Stockholders&#8217; equity</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Capital stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has the authority to issue <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20251231_zyEaGWtevQ5h" title="Issue of shares of capital stock"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2025-12-31" id="Fact000546" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">400,000,000</ix:nonFraction></span>
shares of capital stock, consisting of <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20251231_zXm4V5QyRyj7" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-12-31" id="Fact000548" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000,000</ix:nonFraction></span> shares of Common Stock and <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20251231_zsS9Zuo5gk0i" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-12-31" id="Fact000550" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></span> shares of undesignated preferred stock, whose
rights and privileges will be defined by the Board of Directors when a series of preferred stock is designated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration: underline">2024</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 13, 2024, the Company closed its
initial public offering consisting of&#160;<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zFIkIJZIoWd4" title="IPO units, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-02-132024-02-13_us-gaap_IPOMember" id="Fact000552" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span>&#160;shares at a price of $<span id="xdx_909_eus-gaap--SharePrice_iI_pid_c20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zOrVrnwCQq69" title="Initial public offering shares"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-02-13_us-gaap_IPOMember" id="Fact000554" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></span>&#160;per share for approximately $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z1XB749cGgB1" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2024-02-132024-02-13_us-gaap_IPOMember" id="Fact000556" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.0</ix:nonFraction></span>&#160;million
in gross proceeds. After deducting the underwriting commission and other offering expenses totaling $<span id="xdx_906_eus-gaap--OtherUnderwritingExpense_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zVJZFYDF1mT8" title="Underwriting commission and other offering expenses"><ix:nonFraction name="us-gaap:OtherUnderwritingExpense" contextRef="From2024-02-132024-02-13_us-gaap_IPOMember" id="Fact000558" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span>&#160;million, the net proceeds
to the Company were $<span id="xdx_90B_ecustom--ProceedsFromInitialPublicOfferingNetProceeds_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zXKv8Ejxtd77" title="Initial public offering net proceeds"><ix:nonFraction name="TELO:ProceedsFromInitialPublicOfferingNetProceeds" contextRef="From2024-02-132024-02-13_us-gaap_IPOMember" id="Fact000560" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.8</ix:nonFraction></span>&#160;million (the &#8220;IPO&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 9, 2024, Starwood Trust, a related
party, entered into a stock purchase agreement with the Company to purchase <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241209__20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_ztt5AiAA8fJj" title="Purchase of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-12-092024-12-09_custom_StarwoodTrustMember" id="Fact000562" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">142,857</ix:nonFraction></span> shares of unregistered common stock at $<span id="xdx_90B_eus-gaap--SharePrice_iI_c20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_zBepMB3pLAlb" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-12-09_custom_StarwoodTrustMember" id="Fact000564" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7</ix:nonFraction></span> a share
for a total of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20241209__20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_zyNk5qPycyWh" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-12-092024-12-09_custom_StarwoodTrustMember" id="Fact000566" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million in proceeds to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2024, deferred
offering costs from December 31, 2023 of $<span id="xdx_902_eus-gaap--DeferredOfferingCosts_c20231231_pp0p0" title="Deferred offering costs"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2023-12-31" id="Fact000568" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">303,281</ix:nonFraction></span> and offering costs of $<span id="xdx_90D_ecustom--OfferingCosts_iI_pp0p0_c20241231_zIQahD5ePC2j" title="Offering costs"><ix:nonFraction name="TELO:OfferingCosts" contextRef="AsOf2024-12-31" id="Fact000570" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">863,744</ix:nonFraction></span> incurred in 2024 were charged against additional paid
in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration: underline">2025</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 14, 2025, the Company filed a shelf
registration statement with the SEC to facilitate the issuance of our common stock and entered into an At The Market Offering Agreement
(the &#8220;ATM Agreement&#8221;) with Rodman &amp; Renshaw LLC under which the Company may offer and sell shares of its Common Stock,
with an aggregate offering amount to be sold of up to $<span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250214__20250214__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zRnOSWCvYyI" title="Aggregate offering amount"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-02-142025-02-14_custom_AtTheMarketOfferingAgreementMember" id="Fact000572" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000,000</ix:nonFraction></span>. During the year ended December 31, 2025, the Company sold a total
of <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250101__20251231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketOfferingMember_zv2tnUE5EyFc" title="Common stock shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-01-012025-12-31_custom_AtTheMarketOfferingMember" id="Fact000574" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,218,300</ix:nonFraction></span> shares of its common stock, at a weighted average price of $<span id="xdx_90E_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20251231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketOfferingMember_z4mMUSZ6y28l" title="Weighted average price"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-12-31_custom_AtTheMarketOfferingMember" id="Fact000576" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.12</ix:nonFraction></span> for total proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20250101__20251231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketOfferingMember_zpJYUzirq2O6" title="Proceeds from issuance or sale of equity"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2025-01-012025-12-31_custom_AtTheMarketOfferingMember" id="Fact000578" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,553,209</ix:nonFraction></span>, net of costs of $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250101__20251231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketOfferingMember_zYioGZ9vCGB6" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-01-012025-12-31_custom_AtTheMarketOfferingMember" id="Fact000580" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,092</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 19, 2025, the Company entered into an
agreement to raise $<span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn6n6_c20250519__20250519_zQYzFXbfvhM7" title="Raised amount in equity financing"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="From2025-05-192025-05-19" id="Fact000582" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">3</ix:nonFraction></span>&#160;million in equity financing through a direct investment by The Bayshore Trust, an entity affiliated with the
Company&#8217;s largest shareholder. The transaction was structured as a straight restricted common stock deal with no warrants. The
Company issued&#160;<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20250519__20250519_z4yEpnShA4E8" title="Number of resricted shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2025-05-192025-05-19" id="Fact000584" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">333,334</ix:nonFraction></span>&#160;restricted shares of its common stock, no par value at a purchase price of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250519_zJZ7ZW1XIfC9" title="Purchase price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2025-05-19" id="Fact000586" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></span>&#160;per share, representing
an&#160;<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20250519__20250519_zcF2MfYPlPP7" title="Premium share price percentage"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="From2025-05-192025-05-19" id="Fact000588" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">18</ix:nonFraction></span>% premium to the closing share price of the Common Stock of $<span id="xdx_90D_eus-gaap--SharePrice_iI_pid_c20250519__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7DclcrM4CRj" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-05-19_us-gaap_CommonStockMember" id="Fact000590" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.54</ix:nonFraction></span>&#160;on the date of execution (the &#8220;Bayshore Financing&#8221;).
The Company received the initial payment of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn6n6_c20250520__20250520_z5llPktz0U82" title="Initial payment"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2025-05-202025-05-20" id="Fact000592" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">1</ix:nonFraction></span>&#160;million for the Bayshore Financing on May 20, 2025. In July 2025, an additional $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn6n6_c20250724__20250724_zNdiOKqdS4C4" title="Additional payment received"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2025-07-242025-07-24" id="Fact000594" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">2</ix:nonFraction></span>&#160;million
was received, for the issuance of&#160;<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250701__20250731_zvKZmg3wh0Ra" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-07-012025-07-31" id="Fact000596" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">666,667</ix:nonFraction></span>&#160;shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 27, 2025,&#160;<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250527__20250527_zNKJmeF0jMBa" title="Vested common shares service"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2025-05-272025-05-27" id="Fact000598" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">400,000</ix:nonFraction></span>&#160;fully vested
common shares were granted for services to the Company&#8217;s CEO. The restricted shares were valued at $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250527__20250527_zKcrYhQZDh75" title="Vested common shares service, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-05-272025-05-27" id="Fact000600" format="ixt:numdotdecimal" decimals="0" unitRef="USD">840,000</ix:nonFraction></span>&#160;based on the stock
quoted trading price at the grant date and were expensed immediately as compensation expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Warrants </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with various transactions and the
IPO summarized below, the Company issue stock warrants. Warrant activity for the years ended December 31, 2025 and 2024 is summarized
below:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000602" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zbF16ohohb73" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B7_zLWTij5Zc7x3" style="display: none">Schedule of Warrant Activity</span>&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Remaining Contractual</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Aggregate Intrinsic</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Warrants</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Exercise Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Term (Years)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Value</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 36%">Outstanding as of December&#160;&#160;31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSgzcXCqO8Bd" title="Number of Warrants Outstanding, Beginning Balance" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact000604" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,774,057</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaOWzKyPNL4b" title="Weighted Average Exercise Price, Outstanding Beginning Balance" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="TELO:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact000606" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.85</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_zyDrtLyYTlU5" title="Weighted Average Remaining Contractual Term (Years), Outstanding Balance"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact000608" name="TELO:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2">4.5</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">(1)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlO6WbuaHBab" title="Aggregate Intrinsic Value, Outstanding Beginning Balance" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0610">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zekvfhw65G1d" title="Number of Warrants, Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember17385937" id="Fact000612" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4VeUTvz9QS6" title="Weighted Average Exercise Price, Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="TELO:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember17385937" id="Fact000614" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdK1dWmryMj4" title="Weighted Average Remaining Contractual Term (Years), Granted"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember17385937" format="ixt-sec:duryear" id="Fact000616" name="TELO:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted">3.2</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfY5uuixhkXc" title="Number of Warrants, Exercised" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember17385937" id="Fact000618" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">10,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWfw2ZLktGL9" title="Weighted Average Exercise Price, Exercised" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember17385937" id="Fact000620" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.73</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;&#160;&#160;&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Outstanding as December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKVUmero7Gj7" title="Number of Warrants Outstanding, Beginning Balance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact000622" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,814,057</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsO5r9vgaU38" title="Weighted Average Exercise Price, Outstanding Beginning Balance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="TELO:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact000624" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.97</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDIp_zRAzKSd2xari" title="Weighted Average Remaining Contractual Term (Years), Outstanding Balance"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember17385937" format="ixt-sec:duryear" id="Fact000626" name="TELO:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.49</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">(2)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZVF5Pk3yu4i" title="Aggregate Intrinsic Value, Outstanding Beginning Balance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0628">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsGhpzl8Y4We" title="Number of Warrants, Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0630">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbpvVCVaQ5Ea" title="Number of Warrants, Exercised" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0632">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Outstanding as of December 31, 2025</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zf0wLrTBFHVe" title="Number of Warrants Outstanding, Ending Balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-12-31_us-gaap_WarrantMember" id="Fact000634" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,814,057</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsfxDR0OeTV7" title="Weighted Average Exercise Price, Outstanding Ending Balance" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="TELO:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-12-31_us-gaap_WarrantMember" id="Fact000636" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.97</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDIp_z9tUtCU4y52f" title="Weighted Average Remaining Contractual Term (Years), Outstanding Balance"><ix:nonNumeric contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember17385953" format="ixt-sec:duryear" id="Fact000638" name="TELO:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2">2.45</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">(2)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3XbuYdeo4mj" title="Aggregate Intrinsic Value, Outstanding Ending Balance" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0640">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="vertical-align: top; width: 0.25in; padding-bottom: 0pt; text-align: left"><span id="xdx_F00_zDaoA1QFIxJ3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="padding-bottom: 0pt; text-align: justify"><span id="xdx_F18_zK8FIGlqJnkb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000641" xml:lang="en-US">The
    warrants herein consist of various contractual terms. The warrants herein consist of <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember_zql5MGAc3hig" title="Class of warrants or right number of securities called by warrants or rights" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_BayShoreTrustWarrantsMember" id="Fact000643" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,439,025</ix:nonFraction></span> warrants issued to Bay Shore Trust
    that have a remaining contractual term of <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember_zzBNVlLe1s7g" title="Warrants and rights outstanding term" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_BayShoreTrustWarrantsMember" format="ixt-sec:duryear" id="Fact000645" name="us-gaap:WarrantsAndRightsOutstandingTerm">2.5</ix:nonNumeric></span> years as of December 31, 2025, and <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zzKKbMRXLy43" title="Class of warrants or right number of securities called by warrants or rights" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_TwoThousandTwentyThreePrivatePlacementWarrantsMember_us-gaap_InvestorMember" id="Fact000647" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">335,032</ix:nonFraction></span> warrants issued to investors associated
    with the 2023 Private Placement that currently have an indeterminable contractual term. See disclosures below for more information
    on these warrants</ix:footnote></span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left"><span id="xdx_F0F_zOO4wfwv8DSa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="padding-bottom: 0pt; text-align: justify"><span id="xdx_F1C_zYWuwkJCT5G5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000648" xml:lang="en-US">The
    warrants herein consist of various contractual terms. The warrants herein consist of <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zR74nO7EjC5e" title="Warrants issued" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_BayShoreTrustWarrantsMember_us-gaap_WarrantMember" id="Fact000650" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,429,025</ix:nonFraction></span> warrants issued to Bay Shore Trust
    that have a remaining contractual term of <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYImeeA0dK1e" title="Warrants remaining contractual term" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_BayShoreTrustWarrantsMember_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact000652" name="us-gaap:WarrantsAndRightsOutstandingTerm">2.5</ix:nonNumeric></span> years as of December 31, 2025; <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zhi1RrUuEnck" title="Warrants issued" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_TwoThousandTwentyThreePrivatePlacementWarrantsMember_us-gaap_InvestorMember" id="Fact000654" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">335,032</ix:nonFraction></span> warrants issued to investors associated with
    the 2023 Private Placement that currently have an indeterminable contractual term, and <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantMember_zNmj2VNvS6hi" title="Warrants issued" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_UnderwriterWarrantMember" id="Fact000656" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> warrants issued to underwriters as
    part of the IPO with a remaining contractual life of <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantMember_zULkKyLPZwji" title="Warrants remaining contractual term" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_UnderwriterWarrantMember" format="ixt-sec:duryear" id="Fact000658" name="us-gaap:WarrantsAndRightsOutstandingTerm">3.2</ix:nonNumeric></span> years. See disclosures below for more information on these warrants</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A9_zEa452R8zOSh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 74; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Private placement Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2023, the
Company issued to the 2023 Private Placement investors a Common Stock warrant the right to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zvc2ULAczpu8" title="Purchase of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2023-12-31_us-gaap_PrivatePlacementMember" id="Fact000660" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">268,025</ix:nonFraction></span> shares of common stock
at an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zATUyVfStDOd" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_us-gaap_PrivatePlacementMember" id="Fact000662" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.42</ix:nonFraction></span> per share. The Company also issued to the placement agent a Common Stock warrant the right to purchase
up to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--PlacementAgentMember_z5IeBiA3nDg7" title="Purchase of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2023-12-31_custom_PlacementAgentMember" id="Fact000664" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">67,007</ix:nonFraction></span> shares of common stock at an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--PlacementAgentMember_zBJlgu0kOCjj" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_PlacementAgentMember" id="Fact000666" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.73</ix:nonFraction></span> per share. Both issuances of warrants are immediately vested and will
be exercisable any time until the day that is one year plus ninety days from the date an Investigational New Drug, or IND, filing is
made with the FDA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Bay Shore Trust Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In consideration of the line of credit provided
by the Bay Shore Trust, the Company issued to the Bay Shore Trust a common stock purchase warrant on June 15, 2023 giving the Bay Shore
Trust the right to purchase up to&#160;<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zizjv4p1mJ92" title="Shares of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-06-15_custom_BayShoreTrustMember" id="Fact000668" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,439,025</ix:nonFraction></span>&#160;shares of common stock at an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zGRQwMMfrJ2i" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-06-15_custom_BayShoreTrustMember" id="Fact000670" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.73</ix:nonFraction></span>&#160;per share. This warrant
will expire <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zsfm4vhTwd01" title="Exercise price"><ix:nonNumeric contextRef="AsOf2023-06-15_custom_BayShoreTrustMember" format="ixt-sec:durwordsen" id="Fact000672" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric></span> after the date of grant.. The fair value of the warrants were estimated on the grant date using the Black-Scholes
valuation model and level 3 inputs based on assumptions for expected volatility, expected dividends, expected term, and the risk-free
interest rate, which resulted in $<span id="xdx_90E_eus-gaap--DeferredFinanceCostsNet_iI_pn4n6_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zKLhU6aA3gub" title="Deferred financing costs"><ix:nonFraction name="us-gaap:DeferredFinanceCostsNet" contextRef="AsOf2023-06-15_custom_BayShoreTrustMember" id="Fact000674" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">5.95</ix:nonFraction></span>&#160;million of deferred financing costs. In 2023 this cost was recorded as deferred financing
costs and additional paid in capital on the balance sheet and was amortized straight-line over the term of the line of credit (which
is 24 months). Associated amortization of deferred finance costs was recorded to interest expense on the statement of operations. The
line of credit expired upon the IPO occurring in February 2024, and as such the remaining deferred financing costs associated with the
warrant was fully amortized to interest expense in 2024. As of December 31, 2024, the warrant is fully amortized (see Note 4).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 22, 2024, Bay Shore Trust transferred
<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241122__dei--LegalEntityAxis__custom--BayShoreTrustMember_zdTH8apfOer9" title="Shares of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-11-22_custom_BayShoreTrustMember" id="Fact000676" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> warrants to an unaffiliated party as part of a gift transfer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2024,&#160;<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__dei--LegalEntityAxis__custom--BayShoreTrustMember_zbBwXnGX684" title="Shares of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_BayShoreTrustMember" id="Fact000678" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span> Common Stock warrants
were exercised at an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__dei--LegalEntityAxis__custom--BayShoreTrustMember_zX0XLRJrEzTj" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_BayShoreTrustMember" id="Fact000680" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.73</ix:nonFraction></span> per share and the Company issued&#160;<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241201__20241231__dei--LegalEntityAxis__custom--BayShoreTrustMember_zHN2GXRElpSg" title="Issuance of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-12-012024-12-31_custom_BayShoreTrustMember" id="Fact000682" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span>&#160;shares of Common Stock upon such exercise
in exchange for $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20241201__20241231__dei--LegalEntityAxis__custom--BayShoreTrustMember_zO1C5Ee8Gzbc" title="Issuance of common stock, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-12-012024-12-31_custom_BayShoreTrustMember" id="Fact000684" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">37,300</ix:nonFraction></span> delivered to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Underwriter warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the IPO in February 2024,
the Company issued&#160;<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240229__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqHCIbWDXnpj" title="Warrants to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-02-29_us-gaap_IPOMember_us-gaap_WarrantMember" id="Fact000686" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span>&#160;warrants to purchase Common Stock to the IPO underwriter (or its designees) at an exercise price
of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240229__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUysGADoXYcf" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-02-29_us-gaap_IPOMember_us-gaap_WarrantMember" id="Fact000688" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></span>&#160;which are exercisable immediately and expire in the four-and-a-half-year period commencing six months after the commencement
of sales in the IPO. The warrants provide for registration rights (including a one-time demand registration right and piggyback registration
rights that expire 5 years from the commencement of sales of the offering) and customary anti-dilution provisions as permitted under
FINRA Rule 5110(g)(8). The fair value of the warrants were estimated on the grant date using the Black-Scholes valuation model and level
3 inputs based on assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate, which resulted
in $<span id="xdx_900_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20240229__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpx3YmSwkfPc" title="Equity issuance cost"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2024-02-29_us-gaap_WarrantMember" id="Fact000690" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million of equity issuance costs. The warrants were considered equity issuance costs and therefore there was no financial statement
impact during the year ended December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_UnderwriterWarrantMember" escape="true" id="Fact000692" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember_zaEH1wv1i3d7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Key assumptions used to value underwriter warrants in February 2024
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BD_z5zAKzgwTGh4" style="display: none">Schedule of Key Assumptions Used to Value Warrants</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 50%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-size: 10pt">Expected price volatility</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 16%; font-size: 10pt; text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zNEHZOZqCEgc" title="Warrant measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact000694" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">84.78</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Risk-free interest rate</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zTufeFAJ6ks1" title="Warrant measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact000696" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.14</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Fair Market Value of underlying Common Stock</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputFairMarketValueUnderlyingCommonStockMember_zkiSfvatqy75" title="Warrant measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-02-29_custom_UnderwriterWarrantMember_custom_MeasurementInputFairMarketValueUnderlyingCommonStockMember" id="Fact000698" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">7.01</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Expected term in years</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_znhy7r5V7c14" title="Expected term in years"><ix:nonNumeric contextRef="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" id="Fact000700" name="us-gaap:WarrantsAndRightsOutstandingTerm">5</ix:nonNumeric></span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Dividend yield</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zabaLxhKp6T5" title="Warrant measurement input"><span style="-sec-ix-hidden: xdx2ixbrl0702">-</span></span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_z1EAasvFtAHa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>2023 Omnibus Incentive Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2023, the Company&#8217;s Board of
Directors adopted the Company&#8217;s 2023  Omnibus Incentive Plan, (&#8220;2023  Plan&#8221;). The 2023  Plan authorizes
the grant of incentive stock options, within the meaning of Section 422 of the Internal Revenue Code, to the Company&#8217;s employees
and any of its parent and subsidiary corporations&#8217; employees, and for the grant of nonstatutory stock options, restricted stock,
restricted stock units, stock appreciation rights, performance units and performance shares to the Company&#8217;s employees, directors,
and consultants and any of its future subsidiary corporations&#8217; employees and consultants</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2023  Plan provides that <span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusIncentivePlanMember_zWDlk1hkVxN6" title="Common stock are reserved for issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeOmnibusIncentivePlanMember" id="Fact000704" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,500,000</ix:nonFraction></span>
shares of the Company&#8217;s Common Stock are reserved for issuance under the 2023  Plan, all of which may be issued pursuant
to the exercise of incentive stock options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock-based compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Stock options</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The vesting period for stock options granted is generally
immediately to one year. All stock options granted under the 2023 Plan have a maximum contractual term of ten years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The grant-date fair value of each option award
is estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility,
expected dividends, expected term, and the risk-free interest rate. In 2024 expected price volatility is based on the historical volatilities
of a peer group as the Company does not have a multi-year trading history for its shares. Industry peers consist of several public companies
in the biotech industry similar to the Company in size, stage of life cycle and product indications. Starting in 2025 expected price
volatility is based solely on the Company&#8217;s trading history for its common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Expected term of options granted is derived using
the &#8220;simplified method&#8221; which computes expected term as the average of the sum of the vesting term plus contract term. The
risk-free rate is based on the 5-year U.S. Treasury yield curve in effect at the time of grant. The Company recognizes forfeitures as
they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000706" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zS4fJ3wBJQFf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighted average assumptions for grants are
provided in the following table:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BB_zXrSBk08wuH3" style="display: none">Schedule of Key Assumptions Used to Value Stock Options</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Year ended December 31,</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20250101__20251231_zywcppCibDml" title="Expected volatility, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2025-01-01to2025-12-31" id="Fact000708" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">92.5</ix:nonFraction></span> - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20250101__20251231_zbwf8du1R1F6" title="Expected volatility, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2025-01-01to2025-12-31" id="Fact000710" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">139.0</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231_z8hUUw8m1gJa" title="Expected volatility, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2024-01-012024-12-31" id="Fact000712" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">88.8</ix:nonFraction></span> - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231_zO12gstweCwk" title="Expected volatility, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2024-01-012024-12-31" id="Fact000714" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">90.4</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected term (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__srt--RangeAxis__srt--MinimumMember_ziC3JP46oGs" title="Expected term"><ix:nonNumeric contextRef="From2025-01-012025-12-31_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000716" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.0</ix:nonNumeric></span> - <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__srt--RangeAxis__srt--MaximumMember_zc4OMCC36rE6" title="Expected term"><ix:nonNumeric contextRef="From2025-01-012025-12-31_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000718" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.4</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zjsn0ym2t798" title="Expected term"><ix:nonNumeric contextRef="From2024-01-012024-12-31_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000720" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.1</ix:nonNumeric></span> - <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zOVvuFZW7rL1" title="Expected term"><ix:nonNumeric contextRef="From2024-01-012024-12-31_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000722" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.6</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Expected dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20250101__20251231_z2Nja1MEldtl" title="Expected dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2025-01-01to2025-12-31" id="Fact000724" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20240101__20241231_zA8eR4LadDb7" title="Expected dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-01-012024-12-31" id="Fact000726" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20250101__20251231_zFsnrmOeG4jl" title="Risk-free interest rate, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2025-01-01to2025-12-31" id="Fact000728" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.1</ix:nonFraction></span> - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20250101__20251231_z692LynCcp9i" title="Risk-free interest rate, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2025-01-01to2025-12-31" id="Fact000730" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.2</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231_zm7wWKx569h5" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-12-31" id="Fact000732" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.7</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A0_zTmXHVtygsOl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000734" name="us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_zaFp6iB3kB62" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2025, the Company
issued stock options under the 2023 Plan as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BD_zdK9D3paRZq9" style="display: none">Schedule of Issued Stock Options</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of stock options</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    Price</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vesting
    period</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    13</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--AwardDateAxis__custom--MayThirteenMember_zlBVXwSDtx2g" title="Number of stock options" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-12-31_custom_MayThirteenMember" id="Fact000736" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardDateAxis__custom--MayThirteenMember_zrBxREo8KkEj" title="Exercise price" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-12-31_custom_MayThirteenMember" id="Fact000738" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.75</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: left; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_c20250101__20251231__us-gaap--AwardDateAxis__custom--MayThirteenMember_z74jNDAkPBa2" title="Vesting period"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_MayThirteenMember" id="Fact000740" name="TELO:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod">one
    year</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    27</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--AwardDateAxis__custom--MayTwentySevenMember_z8G6KovnsyQc" title="Number of stock options" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-12-31_custom_MayTwentySevenMember" id="Fact000742" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardDateAxis__custom--MayTwentySevenMember_zNuixU0cFoza" title="Exercise price" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-12-31_custom_MayTwentySevenMember" id="Fact000744" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.10</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_c20250101__20251231__us-gaap--AwardDateAxis__custom--MayTwentySevenMember_zb5YC6ebnGs4" title="Vesting period"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_MayTwentySevenMember" id="Fact000746" name="TELO:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod">immediate</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    15</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--AwardDateAxis__custom--OctoberFifteenMember_z8zUDjKZywYg" title="Number of stock options" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-12-31_custom_OctoberFifteenMember" id="Fact000748" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">37,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardDateAxis__custom--OctoberFifteenMember_z0MUJoaljh9e" title="Exercise price" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-12-31_custom_OctoberFifteenMember" id="Fact000750" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.73</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_c20250101__20251231__us-gaap--AwardDateAxis__custom--OctoberFifteenMember_z9jcuVPMlp67" title="Vesting period"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_OctoberFifteenMember" id="Fact000752" name="TELO:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod">one
    year</ix:nonNumeric></span></span></td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8A5_zn9W7dCunDT9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000754" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zy9gyeG1mzJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&#8217;s stock option activity is as follows:</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><span id="xdx_8B1_zMPMC2XBN3cj" style="display: none">Schedule of Stock Option Activity</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Number of<br/>
 stock options</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Exercise price</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Remaining<br/>
 contractual life <br/>
(years)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Aggregate<br/>
 intrinsic value</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 36%">Balance at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20251231_ze4xV0HqTgN6" title="Number of stock option, Beginning balance" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31" id="Fact000756" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,352,670</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20251231_zZck69flFVN8" title="Weighted average exercise price, Beginning balance" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact000758" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.02</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_ziGNoSuEMNHf" title="Weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2024-01-012024-12-31" format="ixt-sec:duryear" id="Fact000760" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">9.6</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20250101__20251231_zQ2TfN5EKKXf" title="Aggregate intrinsic value, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl0762">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250101__20251231_z2iyPgtS5G27" title="Number of stock option, Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2025-01-01to2025-12-31" id="Fact000764" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,087,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231_zfBB0JIAPDxc" title="Weighted average exercise price, Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-01to2025-12-31" id="Fact000766" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.11</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Expired</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_c20250101__20251231_zKt0klDuKVvf" title="Number of stock option, Expired" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="TELO:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" contextRef="From2025-01-01to2025-12-31" id="Fact000768" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">72,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231_zT4q1hQBGNE8" title="Weighted average exercise price, Expired" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-01to2025-12-31" id="Fact000770" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.02</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20250101__20251231_z9TM7EPjOsYl" title="Number of stock option, Forfeitures" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2025-01-01to2025-12-31" id="Fact000772" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">180,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20250101__20251231_zOZaJmlN7UDd" title="Weighted average exercise price, Forfeitures" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-01to2025-12-31" id="Fact000774" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.02</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance at December 31, 2025</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250101__20251231_z6c2PLjdlsgh" title="Number of stock option, Ending balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-12-31" id="Fact000776" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,187,670</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231_zCclC1UlfKx3" title="Weighted average exercise price, Ending balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-12-31" id="Fact000778" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.57</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_zhaK4RzoDfC8" title="Weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:duryear" id="Fact000780" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">9.0</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20250101__20251231_znyBlOTnxyDf" title="Aggregate intrinsic value, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl0782">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Vested and exercisable at December 31, 2025</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20250101__20251231_z7XnINVLnQ0k" title="Number of stock option, Vested and exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2025-12-31" id="Fact000784" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,125,170</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_c20250101__20251231_zN5sX437SXng" title="Weighted average exercise price, Vested and exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-12-31" id="Fact000786" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.60</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231_ztHDm5D4IZO3" title="Weighted average remaining contractual life (years), Vested and exercisable"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:duryear" id="Fact000788" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">9.0</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_c20250101__20251231_zTUp8XCzPB9b" title="Aggregate intrinsic value, Vested and exercisable" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0790">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Vested and expected to vest at December 31, 2025</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20250101__20251231_zal0giAgRPxj" title="Number of stock option, Vested and expected to vest" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2025-12-31" id="Fact000792" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,187,670</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231_zQpvIvalTXzc" title="Weighted average exercise price, Vested and expected to vest" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-12-31" id="Fact000794" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.14</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231_zA4ZCS8VW7fa" title="Weighted average remaining contractual life (years), Vested and expected to vest"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:duryear" id="Fact000796" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">9.6</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20250101__20251231_zQxM897GxpKh" title="Aggregate intrinsic value, Vested and expected to vest" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0798">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AE_zNC8hTkKNP44" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognized approximately $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20250101__20251231_zMa96kw0CF7e" title="Stock-based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000800" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.3</ix:nonFraction></span> million
and $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20240101__20241231_z5I2iuvlKlJ9" title="Stock-based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31" id="Fact000802" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.9</ix:nonFraction></span> million in stock-based compensation in 2025 and 2024, respectively. The weighted average grant-date fair values of options granted
during the years ended December 31, 2025 and 2024 were $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20250101__20251231_zVirPPE4xA5b" title="Weighted average grant-date fair values of options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2025-01-01to2025-12-31" id="Fact000804" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.84</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231_zXTzKxBCPQH8" title="Weighted average grant-date fair values of options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31" id="Fact000806" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.80</ix:nonFraction></span> per share, respectively. The grant date fair value of shares vested
during the years ended December 31, 2025 and 2024 was $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_pn5n6_c20250101__20251231_z9dwPYal4RV" title="Grant date fair value of shares vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="From2025-01-01to2025-12-31" id="Fact000808" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">11.8</ix:nonFraction></span> million and $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_pn5n6_c20240101__20241231_zsY6mRPM2P5c" title="Grant date fair value of shares vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="From2024-01-012024-12-31" id="Fact000810" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.0</ix:nonFraction></span> million, respectively. As of December 31, 2025, there is
$<span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20251231_zHQuLNhvtX81" title="Unrecognized compensation costs"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2025-12-31" id="Fact000812" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83,600</ix:nonFraction></span> of unrecognized compensation cost related to unvested stock options granted under the Company&#8217;s 2023 Plan that is expected
to be recognized over the next year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Restricted Stock Units (RSUs)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2025 the Chairman and CEO was issued RSUs
for <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdCO9dDscqO8" title="Issued shares which were fully vested upon grant"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000814" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">400,000</ix:nonFraction></span>&#160;common shares which were fully vested upon grant. These RSUs were valued at $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z85DkXyKZbJe" title="Issuance of common stock for services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000816" format="ixt:numdotdecimal" decimals="0" unitRef="USD">840,000</ix:nonFraction></span>&#160;based on the stock quoted
trading price at the grant date and were expensed immediately as compensation expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000818" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_803_eus-gaap--IncomeTaxDisclosureTextBlock_zmI1R2AqgVPl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 8 &#8211; <span id="xdx_82A_zfrBjCgjHwM1">Income Taxes</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000820" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zyTHSdHVUPf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify">The significant components of the
Company&#8217;s net deferred tax assets and liabilities consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify"><span id="xdx_8BE_ziJ8CRKjCSBf" style="display: none">Schedule of Net Deferred Tax Assets</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20251231_zvdlN2wv7OK5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20241231_z4fI6gmPOaAd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred tax assets:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGz55t_zwLhxDmaoGRg" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Net operating loss carryforward</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2025-12-31" id="Fact000822" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,643,465</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-12-31" id="Fact000823" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,427,679</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGz55t_zQ3dH2jHDb89" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Section 174 capitalized research and development</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2025-12-31" id="Fact000825" format="ixt:numdotdecimal" decimals="0" unitRef="USD">700,121</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2024-12-31" id="Fact000826" format="ixt:numdotdecimal" decimals="0" unitRef="USD">995,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_maDTAGz55t_zoh0x94PgLl7" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Goodwill and intangibles</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2025-12-31" id="Fact000828" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,339</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2024-12-31" id="Fact000829" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,007</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGz55t_z4oqjyn0ikp6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2025-12-31" id="Fact000831" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,856,673</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2024-12-31" id="Fact000832" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,680,018</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_maDTAGz55t_z9nf4C0NHVAj" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">Tax credits</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="AsOf2025-12-31" id="Fact000834" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,278</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="AsOf2024-12-31" id="Fact000835" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,278</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGz55t_maDTANzg2r_z2JYdq0N1oc6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred tax assets, gross</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2025-12-31" id="Fact000837" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,274,876</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-12-31" id="Fact000838" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,182,482</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzg2r_zAUxIxWqATCa" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less: valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2025-12-31" id="Fact000840" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,274,876</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact000841" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,182,482</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzg2r_maDTALNzcuf_zfxyiGxuzym" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred tax assets, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0843">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0844">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredIncomeTaxLiabilities_iNI_di_msDTALNzcuf_zbksbSThWZP8" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Deferred tax liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0846">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0847">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzcuf_z6K4R2F1LZX4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total net deferred tax asset</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0849">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0850">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A5_zLeibNXoR1xf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000852" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zVIEFs8ddJJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify">Provision for (benefit from) income taxes consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BF_zbfAWeBapp8j" style="display: none">Schedule of Provision for  Income Taxes</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20250101__20251231_ztiGjjaoR3v8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zgFgkdt8Rhpl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zMXvmntFXiQa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred tax:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDITEBz7I1_zaQaSXoo1ycg" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Federal</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="Fact000857" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">463,477</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0858">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDITEBz7I1_z4PzOlw9UAc3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">State</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="Fact000860" format="ixt:numdotdecimal" decimals="0" unitRef="USD">463,477</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0861">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_mtDITEBz7I1_maITEBzknf_z1ZkK8ubmzv2" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total deferred tax expense (benefit)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0863">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"/><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0864">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzknf_zdEwF8Bg8Pn6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total provision for income taxes</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0866">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"/><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0867">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A2_zZpgfiKQUEOj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Beginning in 2022, in accordance with Internal
Revenue Code Section 174, Qualified Research Expenditures are capitalized for tax purposes and amortized over a period of five years.
Accordingly, for income tax purposes, and as of December 31, 2025 and 2024, the Company has recorded a deferred tax asset
totaling approximately $<span id="xdx_90F_eus-gaap--DeferredTaxAssetsOtherLossCarryforwards_iI_pn5n6_c20251231_zbxuSdeLfza9" title="Deferred tax asset"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOtherLossCarryforwards" contextRef="AsOf2025-12-31" id="Fact000869" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.7</ix:nonFraction></span> million and $<span id="xdx_903_eus-gaap--DeferredTaxAssetsOtherLossCarryforwards_iI_pn5n6_c20241231_zL88S2PKw9Mi" title="Deferred tax asset"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOtherLossCarryforwards" contextRef="AsOf2024-12-31" id="Fact000871" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million, respectively, related to the timing difference between GAAP and Tax recognition
of these expenditures. Under current law, beginning in tax years after December 31, 2024, domestic research and experimental expenditures may again be deducted
currently for U.S. federal income tax purposes; however, the Company continues to carry deferred tax assets related to research costs
capitalized in prior periods that will reverse as amortization deductions are claimed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000873" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z0kmSDp65Qsj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A reconciliation of the statutory U.S. federal income
tax rate to the Company&#8217;s effective income tax rate is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B3_zzTcm5qpDRQ2" style="display: none">Schedule of Reconciliation  Effective Income Tax Rate</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250101__20251231_zlMGFEmExkaf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Amount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Rate</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzgzx_zkJ1UtGDgrQ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Provision for income taxes at U.S. federal statutory rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2025-01-01to2025-12-31" id="Fact000875" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,186,773</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maGOLD_c20250101__20251231_zXnLOtWUO9P" title="Provision for income taxes at U.S. federal statutory rate, Percentage" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2025-01-01to2025-12-31" id="Fact000877" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzgzx_zsTK6bVo3A14" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">State income taxes, net of federal benefit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2025-01-01to2025-12-31" id="Fact000879" format="ixt:numdotdecimal" decimals="0" unitRef="USD">463,477</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maGOLD_c20250101__20251231_zbR9tqDhuNNh" title="State income taxes, net of federal benefit, Percentage" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2025-01-01to2025-12-31" id="Fact000881" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">4.45</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzgzx_z2ZE0Vd0HRDg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Other</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2025-01-01to2025-12-31" id="Fact000883" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,616</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maGOLD_c20250101__20251231_zjE9R5GdGww8" title="Other, Percentage" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2025-01-01to2025-12-31" id="Fact000885" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.02</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzgzx_zAWzEe8INaF8" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Changes in valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2025-01-01to2025-12-31" id="Fact000887" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,928,495</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maGOLD_c20250101__20251231_zu09xbp4Ev71" title="Changes in valuation allowance, Percentage" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2025-01-01to2025-12-31" id="Fact000889" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">28.12</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_maITEBzgzx_z50HosJpRgBl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">True-ups</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" contextRef="From2025-01-01to2025-12-31" id="Fact000891" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,228,815</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_maGOLD_c20250101__20251231_zYyiPd8PdGhe" title="True-ups, Percentage" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="From2025-01-01to2025-12-31" id="Fact000893" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11.80</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzgzx_ztasadz5Bmb3" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net actual effective rate</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0895">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"/><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtGOLD_c20250101__20251231_zNtGJIqSrFWa" title="Net actual effective rate, Percentage" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2025-01-01to2025-12-31" id="Fact000897" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.21</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AE_zEDJTTvZtMh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC Topic 740 requires that a deferred tax amount
be reduced by a valuation allowance if, based on the weight of available evidence it is more likely than not (a likelihood of more than
50%) that some portion or all of the deferred tax assets will not be realized. The valuation allowance should be sufficient to reduce
the deferred tax asset to the amount that is more likely than not to be realized. The Company has recorded a full valuation allowance
against its deferred tax assets generated by net operating loss carryforwards as it has determined that such amounts may not be recognizable,
given the historical losses of the Company to date. As of December 31, 2025, the Company has a cumulative federal net operating loss
carryforward of approximately $<span id="xdx_900_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20251231_ziX4kblBaEGd"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" contextRef="AsOf2025-12-31" id="Fact000898" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">30.2</ix:nonFraction></span>
million. The net operating loss carryforward have no expiry date.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

</ix:nonNumeric><p id="xdx_81D_z24dDPi77znd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_028"></span>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">In accordance with Section
13 or 15(d) of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TELOMIR
    PHARMACEUTICALS, INC.</b></span></td></tr>
  <tr>
    <td style="width: 50%; padding-bottom: 0pt">&#160;</td>
    <td style="width: 3%; padding-bottom: 0pt">&#160;</td>
    <td style="text-align: left; width: 47%; padding-bottom: 0pt">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 17, 2026</span></td>
    <td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Erez Aminov</i></span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Erez
    Aminov</b></span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Chief
    Executive Officer</b></span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Principal
    Executive Officer)</b></span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: left">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Alan Weichselbaum</i></span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Alan
    Weichselbaum</b></span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Chief
    Financial Officer</b></span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Principal
    Financial Officer)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the Exchange Act, this report
has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="border-bottom: black 1pt solid; width: 30%; padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Person</span></td>
    <td style="width: 2%; padding-bottom: 0pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 48%; padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capacity</span></td>
    <td style="width: 2%; padding-bottom: 0pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 18%; padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Erez Aminov</i></span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Chair</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    17, 2026</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Erez
    Aminov</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: center">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Alan Weichselbaum</i></span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    17, 2026</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alan
    Weichselbaum</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer and Principal Accounting Officer)</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: center">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Ned MacPherson</i></span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    17, 2026</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ned
    MacPherson.</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: center">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Matthew Pratt Whalen, CPA</i></span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    17, 2026</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew
    Pratt Whalen, CPA</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: center">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Matthew P. Del Giudice</i></span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    17, 2026</span></td></tr>
  <tr>
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew
    P. Del Giudice</span></td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 0pt">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: center">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 78; Options: NewSection Last; Value: 62 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>ex23-1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Consent of Independent Registered Public Accounting Firm</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We hereby consent to the incorporation by reference in the Registration
Statement on Form S-3, which became effective on February 28, 2025, (File No. 333-284990) of Telomir Pharmaceuticals, Inc. of our report
dated March 17, 2026 relating to the financial statements of Telomir Pharmaceuticals, Inc. as of December 31, 2025 and 2024 and for the
each of the two years in the period ended December 31, 2025, appearing in this Annual Report on Form 10-K of Telomir Pharmaceuticals,
Inc. for the year ended December 31, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We also consent to the reference to our firm under the heading
&ldquo;Experts&rdquo; in such Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">/s/ Salberg &amp; Company, P.A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">SALBERG &amp; COMPANY, P.A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Boca Raton, Florida</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">March 17, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ex31-1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Erez Aminov, Chief Executive Officer and Chairman
of Telomir Pharmaceuticals, Inc., certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR>
    <TD STYLE="text-align: left; width: 0.25in; padding-bottom: 0pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this annual report on Form 10-K of Telomir Pharmaceuticals, Inc.;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: left; padding-bottom: 0pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left; padding-bottom: 0pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: left; padding-bottom: 0pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left; padding-bottom: 0pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: left; padding-bottom: 0pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left; padding-bottom: 0pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR>
    <TD STYLE="width: 0.25in; padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in; padding-bottom: 0pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 0pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 0pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 0pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 0pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 0pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 0pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR>
    <TD STYLE="text-align: left; width: 0.25in; padding-bottom: 0pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
    reporting, to the registrant&rsquo;s auditors and audit committee:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR>
    <TD STYLE="width: 0.25in; padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in; padding-bottom: 0pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 0pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 0pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR>
    <TD STYLE="width: 50%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March
    17, 2026</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 50%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Erez Aminov</I></FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Erez Aminov</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer
    and Chair</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive
    Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ex31-2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Alan Weichselbaum, Chief Financial Officer
of Telomir Pharmaceuticals, Inc., certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR>
    <TD STYLE="text-align: left; width: 0.25in; padding-bottom: 0pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this annual report on Form 10-K of Telomir Pharmaceuticals, Inc.;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: left; padding-bottom: 0pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left; padding-bottom: 0pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: left; padding-bottom: 0pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left; padding-bottom: 0pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: left; padding-bottom: 0pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left; padding-bottom: 0pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR>
    <TD STYLE="width: 0.25in; padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in; padding-bottom: 0pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 0pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 0pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 0pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 0pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 0pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 0pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    fourth fiscal quarter in that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal
    control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR>
    <TD STYLE="text-align: left; width: 0.25in; padding-bottom: 0pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
    reporting, to the registrant&rsquo;s auditors and audit committee:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR>
    <TD STYLE="width: 0.25in; padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in; padding-bottom: 0pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 0pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 0pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR>
    <TD STYLE="padding-bottom: 0pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March
    17, 2026</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 0pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Alan Weichselbaum</I></FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alan Weichselbaum</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal Financial
    Officer and</I></FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accounting
    Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>ex32-1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION
1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">In connection with the annual
report of Telomir Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December 31, 2025, as filed with
the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Erez Aminov, Chief Executive Officer of the
Company, certify, pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR>
    <TD STYLE="width: 0.25in; padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of
    the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR>
    <TD STYLE="width: 50%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March
    17, 2026</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 50%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Erez Aminov</I></FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Erez Aminov</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer
    and Chair</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal Executive
    Officer)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>ex32-2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION
1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">In connection with the annual
report of Telomir Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December 31, 2025, as filed with
the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Alan Weichselbaum, Chief Financial Officer of
the Company, certify, pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR>
    <TD STYLE="width: 0.25in; padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of
    the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR>
    <TD STYLE="width: 50%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March
    17, 2026</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 50%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Alan Weichselbaum</I></FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alan Weichselbaum</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal Financial
    Officer and</I></FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accounting
    Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>form10-k_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-k_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $U G # 2(  A$! Q$!_\0
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MEEV*U%6?[-U#_H'WG_?AO\*/[-U#_H'WG_?AO\*.>/=!RR[%:BK/]FZA_P!
M^\_[\-_A1_9NH?\ 0/O/^_#?X4<\>Z#EEV*U%6?[-U#_ *!]Y_WX;_"C^S=0
M_P"@?>?]^&_PHYX]T'++L5J*L_V;J'_0/O/^_#?X4?V;J'_0/O/^_#?X4<\>
MZ#EEV*U%6?[-U#_H'WG_ 'X;_"C^S=0_Z!]Y_P!^&_PHYX]T'++L5J*L_P!F
MZA_T#[S_ +\-_A1_9NH?] ^\_P"_#?X4<\>Z#EEV*U%6?[-U#_H'WG_?AO\
M"C^S=0_Z!]Y_WX;_  HYX]T'++L5J*L_V;J'_0/O/^_#?X4R6SNX$WS6=S&G
M]YXF _,BCGCW#EEV(:*3-+5$A1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !2'[I^E+2'[I^E 'N_@_P#Y%/3?^N(K<K#\'_\
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M(4AE5V SA3GCI611:HI!TI: "D-+2&@#Q3XA_P#([W?_ %QB_D:YFNF^(?\
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M%;&);TR:*#5;>690R*V=I&<GM7J2^.+8V0<.OW>*\QT8S1ZE'-;3>5<(?D?
M.T_CQ4ODW.E:K<OJUO;7D=P<8?MG^(8Q@U\]C:BJ5-.A]!@J;A3][J9&K744
MVN7<D*JL;OD*O0&B,Y K(C $\BCH'./IFM6'H*]BA\*1X]?XFR>BBBNDYPHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#]T_2EI#]T_2@
M#W?P?_R*>F_]<16TZ+*C(X#*PP0>XK$\(?\ (IZ;_P!<15V_UBUTZ01SRHCL
MA=0[8W8[#WKY6K\;]3ZFE\"]#S;QNUSX.U2U&F6UY]@O8V4BV9G9IATXZ\#I
MVJIK-SXZT_1K74[B">>WG@Q<10KF2(#D;Q]/2K&G?$/^T?&6G+<R(7\Z2%K<
M+A8%(^_NZD\<Y]:[GQ#XDM+#1]0:VN;>6\C@8QQ$Y#-C@>_TJ(KF:1H9'AKP
MI9ZIX8TVY\1Z=#=7QS.&F.]E!.5!/?C'%4?&7PRD\1:O%>Z;J2Z?')&(+J(1
M\.@[C'>LWX3^)M7U?4;BPD%U+IT%N"S7"8\F7/W%.!QCL>F*]8KJFJF$JVC+
M7R(5IQU13L]-M+&&WCBACW01+$DA0;MH&.M>;ZSX(BU7X@36MOJXAM+E/M5U
M:H!N!& 0/3/6O5#TXKQ&?PSXP\*^(;C7IY+6YTZRN'NC.9-KSJQY!'4=?IQ4
M480GS.<K67WL)-JUD=!#X-M?!/B6PU>34KBYL!*T4-L_)B9AP1W;O^=>AV>J
M6E_:K<VTPDB)(R!T(ZY':O,KNZG^)SOIUG=P6EUI\8NX+B'+*6;C8P/0>];W
MAGP#)IVD1)?ZE=B^:0O</;S8613_  $>GTYKG+.[!S2TU0  !T' IU !1110
M F*3:*=10 W:*\[^,5Y>6OA>VA@=X[>YN!'<,O'RXR%)[ FO1JJ:EI]IJMC+
M97UO'<6TJ[7CD&01_GO4R5TT;X>JJ56-22NDT[=SY;LY9M/O8+FR)BN8Y%,;
M1\$G/3WS7U3:/))9PO,NV5D4N/0XYKE=)^&WAC1]16_M[)Y)HSF+SY6=8S[
M_P SFNO'2L,/1=*+3=SU,YS*ECZL9TH<ME]_W"GFF[>*=172>(-V"C:*=10
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MM5D76CR7&J+>+?3I$,%[4?<=AT)/:LS0U$BBBW>6B)N.3M &3ZT^N53QA'%
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MXTFEZ/JEIJ%K)=WCW&PS&21G)RK!0$Q]1N]L4 =-111F@ HHS1F@ HHS1F@
MHHS1F@ Q67K\*SZ5*C:>-03@M;X&6'MGO6IFJU]/);64\\48D>-"P4G&<>]
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MR/(R[>1@8JA &)+,<DG)->M@_:QNI'E8SV4K..YHJ<BG4Q.E/KTT>6%%%%,
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M1_Y^!]:K?\^SV7^UM._Y_P"U_P"_JT?VMIW_ #_VO_?U:\:_X5]XB_Z!D?\
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MK@75D)F&TR>8NXCTS7D'_"OO$7_0,C_[^+1_PK[Q%_T#(_\ OXM'U6C_ ,_
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MI7I<<B2('1@RGD$46 =12T4 )12T4 )12T4 0S3PVZ;YYDB3.-SL%'ZT]6#
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MZM$^C7YTT:<FV1YD#%R_. N>F!UKLM'TB[TZ262[U2:^=U51O0*% ] *\_\
MA=JFB:7)<:=%=!Y+A/M'GR2Y^5>-I]"!7H#>)]'4#_3HCGC!.#611KCI2TB,
M'16'0C/-+0 4444 %%%&: .=U[P=I'B&=;B[BDCN%&WSH7VL1Z'UJ_HVAV&A
M6?V73X/+0MN9B<L[>I/>M$GF@'FBQFJ<%+G2U'4AZTM-8@<DX'<T&AQ/Q"\-
M7NM6UK=Z?'YUQ:%@T&<%T/7:?45R/AOP;J]]K=K)=V$]G9V\JS2R3X4MM.0J
MC/<]3Z5[!'+',NZ*1) #@E6!J0<BH<$WS'!4P%&I65>6Z#\#3J**L[PHHHH
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M\&&! [UYE7!IS<TSTJ6,:@H-&SHOV1Y1&698\GYF^\?K5C7$LXG"QL)$]_\
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M&U@S@LV>&8] M 'K:N& *D%2,@@YR*<3BJ.D:;#H^D6FFP/(\5K$L2-(V6(
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MBI44FVNI3DVDGT%HHHJB0I#]T_2EI#]T_2@#W?P?_P BGIO_ %Q%;E8?@_\
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M/N5(\?-M!Z<T =)FC-<C$WC''E%8EP#F1@K=CC'KGC.:OZ?_ ,)$;R3[:(1
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M%U)*WX!/)Q$W/Z4[_A87AG_H(_\ D-O\*Y#_ (57J?\ T$[;_O@T?\*KU/\
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M*CAF2=-R," <'!Z'TJ2@ I#2TAH \4^(?_([W?\ UQB_D:YFNF^(?_([W?\
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M>?$=ZRNLD=M(CQ>4R-'QC=N!Z]0>E96Q"ZHTO0%N/"VL6D22W%JL2.I8,\@
M'&<'WQVJM;Z3/=6]G-$"RW$K1G&/DP0,\GGK5J\\2WNH%3=06DK!2&9HSESC
M&X\XR*S5NY4BM8QMQ:N9(^.Y()S^(K2/M;>]8B7L[^Z6#H]X;IX(T#[>0^[
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M12'-8FLW.II>6T=@LP7#/(RQAD;'1.>A)[]J -RBL"TU#77N8DNM/1$8;BR
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MT"[G_OI:\PHKDG@Z,Y<S1U0Q=:$>5,]/_P"%K67_ $"[G_OM:/\ A:UE_P!
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MG_OI:/\ A:UE_P! NY_[[6O,**/J%'M^(?7JW<]/_P"%K67_ $"[G_OM:/\
MA:UE_P! NY_[[6O,**/J%'M^(?7JW<]/_P"%K67_ $"[G_OM:/\ A:UE_P!
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M!T"BBBA@%%%% = HHHH *6BBA[AT"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
F*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>form10-k_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-k_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $J E$# 2(  A$! Q$!_\0
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MO/\ &G_/CH?_ ($R_P#Q%'G^-/\ GQT/_P "9?\ XBNEHH YKS_&G_/CH?\
MX$R__$4>?XT_Y\=#_P# F7_XBNEHH YKS_&G_/CH?_@3+_\ $4>?XT_Y\=#_
M / F7_XBNEHH YKS_&G_ #XZ'_X$R_\ Q%'G^-/^?'0__ F7_P"(KI:* .:\
M_P :?\^.A_\ @3+_ /$4>?XT_P"?'0__  )E_P#B*Z6B@#FO/\:?\^.A_P#@
M3+_\11Y_C3_GQT/_ ,"9?_B*Z6B@#FO/\:?\^.A_^!,O_P 11Y_C3_GQT/\
M\"9?_B*Z6B@#FO/\:?\ /CH?_@3+_P#$4>?XT_Y\=#_\"9?_ (BNEHH YKS_
M !I_SXZ'_P"!,O\ \11Y_C3_ )\=#_\  F7_ .(KI:* .:\_QI_SXZ'_ .!,
MO_Q%'G^-/^?'0_\ P)E_^(KI:* .:\_QI_SXZ'_X$R__ !%'G^-/^?'0_P#P
M)E_^(KI:* .:\_QI_P ^.A_^!,O_ ,11Y_C3_GQT/_P)E_\ B*Z6B@#FO/\
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M 9+_ *E_]TT1_P"K3_=%)*?W+_[II8_]6G^Z* 'T444 %%%% !1110 4444
M%%%% !7-^//^11NO^NL'_HU*Z2N;\>?\BC=?]=8/_1J4 =%1110!@>.?^1'U
MG_KV:MVW_P"/:+_<'\JPO'/_ "(^L_\ 7LU;D!"VL1/ "#^5 $M%92^(]'?&
MW4(6R<#!SS6K0 56OQ<-8S+;(CS,I"AVVCGWJS10!G:);W-GI%O;7:QK+$NP
M^6Q93COS6'KGA6VO]66\:=T67_6HHSNVCM^5=95>?_C[M?\ >;_T&KA4E!WB
MR)PC-6DCB9=9N=2B-C9V@CW<1^63OVCM6CHR:I8VS&XTZ6>)CD O\Z_@:Z.#
M3;.VN'GAMD25_O,HYJW4%G+)XHL#>>4]F\<6<%V'(/\ NU=_MW1O5_\ ORW^
M%65T&P74?MPB_>YW8S\N?7%:6!Z4 8AUW1@"<O\ ]^F_PJK9>)=.N;EHIH!;
MI_ [G@_7TKI&164JP!!&"*S;3P_IUG,\L<&6;L_S ?2@">*;3IQF*6!_]UA4
MXMX3R$4U5ET339N7LXOP&/Y5 ?#UJIS#-=0G_8F.* +KP1":(;!@YJ7[-#_S
MS%9+:;?Q31^3JTIZX$J!@*DQKT/\5G<>V"E &E]FA_YYBC[-#_SS%<WJVOZI
MIZ1I)9Q0R/SOW;U-6[/7+VZM8Y5TF9]P^\K@ _3- &S]FA_YYBC[-#_SS%9O
M]IZD>FCR#ZRK1]OU4]-)_.44 :7V:'_GF*/LT/\ SS%9OVW63TTR,?6:C[5K
MG;3K?\9Z -+[-#_SS%1B"+[21L&-@_G5'[1KQ_Y<+0?]MS_A3!+KAG/^BV8;
M;_ST- &K]FA_YYBC[-#_ ,\Q6;OUX_\ +*S'_ C2_P#$^/>R'_?5 &C]FA_Y
MYBD,$"C)10/4UG^7KQ_Y;V0_X U9FM:?KEW9A6EAF4-DQP@J3^= '1BWA(R$
M4BE^S0_\\Q6!I=AKUM8)&+F",=0DJ%BOMFKOV?7O^?ZT_P"_)_QH TOLT/\
MSS%'V:'_ )YBLW[/KO\ S_6G_?D_XT?9M=_Y_P"U_P"_- %V*"(R2_(.&_I4
MOV:'_GF*RH[;6M\F+^VSNY_<^U2?9=;_ .@A;_\ ?F@#1^S0_P#/,4?9H?\
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M;2ZHFJH*34'=#/M$/_/1?SH^T0_\]%_.I,#THP/2NHS(_M$/_/1?SH^T0_\
M/1?SJ3 ]*,#TH C^T0_\]%_.C[1#_P ]%_.I,#THP/2@""6>$Q.!(OW3WJ6/
M_5I_NBDE \E^/X32Q_ZM/]T4 /HHHH **** "BBB@ HHHH **** "N;\>?\
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M7*@LOT--CL;)+8K]EMUC<#>/+4!OK7+W,FFS>);N5%BANK2-_+ 0AY9MO7W
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M %U@_P#1J4 =%1110!@>.?\ D1]9_P"O9JV49UL4:--[B,;5SC)QZUC>.?\
MD1]9_P"O9JW(#BUB)Z;!_*@#C;S3VN[^1I; P3.?,N%74$RR<<$8^[P*[9>%
M '2O/KT6%]KDUS:ZA)MO,1O"+1FDE7(!\MO[OR]>@KT!1A0/04 5-1U&+384
M>1))'D;9'%$NYW;T I@U6*33([ZW@GN(WZ)$F7'KD>U1:S975P;2XLO*:>UF
M\Q4E)"N,$$9[=:@M[#4;719;*)H1.Z,RR[C@2.Q)X]!GB@"_IFHQ:I9BYA25
M$+,N)5VMD'!J2?\ X^[7_>;_ -!HL;1+&QAM8_N1(%!]?>FW*AKFU!)'S-T.
M/X: +=%0_9U_O2?]]FC[.O\ >D_[[- $U%0_9U_O2?\ ?9H^SK_>D_[[- $U
M%0_9U_O2?]]FC[.O]Z3_ +[- $U%0_9U_O2?]]FC[.O]Z3_OLT +)_Q\0_\
M JEJJ\*B>(;GYS_$:D^SK_>D_P"^S0!-14/V=?[TG_?9H^SK_>D_[[- $U%0
M_9U_O2?]]FC[.O\ >D_[[- $U%0_9U_O2?\ ?9H^SK_>D_[[- $U1#_C[/\
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MFX'UQ0!OU6G_ ./NU_WF_P#0:?;3-/;I*T31%AG8Q!(_+BF7!Q=VN3CYF_\
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MOM.M-2A$5Y LJ Y ;L:A&B:8+B"864(D@4+&V/N@=* -&BBB@ HHHH ****
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M1K*-A"Q:/=D[2: +]O(9;>*1AM9T#$>F14M%% !1110 4444 %%%% !1110
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=_G5O346;5[..51(AN8\JPR/O#M0!]!44M% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>form10-k_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-k_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %3 F$# 2(  A$! Q$!_\0
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M6FJ?\_MG_P"/?X5ZA11]=K=_P#ZE1[?B>8?\*UU7_G]L_P#Q[_"HS\,M6/\
MR^V?_C_^%>I?A1^%'UVMW_ /J=+M^)Y9_P *QU;_ )_;+_Q__"C_ (5CJW_/
M[9?^/_X5ZG^%'X4?7:W?\!_4Z7;\3RW_ (5EJW_/[9_^/_X4G_"L=6_Y_;+_
M ,?_ ,*]3_"C\*/KM;O^ ?4Z7;\3RP?#'5O^?VR_\?\ \*D'PTU4#_C]L_\
MQ[_"O3_PH_"CZ[6[_@'U.EV_$\P_X5IJO_/[9_\ CW^%(?AIJO\ S^V7_CW^
M%>H?A1^%'UVMW_ /J=+M^)Y=_P *SU7_ )_;+_Q[_"D_X5EJW_/]9?\ CW^%
M>I?A1^%'UVMW_ /J=+M^)Y;_ ,*RU;_G]L__ !__  I/^%8ZM_S^V7_C_P#A
M7J?X4?A1]=K=_P  ^ITNWXGEO_"LM6_Y_;/_ ,?_ ,*3_A6.K?\ /[9?^/\
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M  H_X57K'_/_ &/_ (__ (5ZSFC-'URKW_ ?U6E_3/)O^%6:Q_S_ %E_X_\
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M .=_X1,?]!W6O_ O_P"M1_PB8_Z#NM?^!?\ ]:NBHH YW_A$Q_T'=:_\"_\
MZU'_  B8_P"@[K7_ (%__6KHJ* .=_X1,?\ 0=UK_P "_P#ZU'_")C_H.ZU_
MX%__ %JZ*HQ+&9/+#KOQG;GG'TH P?\ A$Q_T'=:_P# O_ZU'_")C_H.ZU_X
M%_\ UJWO-C\SR]Z;R,[<\X^E'FH9/+WKOQG;GG'KB@#!_P"$3'_0=UK_ ,"_
M_K4?\(F/^@[K7_@7_P#6K>$L;2&,.I<#)4'D?A4E '._\(F/^@[K7_@7_P#6
MH_X1,?\ 0=UK_P "_P#ZU=%10!SO_")C_H.ZU_X%_P#UJ/\ A$Q_T'=:_P#
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M+*;1O%>D01ZIJ%Q%=).)([F;>IVJ"#TZUUU0O;Q/-',\:-)'G8Q'*YZX-34
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M,_AMM3N9%F.XW'\:GV-;'A#PTOA/0(M,6[DNMAR9).N?KZ4 =#1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %-(##! (]#3J* "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** /,?B__ *C2/]^3^2UY=7J/Q?\
M]1I'_723^2UY;FO;P?\ !1X^*_BL7%%&:*ZSF-6KFD?\AS3_ /KYB_\ 0A5.
MKFC_ /(<T_\ Z^HO_0A1/X690^)'OPZ44#I17S)],%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 56OG9+"Y="0RQ,5(Z@X-6:* ./T'P_'?Z#87
M=SJ.KF>:!7D/VV0?,1SQGBM'_A$[7_H(:M_X'2?XUO  # &!2T 8'_")VO\
MT$-6_P# Z3_&C_A$[7_H(:M_X'2?XUOT4 8'_")VO_00U;_P.D_QH_X1.U_Z
M"&K?^!TG^-;]% &!_P (G:_]!#5O_ Z3_&C_ (1.U_Z"&K?^!TG^-;]% &!_
MPB=K_P!!#5O_  .D_P :/^$3M?\ H(:M_P"!TG^-7[S6M,T^>*"\OH()93A$
M=P">O^!I+W6M-TTQ"\OH(3*0(P[@;L]/P]Z */\ PB=K_P!!#5O_  .D_P :
M/^$3M?\ H(:M_P"!TG^-7;O7-+L9(4N;^WB:?'EAI -V>A^G'6BYUW2K.XAM
M[F_MXIION(T@!/&?Y4 4O^$3M?\ H(:M_P"!TG^-'_")VO\ T$-6_P# Z3_&
MMX$$ @Y!I: ,#_A$[7_H(:M_X'2?XT?\(G:_]!#5O_ Z3_&M^B@# _X1.U_Z
M"&K?^!TG^-'_  B=K_T$-6_\#I/\:WZ* ,#_ (1.U_Z"&K?^!TG^-'_")VO_
M $$-6_\  Z3_ !K?HH P/^$3M?\ H(:M_P"!TG^-'_")VO\ T$-6_P# Z3_&
MM^B@# _X1.U_Z"&K?^!TG^-'_")VO_00U;_P.D_QK?HH P/^$3M?^@AJW_@=
M)_C1_P (G:_]!#5O_ Z3_&M^B@#GV\*6H4G^T-6Z?\_\G^-2^$YI[CPIIDMS
M))),T WO(?F)]_>MND  & ,"@!:*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH \Q^+_^HTC_ *Z2?R6O+:]3^+PS;Z3_
M +\G\EKRTBO;P?\ !1X^*_BL;11CWHKK.8UJNZ/_ ,AS3_\ KYB_]"%4JNZ/
M_P AS3_^OF+_ -"%$_A9G3^)'OW:BCM17S)]*%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4455U#(TVZVYSY+XQUS@T 6/,3^^OYT>8G]]?SKD
M/#GA31+CPYITUSI<33O;HTC.#N+8YSSUK3_X0WP]_P! FW_(_P"- &YYB?WU
M_.CS$_OK^=8?_"&^'O\ H$V_Y'_&C_A#?#W_ $";?\C_ (T ;GF)_?7\Z/,3
M^^OYUA_\(;X>_P"@3;_D?\:/^$-\/?\ 0)M_R/\ C0!N>8G]]?SH\Q/[Z_G6
M'_PAOA[_ *!-O^1_QH_X0WP]_P! FW_(_P"- %3Q)X)T/Q1J-C?:B',UFV8R
MLF./3\\'\*/$O@O1?%@LCJ9D<V;!HRLF.G7IZ^M6_P#A#?#W_0)M_P C_C1_
MPAOA[_H$V_Y'_&@"AKW@70O$=QI\]_YC26&!$1)C@=OY<^U+K?@;0]?U>PU.
M^,C7-ECRV$N.!T_7FKW_  AOA[_H$V_Y'_&C_A#?#W_0)M_R/^- &T'0 #>O
M'O3O,3^^OYUA_P#"&^'O^@3;_D?\:/\ A#?#W_0)M_R/^- &YYB?WU_.CS$_
MOK^=8?\ PAOA[_H$V_Y'_&C_ (0WP]_T";?\C_C0!N>8G]]?SH\Q/[Z_G6'_
M ,(;X>_Z!-O^1_QH_P"$-\/?] FW_(_XT ;GF)_?7\Z/,3^^OYUA_P#"&^'O
M^@3;_D?\:/\ A#?#W_0)M_R/^- &X"&&001[4ZN7\+6<=AJ6O6UO"8;=+M?+
M3G: 8USC/O744 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 >9_%S_ %&D_P"_)_):\L)KU'XO
MG%OI'_723^2UY97MX/\ @H\?%?Q6+1245UG,:Y&#5S1_^0YI_P#U\Q?^A"JS
M#(SW%6M'_P"0YI__ %\Q?^A"E/X61'XD>^]J*.U%?-'T@4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 45 ;RV!P;B+_OL4GVRU_P"?B'_O
ML4 6**K_ &RU_P"?B'_OL4?;+7_GXA_[[% $Q8*I8G  R2:S[+7M+U*YFMK*
M_@GFA.'1'!(XS5EKJU92IN8L$8_U@KG-"\)^'?#NJWNHZ<ZQS79S)F;(_GZ\
MT ;-MK^DWEY+9VU_;RW$7+QJX)'&:2T\0:3?W$\%KJ%O+)!S(J.#M&,YK&TK
MPCX;T?Q!=ZU:.J7=T,2'S^.>O?OUINC>$/#>@ZI?W]@ZQSWN1+^_[$<]_7G\
M: -VPUS2]4FFBL;Z"XDA.UUC<$C_ #FM*N4\.>%/#OA>\O+K3'2.2[;=)F;(
M^G7US^==']LM?^?B'_OL4 6**K_;+7_GXA_[[%'VRU_Y^(?^^Q0!8HJO]LM?
M^?B'_OL4])X921'*CD=0K T 2T444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 >8_%__ (]](_ZZ2?R6O+*]3^+_ /Q[Z1_UTD_DM>65[>#_ (*/'Q7\
M5AFBDHKK.8W15G21C7=/_P"OF+_T(55!JWI7_(<T[_KYC_\ 0A2G\+(C\2/>
M^U%':BOFCZ0**** "BBB@ HHHH **** "BBB@ HHHH **KW=Y;6%LUS=S)#"
MGWG<X K/A\3:--I)U1-1@-D.LV[@>Q]Z -BBL<^)M%&C_P!K'4(/L./]=NXZ
M9Q]?:B;Q-HUOI2ZI+J,"V3?=EW<'C.![T ;%5=0S_9MUC.[R7QCKT-.M+RWO
M[9+FUF2:%QE70Y!JQ0!R'AOPMHTOAO3I+G2+8SM;H7,D7S$XYSGO6K_PB/A_
M_H#V?_?H5M5#<7$-K \]Q(L<2#+.QP />@#+_P"$1\/_ /0'L_\ OT*/^$1\
M/_\ 0'L_^_0J2T\2Z-?6$M];ZA!);1'$D@;A><<TEOXFT6ZTMM2AU&!K-.&E
MW<+]: &?\(CX?_Z ]G_WZ%'_  B/A_\ Z ]G_P!^A4]MX@TJ\TLZE!?0O9@9
M:;=\J_7TJ32M9T_6[7[3IMW'<19P60YP: *G_"(^'_\ H#V?_?H4?\(CX?\
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MLQS#P!U_Y:5X9_PGOC/_ *&.;_P'B_\ B:;)XX\82QM&_B&4HZE6'D1\@_\
M :Y/KE'^;\&?0KAK,OY%]Z/<[?Q/<W5M'<0^'-5:*10Z',(R#T_Y:5MVTSSV
MT<CP2P,PR8Y,;E]C@D?K7S?!XU\76T$<$/B"58HU"(OD1\ =/X:D_P"$]\9_
M]#'-_P" \7_Q-'URC_-^##_5K,OY%]Z/I.BN&^%FN:GK_A%[O5+DW-PMW+%Y
MI4*2H(QP!BNYKK/GIQ<9.+W0M%%% @HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /,/C!_Q[Z1_UTE_DM>6!:]4^+_\
MQ[Z1_P!=)?Y+7EM>S@_X2/)Q/\1B4445UG.;0J]H_P#R&K#_ *^8_P#T(52%
M7=(_Y#>G_P#7S'_Z$*<_A9C'XD>\]J*.U%?-'T@4444 %%%<_P"(M:N]&\EH
M+<21NK;CM+$-CY> 1@9ZF@#7NKVULHU>ZN(H$9@BM(P4$GH.:/MMK]L^Q_:(
MOM.W?Y.\;MOKBN7\96NHZWX-C@M=.^T74[PR%%D7$>&5B<D^QZ50C\,ZL?B!
M_:AC MFNA=^<7&53R?+\K'7.>?2@#-^,O_'QX,_[#D/\Q7J5>'_$G1-0TO5?
M"L]YXAOM2CEUN+9!.B!8_F!XV@'VKW"@ HHHH **** "BBB@!#7 ?&/_ ))[
M-_U]6_\ Z,%=^:X#XQ_\D]F_Z^K?_P!&"I>S-L/_ !H>J_-'AE%%%?+,_>%L
M@HHHH0/9GM7P4_Y$:;_K_F_F*](KS?X*?\B--_U_S?S%>D5]2MD?@^(_C3]7
M^;%HHHJC$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#S'XO_P#'OI'_ %TD_DM>65ZG\7_^/?2/^NDG\EKRLU[.$_A(
M\G$_Q&+13>:*ZCG-T5=TC_D-6'_7S'_Z$*I"KND_\AJP_P"OF+_T(553X68Q
M^)'O/:BCM17S1](%%%% !7!^*S>-<;KHV4$95XX@R^8SKZ]#BN\KB=0U6&XF
MN(&MVU>92R^5:PNCJ,_=W?=R/7- '3Z-D:+9 ]?)7^57ZKV8"V<"K$80$'[L
MG)3CH:L4 >6_&7_CX\&?]AR'^8KU*O+?C+_Q\>#/^PY#_,5ZE0 4444 %%%%
M !1110 AK@/C'_R3V;_KZM__ $8*[\UP'QC_ .2>S?\ 7U;_ /HP5#V9MA_X
MT/5?FCPRBBBOEV?O"V04444('LSVKX*?\B--_P!?\W\Q7I%>;_!3_D1IO^O^
M;^8KTBOJ5LC\'Q'\:?J_S9DZMXBT?06A&JZE;V9FSY?G/MW8ZX_,5AW_ (Z\
M*W< CA\76MJV<^9%*I/TY!KF/BTH;7_#X901Y-SU&?\ GG7$^7$#_JT_[Y%1
M.JH.UCY[&YK]6J^SY;Z=SOM4\7Z5;V\;67C\2N9XU89B.$+88_=["KZ^*O#J
MR*Q^(@8 Y*EXN?;[M>8^7'_SS3_OD4>7'_SS3_OD5'MUV.+^W_[GXGM/_"Q/
M!X'/B/3_ /O\*W[2[M[^UBNK:9)K>50\<B'*L#T(-?.TD<7DO^[3[I_A'I7M
MOP__ .1 T'_KRC_E6D)J:>AZF Q_UOF]VUCI:***T/4"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH \P^,/_ ![Z1_UTE_DM>5$UZI\8O^/?
M2/\ KI+_ "6O*J]K!_PD>3B?XC"BBBNLYSH*MZ2?^)UI_P#U]1?^A"JE6M*_
MY#>G?]?,?_H0HG\+,8_$CWOM11VHKYH^D"BBB@ K&U6\OK.9([&WBD#H2?,.
MQ4/][/?Z#FMFO//&5W=QW'FWMM;VD2!XX+AKW;YJD8(QL.": .ZLGEELH7GQ
MYK("^!@9^E6:HZ1M_L:RV*57R$P"V[' []ZS3XF4^+!H$-H\KK'YDTXE0"+(
MR 5SN/X"@#C?C+_Q\>#/^PY#_,5ZE7DGQ<O[.[N_!R6]W!,Z:Y#N6.0,1R.H
M!KUN@ HHHH **** "BBB@!#7 ?&/_DGLW_7U;_\ HP5WYK@/C'_R3V;_ *^K
M?_T8*A[,VP_\:'JOS1X91117R[/WA;(****$#V9[5\%/^1&F_P"O^;^8KTBO
M-_@I_P B--_U_P W\Q7I%?4K9'X/B/XT_5_FSRCXM?\ (P^'_P#KC<_^TZXB
MNW^+7_(P^'_^N-S_ .TZXBN:O\1\%G7^]/T04445@>,-D_U3_P"Z?Y5[9\/_
M /DG^@_]>4?\J\3D_P!4_P#NG^5>V?#_ /Y)]H/_ %Y1_P JZJ&S/J,@^W\C
MI:***Z#Z@**** "BBB@ HHHH **** "BBB@ HHHH AN+F&UA::XF2&-?O/(P
M51^)K/;Q%HVT[=7T\MCC-RO7\ZY/XU?\DMU/_>B_]#%?(QF?^^WYT[*Q-W?0
M^R/^$JU+/^M\.?\ @S_^M5:Q\:ZA?645RI\/Q"09V2:EAASCGBOD#SI/[[?G
M1YTG]]OSHT'J?;UAXEL'M%:_U+2HKCG<L-VK*/Q.*U+2^M+Z,R6ES#.@."T3
MA@#Z<5\&B5_[[?G7TO\ LZDGP;J1)R3??^R+19"UN>R4444B@HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \P^,'_ ![Z1_UTE_DM
M>5&O5/C"<6^D?]=)?Y+7E1.:]G!_PD>3B?XC$HHHKK.<Z&K.E?\ (=T__KYB
M_P#0A54G JSI'.N:?_U]1?\ H0IS^%F,?B1[[VHH[45\T?2!1110 5QNM&34
MKU)18ZBOD*\?%HLBOSU&3[5V5% %+2MRZ5;!@P81C(==I'U':LQ?"MD?$K:Y
M+^\N<YBRB@QG&#A@,D$=C7044 >,?%#PYHNC:CX2N=-TNUM)YM;B\R2&,*S?
M,#R1[U[/7EOQE_X^/!G_ &'(?YBO4J "BBB@ HHHH **** $-<!\8_\ DGLW
M_7U;_P#HP5WYK@/C'_R3V;_KZM__ $8*A[,VP_\ &AZK\T>&4445\NS]X6R"
MBBBA ]F>U?!3_D1IO^O^;^8KTBO-_@I_R(TW_7_-_,5Z17U*V1^#XC^-/U?Y
ML\H^+7_(P^'_ /KC<_\ M.N(KM_BU_R,/A__ *XW/_M.N(KFK_$?!9U_O3]$
M%%%%8'C#9/\ 5/\ [I_E7MGP_P#^2?:#_P!>4?\ *O$Y/]4_^Z?Y5[9\/_\
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M^SZI+!=ZC)*SF$-MDD<# QV)Z5W?VYC.Z^Y'+_9=#L_O/+/^$-\8?]"U<_\
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MT?5Z7\J#^W,Q_P"?K_ \@\!3^+/"'AYM-N? ^H7$K7#S%XKF +AL<<M74_\
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MHHHH **** "BBB@ HHHH **** .0USP+:ZW?ZG=-=21#4+$6LL:CC>IRDO\
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MPG$]Q%>W$!LUEF?[5*;KSB!\HQ\P&?0\<\5TFI7\6EV,EU*KNJ8 1!EF8G
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M_P#OA_\ "CV53^5_<'M(=T=!17/_ /";>'/^@G'_ -\/_A1_PFWAS_H)Q_\
M?#_X4>RJ?RO[@]I#NCH**Y__ (3;PY_T$X_^^'_PH_X3?PX/^8G'_P!\/_A1
M[*I_*_N#VD.Z.@HKG_\ A-_#?_04C_[X?_"C_A-_#?\ T%(_^^'_ ,*/95/Y
M7]P>TAW1T%%<]_PG'AO_ *"D?_?#_P"%'_"<>&_^@I'_ -\/_A1[*I_*_N#V
MD.Z.AHKG_P#A-_#G_03C_P"^'_PH_P"$W\.?]!./_OA_\*/95/Y7]P>TAW1T
M&:,USW_"<>&_^@K'_P!\/_A1_P )QX;_ .@K'_WP_P#A1[*I_*_N#VL/YD=#
MFC-<]_PG/AO_ *"L?_?#_P"%)_PG/AO_ *"L?_?#_P"%'LJG\K^X/:P_F1T5
M%<[_ ,)UX:_Z"D?_ 'P_^%'_  G7AK_H*1_]\/\ X4>RJ?RO[@]I#NCHJ*YW
M_A.O#7_05C_[X?\ PH_X3KPU_P!!6/\ [X?_  H]E4_E?W![2'='145SO_"=
M>&O^@K'_ -\/_A1_PG7AK_H*Q_\ ?#_X4>RJ?RO[@]I#NCHJ*YW_ (3KPU_T
M%(_^^'_PH_X3KPU_T%(_^^'_ ,*/95/Y7]P>TAW1T5%<[_PG7AK_ *"D?_?#
M_P"%'_"=>&O^@K'_ -\/_A1[*I_*_N#VD.Z.BHKG/^$[\,_]!6/_ +X?_"C_
M (3SPS_T%8_^^'_PH]E4_E?W![2'=#_%ND_VMI<4:BX$D,HFB> *Q1E!P2K<
M,/:N5ELO&X$,L!$$T>D.%B@"B(W7F9&5/0E<'TSFNG_X3SPS_P!!6+_OA_\
M"C_A//#/_05C_P"^'_PH]E4_E?W![6'='):C'XWU7PU<V=Q:R$3R7,;IM3>8
MS&/*'IC=G)ZUK>%DUC^T4LI+QCI]I:P"2(J T$RJ T)X^93PV:U_^$\\,_\
M05C_ .^'_P *0>.O# )(U2+)Z_NW_P */95/Y7]P>UAW1SVH:)JEOX@\073Z
M/%K/]HB,632OA8E"X:,GJ@[Y'6K4\?C'[5JJ6;&&.W@B-C%L4QNVW#J&//';
M-;'_  G?AG_H*Q_]\/\ X4?\)WX9_P"@K'_WP_\ A1[*I_*_N#VL.Z.5U&3X
MAIH]O)9B1[@K<)MVIOZCR6<= >N<4^PU?Q7?^,-4MH))6M+:X,;J\:!8T,((
MVGJ6WGZ5T_\ PGGAG_H+1_\ ?#_X4P>._"ZDD:I$">I$;\_^.T>RJ?RO[@]K
M#^9%WPP-471476'D>\5V!>0*"PSP<+P*V<US?_">^&/^@O'_ -^W_P *3_A/
M_"__ $%XO^_;_P"%'LJG\K^X/:P_F1TM%<U_PL#PO_T%XO\ OV_^%'_"P/"_
M_07B_P"_;_X4>RJ?RO[@]I#NCI:*YO\ X3[PO_T%HO\ OA_\*3_A/_"__06B
M_P"^'_PH]E4_E?W![2'='2T5S7_"P/"__07B_P"_;_X4?\+ \+_]!>+_ +]O
M_A1[*I_*_N#VD.Z.ES1FN:_X6!X7_P"@O%_W[?\ PH/C[PN.NKQ?]^W_ ,*/
M95/Y7]P>UA_,CI:*YK_A8'A;_H+Q?]\/_A1_PL#PM_T%XO\ OA_\*/95/Y7]
MP>TAW1TM%<U_PL#PM_T%XO\ OA_\*/\ A8'A;_H+Q?\ ?#_X4>RJ?RO[@]I#
MNCI:*YG_ (6#X6_Z"\?_ '[?_P")H_X6#X5_Z"\?_?M__B:/95/Y7]P>TAW1
MTU%<S_PL'PM_T%X_^_;_ /Q-+_PL#PM_T%XO^^'_ ,*/95/Y7]P>TAW1TM%<
MU_PL#PM_T%XO^^'_ ,*/^%@>%O\ H+Q?]\/_ (4>RJ?RO[@]I#NCI:*YG_A8
M/A;_ *"\?_?M_P#XFE_X6!X6_P"@O%_WP_\ A1[*I_*_N#VD.Z.EHKFO^%@>
M%O\ H+Q?]\/_ (4?\+ \+?\ 07B_[X?_  H]E4_E?W![2'='2T5S/_"P?"W_
M $%XO^_;_P"%+_PL#PM_T%XO^^'_ ,*/95/Y7]P>TAW1TM%<S_PL'PM_T%X_
M^_;_ /Q-'_"P?"W_ $%X_P#OV_\ \31[*I_*_N#VD.Z.GHKF/^%A>%?^@O'_
M -^W_P#B::_Q$\+(N1JJ-[+&^?Y4O95/Y6'M(=T=3FL?Q'XAM/#FE27ERP+=
M(HL\R-V KC=7^+EC%&Z:3:2SR]!),-B#WQU->8ZMK-_KEZUY?W#2RG@#HJ#T
M ["NJCA)2=YZ(YZN*C%6AJR.^O9M0OI[NX;=+*Y=S[FJQI12&O82Z'EMW$HH
MHHL(WJ*** $[TE%% PI*** "BBB@0M+110 4UJ** "FFBBF(*4444#"BBB@!
M*0]***0#:::**"A****!!1110 E+110 HI:**!"'I33110-#:::**!AVH[T4
M4Q"THHHH$!I#110 E-HHIB8VFFBB@$!H/6BBD,6FGK110 E+_!110(4=:1N]
M%% #3VHHHH&%(:** $H%%%(8X4ZBBF(2BBBD 4444P$[4T=:** %I.U%% Q*
<.]%% !1114LH:PXH%%%,3%[4E%%!(E%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form10-k_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-k_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %F HH# 2(  A$! Q$!_\0
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M7?\ SYW/_?EO\*;]CN_^?.Y_[\-_A7T)BC%']H/^4/J$?YCY\^QW?_/G<_\
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M465W_P ^=S_WY;_"OH+%&*/[0?\ *'U%=SY]^QW?_/G<_P#?EO\ "C['=_\
M/G<_]^6_PKZ"Q1BC^T'_ "A]17<^?/L5W_SYW/\ WY;_  I/L=W_ ,^=S_WX
M;_"OH3%&*/[0?\H?45W/GP6=WG_CSN?^_#?X4?8KO_GSN?\ OPW^%?0>*,4?
MV@_Y0^HKN?/GV*\_Y\[G_OPW^%--E>?\^=S_ -^&_P *^A<48]J/[0?\H?45
MW/GC[%>9_P"/.Y_[\-_A1]BO/^?.Z_[\-_A7T/CVHQ1_:#_E#ZBNY\[_ &*\
M_P"?.Z_[\/\ X4GV*\_Y\[K_ +\/_A7T3BC'M1_:#_E#ZBNY\[?8KS_GSNO^
M_#_X4?8KS_GSNO\ OP_^%?1./:C'M1_:#_E']17<^=OL5Y_SY77_ 'X?_"E%
ME>?\^=U_WX?_  KZ(Q[48]J7U]_RA]17\Q\\"RO,_P#'G=?]^&_PI?L5Y_SY
MW7_?A_\ "OH;%&/:CZ_+^4/J*[GSQ]BO/^?.Z_[\/_A3397G_/G=?]^'_P *
M^B<48]J?U]_RB^HKN?.ILKS_ )\KK_OP_P#A3?L5Y_SY77_?A_\ "OHS%%']
MH/\ E#ZBNY\Y?8KS_GRNO^_#_P"%'V*\_P"?*Z_[\/\ X5]&T?A1]?E_*/ZD
MNY\Y"QO,_P#'E=?]^'_PIWV*\_Y\[K_OP_\ A7T7^%%+Z_+^4/J2[GSI]BO/
M^?.Z_P"_#_X4W[%>_P#/E=?]^'_PKZ-HQ1]??\H?4EW/G'[%>_\ /E=?]^'_
M ,*3[%>G_ERNO^_#_P"%?1^**?U]_P H?45W/F_[#>_\^5U_WX?_  H^PWG_
M #Y77_?A_P#"OI#\*/PI?7Y?RA]27<^;C8WO_/E=?]^'_P *06-Y_P ^5W_W
MX?\ PKZ2H_"CZ_+^4/J2[GS;]AO?^?*[_P"_#_X4?8;W_GRNO^_#_P"%?27X
M4?A1]??\H?4EW/FW[#>_\^5U_P!^'_PH^PWO_/E=?]^'_P *^DOPHH^OO^4/
MJ2[GS?\ 8+S'_'E=?]^'_P */L-Y_P ^5U_WX?\ PKZ0_"C\*/K\OY0^I+N?
M-OV"\_Y\KO\ [\/_ (4?8;W_ )\KK_OP_P#A7TE^%'X4?7Y?RA]27<^:VL[M
M1EK.Z ]3 P_I5<@JQ5@0PZ@\$5].$9[5EZEX<TG5HF2\L87)'W@N&'XBJCC]
M?>0G@M-&?.U(>M=MXN\ 7&AH][IY:XL1]X'EXO<^HKB1TS7?3J1J1O$XIPE!
MVD+1Q11FK(-.N]^'?AY+F5M7NDW)&=L"GIN[M^%<$3P3[5[KX;M%L?#UC @Q
MB(,?<GFN7&U'"G9=3;!TU.=WT-0#%.HHKQ#VPHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9(BR(R
M.H96&"#T(KPKQUX='A_72(%(L[@%X?;U7\/ZU[N:X7XJ623^%X[HCY[>=2#[
M-P?Z5U86HXU$NC.;$P4H7['C9HS117MGCFFP^0_2OH+3_P#D'6O_ %R7^5?/
MQ^XWTKZ"L/\ D'VW_7)?Y5Y^8;1.S ;R+-%%%>4>J%%%% !1110 444UW$:%
MV.%4$D^U #J*\6U[XQ7]QXETBPT&PGM]-GO4A>]NX"HG&[!" ]O>NH^)?C?4
M?#<NE:/HD43ZOJLNR)YAE(U&!NQWY(H ]!HKR[P]XP\3:1X]7PCXO:TN9+BW
M-Q;7=JFT< D@C\#6(GCKQUXK;7=7\,MI]MI.D.RK#.FYYPO)Y^@SVH ]LHKF
MO GBM?&7A*SUD1>3)("DL8.0KKP<>V:Z'S8_^>B_]]"@"2BH_-C_ .>B_P#?
M0I//B_YZI_WT*=FP):*B\^+_ )ZI_P!]"C[1%_SU3_OH46?8+DM%1>?%_P ]
M4_[Z%'GQ?\]4_P"^A19]@N2T5%Y\7_/5/^^A1Y\7_/5/^^A19]@):*B\^+_G
MJG_?0H\^+_GJG_?0HL^P7):*B\^+_GJG_?0H\^+_ )ZI_P!]"BS[ 2T5%Y\7
M_/5/^^A1Y\7_ #U3_OH46?8"6BHO/B_YZI_WT*7SH_\ GHO_ 'T*+/L!)148
MD7&=X_.E#9'!S4BN/HIN<FES3&+13<T$T .HI >*6@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH 0UR?Q( /@:^_WH__ $-:ZPURGQ'_ .1&OOK'
M_P"AK6M'^)'U,JOP,\,I,T45]">&:I^XWT-?0.G_ /(/MO\ KDO\J^?F/R-]
M*^@M/_Y!UK_UR7^5>=F&T3LP&\BS1117E'JB&O/=;\.?$&XU>\N=-\96MG8,
MY:*![;/EKZ$UZ'7GOQEFN(O ;)'.]O;3WD$-W*AP5A9\-^'04 <X]OXT1BK?
M%31%(Z@HH(_6O7;/S!90"699I/+7=*O1SCDCV-?,WBGPUX3T#4?%MBT"0W%K
M':SZ3&[EC-DC<!S\P;O^E?2NE_\ ()LL1>4/(3$?]SY1Q0!<H(!&",BBB@#R
M7XNV%Y=>)/!9M+.>:.&_#2&*,L$&Y>3CI3_BUH.JOKGAWQ5IMC)?QZ3*3<6T
M/,A4D'('?H:]7HH \9T>/5?'WQ5M_%']C7FEZ586;0 WJ;7D8@\ ?\"_2L'1
MI]>^'%CXC\,W'AG4+Z?4)7-G<VJ;HF# J"3VZU]"44 <3\+/#-[X7^']GINI
M*$NV+RR1@_<W'.WZ@=:RY/@GX<EF>5[_ %G<[%B!>$#).?2O2JSM=&JMHET-
M#:W74RO[@W.?+#9'WL>V: /"?B9X#TSP9'H4^EW>I%[N_6"43718%*]:C^'G
MAHHI^POR ?\ 7/\ XUY'\3(_'2#P]_PE<VD26QU)/*^PA@V_WSVQ7T-%_JE^
M@K2%:I!6C)H5D<Q_PKSPV/\ EQ;_ +^M_C2_\*^\.#_ER?\ [^M_C74T5?UF
MM_.PLCE_^%?^'?\ GS?_ +_-_C2?\*_\._\ /F__ '^;_&NIHH^LUOYV%EV.
M6_X5_P"'?^?-_P#OZW^-'_"O_#O_ #YR?]_6_P :ZFBCZS6_G861RW_"O_#O
M_/F__?YO\:7_ (5_X=_Y\W_[_-_C7444?6:W\["R['+?\*_\._\ /F__ '];
M_&C_ (5_X=_Y\W_[^M_C74T4?6:W\["R.6_X5_X=_P"?-_\ OZW^-'_"O_#O
M_/F__?UO\:ZFBCZS6_G861RW_"O_  [_ ,^;_P#?YO\ &C_A /#O_/F__?YO
M\:ZFD-'UFM_.PLCS/7;!?!FKQZE;:=<2Z"+8BZ6.?[C[OE;#'FNJL&N;-I7@
MM)9;:;;)&0XZ$>]3^+M(GUWPMJ&F6S(L\\>U"YPN?>N$A\:>)O#UA=1ZQ9:9
M)_9VQ'"3,C,O RH(^:BK0CBHPE%VJ)VWU:MIN9O"N;<XZ<NNAZ%_:-Y_T"YO
M^^U_QH_M"\_Z!DW_ 'VO^-6K.^MKZ!9K6>.:,_Q1L&Q^56<UQ.E43LY/[D3[
M.?\ -^1E2ZI<PQM+)ITP5!DD,IQ^M7[>X6YMTE3.UQGFGRQK)$R.,JPP1[5C
M1P+I^LP06[,L+H24SD<5E)SI23D[ID-SIM-NZ9NKTI::O2G5UG4%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M UUW.H6BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "&N4^(_P#R(U]]8_\
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MC-+6IQA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 AZUR?Q(_Y$:^^L?_ *&*ZSO7)_$C_D1K[ZQ_^AK6M'^)
M'U,ZOP,\*_&BBBOH#Q#7<?*?I7T%I_\ R#[;_KDO\J^?V^Z?I7T!I_\ R#[;
M_KDO\J\_,-HG7@-V6:***\H]00]:Y^\U/PM>W<D5]-I\L]E.D+?: I,<K<JH
M+=SZ5T->,_$#X::[/JLVI>'-1(AOK^"XN+4H/W4J\";)[+UQ[T >O7-E:WD:
MQW-O%,BL'59$#!2.A'H:G[UX];:/XVO;IK6U^+%E/<#K''%&S>_ %>N6J2QV
ML,<\OFRJ@#R8QN8#DX]Z )J*** "BBB@ HHHH *BN;>"[MW@N(4FA?ADD4,I
M^H-2UG:];:E>:)=6^D7J65_(N(;ATW",Y'.._&: /)OC7I&FZ=;^&)+*PMK9
MVU1 S11!21CH<5[/'_JE^@KYW^)6C^,-,_X1Y_$?B2'5(&U)!''';B/8WKGO
MQ7T3'_JU^@H =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !2&EI",T 036T$^/.B1\=-RYQ7'>-O"5MJ5@\L<4"E0
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M]!7SO\2X?',?_"/'Q7=:5+;G4D\H6:$,']\]L5]$1_ZI?H* '444E "T4E%
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M<<'JT>ABHMPIU%M9+YK<EHHHK4X@HHHH **** "BBB@ HHHH **** "BBB@
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MJV22WE26/&-R,"*LCK6BU1Q25G9BT444Q!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 AKE/B1_R(U]]8_P#T-:ZLUR?Q(_Y$:^^L
M?_H:UK1_B1]3.K\#/"R*3%.HKZ \4TW^X?I7T)I__(/M?^N2_P J^>W^X?I7
MT)I__(/M?^N2_P J\[,-HG5@-V6:***\L]03O7"ZAX?\7"UUEX?%ZVOG7@N+
M:1XP1;0 '*'/&/\ "NZ->;_&2]CD\"SVT5[&L7VJ$7R1R#S!!N&[@'/IGVH
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M+>SL1.+EL[&9]MO?^?%_^^A1]MO?^?%O^^Q6G1BH]G+^8S]E/^=_@9JWMYN
M-BP!.,[QQ6CDGM0<C&*.:N,6MW<N$7'=W%%177_'I/\ ]<V_E4HILB"2-D;H
MP(/T-6:' ?#2:2#X<W$T(W2QRW#(OJ1R*XCP7%+KFB2:KJ?@J3Q!?7DTGG7L
MUTG&#@(H/W /2O9=!T"Q\.:<;#3D=(-[28=RQR>O)K$O/AOH-U?7%W";ZQ>X
M.Z9+&[>%)&]2H.,^] 'G,5EK.G:EX;LM5A$%O%K+FPA>X$TD,)&=C,/3MFO4
MM6\7VVDZF;&73]2E;"GS(+<LG/O4</@'P_!'IRQ6LB_V?.;B%O-8L9#U9B>6
M/UKIL>U '%>-_%EW8M;^'_#T7VCQ%J(Q$N/EMD[ROZ =JU?"/A2V\)Z1]EB=
MI[J9O-N[N3EYY3U8G^0K.N/AIH=QK=UK"SZI!?W1_>RP7KH2/3V'M5ZP\&VN
MGW<5S'J>LR-&<A)KYW4_4'K0!TG:BBB@"K>Z?9ZE;&WOK:*Y@)!,<JAE)'3@
MUP/AR..'XU^)8XD6.--/@ 51@#D=J](-9%KX<TZS\1WFO0QN-0O(EBF<N2"J
M],#H* .2TKP/H6IZKJ^J1:_?WCW%R?.2WN3$L3#^$A><CWK"O[[4Y/#WC_PN
M9YKZ'3+?-M<.=TFUEW&-CW(_.NYO? >C7>HS7\)O+"XG_P!>UC<M")3ZL!P3
M[UK:3H6G:'8FSL+58XG):3/S-(QZEB>6)]Z ,/2KRS'PHM;I9$%J-(!+9XP(
M\']:\OLA+%X!^';2!HU?60R@DCY23BO2G^%WAIY''EWBV3R>8VGK=.+8MG)_
M=YQC/;I6[K/AK2M=T@:7?6BFU0J8Q'\AB*]"A'W2/:@#C_B8X7Q)X(3=@MJA
MX!QGY:Y-=,:_UKQQ=6R_Z;IUXES"W?CDC\0*]"A^&GAY-0M+^9;ZYO+2020S
M7-V\C*1VY/2M;3?"VE:5J.IWUK"XFU-MUSN<L&/L.W6@#A]4U&'QQ<6RQE9;
M"PTQK^X7J//92$4^XP36K\'CGX?V_P#UUD_G6WH?@C1/#UCJ%GI]NZ17[L\^
MZ0L3D8P#V%7O#WAZP\,:4FFZ:DB6RL6 D<N<GKR: -6BBB@ HHHH **** "B
MBB@!*Y[QGH-QXC\-S:?:31PW#.CH\H)4%6!YQ]*Z&@]#50FX24ENA-75C@O#
M>M:]JNDW%Y-+&9K2[:WDACC^5@IP2.]6-,\/WBI/)I/B"6WMYIFE,9MU)5B<
MD9--M?!^N:5/>C2?$8M[6YN'N/+DLT<J6ZC)JIX,\61QRSZ/K4Q35%GEPQA*
M+*@/WAVHKX2+JRK4I7CVN[K^NIG1JU,-)VE[KWOKMMN;,FC>((XV8>)I6(!(
M'V5.:@T+QSI]SIL1U.YCMKP$I(K @9!QGVS750SQ3Q"2)PZMT(K'\2:$-9T*
M\L[=(8YY5PKLO0US-65X,].E7I5K1K+1M:JRM^&IN*=P# Y!Y%.'2N&U+6O$
MWA[2UNKJRT][>(HC;96W<D#-=I;7"7%O'*K AE!X.:TC)-V,:N'E3BIZ-/JB
M:BC(HJSG"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2N4^(_P#R
M(U]]8_\ T-:ZNN3^)'_(C7WUC_\ 0UK6C_$CZF57X&>&44F:*^@/%-1ON-]*
M^@]/_P"0=:_]<E_E7S^P^1OI7T#I_P#R#[;_ *Y+_*O/S#:)UX'=EFBBBO*/
M4"N*^*.N:CH7@YGTJ007MW<1V<=P>D.\X+>W'>NT(S7F'C+X?^(]?;5#<>-Q
M;:).=[6DMN#'$@P>6R.A&<T 8OB/P5JG@#P^_BK2_%NK3ZA8E9+I+N<O'<J6
M 8%3]>^:]BL;@W=A;7)7898E<KZ9&<?K7S[%H:>*9+705^+\5\874P6TD)VL
MR],$G#D=N37T):Q20VL,4LGFR(BJSXQN(')Q0!-1110 4444 %%%% !6;KZ:
MM)H=TFARPQ:F5_</,,H#GN/IFM*J6KZM9:%I5QJ>HS>39VZ[I9-I.T9QT'/>
M@#P'XDVWCF#_ (1X^*[_ $ZXMSJ2>4MI'M8/ZGCIBOHF/_5+]!7@/Q5\=^&_
M%L?ARWT34ENI8=22211&ZE5Z9^8"O?8_]6GT% #Z**3- "T4F:,T +129HS0
M M)FEKF]8OO%EO>R#2])TZXLU4$23W11B<<C !H Z2C->>^'_%OC#Q)IJW]I
MH&F) 9&C/F7C!LJ<'C;75WOB71=*ECM]4U?3[.Y< ^5-<*IY]B<X]Z -;(I<
MUS'B'Q9_8NHZ%;0VZW4>J3^4)%DX48SN'K734 +FC-<YK%[XLAORFD:3I]U:
M;1B2>Z,;;NXQ@UA:%XWUW5/&4N@2Z+:,MJH-Y=6MT7C@)Z*3CEO:@#T"BBB@
M S29KG_&7B1O"^@-?Q6WVFX:1(H82VW>S' YJKI^H>,Y[N$7>D:5%;,1YC1W
M;,RJ?;'6@#J\T5Q,OC#5M4U>\LO"ND0WL5BVRXNKF?RD+_W$XY/O6EX:\86F
MO65X\\9L+O3Y#%?6\[ >0P[YZ%3V- '2457:]M5M/M;7,(MMN[SC(-F/7=TQ
M7+^/?&K^$/#]OJ=G9KJ)GF6-%63 ((SD'O0!U^:6L?PUKT'B;0+75($:-9E^
M:-NJ,.H-<K9?$O\ M#XE/X7M].W6J%D^V>9U=1DX'IVH ]"HI*P_&%]/IWAN
MYNK;5K/2I4P1=7B;HUYZ$>_2@#<W#.,C/IFES7S'%\1-9'Q$FUS[)$DSV?V8
MSR++]F1>/W^,9V\>E?0/A2ZFOO#=G<W&J6VIRR*6:[MEVQOS_"/;I0!MT444
M %%%% !1110 4'I110 G:N)\46=[;^,-&UJVTV6]M[>":*98<;EW $'GZ5VV
M*0KGKTK2E4]G*]KZ-?>2XIJS./\ #M^=4T;[;IUZ((2[CR9T&Y&!Y4\UMZ?K
M=M<VJ/--$DN2K+N'!'%9[_#WPL\KR'1X-SL7;!89)ZG&:Y#Q7X='A"YDUW1=
M/METU+;9<PB0J02W# =Z2PD)3:PLFM[)[>2N<KISI*]/[CTN\LK74+5[:[@C
MF@?[R.,@UQ>B32>$)[^WOK.6+3Y+O]Q,#E$4\ ?G70Z;>7?VY;:=TD1H%E4J
MN",U:UK2+?6]+DL[@NL;$-E#@@@Y&#]17(G[1<R5FM#T\'BHN+IS^%O7R\T:
M(.<$<BGUR?@:YN9=/NXKFYEN&ANGC1Y3D[1T%=7FMHOF5R:U+V51P;V%HI,T
M9JC(6BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*Y/XD_\B+??6/_ -#6
MNLKD_B3_ ,B+??6/_P!#6M:/\2/J95?@9X5FBFT5] >*;;?<;Z5[_8?\@^V_
MZY+_ "KY_;[I^E?0%A_R#[;_ *Y+_*O/S#:)V8'=EJBBBO*/3"O//C1YQ^'L
MP7S?L9NH?MWE?>\C>-V/TKT.N1^(_B&3PQX3DU%8+.XB$J1SP7722)CA@HR,
MMCG'L: .!^(,/@!/ ,3: NG#4MT7]EFQV^<TF1C./FZ=<U['I_G?V=:_:?\
M7^4GF?[V!G]:\XT1/A#I]Y'K&FS:+#<-AXV>4 QD^BL?E->FQ2)-&DD;!D<!
ME8'((/>@!]%%% !1110 4444 %1SPQ3PM%-&DD;?>5QD'ZBI*S?$&CIK^A76
MER7$]LEPNTRV[;77D'@_A0!Y7\;M/LK2U\,/:VD$+'55!,<87/'M7L<?^K7_
M '17SM\2/A_:^#SX>N8-7U2],VHI&4O)MZJ.N1[U]$Q_ZM?H* '&N<FO_$ZS
MR"+1;9HPQ",;K!(SP<8KI,4F*EJ_4TA-1WBGZG,_;_%7_0#M?_ K_P"M1]O\
M5?\ 0#MO_ K_ .M738HQ2Y7W9K[:'_/M?C_F<S]O\5=]$M?_  *_^M6_:/.]
MM&US$L4Q7+HK;@I],]ZGQ1BFDUU,ZE126D4O3_AP%0W7_'I/_P!<V_E4]-=%
M=&5AE6&"/451D>??#225/AQ</;C,RRW!0 =6ZBN+\ +JUWX?GO/^$5TG5KFY
MGD-Y=WM\HE+YQM964E,>E>T:3HUAH=G]DTVV6W@WE]B]-QZFL?4?A[X7U2_E
MO;G2T^T3<RM&[)YA]6"D9- 'EUOIVH:3J/ARTO);(6IUIWL[:UN/.%JI&3&6
M]CT%>K:IXFN--U,VB>'M6NT&W_2+>-6CY]\YXJ2'P9X>MX;"*'2X(X["4RVR
MJ,;'/5O<_6MV@#A/&GB>]DNHO"?ADAM>O5S)*?NV,/\ %(WOZ"N@\+>&[#PK
MHL6G67SG.^:9CEYI#U=CW)JC=?#KPO>:C/J$NG8NYSNEE25U9C[D&I[#P/H.
MFW<=U;6TJS1G*%KAVQ^!- '1T444 <?XYL/#VJMI5AX@OY;59;G]PBR%%E<#
M[I-8/B[2K3P796.H>%PUOJCW*0);K*SBZ5N"I4GGUSVQ7H&J:1I^M6+6>I6D
M5U;MU21<\^H]#6?I7@W0M'NUN[2R'VA1A))7:0H/]G<3C\* .5^$TWD6>M6%
MV!#J,%\SW$+G#+NYS].O-<XC?;HOBG?VP\RSD'E)(O*NRI\V#WQ7IFK^#-!U
MR]%Y?6(:YV[#+&Y1F7T8@C(^M:5EI5AI^G+I]I:0PV:J5$*J-N#UR.^: /.+
MZZMA^SW"S31JKZ;&JY;J>.!ZU3\9E1\-_"'3:;BV&/PKM#\-?")5T;1H6B?/
M[MF8H,\\+G _"M6]\,:/J.G6EA=64<EK:,K01G.$*],?2@#@IM87P+?>(-+R
M%%S$+G34_O2-\NT>^2#6=9:2NA_%'PK9''G#3R\S=WD8DL?S->G:EX9T?6+^
MROK^QCFN;)MT$C=4-23^']+N==@UJ:T5M0@0I%,2<JOI0!I"H;NRM;^W-O>6
M\<\)()CD4,I(Z<&IZ* .>7P=IJ^+I/$>Z4W,EM]E,)(\K9_NXK:M;.VL;9;>
MU@C@A7[L<:A5'X"IZ* "BBB@ HHHH **** "BBB@ HHHH *Y/XDQ23> =62*
M-Y'\H$*@R3@CM764A&:TI5/9U(S[.XFKG%6NJ0W4$.I:=<JSP01QSPRH5(SC
MGFNNMYDN;</&RL".JFN(\96VJ:%J,OBG37MY;=84ANK.2$G>N[[P(/4?2EM/
M$^FV^3;ZK#;QSN"%F@?Y6;MGI45<+4C/VU!.4);I:M/J<MI4YW6J9;LM/UWP
M_+=Q6-E!>Q3S-,)&FV$9[$8JY_:'BK_H!6W_ (%?_6K0$>K[<_:;;'M$?\:3
M3=76:V;[9-"DR.R, <=#7&JD5+E=T=\L?&4OWD%=]7_PYG_VAXK_ .@':_\
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MZT_Y^H/^_@H^WV?_ #]P?]_!0!8HJO\ ;K3_ )^H/^_@I?MUI_S]0?\ ?P4
M3T5!]MM!_P O4/\ W\% O;0]+J'_ +^"@">BH#>V@ZW,(_[:"C[;:?\ /U#_
M -_!0!/15?[=:?\ /U!_W\%+]NM/^?J#_OX* )Z*K_;K3_GZ@_[^"E^VVG_/
MU#_W\% $]%5_MUI_S]0?]_!2_;K3_GZ@_P"_@H GHJO]NL_^?J#_ +^"E^W6
MG_/U!_W\% $]%0?;K3_GZA_[^"@WMH.MU#_W\% $]%5_MUI_S]0?]_!0;ZS'
M_+U!_P!_!0!8HJO]NM/^?J#_ +^"C[=:?\_4'_?P4 6**@^VVO\ S\P_]_!1
M]NM/^?J#_OX* )Z*@^VVO_/S#_W\%'VZT_Y^H/\ OX* )Z*@^VVO_/S#_P!_
M!1]MM#_R]0_]_!0!/25#]MM1UN8?^_@H^W6G_/U!_P!_!0!*5# @@$'L:QO$
M7AVV\1:/)ITDK6^YU=980-R,IR#S]*TS?68ZW4 _[:"C[?9_\_<'_?P54)RI
MR4HO5 U<X77=+\3:#IZ7]AXAU+49(IDW6QBC(9,_-T'I5M_$^FLQ9M!ORQY)
M^R]377_;K,_\O4'_ '\%+]KM?^?F'_OL5O*M"I%*K!-KY?DB'!/<XT^)M, +
M'P_?@ 9)^S5GZMJ-AJWABYU+3D*VUU9,54KM)*L.WX5Z ]S:LI4W$)!&#\XK
MRO7= B\'WLNI:1:F71?L[&XB%UNV2%L[@K'^58U,+1Q%-QHQY9K5=G;IZ]B+
M>RE&I%?"T_N.VLO&.A):V\;WZ*Y55PP(YQ]*Z1&#*&!R#R#7-:YIT.N>%WMK
M>:WBFFC1D9L8SP:AT/6M0&MS:/J?V+]S;)*CP/U&<<Y^E<\7*+Y9(].=.G4I
M^TIZ/6Z;Z>7WG745!]KMAUN(1_P,4&^M!UNH/^_@K4XB>BJ_VZS_ .?N#_OX
M*7[=:?\ /U!_W\% $]%5_MUI_P _4'_?P4&^M!UNH/\ OX* +%%1Q7$,Q(BF
MCD(Z[6!Q4E !1110 4444 )7)?$K_D1+[ZQ_^AK76UR7Q*_Y$2^^L?\ Z&M:
MT/XD?4RJ_ SPC-)Q11FOH#Q3=?[A^E?0%A_R#[;_ *Y+_*OGYS\K?2OH&P_Y
M!]M_UR7^5>=F&T3LP.[+-%%%>6>F(112T4 )12T4 %%%% !1110 R1!)&R-]
MU@0?H:\2@\%^/?!\>N:+X<MK&^TS579DN99=CP;A@Y!]C7N%)B@#F/ 7A/\
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M75U_391IJS8TXBXY*9/H?3'6MO6_@9X570[TZ3I\QU#R6-OFX/W\<5ZOBE-
M'C'@WX':))X7M6\3Z;*NK$L90MP>!GCH<=*G\4? [P['X;OFT#3IFU01YMP;
M@XW9]^*]@HH \?\ "WP.\.R>&+!M?TV9=5,>;D+<'&[)]..F*Y'XI?#CPWX7
MF\.II5M+$+V^6&?,Q;<I(_+K7T8S*BDL0 .Y-8/B+PEI'BQK"34DDD^Q3":
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1BBB@ HHHH ****
M"BBB@ HK \:>(G\*>$[[6DMQ<-;*&\HMM#9('7\:Y&W\=^.I=-M]4_X0(36,
MT:S V]^KR%",@A<9SCM0!Z;17/\ A+Q?I?C'2#?Z<SH8VV3P2C;)"XZJPK8A
MO;6>0QPW4,D@ZJD@)'X"@"Q144<\,S.D4T;M&<.%8$J?0^E'VB'SS#YT?FJ-
MQ3<-P'KCTH EHJO#?6D\A2&Z@D<=520$C\C5B@ HHHH 3 I<444 &**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ QFC%%% !BBBB@ HHHH ****
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3I:A=B'I1VHHI"B'>ES1104?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>form10-k_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-k_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %% HH# 2(  A$! Q$!_\0
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M_P!_?_K4G_"N-"_Z>O\ O[_]:NOQ0S*JEF("@9)/05R^WJ_S,ZO84OY3D?\
MA7&A?]/7_?W_ .M1_P *XT+_ *>O^_O_ -:NI:[ME$):XB G($1+@>82,C;Z
M\>E2Y%'MZO\ ,P]A2_E.1_X5SH?_ $]?]_?_ *U+_P *ZT/_ *>O^_O_ -:N
MMI:/;U?YF/V%/^4Y'_A76A^MU_W]_P#K4T_#C0CU-U_W]_\ K5V%)1[>K_,P
M]A3_ )3D/^%;Z#ZW7_?W_P"M1_PK?0AWNO\ O[_]:NOHH]O5_F8>PI]CD/\
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MGO<22J#(%.[)()Z^U0IQE>S+]G*Z5MR^GQ!A>"VE.AZL!/827N#!RFS.4/\
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M^9/H@ILD:R(R.JLK#!5AD'ZTZB@",01 $"- #@\*.W2N?\0?\C'X9_Z^I?\
MT6U=)7-^(/\ D8_#/_7U+_Z*:@#I**3-&: %HI,T9H 6BDS10 'I7&^.;+2[
M..#Q3=6,EY>Z?B&"-9O+4^:P0Y['[W>NR-<A\2A_Q14__7S;?^CDK.K)Q@VN
MB+@KS29YYLTO2;:VF_X1*7R].64QG^U=QQ)]_/R_-[9Z5I?$'0M-T3P'H.FZ
M?"PLQ?!U25MY^96;DGKUJMKO_($O_P#KDU;/Q5'_ !2>@C_I[C_]%M7C8#&U
M<31J2J;H]QX6G0QE&,=FU^9YE8VMO'K.DLD$2L+^WY5 #_K%KZ=%?,]I_P A
M?2O^O^V_]&+7TQBNW -NF[G1Q+",<5%15M!:0]*6@UZ!\P>9_%W_ (]](_ZZ
M2_R6O+L<UZA\7O\ CWTC_KI+_):\NS@U[>#_ (*/'Q7\5BD4F,TN3ZT9KK.8
M**6C-(=C4I1245J<@&D%+UHQ0 X&@]:!Q10,;12TE(8444AH 6C-)10 44 4
MN*!@ *<!28XH+ >] 'K/P[_Y%8?]=WKKJY'X<G/A4?\ 7=ZZZOG*_P#%EZGT
M5#^%'T*.I:QI^CP";4;R&VC8X4R-C<?0#O6/K.LMJ/A*]NO#=W]IF7:NZUP\
MB+N&_:#_ !A=Q /?%9WC[4SHMQHNHL!-%#+*'M0^QI<I@$-@].N.,_A6GX&5
MCX2L9Y;J&ZEF4NT\;!]R[CM4O@;BHPI)ZD5B;',7FI>+VM?#*V\6H"99@+\^
M1_K%++M#<8!V9)Z#(/?%;=R=5/Q T7[:ED+4)=_9S SER-J?>!&.GI785SFK
M?\CMX<_ZYW?_ *"E &/?_$J.TU:^L8M#OK@6DY@:59(E5F !.-S XYK2T;Q0
MGB?1=4D6QGLWM@T3QS,K')3<""I([UYQ>8_X27Q#_P!A.3_T%*ZCP!_R"/$_
M_78_^B17HU\)"&&C56[(4FY6'>'?^1<TS_KU3^55+C_DC.F?]=H?_1]6_#O_
M "+FF?\ 7LG\JIW'_)&=,_Z[0_\ H^OFL'\4SUZN]/Y&1K__ "!KK_@/_H:U
M[0O2O%]?_P"0-=?\!_\ 0UK>^+/BO6O#*:,-&NTMC=/,)2T2R9"JI'7IU->G
M@Z,JTE3ANV5G$E&<6^QZ77E>N_\ (]ZU_P!<[?\ ] -8/@7X@>*=7\;:=IVH
MZE'/:S^9O06R(>%)'(YK=UWGQUK/^Y;_ /H!KAXCPM3"T)4JN^AAE,U/$)KS
M-#P)_P C5K'_ %Z6_P#Z$]>52?\ '[>_]?<W_H9KU7P)_P C7K'_ %Z6_P#Z
M$]>52?\ '[>_]?<W_H9KS8_[C3/J,E_Y&-7T/7OA+_R)A_Z_;C_T,UWE<'\)
M?^1,/_7[<?\ H9KO*]VE\"]#Y+&?[Q4]7^8G>DIU--:'*?/$G^MD_P!]OYTT
M4LG^MD_WV_G25]-'9'SDMV.%+FFBCK3$!&30!2TAH ,TM-H'6@!33#3Z::8"
M=Z:?:E^M(: $[4G-+2&DQBYI13:=2 <*0THII- "&F9Y'U'\Z<>M,[CZBA[#
MCN?28[4&@4'I7S)]$<UXAUK4K748-.TM[!9WMY+ES<I+(P1.N$0<_B1GH,U0
MN_%&J1^ 'UM3IYDD,?E74&]X1&[*/-*L PV@DE3TQUK.^(_EQZC83)K-AI5R
M(7432WLMO*Z$C*@H""OUY!Z5U'@\P7'@K2C'IWV*![9<6CY;8/3GDYZY/)S0
M!S5]XWOH]!T*]BN+-+JXF1+JU:,LT@) R@SD<'=CDX/UK0U:_NI_&F@V\NE7
M,$$=W+LNG="DO[L] &W#\0*Z\P0D@F),@@@[1P:Y_P 0?\C'X9_Z^I?_ $4U
M &E=Z_I%A<&WN]4LX)E )CEF56 /L33[+5]-U-W6QO[:Y:/!80RABN?7%>3>
M*+>&7Q]K9DAC=L0 %D!_Y9^X_P _SU/AQ%%%XQU,11H@-A%D*H'\;5W3P?+A
MU7N3S:V+%M)JFI7&I3/KVI0A+^>)(X70*JJV  -IK>\&7%ZUYK5I=7]Q>+;3
M1B)YR"P#1@D9 ]:Q-%Z:K_V%+G_T.M;PC_R%O$O_ %UA_P#10KP*-23KRBWI
MJ>A5A%48R2U.J-_9@X-W!D?]-!_C3_M,(@,YFC\E029-PV@#OFO#="TG3IM$
MLY)+&W=V3+,R DG)_P#K_P">G5Z-&D?P=UR-%"HHO0%'0#+<5W0ESRY18C"2
MH4U-O<[;_A)M"_Z#.G_^!"_XUA_$2:.?P+)-#(LD;W%L5=#D$><G(-?-200_
M9E_=)]P?PCTKW2X_Y(1I'_7.R_\ 1J5ZN<96\#13<K\R?Y'GX6M[2HM-FC)U
MW_D"7_\ UR:MGXJ_\BIH/_7U'_Z+:L;7?^0)?_\ 7)JV?BK_ ,BIH/\ U]1_
M^BVKX/)O]WJ_UT/J\1_OM#U7YGF]I_R%]*_Z_P"V_P#1BU],CI7S-:?\A?2O
M^O\ MO\ T8M?3(Z5[.7_ ,-^H^)_]ZCZ!0:*#7HGRQYE\7_^/?2/^NDO\EKR
MSJ:]2^,'_'OI'_727^2UY:*]O!_P4>/BOXK'"E%-%.KK.8#24O:D_"I*-< U
MI/H-_'-/&Z1J((1.\A<;-AZ$-WSVK/)K=DUX-X9L=/9FDEBN-TR%<!XE)*KN
M[C)Z4ZCFK<IA!1=^8Q/*<!3Y,GS_ '<H?F^GK2".4XVQ2'G PA//I]:[2;Q;
M8+*9UGNKK?<Q3);R1;5M57J%/?CTIMIX@T33YK40W=S*B7TMTY:W*X#JPP/7
MDBL/;5+? ;>QIW^(XPQR!@ICD#'HI4Y/T%#1NA >-U)Z;U(S^==EI6O_ &V6
MPCD:2XOE^THTK$(Z(V"I5FP,\=*I^,95QI%LUQ+-/!"WFF9U:0988W%21GCL
M::KS<U!Q!T8J#DF9UYX9U.QAGEE6W?R%#3)%,&>-3T++U K),<@VYCD ?[N5
M/S?3UKJM8\4VDNHW<NGV2.+F...6>0L&=!C<NT\#/2K[>(K"\NXXX[FXG:YO
MH)8XYX]BV:J1D ]_3CUJ55K)7E$ITJ3?NR.&,,H91Y,H+?=!0@GZ>M3V6GW.
MH3B&W3+%68%OE!"CGFNTN?$]C9:EMDN[J_*7[2[GBP+=,%2JG^+KVJE!KFD6
M,5C!#=3S1P+<[I&MRO,@../J:/;5&OA%[*"?Q'(I%-+Y>V&4^:0$^0_,3T /
M>K;Z1=P1WK7"K ]GM\R*0X8[CQM]:Z63Q'I4?AM;2VN+UKI5@,:R!CY;(P)V
MGH. >127'B/33=ZK<>?/=K>&W>.&6(@*$<DQY/&.<^G-'M:K^R/V5-?:.2\J
M4%08I06^Z"ARWT]::^Z/ 9'4D9&Y2,C\:[@^*]-2^AD>\N[I#>?: TL&/LR;
M2-B^O7M7/:MK2ZIH]O%/-)->1W4K[G4\1-T&?Z5<*M1M)QL3*G!*ZD8F<]:*
M**Z3G/6_AQ_R*@_Z[R?SKKZY#X<?\BH/^N\G\ZZ^OG*_\67J?14/X4?0XCXE
M:K/H^D6US VLIAVW-IVT(OR_\M6*MM7TXZU'HFIKX>^%%IJ=N(+AFC$H(G+(
MTDLG)>3V9\L?4&MKQ<L$6CF_GEU*);4[M^GRA)%!X)P2 P]CGVJKX./AW4M
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M=_Y'O6O]RW_] -1QW\<_^W3ER+^+'YFCX$_Y&S6/^O2W_P#0GKRF3_C]O?\
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MV6D-)"_R7#" RGMMG8$+CTX)KJ/"%_8W_AJT_L\MY4*")@TIEVL!R/,.=_\
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M4 :QAC8@F-"1ZJ*Y_P 0?\C'X9_Z^I?_ $4U='FN<\0?\C'X9_Z^I?\ T4U
M'G_B7_D?-<Z?\L/_ $76E\//^1SU+_KPC_\ 0VK-\2G_ (KW7.?^>'?I^[K2
M^'?_ ".>I<?\N$7;_;:O>J_\B]?(R7QEG1.FJ_\ 84N?_0ZUO"7_ "%?$O\
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M6+!H7BC1O[*TB6PT]YKC>D;K=MCY07.?E]*W+30O%UKX0O\ 0?[,TUC=>?\
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MT.LS0]$MM"TR*SMRSE0/,FD.7E;'WF/<UIT %!HH- 'F'QA_X]]'_P"NDO\
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M !1110 4444 %!HH/2@#S'XP?\>^D?\ 727^2UY43S7JGQA_X]M(_P"NDO\
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MQ.*Y_P 76ND2:))J.LV O(M,!O(T[AD&01SUK$LM,\2P/IYN?&=M,(+:2.X
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M@=Z=VI!TI,UH<PZD--S29H&+FG=J93A4LI"TA%.I"*0QN*,4XBBF VE%&**
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MT'P\_P"0SXC_ -^W_P#19KGXO^0EK/\ V$9OYC_/^>>@^'G_ "&O$G^_;_\
MHLUUP_B,[<7_ +E#Y'@=Q_Q_7G_7U-_Z,:O9/A+_ ,DVUC_KO/\ ^@"O&[C_
M (_KS_KZF_\ 1C5[)\)?^2;:Q_UWG_\ 0!7WV>?\BVC\OR/DL/\ QI&;H?\
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MU%KX_P")/=?5?_0UJ;X[]?#?_72X_P#05KW\D_WRGZBSWIZ'&?#3_DI.D?\
M;7_T UZ#KO\ R/>M?[EO_P"@&O/OAI_R4G2/^VO_ * :]!UW_D>]:_W+?_T
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MT_Y*!='M]BA_]":F^#?^2AV7_7A<?^A1T[QIQ\0+D_\ 3C#S_P ";O3?!O\
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M<XM%)FC!H W0:<#3:,UH8#NM-.*3/-&32 ":2BDS0,<*6D%+VH&)1VHI1TI
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M,T@I9/\ 6R?[[?S-(*^ECLCYY[L=2'I2YHI@-Q0<4$TPFD-"YHS32?:B@8N
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M+_D;/$O_ %]1?^B5JUX?_P"1\N?^P:G_ *,-58Q_Q5?B;C_EZB_]$K5KP_\
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MO+19HG+22$A<9(:.10#L< 9SG*DC@@FMTPZ+X(TR^FMFB6>3]\_VF<[Y6)P
M6Y(!8GMC)- &AHND:?X?MWLK5D\S)E?A0Y#,>P PN<@<8K%O?!?]JZI--J%V
M+NTD<R1F1!YUME@3'&V.$('U!Z$9JKI%E=ZUXC7Q+IWE:?:3(8;L2[GN)L;3
MM(/RJ 05&,\<CK7=!0JX P* $CBCAC$<4:H@Z*HP!^%/HHH **** $-%!I*
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MOB;0U952[TR^AQ\RD!U/4$'D']0:K^'_  M8^'C.UNJ%I7W ^6J^6N  HQ[
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M_P#?T4G_  M:U'_,*N/^_HH^K5?Y0^L4NYZ'1FO._P#A:]K_ - F?_OZ*/\
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MWV2C'\J\>I@ZBD^571ZE/%0<?>T9Z93)H8[B)XI422-U*LCC(8'J".]><_\
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G% @I,<444,H4"FL<444AC<T444Q!1110)ATI#110 =J7%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>form10-k_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-k_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $Y @0# 2(  A$! Q$!_\0
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MBN/^@A<?]\I_\319=PN^Q>HJC]BN/^@A<?\ ?*?_ !-'V*X_Z"%Q_P!\I_\
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MN^Q>HJC]BN/^@A<?]\I_\31]CN/^@A<?]\I_\319=PN^Q>HJC]BN/^@A<?\
M?*?_ !-'V.X_Z"%Q_P!\I_\ $T67<+OL7J*H_8KC_H(7'_?*?_$T?8KC_H(7
M'_?*?_$T67<+OL7J*H_8KC_H(7'_ 'RG_P 31]BN/^@A<?\ ?*?_ !-%EW"[
M[%ZBJ/V*X_Z"%Q_WRG_Q-'V*X_Z"%Q_WRG_Q-%EW"[[%[-%9-RMS:B*07LKY
MF12K*N""<'H*UJ&K#3N%%%%(84444 %%%% !1110 4444 %4-0_UUC_U\#_T
M%JOU0U#_ %UC_P!? _\ 06H6XI;%^BBB@84444 %%%% !1110 4444 %%%%
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MRJUCAQ6#EAK<SO<FHHHKM.,**** "BBB@ HHHH **** "BBB@ HHHH ****
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MHHKWCP HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM06)-0@\G<\JQDX57S\H8'!X/ZT 9?@J2[GUB]U#3[#1%TR[=$E_LZ]W+$R
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_KI/]]OYU[*_W3]*\:E_UTG^^W\Z\/-MH?,]W)OBG\AM%%%>$?0B'I7LEO\
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MY>A]>U=C10!GZ5:2V=B(YL>8SM(P4Y"EF)P/IFEU#_76/_7P/_06J_5#4/\
M76/_ %\#_P!!:A;BEL7Z***!A1110 4444 %%%% #7^Z?I7C4O\ KI/]]OYU
M[*_W3]*\:E_UTG^^W\Z\/-MH?,]W)OBG\AM%%%>$?0B'I7LEO_Q[1?[@_E7C
M9Z5[);_\>T7^X/Y5[>4[S^1X&<_8^9-1117O'@!1110 4444 %%%% !1110
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M3[2Q21EV117+W,H &!YDC=2!P .!77T %%%% !1110 50U#_ %UC_P!? _\
M06J_5#4/]=8_]? _]!:A;BEL7Z***!A2-TI:1NE ,\3N0/M<_ _UK?S-1;5]
M!^537/\ Q]S_ /75OYFHJ^F@M$?.2W$P/0?E4MN!]J@X'^L7^8J.I+?_ (^H
M/^NB_P Q1):!'<]J/W#]*\;E_P!=)_OM_.O9#]P_2O&Y?]=)_OM_.OSW-]H_
M,_0,FWG\AM%%%>$?0B'I7LEO_P >T7^X/Y5XV>E>R6__ ![1?[@_E7MY3O/Y
M'@9S]CYDU%%%>\> %%%% !1110 4E'>L7Q/?3Z=H<MQ;2;)0R@-@'J:<8N4E
M%=29248N3Z&U^-0R7,,) DFC0GH&8#->8_\ "7ZY_P _H_[]K_A6?J&JWNJ3
M12WD[.\)RA "XKN^H5.Z./Z[3[,]CSD45Y6/%NN  "]&!_TS7_"M?PSXAU2_
MUV&VN;@/"RL2NP#H.*B>#J1BY-K0J.+A)J*ZG3^)_P#D7+[_ '/ZBO+LG^\W
MYUZCXG_Y%R^_W/ZBO+J^1S1VJQ]#[#*$G2EZ_H!YZ\_7FC)]3^=%%>5S2/8Y
M8F]X.)_X2.+D_P"K?O[5Z2*\V\'?\C'%_P!<G_E7I5?1Y9_!^9\QFO\ O'R0
MM%%%>H>4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4-4_
MU$/_ %\1_P#H0J\.E4=4_P!1#_U\1_\ H0J\.E/HB5N+1112*"L#5?!WA[6[
MPWFI:3;W-P5"F1P<D#H#6_10!DZ/X=TC01*-*L(K42D&39GYL=.M:U%% !11
M7/W&JW\5S/:A;=9/M$4,3$$@!P3ENF3QT&.M '045S;ZW>2:?9/ L"3SI([F
M3)3]V.0.>_Z543Q+?2BWDCCMU2]D,, 8',3!@,OSR.3P,=J .OJAJ'^NL?\
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M_'M%_N#^5>-GI7LEO_Q[1?[@_E7MY3O/Y'@9S]CYDU%%%>\> %%%% !1110
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MM=,L;&=YK:VCBDDC2-F48)5!A1] *BU71--UVW%MJ=JMS"#GRV8@'Z@'G\:
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M"4J+2,--Y@/RY [D #&.M+K7B^>;3I8+99-/U&WN[/S(_,23,4LH7AE)'/S
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
(* "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>form10-k_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-k_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #V @D# 2(  A$! Q$!_\0
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MR1L[0'*EF&6 !^8*IY]_I4,&KZJ]RB/#QO18QY##[0A<J7S_  84!L&NIHH
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445@6^MS/JKV\J
MQ)&LLB,O(>-5'#L>F&[?4<F@#?HKE6\1W:S3(;=%"S&,':6$2APN^0@Y P<@
M8&1WIT/B*\DG6)H81AT50%;-PI<J7C]  -W?B@#J**!10 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111F@
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MF"# FFCC)Z!W S^=2J0PR""#T(H =1110 4444 %%%% !1110 4444 %%%%
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M10!NZ7XPDCBD\Z"YF<NW^NDQA=QVX^4=L5H?\)L/^? _]_?_ *U<E10!UO\
MPFP_Y\#_ -_?_K5):>+A=7D-N+(KYKA-WFYQD_2N.JWI/_(9LO\ KNG\Z /3
MJI:I_P @RY_ZYFKM4M4_Y!ES_P!<S7-B_P"!/T?Y%T_C7J<72TE+7X\]SZP2
MBBBD 4444 '\-=9X>_Y!:_[[?SKD_P"&NL\/?\@M?]]OYU]/PU_O;]&>;F'\
M+YFKVKQ;X@?\CG=_[D?_ *"*]I[5XM\0/^1SN_\ <C_]!%?JN7?QODSYC%?
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MNND\9_\ (3M_^N/_ +,:YNNPY HHHH **** "K>D_P#(9LO^NZ?SJI5O2?\
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M> O^/*]_ZZC_ -!KKQ7UN"_@1/C,=_O$_4XKQG_R$[?_ *X_^S&N;KI/&?\
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M=1_Z#77BN0\!?\>5[_UU'_H-=>*^MP7\")\9CO\ >)^IQ7C/_D)V_P#UQ_\
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M#U?_ )ZVO_?1_P */K-'^8/J]7^4YBBNG_X0/5_^>MK_ -]'_"C_ (0/5_\
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M*!V%?HF!J1IU;S=E8\#$1<H61YK179_\*RUW_GM8_P#?QO\ XFC_ (5EKO\
MSVL?^_C?_$U[?URA_,>?["IV.,HKL_\ A66N_P#/:Q_[^-_\31_PK+7?^>UC
M_P!_&_\ B:7URA_,'L*G8XRBNS_X5EKO_/:Q_P"_C?\ Q-'_  K+7?\ GM8_
M]_&_^)I_6Z'\R#V%3L4/ 7_(YV/TD_\ 0#7M@[5YQX9\#ZKHWB"VO[F6U,,0
M?<(W8GE2/3WKT?M7B8ZI&I5YHN^AWX>+C&S%HHHKC.D**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ ICMM4G!.!G ZFGT8H P!XLTP^&UUT-,;1F
M"!/+/F^9OV>7LZ[]W&*T5U73Y+LVD=[;FZ!(, E4N".2,9ZU@KX.">*6U$79
M_LW[1]N%AY? NRNTR[L],<[<?>YJ'2_!(T^2VAEG%S:VUTUW"96EWARS,#@/
MLR"QYQSZ4 :NB>*=,UN")X+A(YI&D5;>611+\C%3\H/^R3]*FAU^R>S-S=31
M6B><\(\V>,Y921P58C/&<9R.X%8]IX,^RZ/I-B+I"UAJ1OS((<>9EG;;UX.'
MQGVJ*T\%SZ;+8W5K?1O=6=Q=RJ)H2499V+$8!R&''S?7CF@#;A\0V,^L36$;
MY\JT2\-P&7RC&S,!AL_[)]JNV>I6.H!C9WD%QLQN\J0-C/3.*YG5/!3:Q)?O
M<WXC-[816C"&+:%9)"^X<]#G&/KSS6EI&@FPOY=0N3')=R0K!YB-*QV DX^=
MVXR>@H Z"BBB@ HHHH Q/$B+)9VD;C*/?6ZNO9@7'!]JM_V'I7_0/M_^^!5?
MQ#_Q[V'_ &$+?_T8*V*!&?\ V'I7_0/M_P#O@4?V'I7_ $#[?_O@5?HH'8H?
MV'I7_0/M_P#O@4?V'I7_ $#[?_O@5?HH"Q0_L/2O^@?;_P#? H_L/2O^@?;_
M /? J_10%BA_8>E?] ^W_P"^!1_8>E?] ^W_ .^!5_-&:+A8H?V'I7_0/M_^
M^!64DOA:2X\A$M'?S/*RD>5W_P!W<!MSVQFNAE7S(F3<5W*1D=17,^&;+5=!
MT>RT5K.VEBM5\H723;0Z9^\4*Y#>HZ9[T!8V?[#TK_GPM_\ O@4?V'I7_/A;
M_P#? KD;+PKJL0TV*1;=+NUO1<7&K"8F6Y0,25(QGY@=I!.!VZ"L_1O#>K75
MG@V(M+E=:DN1?RR,)EA6=FVA2,X9> ,[2&S0%CO_ .P]*_Z!]O\ ]\"D_L/2
MO^?"W_[X%<#I_AO5;R"^7[$+.X;7);B+4)I&$L<*S;OE4C."H( !VD-S6FGA
M+43K,TUU.\F_43=QWD4J(Z1[LK'DH6P!\NT'!'IDT!8ZO^P]*_Y\+?\ [X%9
MER_A>SNOLUU':12;UCRT9"AFZ MC )XXSWI/#'A]M)?4KF[BB:[N;Z>9)0Q9
MA$S95<GIQV'%5/$^D:EK:F""W6*19(WAN)+LM"NU@VYH2,,1SQCTY'8"Q<9_
M#"ZC)8>5;M=1,JR1I 6*%AD!L# R#GFM/^P]*_Y\+?\ [X%<]JNA:E+?7D^C
MPBPO;F2,M?K>ML;: -S0XP3@;<?K4_C>WOI]-TW^S[66YFCU6VD:.,D?*'^8
MD]ACJ>E &AJ%IX?TJQFO;Z"TM[6$;I)74!5'3FHWC\-1Z0=7>.Q&G^4)OM.!
MLV8R#FN>U3PWKNJ0^)$:*VC_ +4^S/;C[06$?EE<JWR]3@GC(J=/"-\NK261
ME@/AI)6O+>VYW^<W_+-AT\M6RX]R!VH"QT%E8:#J-E#>6=M:3VTR!XY$4$,I
MZ$59_L/2O^@?;_\ ? JGX2TRYT7PEI6F790W%K;+%)Y9RNX#L:VZ L4/[#TK
M_H'V_P#WP*/[#TK_ *!]O_WP*OT4!8H?V'I7_0/M_P#O@4?V'I7_ $#[?_O@
M5?HH"Q0_L/2O^@?;_P#? H_L/2O^@?;_ /? J_10%BA_8>E?] ^W_P"^!1_8
M>E?] ^W_ .^!5^B@+&!;VEO9^+A';1+$C6!9E08!/F#G%=!6,W_(YI_V#V_]
M&"MF@04444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** *&I:?_:%ND8F,3QRI,CA0<,K C@]N
M*;]DU/\ Z"B_^ P_QK1HH S?LFI_]!1?_ 8?XT?9-3_Z"B_^ P_QK2HH S?L
MFI_]!1?_  &'^-'V34_^@HO_ (##_&M*B@#-^R:G_P!!1?\ P&'^-'V34_\
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MU\]KVY\SRP=Q!3*J0, 9R371P2B>".571U=0P:,Y5@1U![B@":BBB@ HHHH
M**** "BL#7_$,F@O:$Z?-<0SW$<#3*ZJL9=@HSDY)R>@'3O6_0 4444 %%%%
M !1110 4444 %%<UK6KZG8ZS'#%;[--^RM-+>?9)+C;(& V80@CY<G/M6UI]
MW%?V%O=V\T<\,T:NDL7W7!'4>U %NBBB@ HHHH **** "BBB@ HHHH ****
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MPGXBU76=<U2WO[>&WMXX(+FTC52)$CEWX$A)^]A0< #&<5V5 !1110 4444
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,[0?ID_G5RBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>form10-k_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-k_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +N EH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?*2N,9SWSVJQIGQ _M'Q!9V$=M%);7JW;07,+.4_<E>C,H60,&Y*$@'C)ZT
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MM;Q&B99XED!AD$B<C/RL/O#W[T 6J*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#,\1ZU!X=\.:CK%QCR[.!I=I.-Q ^5?J3@
M#ZU\H2>+M"N/AE<Z5/%J+^)I]3.IF\"(L8E+8)W!MWW,_P /WC^-?3/C_P (
M3>./#JZ*FJMIT#SI).RP^8947)V?>&.=ISS]T5T:6L$=FMFL2"W6,1"/'R[
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MFH\"?\D\\-?]@JU_]%+1X[_Y)YXE_P"P5=?^BFH\"?\ )//#7_8*M?\ T4M
M%[Q!&DGAW4MZ*V+27&1G'R&JO@V-$\$Z$515)TZWR0,9_=K5S7O^1=U/_KTE
M_P#0#57P?_R)&@?]@ZW_ /1:T ;5%%% !1110 4444 %%%<7X[LO$E]<6$>@
MRR1!$E=G6944.0(USFWESQ(QZKP&/8$ ':45YSH>D>,D\56LNJ7+R643LQS=
MQ, $38!@6<9/,CXPRY&?3+>C4 %%%% !1110 4444 %%%% !1110 5S_ (KC
MLO(L+BYO+BUN8+G-F]O'YDC2M&Z$!,'=\C.3QP 6. #705B>(X;"<Z6EU<30
M7?VP"Q>!=SB4QN&X(((\LR9R, 9/! - &=X3@T1&LCI5S<O$FDVXLXI8]JK;
M,,A@=HW,Q W9)Q@<#//65Q?@==(5((['4;R],%A';VCW$'EJ;9#L#1G: P)4
M$MDY^4\ KF?XB2W":!9Q0D"*YU2TM[@M]WRWF4$-TRA. P[@D<9H ZVO/S_R
M<*/^Q5_]NJ=I&IZKI7A&2+P_X9@U.XM-3GM'MK:]%O#M5FW21F0MM7=@>6"=
MI) X6L7PYJ.LZG\='FUS0?[%N5\-%%M_MB7.Y/M((?<@P.21CV]Z /6****
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M4M=!0!S_ /PF6E_\^NN?^"*]_P#C-'_"9:7_ ,^NN?\ @BO?_C-=!10!S_\
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MT?\ [;?^CGK;\8_\B1K_ /V#;C_T6U 'HM5[^^@TVREO+IF6"(9=E0M@9QG
M!X]3T Y. *L57OH+2[LI;6^6-[:=#')'(?E=2.0?4$4 9OA&73I/".DII,D\
MEA%:110/.N'9%10I/ !.,9(XSG%;55K**SMH/L]F(UC4LP1#D L23].2:LT
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M5RN?\,2WOVG7K*]U&>_^PZ@L,,TZ1J^PVT$F#Y:*I^:1NU=!0 4444 %%%%
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M?]C-9?S:NP'05Q_CS_CY\'?]C-9?S:@#UNBBB@ HHHH **** "BBB@ HHHH
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M\XYZ8&,9YKH:X3X=:-"EG/J;WFISW*7MY;+]HOYI4V).Z*-C,5R%4#.,UW=
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MGK0L?^2A:9_V"KW_ -&VM9_Q>_X\O"7_ &,UG_)Z -JN5U3_ )*[X!^NH?\
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M3@@'MU%;E &;HFC1:):30I/-/)/<27,TTQ!9Y';<>@  '0 = !7(G_DX4?\
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M_P )'_PJ3PS_ ,(O_97V[[-#O_M/S/+\O8<X\OG=G;[8S63X<_X23_A>C_\
M"4?V5]M_X1H[/[,\SR_+^TC&?,YW9W>V,4 7OB!_R4WX?_74?_1*UOU@?$#_
M )*;\/\ ZZC_ .B5K?H B\.?\CQK?_8-L?\ T9=5B_$#_DIOP_\ KJ/_ *)6
MMKPY_P CQK?_ &#;'_T9=5B_$#_DIOP_^NH_^B5H WZYK2/^2\M_V+)_]*17
M2US6D?\ )>6_[%D_^E(H Z7QI_Q]^&/^PJW_ *27-%'C3_C[\,?]A5O_ $DN
M:* *MC_R4+3/^P5>_P#HVUK/^+W_ !Y>$O\ L9K/^3UH6/\ R4+3/^P5>_\
MHVUK/^+W_'EX2_[&:S_D] &U7*ZI_P E=\ _74/_ $0*ZJN5U3_DKO@'ZZA_
MZ(% '8>//^187_L(Z?\ ^ED-0U-X\_Y%A?\ L(Z?_P"ED-0T 9]U_P C-X6_
M["4G_I)<5'\;/^20Z[](/_1\=277_(S>%O\ L)2?^DEQ4?QL_P"20Z[](/\
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M "3SQ+_V"KK_ -%-1X$_Y)YX:_[!5K_Z*6CQW_R3SQ+_ -@JZ_\ 134>!/\
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M@"+PY_R/&M_]@VQ_]&758OQ _P"2F_#_ .NH_P#HE:VO#G_(\:W_ -@VQ_\
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MG@ANK>6WN(HYH)4*21R*&5U(P00>"".,4000VMO%;V\4<,$2!(XXU"JB@8
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M4UC86>F6<=G86D%I:QYV0P1B-%R23A1P,DD_C0!P<'PDAM;>*WM_&_C6&")
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M7H%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 56O[J*SL)IYKJ&U55_UTY^1"> 3R,\D<9&:;=:I8V4OE
M7-U%%)Y3S!&;YBBXW,!U(&1T]17$7VNO=RV;6LQ:.VO5>VGOE>';<$,IMKI"
MH:+<DO[MRI&=F03MW@%74M>N-8>RANK3S5\D_:&LU>Y55?:4NX(T!,R, 0"
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M&/2-&OM3ECDDCL[>2=DC&68(I8@>_%<YJ>M>(;=K.$6MI!<SR;K9XY3+;7)
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MMIE+/+ /O^6H8989!_\ KD5RDCGQ%K.EZA;V\]A?W,3"WU&U1KB!9%7<#O
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M"@] !4-QXALTTZ_N[9A.+.0P.>50R9 (WXQ@$X8C.TA@>5(H L7&KVT5FUQ
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M#T(- $][96VI64UE>P1SVTZ%)(I!E64]B*F50BA1T P.<TM% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% $%M96UFTYMH$B,\AFEV#&YR
M "Q]S@5/110 57M[&UM);B6WMXXGN9/-F*+CS'P%W'WP ,^U6** *NHV1U"P
MDM/M,]L),!I+=MK[<C(#=5R,C(P1G((.".?@TA] <:3%9F]\,WF8?LQ7>;,M
MP5P?O0-D\<E,]T/R=510!F:5H&GZ,/\ 1%G)"^6AGN9)BB9SM4NQVKTX'H/0
M5;OIWMM/N;B/R=\43.OGR>7'D#/S-@[1ZG!Q6;=^(-'?5)_#[ZHMMJ31#"Y*
M,-X;;L8C!;Y6.!D\=*Q_"^J:C9I!HFONUU)EK>&^*Y\QT!W1R^C8&Y6Z.I!X
M.10!K>&/$:^)K*:Z6TDM!'((_(G8><IV@_.H^[G.1R<J0W0BM5;*V2^>]6"-
M;J2-8GE PS*"2 3W )./J:F  )( R>II: "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***K:C?PZ7I=WJ%P',%K"\\@1<MM52QP.YP* "]
MO[;3K?S[J38A8(N 6+,3@*H'))/85FZO??:9+C1;-K?^TC")DM[V,^5<Q9PZ
MY[C^$D9*[E)!! +]=T>754M9[*[^RWMLY:&?:' 5QM?@\9VDD'L0.HR#SD7A
MRTUR:ZMH'UJ&Q2,;)KQIUEM[I>!) TWS_=)#'E&XZY?(!%H'AJRU54N/(FCL
MD='A+2/#=VTL,F1;R%>)HU8$J6+ =LC#5Z!573;9[+3+6UD,)>*)48P1^7&2
M!@[5R=H]LFK5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !5"36;-(K^1&DF%B/WX@B:0@XR5  ^9@/X1D\CUJ5+^
M&359].&[SX8(YVR.-KLZC![G,;9_#UKD-0T%=+CGCDO-9>*1F72XM+24&V9F
MWDN8_E)WG :7Y J@'JY8 BUZV77;^T8-:SQWT9.DZC'#YL3*5W/;W"<AXG W
M ]/]UE5FZ?0-%BTFWDD6)X)[LK+<0_:7G1)-H!",W.T8 ' X     %+1_"_]
MFZP-45HD>>W/VFV"91)V(+O"<_(&.2PQ\Q"G@YSTE !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%1SR&&"258GE9%+"-,;GP.@R0,GW-
M %?4]3MM(L'N[IFV+PJ1H7>1CT5%'+,>@ K"2UG\7^'X[U-7N;$7D+#99-'(
MFPY 5A(C L!PV .<CM6?8:K>:KJ&BZA'J23O=2,SZ6L"E+6,!E9BQ42)(API
M+$ DE=HSD=##HK6.NO?Z?.(;:Y):\M"N4D?'$B?W7Z!NS#KR,T 9?A ^(;O1
MM&OKK5+22VFM(WGMY+(^<'*<@2+(%X;U0]#Z\=934C2) D:JJ#@*HP!3J "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "N>N?$,%SXBC\/VLH61E<SSY*A<#F.-L8:09!(_A')[4:]JLT6IV>D)=?V
M:EW&[G4&"G&T9,<>X%?,QEOF&-JD@-@XKZ3IJZ]X5^SZ@[2I]HDDM;U(Q!*P
M#DI. H 5SG.X !NN &Q0!1GTO6+#QC:QV?B&Y?[98S8>^MXI51HWCVKA%1B"
M)'/+9X/-==8)>QV4:ZA/!/=#.^2WA,2-SQA2S$<8_B/X=*;86]Q%:0+?S1W5
MW$I4W"Q;-WOC)P2,9QQG\JMT %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% &.N@1VWB1M9L)%MI+E0E_$(\K=!0=C=MKJ3][G
M*Y!!^4KL444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJYBL[62YG8K%&NYB%+''L!DD^PY- $U%4=-U:TU59C;-*&@?RY8YH7B=&P"
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MG )[5UE% 'EFBOJ.L:O%'%=7]FFI:1=><&NII6MI]\93<7PB2KO;Y548QCD
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M4?\ "^/'O_/_ &O_ (")_A7FE% 'I?\ POCQ[_S_ -K_ . B?X4?\+X\>_\
M/_:_^ B?X5YI10!Z7_POCQ[_ ,_]K_X")_A1_P +X\>_\_\ :_\ @(G^%>:4
M4 >E_P#"^/'O_/\ VO\ X")_A1_POCQ[_P _]K_X")_A7FE% 'I?_"^/'O\
MS_VO_@(G^%'_  OCQ[_S_P!K_P" B?X5YI10!Z7_ ,+X\>_\_P#:_P#@(G^%
M:WA;XU>-=5\7Z+IUU>VS6UW?P02J+9 2C2*I&<<<$UX]70>!/^2A>&O^PK:_
M^C5H ]8^)OQ:\6^&/B%JFCZ9=P1V=OY7EJ]NK$;HD8\D>K&N2_X7QX]_Y_[7
M_P !$_PJI\;?^2O:Y_V[_P#HB.O/Z /2_P#A?'CW_G_M?_ 1/\*/^%\>/?\
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MM_+,R[?,4.O(.0:AI)IJZ'.$H2Y9*S/2_P#A?'CW_G_M?_ 1/\*/^%\>/?\
MG_M?_ 1/\*\THIDGI?\ POCQ[_S_ -K_ . B?X5].^%+^XU7P?HNHW;!KF[L
M()Y6 P"[1JQ..W)KX7K[>\!_\D\\-?\ 8*M?_12T =#1110 4444 %%%% !1
M110!YM\=_P#DE.H?]=H/_1@KSJ#XB_"UM!AL#X$:XOS;+"2NFVZF23:!PX;<
M,GN!FOHZB@#SWX*Z3J^C?#>UMM722*1YI)8()%VM%$Q! ([9.YO^!5Z%110
M4444 %%%% !1110 4444 8OC#_D2=?\ ^P=<?^BVKX;K[D\8?\B3K_\ V#KC
M_P!%M7PW0,**** "BBB@ HHHI %%%%, HHHH **** /6O'/_ "0KP'_OR_\
MLU>25ZWXY_Y(5X#_ -^7_P!FKR2@04444 %%%% !1110 4444 %%%% !70>!
M/^2A>&O^PK:_^C5KGZZ#P)_R4+PU_P!A6U_]&K0!T'QM_P"2O:Y_V[_^B(Z\
M_KT#XV_\E>US_MW_ /1$=>?T %+@\=LTE31!(YP+I'*+U0<$^WM2;L7"/,[?
M\,0T_" 'YLG':K45B]Q9O-# Q/F8!W]L=,=_K713Z1:KID"-;[YPFT.G !/<
M^WUKGJ8B,&DSU\'D]?$QE.-DDKZWUNVK+3<Y-X98U5GC95;H2,9J3['.#ADV
MG9O 8X)%:PN=VJL\UO!^YBVN96W#(_B^IZ59ELDOHVF_LZ6+S0&1DD!Y^G85
M+Q#C;F1M3RF%52=*3;3VLUMN]$^NG3U9@?9)0ZQG:LC,%"$\G/0_2FW-M+:3
MM#,NUUZBN@6TBTF))XV9KU1\R<&LV_BN[Q'U-LM"6V@DC*CW IPK<TO+]2,5
MEBHTFK/VF]EJE&VK?FG:_;J9E%%%=1X05[!\'_\ DGWQ-_[!0_\ 15Q7C]>P
M?!__ ))]\3?^P4/_ $5<4 >/U+;X,P4B+YN,RG"CWJ*I()%BF5VC610>4;H:
M4MC2DTIIO:Y/;Z?/>@FV0.0<%=XW?7'I4#1M!<;)HSE&PR'C\*DM9_L\YE53
MP#@AL%?>M#3W22<WT]P7N4<?(R9W#UK&4I1NWL>A0H4:ZA&+M.^M[6LNMG;7
MRUN/EET:;B&U82R)M4;L!&/<UBL-K$<'![5V@T[38R;QD1O-.Y0W3GMBL&Z%
M@?M!6-EN-^4"GY0/I7/0K1;M%/YGKYKEM6,5.K*">OPJUU:_3J^B\[;$MK%<
M:Y<0RW&UHXL(P7@X]Z35M'BMH#=VLFZ$L %ZX]3GZTS3YS+=S2RW#)D%V*C&
M<>U5I]0N6A>)FVQRG<RCO_\ 6JE&HJGNNR70SG5PDL&W6BY3E?WNMUHGY+:Z
M=_+8H$D]3FBBBNT^8%&.<FDHHH *^WO ?_)//#7_ &"K7_T4M?$-?;W@/_DG
MGAK_ +!5K_Z*6@#H:*** "BBB@ HHHH **** "BBB@ HHHH **** *FHZE:Z
M5!'->2&..2:.!6"EAOD8(H..@+$#/3FB34K6+58-,:0_:YX9)TC"D_(A4,2>
M@Y=1SUS5?Q#I7]M^'K_30_EO/"RQR?\ /.3JCCW# '\*XNUO=6UCP]XD\5VM
MI=6^H26"VME;E#YB>4A9]JX)W>:\B]#GRUP#W .\U#4K72[9+B\D,<;S1P A
M2?GD<(HX]68"G7-]!:3VL,Q8/=2F*+"$@L%9N2!P,*>3QVZD5YA?P7%UI=S;
MPW<LU@UWI6V..YN+@QO]J4.PFD (.T+E0?E*[C@MDZ"2:E:>,%TZWFOC90:\
M%C$DTD@,3:<7*EF))7S>>3@'Z4 =]J.H6VE6$E[>2&.WCQN8*3C) ' ]R*M5
MY5-MF\!$2W6J3Z[+91'48)GE=5F$L9?<IRL9#%@H7;E<X!51B_9SZO-XHD\Z
MX:"^35I%\I[B<[[0,0N(0OE[3'M._. V<D'( !UGC#_D2=?_ .P=<?\ HMJ^
M&Z^Y/&'_ ").O_\ 8.N/_1;5\-T#"BBB@ I0I-)5ZPCMW;]^^WFHE+E5S>A2
M]K-03M?N1PV,DV2N,#KFIUTF5Q\O)KJ;&"U$1:% <=SSFK#K$3POS?Q!:\R6
M-ES62/N*'#-%TU*<KM]OT.%FM)("0XP1VJO75:LT$:E'=2<<>M<LQRQKNH57
M4C=H^6S3 PPE7DC*XE%%%=!Y(4444 >M>.?^2%> _P#?E_\ 9J\DKUOQS_R0
MKP'_ +\O_LU>24""BBB@  R<5M6&CO<6;.T9R3P3699A3<IN&1GI77)JB(!&
M[I" .C#]*X\34G&R@CZ3(\'AJKE4Q,K+9+U\V9EIX=BF.9)\8/*CTJS<>&(7
M(6!R@QU;GFM"TF,YEF2W1B.$93]ZKVY7CW.,#N#VKS9XFLI;GV>&R7+IT;>S
M3OUUU7K_ )>IPM[H]Y9.V^(L@/#KR#5 @CJ*]#:XB.TI^\(.%VG(KC]=8MJ+
M%H1$V.5'\Z]##8F51\LD?)9UDM#!P]M1FVF]M_Q,RBBBNX^5"N@\"?\ )0O#
M7_85M?\ T:M<_70>!/\ DH7AK_L*VO\ Z-6@#H/C;_R5[7/^W?\ ]$1UY_7H
M'QM_Y*]KG_;O_P"B(Z\_)SVQ0 4^3.X$OO8@$G.<4WG-)2*OHT6K:^N+5"D;
ME%9@25Z_@:O1ZS<06CQV]P2-Y"(Z9<+USFL?/%.61DY0[3ZC@UG*E&6Z.VAC
MZ]%6C-I6MHWI?MJ7;PV2K!):,[,PS*K]C6K=ZA']FM(K.=G)X,?0@USC,6.6
M))QCFM#3)H5:1+I@+=L;@!\V<\8-95*2Y4WK8[L'CY.K.$;04[*^UK==]+VU
MW6M[%K599H9%BD96R _N#Z&LZ>ZFGWG_ %<+'!1.$S]*2Y;RY[B)9!*I;_6,
M.3@_I5:M*=-**.7&XN=2K))M+M>^VEK]5^&O44 G..W-)116QY@5[!\'_P#D
MGWQ-_P"P4/\ T5<5X_7L'P?_ .2??$W_ +!0_P#15Q0!X_GC%%%% !4D0D:1
M4C#%F. %ZGVJ.I()Y+:=)HCAT.0<4G>VA=-QYUS.RZVWL2WDQ>Y/[KRE3@1$
MDA<=>M);AR^Z)=[CD)MSQCDFHI9'FE:20Y=CDFF@D="1VXJ5'W;&LJUZKF]=
M?)/_ "[>19M+F."Z\Z6!95 /[L],U7=M[LV,9.<#M3:4$@Y!P:?*D[D.K*4%
M![)M_>/F,9E)B1D3C 8Y-,P< ] >])2DD@ DX'0>E/8AN[;8E7K>TMI-/FN)
M;H)(APL0&2:HT4I)M:.QI1J1A)N45+1[W^_3L3RW(GN%DEC&Q0!L3Y>!VK[8
M\"8/P]\-8&!_9=MQ_P!LEKX@K[>\!_\ )//#7_8*M?\ T4M-)+8B=24VW+=G
M0T444R HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#%\8?\
MB3K_ /V#KC_T6U?#=?<GC#_D2=?_ .P=<?\ HMJ^&Z!A1110 49Q110!;@O9
MH4*K(P'IFA]1N6R!,P!]#52BL_9QO>QU+%UE%14G;U8YG9SEB2?>FT45=CF;
M;U84444Q!1110!ZUXY_Y(5X#_P!^7_V:O)*];\<_\D*\!_[\O_LU>24""BBB
M@!02.E3_ &V<MN+9;U/)JO12:3W-(5)P^%V-=/$-VD/E@(%[8&,5#)K5[)G]
MZ1D8.#UK.HK)4*:UY3MGFF,G'E=5V]2Q'>W$3AXY"C#N*CEFDG<R2N7<]2:C
MIT;F-L@ \$<UIRI:I'(ZLY+DE)V_KH-HHHJC$*Z#P)_R4+PU_P!A6U_]&K7/
MUT'@3_DH7AK_ +"MK_Z-6@#I/C1,T/Q>\0;0IWI AW#/!MX_UKS^*1(]^Z)9
M"5PNX_=/K7>?&W_DKVN?]N__ *(CKS^E9&BJ25M=MOF%'&/>BBF9D\TD4[RR
M[5A.!LC0<>G_ ->H***25M"YS<WS/?\ K^N@4444R"Q<6DEMM9RK*^=CJV0V
M.M0$Y4# X[XI*7C'O22=M32<HN3<%9>MQ****9F* ,$Y_#UKU_X/_P#)/OB;
M_P!@H?\ HJXKQ^O8/@__ ,D^^)O_ &"A_P"BKB@#Q^BBB@ HHHH ***>B[\H
MJ,[M]W'^'>@:5W8?;NOGJ)%5E(V_-VSWIDJ>5,\>0=K$9'>IF\Z"T$;;0DA$
M@Z$Y''U%5R222223U)J%J[F]3W8*#6N_W]/R8 D$$=103N.3U-)15F%W:P44
M44""OM[P'_R3SPU_V"K7_P!%+7Q#7V]X#_Y)YX:_[!5K_P"BEH Z&BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#%\8?\ (DZ__P!@
MZX_]%M7PW7W)XP_Y$G7_ /L'7'_HMJ^&Z!A1110 4444 %%%% !1110 4444
M %%%% 'K7CG_ )(5X#_WY?\ V:O)*];\<_\ )"O ?^_+_P"S5Y)0(**** "B
MBB@ HHHH **** "BBB@ KH/ G_)0O#7_ &%;7_T:M<_70>!/^2A>&O\ L*VO
M_HU: .@^-O\ R5[7/^W?_P!$1UY_7H'QM_Y*]KG_ &[_ /HB.O/Z "BBB@ H
MHHH **,<9HR3CVH 4$J00<$=#3I)#*Y<@ GKBF44K=1W=N7H%%%%,05[!\'_
M /DGWQ-_[!0_]%7%>/U[!\'_ /DGWQ-_[!0_]%7% 'D&/E!R.>U"G!R0#[&D
MHH'?L%%':B@0I!4X(([\T^*>2'=Y9 +#&<<CZ'M2SS&=E8@[@H4DG.<<5%2W
M6IHWR3O3?S%+%CDG-)113,PH/7CI110 4444 %?;W@/_ ))YX:_[!5K_ .BE
MKXAK[>\!_P#)//#7_8*M?_12T =#1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!2UC3_[6T2_TWS?*^UVTD'F;=VS>I7.,C.,],UX;
M_P ,S?\ 4W?^4W_[;7M^O7\NE^'=3U"!4::UM)9T5P2I94+#.,<9%?.'_#1W
MB_\ Z!NA_P#?B;_X[0!T'_#,W_4W?^4W_P"VT?\ #,W_ %-W_E-_^VUS_P#P
MT=XO_P"@;H?_ 'XF_P#CM'_#1WB__H&Z'_WXF_\ CM SH/\ AF;_ *F[_P I
MO_VVC_AF;_J;O_*;_P#;:Y__ (:.\7_] W0_^_$W_P =H_X:.\7_ /0-T/\
M[\3?_': .@_X9F_ZF[_RF_\ VVC_ (9F_P"IN_\ *;_]MKG_ /AH[Q?_ - W
M0_\ OQ-_\=H_X:.\7_\ 0-T/_OQ-_P#': .@_P"&9O\ J;O_ "F__;:/^&9O
M^IN_\IO_ -MKG_\ AH[Q?_T#=#_[\3?_ !VC_AH[Q?\ ] W0_P#OQ-_\=H Z
M#_AF;_J;O_*;_P#;:/\ AF;_ *F[_P IO_VVN?\ ^&CO%_\ T#=#_P"_$W_Q
MVC_AH[Q?_P! W0_^_$W_ ,=H Z#_ (9F_P"IN_\ *;_]MH_X9F_ZF[_RF_\
MVVN?_P"&CO%__0-T/_OQ-_\ ':/^&CO%_P#T#=#_ ._$W_QV@#TW7/@Y_;7@
M30?#/]O>3_9+.?M'V/=YN[/\.\;>OJ:Y'_AF7_J;O_*;_P#;:V?$GQ<U_1_A
MMX:\1V]IIK7FJ,XG22.0QKC.-H#@CIW)KA_^&CO&'_0-T/\ [\3?_':!&_\
M\,R_]3=_Y3?_ +;1_P ,R_\ 4W?^4W_[;6!_PT=XP_Z!NA_]^)O_ ([1_P -
M'>,/^@;H?_?B;_X[0!O_ /#,O_4W?^4W_P"VT?\ #,O_ %-W_E-_^VU@?\-'
M>,/^@;H?_?B;_P".T?\ #1WC#_H&Z'_WXF_^.T ;_P#PS+_U-W_E-_\ MM'_
M  S+_P!3=_Y3?_MM8'_#1WC#_H&Z'_WXF_\ CM'_  T=XP_Z!NA_]^)O_CM
M&_\ \,R_]3=_Y3?_ +;1_P ,R_\ 4W?^4W_[;6!_PT=XP_Z!NA_]^)O_ ([1
M_P -'>,/^@;H?_?B;_X[0!O_ /#,O_4W?^4W_P"VT?\ #,O_ %-W_E-_^VU@
M?\-'>,/^@;H?_?B;_P".T?\ #1WC#_H&Z'_WXF_^.T ;_P#PS+_U-W_E-_\
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M,/\ H&Z'_P!^)O\ X[0.[M8W_P#AF7_J;O\ RF__ &VNP\'_  ?_ .$4\/\
MB?2O[=^U?VY:?9O-^R;/(^21=V-YW?ZS.,CI[UYA_P -'>,/^@;H?_?B;_X[
M7=^ _BSKWBCPOXPU.]M--CGT6R^T6ZP1N%=MDK8?+DD9C'0CO0(P_P#AF7_J
M;O\ RF__ &VC_AF7_J;O_*;_ /;:P/\ AH[QA_T#=#_[\3?_ !VC_AH[QA_T
M#=#_ ._$W_QV@#?_ .&9?^IN_P#*;_\ ;:/^&9?^IN_\IO\ ]MK _P"&CO&'
M_0-T/_OQ-_\ ':/^&CO&'_0-T/\ [\3?_': -_\ X9E_ZF[_ ,IO_P!MI?\
MAF7_ *F[_P IO_VVN?\ ^&CO&'_0-T/_ +\3?_':/^&CO&'_ $#=#_[\3?\
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MU]%^&=2FUGPKI&J7"QK/>64-Q(L8(4,Z!B!DDXR?4T :E%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% &+XP_Y$G7_^P=<?^BVKX;K[
MD\8?\B3K_P#V#KC_ -%M7PW2&@HHHH ***44#0E%+24 %%%% @HHHH ****
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M![TABC:+RF13'C&TCC'IB@#RG4=7U:*[L=1BDBOKZUTW6S:/&PF\S8T.P-L
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MT =!\;?^2O:Y_P!N_P#Z(CKS^O0/C;_R5[7/^W?_ -$1UY_0 44$Y))ZFB@
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M^,/^@EH?_?\ F_\ C5'_  SCXP_Z"6A_]_YO_C5 'C]%>P?\,X^,/^@EH?\
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M&H?V3HE_J7E>;]DMI)_+W;=^Q2V,X.,XZXKPW_AIG_J4?_*E_P#:J]E\8?\
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M /#37_4H_P#E2_\ M5'_  TU_P!2C_Y4O_M5> 44 >__ /#37_4H_P#E2_\
MM5:&A?M#_P!M^(=,TK_A%O)^VW<5MYO]H;MF]PN['EC.,YQD5\X5T'@3_DH7
MAK_L*VO_ *-6@#Z \;_'/_A#O%]]H/\ PCGVS[+Y?[_[=Y>[=&K_ '?+.,;L
M=>U<]_PTU_U*/_E2_P#M5<!\;?\ DKVN?]N__HB.O/Z /?\ _AIK_J4?_*E_
M]JH_X::_ZE'_ ,J7_P!JKP"B@#W_ /X::_ZE'_RI?_:J/^&FO^I1_P#*E_\
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M ,J7_P!JKP"KMO#:I");ESN/*(O.X=\^E3*7*C6E2=65DTO-Z(]S_P"&FO\
MJ4/_ "I?_:J3_AIK_J4?_*E_]JKR2#7--M[=DCL=A(P0 .?QKG68>8648&<@
M>E13G*3=XV.O%X6C0C!TZJFWO9/3[SW[_AIK_J4/_*E_]JI/^&FO^I1_\J7_
M -JKP \FBM3SSW__ (::_P"I1_\ *E_]JH_X::_ZE'_RI?\ VJO ** /?_\
MAIK_ *E'_P J7_VJC_AIK_J4?_*E_P#:J\ HH ]__P"&FO\ J4?_ "I?_:J]
MPT'5/[;\.Z9JWD^3]NM8KGRMV[9O0-MS@9QG&<"OA"OM[P'_ ,D\\-?]@JU_
M]%+0!T-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &
M+XP_Y$G7_P#L'7'_ *+:OANON3QA_P B3K__ &#KC_T6U?#= PHHHH ****
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M.>%XI45XW4JZL,A@>"#4%QIEA=6*V-Q9V\MHNW;#)&&0;<%< \<8&/3%6J*
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M*VO_ *-6@#H/C;_R5[7/^W?_ -$1UY_7H'QM_P"2O:Y_V[_^B(Z\_H ****
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MH Q?&'_(DZ__ -@ZX_\ 1;5\-U]R>,/^1)U__L'7'_HMJ^&Z!A1110 4444
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MI_C1_P -):%_T ]2_P"^T_QH \K_ .%)?$/_ *%[_P G;?\ ^.4?\*2^(?\
MT+W_ ).V_P#\<KU3_AI+0O\ H!ZE_P!]I_C1_P -):%_T ]2_P"^T_QH \K_
M .%)?$/_ *%[_P G;?\ ^.4?\*2^(?\ T+W_ ).V_P#\<KU3_AI+0O\ H!ZE
M_P!]I_C1_P -):%_T ]2_P"^T_QH S_%?PY\5ZE\)_"6B6FE>9J-@TAN8?M$
M0\O.<?,6P>O8FO._^%)?$/\ Z%[_ ,G;?_XY7O6L?%_3-&\':-XDETV[DM]5
M+".)67<FW/7G':N8_P"&D]!_Z 6I?]]I_C0(\L_X4E\0_P#H7O\ R=M__CE.
M;X*?$)L8\.!<#'%[!S[_ .LKU'_AI/0?^@%J7_?:?XT?\-)Z#_T M2_[[3_&
M@=^AY9_PI+XA_P#0O?\ D[;_ /QRC_A27Q#_ .A>_P#)VW_^.5ZG_P -)Z#_
M - +4O\ OM/\:/\ AI/0?^@%J7_?:?XT"/+/^%)?$/\ Z%[_ ,G;?_XY1_PI
M+XA_]"]_Y.V__P <KU/_ (:3T'_H!:E_WVG^-'_#2>@_] +4O^^T_P : /+/
M^%)?$/\ Z%[_ ,G;?_XY1_PI+XA_]"]_Y.V__P <KU/_ (:3T'_H!:E_WVG^
M-'_#2>@_] +4O^^T_P : /+/^%)?$/\ Z%[_ ,G;?_XY1_PI+XA_]"]_Y.V_
M_P <KU/_ (:3T'_H!:E_WVG^-'_#2>@_] +4O^^T_P : /+/^%)?$/\ Z%[_
M ,G;?_XY6OX3^$'CO3/&6AW]YH7EVMKJ$$TS_:X#M19%+' ?)P >E=Y_PTGH
M/_0"U+_OM/\ &KVC?M Z+K.N:?I<6C7\<E[<QVZ.[)A2[!03STYH X[XI?"W
MQEXC^(^JZMI.C?:+&?R?+E^U0INVPHIX9P1R".E<?_PI+XA_]"]_Y.V__P <
MKV[Q=\;M)\(>*+S0KK2KV>:UV;I(F0*=R*XQDYZ-6)_PTGH/_0"U+_OM/\:
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MY.V__P <KU/_ (:3T'_H!:E_WVG^-'_#2>@_] +4O^^T_P : /+/^%)?$/\
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M[!5K_P"BEH Z&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5/7!%2X1=O(TIXJM!3L]);]G?7\_G^(^&58R-Z;P/X34;$%B0-H)X'I3S*3
ML6%VJ2<@<G-1U:74PE+113NO0*FDC@6WC:.8M*?OH4QM_'O4-%#0HR2335[_
M (!7L'P?_P"2??$W_L%#_P!%7%>/U[!\'_\ DGWQ-_[!0_\ 15Q3(/'Z***
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M;&,U 7<J%+,5!) SP,TVBK44MD<DZU2?Q2;]6_\ /R'QN$8DHK@@C#?S^M-
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M6OB&OM[P'_R3SPU_V"K7_P!%+0(Z&BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#%\8?\ (DZ__P!@ZX_]%M7PW7W)XP_Y$G7_ /L'
M7'_HMJ^&Z0PHHHH ****!A1110 4444 %%%% !1110(]:\<_\D*\!_[\O_LU
M>2Y->M>.?^2%> _]^7_V:O)*8A<\8[4E%% [A1110(**** "BBB@ H&,C)P*
M** "N@\"?\E"\-?]A6U_]&K7/UT'@3_DH7AK_L*VO_HU: .@^-O_ "5[7/\
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M_DGGAK_L%6O_ **6OB&OM[P'_P D\\-?]@JU_P#12T =#1110 4444 %%%%
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M  K/QM_T+&I_]^#0!RE%=7_PK/QM_P!"QJ?_ 'X-'_"L_&W_ $+&I_\ ?@T
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H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>form10-k_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-k_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'B EH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MIWB$N++S@1#%<KYL>W?#)N\N0>QV-P<$8Y K:H **** "BBB@ HHHH ****
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M[:* VC9@M<2IY#E@B/GA#G;C' +==W !:\=_\D\\2_\ 8*NO_135T%<7\0=
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M*\^LT\56-UJ%Q%J^C%[^X%Q*&TJ7 81)'@?Z1TVQKZ\YKIO">J7FKZ MU?\
MD&Z6YN8',$91&\J=XP0I9B,A <9/6@#;HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F2H9(RJR-&3_$
MF,C\P:?10!Y_/9Z?<3P"YUW69+07'GI:O9VKPQA9=JL?W!*J6X!SNX)R,$UZ
M!6/9V'AZ423VEEI_[VX\Z1DA0%IE8_,W'+AMW)YSGO6I/,+>WEF9798T+E47
M<QP,X [F@"2BN,L/&UWJ>F64L.D^1>WNIW&GQV]S)CRS$)6)<C/.(B,#/)ZD
M<TVU\>27@T^[BTX+I]Q%8-)(\O[Q7NV*JH4#G:=F3GG=QTY -7QW_P D\\2_
M]@JZ_P#135T%<_X[_P"2>>)?^P5=?^BFKH* .?\ $&L:WI#1R6>E:?=6KRPP
M!YM0>%]\DBH/E$+# +#G=G&>*V+%[R2T1K^"""Y.=\<$QE0<\88HI/&/X167
MXK_Y!5K_ -A.Q_\ 2J*MR@ K'?\ Y'.'_L'R?^C$K,\:3ZE!/H,>GZM<Z>+J
M]>WF\B.%MR^1+(#^\1L$&(=.S'.>,9)TO53>K>'Q9K'GK&8@_DV?W202,>1C
MJ!0!Z#17*>"Y]2GGUZ/4-6N=0%K>I;P^?'"NU?(BD)_=HN23*>O91C'.>KH
M**Y\^,](\V:.--5F\F5X7>#1[N5-Z,48!UB*G#*1P3TH_P"$RTO_ )]=<_\
M!%>__&: .@K"\77.J6N@LVCQE[MY4BPL:N0K'!(#2Q#(SUW?XAG_  F6E_\
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M%<$E@,Y/L:U;*&YA@VW5U]IDSG?Y83CTP* +%%%% !7%7_\ R4/4?^P59?\
MHVZKM:XJ_P#^2AZC_P!@JR_]&W5 %JIO ?\ R++_ /82U#_TKFJ&IO ?_(LO
M_P!A+4/_ $KFH W+S4++3D5[Z\M[9&.%:>54!/H,FFV6J:=J08V%_:W6S!;R
M)E?;GIG!J>>-)(F#HK  _>&:Q_!L:)X*T(JBJ3IUOD@8S^[6@#<HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2?\ ([Z'_P!@Z^_]&6M2U%XD_P"1WT/_ +!U]_Z,M:EH /!G_'YXG_["J_\
MI);5T=[;/=V_E1W<]JV0?,@V[OI\RD?I7.>#/^/SQ/\ ]A5?_22VJ2[\9"WU
M:^T^WT'5;UK*18I98#;A-QC23 \R52?E=>U $WA6*\DLVO+O5KV[8RSQ>7,(
M]H"RLH/RH#G"COW-;L\\-K;RW%Q*D,$2%Y))&"JB@9))/  '.:X*Q\83>'M
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M@"UXT_X_/#'_ &%6_P#2.YHH\:?\?GAC_L*M_P"D=S10 >"_^/SQ/_V%5_\
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MFB@ \%_\?GB?_L*K_P"D=M56^_Y*'J7_ &"K+_T;=5:\%_\ 'YXG_P"PJO\
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M26U9]M_R,_BG_L(Q_P#I';T 5?&'_(DZ_P#]@ZX_]%M7HHZ"O.O&'_(DZ_\
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M?^BFH J55L?^2AZ;_P!@J]_]&VM6JJV/_)0]-_[!5[_Z-M: +7C3_C\\,?\
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M:AJ;QY_R+"_]A'3_ /TLAJ&@"K8_\E"TW_L%7O\ Z-M:E\2?\COH?_8.OO\
MT9:U%8_\E"TW_L%7O_HVUJ7Q)_R.^A_]@Z^_]&6M $M3> _^19?_ +"6H?\
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M0 >#/^/SQ/\ ]A5?_22VK/MO^1G\4_\ 81C_ /2.WK0\&?\ 'YXG_P"PJO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQVDGY0?4;<UOXPE\0V6J_P!D:&/LUK/;>5_:\WS>:\+;L_9N,>3C&.=W;'(
M>)/^1WT/_L'7W_HRUJ6J6I:=XPU#6['4O[+T./[+;3P>7_:TQW>8T39S]FXQ
MY73'.[MCFM')XJEUFYTM=(T;S[>WBN'8ZK+M*R-(J@?Z/G.8FSQW'X &MX,_
MX_/$_P#V%5_])+:L^V_Y&?Q3_P!A&/\ ]([>IM%L?&&D3:I)_96AR_;KH7./
M[6F79B&./;_Q['/^KSGCKCMFJ\6C^,(]4U6]_LW0S]ON5GV?VK-^[Q#'%C/V
M;G_5YSQUQVS0!7\8?\B3K_\ V#KC_P!%M7HHZ"O,9;/Q5XK\-:G:P:;HT"7
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M'M-0C$FJ2[MJR1S!2!;X!(7'4XSWH ],HKG_ +9XP_Z 6A_^#F;_ .1:Z"@
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MI9F"JHR23@ 4M<UK^NZEI.JVXBM;.XTQD"3EIBDD<C-A<\$*I&0"V 6X++W
M-BSCT^YG.LV;1S->6\2?:(Y-RR1*79,<XQF1SD=<^PJ[7%>#;"33KF>WTVWF
ML=-BE,<UA=0M&$RNY7A/*YYV.%)5B-X(.[?VM !1110 4444 %%%% !1110
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MAPW(!;M: (X(5M[>.%"Y2-0BEW+M@#'+$DD^YYJ2BB@ HHHH **** "BBB@
MHHHH *BN;6WO;66UNH8Y[>52DD4BAE=3U!!X(J6B@#GI/#,L5U:2V&J3116]
MPLP@N0;A5'S!PC$AE+*Q7EF51C"BM;4=1@TRU\^<DEG$<<:<M*[<*BCN2?P[
MG !-6ZJ:EIMIJ^GRV-]")K>48922""#D$$<A@0"".00".: .9>UN]>U&X\YI
M=,US3A'-:M'.9X(U<.!D;5#;@K!U/(&,,/E:MRQ2XU%;*^U"T:ROK;S$>$.K
MJ<\'#=T. PZ'ID \57\+Z/=Z'9W5G=3+=?Z0TB7C.6FN%;!W2Y_C'W>#C"C
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ME20#M(!&: (=)%UK-S%J]_9BTBC'^@P2(5G4$89Y/[N[C$?8 %OF^5-^BB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BH;N[@L;5[FYD"1(.3@D\G   Y))(
M  Y)( KF9?$=SJ/A6^U&QMKEYK:XV2V5LO\ I4:*PWH5;&)"N6P.S#;N^4D
MM7FNR7-S8V6FW-O:S7:S!9;R!G"RQ[?W)0,OSX);&[.U&P#R12\-::U[903S
MQA8(KB2:W E8R6\PD82A), R0N0Q!."5;D$$8-'T=-5CE&I1B\@("S"YAW1W
M.22$*R*"XCR@$A&3@Y]!K:_KUMX<TT.(6EEVGRK>)3PHP"[;0=L:@@LV#@=
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M HHHH **** "BBB@ HHK#\0^)+;0HE#D>:Q7<S*QCMT9MOFRD#Y4![G&<'D
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A(52S$
M9)/:E) &3P*HB[@O-0O-+DC1_+@CD=6P0Z2;U&1Z?(P]Z *__"0V,FD1ZI$9
MFT^1ROVH)A43D>:<_P#+/('S $8(;[N6',6>@PZUJ-[;WD4$JQ.8[QXB420O
M'D30NIW12," Z X.<]\MH)X46TOK5K>)Y+N*16_M:=U:58 __'O_ 'F79\N#
MQR7.6Y._I6E6VC6K6ED#':[R\4 QMA!ZJF!PN<D#G&<#    +D:"*)(U+$*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M $,/_DE<?_&Z/^%V_#S_ *&'_P DKC_XW7R!10!]?_\ "[?AY_T,/_DE<?\
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M[_L%2?\ HV*O(*]?_9R_Y*'??]@J3_T;%3)N?4%%%% @HHHH **** "BBB@
MHHHH **** "BBB@#*\3_ /(IZQ_UXS_^@&OA:ONGQ/\ \BGK/_7C/_Z :^%J
M!A1124 +2444 +FBDHH"X[-&ZFT4@NQV\T;C3:*+#YF.W'%)FDHIBNQ:,TE%
M "YHS244!<7-&:2B@+BYHS244!<7-&:2B@!<TE%% "YH#$=*2B@+BEB3DT9I
M** NPI<TE% @HHHH **** "BBB@ HHHH **** "EI** "BBB@ HHHH ****
M"BBB@ HHHH ***]1T7Q-\*;;1+*#5/!M_<ZA'"JW$R2D"20#YF'[P=3["@#R
MZBO7_P#A+?@U_P!"+J/_ ']/_P =H_X2WX-?]"+J/_?T_P#QV@#R"BO7_P#A
M+?@U_P!"+J/_ ']/_P =H_X2WX-?]"+J/_?T_P#QV@#R"O7_ -G+_DH=]_V"
MI/\ T;%4=QXK^#SVTJP>!]025D(1C*>&QP?];ZU)^SE_R42^_P"P7)_Z-BH
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M_P": /I3_A27P\_Z%[_R=N/_ (Y1_P *2^'G_0O?^3MQ_P#'*^:_^%F>-O\
MH9]3_P"_YH_X69XV_P"AGU/_ +_F@#Z4_P"%)?#S_H7O_)VX_P#CE'_"DOAY
M_P!"]_Y.W'_QROFO_A9GC;_H9]3_ ._YH_X69XV_Z&?4_P#O^: /I3_A27P\
M_P"A>_\ )VX_^.4?\*2^'G_0O?\ D[<?_'*^:_\ A9GC;_H9]3_[_FC_ (69
MXV_Z&?4_^_YH ^E/^%)?#S_H7O\ R=N/_CE'_"DOAY_T+W_D[<?_ !ROFO\
MX69XV_Z&?4_^_P":/^%F>-O^AGU/_O\ F@#Z4_X4E\//^A>_\G;C_P".4?\
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M_CE'_"DOAY_T+W_D[<?_ !ROFO\ X69XV_Z&?4_^_P":/^%F>-O^AGU/_O\
MF@#Z4_X4E\//^A>_\G;C_P".4?\ "DOAY_T+W_D[<?\ QROFO_A9GC;_ *&?
M4_\ O^:/^%F>-O\ H9]3_P"_YH ^E/\ A27P\_Z%[_R=N/\ XY1_PI+X>?\
M0O?^3MQ_\<KYK_X69XV_Z&?4_P#O^:/^%F>-O^AGU/\ [_F@#Z4_X4E\//\
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MG_\ 0#7PK7W5XG_Y%/6?^O&?_P! -?"M !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%+@GM24 %%&** "BBB@ HHHH **7'&:2@84444""E52
MQ '4T44#7F!&#BDH/)I: $K9T?1DU*-WDE*!> %ZFLZ5HC!&L:88?>/J:2VN
MIK24/%(RGV/6L:BG*#Y'9G?A)8>AB(O$1YX=4O/_ "$NH/LUU)#N#;&*Y'>H
M:?+(996D;[S')IM:QO;4XZG*YMPVOIZ=!**=L;!..*2F0TUN%!HI0,@\T@M<
M;13PN3UXJZUA$UC]IBGR5.'5L#\JF4U'<WI8>I53Y.BO\C/HI2 #P<T<59A8
M "QP!D^@HP<XQS5S3;U+&Y$KP++V^;M[BH[VX%S>R3H@C#'("]JCFES6MIW.
MATJ2H*IS^]>W+9[=[[%<@#O4]G<BTN4E\M7"_P +=#4);/7%-/6FU=69G&;I
MS4X;HDFD629W50H8Y ':HZ**:5M")2<FY/J%%+13$)VHHI: $I110#0 4<TI
MQZTF:0["5Z_^SE_R4.^_[!4G_HV*O(<XKU[]G+_DH=]_V"I/_1L5,1]04444
M""BBB@ HHHH **** "BBB@ HHHH **** ,KQ/_R*>L_]>,__ * :^%:^ZO$_
M_(IZS_UXS_\ H!KX5H **** "BBB@ HHHH **6DH * ,T44 %%+G%)0,*6DH
MH$%%%% $L<[1QN@ P_4]ZCQ244K%N;:2?06GHRJ3D BHZ*+"4K.Z))61WRB[
M1CI4=%%"5@E+F=Q:*2BF(*7 I** "EI**!!2TE% "YH)S244#N+DXQ2444"N
M%%%% "Y.,4E%% 7"ES244 +0&(R >#244#N%%%% @HHHH **** "BBB@ HHH
MH ***]0T7X&:_KFB66JP:KH\<-W"LR)+*X90PR <(>: /+Z*]>_X9W\2_P#0
M9T/_ +_2?_$4O_#._B7_ *#.A_\ ?Z3_ .(H \@HKU[_ (9W\2_]!G0_^_TG
M_P 11_PSOXE_Z#.A_P#?Z3_XB@#R&O7_ -G+_DH=]_V"I/\ T;%45Q^S]XCM
MK66=M8T0K$A<@329( S_ '*E_9R_Y*)??]@N3_T;%0!]04444 %%%% !1110
M 4444 %%%% !1110 4444 4M8LY-0T2_LHBJR7%M)$A<X +*0,^W-?-O_#./
MC#_H):'_ -_YO_C5?3]% 'S!_P ,X^,/^@EH?_?^;_XU1_PSCXP_Z"6A_P#?
M^;_XU7T_10!\P?\ #./C#_H):'_W_F_^-4?\,X^,/^@EH?\ W_F_^-5]/T4
M?,'_  SCXP_Z"6A_]_YO_C5'_#./C#_H):'_ -_YO_C5?3]% 'S!_P ,X^,/
M^@EH?_?^;_XU1_PSCXP_Z"6A_P#?^;_XU7T_10!\P?\ #./C#_H):'_W_F_^
M-4?\,X^,/^@EH?\ W_F_^-5]/T4 ?,'_  SCXP_Z"6A_]_YO_C5'_#./C#_H
M):'_ -_YO_C5?3]% 'S!_P ,X^,/^@EH?_?^;_XU1_PSCXP_Z"6A_P#?^;_X
MU7T_10!\P?\ #./C#_H):'_W_F_^-4?\,X^,/^@EH?\ W_F_^-5]/T4 ?,'_
M  SCXP_Z"6A_]_YO_C5'_#./C#_H):'_ -_YO_C5?3]% 'S!_P ,X^,/^@EH
M?_?^;_XU1_PSCXP_Z"6A_P#?^;_XU7T_10!\P?\ #./C#_H):'_W_F_^-4?\
M,X^,/^@EH?\ W_F_^-5]/T4 ?,'_  SCXP_Z"6A_]_YO_C5'_#./C#_H):'_
M -_YO_C5?3]% 'S!_P ,X^,/^@EH?_?^;_XU1_PSCXP_Z"6A_P#?^;_XU7T_
M10!\P?\ #./C#_H):'_W_F_^-4?\,X^,/^@EH?\ W_F_^-5]/T4 ?,'_  SC
MXP_Z"6A_]_YO_C5'_#./C#_H):'_ -_YO_C5?3]% 'S!_P ,X^,/^@EH?_?^
M;_XU1_PSCXP_Z"6A_P#?^;_XU7T_10!\P?\ #./C#_H):'_W_F_^-4?\,X^,
M/^@EH?\ W_F_^-5]/T4 ?,'_  SCXP_Z"6A_]_YO_C5'_#./C#_H):'_ -_Y
MO_C5?3]% 'S!_P ,X^,/^@EH?_?^;_XU1_PSCXP_Z"6A_P#?^;_XU7T_10!\
MP?\ #./C#_H):'_W_F_^-4?\,X^,/^@EH?\ W_F_^-5]/T4 ?,'_  SCXP_Z
M"6A_]_YO_C5'_#./C#_H):'_ -_YO_C5?3]% 'S!_P ,X^,/^@EH?_?^;_XU
M1_PSCXP_Z"6A_P#?^;_XU7T_10!\P?\ #./C#_H):'_W_F_^-4?\,X^,/^@E
MH?\ W_F_^-5]/T4 ?,'_  SCXP_Z"6A_]_YO_C5'_#./C#_H):'_ -_YO_C5
M?3]% 'S!_P ,X^,/^@EH?_?^;_XU1_PSCXP_Z"6A_P#?^;_XU7T_10!\P?\
M#./C#_H):'_W_F_^-4?\,X^,/^@EH?\ W_F_^-5]/T4 ?,'_  SCXP_Z"6A_
M]_YO_C5'_#.7C#_H):'_ -_YO_C5?3]% 'S!_P ,Y>,?^@GH?_?^;_XU1_PS
MEXQ_Z">A_P#?^;_XU7T_10!\P?\ #.7C'_H)Z'_W_F_^-4?\,Y>,?^@GH?\
MW_F_^-5]/T4 ?,'_  SEXP_Z">A_]_YO_C5=W\)_A+KW@3Q5<ZIJEWILT$MD
M]NJVLCLVXNC9.Y%&,*>_I7LE% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
K %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>fin_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_001.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "I!7,# 2(  A$! Q$!_\0
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M^'6GQ5_Z#_@[_P #KO\ ^1J/^'6GQ5_Z#_@[_P #KO\ ^1J/[1R__GY'[O\
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M /%4?\+$\5_]#/K/_@QE_P#BJYZBM/9P_E7W(CVDN_XLZ'_A8GBO_H9]9_\
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M\%Y>B;7WI'UY17PSKG[97QX^&L;W/C3X&E=/B&Z6>R,R1(OO,OFH*ZGX:_\
M!2GX9^,IX[3Q%;ZCX+NV_P"6ETGVBU_[^Q\_]](!52RO%J//&/,N\6G^1,<S
MPKERREROS37YGU[165IFO:;K.C0:K8W]K>Z;-'YL5[!,KPNG]X..,5IJVZO*
M/43OJ.HHHH&%%%% !117SEX__;9\'>'/%,GA3PII>L?$CQ5'N5M.\-6_G(C+
M]X-)[=]@;'>MZ5"K7=J4;V_#U?0PJUZ=!7J2L?1M%?&'B_\ ;V\9_#IXY_%O
MP$U_0=*9PGVZ?4&V<].?LX3=[;Z['P3_ ,%"OA'XQM;02WVHZ'J5Q<QVB:=?
M6+/+O=MH(:+>FW\?PKKEEN+C#G]G==TT_P F<L<QPLI<O/9^::_,^GJ***\T
M]$**** "BBB@ HHHH ***\2^,W[7?PV^!LKV6N:R;[6E_P"81I:?:+E?]_G;
M'_P-EK6E2J5I<E*+;\C*I5A1CSU'9'MM%?$]A^VS\5?B6/-^&WP/U&^TUO\
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MO+M%;O\ KN<!^SU_P3G\*^![:TU?XAB'Q;K^%<::?^0?;-Z;?^6Q_P!_Y?\
M9[UW?Q8_;?\ A1\#]^A6<_\ ;NI68\G^RM C7RK;'\+R<1IC^ZNYA_=KYQ_;
ML_;*O]1UC4OAOX'OY+/3;5FMM8U6U?Y[J3H]NC#[J+]UO[Q^7[OWO@^O"PV5
MULQMB,PF]=4EV_0]K$YC2R^^'P,5IN]_^'/MOQ9_P5.\;WT[KX<\*:'I%O\
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M%?!^C>"=%ATCP_I5IHVF0?<M;*%8D'X#O[UNT45\HVV[MW9]2DHJRV"OF/\
M:,_8;\&?&JRN]2TBU@\*^+SN==0M(]L5R_\ TWC7[V?[X^;Z]*^G**WH8BKA
MIJI2E9F%:A3Q$>2K&Z/PI\8Q>//A#<:W\.-8OM5TBW2;_3M(2Z;[),P^97V
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M&HY2=!A7QRK?[2.G_?2O7[0_"?XA6/Q5^'/A[Q;IWRVVJVBW'EGK$W1T_P"
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MY+[/WZGQ.:1GC?:5J;]VEIZOK]VA]E_!OXBVOQ;^&/AOQ=9[-NJ6B2RQH?\
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MT*SV]S"?E>-ERK"N+-:&*I5W4Q6KELUMZ>5CLRROAJE%0P^G+NGO_P $\_\
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MZE;-8T(<\Z4TO-6_4]._X**_%R/XH>*_#GPH\(%]>O;&]::^@L1YI>\*^7'
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MSK4HU*D;-Z]PHHHKE.H*_+/_ (*>>-I-=^-^D>'DD_T/0M+3Y/\ IO.V]_\
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MZF$J?7L)I;=?KZ=S]0K*]M]2LH;JUF2YMYE62.6)]RNIZ,I]*MU^8_["?[9
M\"7-K\._&][GPY.VS2]5G?Y=/<_\LG/_ #R8]#_ ?]G[OZ<5\[CL#4P%9TY[
M='W_ *ZGOX+&4\;2]I#?JNQ\K_\ !23_ )-EOO\ L*6G_H1KL?V'O^35_ '_
M %ZS?^E$M<=_P4D_Y-EOO^PI:?\ H1KL?V'O^35_ '_7K-_Z42UV2_Y%,/\
MKX_R../_ ",Y?X/U1[O1117AGN'A7[77P"M_V@/A1=Z=;Q)_PDFF[KS1YW_Y
MZA?FB)_NR#Y?KM/\-?E[^SI\9]4_9Q^+MIK+1S_94=K'6--/RN\&[YUV_P!Y
M#\P]UK]MZ_+/_@I=\(M.\"?$_1?%FF;(%\5QW$EW:H/^7F'R]\O_  ,2I_P+
M<>]?79'BHSYL!65XSV_5?KZH^4SG#.GRXVD[2CO^G^1[7^V7\?S\1M,\.?"7
MX7:C!KFL>,_+:XGL)-Z+9O\ <0L/N;_O/_=C1MW#U]-? GX/Z7\#?AII7A+3
M LGV5-]U=[-K75RP_>2GZGIZ+M':OC7_ ()9_#W2;R3Q;XTNX?.UJR>/3K1Y
M/^6*.FZ1E_VF^49]/]XU^B->;F3CAO\ 8*7PQU;[OS]-CT,N4L0GC:OQ2T2[
M+R]=PHHHKPSVPHHHH **** "OA3_ (*L?\D_\"_]A2;_ -%5]UU\*?\ !5C_
M ))_X%_["DW_ **KV<G_ -_I>OZ'CYO_ +E4_KJBA_P2@_Y 'Q%_Z^[/_P!!
MFK[ZK\W/^"=^J^)M%^%OQ4O_  ?H</B+Q!%<Z>UMI=S=?9TG_P!;O&\\9V[L
M9]!7N;_M5?&.UD^RW'[->OO=C"_N-4WQ-Z_.+<J/SKLS3"U*^-JRA;=;M+HN
M[1R9;B:=#!TXSOL]DWU?9,^L*_)+]K/5+G]I7]KQ_#_A$#57B\G0;1XOF1V3
M<TKY_N([RY/3:F:^G/$S?M2?M 6<FDQZ)I7P@\.W2;9[J2]WWKQD890R;G7_
M +YC_P!ZO6?V;?V3/"O[.6FR2V3OK7B.Z3;=ZW=1A7*_\\XE_P"6:>V23W)X
MPL).GE7-6G)2J6LDG=+S;V^2N/%1J9GRTHQ<:=[MO2_DEO\ >>H_#WP;:?#W
MP/H/AFQ/^BZ38PV2-TW;$V[OJ<9_&NGHHKYQMR;D]V?01BHI16R"BBH9)$@C
M=W?8B_,S-2*/D/\ X*-_&&3P=\+;3P1I3O\ V[XLF\IT@^^+1&'F#_@;;$]P
M7KV;]E_X/Q_ [X+Z!X99$_M/9]KU.0?QW4OS/_WSP@]D6OA?PS\5_"'QQ_;=
MG\;^,O$%KHGA'0MTVC?VE/Y23+;OBW7G[N78W&/PK[O_ .&I?@__ -%)\,_^
M#*+_ !KZ/&4*U##4\)"#_FEH]WLODCYW"5Z5;$5,5*27V8ZK9;OYL\?_ ."C
MOPE_X3WX(?\ "26< DU7PK-]LR/O&U?Y9Q^'R2?]LZ^<?^"9?Q=/A;XG:GX&
MO)MNG>(H?-M5?^&[A3=_X_'O_P"_:U]O:Q^T;\%=>TN^TS4/B%X8NK*\A>WN
M(9-1CVO&Z[67KW4U^0:ZM_PJGXL_;_#&K1ZBF@:MYNG:BGW+E(I/D?\ W74<
MUZV5TJF)P57!58M=5==_^#^9YF95(8?&4\92DGWMKM_P#]X:*YSP/XPL/B#X
M1T;Q'IC[]/U:TCNX2?[KKNP?<=#71U\.TXMIK5'VB:DDULPHHHI#"BBB@ HH
MHH _+3_@J7_R<!H'_8L6W_I7=U\;U^]FN_#_ ,+^++I+O6_#>D:O=(GE+-?6
M44[*O7:&92<<U1_X4O\ #[_H1?#7_@GM_P#XBOLL'G\,-0A1=-OE5MSX_%9'
M/$UI5E-*[['X0T5^[W_"E_A]_P!"+X:_\$]O_P#$4?\ "E_A]_T(OAK_ ,$]
MO_\ $5V?ZS4_^?3^\Y/]7*G_ #\7W'X0T5^[W_"E_A]_T(OAK_P3V_\ \11_
MPI?X??\ 0B^&O_!/;_\ Q%'^LU/_ )]/[P_U<J?\_%]Q^$-%=[\>[.#3OCI\
M1+*T@2VM;?Q'J,,4,*;%15N9 JJHZ 5P5?8PG[2"FNJN?)U(>SFXOH?HM_P2
MAU-9-%^(NG;_ )XKFRN=G^^LRY_\AU]K>/\ P58_$7P1KGAC4<_8=5M)+.5E
M^\@=<;A_M#J/I7YA_P#!-WXD0^"_CTVB7<WE6GB6R:Q0-]W[2A\R+_T&51[O
M7ZQU^8YW"=''RFM+V:_KY'Z/DTHUL$H/I=/^OF?@K\2OAUK?PG\;:KX6\0VG
MV74["7:W]R9/X94_O*R\BN6K]J?VB/V6?"/[16B)#JT?]F:Y;*19:W:1K]HA
M_P!EO[\?^P?P*]:_,CXU?L<_$GX)W%Q<7VC/KF@1?,FL:2C2P[?60?>B_P"!
MC'H37V.6YO1QD%&;Y9]GI?T_JY\GF&55<+)R@KP[]O7^K'AM%%%?0G@!1110
M 4444 :^C>+-;\/65]::5K.HZ7:ZBGE7L%C=21)<K_=D53\Z_6LBBBI44G=(
MIR;T85^I7_!+/_DW_7_^QHN/_22TK\M:_4K_ ()9_P#)O^O_ /8T7'_I):5\
MYQ!_N3]5^9[^1?[ZO1GV31117YB?I04444 %%%% !17R)^R!\4=4/Q<^,'PV
M\4ZS=ZGJ^FZW<7VGO>S-*S6_F%'"9^ZB_NF"_P#32OKNNG$4)8:HZ<M=G\FK
MG-AZ\<13]I%6W7W.P5S7C+X?^&_B'I3:;XET.QURR;_EA?0+*%_W<_=/N*Z6
MBN=2<7>+LS>45)6:NC\O_P!L[]A^R^$VB3^.? DDQ\-Q.JZAI4TC2O9;F"K)
M&W5H]QP=WS+ZD?=]S_X)A>/;OQ%\(-;\.7DCR_V!J.+<O_!!,N\+_P!]K*?^
M!5[K^U/>6-C^SA\2)+\H(&T&[A7?T\UXRD7_ (^R5\T_\$J/#<]GX'\<Z](F
MR"_U"WLXG_O^3&[,?_(]?5/$SQ>4S==W<9*S/F%AXX7-(*CHI)W1]W5Y%^U!
M\8(O@A\&=?\ $:NHU39]DTU/[]U+\J?]\\N?9#7KM?GI^U+J%Q^U#^UEX4^#
MNE3O_86AS!M4D1_DW[?,N6^J1?NU_P!MF%>-E^'C7KKVGP1U?HM?QV/7Q]=T
M*/N?%+1>K*'[,?[ .@?%'X:6'C/Q]J>MB^UO==VUK93K%M@9OE>1G1B[/]_Z
M,*]@_P"'9/PA_P"?OQ-_X,(__C5?5VG:?!I5A#9VL*0VT$:Q10I]U$48 JY6
MU;-L94J2G&HTGT73R,:6586$(QE!-KJ^I\B_\.R?A#_S]^)O_!A'_P#&J\._
M:T_8*\/_  G^&,WC#P1=ZK=?V8Z_VA9:A-',# S;?-3:BG*L5S_L\\;:_2NL
M?Q/X;L?%_AS5-$U.,36&HVLEI<)_?C=2K?H:=#-L73JQG.HVD]4^J%6RK#3I
MRC""3:T?F?GA_P $O/BS_9?BK7OA[?3E+?5$_M33D<_\MT7$JCW:/:W_ &Q-
M?I/7X;VTFM?LT?'M'/.K>$]9^?\ @\]$;G_@$D?_ (Z]?MIH.O67B70]/U;3
MY1/87]O'=V\W]^-UW*?^^2*[\_P\85XXF'PU%^.GYZ''D==RHRP\]X/\/^'-
M2OGC]O\ _P"32?'GUL/_ $OMJ^AZ^>/V_P#_ )-)\>?6P_\ 2^VKQ<!_O=+_
M !1_-'L8[_=:O^%_D?#'_!-S_DYJP_[!=W_Z"*_6ZOR1_P"";G_)S5A_V"[O
M_P!!%?K=7L\1?[ZO\*/(R#_=/FPHHHKY@^D"BL6\\4:3I^MZ=HMSJ-K!JNH+
M(UK922*)9E1<OL7OCO6U3L]Q)I['XX?M_?\ )V_CO_MP_P#2"VK].OV6O^3;
M_AK_ -@&T_\ 12U^8O[?W_)V_CO_ +</_2"VK].OV6O^3;_AK_V ;3_T4M?9
M9O\ \BS#>B_])/D,K_Y&&(]7_P"E'JM%%%?&'V!^6G_!2OX/V/@?XF:5XNTR
M!+6W\3Q2O=QI]W[7$4WR?\#5T_'<:^A_^"9'C>[\1_ W4M#O)&<Z%J;Q6^_^
M&"15D"_]]F6N._X*LW< \(^ +5G474E]=2HI^\46--W_ *$E=3_P2_\ "-SH
MWP1UG6[@,J:UJSM;Y_CBB01[O^^_,7_@%?9UI^UR.$JKNTTE\K_H?'T8>SSB
M:IZ*UW\U_F>[_M2_\FW_ !*_[ -W_P"BFK\Q?V ?^3M_ G_;_P#^D%S7Z=?M
M2_\ )M_Q*_[ -W_Z*:OS%_8!_P"3M_ G_;__ .D%S1E'_(MQ/H__ $D,S_W_
M  WJO_2C]CZ***^,/L#P;PW\!;_PY^UMXF^*,,]E_8>M>'UL9+=7;[1]K\R#
MYMNW;LV6XYW9RW2O>:*P]4\5:1HFIZ5IVH:C!:WNJRM!8P2/M:Y=5WL$'?"C
M-;5*DZ[3EJTDODC"G3A03Y=+MOYLW*_"#X+?\EA\"_\ 8>L/_2E*_=^OP@^"
MW_)8? O_ &'K#_TI2OKN'?X>(]%_[<?+Y]_$P_J__;3]WZ\%_;!_9^A_:#^%
M-Q96L<8\3:7NO-)G_P"FNWYH2?[LB_+_ +VQOX:]ZHKY&C5G0J1JTW9H^IK4
MHUZ;ISV9^)G[-WQPU7]F[XLP:N\<W]GN_P!AUC32-K/!N^;Y?[Z'YE]^.A-?
ML[H6NV7B;1['5=+NH[W3KZ%;BVN83E)8W7<K#ZBOSA_X*0?LY_\ "*^)4^)>
M@VVW2M9E\K5HX_\ EA>'[LO^[)W_ -O_ 'ZZ'_@FW^TB;69_A3XAN_W,K-<:
M#-,_W&^]):_CRZ^^\=UKZ_,Z,,RPL<PH+5?$OS^[\CY/+JTLOQ,L#6>CV?\
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M9A4Q2^&/NKS]/ZZFEK6HII.CWUZVT);6[R_-]WY5S7PI_P $HHU;2/B3<?\
M+1[BP1F]=JS_ /Q5?87QMU(Z-\&/'FH+]ZTT"_N/E_V;>1J^3/\ @E.BCP#X
MY;^(ZI#_ .BJXL+&V78B7=Q_!G7B'?,*$>RE^*/KGXN?#RP^+/PX\0>$M1PM
MKJ=JT/F8_P!5)]Z.3ZJX5OPK\;? 'BG6_P!FGXYVFH3P.FJ^&]4:VOK6-_\
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M&?[7<OQ:_93O/ GBN=Y/%^G7EH]O?/\ \Q"V1NKG_GJO\7][KUW5]Z?L/?\
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M#^+G_"0_#W6/ =Y.&NM F^UV2'J;69LL/^ R[_\ OXM?;]?BM^RG\3)_@?\
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M_!GFL! ?^/K37W?-Y6[^#^]$>_*XYW?K97CGQ=_90^&?QK=[KQ#X?2+5B/\
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M+_&C_AJ7X/\ _12?#/\ X,HO\:/JU?\ Y]O[F'UFC_.OO1ZK17E7_#4OP?\
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MO\:/JU?_ )]O[F'UFC_.OO1ZK17E7_#4OP?_ .BD^&?_  91?XT?\-2_!_\
MZ*3X9_\ !E%_C1]6K_\ /M_<P^LT?YU]Z/5:*\J_X:E^#_\ T4GPS_X,HO\
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M%_C1]6K_ //M_<P^LT?YU]Z/5:*\J_X:E^#_ /T4GPS_ .#*+_&C_AJ7X/\
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MX/\ _12?#/\ X,HO\:/JU?\ Y]O[F'UFC_.OO1ZK17E7_#4OP?\ ^BD^&?\
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M/'C&T\.>(M)UZ^OKFQ74$DTJ"!XA&TDB8/F3(=V8F[5YS_P],^%/_0 \9?\
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M\%^);?QGX/T/7[7Y;75;&&^B_P!R6,./T:OSE_X*IV"P_%?PC??)NGT-H?\
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MX9_\%L7^%>JT4?6:_P#S\?WL/JU'^1?<CRK_ (9:^#__ $3;PS_X+8O\*/\
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M-AE6VL 1^(H]MBE%3<I6VO=V%[+#.7)RQOO:R.%_X9:^#_\ T3;PS_X+8O\
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M8O\ "O5:*/K-?_GX_O8?5J/\B^Y'E7_#+7P?_P"B;>&?_!;%_A1_PRU\'_\
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MU%%%?9'R04444 %%%% !1173?#;P-??$SQ]H'A73D/VO5KN.T5_[BLWS.?\
M95?F-1*2A%RELBXQ<WRQW/V>_9HMI;3]GGX;13D>:/#U@Q_&!"*^ /\ @J!K
M\>H?';1M.BDW_P!FZ)$LH_N2/)*__H.ROTVMH+#P?X<AB4I9:5I=JJ;G.U8H
M8U[^P5:_$7X^?$IOB_\ &#Q5XMZV^HWC?9]_\$"?NXO_ !Q5K\^R&FZ^-GB+
M:*_WMZ'WF=S5'!PH-ZNWX(\^K]2O^"6?_)O^O_\ 8T7'_I):5^6M?J5_P2S_
M .3?]?\ ^QHN/_22TKW^(/\ <GZK\SP<B_WU>C/LFBBBOS$_2@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *_-KX.^$[;]M#]K7QMXI\6(^J>$_#[;+:Q=V\IT\Q
MH[6(C^[MCDD;^\WU-?HKJ]RUII5[/%S+%"[K_O!37PE_P2AB5=&^)$NS#M<V
M*LWKA9Z]W 2=+"XBO#22Y4GVN]3Q,<E5Q-"C+X6VWYV6GYGKO[3G[)WP[\2?
M!SQ'<:-X1TK0M>TJPFO;&[T>R6U<O$F_8WE@;U;9MPV>O'-,_P"">7C/5?%/
M[/D-CK0G^TZ%J$NF1&ZW;S J1R1]>R^9L'LE?4=<G\3O%W_" ?#SQ/XE"K(V
MDZ9<WRHW1VCB9POXD5QQQ52KA_JLO>NTTV]NGXG2\+"E7^LQ?+9--);]3@OB
M9^US\*_A'KS:)XC\4)'JZC][:6D$ERT/^_Y:D*?8\UV7PQ^+WA#XPZ*^K>#]
M=M]9LD;9+Y89)86]'C<!D_$5\C_L$_#/P9XN^'.N^-O&UKH_B3Q-KNK7'G3Z
MVD5PZQKC/RR#@L[2,Q[Y%8_[/]I9?!__ (*">,O!'AI]GAG4[1MEK"^Z%"8(
M[M<?[FZ1%]J]"K@,.E5I4W+GIJ[>EG:U^GF<5/&UKTJLTN2H[)+=7VN?9FJ?
M&;P;HGQ!L?!&H:Y!;>*KV+SK;3GCDWR)M<[MVW;_  /W[5Q%Y^VE\%;#5;K3
MI/'EB\]JNZ5X()I80-VWB5(S&W)[-7R5^V9X3O?'O[;_ (1\-:??/IEQK&EV
MEB]U%]](I6G2;_R&7KZRT#]B[X-Z!I$>GQ^";*^58O*>XO7DEEF&<Y=B?45G
M/"X/#TJ=2M*3<U>RMI]_X%QQ.,KU*D*2BE%VN[_(^/?V1OCKX$^'7Q\^+6O>
M(O$$&EZ/K-Q.]A=/#*ZSJUV[C[JD_=/>OK3X^Z7\']>\>_#:]\?ZO)9:_#<"
M7P[''+(BS2&2(_PJ?X_*ZXKY3_8]^#7@GQY^T'\7=%\0>'+'5=)TBXG2PM)T
M;9 JW;H-O_ :]"_;P@2W^/7[/D,:;8UU)45!_=%W:UZ^)ITZN8QA3<HOEU>G
M2%U:WXGEX>=2E@)2G%-<VBU_FUO^ATW_  4&^-7A.U^$'BCX?Q:_&GC"5[)F
MTKRY-[Q>?'*?FV[?NC=UJU^P=JOPA'@[P_I7A;^RIOB/'HS7&L3063+>[3(A
ME5YF7YE#M&NW<1TQ4'_!0SX4^$3\&/$OC?\ L.U_X2OSK*+^U<?OMOFQQXS_
M +G%=]^Q]\)?"'AGX3^"O%VE>'[2Q\1:GH$"W>HHO[Z=75';<?\ :95->?*5
M&.5)1YE>7E\7*M_([(QK2S)N5M(^>U^GF2_LS:'\(=&\2_$!_AEJLVIZE/=0
MOKRR22/Y,NZ?8/G4?Q>=TKM/BU^T)X ^!\=H?&'B"/3+BZ_U%I'&TT[C^]Y<
M8)V^YXKY@_X)P?\ (_?'O_L*6G_HV^K%_9^T_P /?M#_ +57Q7\;^,TLM8LM
M$N%M-*M-4"O;HC22QPMY;_*Q6.W_ .^GW=<5-;!Q^LUI5I-Q@HM]W=*R_'[B
MJ.+E]7I*E%*4VTNRM>[_  /K+X3?M(_#KXW7$]IX1\1QW]_;INELIXI+>X"_
MWMD@!(]Q7:>,/&6B_#[P[>:[XAU*#2='LTWS75P^%7_$^@%?!?[07AWP_P#!
M']L7X2>*/!$%EI%OJUW!%>VNF[%BYG6&8[4X7?%/@]N_K6]_P4%O;OXB_&+X
M3?".&XDMK+4[F&[N=G]Z:?[.DA_W%6;_ +Z-1_9U.I6I>SDU":<M=TE>_P"1
M?]H5*=*ISI.<6EILV[6_,]E;]L7X2_%'2-?T#0O%*OJUQIETMO!=6D]MYS>4
MW"-(@&?;K7G'_!*W_DCWBS_L/?\ MM#7HOQP_9/^'=_\#-<TK1?"FEZ3J&F:
M?)<:9?6MJJ7$<L2[UW2_>?=MPVX\Y]:\Z_X)6_\ )'O%G_8>_P#;:&MO]G>7
MUWA[_%'1V_3N9?O_ *_15>U^66JO^O8^V*^ ?^"I$*7&M?!V&1/,B>XU%'3U
M4M9U]_5^?W_!4ZY6RU3X.W#_ '(IM1=OP:RKER7_ '^G\_\ TEG5G'^Y3^7_
M *4CZ2O?V,/@M?VCP/\ #W2T5OXX/,B?\&5LBODGX9Z _P"RO^WW!X(\/W\\
MWA77E6%[1WWOY4L+/'O_ -J.4<-_=_WC7L&I?\%/?A3;6KO;:5XFO9_X819P
MIGZEIJ\P_9QTOQ-^U)^U9+\:-5T*31?"VF _9!)RCL(O*BA1\#>1GS&8=_3(
MKT</#%T:-9XVZIN+7O/KTM?J>?7GA:M6DL';GYEMVZW\C[7U?XT^"_#WQ T[
MP/J&NP6OBK445[73GCDWR*=VW#!=O\+=^U;OC+QEHW@#PU?:_K]\FG:19(KW
M-VZ,RQJ6V_PY/4C\Z^)?CI_RDK^&7_7I9?\ H5S7T'^W#_R:OX__ .O6'_TH
MBKR9X*$9X>*;_>)-_-VT/3CBYN%>32]QNWR5]3T;3_&6C_$#X=S>(- OH]1T
MB\M)FM[M%95D4;E[X/4&OAG]@KXY>"/@C\#?$=[XPUR/2$NM?9+>#RVEFFVV
MT.=L: MQW/05]'_LA?\ )F_A+_L&77_HZ:OF?_@FS\!_#?C?2?$?C3Q)H]IK
MIM;M=.L8+Z!98H7\L22OM8;2?GCQ_=KT*-.C1P^*A5;Y8RCMN[-V.&M4JU:V
M&G32YFI;[*Z1]G_"?]HWX??'%KJ+PCX@34+NV7=-921207"+TW;) "1_M"OF
M7_@JQ_R3_P "_P#84F_]%5QW[2'A'3OV7_VN/AEXR\(VL&AZ;K,R_;+&U^2'
MB18KG:OW55HIEXZ!N:['_@JQ_P D_P# O_84F_\ 15:X/#4Z..PU6BWR3U5]
MU:]T9XO$3JX.O3JI<T+)VV>UF?1W[36E?#S6/A;/;_$Z^DTWPM]JA9YXY)$8
M2[OD^X"U=5\)K;P]9?#/PQ;^$IFN/#4>G0IITS%OG@V_(?FP>E>%?\%)/^39
M;[_L*6G_ *$:Q/%/CR[^'/\ P3BT75--F>UU.?PY86-O(C[71IMD;,I_O!6=
MA]*\VGAI5L+2Y9/WIVMT]?4]">(C2Q-2\5[L+WZOR]#T;QC^V]\&O!.O7.C:
MAXO2:_MF*7 L;2>X1&'5=\:%<_0UZMX"^(?A[XF^&[?7?#.JP:SI<^56>W/
M8=593RK?[)YKYG_8M_9F\$VWP!T35_$'A?2]=UCQ%"UY<3:I:I<;8G8^7&F\
M'8NS8>.I_"I_V4_@/XP^ _QL^)=@-*GM?AGJ6Z;2;A[V&5=R2?NUV"0R*?+D
M=<LO/E\]J*^'P:52%*34H=[6EK9V\PH8C%2=.52*<9]KWCVN?7%4=2U*#2=.
MN[Z[<0VMM$TLK_W%5=S&KU?/7[=7Q '@+]FCQ0T<FR]UA5T>WS_'YW$G_D(2
MUYM"DZ]6-)=78]*O55&E*J^BN?GGKGA#4?B5\(_B1\<7CECU$>,8628/_J(G
M\QI /H]Q:X_W*_5[X1^.(OB5\,?"_BE @.K:?#=2(G1)67]XOX/N'X5\]?"+
MX(_:_P#@G_\ \(HT(.H:[H=QJ>/[T\NZ>W/X?N?^^:J?\$R_'_\ PDOP-O\
MPY-)OG\.Z@\2)CI!-^]3_P ?\[\J^CS&:Q="<X_\NIV7^%JWYH^=R^#PM:$9
M?\O(W?JG?\F?1_Q)^*WA3X0Z!_;/B_7;;1-/+[$>;+/*W]U$7+.?90:\_P#
M/[9OPC^)?B.WT+1?%:)JMRRK;6][:RVWG.?X5:10I;_9SD]J^:_BUI<7[1W_
M  4'TKP-K.^Y\+>&K9?-M-_R/M@%Q)Q_MNT4;?[*UZ?^U[^R+I_C;X=6$WPR
M\&Z=9>,M,O(7M_[)2#3V>#HREOD3CY6&>1MXKDC@\+35.G7DU*:O?2T4]K_\
M.=<L7B:GM)T(IQ@[6=[NV^Q]6:AJ%KI-C/=W<\=K:0(TDLTS[411U9F/0"O
M9_V^/@?;ZN+!O%[,0VS[2FGW+PC_ ('Y?3WKR/\ ;S^('B7PU^RSX&T'67>S
M\2^(!:Q:TB.K?-% 'G3<IP?WVSIQ7LW@S]COX<Z9\'K3P?JGA72KRZELECOM
M4>U7[6]R5^>59OOJ=WW<'CI6$,-AZ5"-;$MOF;2Y;;+=Z[^1K/$UZM9TL.DN
M5)N]]WLM/Q/;="UW3_$^CVFJ:5>P:CIUY$LL%W;.&BE0]"K#K7FOQ1_:F^&/
MP;U--,\4^)H;;567=]AMH)+F9%/=UC!V?\"Q7E'[(WAGQ[^SA\"/&MKX_P!,
M^PV^B/<ZIIR27<,H> 0;W&8W;:NY"><??->6_P#!/SX2Z1\78O&?Q0\<6-KX
MJUFYU9K6)M5A6=4DVI+++L;C)\U,?W=O%5'!4(>VJ5)\T(-)6^TWMJ3+&5I^
MRITXJ,YIMWZ);GUO\*/VC?A[\;C<1^$?$D&HW=NNZ6QDC:"X1?[WER ,5_VA
MQ6]\2/BIX6^$6AV^L>+]7CT73I[A;1)Y(V<-*59PGR@G[J-^5?#7[9/A'2_V
M8?C=\-OB;X)L(-!6ZN)#?6.G(L4+^2T>_P"1>/WL<C*V/[N>IKT[_@J2<_L_
MZ!_V,]O_ .DEW6BP%&I5H>S;Y*O?=6W1#QU6G2K<Z7/3[;.^Q]<:-J]IKNDV
M6H6,PN+*\A2X@F7H\;KN5OQ!KE?A_P#&#P?\4K[6;3PMK<.K7&C2K#?QHDB?
M9W8N%!WJ,_ZM^G]VIO@O_P D=\"_]@*P_P#2=*^2/^"<'_(_?'O_ +"EI_Z-
MOJX88:,J->I?6%K?-VU.R>)E&K1A;2=[_)7/J.\_:!^'FG>*M:\-WOBFQLM8
MT6W:[U&"Y+1+;1#9EGD8!/\ EHG?^*N%T7]NOX)Z]K\&DV_C 0S3R^5#<75E
M/#;NW_71T"K]6Q7RKJ?PMT?XP_\ !2'Q1H.O(T^C*_VNXM4?:+GR[2%E1L?P
M[MN:]+_X*$_!7P/X;^ L&MZ)X7TO0=2T[4+>*&?2[2.W/EON5D;8!N7OS_C7
MJK X2%2E0J.3E42?32Z_$\UXW%RIU:T%%1@VNNMOR/>_VG/BUX2^&_PTUC3?
M$FLPZ9?:[I-_;:9#*CO]IE$.W:-JGO(G7^]7S-_P3>^-'@SPA\.+OP;J^NP6
M/B;5O$DDECISQR,\RO!;QI\P7;RZ,.M>LW'@/P[\5_V-/#>N^+='M=:U;2/!
M#W%E=789FAE^Q+F0<_>)B0FO*_\ @FQ\)?"'B?X9W?BW5= L[[Q#I?B:2.SU
M&4'S852WMG7;]&=C3IPH4\OK0GS-J2O:V^MK7Z=Q5)5ZF-I3A;6.E[[:7^?8
M^I_BQ^TG\._@A<V]KXN\11:??W";XK&&"2XG9?[VR,':/=L"JGPK_:F^&?QG
MU>32O"WB1+O5D0R?8IX);>5U'5D$BC>/]VO.M!_9*N=3_:A\9?$?QW!H7BC0
M=0AV:5976Z=[9AY:H7B>,1\(C 8+=?7FO"?V@=)\&^"_VVO@]_P@T>EZ3>RZ
MG8Q:K::-Y:*C-=HGSI'PC-&S!O45A1PF$K_NH2DY\M[JUD[7M:WR]3:MBL51
M_>R24.:UM;VO:]_Q/N3XD_%OPC\']*M-1\7ZS'HEG<S?9X9I4D<-)M+;?D![
M UP?C_\ ;+^$OPSUS^Q]8\5HVI(NZ:"QMI;GR?9S&I"M_L_>]J\9_P""J7_)
M'O"?_8>_]MIJ]2^#7[*_PTTCX2:-I]YX1TK6KK4=/AEU'4=1M5EN;F62,,[>
M8WS)R3MVGY?KS6,,/A:>&IXBOS/F;5E;IUNS:6(Q,\3.A12]U)W=^OH>E^&_
MC/X,\8?#^Z\;Z1K]O?>&+.&2XN;V,./(6-=\F],;U95YVE<^U?"'_"_/ 7_#
MP;_A8'_"1P?\(A_9WE?VKY,NS=]B\O&W9N^_QTKK/^"<OA^TNY_CQX/O(_MV
M@?:+:Q:UG^X\3_;(GS_O(J@_2N.OO@SX)B_X*-:;X&3P[8+X2EMV9]'$;>26
M_LR27U_O_-7JX?#8?#8C$T6VTH/M\+2?WGE8C$5\30P]5)*\UW^)-K[C[WC^
M,'@Z7X>Q^.O^$@M8?"3PM*NJS;HHMH;9_$ <[A@#&3VKRNR_;\^"%[J*68\7
MR0;VVK-/IURD7_?7E_+^->"?\%(]%A\!?#?X8>%M!M#I?@B*^NGFM;(81'4(
M8_Q_>3D5[MK?[.OPB^,/P'N-,\#Z%X:,%SIS)I.L6,$>^&?R_P!V[S(/,SNV
M[\_,><UYT,+A*=&%>KS6FVE:WNI.VNFYZ,L3B9U9T:7+>"3=[ZM]M=CZ#T_4
M;;5K*"\LYXKRTG198IH'5T=3R&5AP0:O5Y)^S)\+=>^#7P?TGPAXBU*UU:[T
M]YA%<6F[9Y32,ZK\P!XW5ZW7C58QA4E&#NEL^Y[%*4IP4IJS?0\J^+'[2_PY
M^"5S!:>+_$4=AJ%PF^.RA@DN)RO][;&K;1[MBJ_PI_:C^&7QHU.;3/"GB..[
MU2)=_P!BG@DMY74=T$BC</\ =KS;P=^R1<S?M)>._B-\0(-!\4:;JA(T>UF#
M7#VZY55\R.2/8&6-%48+5X-\<]/\'>!?VYOA,W@)-+T^ZGU*PBU6TT<*D22/
M=^4VY8^%=HV.1^)ZU[='"82O^Z@VY*-[JUKVO:UOE<\:KBL51_>3247*UM;V
MO:_ZGW3\2?BWX1^#^E6FH^+]9CT2SN9OL\,TJ2.&DVEMOR ]@:X#QW^VA\(?
MASKDFCZMXKCDOT_UT-C:RW/DGT=HU(#?[/4=Z\<_X*I?\D>\)_\ 8>_]MIJ]
M=^&7[)7PS\/?"RPT"Y\(Z3K$ES91_;]0OK99+BYE9/F?S3\R\YV[3\O:L88?
M"TL-3Q%?F?,VK*W3KK_3-95\34Q$Z%&RY4G=WZ^AZEX!^(OAWXH>&K?7_"VK
M0:UI,^Y5G@S]X=596P5;_989KF_BS^T)X ^"$=F/&/B&/3+B[^:WM8XY)IW7
M^]Y<8+;?<\5\I_\ !+.66V?XKZ.'=[&SNK%H5?LS?:E8_B(TK%^!WA33OVG_
M -M#XF>)_%EG#K>BZ \D-G8W2;[?Y9/)MMR'Y679'(VW^]S6\LNI4<16C4DW
M"FD]-W>UE^)C''U:M"C*"7/-V\E:]W^!<_;O^.O@GXV_LX:1>>#]<CU5+7Q3
M;+<P>6\4L.;2[QN1P#SZ]*^TO@O_ ,D=\"_]@*P_])TKX<_X*3? ;POX.\.>
M&_&GAO1K+0Y9[[^R[Z#3X%BBFW1O)&^Q<#<OER<]]W-?<?P7_P"2.^!?^P%8
M?^DZ4\8J7]GT71O;FEONMM/,6$=3Z]556UTEMLSM:_-GX>^%HOVS?VSO&6K^
M*/,U+P=X::1+>R=OW+Q))Y5O%[*^))3Z\^M?I-7Y\_\ !*..6?\ X6G?3'>T
MKZ<N\_>W?Z4S?^A"L\ W2PV)Q$?B227_ &\[,UQT55Q&'H2^%MM_):?F>W_M
M%_LD?#WQ?\)M?71O".D>'M=L;*6[T^]TBQCM7\V-=RQML W(V-N#ZY'-9/\
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M !;\(V'P2\6> KC6(X_%U_#87-MI923?)$+V)]P;&WI&_?\ AKQW_@H_\/\
MP[\,-4^'7BGPGHUEH&L-<S[Y-.@6W5S#Y3Q,53'S*?XNOY#'M7_!0;X8^%K_
M .!'B[QI/H=I-XILX;&VM]5<?O8XS>Q*5!^DK_\ ?5=%##X:G7PM>'-RS>VE
MTTUOMIJ95J^(G1Q%&=N:"U?DT]O,=^PI\:?!>H_!_P %> K77(9O%]K9S/-I
M8CDWHHFD?[VW;]UAWKTKXF_M;_"WX0ZU_8WB3Q1%%JR\RV=I!)<O#_O^6IV_
M0\UYS^PW\)/"=A\#?!OC:R\/62>+KBRN(WU3#+-(//D7!/IA5KP#_@GOI_@;
MQIXV\=2?$&WT[5_'EU<*]M!KR1RN^6D\\QK)UDW_ 'OXOUI5,-AZM;$5WS.,
M'JM+MMO\$%/$8BE2H4?=YI[-WM9)?BS[A^%7[07@+XVP7#>#_$$&IRVR[I[6
M1&AN(U]3'( V/?I7I5?+=A^R+/X-_:JTSXE^#9]*\/>&%MFBU#1;:-HFF=XG
M1]B*NP+_ *M\?WES7U)7BXF%"$D\/*\6D]=T^S/8PTZTHM5U:2=M-GYH****
MY#L/B#]M7]L#QW^S]\5=+\/>%X-'DT^ZT:/4'-_:M*_FM-/'U$B_+B-:\"_X
M><?%_P#Y]/#7_@NE_P#CM:/_  5+_P"3@- _[%BV_P#2N[KXWK],RW+L+5P=
M.=2FFVM['YQF&/Q5/%5(0J-),^M_^'G'Q?\ ^?3PU_X+I?\ X[1_P\X^+_\
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M):5YG$'^Y/U7YGHY%_OJ]&?9-%%%?F)^E!1110 4444 %%%% !1110 4444
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M5?687(9XFC"LJMKJ]K?\$^6Q.=PP]:5)T[V??_@'[N?\(]I7_0-L_P#OPO\
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M-6M_'EC9.1]S44DM-O\ W]517XPT5\]5X>P=1WA>/H_\[GNTL^Q=/25I>O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH _+3_@J7_P G :!_V+%M_P"E=W7QO7ZU?M2_\E!L/^P9'_Z,FKQVOT7+
M\P]EA*<.2]EW_P" ?GV/P'M,3.?-N^W_  3\]Z*_0BBO0_M3^Y^/_ .#^S?[
M_P"'_!/SWHK]"**/[4_N?C_P _LW^_\ A_P3\]Z*_0BBC^U/[GX_\ /[-_O_
M (?\$_/>BOT(HH_M3^Y^/_ #^S?[_P"'_!/SWHK]"**/[4_N?C_P _LW^_\
MA_P3\]Z*_0BBC^U/[GX_\ /[-_O_ (?\$_/>BOT(HH_M3^Y^/_ #^S?[_P"'
M_!/SWHK]"**/[4_N?C_P _LW^_\ A_P3\]Z*_0BBC^U/[GX_\ /[-_O_ (?\
M$_/>OU*_X)9_\F_Z_P#]C1<?^DEI7GM?4?[+/_)/K_\ ["<G_HJ*O$SC'>WP
MKARVU77_ (![.4X+V&)4^:^CZ?\ !/:****^%/MPHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
5BB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>17
<FILENAME>telo-20251231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.4b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWa+KybP9z5Z8mekhvWB1bUnKzy4v4KDA9Csyrnpm8a0P -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:TELO="http://telomirpharma.com/20251231" elementFormDefault="qualified" targetNamespace="http://telomirpharma.com/20251231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://telomirpharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Statements of Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquity" id="StatementsOfChangesInStockholdersEquity">
          <link:definition>00000005 - Statement - Statements of Changes in Stockholders' Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" id="DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies">
          <link:definition>999014 - Disclosure - Description of business and summary of significant accounting policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/GoingConcern" id="GoingConcern">
          <link:definition>999015 - Disclosure - Going Concern</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/LicenseAgreementRelatedParty" id="LicenseAgreementRelatedParty">
          <link:definition>999016 - Disclosure - License agreement, related party</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactions" id="RelatedPartiesBalancesAndTransactions">
          <link:definition>999017 - Disclosure - Related parties balances and transactions</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/ProposedMergerAgreement" id="ProposedMergerAgreement">
          <link:definition>999018 - Disclosure - Proposed Merger Agreement</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/Leases" id="Leases">
          <link:definition>999019 - Disclosure - Leases</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>999020 - Disclosure - Stockholders&#8217; equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999021 - Disclosure - Income Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" id="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999022 - Disclosure - Description of business and summary of significant accounting policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/LeasesTables" id="LeasesTables">
          <link:definition>999023 - Disclosure - Leases (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
          <link:definition>999024 - Disclosure - Stockholders&#8217; equity (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999025 - Disclosure - Income Taxes (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" id="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999026 - Disclosure - Description of business and summary of significant accounting policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/GoingConcernDetailsNarrative" id="GoingConcernDetailsNarrative">
          <link:definition>999027 - Disclosure - Going Concern (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative" id="LicenseAgreementRelatedPartyDetailsNarrative">
          <link:definition>999028 - Disclosure - License agreement, related party (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative" id="RelatedPartiesBalancesAndTransactionsDetailsNarrative">
          <link:definition>999029 - Disclosure - Related parties balances and transactions (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/ProposedMergerAgreementDetailsNarrative" id="ProposedMergerAgreementDetailsNarrative">
          <link:definition>999030 - Disclosure - Proposed Merger Agreement (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>999031 - Disclosure - Leases (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/ScheduleOfComponentsOfLeaseExpensesDetails" id="ScheduleOfComponentsOfLeaseExpensesDetails">
          <link:definition>999032 - Disclosure - Schedule of Components of Lease Expenses (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails" id="ScheduleOfWarrantActivityDetails">
          <link:definition>999033 - Disclosure - Schedule of Warrant Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical" id="ScheduleOfWarrantActivityDetailsParenthetical">
          <link:definition>999034 - Disclosure - Schedule of warrant activity (Details) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails" id="ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails">
          <link:definition>999035 - Disclosure - Schedule of Key Assumptions Used to Value Warrants (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails" id="ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails">
          <link:definition>999036 - Disclosure - Schedule of Key Assumptions Used to Value Stock Options (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/ScheduleOfIssuedStockOptionsDetails" id="ScheduleOfIssuedStockOptionsDetails">
          <link:definition>999037 - Disclosure - Schedule of Issued Stock Options (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/ScheduleOfStockOptionActivityDetails" id="ScheduleOfStockOptionActivityDetails">
          <link:definition>999038 - Disclosure - Schedule of Stock Option Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>999039 - Disclosure - Stockholders&#8217; equity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails" id="ScheduleOfNetDeferredTaxAssetsDetails">
          <link:definition>999040 - Disclosure - Schedule of Net Deferred Tax Assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails" id="ScheduleOfProvisionForIncomeTaxesDetails">
          <link:definition>999041 - Disclosure - Schedule of Provision for Income Taxes (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails" id="ScheduleOfReconciliationEffectiveIncomeTaxRateDetails">
          <link:definition>999042 - Disclosure - Schedule of Reconciliation Effective Income Tax Rate (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999043 - Disclosure - Income Taxes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="telo-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="telo-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="telo-20251231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="telo-20251231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://xbrl.sec.gov/cyd/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd" />
    <element id="TELO_MiralogxLLCMember" name="MiralogxLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_BayshorefinancingMember" name="BayshorefinancingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_BayShoreTrustMember" name="BayShoreTrustMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_StarwoodTrustMember" name="StarwoodTrustMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_TeliPharmaceuticalsIncMember" name="TeliPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_TelomirOneMember" name="TelomirOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_PhaseOneByTwoMember" name="PhaseOneByTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_TampaFloridaMember" name="TampaFloridaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_AtTheMarketOfferingAgreementMember" name="AtTheMarketOfferingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_AtTheMarketOfferingMember" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_PlacementAgentMember" name="PlacementAgentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_TwoThousandTwentyThreeOmnibusIncentivePlanMember" name="TwoThousandTwentyThreeOmnibusIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_UnderwriterWarrantMember" name="UnderwriterWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_BayShoreTrustWarrantsMember" name="BayShoreTrustWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_TwoThousandTwentyThreePrivatePlacementWarrantsMember" name="TwoThousandTwentyThreePrivatePlacementWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_MeasurementInputFairMarketValueUnderlyingCommonStockMember" name="MeasurementInputFairMarketValueUnderlyingCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_MayThirteenMember" name="MayThirteenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_MayTwentySevenMember" name="MayTwentySevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_OctoberFifteenMember" name="OctoberFifteenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_DueToOfficer" name="DueToOfficer" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_AccruedCompensation" name="AccruedCompensation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_IncreaseDecreaseInAccruedCompensation" name="IncreaseDecreaseInAccruedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_ProceedsFromRepaymentsOfOfficer" name="ProceedsFromRepaymentsOfOfficer" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_ProceedsFromSaleOfCommonStockRelatedParty" name="ProceedsFromSaleOfCommonStockRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_ProceedsFromSaleOfCommonStock" name="ProceedsFromSaleOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_DeferredOfferingCostsChargedToAdditionalPaidinCapital" name="DeferredOfferingCostsChargedToAdditionalPaidinCapital" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_NoInsiderTradingFlag" name="NoInsiderTradingFlag" nillable="true" xbrli:periodType="duration" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_DisclosureLicenseAgreementRelatedPartyAbstract" name="DisclosureLicenseAgreementRelatedPartyAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_LicenseAgreementRelatedPartyTextBlock" name="LicenseAgreementRelatedPartyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_DisclosureProposedMergerAgreementAbstract" name="DisclosureProposedMergerAgreementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_ProposedMergerAgreementDisclosureTextBlock" name="ProposedMergerAgreementDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_InitialPublicOfferingPolicyTextBlock" name="InitialPublicOfferingPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_ProposedMergerPolicyTextBlock" name="ProposedMergerPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock" name="RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_ProceedsFromInitialPublicOfferingNetProceeds" name="ProceedsFromInitialPublicOfferingNetProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_LicenseAgreementRelatedPartyDetailsNarrativeTable" name="LicenseAgreementRelatedPartyDetailsNarrativeTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="TELO_LicenseAgreementRelatedPartyDetailsNarrativeLineItems" name="LicenseAgreementRelatedPartyDetailsNarrativeLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_PercentageOfRoyaltyPayable" name="PercentageOfRoyaltyPayable" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardPriceOfCommonStockPercent" name="SharebasedCompensationArrangementBySharebasedPaymentAwardPriceOfCommonStockPercent" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_LeasesDetailsNarrativeTable" name="LeasesDetailsNarrativeTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="TELO_LeasesDetailsNarrativeLineItems" name="LeasesDetailsNarrativeLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_ScheduleOfKeyAssumptionsUsedToValueStockOptionsTable" name="ScheduleOfKeyAssumptionsUsedToValueStockOptionsTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="TELO_ScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems" name="ScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_OfferingCosts" name="OfferingCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>18
<FILENAME>telo-20251231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.4b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#Cover" roleURI="http://telomirpharma.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#BalanceSheets" roleURI="http://telomirpharma.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#BalanceSheetsParenthetical" roleURI="http://telomirpharma.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#StatementsOfOperations" roleURI="http://telomirpharma.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#StatementsOfChangesInStockholdersEquity" roleURI="http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#StatementsOfCashFlows" roleURI="http://telomirpharma.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" roleURI="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#GoingConcern" roleURI="http://telomirpharma.com/role/GoingConcern" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#LicenseAgreementRelatedParty" roleURI="http://telomirpharma.com/role/LicenseAgreementRelatedParty" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#RelatedPartiesBalancesAndTransactions" roleURI="http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ProposedMergerAgreement" roleURI="http://telomirpharma.com/role/ProposedMergerAgreement" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#Leases" roleURI="http://telomirpharma.com/role/Leases" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#StockholdersEquity" roleURI="http://telomirpharma.com/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#IncomeTaxes" roleURI="http://telomirpharma.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#LeasesTables" roleURI="http://telomirpharma.com/role/LeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#StockholdersEquityTables" roleURI="http://telomirpharma.com/role/StockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#IncomeTaxesTables" roleURI="http://telomirpharma.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#GoingConcernDetailsNarrative" roleURI="http://telomirpharma.com/role/GoingConcernDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#LicenseAgreementRelatedPartyDetailsNarrative" roleURI="http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#RelatedPartiesBalancesAndTransactionsDetailsNarrative" roleURI="http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ProposedMergerAgreementDetailsNarrative" roleURI="http://telomirpharma.com/role/ProposedMergerAgreementDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#LeasesDetailsNarrative" roleURI="http://telomirpharma.com/role/LeasesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ScheduleOfComponentsOfLeaseExpensesDetails" roleURI="http://telomirpharma.com/role/ScheduleOfComponentsOfLeaseExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ScheduleOfWarrantActivityDetails" roleURI="http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ScheduleOfWarrantActivityDetailsParenthetical" roleURI="http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails" roleURI="http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails" roleURI="http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ScheduleOfIssuedStockOptionsDetails" roleURI="http://telomirpharma.com/role/ScheduleOfIssuedStockOptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ScheduleOfStockOptionActivityDetails" roleURI="http://telomirpharma.com/role/ScheduleOfStockOptionActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#StockholdersEquityDetailsNarrative" roleURI="http://telomirpharma.com/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ScheduleOfNetDeferredTaxAssetsDetails" roleURI="http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ScheduleOfProvisionForIncomeTaxesDetails" roleURI="http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ScheduleOfReconciliationEffectiveIncomeTaxRateDetails" roleURI="http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#IncomeTaxesDetailsNarrative" roleURI="http://telomirpharma.com/role/IncomeTaxesDetailsNarrative" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_DueToOfficer" xlink:label="loc_TELODueToOfficer" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_TELODueToOfficer" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_AccruedCompensation" xlink:label="loc_TELOAccruedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_TELOAccruedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="loc_us-gaapTravelAndEntertainmentExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapTravelAndEntertainmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Statements of Changes in Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForOtherCreditLosses" xlink:label="loc_us-gaapProvisionForOtherCreditLosses" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForOtherCreditLosses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueToOtherRelatedParties" xlink:label="loc_us-gaapIncreaseDecreaseInDueToOtherRelatedParties" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDueToOtherRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_IncreaseDecreaseInAccruedCompensation" xlink:label="loc_TELOIncreaseDecreaseInAccruedCompensation" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_TELOIncreaseDecreaseInAccruedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ProceedsFromRepaymentsOfOfficer" xlink:label="loc_TELOProceedsFromRepaymentsOfOfficer" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_TELOProceedsFromRepaymentsOfOfficer" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ProceedsFromSaleOfCommonStockRelatedParty" xlink:label="loc_TELOProceedsFromSaleOfCommonStockRelatedParty" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_TELOProceedsFromSaleOfCommonStockRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ProceedsFromSaleOfCommonStock" xlink:label="loc_TELOProceedsFromSaleOfCommonStock" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_TELOProceedsFromSaleOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:title="999014 - Disclosure - Description of business and summary of significant accounting policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/GoingConcern" xlink:title="999015 - Disclosure - Going Concern" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/LicenseAgreementRelatedParty" xlink:title="999016 - Disclosure - License agreement, related party" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactions" xlink:title="999017 - Disclosure - Related parties balances and transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ProposedMergerAgreement" xlink:title="999018 - Disclosure - Proposed Merger Agreement" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/Leases" xlink:title="999019 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StockholdersEquity" xlink:title="999020 - Disclosure - Stockholders&#8217; equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/IncomeTaxes" xlink:title="999021 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999022 - Disclosure - Description of business and summary of significant accounting policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/LeasesTables" xlink:title="999023 - Disclosure - Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StockholdersEquityTables" xlink:title="999024 - Disclosure - Stockholders&#8217; equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/IncomeTaxesTables" xlink:title="999025 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999026 - Disclosure - Description of business and summary of significant accounting policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/GoingConcernDetailsNarrative" xlink:title="999027 - Disclosure - Going Concern (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative" xlink:title="999028 - Disclosure - License agreement, related party (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative" xlink:title="999029 - Disclosure - Related parties balances and transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ProposedMergerAgreementDetailsNarrative" xlink:title="999030 - Disclosure - Proposed Merger Agreement (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/LeasesDetailsNarrative" xlink:title="999031 - Disclosure - Leases (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfComponentsOfLeaseExpensesDetails" xlink:title="999032 - Disclosure - Schedule of Components of Lease Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaapVariableLeaseCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapVariableLeaseCost" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999033 - Disclosure - Schedule of Warrant Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical" xlink:title="999034 - Disclosure - Schedule of warrant activity (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails" xlink:title="999035 - Disclosure - Schedule of Key Assumptions Used to Value Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails" xlink:title="999036 - Disclosure - Schedule of Key Assumptions Used to Value Stock Options (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfIssuedStockOptionsDetails" xlink:title="999037 - Disclosure - Schedule of Issued Stock Options (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999038 - Disclosure - Schedule of Stock Option Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="999039 - Disclosure - Stockholders&#8217; equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails" xlink:title="999040 - Disclosure - Schedule of Net Deferred Tax Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="999041 - Disclosure - Schedule of Provision for Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails" xlink:title="999042 - Disclosure - Schedule of Reconciliation Effective Income Tax Rate (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItems" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="999043 - Disclosure - Income Taxes (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>19
<FILENAME>telo-20251231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.4b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#Cover" roleURI="http://telomirpharma.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#BalanceSheets" roleURI="http://telomirpharma.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#BalanceSheetsParenthetical" roleURI="http://telomirpharma.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#StatementsOfOperations" roleURI="http://telomirpharma.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#StatementsOfChangesInStockholdersEquity" roleURI="http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#StatementsOfCashFlows" roleURI="http://telomirpharma.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" roleURI="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#GoingConcern" roleURI="http://telomirpharma.com/role/GoingConcern" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#LicenseAgreementRelatedParty" roleURI="http://telomirpharma.com/role/LicenseAgreementRelatedParty" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#RelatedPartiesBalancesAndTransactions" roleURI="http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ProposedMergerAgreement" roleURI="http://telomirpharma.com/role/ProposedMergerAgreement" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#Leases" roleURI="http://telomirpharma.com/role/Leases" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#StockholdersEquity" roleURI="http://telomirpharma.com/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#IncomeTaxes" roleURI="http://telomirpharma.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#LeasesTables" roleURI="http://telomirpharma.com/role/LeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#StockholdersEquityTables" roleURI="http://telomirpharma.com/role/StockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#IncomeTaxesTables" roleURI="http://telomirpharma.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#GoingConcernDetailsNarrative" roleURI="http://telomirpharma.com/role/GoingConcernDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#LicenseAgreementRelatedPartyDetailsNarrative" roleURI="http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#RelatedPartiesBalancesAndTransactionsDetailsNarrative" roleURI="http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ProposedMergerAgreementDetailsNarrative" roleURI="http://telomirpharma.com/role/ProposedMergerAgreementDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#LeasesDetailsNarrative" roleURI="http://telomirpharma.com/role/LeasesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ScheduleOfComponentsOfLeaseExpensesDetails" roleURI="http://telomirpharma.com/role/ScheduleOfComponentsOfLeaseExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ScheduleOfWarrantActivityDetails" roleURI="http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ScheduleOfWarrantActivityDetailsParenthetical" roleURI="http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails" roleURI="http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails" roleURI="http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ScheduleOfIssuedStockOptionsDetails" roleURI="http://telomirpharma.com/role/ScheduleOfIssuedStockOptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ScheduleOfStockOptionActivityDetails" roleURI="http://telomirpharma.com/role/ScheduleOfStockOptionActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#StockholdersEquityDetailsNarrative" roleURI="http://telomirpharma.com/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ScheduleOfNetDeferredTaxAssetsDetails" roleURI="http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ScheduleOfProvisionForIncomeTaxesDetails" roleURI="http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ScheduleOfReconciliationEffectiveIncomeTaxRateDetails" roleURI="http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#IncomeTaxesDetailsNarrative" roleURI="http://telomirpharma.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpExecutiveCategoriesOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly" roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTypeOnly" roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TradingArrangmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_TELOStockIssuedDuringPeriodValueWarrantsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TELOStockIssuedDuringPeriodValueWarrantsExercised_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_TELOStockIssuedDuringPeriodSharesWarrantsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TELOStockIssuedDuringPeriodSharesWarrantsExercised_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_50" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:title="999014 - Disclosure - Description of business and summary of significant accounting policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/GoingConcern" xlink:title="999015 - Disclosure - Going Concern" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/LicenseAgreementRelatedParty" xlink:title="999016 - Disclosure - License agreement, related party" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactions" xlink:title="999017 - Disclosure - Related parties balances and transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ProposedMergerAgreement" xlink:title="999018 - Disclosure - Proposed Merger Agreement" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/Leases" xlink:title="999019 - Disclosure - Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StockholdersEquity" xlink:title="999020 - Disclosure - Stockholders&#8217; equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/IncomeTaxes" xlink:title="999021 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999022 - Disclosure - Description of business and summary of significant accounting policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/LeasesTables" xlink:title="999023 - Disclosure - Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StockholdersEquityTables" xlink:title="999024 - Disclosure - Stockholders&#8217; equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_UnderwriterWarrantMember" xlink:label="loc_TELOUnderwriterWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_TELOUnderwriterWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_30" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/IncomeTaxesTables" xlink:title="999025 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999026 - Disclosure - Description of business and summary of significant accounting policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharePrice_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherUnderwritingExpense" xlink:label="loc_us-gaapOtherUnderwritingExpense_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapOtherUnderwritingExpense_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ProceedsFromInitialPublicOfferingNetProceeds" xlink:label="loc_TELOProceedsFromInitialPublicOfferingNetProceeds_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_TELOProceedsFromInitialPublicOfferingNetProceeds_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCashUninsuredAmount_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_100" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/GoingConcernDetailsNarrative" xlink:title="999027 - Disclosure - Going Concern (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative" xlink:title="999028 - Disclosure - License agreement, related party (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_LicenseAgreementRelatedPartyDetailsNarrativeLineItems" xlink:label="loc_TELOLicenseAgreementRelatedPartyDetailsNarrativeLineItems" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_LicenseAgreementRelatedPartyDetailsNarrativeTable" xlink:label="loc_TELOLicenseAgreementRelatedPartyDetailsNarrativeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_TELOLicenseAgreementRelatedPartyDetailsNarrativeLineItems" xlink:to="loc_TELOLicenseAgreementRelatedPartyDetailsNarrativeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_TELOLicenseAgreementRelatedPartyDetailsNarrativeTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_MiralogxLLCMember" xlink:label="loc_TELOMiralogxLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_TELOMiralogxLLCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_TELOLicenseAgreementRelatedPartyDetailsNarrativeTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TELOLicenseAgreementRelatedPartyDetailsNarrativeLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_PercentageOfRoyaltyPayable" xlink:label="loc_TELOPercentageOfRoyaltyPayable_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TELOLicenseAgreementRelatedPartyDetailsNarrativeLineItems" xlink:to="loc_TELOPercentageOfRoyaltyPayable_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative" xlink:title="999029 - Disclosure - Related parties balances and transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_BayshorefinancingMember" xlink:label="loc_TELOBayshorefinancingMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_TELOBayshorefinancingMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_BayShoreTrustMember" xlink:label="loc_TELOBayShoreTrustMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_TELOBayShoreTrustMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_StarwoodTrustMember" xlink:label="loc_TELOStarwoodTrustMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_TELOStarwoodTrustMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_220" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_220" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="loc_us-gaapDebtInstrumentRepurchaseAmount_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentRepurchaseAmount_220" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedPayrollTaxesCurrentAndNoncurrent_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccruedPayrollTaxesCurrentAndNoncurrent_220" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesOther" xlink:label="loc_us-gaapTaxesOther_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapTaxesOther_220" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherReceivablesNetCurrent_220" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherReceivables_220" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaapCostsAndExpensesRelatedParty_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCostsAndExpensesRelatedParty_220" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_220" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_220" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_220" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardPriceOfCommonStockPercent" xlink:label="loc_TELOSharebasedCompensationArrangementBySharebasedPaymentAwardPriceOfCommonStockPercent_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TELOSharebasedCompensationArrangementBySharebasedPaymentAwardPriceOfCommonStockPercent_220" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharePrice_220" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_220" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_220" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_220" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_220" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_220" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_220" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_220" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_220" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="loc_us-gaapTravelAndEntertainmentExpense_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapTravelAndEntertainmentExpense_220" xlink:type="arc" order="21" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ProposedMergerAgreementDetailsNarrative" xlink:title="999030 - Disclosure - Proposed Merger Agreement (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaapRestructuringCostAndReserveLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_TeliPharmaceuticalsIncMember" xlink:label="loc_TELOTeliPharmaceuticalsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_TELOTeliPharmaceuticalsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_LicenseAgreementMember" xlink:label="loc_TELOLicenseAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TELOLicenseAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaapAssetAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapAssetAcquisitionAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_TelomirOneMember" xlink:label="loc_TELOTelomirOneMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionDomain" xlink:to="loc_TELOTelomirOneMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_PhaseOneByTwoMember" xlink:label="loc_TELOPhaseOneByTwoMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionDomain" xlink:to="loc_TELOPhaseOneByTwoMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferredTransactionCost_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferredTransactionCost_60" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/LeasesDetailsNarrative" xlink:title="999031 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_LeasesDetailsNarrativeLineItems" xlink:label="loc_TELOLeasesDetailsNarrativeLineItems" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_LeasesDetailsNarrativeTable" xlink:label="loc_TELOLeasesDetailsNarrativeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_TELOLeasesDetailsNarrativeLineItems" xlink:to="loc_TELOLeasesDetailsNarrativeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_TELOLeasesDetailsNarrativeTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_MiralogxLLCMember" xlink:label="loc_TELOMiralogxLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_TELOMiralogxLLCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_TELOLeasesDetailsNarrativeTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_TampaFloridaMember" xlink:label="loc_TELOTampaFloridaMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_TELOTampaFloridaMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaapVariableLeaseCost_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TELOLeasesDetailsNarrativeLineItems" xlink:to="loc_us-gaapVariableLeaseCost_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfComponentsOfLeaseExpensesDetails" xlink:title="999032 - Disclosure - Schedule of Components of Lease Expenses (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999033 - Disclosure - Schedule of Warrant Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_TELOShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_TELOShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_TELOSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_TELOSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_TELOShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_TELOShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:label="loc_TELOSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_TELOSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical" xlink:title="999034 - Disclosure - Schedule of warrant activity (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_BayShoreTrustWarrantsMember" xlink:label="loc_TELOBayShoreTrustWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TELOBayShoreTrustWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_TwoThousandTwentyThreePrivatePlacementWarrantsMember" xlink:label="loc_TELOTwoThousandTwentyThreePrivatePlacementWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TELOTwoThousandTwentyThreePrivatePlacementWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_UnderwriterWarrantMember" xlink:label="loc_TELOUnderwriterWarrantMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TELOUnderwriterWarrantMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails" xlink:title="999035 - Disclosure - Schedule of Key Assumptions Used to Value Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_UnderwriterWarrantMember" xlink:label="loc_TELOUnderwriterWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_TELOUnderwriterWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_MeasurementInputFairMarketValueUnderlyingCommonStockMember" xlink:label="loc_TELOMeasurementInputFairMarketValueUnderlyingCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_TELOMeasurementInputFairMarketValueUnderlyingCommonStockMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_60" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails" xlink:title="999036 - Disclosure - Schedule of Key Assumptions Used to Value Stock Options (Details)">
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems" xlink:label="loc_TELOScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ScheduleOfKeyAssumptionsUsedToValueStockOptionsTable" xlink:label="loc_TELOScheduleOfKeyAssumptionsUsedToValueStockOptionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_TELOScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems" xlink:to="loc_TELOScheduleOfKeyAssumptionsUsedToValueStockOptionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_TELOScheduleOfKeyAssumptionsUsedToValueStockOptionsTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TELOScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TELOScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TELOScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TELOScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TELOScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TELOScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TELOScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_70" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfIssuedStockOptionsDetails" xlink:title="999037 - Disclosure - Schedule of Issued Stock Options (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_MayThirteenMember" xlink:label="loc_TELOMayThirteenMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_TELOMayThirteenMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_MayTwentySevenMember" xlink:label="loc_TELOMayTwentySevenMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_TELOMayTwentySevenMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_OctoberFifteenMember" xlink:label="loc_TELOOctoberFifteenMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_TELOOctoberFifteenMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:label="loc_TELOShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_TELOShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999038 - Disclosure - Schedule of Stock Option Activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="999039 - Disclosure - Stockholders&#8217; equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_AtTheMarketOfferingMember" xlink:label="loc_TELOAtTheMarketOfferingMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_TELOAtTheMarketOfferingMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_StarwoodTrustMember" xlink:label="loc_TELOStarwoodTrustMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_TELOStarwoodTrustMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_BayShoreTrustMember" xlink:label="loc_TELOBayShoreTrustMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_TELOBayShoreTrustMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_AtTheMarketOfferingAgreementMember" xlink:label="loc_TELOAtTheMarketOfferingAgreementMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TELOAtTheMarketOfferingAgreementMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_230" xlink:type="arc" order="232" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_PlacementAgentMember" xlink:label="loc_TELOPlacementAgentMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TELOPlacementAgentMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_TwoThousandTwentyThreeOmnibusIncentivePlanMember" xlink:label="loc_TELOTwoThousandTwentyThreeOmnibusIncentivePlanMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_TELOTwoThousandTwentyThreeOmnibusIncentivePlanMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_280" xlink:type="arc" order="282" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_300" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_300" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_300" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_300" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharePrice_300" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_300" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherUnderwritingExpense" xlink:label="loc_us-gaapOtherUnderwritingExpense_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapOtherUnderwritingExpense_300" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ProceedsFromInitialPublicOfferingNetProceeds" xlink:label="loc_TELOProceedsFromInitialPublicOfferingNetProceeds_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_TELOProceedsFromInitialPublicOfferingNetProceeds_300" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_300" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts_300" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_OfferingCosts" xlink:label="loc_TELOOfferingCosts_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_TELOOfferingCosts_300" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_300" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_300" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_300" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_300" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_300" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_300" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_300" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_300" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_300" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_300" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_300" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_300" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_300" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_300" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaapDeferredFinanceCostsNet_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsNet_300" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_300" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_300" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_300" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_300" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_300" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_300" xlink:type="arc" order="31" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails" xlink:title="999040 - Disclosure - Schedule of Net Deferred Tax Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="999041 - Disclosure - Schedule of Provision for Income Taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails" xlink:title="999042 - Disclosure - Schedule of Reconciliation Effective Income Tax Rate (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="999043 - Disclosure - Income Taxes (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>20
<FILENAME>telo-20251231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.4b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_MiralogxLLCMember" xlink:label="TELO_MiralogxLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_MiralogxLLCMember" xlink:to="TELO_MiralogxLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_MiralogxLLCMember_lbl" xml:lang="en-US">MIRALOGX, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_BayshorefinancingMember" xlink:label="TELO_BayshorefinancingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_BayshorefinancingMember" xlink:to="TELO_BayshorefinancingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_BayshorefinancingMember_lbl" xml:lang="en-US">Bayshore Financing [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_BayShoreTrustMember" xlink:label="TELO_BayShoreTrustMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_BayShoreTrustMember" xlink:to="TELO_BayShoreTrustMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_BayShoreTrustMember_lbl" xml:lang="en-US">Bay Shore Trust [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_StarwoodTrustMember" xlink:label="TELO_StarwoodTrustMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_StarwoodTrustMember" xlink:to="TELO_StarwoodTrustMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_StarwoodTrustMember_lbl" xml:lang="en-US">Starwood Trust [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Combination [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_TeliPharmaceuticalsIncMember" xlink:label="TELO_TeliPharmaceuticalsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_TeliPharmaceuticalsIncMember" xlink:to="TELO_TeliPharmaceuticalsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_TeliPharmaceuticalsIncMember_lbl" xml:lang="en-US">TELI Pharmaceuticals, Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_LicenseAgreementMember" xlink:label="TELO_LicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_LicenseAgreementMember" xlink:to="TELO_LicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_TelomirOneMember" xlink:label="TELO_TelomirOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_TelomirOneMember" xlink:to="TELO_TelomirOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_TelomirOneMember_lbl" xml:lang="en-US">Telomir-1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_PhaseOneByTwoMember" xlink:label="TELO_PhaseOneByTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_PhaseOneByTwoMember" xlink:to="TELO_PhaseOneByTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_PhaseOneByTwoMember_lbl" xml:lang="en-US">Phase 1/2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_TampaFloridaMember" xlink:label="TELO_TampaFloridaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_TampaFloridaMember" xlink:to="TELO_TampaFloridaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_TampaFloridaMember_lbl" xml:lang="en-US">Tampa, Florida [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_AtTheMarketOfferingAgreementMember" xlink:label="TELO_AtTheMarketOfferingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_AtTheMarketOfferingAgreementMember" xlink:to="TELO_AtTheMarketOfferingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_AtTheMarketOfferingAgreementMember_lbl" xml:lang="en-US">At The Market Offering Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_AtTheMarketOfferingMember" xlink:label="TELO_AtTheMarketOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_AtTheMarketOfferingMember" xlink:to="TELO_AtTheMarketOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_AtTheMarketOfferingMember_lbl" xml:lang="en-US">At The Market Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_PlacementAgentMember" xlink:label="TELO_PlacementAgentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_PlacementAgentMember" xlink:to="TELO_PlacementAgentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_PlacementAgentMember_lbl" xml:lang="en-US">Placement Agent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_TwoThousandTwentyThreeOmnibusIncentivePlanMember" xlink:label="TELO_TwoThousandTwentyThreeOmnibusIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_TwoThousandTwentyThreeOmnibusIncentivePlanMember" xlink:to="TELO_TwoThousandTwentyThreeOmnibusIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_TwoThousandTwentyThreeOmnibusIncentivePlanMember_lbl" xml:lang="en-US">2023 Omnibus Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_UnderwriterWarrantMember" xlink:label="TELO_UnderwriterWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_UnderwriterWarrantMember" xlink:to="TELO_UnderwriterWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_UnderwriterWarrantMember_lbl" xml:lang="en-US">Underwriter Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_BayShoreTrustWarrantsMember" xlink:label="TELO_BayShoreTrustWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_BayShoreTrustWarrantsMember" xlink:to="TELO_BayShoreTrustWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_BayShoreTrustWarrantsMember_lbl" xml:lang="en-US">Bay Shore Trust Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_TwoThousandTwentyThreePrivatePlacementWarrantsMember" xlink:label="TELO_TwoThousandTwentyThreePrivatePlacementWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_TwoThousandTwentyThreePrivatePlacementWarrantsMember" xlink:to="TELO_TwoThousandTwentyThreePrivatePlacementWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_TwoThousandTwentyThreePrivatePlacementWarrantsMember_lbl" xml:lang="en-US">2023 Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_MeasurementInputFairMarketValueUnderlyingCommonStockMember" xlink:label="TELO_MeasurementInputFairMarketValueUnderlyingCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_MeasurementInputFairMarketValueUnderlyingCommonStockMember" xlink:to="TELO_MeasurementInputFairMarketValueUnderlyingCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_MeasurementInputFairMarketValueUnderlyingCommonStockMember_lbl" xml:lang="en-US">Measurement Input Fair Market Value Underlying Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_MayThirteenMember" xlink:label="TELO_MayThirteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_MayThirteenMember" xlink:to="TELO_MayThirteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_MayThirteenMember_lbl" xml:lang="en-US">May 13 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_MayTwentySevenMember" xlink:label="TELO_MayTwentySevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_MayTwentySevenMember" xlink:to="TELO_MayTwentySevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_MayTwentySevenMember_lbl" xml:lang="en-US">May 27 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_OctoberFifteenMember" xlink:label="TELO_OctoberFifteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_OctoberFifteenMember" xlink:to="TELO_OctoberFifteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_OctoberFifteenMember_lbl" xml:lang="en-US">October 15 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Trade accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_DueToOfficer" xlink:label="TELO_DueToOfficer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_DueToOfficer" xlink:to="TELO_DueToOfficer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_DueToOfficer_lbl" xml:lang="en-US">Due to officer</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_AccruedCompensation" xlink:label="TELO_AccruedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_AccruedCompensation" xlink:to="TELO_AccruedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_AccruedCompensation_lbl" xml:lang="en-US">Accrued compensation - officer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Due to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, no par value, 100,000,000 shares authorized and none issued or outstanding.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, no par value; 300,000,000 shares authorized, 34,380,971 and 29,762,671 shares issued and outstanding at December 31, 2025 and 2024, respectively.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating costs:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="us-gaap_TravelAndEntertainmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TravelAndEntertainmentExpense" xlink:to="us-gaap_TravelAndEntertainmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TravelAndEntertainmentExpense_lbl" xml:lang="en-US">Related party travel costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic weighted average common stock shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted weighted average common stock shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock for cash in ATM, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock for cash in ATM, net, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="TELO_StockIssuedDuringPeriodValueWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="TELO_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="TELO_StockIssuedDuringPeriodSharesWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="TELO_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Exercise of Warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of common stock for cash, related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of common stock for cash, Related party, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock for services, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from Operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Issuance of common stock for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForOtherCreditLosses" xlink:label="us-gaap_ProvisionForOtherCreditLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForOtherCreditLosses" xlink:to="us-gaap_ProvisionForOtherCreditLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForOtherCreditLosses_lbl" xml:lang="en-US">Credit loss expenses - loan due from related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Trade accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueToOtherRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueToOtherRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToOtherRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToOtherRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDueToOtherRelatedParties_lbl" xml:lang="en-US">Due to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_IncreaseDecreaseInAccruedCompensation" xlink:label="TELO_IncreaseDecreaseInAccruedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_IncreaseDecreaseInAccruedCompensation" xlink:to="TELO_IncreaseDecreaseInAccruedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TELO_IncreaseDecreaseInAccruedCompensation_lbl" xml:lang="en-US">Accrued compensation - officer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from Financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xml:lang="en-US">Payments under related party line of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Repayments to related party</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ProceedsFromRepaymentsOfOfficer" xlink:label="TELO_ProceedsFromRepaymentsOfOfficer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_ProceedsFromRepaymentsOfOfficer" xlink:to="TELO_ProceedsFromRepaymentsOfOfficer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_ProceedsFromRepaymentsOfOfficer_lbl" xml:lang="en-US">Repayment from officer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from warrant exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ProceedsFromSaleOfCommonStockRelatedParty" xlink:label="TELO_ProceedsFromSaleOfCommonStockRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_ProceedsFromSaleOfCommonStockRelatedParty" xlink:to="TELO_ProceedsFromSaleOfCommonStockRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_ProceedsFromSaleOfCommonStockRelatedParty_lbl" xml:lang="en-US">Proceeds from sale of common stock, related party</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ProceedsFromSaleOfCommonStock" xlink:label="TELO_ProceedsFromSaleOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_ProceedsFromSaleOfCommonStock" xlink:to="TELO_ProceedsFromSaleOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_ProceedsFromSaleOfCommonStock_lbl" xml:lang="en-US">Net proceeds from sale of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash, beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash, end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Cash paid for income tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_DeferredOfferingCostsChargedToAdditionalPaidinCapital" xlink:label="TELO_DeferredOfferingCostsChargedToAdditionalPaidinCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_DeferredOfferingCostsChargedToAdditionalPaidinCapital" xlink:to="TELO_DeferredOfferingCostsChargedToAdditionalPaidinCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_DeferredOfferingCostsChargedToAdditionalPaidinCapital_lbl" xml:lang="en-US">Deferred offering costs charged to additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xml:lang="en-US">Aggregate Available</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_NoInsiderTradingFlag" xlink:label="TELO_NoInsiderTradingFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_NoInsiderTradingFlag" xlink:to="TELO_NoInsiderTradingFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_NoInsiderTradingFlag_lbl" xml:lang="en-US">No insider trading flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="cyd_MaterialCybersecurityIncidentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentAbstract" xlink:to="cyd_MaterialCybersecurityIncidentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentAbstract_lbl" xml:lang="en-US">Material Cybersecurity Incident [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Nature [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Scope [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Timing [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Description of business and summary of significant accounting policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">Going Concern</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_DisclosureLicenseAgreementRelatedPartyAbstract" xlink:label="TELO_DisclosureLicenseAgreementRelatedPartyAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_DisclosureLicenseAgreementRelatedPartyAbstract" xlink:to="TELO_DisclosureLicenseAgreementRelatedPartyAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_DisclosureLicenseAgreementRelatedPartyAbstract_lbl" xml:lang="en-US">License Agreement Related Party</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_LicenseAgreementRelatedPartyTextBlock" xlink:label="TELO_LicenseAgreementRelatedPartyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_LicenseAgreementRelatedPartyTextBlock" xlink:to="TELO_LicenseAgreementRelatedPartyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_LicenseAgreementRelatedPartyTextBlock_lbl" xml:lang="en-US">License agreement, related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related parties balances and transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_DisclosureProposedMergerAgreementAbstract" xlink:label="TELO_DisclosureProposedMergerAgreementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_DisclosureProposedMergerAgreementAbstract" xlink:to="TELO_DisclosureProposedMergerAgreementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_DisclosureProposedMergerAgreementAbstract_lbl" xml:lang="en-US">Proposed Merger Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ProposedMergerAgreementDisclosureTextBlock" xlink:label="TELO_ProposedMergerAgreementDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_ProposedMergerAgreementDisclosureTextBlock" xlink:to="TELO_ProposedMergerAgreementDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TELO_ProposedMergerAgreementDisclosureTextBlock_lbl" xml:lang="en-US">Proposed Merger Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_DisclosureLeasesAbstract" xlink:label="TELO_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_DisclosureLeasesAbstract" xlink:to="TELO_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Overview</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_InitialPublicOfferingPolicyTextBlock" xlink:label="TELO_InitialPublicOfferingPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_InitialPublicOfferingPolicyTextBlock" xlink:to="TELO_InitialPublicOfferingPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_InitialPublicOfferingPolicyTextBlock_lbl" xml:lang="en-US">Initial public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ProposedMergerPolicyTextBlock" xlink:label="TELO_ProposedMergerPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_ProposedMergerPolicyTextBlock" xlink:to="TELO_ProposedMergerPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_ProposedMergerPolicyTextBlock_lbl" xml:lang="en-US">Proposed merger</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value Measurements and Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="TELO_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="TELO_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xml:lang="en-US">Recent accounting pronouncements not yet adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Lease Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Warrant Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Key Assumptions Used to Value Stock Options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Issued Stock Options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Net Deferred Tax Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Provision for Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Reconciliation Effective Income Tax Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">IPO units, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Initial public offering shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherUnderwritingExpense" xlink:label="us-gaap_OtherUnderwritingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherUnderwritingExpense" xlink:to="us-gaap_OtherUnderwritingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherUnderwritingExpense_lbl" xml:lang="en-US">Underwriting commission and other offering expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ProceedsFromInitialPublicOfferingNetProceeds" xlink:label="TELO_ProceedsFromInitialPublicOfferingNetProceeds" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_ProceedsFromInitialPublicOfferingNetProceeds" xlink:to="TELO_ProceedsFromInitialPublicOfferingNetProceeds_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_ProceedsFromInitialPublicOfferingNetProceeds_lbl" xml:lang="en-US">Initial public offering net proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash insured amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash, Uninsured Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Raised amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Cash in operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders equity</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_LicenseAgreementRelatedPartyDetailsNarrativeTable" xlink:label="TELO_LicenseAgreementRelatedPartyDetailsNarrativeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_LicenseAgreementRelatedPartyDetailsNarrativeTable" xlink:to="TELO_LicenseAgreementRelatedPartyDetailsNarrativeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_LicenseAgreementRelatedPartyDetailsNarrativeTable_lbl" xml:lang="en-US">LicenseAgreementRelatedPartyDetailsNarrativeTable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_LicenseAgreementRelatedPartyDetailsNarrativeLineItems" xlink:label="TELO_LicenseAgreementRelatedPartyDetailsNarrativeLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_LicenseAgreementRelatedPartyDetailsNarrativeLineItems" xlink:to="TELO_LicenseAgreementRelatedPartyDetailsNarrativeLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_LicenseAgreementRelatedPartyDetailsNarrativeLineItems_lbl" xml:lang="en-US">LicenseAgreementRelatedPartyDetailsNarrativeLineItems [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Ownership percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_PercentageOfRoyaltyPayable" xlink:label="TELO_PercentageOfRoyaltyPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_PercentageOfRoyaltyPayable" xlink:to="TELO_PercentageOfRoyaltyPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_PercentageOfRoyaltyPayable_lbl" xml:lang="en-US">Percentage of royalty payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xml:lang="en-US">Vested common shares service, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="us-gaap_DebtInstrumentRepurchaseAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRepurchaseAmount" xlink:to="us-gaap_DebtInstrumentRepurchaseAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRepurchaseAmount_lbl" xml:lang="en-US">Debt Instrument, Repurchase Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent_lbl" xml:lang="en-US">Payroll taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesOther" xlink:label="us-gaap_TaxesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesOther" xlink:to="us-gaap_TaxesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesOther_lbl" xml:lang="en-US">Medicare taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Amount due from related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Amount due from related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="us-gaap_CostsAndExpensesRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesRelatedParty" xlink:to="us-gaap_CostsAndExpensesRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl" xml:lang="en-US">Costs and Expenses, Related Party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Raised amount in equity financing</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Number of restricted shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Purchase price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardPriceOfCommonStockPercent" xlink:label="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardPriceOfCommonStockPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardPriceOfCommonStockPercent" xlink:to="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardPriceOfCommonStockPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardPriceOfCommonStockPercent_lbl" xml:lang="en-US">Premium share price percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Share price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_2_lbl" xml:lang="en-US">Initial payment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Issuance of common stock, net, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Unused line of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Fair value of total warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Aggregate borrowings amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xml:lang="en-US">Restructuring Cost [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US">Cash or marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl" xml:lang="en-US">Contingent consideration transaction cost</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_LeasesDetailsNarrativeTable" xlink:label="TELO_LeasesDetailsNarrativeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_LeasesDetailsNarrativeTable" xlink:to="TELO_LeasesDetailsNarrativeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_LeasesDetailsNarrativeTable_lbl" xml:lang="en-US">LeasesDetailsNarrativeTable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_LeasesDetailsNarrativeLineItems" xlink:label="TELO_LeasesDetailsNarrativeLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_LeasesDetailsNarrativeLineItems" xlink:to="TELO_LeasesDetailsNarrativeLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_LeasesDetailsNarrativeLineItems_lbl" xml:lang="en-US">LeasesDetailsNarrativeLineItems [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Variable lease, cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_DisclosureLeasesAbstract" xlink:to="TELO_DisclosureLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TELO_DisclosureLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Components Of Lease Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_VariableLeaseCost_2_lbl" xml:lang="en-US">Variable lease costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of Warrants Outstanding, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), Outstanding Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of Warrants, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="TELO_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="TELO_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:label="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:to="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Warrants, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Warrants Outstanding, Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants remaining contractual term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Warrant measurement input</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xml:lang="en-US">Expected term in years</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ScheduleOfKeyAssumptionsUsedToValueStockOptionsTable" xlink:label="TELO_ScheduleOfKeyAssumptionsUsedToValueStockOptionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_ScheduleOfKeyAssumptionsUsedToValueStockOptionsTable" xlink:to="TELO_ScheduleOfKeyAssumptionsUsedToValueStockOptionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_ScheduleOfKeyAssumptionsUsedToValueStockOptionsTable_lbl" xml:lang="en-US">ScheduleOfKeyAssumptionsUsedToValueStockOptionsTable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems" xlink:label="TELO_ScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_ScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems" xlink:to="TELO_ScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_ScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems_lbl" xml:lang="en-US">ScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Expected volatility, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Expected volatility, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:label="TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:to="TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_lbl" xml:lang="en-US">Vesting period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of stock option, Beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of stock option, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:label="TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:to="TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_lbl" xml:lang="en-US">Number of stock option, Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of stock option, Forfeitures</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Forfeitures</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Number of stock option, Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Weighted average exercise price, Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate intrinsic value, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US">Number of stock option, Vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual life (years), Vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, Vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of stock option, Vested and expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Vested and expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual life (years), Vested and expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, Vested and expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Issue of shares of capital stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_3_lbl" xml:lang="en-US">Additional payment received</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Equity issuance cost</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_OfferingCosts" xlink:label="TELO_OfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_OfferingCosts" xlink:to="TELO_OfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_OfferingCosts_lbl" xml:lang="en-US">Offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Aggregate offering amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Common stock shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Weighted average price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2_lbl" xml:lang="en-US">Proceeds from issuance or sale of equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xml:lang="en-US">Number of resricted shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Premium share price percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xml:lang="en-US">Issued shares which were fully vested upon grant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Purchase of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xml:lang="en-US">Warrants to purchase common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_3_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Deferred financing costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Issuance of common stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common stock are reserved for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant-date fair values of options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Grant date fair value of shares vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforward</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Section 174 capitalized research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Goodwill and intangibles</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US">Tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred tax assets, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Total net deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Deferred tax:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total deferred tax expense (benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Provision for income taxes at U.S. federal statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Provision for income taxes at U.S. federal statutory rate, Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes, net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes, net of federal benefit, Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other, Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Changes in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Changes in valuation allowance, Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xml:lang="en-US">True-ups</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US">True-ups, Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Net actual effective rate, Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOtherLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOtherLossCarryforwards_lbl" xml:lang="en-US">Deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_AccruedCompensation" xlink:to="TELO_AccruedCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_AccruedCompensation_doc" xml:lang="en-US">Accrued compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_DueToOfficer" xlink:to="TELO_DueToOfficer_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_DueToOfficer_doc" xml:lang="en-US">Due to officer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="TELO_StockIssuedDuringPeriodValueWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_StockIssuedDuringPeriodValueWarrantsExercised_doc" xml:lang="en-US">Stock issued during period value warrants exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="TELO_StockIssuedDuringPeriodSharesWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_StockIssuedDuringPeriodSharesWarrantsExercised_doc" xml:lang="en-US">Stock issued during period shares warrants exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_IncreaseDecreaseInAccruedCompensation" xlink:to="TELO_IncreaseDecreaseInAccruedCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_IncreaseDecreaseInAccruedCompensation_doc" xml:lang="en-US">Increase decrease in accrued compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_ProceedsFromRepaymentsOfOfficer" xlink:to="TELO_ProceedsFromRepaymentsOfOfficer_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_ProceedsFromRepaymentsOfOfficer_doc" xml:lang="en-US">Proceeds from repayments of officer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_ProceedsFromSaleOfCommonStockRelatedParty" xlink:to="TELO_ProceedsFromSaleOfCommonStockRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_ProceedsFromSaleOfCommonStockRelatedParty_doc" xml:lang="en-US">Proceeds from sale of common stock related party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_ProceedsFromSaleOfCommonStock" xlink:to="TELO_ProceedsFromSaleOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_ProceedsFromSaleOfCommonStock_doc" xml:lang="en-US">Proceeds from sale of common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_DeferredOfferingCostsChargedToAdditionalPaidinCapital" xlink:to="TELO_DeferredOfferingCostsChargedToAdditionalPaidinCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_DeferredOfferingCostsChargedToAdditionalPaidinCapital_doc" xml:lang="en-US">Deferred offering costs charged to additional paidin capital.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_ProceedsFromInitialPublicOfferingNetProceeds" xlink:to="TELO_ProceedsFromInitialPublicOfferingNetProceeds_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_ProceedsFromInitialPublicOfferingNetProceeds_doc" xml:lang="en-US">Proceeds from initial public offering net proceeds.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_InitialPublicOfferingPolicyTextBlock" xlink:to="TELO_InitialPublicOfferingPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_InitialPublicOfferingPolicyTextBlock_doc" xml:lang="en-US">Initial Public Offering [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_ProposedMergerPolicyTextBlock" xlink:to="TELO_ProposedMergerPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_ProposedMergerPolicyTextBlock_doc" xml:lang="en-US">Proposed merger [policy text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="TELO_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_doc" xml:lang="en-US">Recent Accounting Pronouncements Not Yet Adopted [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_LicenseAgreementRelatedPartyTextBlock" xlink:to="TELO_LicenseAgreementRelatedPartyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_LicenseAgreementRelatedPartyTextBlock_doc" xml:lang="en-US">License Agreement Related Party [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_PercentageOfRoyaltyPayable" xlink:to="TELO_PercentageOfRoyaltyPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_PercentageOfRoyaltyPayable_doc" xml:lang="en-US">Percentage of royalty payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_StarwoodTrustMember" xlink:to="TELO_StarwoodTrustMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_StarwoodTrustMember_doc" xml:lang="en-US">Starwood Trust [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_BayShoreTrustMember" xlink:to="TELO_BayShoreTrustMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_BayShoreTrustMember_doc" xml:lang="en-US">Bay Shore Trust [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_BayshorefinancingMember" xlink:to="TELO_BayshorefinancingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_BayshorefinancingMember_doc" xml:lang="en-US">Bayshore Financing [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardPriceOfCommonStockPercent" xlink:to="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardPriceOfCommonStockPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardPriceOfCommonStockPercent_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award price of common stock percent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_NoInsiderTradingFlag" xlink:to="TELO_NoInsiderTradingFlag_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_NoInsiderTradingFlag_doc" xml:lang="en-US">No Insider Trading Flag</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_ProposedMergerAgreementDisclosureTextBlock" xlink:to="TELO_ProposedMergerAgreementDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_ProposedMergerAgreementDisclosureTextBlock_doc" xml:lang="en-US">Proposed merger agreement disclosure [text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_TeliPharmaceuticalsIncMember" xlink:to="TELO_TeliPharmaceuticalsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_TeliPharmaceuticalsIncMember_doc" xml:lang="en-US">TELI Pharmaceuticals, Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_LicenseAgreementMember" xlink:to="TELO_LicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_LicenseAgreementMember_doc" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_TelomirOneMember" xlink:to="TELO_TelomirOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_TelomirOneMember_doc" xml:lang="en-US">Telomir-1 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_PhaseOneByTwoMember" xlink:to="TELO_PhaseOneByTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_PhaseOneByTwoMember_doc" xml:lang="en-US">Phase 1/2 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_MiralogxLLCMember" xlink:to="TELO_MiralogxLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_MiralogxLLCMember_doc" xml:lang="en-US">MIRALOGX, LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_TampaFloridaMember" xlink:to="TELO_TampaFloridaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_TampaFloridaMember_doc" xml:lang="en-US">Tampa, Florida [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_OfferingCosts" xlink:to="TELO_OfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_OfferingCosts_doc" xml:lang="en-US">Offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_AtTheMarketOfferingAgreementMember" xlink:to="TELO_AtTheMarketOfferingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_AtTheMarketOfferingAgreementMember_doc" xml:lang="en-US">At The Market Offering Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_AtTheMarketOfferingMember" xlink:to="TELO_AtTheMarketOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_AtTheMarketOfferingMember_doc" xml:lang="en-US">At The Market Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which grantees can acquire the shares reserved for issuance under the warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_doc" xml:lang="en-US">Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term 2</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="TELO_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average per share amount at which grantees can acquire shares of common stock by exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:to="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted_doc" xml:lang="en-US">Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_BayShoreTrustWarrantsMember" xlink:to="TELO_BayShoreTrustWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_BayShoreTrustWarrantsMember_doc" xml:lang="en-US">Bay Shore Trust Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_TwoThousandTwentyThreePrivatePlacementWarrantsMember" xlink:to="TELO_TwoThousandTwentyThreePrivatePlacementWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_TwoThousandTwentyThreePrivatePlacementWarrantsMember_doc" xml:lang="en-US">2023 Private Placement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_UnderwriterWarrantMember" xlink:to="TELO_UnderwriterWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_UnderwriterWarrantMember_doc" xml:lang="en-US">Underwriter Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_PlacementAgentMember" xlink:to="TELO_PlacementAgentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_PlacementAgentMember_doc" xml:lang="en-US">Placement Agent [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_MeasurementInputFairMarketValueUnderlyingCommonStockMember" xlink:to="TELO_MeasurementInputFairMarketValueUnderlyingCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_MeasurementInputFairMarketValueUnderlyingCommonStockMember_doc" xml:lang="en-US">Measurement Input Fair Market Value Underlying Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_TwoThousandTwentyThreeOmnibusIncentivePlanMember" xlink:to="TELO_TwoThousandTwentyThreeOmnibusIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_TwoThousandTwentyThreeOmnibusIncentivePlanMember_doc" xml:lang="en-US">2023 Omnibus Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_MayThirteenMember" xlink:to="TELO_MayThirteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_MayThirteenMember_doc" xml:lang="en-US">May 13 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_MayTwentySevenMember" xlink:to="TELO_MayTwentySevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_MayTwentySevenMember_doc" xml:lang="en-US">May 27 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_OctoberFifteenMember" xlink:to="TELO_OctoberFifteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_OctoberFifteenMember_doc" xml:lang="en-US">October 15 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:to="TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award vesting period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:to="TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_doc" xml:lang="en-US">Sharebased compensation arrangement by sharebased payment award opttions expired in period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_2_lbl" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_2_lbl" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToOtherRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToOtherRelatedParties_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToOtherRelatedParties_2_lbl" xml:lang="en-US">Increase (Decrease) in Due to Other Related Parties</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_IncreaseDecreaseInAccruedCompensation" xlink:to="TELO_IncreaseDecreaseInAccruedCompensation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_IncreaseDecreaseInAccruedCompensation_3_lbl" xml:lang="en-US">IncreaseDecreaseInAccruedCompensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_2_lbl" xml:lang="en-US">Repayments of Lines of Credit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_ProposedMergerAgreementDisclosureTextBlock" xlink:to="TELO_ProposedMergerAgreementDisclosureTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_ProposedMergerAgreementDisclosureTextBlock_3_lbl" xml:lang="en-US">ProposedMergerAgreementDisclosureTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_2_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_2_lbl" xml:lang="en-US">Other Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_2_lbl" xml:lang="en-US">Lease, Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>21
<FILENAME>telo-20251231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.4b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#Cover" roleURI="http://telomirpharma.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#BalanceSheets" roleURI="http://telomirpharma.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#BalanceSheetsParenthetical" roleURI="http://telomirpharma.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#StatementsOfOperations" roleURI="http://telomirpharma.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#StatementsOfChangesInStockholdersEquity" roleURI="http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#StatementsOfCashFlows" roleURI="http://telomirpharma.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" roleURI="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#GoingConcern" roleURI="http://telomirpharma.com/role/GoingConcern" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#LicenseAgreementRelatedParty" roleURI="http://telomirpharma.com/role/LicenseAgreementRelatedParty" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#RelatedPartiesBalancesAndTransactions" roleURI="http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ProposedMergerAgreement" roleURI="http://telomirpharma.com/role/ProposedMergerAgreement" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#Leases" roleURI="http://telomirpharma.com/role/Leases" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#StockholdersEquity" roleURI="http://telomirpharma.com/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#IncomeTaxes" roleURI="http://telomirpharma.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#LeasesTables" roleURI="http://telomirpharma.com/role/LeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#StockholdersEquityTables" roleURI="http://telomirpharma.com/role/StockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#IncomeTaxesTables" roleURI="http://telomirpharma.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#GoingConcernDetailsNarrative" roleURI="http://telomirpharma.com/role/GoingConcernDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#LicenseAgreementRelatedPartyDetailsNarrative" roleURI="http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#RelatedPartiesBalancesAndTransactionsDetailsNarrative" roleURI="http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ProposedMergerAgreementDetailsNarrative" roleURI="http://telomirpharma.com/role/ProposedMergerAgreementDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#LeasesDetailsNarrative" roleURI="http://telomirpharma.com/role/LeasesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ScheduleOfComponentsOfLeaseExpensesDetails" roleURI="http://telomirpharma.com/role/ScheduleOfComponentsOfLeaseExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ScheduleOfWarrantActivityDetails" roleURI="http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ScheduleOfWarrantActivityDetailsParenthetical" roleURI="http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails" roleURI="http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails" roleURI="http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ScheduleOfIssuedStockOptionsDetails" roleURI="http://telomirpharma.com/role/ScheduleOfIssuedStockOptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ScheduleOfStockOptionActivityDetails" roleURI="http://telomirpharma.com/role/ScheduleOfStockOptionActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#StockholdersEquityDetailsNarrative" roleURI="http://telomirpharma.com/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ScheduleOfNetDeferredTaxAssetsDetails" roleURI="http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ScheduleOfProvisionForIncomeTaxesDetails" roleURI="http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#ScheduleOfReconciliationEffectiveIncomeTaxRateDetails" roleURI="http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20251231.xsd#IncomeTaxesDetailsNarrative" roleURI="http://telomirpharma.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosureWithAdditionalMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpTable" roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsToCompensation" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListsByExecutiveCategory" roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListMeasures" roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpPensionBenefitsAdjustments" roleURI="http://xbrl.sec.gov/ecd/role/PvpPensionBenefitsAdjustments" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ForgoneRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#OutstandingRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardsCloseToMnpiDisc" roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangemenstByInd" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#Defaults" roleURI="http://xbrl.sec.gov/ecd/role/Defaults" />
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_DueToOfficer" xlink:label="loc_TELODueToOfficer" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_TELODueToOfficer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_AccruedCompensation" xlink:label="loc_TELOAccruedCompensation" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_TELOAccruedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="loc_us-gaapTravelAndEntertainmentExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapTravelAndEntertainmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_TELOStockIssuedDuringPeriodValueWarrantsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TELOStockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_TELOStockIssuedDuringPeriodSharesWarrantsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TELOStockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForOtherCreditLosses" xlink:label="loc_us-gaapProvisionForOtherCreditLosses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForOtherCreditLosses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueToOtherRelatedParties" xlink:label="loc_us-gaapIncreaseDecreaseInDueToOtherRelatedParties" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDueToOtherRelatedParties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_IncreaseDecreaseInAccruedCompensation" xlink:label="loc_TELOIncreaseDecreaseInAccruedCompensation" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_TELOIncreaseDecreaseInAccruedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ProceedsFromRepaymentsOfOfficer" xlink:label="loc_TELOProceedsFromRepaymentsOfOfficer" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_TELOProceedsFromRepaymentsOfOfficer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ProceedsFromSaleOfCommonStockRelatedParty" xlink:label="loc_TELOProceedsFromSaleOfCommonStockRelatedParty" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_TELOProceedsFromSaleOfCommonStockRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ProceedsFromSaleOfCommonStock" xlink:label="loc_TELOProceedsFromSaleOfCommonStock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_TELOProceedsFromSaleOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_DeferredOfferingCostsChargedToAdditionalPaidinCapital" xlink:label="loc_TELODeferredOfferingCostsChargedToAdditionalPaidinCapital" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_TELODeferredOfferingCostsChargedToAdditionalPaidinCapital" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="loc_ecdEqtyAwrdsAdjFnTextBlock" />
      <link:presentationArc order="2290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdEqtyAwrdsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="loc_ecdTrdArrSecuritiesAggAvailAmt" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrSecuritiesAggAvailAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_NoInsiderTradingFlag" xlink:label="loc_TELONoInsiderTradingFlag" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_TELONoInsiderTradingFlag" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="loc_cydCybersecurityRiskRoleOfManagementTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskRoleOfManagementTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="loc_cydMaterialCybersecurityIncidentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentNatureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentNatureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentScopeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentScopeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentTimingTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentTimingTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:title="999014 - Disclosure - Description of business and summary of significant accounting policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/GoingConcern" xlink:title="999015 - Disclosure - Going Concern">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/LicenseAgreementRelatedParty" xlink:title="999016 - Disclosure - License agreement, related party">
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_DisclosureLicenseAgreementRelatedPartyAbstract" xlink:label="loc_TELODisclosureLicenseAgreementRelatedPartyAbstract" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_LicenseAgreementRelatedPartyTextBlock" xlink:label="loc_TELOLicenseAgreementRelatedPartyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELODisclosureLicenseAgreementRelatedPartyAbstract" xlink:to="loc_TELOLicenseAgreementRelatedPartyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactions" xlink:title="999017 - Disclosure - Related parties balances and transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ProposedMergerAgreement" xlink:title="999018 - Disclosure - Proposed Merger Agreement">
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_DisclosureProposedMergerAgreementAbstract" xlink:label="loc_TELODisclosureProposedMergerAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ProposedMergerAgreementDisclosureTextBlock" xlink:label="loc_TELOProposedMergerAgreementDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELODisclosureProposedMergerAgreementAbstract" xlink:to="loc_TELOProposedMergerAgreementDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/Leases" xlink:title="999019 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_DisclosureLeasesAbstract" xlink:label="loc_TELODisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELODisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StockholdersEquity" xlink:title="999020 - Disclosure - Stockholders&#8217; equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/IncomeTaxes" xlink:title="999021 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999022 - Disclosure - Description of business and summary of significant accounting policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_InitialPublicOfferingPolicyTextBlock" xlink:label="loc_TELOInitialPublicOfferingPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_TELOInitialPublicOfferingPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ProposedMergerPolicyTextBlock" xlink:label="loc_TELOProposedMergerPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_TELOProposedMergerPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="loc_TELORecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_TELORecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/LeasesTables" xlink:title="999023 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_DisclosureLeasesAbstract" xlink:label="loc_TELODisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELODisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StockholdersEquityTables" xlink:title="999024 - Disclosure - Stockholders&#8217; equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_UnderwriterWarrantMember" xlink:label="loc_TELOUnderwriterWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_TELOUnderwriterWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/IncomeTaxesTables" xlink:title="999025 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999026 - Disclosure - Description of business and summary of significant accounting policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherUnderwritingExpense" xlink:label="loc_us-gaapOtherUnderwritingExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapOtherUnderwritingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ProceedsFromInitialPublicOfferingNetProceeds" xlink:label="loc_TELOProceedsFromInitialPublicOfferingNetProceeds" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_TELOProceedsFromInitialPublicOfferingNetProceeds" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCashUninsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/GoingConcernDetailsNarrative" xlink:title="999027 - Disclosure - Going Concern (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative" xlink:title="999028 - Disclosure - License agreement, related party (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_DisclosureLicenseAgreementRelatedPartyAbstract" xlink:label="loc_TELODisclosureLicenseAgreementRelatedPartyAbstract" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_LicenseAgreementRelatedPartyDetailsNarrativeTable" xlink:label="loc_TELOLicenseAgreementRelatedPartyDetailsNarrativeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELODisclosureLicenseAgreementRelatedPartyAbstract" xlink:to="loc_TELOLicenseAgreementRelatedPartyDetailsNarrativeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_LicenseAgreementRelatedPartyDetailsNarrativeLineItems" xlink:label="loc_TELOLicenseAgreementRelatedPartyDetailsNarrativeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELOLicenseAgreementRelatedPartyDetailsNarrativeTable" xlink:to="loc_TELOLicenseAgreementRelatedPartyDetailsNarrativeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELOLicenseAgreementRelatedPartyDetailsNarrativeTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_MiralogxLLCMember" xlink:label="loc_TELOMiralogxLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_TELOMiralogxLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELOLicenseAgreementRelatedPartyDetailsNarrativeTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELOLicenseAgreementRelatedPartyDetailsNarrativeLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_PercentageOfRoyaltyPayable" xlink:label="loc_TELOPercentageOfRoyaltyPayable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELOLicenseAgreementRelatedPartyDetailsNarrativeLineItems" xlink:to="loc_TELOPercentageOfRoyaltyPayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative" xlink:title="999029 - Disclosure - Related parties balances and transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_BayshorefinancingMember" xlink:label="loc_TELOBayshorefinancingMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_TELOBayshorefinancingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_BayShoreTrustMember" xlink:label="loc_TELOBayShoreTrustMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_TELOBayShoreTrustMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_StarwoodTrustMember" xlink:label="loc_TELOStarwoodTrustMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_TELOStarwoodTrustMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="loc_us-gaapDebtInstrumentRepurchaseAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentRepurchaseAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedPayrollTaxesCurrentAndNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccruedPayrollTaxesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesOther" xlink:label="loc_us-gaapTaxesOther" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapTaxesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaapCostsAndExpensesRelatedParty" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCostsAndExpensesRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardPriceOfCommonStockPercent" xlink:label="loc_TELOSharebasedCompensationArrangementBySharebasedPaymentAwardPriceOfCommonStockPercent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TELOSharebasedCompensationArrangementBySharebasedPaymentAwardPriceOfCommonStockPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="loc_us-gaapTravelAndEntertainmentExpense" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapTravelAndEntertainmentExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ProposedMergerAgreementDetailsNarrative" xlink:title="999030 - Disclosure - Proposed Merger Agreement (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_DisclosureProposedMergerAgreementAbstract" xlink:label="loc_TELODisclosureProposedMergerAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELODisclosureProposedMergerAgreementAbstract" xlink:to="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaapRestructuringCostAndReserveLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapRestructuringCostAndReserveLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_TeliPharmaceuticalsIncMember" xlink:label="loc_TELOTeliPharmaceuticalsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_TELOTeliPharmaceuticalsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_LicenseAgreementMember" xlink:label="loc_TELOLicenseAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TELOLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaapAssetAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapAssetAcquisitionAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_TelomirOneMember" xlink:label="loc_TELOTelomirOneMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionDomain" xlink:to="loc_TELOTelomirOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_PhaseOneByTwoMember" xlink:label="loc_TELOPhaseOneByTwoMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionDomain" xlink:to="loc_TELOPhaseOneByTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferredTransactionCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferredTransactionCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/LeasesDetailsNarrative" xlink:title="999031 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_LeasesDetailsNarrativeTable" xlink:label="loc_TELOLeasesDetailsNarrativeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_TELOLeasesDetailsNarrativeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_LeasesDetailsNarrativeLineItems" xlink:label="loc_TELOLeasesDetailsNarrativeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELOLeasesDetailsNarrativeTable" xlink:to="loc_TELOLeasesDetailsNarrativeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELOLeasesDetailsNarrativeTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_MiralogxLLCMember" xlink:label="loc_TELOMiralogxLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_TELOMiralogxLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELOLeasesDetailsNarrativeTable" xlink:to="loc_srtStatementGeographicalAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_TampaFloridaMember" xlink:label="loc_TELOTampaFloridaMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_TELOTampaFloridaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaapVariableLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELOLeasesDetailsNarrativeLineItems" xlink:to="loc_us-gaapVariableLeaseCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfComponentsOfLeaseExpensesDetails" xlink:title="999032 - Disclosure - Schedule of Components of Lease Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_DisclosureLeasesAbstract" xlink:label="loc_TELODisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELODisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaapVariableLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELODisclosureLeasesAbstract" xlink:to="loc_us-gaapVariableLeaseCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELODisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999033 - Disclosure - Schedule of Warrant Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_TELOShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_TELOShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_TELOSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_TELOSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_TELOShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_TELOShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:label="loc_TELOSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_TELOSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_TELOShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_TELOShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical" xlink:title="999034 - Disclosure - Schedule of warrant activity (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_BayShoreTrustWarrantsMember" xlink:label="loc_TELOBayShoreTrustWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TELOBayShoreTrustWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_TwoThousandTwentyThreePrivatePlacementWarrantsMember" xlink:label="loc_TELOTwoThousandTwentyThreePrivatePlacementWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TELOTwoThousandTwentyThreePrivatePlacementWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_UnderwriterWarrantMember" xlink:label="loc_TELOUnderwriterWarrantMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TELOUnderwriterWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails" xlink:title="999035 - Disclosure - Schedule of Key Assumptions Used to Value Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_UnderwriterWarrantMember" xlink:label="loc_TELOUnderwriterWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_TELOUnderwriterWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_MeasurementInputFairMarketValueUnderlyingCommonStockMember" xlink:label="loc_TELOMeasurementInputFairMarketValueUnderlyingCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_TELOMeasurementInputFairMarketValueUnderlyingCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails" xlink:title="999036 - Disclosure - Schedule of Key Assumptions Used to Value Stock Options (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ScheduleOfKeyAssumptionsUsedToValueStockOptionsTable" xlink:label="loc_TELOScheduleOfKeyAssumptionsUsedToValueStockOptionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_TELOScheduleOfKeyAssumptionsUsedToValueStockOptionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems" xlink:label="loc_TELOScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELOScheduleOfKeyAssumptionsUsedToValueStockOptionsTable" xlink:to="loc_TELOScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELOScheduleOfKeyAssumptionsUsedToValueStockOptionsTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELOScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELOScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELOScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELOScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELOScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELOScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELOScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfIssuedStockOptionsDetails" xlink:title="999037 - Disclosure - Schedule of Issued Stock Options (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_MayThirteenMember" xlink:label="loc_TELOMayThirteenMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_TELOMayThirteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_MayTwentySevenMember" xlink:label="loc_TELOMayTwentySevenMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_TELOMayTwentySevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_OctoberFifteenMember" xlink:label="loc_TELOOctoberFifteenMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_TELOOctoberFifteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:label="loc_TELOShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_TELOShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999038 - Disclosure - Schedule of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:label="loc_TELOShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_TELOShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="999039 - Disclosure - Stockholders&#8217; equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_AtTheMarketOfferingMember" xlink:label="loc_TELOAtTheMarketOfferingMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_TELOAtTheMarketOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_StarwoodTrustMember" xlink:label="loc_TELOStarwoodTrustMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_TELOStarwoodTrustMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_BayShoreTrustMember" xlink:label="loc_TELOBayShoreTrustMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_TELOBayShoreTrustMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_AtTheMarketOfferingAgreementMember" xlink:label="loc_TELOAtTheMarketOfferingAgreementMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TELOAtTheMarketOfferingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtTitleOfIndividualAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_PlacementAgentMember" xlink:label="loc_TELOPlacementAgentMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TELOPlacementAgentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapPlanNameAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_TwoThousandTwentyThreeOmnibusIncentivePlanMember" xlink:label="loc_TELOTwoThousandTwentyThreeOmnibusIncentivePlanMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_TELOTwoThousandTwentyThreeOmnibusIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapAwardTypeAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherUnderwritingExpense" xlink:label="loc_us-gaapOtherUnderwritingExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapOtherUnderwritingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_ProceedsFromInitialPublicOfferingNetProceeds" xlink:label="loc_TELOProceedsFromInitialPublicOfferingNetProceeds" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_TELOProceedsFromInitialPublicOfferingNetProceeds" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20251231.xsd#TELO_OfferingCosts" xlink:label="loc_TELOOfferingCosts" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_TELOOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaapDeferredFinanceCostsNet" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails" xlink:title="999040 - Disclosure - Schedule of Net Deferred Tax Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="999041 - Disclosure - Schedule of Provision for Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails" xlink:title="999042 - Disclosure - Schedule of Reconciliation Effective Income Tax Rate (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItems" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="999043 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOtherLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOtherLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 12, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Telomir
Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001971532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-3354547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 SE 2nd St<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200 #1009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Miami<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">396-6723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock,
    no par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TELO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,380,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">SALBERG & COMPANY, P.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boca
Raton, Florida<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 7,286,670<span></span>
</td>
<td class="nump">$ 1,266,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">54,691<span></span>
</td>
<td class="nump">57,874<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">7,341,361<span></span>
</td>
<td class="nump">1,324,005<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">7,341,361<span></span>
</td>
<td class="nump">1,324,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Trade accounts payable and accrued liabilities</a></td>
<td class="nump">536,769<span></span>
</td>
<td class="nump">587,536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_DueToOfficer', window );">Due to officer</a></td>
<td class="nump">155,518<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_AccruedCompensation', window );">Accrued compensation - officer</a></td>
<td class="nump">417,470<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="nump">318,234<span></span>
</td>
<td class="nump">93,432<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,427,991<span></span>
</td>
<td class="nump">680,968<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,427,991<span></span>
</td>
<td class="nump">680,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, no par value, 100,000,000 shares authorized and none issued or outstanding.</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, no par value; 300,000,000 shares authorized, 34,380,971 and 29,762,671 shares issued and outstanding at December 31, 2025 and 2024, respectively.</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">46,923,433<span></span>
</td>
<td class="nump">31,239,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(41,010,063)<span></span>
</td>
<td class="num">(30,596,858)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">5,913,370<span></span>
</td>
<td class="nump">643,037<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 7,341,361<span></span>
</td>
<td class="nump">$ 1,324,005<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_AccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_AccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_DueToOfficer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Due to officer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_DueToOfficer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">34,380,971<span></span>
</td>
<td class="nump">29,762,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">34,380,971<span></span>
</td>
<td class="nump">29,762,671<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">8,103,280<span></span>
</td>
<td class="nump">9,636,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TravelAndEntertainmentExpense', window );">Related party travel costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">370,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">2,435,569<span></span>
</td>
<td class="nump">2,235,341<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating costs</a></td>
<td class="nump">10,538,849<span></span>
</td>
<td class="nump">12,242,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">125,644<span></span>
</td>
<td class="nump">48,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(4,338,542)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (10,413,205)<span></span>
</td>
<td class="num">$ (16,532,716)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share</a></td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.56)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share</a></td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.56)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common stock shares outstanding</a></td>
<td class="nump">31,653,094<span></span>
</td>
<td class="nump">29,539,219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average common stock shares outstanding</a></td>
<td class="nump">31,653,094<span></span>
</td>
<td class="nump">29,539,219<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TravelAndEntertainmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses incurred for travel and entertainment during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TravelAndEntertainmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 17,502,346<span></span>
</td>
<td class="num">$ (14,064,142)<span></span>
</td>
<td class="nump">$ 3,438,204<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">28,609,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash in ATM, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,832,973<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,832,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash in ATM, net, shares</a></td>
<td class="nump">1,142,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">37,300<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">37,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of Warrants, shares</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,867,276<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,867,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(16,532,716)<span></span>
</td>
<td class="num">(16,532,716)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">31,239,895<span></span>
</td>
<td class="num">(30,596,858)<span></span>
</td>
<td class="nump">643,037<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="nump">29,762,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash in ATM, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,553,209<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,553,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash in ATM, net, shares</a></td>
<td class="nump">3,218,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,290,329<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,290,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,413,205)<span></span>
</td>
<td class="num">(10,413,205)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock for cash, related party</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock for cash, Related party, shares</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">840,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">840,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services, shares</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 46,923,433<span></span>
</td>
<td class="num">$ (41,010,063)<span></span>
</td>
<td class="nump">$ 5,913,370<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2025</a></td>
<td class="nump">34,380,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (10,413,205)<span></span>
</td>
<td class="num">$ (16,532,716)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">5,290,329<span></span>
</td>
<td class="nump">6,867,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of common stock for services</a></td>
<td class="nump">840,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForOtherCreditLosses', window );">Credit loss expenses - loan due from related party</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">130,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,338,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">3,183<span></span>
</td>
<td class="num">(57,160)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Trade accounts payable and accrued liabilities</a></td>
<td class="num">(50,767)<span></span>
</td>
<td class="nump">183,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToOtherRelatedParties', window );">Due to related parties</a></td>
<td class="nump">224,802<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_IncreaseDecreaseInAccruedCompensation', window );">Accrued compensation - officer</a></td>
<td class="nump">417,470<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(3,688,188)<span></span>
</td>
<td class="num">(5,070,428)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Payments under related party line of credit</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(101,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt', window );">Repayments to related party</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(433,945)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_ProceedsFromRepaymentsOfOfficer', window );">Repayment from officer</a></td>
<td class="nump">155,518<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercise</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">37,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_ProceedsFromSaleOfCommonStockRelatedParty', window );">Proceeds from sale of common stock, related party</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_ProceedsFromSaleOfCommonStock', window );">Net proceeds from sale of common stock</a></td>
<td class="nump">6,553,209<span></span>
</td>
<td class="nump">6,832,973<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">9,708,727<span></span>
</td>
<td class="nump">6,335,328<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash</a></td>
<td class="nump">6,020,539<span></span>
</td>
<td class="nump">1,264,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, beginning of year</a></td>
<td class="nump">1,266,131<span></span>
</td>
<td class="nump">1,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, end of year</a></td>
<td class="nump">7,286,670<span></span>
</td>
<td class="nump">1,266,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income tax</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_DeferredOfferingCostsChargedToAdditionalPaidinCapital', window );">Deferred offering costs charged to additional paid-in capital</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 303,281<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_DeferredOfferingCostsChargedToAdditionalPaidinCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs charged to additional paidin capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_DeferredOfferingCostsChargedToAdditionalPaidinCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_IncreaseDecreaseInAccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_IncreaseDecreaseInAccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_ProceedsFromRepaymentsOfOfficer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from repayments of officer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_ProceedsFromRepaymentsOfOfficer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_ProceedsFromSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_ProceedsFromSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_ProceedsFromSaleOfCommonStockRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of common stock related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_ProceedsFromSaleOfCommonStockRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToOtherRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in related party payables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToOtherRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForOtherCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to credit loss from transactions other than loan and lease transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForOtherCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (10,413,205)<span></span>
</td>
<td class="num">$ (16,532,716)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_NoInsiderTradingFlag', window );">No insider trading flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_NoInsiderTradingFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>No Insider Trading Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_NoInsiderTradingFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><b><span id="a_006"></span>Item 1C. Cybersecurity.</b>&#160;<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We recognize the importance of assessing, identifying,
and managing material risks associated with cybersecurity threats, as such term is defined in Item 106(a) of Regulation S-K. These risks
include, among other things: operational risks, intellectual property theft, fraud, extortion, harm to employees and violation of data
privacy or security laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_z6pWW8gNJ48d">Identifying and assessing cybersecurity risk
is integrated into our overall risk management systems and processes.</span> <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20250101__20251231_zCY4SzqjJQ56">Cybersecurity risks related to our business, technical operations,
privacy and compliance issues are identified and addressed through a multi-faceted approach including third party assessments, internal
IT Audit, IT security, governance, risk and compliance reviews. To defend, detect and respond to cybersecurity incidents, we, among other
things: conduct proactive privacy and cybersecurity reviews of systems and applications, audit applicable data, conduct employee training,
monitor emerging laws and regulations related to data protection and information security and implement appropriate changes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_903_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20250101__20251231_zUUz7GzxCRYh">Our risk management program also assesses third
party risks, and we perform third-party risk management to identify and mitigate risks from third parties such as vendors, suppliers,
and other business partners associated with our use of third-party service providers.</span> <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90C_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20250101__20251231_zoG6IEFrmC26">Cybersecurity risks are evaluated when determining
the selection and oversight of applicable third-party service providers and potential fourth-party risks when handling and/or processing
our employee, business or customer data.</span></p>

&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">Cybersecurity risks related to our business, technical operations,
privacy and compliance issues are identified and addressed through a multi-faceted approach including third party assessments, internal
IT Audit, IT security, governance, risk and compliance reviews. To defend, detect and respond to cybersecurity incidents, we, among other
things: conduct proactive privacy and cybersecurity reviews of systems and applications, audit applicable data, conduct employee training,
monitor emerging laws and regulations related to data protection and information security and implement appropriate changes.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of business and summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock', window );">Description of business and summary of significant accounting policies</a></td>
<td class="text"><p id="xdx_805_eus-gaap--BusinessDescriptionAndAccountingPoliciesTextBlock_zk8HENW6SSVc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1. <span id="xdx_82B_zhM3PaX6UYEd">Description of business and summary
of significant accounting policies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zcyNcuoCf5Wk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86C_zEHeuZaF5tl">Overview</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Telomir Pharmaceuticals, Inc.
(&#8220;Telomir&#8221; or the &#8220;Company&#8221;) was formed in August 2021 and is a Florida-incorporated pre-clinical stage
biotechnology company developing therapies designed to target the root epigenetic mechanisms underlying cancer, aging, and
degenerative disease. The Company&#8217;s lead candidate, Telomir-1, has demonstrated activity in preclinical studies involving
modulation of DNA and histone methylation patterns, which may contribute to balanced gene expression, cellular function, and genomic
stability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Telomir-1 is a novel oral small molecule metal
ion regulator designed to extend telomere caps, maintain cellular balance, and combat oxidative stress, a key driver of aging and disease
progression. By modulating essential metal ions such as iron, and copper, Telomir-1 may help protect against age related conditions,
including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson&#8217;s disease (a genetic disorder leading
to toxic copper buildup in the body), and Age-related Macular Degeneration (AMD), as well as Type 2 diabetes, breast cancer, and Alzheimer&#8217;s
disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As used herein, the Company&#8217;s common stock,
no par value per share, is referred to as the &#8220;Common Stock&#8221; and the Company&#8217;s preferred stock, no par value per share,
is referred to as the &#8220;Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84D_ecustom--InitialPublicOfferingPolicyTextBlock_zBngH3MgXwqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_867_zOe80Bfe0g8l">Initial public offering</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 13, 2024, the Company closed its
initial public offering (the &#8220;IPO&#8221;) consisting of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240212__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zXhzjf4GcOrg" title="IPO units, shares">1,000,000</span> shares of Common Stock at a price of $<span id="xdx_908_eus-gaap--SharePrice_iI_c20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zXACQWFfZiP9" title="Initial public offering shares">7.00</span> per share for approximately
$<span id="xdx_904_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20240212__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zwLJpZMWDhe6" title="Gross proceeds">7.0</span> million in gross proceeds. After deducting the underwriting commission and other offering expenses totaling $<span id="xdx_90D_eus-gaap--OtherUnderwritingExpense_pn5n6_c20240212__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z7zUzOHXJlkl" title="Underwriting commission and other offering expenses">1.2</span> million, the net
proceeds to the Company were $<span id="xdx_904_ecustom--ProceedsFromInitialPublicOfferingNetProceeds_pn5n6_c20240212__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zACg2SryjJub" title="Initial public offering net proceeds">5.8</span> million. The Common Stock began trading on The Nasdaq Capital Market on February 9, 2024 under the
symbol &#8220;TELO&#8221; (See Note 7 &#8220;Common Stock&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84E_ecustom--ProposedMergerPolicyTextBlock_zcv5hFANvy8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86A_zDrtsOS9yay7">Proposed merger</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Company and TELI Pharmaceuticals, Inc., a related party private
company incorporated under the laws of Delaware (&#8220;TELI&#8221;) have entered into an Agreement and Plan of Merger and Reorganization,
dated November 20, 2025, and as amended on February 4, 2026 (collectively, the &#8220;Merger Agreement&#8221;), pursuant to which a wholly
owned subsidiary of Telomir will merge with and into TELI, with TELI surviving as a wholly owned subsidiary of Telomir (the &#8220;Merger&#8221;),
subject to shareholder approval. At the effective time of the Merger (the &#8220;Effective Time&#8221;), each outstanding share of common
stock of TELI, $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251120_zJCp5dWMrgqf" title="Common stock, par value">0.0001</span> par value per share (&#8220;TELI Common Stock&#8221;), will be converted into the right to receive such number
of Telomir Common Stock as is calculated based on the exchange ratio of the shares for the Merger (the &#8220;Exchange Ratio&#8221;).
The Exchange Ratio is calculated using the relative company valuations of each of Telomir and TELI, as determined by a third-party valuation
firm (as further described herein). It is expected that shareholders of TELI will receive one share of Telomir Common Stock for each
share of TELI Common Stock held (the &#8220;Merger Share Consideration&#8221;). The Telomir Common Stock issued as the consideration
will not be registered for trading under the Securities Act. The Merger will result in an alignment of U.S. and non-U.S. rights to Telomir-1
within a single public company structure, thereby simplifying global development and partnership efforts. As a result of the Merger,
TELO will own the entire worldwide intellectual property portfolio and development programs related to Telomir-1. See Note 5, <i>Merger
Agreement.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zAoI6yYkHcLg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_866_zmlQbeYRYKj2">Revenue recognition</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company currently has no source of revenue.
Miscellaneous income, including interest, is recognized when earned by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_z8RxvchywP9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_869_zntlUZHp0BVf">Income taxes</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes pursuant
to the provision of Accounting Standards Codification (&#8220;ASC&#8221;) 740-10, &#8220;Accounting for Income Taxes&#8221; (&#8220;ASC
740-10&#8221;), which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and
liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary
differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any
net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows the provision of&#160;ASC
740-10&#160;related to Accounting for Uncertain Income Tax Positions. When tax returns are filed, there may be uncertainty about the
merits of positions taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of&#160;ASC
740-10, the benefit of a tax position is recognized in the consolidated financial statements in the period during which, based on all
available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the
resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions
that meet the more likely than not recognition threshold are measured at the largest amount of tax benefit that is more than&#160;50&#160;percent
likely of being realized upon settlement with the applicable taxing authority. The portion of the benefit associated with tax positions
taken that exceed the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying
balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The
Company believes its tax positions are all more likely than not to be upheld upon examination. As such, the Company has not recorded
a liability for uncertain tax benefits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has adopted&#160;ASC 740-10-25, &#8220;Definition
of Settlement&#8221;, which provides guidance on how an entity should determine whether a tax position is effectively settled for the
purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion
and examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity
would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based
solely on the basis of its technical merits and the statute of limitations remains open. The federal and state income tax returns of
the Company are subject to examination by the IRS and state taxing authorities, generally for three years after they are filed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_z3CMQ6zURrRb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_861_zIeIdv2Cy7zk">Research and development expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development costs are expensed in
the period in which they are incurred and include the expenses paid to third parties, such as contract research organizations and consultants,
who conduct research and development activities on behalf of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84A_eus-gaap--UseOfEstimates_zi4qYvdAfKF7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_864_zoZkUJLUcC3k">Use of estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in accordance
with generally accepted accounting principles in the United States of America requires the Company&#8217;s management to make estimates
and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at
the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results may differ from
such estimates and such differences could be material. Significant estimates during the reporting periods include stock-based compensation
and the deferred tax asset valuation allowance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zhNPo926zCNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_866_zEIO4qLaV7S4">Cash and Cash Equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid debt
instruments and other short-term investments with maturities of three months or less, when purchased, to be cash equivalents. The Company
maintains cash and cash equivalent balances at two financial institutions that are insured by the Federal Deposit Insurance Corporation
(&#8220;FDIC&#8221;). The Company&#8217;s accounts at these institutions are insured by the FDIC up to $<span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_c20251231_zhzTq8QqQ3Ih" title="Cash insured amount">250,000</span>. On December 31, 2025
and 2024, the Company had cash in excess of FDIC limits of approximately $<span id="xdx_907_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20251231_zYb8zhGQf1Lg" title="Cash, Uninsured Amount">7.0</span> million and $<span id="xdx_902_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20241231_z5LbG5jXtJD5" title="Cash, Uninsured Amount">1.0</span> million, respectively. To reduce its risk
associated with the failure of such financial institution, the Company evaluates at least annually the rating of the financial institution
in which it holds deposits. Any material loss that the Company may experience in the future could have an adverse effect on its ability
to pay its operational expenses or make other payments and may require the Company to move its cash to other high quality financial institutions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zwFZJoo8kq0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_863_z0OyzotJZQx9">Stock-based compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for stock-based compensation
under the provisions of FASB&#160;ASC 718, &#8220;Compensation - Stock Compensation&#8221;, which requires the measurement and recognition
of compensation expense for all stock-based awards made to employees, directors and consultants based on estimated fair values on the
grant date. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value
of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the
straight-line method. The Company has elected to account for forfeitures of stock-based awards as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84B_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zdeiGi41SuNj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_862_znF1qK7olRO9">Fair Value Measurements and Financial Instruments</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures the fair value of financial
instruments in accordance with GAAP which defines fair value, establishes a framework for measuring fair value, and expands disclosures
about fair value measurements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">GAAP defines fair value as the exchange price
that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for
the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes a fair value
hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring
fair value. GAAP describes three levels of inputs that may be used to measure fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 1 &#8211; quoted prices
in active markets for identical assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 2 &#8211; quoted prices
for similar assets and liabilities in active markets or inputs that are observable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 3 &#8211; inputs that
are unobservable (for example cash flow modeling inputs based on assumptions).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers the carrying amount of
prepaid assets and all current liabilities to approximate fair value due to the short-term nature of those elements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zWfpQBLGwnH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_866_zO7MsxX3Q3zd">Earnings per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Earnings (loss) per share is computed in accordance
with ASC Topic 260, &#8220;Earnings per Share&#8221; Basic weighted-average number of shares of common stock outstanding for the year
ended December 31, 2025 and December 31, 2024 include the shares of the Company issued and outstanding during such period, on a weighted
average basis. The basic weighted average number of shares of common stock outstanding excludes common stock equivalents such as stock
options and warrants, while diluted weighted average number of shares outstanding includes such stock options and warrants. As of December
31, 2025 there were <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zY1vFKjEfDHj" title="Antidilutive securities excluded from computation of earnings per share">2,814,057</span> common stock warrants and <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zAjoxzE3nv6e" title="Antidilutive securities excluded from computation of earnings per share">4,187,670</span> common stock options that were not included in the computation of diluted
earnings per share, because to do so would have an antidilutive effect. As of December 31, 2024 there were <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zDJUG8wNt7E6" title="Antidilutive securities excluded from computation of earnings per share">2,814,057</span> stock warrants and
<span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z6tprkC9Tt49" title="Antidilutive securities excluded from computation of earnings per share">2,352,670</span> stock options that were not included in the computation of diluted earnings per share, because to do so would have an antidilutive
effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_846_ecustom--RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_zBRaUZBi3TX9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_865_zqWhF34cwIFb">Recent accounting pronouncements not yet
adopted</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2023, the FASB issued ASU 2023-09,
<i>Income Taxes (Topic 740) - Improvements to Income Tax Disclosures</i>. The new standard requires a company to expand its existing
income tax disclosures, specifically related to the rate reconciliation and income taxes paid. The standard is effective for the Company
beginning in fiscal year 2025. The Company applied the amendments prospectively for the year ended December 31, 2025, and the impact
of the adoption of the amendments in this update was not material to the Company&#8217;s financial position and results of operations
for the year ended December 31, 2025, since the amendments require only enhancement of existing income tax disclosures in the footnotes
to the Company&#8217;s financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2024, the FASB issued ASU 2024-03,&#160;<i>Income
Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures&#160;</i>(Subtopic 220-40), which requires entities to provide
more detailed disaggregation of expenses in the income statement, focusing on the nature of the expenses rather than their function.
The new disclosures will require entities to separately present expenses for significant line items, including but not limited to, depreciation,
amortization, and employee compensation. Entities will also be required to provide a qualitative description of the amounts remaining
in relevant expense captions that are not separately disaggregated quantitatively, disclose the total amount of selling expenses and,
in annual reporting periods, provide a definition of what constitutes selling expenses. This pronouncement is effective for fiscal years
beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted.
The Company does not expect the adoption of this new guidance to have a material impact on the consolidated financial statements.</p>

<p id="xdx_857_zsBX1Un9Bvc4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Going Concern</a></td>
<td class="text"><p id="xdx_802_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zLT3LOnHb4Dc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2. <span><span id="xdx_82B_zKAs4dlBKZTk">Going Concern</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have been
prepared assuming the Company will continue as a going concern which contemplates the realization of assets and settlement of liabilities
and commitments in the normal course of business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the Company had cash of approximately $<span id="xdx_905_eus-gaap--Cash_iI_pn5n6_c20251231_zbwqPtCpZZU4" title="Cash">7.3</span> million. The Company raised approximately $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250101__20251231_zdUdRSVqKBCb" title="Raised amount">9.6</span> million in 2025, used
approximately $<span id="xdx_90D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20250101__20251231_zUkOpn2Azphl" title="Cash in operations">3.7</span> million of cash in operations during the year ended December 31, 2025, had a net loss of $<span id="xdx_90D_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20250101__20251231_zIMI4waMEKYc" title="Net Loss">10.4</span> million in 2025 and
had stockholders&#8217; equity of approximately $<span id="xdx_903_eus-gaap--StockholdersEquity_iI_pn5n6_c20251231_zMNVUjpEMC28" title="Stockholders equity">5.9</span> million at December 31, 2025, versus stockholders&#8217; equity of approximately
$<span id="xdx_905_eus-gaap--StockholdersEquity_iI_pn5n6_c20241231_zvZDwnTwCI6j" title="Stockholders equity">0.6</span> million at December 31, 2024.</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Historically, the Company has been primarily
engaged in developing Telomir-1. During these activities, the Company sustained substantial losses. The Company&#8217;s ability to fund
ongoing operations and future clinical trials required for FDA approval is dependent on the Company&#8217;s ability to obtain significant
additional external funding in the near term. Since inception, the Company has financed its operations through related party financings-see
Note 4, an initial public offering &#8211; see Note 1, and ATM financings. Additional sources of financing may be sought by the Company.
However, there can be no assurance that any fundraising will be achieved on commercially reasonable terms, if at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of filing this Annual Report,
the Company will continue to generate losses and have insufficient cash and cash equivalents on hand to support its operations for at
least the 12 months following the date the financial statements are issued. These factors raise substantial doubt about the Company&#8217;s
ability to continue as a going concern for a period of twelve months from the issuance date of this report. Management cannot provide
assurance that the Company will ultimately achieve profitable operations or become cash flow positive or raise additional debt and/or
equity capital. The Company is seeking to raise capital through additional debt and/or equity financings to fund our operations in the
future. If the Company is unable to raise additional capital or secure additional lending in the near future, management expects that
the Company will need to curtail its operations. These financial statements do not include any adjustments related to the recoverability
and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to
continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License agreement, related party<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_DisclosureLicenseAgreementRelatedPartyAbstract', window );"><strong>License Agreement Related Party</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_LicenseAgreementRelatedPartyTextBlock', window );">License agreement, related party</a></td>
<td class="text"><p id="xdx_80A_ecustom--LicenseAgreementRelatedPartyTextBlock_zuHDf3ShNRIe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 3. <span id="xdx_821_zX0Qk8kWsmkc">License agreement, related party</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company licenses the U.S. patent rights for
the use of Telomir-1 in human applications from MIRALOGX, LLC (&#8220;MIRALOGX&#8221;), an intellectual property development and holding
company owned by a trust established by the Company&#8217;s founder&#8212;a related party to the Company and greater than <span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MiralogxLLCMember_zN1c5biwwgt7" title="Ownership percentage">10</span>% shareholder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 11, 2023, (the &#8220;Effective Date&#8221;),
the Company and MIRALOGX entered into an Amended and Restated Exclusive License Agreement, under which the Company has the exclusive
perpetual right and license under the above-described patent rights to make, have made, use, and sell &#8220;Licensed Products&#8221;
in the U.S. for human uses and preclinical studies and activities of any kind conducted in furtherance of obtaining regulatory approval
or commercialization for human uses (the &#8220;MIRALOGX License Agreement&#8221;). On November 10, 2023, the Company and MIRALOGX entered
into the Amendment No. 1 to the Amended and Restated License Agreement, pursuant to which the field of use relating to the license was
amended to include therapeutic treatments and other medical or health uses in animals, in addition to humans, and related preclinical
studies and activities conducted in furtherance of obtaining regulatory approval for and commercialization of veterinary, in addition
to human, therapeutic treatments and uses (together with the &#8220;Initial MIRALOGX License Agreement, the &#8220;MIRALOGX License Agreement&#8221;).
&#8220;Licensed Product&#8221; is defined in the agreement as a drug product containing as an active agent 2,4,6-tris(3,4-dihydro-2H-pyrrol-2-yl)
pyridine or a pharmaceutically acceptable salt, ester, or solvate thereof. The Company also has the right to grant corresponding sublicenses
under the licensed patent rights. The MIRALOGX License Agreement provides for the payment to MIRALOGX of an <span id="xdx_90D_ecustom--PercentageOfRoyaltyPayable_iI_dp_uPure_c20230811__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zmwA0puwMBQ1" title="Percentage of royalty payable">8</span>% royalty (payable quarterly)
on the Company&#8217;s net sales of Licensed Products by the Company or its sublicensees and on non-royalty bearing milestone revenue.
There are no up-front, execution, or milestone payments in the license agreement. Further, no payments have been made to date under the
agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The term of the license from MIRALOGX will continue
through the date of the expiration of the last-to-expire licensed patent or, if later, the date of the expiration of the last strategic
partnership/sublicensing agreement covering the licensed products. The patent rights are expected to extend through 2043, and additional
patent terms may be awarded, including additional patent terms based on the time taken for regulatory review of drug products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The agreement also provides that Telomir may
bring suit in its own name to enforce patent rights. MIRALOGX will control the prosecution of the patent applications for Telomir-1.
Telomir is required to be kept informed by MIRALOGX of patent prosecution activities and may select identified countries for patent protection.
Telomir is to reimburse MIRALOGX for patent prosecution and maintenance costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_DisclosureLicenseAgreementRelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_DisclosureLicenseAgreementRelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_LicenseAgreementRelatedPartyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement Related Party [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_LicenseAgreementRelatedPartyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related parties balances and transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related parties balances and transactions</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zFCAYHHwfmG9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 4. <span id="xdx_82F_z0B6Wg15XUX9">Related parties balances and transactions</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Due to Officer</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 27, 2025, <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250526__20250527_zxEPbzG6hY5b" title="Issuance of common stock for services, shares">400,000</span> fully vested common
shares were granted for services to our Chairman and Chief Executive Officer, Erez Aminov, who is the son-in-law of Jonnie R. Williams
(see below). The shares were valued at $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250527__20250527_zz3hgQpaTP0f" title="Vested common shares service, value">840,000</span> based on the stock quoted trading price at the grant date and were expensed immediately
as compensation expense. In December 2025, Mr. Aminov transferred $<span id="xdx_90F_eus-gaap--DebtInstrumentRepurchaseAmount_iI_c20251231_zijLWuntQxUk" title="Debt Instrument, Repurchase Amount">155,518</span> to the Company, for the Company to use to pay certain payroll
withholding taxes Mr. Aminov owed as a result of this RSU grant. These payroll taxes ultimately were not paid in the Company&#8217;s
payroll processing. Therefore, in January 2026, $<span id="xdx_903_eus-gaap--AccruedPayrollTaxesCurrentAndNoncurrent_iI_c20260131_zWxdXEoGZr1a" title="Payroll taxes">155,518</span> was paid back to Mr. Aminov so he can remit this amount directly to the IRS.
The company, however, did remit the employer portion of his Medicare taxes totaling $<span id="xdx_909_eus-gaap--TaxesOther_c20250101__20251231_zknPUSYV97d8" title="Medicare taxes">12,180</span> in 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Due from related parties</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2023, the
Company provided working capital advances to companies under common control. These advances were due on demand and are non-interest bearing.
Amounts due from related parties as of December 31, 2023 were $<span id="xdx_903_eus-gaap--OtherReceivablesNetCurrent_iI_pn4n6_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zto98vd8Jmj5" title="Amounts due from related parties">0.13</span>&#160;million. In 2024, the company under common control was dissolved
and therefore the amount due become uncollectable and was written off and reflected as credit loss expense, which is included in general
and administration expenses. As of December 31, 2024, there was&#160;<span id="xdx_90D_eus-gaap--OtherReceivables_iI_do_c20241231_zvqs9AyY7Eu9" title="Amount due from related parties">no</span>&#160;amount due from related parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Due to related parties</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2024, the
Company received working capital advances from related party companies under common control. These advances are due on demand and are
non-interest bearing. During the year ended December 31, 2025, a related party, MIRALOGX, shipped pharmaceutical chemicals to Telomir&#8217;s
service provider for ongoing research at a cost of approximately $<span id="xdx_907_eus-gaap--CostsAndExpensesRelatedParty_c20250101__20251231_zq3bixHxPxQ8" title="Costs and Expenses, Related Party">224,800</span>. As of December 31, 2025 and 2024, the amounts due to related
parties is $<span id="xdx_906_eus-gaap--OtherReceivablesNetCurrent_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zlX3PKC7d4s3" title="Amount due from related parties">318,234</span> and $<span id="xdx_90A_eus-gaap--OtherReceivablesNetCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zH3M4OpdHLYe" title="Amount due from related parties">93,432</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Investment from Largest Shareholder</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 19, 2025, the Company entered into an
agreement to raise $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn6n6_c20250518__20250519_zV85LNB5zcn6" title="Raised amount in equity financing">3</span> million in equity financing through a direct investment by The Bayshore Trust, an entity affiliated with the Company&#8217;s
largest shareholder, Jonnie R. Williams, Sr. The transaction was structured as a straight restricted common stock deal with no warrants.
The Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20250518__20250519_zF4UueDlZZk2" title="Number of restricted shares issued">333,334</span> restricted shares of its common stock, no par value (the &#8220;Common Stock&#8221;) at a purchase price of
$<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20250519_zEGG0u3gJf6g" title="Purchase price per share">3.00</span> per share, representing an <span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardPriceOfCommonStockPercent_pid_dp_uPure_c20250518__20250519_zWjL1lsVjamd" title="Premium share price percentage">18</span>% premium to the closing share price of the Common Stock of $<span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20250519__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNI76Ln9ibDj" title="Purchase price per share">2.54</span> on the date of execution (the &#8220;Bayshore
Financing&#8221;). The Company received the initial payment of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn6n6_c20250520__20250520_zfPI6521hmyb" title="Initial payment">1</span> million for the Bayshore Financing on May 20, 2025. In July 2025, an
additional $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn6n6_c20250701__20250731__dei--LegalEntityAxis__custom--BayshorefinancingMember_zXpPCvPz7jLg" title="Initial payment">2</span> million was received, for the issuance of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250701__20250731__dei--LegalEntityAxis__custom--BayshorefinancingMember_zc5JH9hKDeke" title="Issuance of common stock for cash in ATM, net, shares">666,666</span> shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Bay Shore Trust Line of Credit </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 15, 2023, the Company entered into a
Promissory Note and Loan Agreement with the Bay Shore Trust, a trust established by the Company&#8217;s founder, Jonnie R. Williams,
Sr., and under which various of his family members are beneficiaries. Under this Promissory Note and Loan Agreement (the &#8220;Bay Shore
Note&#8221;), the Company had the right to borrow up to an aggregate of $<span id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zFFmnsa4vjAf" title="Unused line of credit">5</span> million from the Bay Shore Trust at any time up to the second
anniversary of the issuance of the Bay Shore Note or, if earlier, upon the completion of the Company&#8217;s IPO. As of December 31,
2025 and 2024, the line of credit is no longer available as the IPO was completed in February 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In consideration of the loan facility provided
by the Bay Shore Trust, the Company issued to the Bay Shore Trust a Common Stock purchase warrant on June 15, 2023 giving the Bay Shore
Trust the right to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zrdGKXcSPqfa" title="Fair value of total warrants issued">2,439,025</span> shares of Common Stock at an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zl6v0E13OVr5" title="Exercise price">3.73</span> per share (See Note 7).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Starwood Trust Line of Credit and Stock
Purchase Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 24, 2024 the Company entered into
an unsecured Promissory Note and Loan Agreement (&#8220;the Starwood Note&#8221;) with the Starwood Trust, a separate related party trust
established by the Company&#8217;s founder, Jonnie R. Williams, Sr. who is the sole owner of Bay Shore Trust as well as our largest shareholder,
and under which various of his family members are beneficiaries. Under the Starwood Note, the Company has the right to borrow up to an
aggregate of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20240924__dei--LegalEntityAxis__custom--StarwoodTrustMember_ziLnTzY1SvH" title="Aggregate borrowings amount">5</span>&#160;million from the Starwood Trust at any time up until September 24, 2026, the second anniversary of the note. The
Company&#8217;s right to borrow funds under the Starwood Note is subject to the absence of a material adverse change in its assets, operations,
or prospects The Starwood Note contains default provisions in which in the event of the Company misses payment, makes false representations,
fails to comply in any material respect to covenants, files for bankruptcy, or experiences a material adverse change in is assets or
operations than the Company is considered in default and the entire unpaid principal and accrued interest is due immediately. The Starwood
Note, together with accrued interest, is to become due and payable on the second anniversary of the issuance of the note, provides for
prepayment at any time without penalty, and accrues simple interest at a rate equal&#160;<span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240924__dei--LegalEntityAxis__custom--StarwoodTrustMember_zAYufrXDzly9" title="Interest rate">7</span>% per annum. As of December 31, 2025 and 2024,
the Company has not borrowed any amounts under the Starwood Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, on December 9, 2024, Starwood Trust
entered into a stock purchase agreement with the Company to purchase <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241209__20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_zUI8d2yFppZk" title="Issuance of common stock, net, shares">142,857</span> shares of unregistered common stock at $<span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_zCYpV9BNajWd" title="Share price">7</span> a share for a
total of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20241209__20241209_zzG7EfP120ib" title="Proceeds from common stock">1.0</span> million in proceeds to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>License agreement</i> - </b>See Note 3</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Related Party Travel Costs</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 1, 2023 the Company entered into an
Agreement For Shared Lease Costs (the &#8220;Shared Agreement&#8221;) with MIRALOGX, LLC, a related party under which we have agreed
to pay our pro rata share of the operating usage costs owing by MIRALOGX under an aircraft lease agreement between MIRALOGX and Supera
Aviation I LLC (&#8220;Supera Aviation&#8221;) based on our usage of the leased aircraft each month. No amounts are payable by the Company
under this agreement unless and to the extent the Company chooses to utilize the leased aircraft, and the Company may discontinue the
use of the aircraft and terminate this agreement at any time. Supera Aviation is a company owned by Starwood Trust, a trust established
by Mr. Williams, the Company&#8217;s founder and largest shareholder. For the year ended December 31, 2025 and December 31, 2024, the
Company incurred <span id="xdx_90C_eus-gaap--TravelAndEntertainmentExpense_dxL_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zm7D8mwFSaHg" title="Related party travel costs::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0509">nil</span></span> and $<span id="xdx_906_eus-gaap--TravelAndEntertainmentExpense_pn4n6_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zJQAQorqVN5l" title="Related party travel costs">0.37</span> million, respectively, in expenses under the aircraft lease agreement. The aircraft lease was terminated
in April 2024 and no other costs have been incurred under this agreement since the lease termination (See Note 6 Variable lease costs).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Related Party Rental Agreement</i></b><i>-</i>
see Note 6 for Variable lease costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Proposed Merger Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_DisclosureProposedMergerAgreementAbstract', window );"><strong>Proposed Merger Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_ProposedMergerAgreementDisclosureTextBlock', window );">Proposed Merger Agreement</a></td>
<td class="text"><p id="xdx_802_ecustom--ProposedMergerAgreementDisclosureTextBlock_zHCyNwcpprFi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 5. <span id="xdx_824_z4AiPPcQ1D69">Proposed Merger Agreement</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company and TELI Pharmaceuticals, Inc., a
related party private company incorporated under the laws of Delaware (&#8220;TELI&#8221;) have entered into an Agreement and Plan of
Merger and Reorganization, dated November 20, 2025, and as amended on February 4, 2026 (collectively, the &#8220;Merger Agreement&#8221;),
pursuant to which a wholly owned subsidiary of Telomir will merge with and into TELI, with TELI surviving as a wholly owned subsidiary
of Telomir (the &#8220;Merger&#8221;), subject to shareholder approval. At the effective time of the Merger (the &#8220;Effective Time&#8221;),
each outstanding share of common stock of TELI, $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20260204__us-gaap--BusinessAcquisitionAxis__custom--TeliPharmaceuticalsIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zynZBUfk5HZ4" title="Common stock, par value">0.0001</span> par value per share (&#8220;TELI Common Stock&#8221;), will be converted into
the right to receive such number of Telomir Common Stock as is calculated based on the exchange ratio of the shares for the Merger (the
&#8220;Exchange Ratio&#8221;). The Exchange Ratio is calculated using the relative company valuations of each of Telomir and TELI, as
determined by an independent valuation firm. It is expected that shareholders of TELI will receive one share of Telomir Common Stock
for each share of TELI Common Stock held (the &#8220;Merger Share Consideration&#8221;). The Telomir Common Stock issued as the consideration
will not be registered for trading under the Securities Act. The Merger will result in an alignment of U.S. and non-U.S. rights to Telomir-1
within a single public company structure, thereby simplifying global development and partnership efforts. As a result of the Merger,
Telomir will own the entire worldwide intellectual property portfolio and development programs related to Telomir-1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transaction is expected to be recorded
as an asset acquisition from a related party at acquired cost basis with two assets to be acquired, the license agreement and
$<span id="xdx_903_eus-gaap--PaymentsToAcquireMarketableSecurities_c20260204__20260204__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLImq8MQek" title="Cash or marketable securities">1,000,000</span> in cash or marketable securities. TELI is a newly formed legal entity with no revenue, no employees, no facilities, and
no infrastructure. TELI&#8217;s assets as of the Merger Date will consist exclusively of the $<span id="xdx_90D_eus-gaap--PaymentsToAcquireMarketableSecurities_c20260204__20260204__us-gaap--BusinessAcquisitionAxis__custom--TeliPharmaceuticalsIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zEnGKa9sWeca" title="Cash or marketable securities">1,000,000</span> in cash or marketable
securities and the Telo-1 license agreement with MIRALOGX. MIRALOGX is the licensor of the Company&#8217;s and TELI&#8217;s rights
to Telomir-1. MIRALOGX is a separate intellectual property development company owned by the Bayshore Trust. The Bayshore Trust, a
related party, is also TELI&#8217;s largest stockholder. The license agreement grants rights to develop and commercialize the
Telomir-1 compound in the United Arab Amirates, Australia, Canada, China, European Union, Israel, India, Japan, South Korea, Mexico,
Argentina, Taiwan and Uruguay. No other tangible or intangible assets, such as equipment, customer relationships, or developed
technologies, will be transferred. The contingent consideration to Telomir in the transaction consists of two possible payments.
Certain shareholders of TELI will agree to provide $<span id="xdx_900_eus-gaap--AssetAcquisitionConsiderationTransferredTransactionCost_pn6n6_c20260204__20260204__us-gaap--AssetAcquisitionAxis__custom--TelomirOneMember_z8MGnuVeLV19" title="Contingent consideration transaction cost">2</span> million upon FDA acceptance of an Investigational New Drug or IND application
for Telomir-1, and $<span id="xdx_905_eus-gaap--AssetAcquisitionConsiderationTransferredTransactionCost_pn6n6_c20260204__20260204__us-gaap--AssetAcquisitionAxis__custom--PhaseOneByTwoMember_z7u2ANPLaGZc" title="Contingent consideration transaction cost">2</span> million upon initiation of a Phase 1/2 study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_DisclosureProposedMergerAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_DisclosureProposedMergerAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_ProposedMergerAgreementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proposed merger agreement disclosure [text block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_ProposedMergerAgreementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_806_eus-gaap--LesseeOperatingLeasesTextBlock_zawm3LcwKda7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 6. <span id="xdx_827_zNYFHJwCCwq9">Leases</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s former corporate headquarters
was located in Baltimore, Maryland, which included a lease for office space. This lease began in November 2022 and expired in April 2024.
The lease was not renewed. To align with the accounting and administrative staff detailed below, the Company moved all remaining corporate
activities in April 2024 to the shared space in Tampa, Florida referenced below within variable lease costs. In September 2024, the Company
decided to no longer utilize the shared space and moved to a virtual office model. The Company has not had a physical office space since
October 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Variable lease costs</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Variable lease costs primarily include utilities,
property taxes, and other operating costs that are passed on from the lessor for the former corporate headquarters in Baltimore, Maryland.
Variable lease costs related to the usage of the MIRALOGX airplane include usage expenses, which includes pilot expenses, jet fuel and
general flight expenses that totaled <span id="xdx_90B_eus-gaap--VariableLeaseCost_pn6n6_dxL_c20250101__20251231__dei--LegalEntityAxis__custom--MiralogxLLCMember_zlvaIoQgaSDf" title="Variable lease, cost::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0527">nil</span></span> and $<span id="xdx_90A_eus-gaap--VariableLeaseCost_pn4n6_c20240101__20241231__dei--LegalEntityAxis__custom--MiralogxLLCMember_za7jS8eni2Ya" title="Variable lease, cost">0.32</span> million in 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Beginning August 1, 2023, the Company&#8217;s
accounting and administrative staff began sharing office space with a related party in Tampa, Florida. During the year ended December
31, 2024, this variable least cost related to the Tampa, Florida space totaled $<span id="xdx_90E_eus-gaap--VariableLeaseCost_pn4n6_c20240101__20241231__srt--StatementGeographicalAxis__custom--TampaFloridaMember_zOrri1CkaEWa" title="Variable lease, cost">0.02</span> million. The Company did not have lease costs during
the year ended December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_899_eus-gaap--LeaseCostTableTextBlock_zskfffFPOTjb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The components of lease expense were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B9_zK7BPagaSni4" style="display: none">Schedule of Components of Lease Expenses</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20250101__20251231_zwRyEPX32mg1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zCUrlNHyobJc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Lease Costs</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Operating lease cost</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseCost_maLCzhnC_zazPIYT7LTdk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; width: 60%; text-align: left">Operating lease</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0535">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">55,667</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--VariableLeaseCost_maLCzhnC_zMpYOHkOlHZ2" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Variable lease costs</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0538">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">336,656</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LeaseCost_iT_mtLCzhnC_zK7pGGuKPHIj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0541">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">392,323</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A3_ziVK133MZsq" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; equity</a></td>
<td class="text"><p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zpCZYr7cerTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 7. <span id="xdx_82F_zzuTRjiR7yRa">Stockholders&#8217; equity</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Capital stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has the authority to issue <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20251231_zyEaGWtevQ5h" title="Issue of shares of capital stock">400,000,000</span>
shares of capital stock, consisting of <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20251231_zXm4V5QyRyj7" title="Common stock, shares authorized">300,000,000</span> shares of Common Stock and <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20251231_zsS9Zuo5gk0i" title="Preferred stock, shares authorized">100,000,000</span> shares of undesignated preferred stock, whose
rights and privileges will be defined by the Board of Directors when a series of preferred stock is designated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration: underline">2024</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 13, 2024, the Company closed its
initial public offering consisting of&#160;<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zFIkIJZIoWd4" title="IPO units, shares">1,000,000</span>&#160;shares at a price of $<span id="xdx_909_eus-gaap--SharePrice_iI_pid_c20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zOrVrnwCQq69" title="Initial public offering shares">7.00</span>&#160;per share for approximately $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z1XB749cGgB1" title="Gross proceeds">7.0</span>&#160;million
in gross proceeds. After deducting the underwriting commission and other offering expenses totaling $<span id="xdx_906_eus-gaap--OtherUnderwritingExpense_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zVJZFYDF1mT8" title="Underwriting commission and other offering expenses">1.2</span>&#160;million, the net proceeds
to the Company were $<span id="xdx_90B_ecustom--ProceedsFromInitialPublicOfferingNetProceeds_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zXKv8Ejxtd77" title="Initial public offering net proceeds">5.8</span>&#160;million (the &#8220;IPO&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 9, 2024, Starwood Trust, a related
party, entered into a stock purchase agreement with the Company to purchase <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241209__20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_ztt5AiAA8fJj" title="Purchase of shares">142,857</span> shares of unregistered common stock at $<span id="xdx_90B_eus-gaap--SharePrice_iI_c20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_zBepMB3pLAlb" title="Share price">7</span> a share
for a total of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20241209__20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_zyNk5qPycyWh" title="Proceeds from issuance of common stock">1.0</span> million in proceeds to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2024, deferred
offering costs from December 31, 2023 of $<span id="xdx_902_eus-gaap--DeferredOfferingCosts_c20231231_pp0p0" title="Deferred offering costs">303,281</span> and offering costs of $<span id="xdx_90D_ecustom--OfferingCosts_iI_pp0p0_c20241231_zIQahD5ePC2j" title="Offering costs">863,744</span> incurred in 2024 were charged against additional paid
in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration: underline">2025</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 14, 2025, the Company filed a shelf
registration statement with the SEC to facilitate the issuance of our common stock and entered into an At The Market Offering Agreement
(the &#8220;ATM Agreement&#8221;) with Rodman &amp; Renshaw LLC under which the Company may offer and sell shares of its Common Stock,
with an aggregate offering amount to be sold of up to $<span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250214__20250214__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zRnOSWCvYyI" title="Aggregate offering amount">100,000,000</span>. During the year ended December 31, 2025, the Company sold a total
of <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250101__20251231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketOfferingMember_zv2tnUE5EyFc" title="Common stock shares">3,218,300</span> shares of its common stock, at a weighted average price of $<span id="xdx_90E_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20251231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketOfferingMember_z4mMUSZ6y28l" title="Weighted average price">2.12</span> for total proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20250101__20251231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketOfferingMember_zpJYUzirq2O6" title="Proceeds from issuance or sale of equity">6,553,209</span>, net of costs of $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250101__20251231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketOfferingMember_zYioGZ9vCGB6" title="Proceeds from issuance of common stock">72,092</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 19, 2025, the Company entered into an
agreement to raise $<span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn6n6_c20250519__20250519_zQYzFXbfvhM7" title="Raised amount in equity financing">3</span>&#160;million in equity financing through a direct investment by The Bayshore Trust, an entity affiliated with the
Company&#8217;s largest shareholder. The transaction was structured as a straight restricted common stock deal with no warrants. The
Company issued&#160;<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20250519__20250519_z4yEpnShA4E8" title="Number of resricted shares issued">333,334</span>&#160;restricted shares of its common stock, no par value at a purchase price of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250519_zJZ7ZW1XIfC9" title="Purchase price per share">3.00</span>&#160;per share, representing
an&#160;<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20250519__20250519_zcF2MfYPlPP7" title="Premium share price percentage">18</span>% premium to the closing share price of the Common Stock of $<span id="xdx_90D_eus-gaap--SharePrice_iI_pid_c20250519__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7DclcrM4CRj" title="Share price">2.54</span>&#160;on the date of execution (the &#8220;Bayshore Financing&#8221;).
The Company received the initial payment of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn6n6_c20250520__20250520_z5llPktz0U82" title="Initial payment">1</span>&#160;million for the Bayshore Financing on May 20, 2025. In July 2025, an additional $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn6n6_c20250724__20250724_zNdiOKqdS4C4" title="Additional payment received">2</span>&#160;million
was received, for the issuance of&#160;<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250701__20250731_zvKZmg3wh0Ra" title="Number of shares issued">666,667</span>&#160;shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 27, 2025,&#160;<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250527__20250527_zNKJmeF0jMBa" title="Vested common shares service">400,000</span>&#160;fully vested
common shares were granted for services to the Company&#8217;s CEO. The restricted shares were valued at $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250527__20250527_zKcrYhQZDh75" title="Vested common shares service, value">840,000</span>&#160;based on the stock
quoted trading price at the grant date and were expensed immediately as compensation expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Warrants </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with various transactions and the
IPO summarized below, the Company issue stock warrants. Warrant activity for the years ended December 31, 2025 and 2024 is summarized
below:</p>

<p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zbF16ohohb73" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B7_zLWTij5Zc7x3" style="display: none">Schedule of Warrant Activity</span>&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Remaining Contractual</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Aggregate Intrinsic</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Warrants</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Exercise Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Term (Years)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Value</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 36%">Outstanding as of December&#160;&#160;31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSgzcXCqO8Bd" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of Warrants Outstanding, Beginning Balance">2,774,057</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaOWzKyPNL4b" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">4.85</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_zyDrtLyYTlU5" title="Weighted Average Remaining Contractual Term (Years), Outstanding Balance">4.5</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">(1)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlO6WbuaHBab" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Aggregate Intrinsic Value, Outstanding Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl0610">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zekvfhw65G1d" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Granted">50,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4VeUTvz9QS6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted">7.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdK1dWmryMj4" title="Weighted Average Remaining Contractual Term (Years), Granted">3.2</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfY5uuixhkXc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised">(10,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWfw2ZLktGL9" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Exercised">3.73</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;&#160;&#160;&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Outstanding as December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKVUmero7Gj7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants Outstanding, Beginning Balance">2,814,057</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsO5r9vgaU38" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">4.97</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDIp_zRAzKSd2xari" title="Weighted Average Remaining Contractual Term (Years), Outstanding Balance">3.49</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">(2)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZVF5Pk3yu4i" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Outstanding Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl0628">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsGhpzl8Y4We" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0630">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbpvVCVaQ5Ea" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0632">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Outstanding as of December 31, 2025</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zf0wLrTBFHVe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants Outstanding, Ending Balance">2,814,057</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsfxDR0OeTV7" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance">4.97</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDIp_z9tUtCU4y52f" title="Weighted Average Remaining Contractual Term (Years), Outstanding Balance">2.45</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">(2)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3XbuYdeo4mj" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Outstanding Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl0640">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="vertical-align: top; width: 0.25in; padding-bottom: 0pt; text-align: left"><span id="xdx_F00_zDaoA1QFIxJ3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="padding-bottom: 0pt; text-align: justify"><span id="xdx_F18_zK8FIGlqJnkb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    warrants herein consist of various contractual terms. The warrants herein consist of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember_zql5MGAc3hig" title="Class of warrants or right number of securities called by warrants or rights">2,439,025</span> warrants issued to Bay Shore Trust
    that have a remaining contractual term of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember_zzBNVlLe1s7g" title="Warrants and rights outstanding term">2.5</span> years as of December 31, 2025, and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zzKKbMRXLy43" title="Class of warrants or right number of securities called by warrants or rights">335,032</span> warrants issued to investors associated
    with the 2023 Private Placement that currently have an indeterminable contractual term. See disclosures below for more information
    on these warrants</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left"><span id="xdx_F0F_zOO4wfwv8DSa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="padding-bottom: 0pt; text-align: justify"><span id="xdx_F1C_zYWuwkJCT5G5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    warrants herein consist of various contractual terms. The warrants herein consist of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zR74nO7EjC5e" title="Warrants issued">2,429,025</span> warrants issued to Bay Shore Trust
    that have a remaining contractual term of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYImeeA0dK1e" title="Warrants remaining contractual term">2.5</span> years as of December 31, 2025; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zhi1RrUuEnck" title="Warrants issued">335,032</span> warrants issued to investors associated with
    the 2023 Private Placement that currently have an indeterminable contractual term, and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantMember_zNmj2VNvS6hi" title="Warrants issued">50,000</span> warrants issued to underwriters as
    part of the IPO with a remaining contractual life of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantMember_zULkKyLPZwji" title="Warrants remaining contractual term">3.2</span> years. See disclosures below for more information on these warrants</span></td></tr>
  </table>
<p id="xdx_8A9_zEa452R8zOSh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Private placement Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2023, the
Company issued to the 2023 Private Placement investors a Common Stock warrant the right to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zvc2ULAczpu8" title="Purchase of common stock">268,025</span> shares of common stock
at an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zATUyVfStDOd" title="Exercise price">15.42</span> per share. The Company also issued to the placement agent a Common Stock warrant the right to purchase
up to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--PlacementAgentMember_z5IeBiA3nDg7" title="Purchase of common stock">67,007</span> shares of common stock at an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--PlacementAgentMember_zBJlgu0kOCjj" title="Exercise price">3.73</span> per share. Both issuances of warrants are immediately vested and will
be exercisable any time until the day that is one year plus ninety days from the date an Investigational New Drug, or IND, filing is
made with the FDA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Bay Shore Trust Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In consideration of the line of credit provided
by the Bay Shore Trust, the Company issued to the Bay Shore Trust a common stock purchase warrant on June 15, 2023 giving the Bay Shore
Trust the right to purchase up to&#160;<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zizjv4p1mJ92" title="Shares of common stock">2,439,025</span>&#160;shares of common stock at an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zGRQwMMfrJ2i" title="Exercise price">3.73</span>&#160;per share. This warrant
will expire <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zsfm4vhTwd01" title="Exercise price">five years</span> after the date of grant.. The fair value of the warrants were estimated on the grant date using the Black-Scholes
valuation model and level 3 inputs based on assumptions for expected volatility, expected dividends, expected term, and the risk-free
interest rate, which resulted in $<span id="xdx_90E_eus-gaap--DeferredFinanceCostsNet_iI_pn4n6_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zKLhU6aA3gub" title="Deferred financing costs">5.95</span>&#160;million of deferred financing costs. In 2023 this cost was recorded as deferred financing
costs and additional paid in capital on the balance sheet and was amortized straight-line over the term of the line of credit (which
is 24 months). Associated amortization of deferred finance costs was recorded to interest expense on the statement of operations. The
line of credit expired upon the IPO occurring in February 2024, and as such the remaining deferred financing costs associated with the
warrant was fully amortized to interest expense in 2024. As of December 31, 2024, the warrant is fully amortized (see Note 4).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 22, 2024, Bay Shore Trust transferred
<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241122__dei--LegalEntityAxis__custom--BayShoreTrustMember_zdTH8apfOer9" title="Shares of common stock">100,000</span> warrants to an unaffiliated party as part of a gift transfer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2024,&#160;<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__dei--LegalEntityAxis__custom--BayShoreTrustMember_zbBwXnGX684" title="Shares of common stock">10,000</span> Common Stock warrants
were exercised at an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__dei--LegalEntityAxis__custom--BayShoreTrustMember_zX0XLRJrEzTj" title="Exercise price">3.73</span> per share and the Company issued&#160;<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241201__20241231__dei--LegalEntityAxis__custom--BayShoreTrustMember_zHN2GXRElpSg" title="Issuance of common stock">10,000</span>&#160;shares of Common Stock upon such exercise
in exchange for $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20241201__20241231__dei--LegalEntityAxis__custom--BayShoreTrustMember_zO1C5Ee8Gzbc" title="Issuance of common stock, value">37,300</span> delivered to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Underwriter warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the IPO in February 2024,
the Company issued&#160;<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240229__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqHCIbWDXnpj" title="Warrants to purchase common stock">50,000</span>&#160;warrants to purchase Common Stock to the IPO underwriter (or its designees) at an exercise price
of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240229__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUysGADoXYcf" title="Exercise price">7.00</span>&#160;which are exercisable immediately and expire in the four-and-a-half-year period commencing six months after the commencement
of sales in the IPO. The warrants provide for registration rights (including a one-time demand registration right and piggyback registration
rights that expire 5 years from the commencement of sales of the offering) and customary anti-dilution provisions as permitted under
FINRA Rule 5110(g)(8). The fair value of the warrants were estimated on the grant date using the Black-Scholes valuation model and level
3 inputs based on assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate, which resulted
in $<span id="xdx_900_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20240229__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpx3YmSwkfPc" title="Equity issuance cost">0.2</span> million of equity issuance costs. The warrants were considered equity issuance costs and therefore there was no financial statement
impact during the year ended December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_892_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember_zaEH1wv1i3d7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Key assumptions used to value underwriter warrants in February 2024
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BD_z5zAKzgwTGh4" style="display: none">Schedule of Key Assumptions Used to Value Warrants</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 50%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-size: 10pt">Expected price volatility</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 16%; font-size: 10pt; text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zNEHZOZqCEgc" title="Warrant measurement input">84.78</span></td><td style="width: 1%; font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Risk-free interest rate</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zTufeFAJ6ks1" title="Warrant measurement input">4.14</span></td><td style="font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Fair Market Value of underlying Common Stock</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputFairMarketValueUnderlyingCommonStockMember_zkiSfvatqy75" title="Warrant measurement input">7.01</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Expected term in years</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_znhy7r5V7c14" title="Expected term in years">5</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Dividend yield</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zabaLxhKp6T5" title="Warrant measurement input"><span style="-sec-ix-hidden: xdx2ixbrl0702">-</span></span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_z1EAasvFtAHa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>2023 Omnibus Incentive Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2023, the Company&#8217;s Board of
Directors adopted the Company&#8217;s 2023  Omnibus Incentive Plan, (&#8220;2023  Plan&#8221;). The 2023  Plan authorizes
the grant of incentive stock options, within the meaning of Section 422 of the Internal Revenue Code, to the Company&#8217;s employees
and any of its parent and subsidiary corporations&#8217; employees, and for the grant of nonstatutory stock options, restricted stock,
restricted stock units, stock appreciation rights, performance units and performance shares to the Company&#8217;s employees, directors,
and consultants and any of its future subsidiary corporations&#8217; employees and consultants</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2023  Plan provides that <span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusIncentivePlanMember_zWDlk1hkVxN6" title="Common stock are reserved for issuance">6,500,000</span>
shares of the Company&#8217;s Common Stock are reserved for issuance under the 2023  Plan, all of which may be issued pursuant
to the exercise of incentive stock options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock-based compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Stock options</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The vesting period for stock options granted is generally
immediately to one year. All stock options granted under the 2023 Plan have a maximum contractual term of ten years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The grant-date fair value of each option award
is estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility,
expected dividends, expected term, and the risk-free interest rate. In 2024 expected price volatility is based on the historical volatilities
of a peer group as the Company does not have a multi-year trading history for its shares. Industry peers consist of several public companies
in the biotech industry similar to the Company in size, stage of life cycle and product indications. Starting in 2025 expected price
volatility is based solely on the Company&#8217;s trading history for its common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Expected term of options granted is derived using
the &#8220;simplified method&#8221; which computes expected term as the average of the sum of the vesting term plus contract term. The
risk-free rate is based on the 5-year U.S. Treasury yield curve in effect at the time of grant. The Company recognizes forfeitures as
they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zS4fJ3wBJQFf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighted average assumptions for grants are
provided in the following table:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BB_zXrSBk08wuH3" style="display: none">Schedule of Key Assumptions Used to Value Stock Options</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Year ended December 31,</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20250101__20251231_zywcppCibDml" title="Expected volatility, minimum">92.5</span> - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20250101__20251231_zbwf8du1R1F6" title="Expected volatility, maximum">139.0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231_z8hUUw8m1gJa" title="Expected volatility, minimum">88.8</span> - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231_zO12gstweCwk" title="Expected volatility, maximum">90.4</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected term (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__srt--RangeAxis__srt--MinimumMember_ziC3JP46oGs" title="Expected term">5.0</span> - <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__srt--RangeAxis__srt--MaximumMember_zc4OMCC36rE6" title="Expected term">5.4</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zjsn0ym2t798" title="Expected term">5.1</span> - <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zOVvuFZW7rL1" title="Expected term">5.6</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Expected dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20250101__20251231_z2Nja1MEldtl" title="Expected dividend yield">0</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20240101__20241231_zA8eR4LadDb7" title="Expected dividend yield">0</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20250101__20251231_zFsnrmOeG4jl" title="Risk-free interest rate, minimum">4.1</span> - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20250101__20251231_z692LynCcp9i" title="Risk-free interest rate, maximum">4.2</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231_zm7wWKx569h5" title="Risk-free interest rate">3.7</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>


<p id="xdx_8A0_zTmXHVtygsOl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_zaFp6iB3kB62" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2025, the Company
issued stock options under the 2023 Plan as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BD_zdK9D3paRZq9" style="display: none">Schedule of Issued Stock Options</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of stock options</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    Price</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vesting
    period</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    13</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--AwardDateAxis__custom--MayThirteenMember_zlBVXwSDtx2g" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of stock options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardDateAxis__custom--MayThirteenMember_zrBxREo8KkEj" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.75</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: left; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_c20250101__20251231__us-gaap--AwardDateAxis__custom--MayThirteenMember_z74jNDAkPBa2" title="Vesting period">one
    year</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    27</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--AwardDateAxis__custom--MayTwentySevenMember_z8G6KovnsyQc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardDateAxis__custom--MayTwentySevenMember_zNuixU0cFoza" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.10</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_c20250101__20251231__us-gaap--AwardDateAxis__custom--MayTwentySevenMember_zb5YC6ebnGs4" title="Vesting period">immediate</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    15</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--AwardDateAxis__custom--OctoberFifteenMember_z8zUDjKZywYg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardDateAxis__custom--OctoberFifteenMember_z0MUJoaljh9e" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.73</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_c20250101__20251231__us-gaap--AwardDateAxis__custom--OctoberFifteenMember_z9jcuVPMlp67" title="Vesting period">one
    year</span></span></td></tr>
  </table>



<p id="xdx_8A5_zn9W7dCunDT9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zy9gyeG1mzJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&#8217;s stock option activity is as follows:</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><span id="xdx_8B1_zMPMC2XBN3cj" style="display: none">Schedule of Stock Option Activity</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Number of<br/>
 stock options</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Exercise price</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Remaining<br/>
 contractual life <br/>
(years)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Aggregate<br/>
 intrinsic value</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 36%">Balance at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20251231_ze4xV0HqTgN6" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of stock option, Beginning balance">2,352,670</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20251231_zZck69flFVN8" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price, Beginning balance">5.02</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_ziGNoSuEMNHf" title="Weighted average remaining contractual life (years)">9.6</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20250101__20251231_zQ2TfN5EKKXf" title="Aggregate intrinsic value, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl0762">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250101__20251231_z2iyPgtS5G27" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock option, Granted">2,087,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231_zfBB0JIAPDxc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Granted">2.11</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Expired</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_c20250101__20251231_zKt0klDuKVvf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock option, Expired">(72,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231_zT4q1hQBGNE8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Expired">5.02</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20250101__20251231_z9TM7EPjOsYl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock option, Forfeitures">(180,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20250101__20251231_zOZaJmlN7UDd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Forfeitures">5.02</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance at December 31, 2025</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250101__20251231_z6c2PLjdlsgh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock option, Ending balance">4,187,670</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231_zCclC1UlfKx3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Ending balance">3.57</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_zhaK4RzoDfC8" title="Weighted average remaining contractual life (years)">9.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20250101__20251231_znyBlOTnxyDf" title="Aggregate intrinsic value, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl0782">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Vested and exercisable at December 31, 2025</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20250101__20251231_z7XnINVLnQ0k" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock option, Vested and exercisable">4,125,170</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_c20250101__20251231_zN5sX437SXng" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Vested and exercisable">3.60</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231_ztHDm5D4IZO3" title="Weighted average remaining contractual life (years), Vested and exercisable">9.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_c20250101__20251231_zTUp8XCzPB9b" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, Vested and exercisable"><span style="-sec-ix-hidden: xdx2ixbrl0790">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Vested and expected to vest at December 31, 2025</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20250101__20251231_zal0giAgRPxj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock option, Vested and expected to vest">4,187,670</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231_zQpvIvalTXzc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Vested and expected to vest">2.14</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231_zA4ZCS8VW7fa" title="Weighted average remaining contractual life (years), Vested and expected to vest">9.6</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20250101__20251231_zQxM897GxpKh" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, Vested and expected to vest"><span style="-sec-ix-hidden: xdx2ixbrl0798">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8AE_zNC8hTkKNP44" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognized approximately $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20250101__20251231_zMa96kw0CF7e" title="Stock-based compensation">5.3</span> million
and $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20240101__20241231_z5I2iuvlKlJ9" title="Stock-based compensation">6.9</span> million in stock-based compensation in 2025 and 2024, respectively. The weighted average grant-date fair values of options granted
during the years ended December 31, 2025 and 2024 were $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20250101__20251231_zVirPPE4xA5b" title="Weighted average grant-date fair values of options granted">1.84</span> and $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231_zXTzKxBCPQH8" title="Weighted average grant-date fair values of options granted">3.80</span> per share, respectively. The grant date fair value of shares vested
during the years ended December 31, 2025 and 2024 was $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_pn5n6_c20250101__20251231_z9dwPYal4RV" title="Grant date fair value of shares vested">11.8</span> million and $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_pn5n6_c20240101__20241231_zsY6mRPM2P5c" title="Grant date fair value of shares vested">4.0</span> million, respectively. As of December 31, 2025, there is
$<span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20251231_zHQuLNhvtX81" title="Unrecognized compensation costs">83,600</span> of unrecognized compensation cost related to unvested stock options granted under the Company&#8217;s 2023 Plan that is expected
to be recognized over the next year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Restricted Stock Units (RSUs)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2025 the Chairman and CEO was issued RSUs
for <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdCO9dDscqO8" title="Issued shares which were fully vested upon grant">400,000</span>&#160;common shares which were fully vested upon grant. These RSUs were valued at $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z85DkXyKZbJe" title="Issuance of common stock for services">840,000</span>&#160;based on the stock quoted
trading price at the grant date and were expensed immediately as compensation expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_803_eus-gaap--IncomeTaxDisclosureTextBlock_zmI1R2AqgVPl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 8 &#8211; <span id="xdx_82A_zfrBjCgjHwM1">Income Taxes</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zyTHSdHVUPf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify">The significant components of the
Company&#8217;s net deferred tax assets and liabilities consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify"><span id="xdx_8BE_ziJ8CRKjCSBf" style="display: none">Schedule of Net Deferred Tax Assets</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20251231_zvdlN2wv7OK5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20241231_z4fI6gmPOaAd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred tax assets:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGz55t_zwLhxDmaoGRg" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Net operating loss carryforward</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">7,643,465</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">4,427,679</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGz55t_zQ3dH2jHDb89" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Section 174 capitalized research and development</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">700,121</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">995,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_maDTAGz55t_zoh0x94PgLl7" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Goodwill and intangibles</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">23,339</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">28,007</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGz55t_z4oqjyn0ikp6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,856,673</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,680,018</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_maDTAGz55t_z9nf4C0NHVAj" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">Tax credits</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">51,278</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">51,278</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGz55t_maDTANzg2r_z2JYdq0N1oc6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred tax assets, gross</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">11,274,876</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,182,482</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzg2r_zAUxIxWqATCa" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less: valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(11,274,876</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,182,482</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzg2r_maDTALNzcuf_zfxyiGxuzym" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred tax assets, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0843">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0844">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredIncomeTaxLiabilities_iNI_di_msDTALNzcuf_zbksbSThWZP8" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Deferred tax liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0846">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0847">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzcuf_z6K4R2F1LZX4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total net deferred tax asset</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0849">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0850">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A5_zLeibNXoR1xf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_895_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zVIEFs8ddJJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify">Provision for (benefit from) income taxes consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BF_zbfAWeBapp8j" style="display: none">Schedule of Provision for  Income Taxes</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20250101__20251231_ztiGjjaoR3v8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zgFgkdt8Rhpl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zMXvmntFXiQa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred tax:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDITEBz7I1_zaQaSXoo1ycg" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Federal</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(463,477</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0858">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDITEBz7I1_z4PzOlw9UAc3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">State</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">463,477</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0861">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_mtDITEBz7I1_maITEBzknf_z1ZkK8ubmzv2" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total deferred tax expense (benefit)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0863">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0864">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzknf_zdEwF8Bg8Pn6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total provision for income taxes</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0866">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0867">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A2_zZpgfiKQUEOj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Beginning in 2022, in accordance with Internal
Revenue Code Section 174, Qualified Research Expenditures are capitalized for tax purposes and amortized over a period of five years.
Accordingly, for income tax purposes, and as of December 31, 2025 and 2024, the Company has recorded a deferred tax asset
totaling approximately $<span id="xdx_90F_eus-gaap--DeferredTaxAssetsOtherLossCarryforwards_iI_pn5n6_c20251231_zbxuSdeLfza9" title="Deferred tax asset">0.7</span> million and $<span id="xdx_903_eus-gaap--DeferredTaxAssetsOtherLossCarryforwards_iI_pn5n6_c20241231_zL88S2PKw9Mi" title="Deferred tax asset">1.0</span> million, respectively, related to the timing difference between GAAP and Tax recognition
of these expenditures. Under current law, beginning in tax years after December 31, 2024, domestic research and experimental expenditures may again be deducted
currently for U.S. federal income tax purposes; however, the Company continues to carry deferred tax assets related to research costs
capitalized in prior periods that will reverse as amortization deductions are claimed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify">&#160;</p>

<p id="xdx_89A_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z0kmSDp65Qsj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A reconciliation of the statutory U.S. federal income
tax rate to the Company&#8217;s effective income tax rate is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B3_zzTcm5qpDRQ2" style="display: none">Schedule of Reconciliation  Effective Income Tax Rate</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250101__20251231_zlMGFEmExkaf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Amount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Rate</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzgzx_zkJ1UtGDgrQ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Provision for income taxes at U.S. federal statutory rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(2,186,773</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maGOLD_c20250101__20251231_zXnLOtWUO9P" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Provision for income taxes at U.S. federal statutory rate, Percentage">21.00</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzgzx_zsTK6bVo3A14" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">State income taxes, net of federal benefit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">463,477</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maGOLD_c20250101__20251231_zbR9tqDhuNNh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="State income taxes, net of federal benefit, Percentage">(4.45</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzgzx_z2ZE0Vd0HRDg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Other</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">23,616</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maGOLD_c20250101__20251231_zjE9R5GdGww8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other, Percentage">(0.02</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzgzx_zAWzEe8INaF8" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Changes in valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,928,495</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maGOLD_c20250101__20251231_zu09xbp4Ev71" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Changes in valuation allowance, Percentage">(28.12</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_maITEBzgzx_z50HosJpRgBl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">True-ups</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,228,815</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_maGOLD_c20250101__20251231_zYyiPd8PdGhe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="True-ups, Percentage">11.80</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzgzx_ztasadz5Bmb3" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net actual effective rate</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0895">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtGOLD_c20250101__20251231_zNtGJIqSrFWa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net actual effective rate, Percentage">0.21</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>


<p id="xdx_8AE_zEDJTTvZtMh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC Topic 740 requires that a deferred tax amount
be reduced by a valuation allowance if, based on the weight of available evidence it is more likely than not (a likelihood of more than
50%) that some portion or all of the deferred tax assets will not be realized. The valuation allowance should be sufficient to reduce
the deferred tax asset to the amount that is more likely than not to be realized. The Company has recorded a full valuation allowance
against its deferred tax assets generated by net operating loss carryforwards as it has determined that such amounts may not be recognizable,
given the historical losses of the Company to date. As of December 31, 2025, the Company has a cumulative federal net operating loss
carryforward of approximately $<span id="xdx_900_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20251231_ziX4kblBaEGd">30.2</span>
million. The net operating loss carryforward have no expiry date.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of business and summary of significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Overview</a></td>
<td class="text"><p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zcyNcuoCf5Wk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86C_zEHeuZaF5tl">Overview</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Telomir Pharmaceuticals, Inc.
(&#8220;Telomir&#8221; or the &#8220;Company&#8221;) was formed in August 2021 and is a Florida-incorporated pre-clinical stage
biotechnology company developing therapies designed to target the root epigenetic mechanisms underlying cancer, aging, and
degenerative disease. The Company&#8217;s lead candidate, Telomir-1, has demonstrated activity in preclinical studies involving
modulation of DNA and histone methylation patterns, which may contribute to balanced gene expression, cellular function, and genomic
stability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Telomir-1 is a novel oral small molecule metal
ion regulator designed to extend telomere caps, maintain cellular balance, and combat oxidative stress, a key driver of aging and disease
progression. By modulating essential metal ions such as iron, and copper, Telomir-1 may help protect against age related conditions,
including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson&#8217;s disease (a genetic disorder leading
to toxic copper buildup in the body), and Age-related Macular Degeneration (AMD), as well as Type 2 diabetes, breast cancer, and Alzheimer&#8217;s
disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As used herein, the Company&#8217;s common stock,
no par value per share, is referred to as the &#8220;Common Stock&#8221; and the Company&#8217;s preferred stock, no par value per share,
is referred to as the &#8220;Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_InitialPublicOfferingPolicyTextBlock', window );">Initial public offering</a></td>
<td class="text"><p id="xdx_84D_ecustom--InitialPublicOfferingPolicyTextBlock_zBngH3MgXwqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_867_zOe80Bfe0g8l">Initial public offering</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 13, 2024, the Company closed its
initial public offering (the &#8220;IPO&#8221;) consisting of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240212__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zXhzjf4GcOrg" title="IPO units, shares">1,000,000</span> shares of Common Stock at a price of $<span id="xdx_908_eus-gaap--SharePrice_iI_c20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zXACQWFfZiP9" title="Initial public offering shares">7.00</span> per share for approximately
$<span id="xdx_904_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20240212__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zwLJpZMWDhe6" title="Gross proceeds">7.0</span> million in gross proceeds. After deducting the underwriting commission and other offering expenses totaling $<span id="xdx_90D_eus-gaap--OtherUnderwritingExpense_pn5n6_c20240212__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z7zUzOHXJlkl" title="Underwriting commission and other offering expenses">1.2</span> million, the net
proceeds to the Company were $<span id="xdx_904_ecustom--ProceedsFromInitialPublicOfferingNetProceeds_pn5n6_c20240212__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zACg2SryjJub" title="Initial public offering net proceeds">5.8</span> million. The Common Stock began trading on The Nasdaq Capital Market on February 9, 2024 under the
symbol &#8220;TELO&#8221; (See Note 7 &#8220;Common Stock&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_ProposedMergerPolicyTextBlock', window );">Proposed merger</a></td>
<td class="text"><p id="xdx_84E_ecustom--ProposedMergerPolicyTextBlock_zcv5hFANvy8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86A_zDrtsOS9yay7">Proposed merger</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Company and TELI Pharmaceuticals, Inc., a related party private
company incorporated under the laws of Delaware (&#8220;TELI&#8221;) have entered into an Agreement and Plan of Merger and Reorganization,
dated November 20, 2025, and as amended on February 4, 2026 (collectively, the &#8220;Merger Agreement&#8221;), pursuant to which a wholly
owned subsidiary of Telomir will merge with and into TELI, with TELI surviving as a wholly owned subsidiary of Telomir (the &#8220;Merger&#8221;),
subject to shareholder approval. At the effective time of the Merger (the &#8220;Effective Time&#8221;), each outstanding share of common
stock of TELI, $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251120_zJCp5dWMrgqf" title="Common stock, par value">0.0001</span> par value per share (&#8220;TELI Common Stock&#8221;), will be converted into the right to receive such number
of Telomir Common Stock as is calculated based on the exchange ratio of the shares for the Merger (the &#8220;Exchange Ratio&#8221;).
The Exchange Ratio is calculated using the relative company valuations of each of Telomir and TELI, as determined by a third-party valuation
firm (as further described herein). It is expected that shareholders of TELI will receive one share of Telomir Common Stock for each
share of TELI Common Stock held (the &#8220;Merger Share Consideration&#8221;). The Telomir Common Stock issued as the consideration
will not be registered for trading under the Securities Act. The Merger will result in an alignment of U.S. and non-U.S. rights to Telomir-1
within a single public company structure, thereby simplifying global development and partnership efforts. As a result of the Merger,
TELO will own the entire worldwide intellectual property portfolio and development programs related to Telomir-1. See Note 5, <i>Merger
Agreement.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zAoI6yYkHcLg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_866_zmlQbeYRYKj2">Revenue recognition</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company currently has no source of revenue.
Miscellaneous income, including interest, is recognized when earned by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_z8RxvchywP9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_869_zntlUZHp0BVf">Income taxes</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes pursuant
to the provision of Accounting Standards Codification (&#8220;ASC&#8221;) 740-10, &#8220;Accounting for Income Taxes&#8221; (&#8220;ASC
740-10&#8221;), which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and
liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary
differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any
net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows the provision of&#160;ASC
740-10&#160;related to Accounting for Uncertain Income Tax Positions. When tax returns are filed, there may be uncertainty about the
merits of positions taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of&#160;ASC
740-10, the benefit of a tax position is recognized in the consolidated financial statements in the period during which, based on all
available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the
resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions
that meet the more likely than not recognition threshold are measured at the largest amount of tax benefit that is more than&#160;50&#160;percent
likely of being realized upon settlement with the applicable taxing authority. The portion of the benefit associated with tax positions
taken that exceed the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying
balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The
Company believes its tax positions are all more likely than not to be upheld upon examination. As such, the Company has not recorded
a liability for uncertain tax benefits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has adopted&#160;ASC 740-10-25, &#8220;Definition
of Settlement&#8221;, which provides guidance on how an entity should determine whether a tax position is effectively settled for the
purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion
and examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity
would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based
solely on the basis of its technical merits and the statute of limitations remains open. The federal and state income tax returns of
the Company are subject to examination by the IRS and state taxing authorities, generally for three years after they are filed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_z3CMQ6zURrRb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_861_zIeIdv2Cy7zk">Research and development expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development costs are expensed in
the period in which they are incurred and include the expenses paid to third parties, such as contract research organizations and consultants,
who conduct research and development activities on behalf of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--UseOfEstimates_zi4qYvdAfKF7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_864_zoZkUJLUcC3k">Use of estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in accordance
with generally accepted accounting principles in the United States of America requires the Company&#8217;s management to make estimates
and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at
the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results may differ from
such estimates and such differences could be material. Significant estimates during the reporting periods include stock-based compensation
and the deferred tax asset valuation allowance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zhNPo926zCNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_866_zEIO4qLaV7S4">Cash and Cash Equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid debt
instruments and other short-term investments with maturities of three months or less, when purchased, to be cash equivalents. The Company
maintains cash and cash equivalent balances at two financial institutions that are insured by the Federal Deposit Insurance Corporation
(&#8220;FDIC&#8221;). The Company&#8217;s accounts at these institutions are insured by the FDIC up to $<span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_c20251231_zhzTq8QqQ3Ih" title="Cash insured amount">250,000</span>. On December 31, 2025
and 2024, the Company had cash in excess of FDIC limits of approximately $<span id="xdx_907_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20251231_zYb8zhGQf1Lg" title="Cash, Uninsured Amount">7.0</span> million and $<span id="xdx_902_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20241231_z5LbG5jXtJD5" title="Cash, Uninsured Amount">1.0</span> million, respectively. To reduce its risk
associated with the failure of such financial institution, the Company evaluates at least annually the rating of the financial institution
in which it holds deposits. Any material loss that the Company may experience in the future could have an adverse effect on its ability
to pay its operational expenses or make other payments and may require the Company to move its cash to other high quality financial institutions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zwFZJoo8kq0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_863_z0OyzotJZQx9">Stock-based compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for stock-based compensation
under the provisions of FASB&#160;ASC 718, &#8220;Compensation - Stock Compensation&#8221;, which requires the measurement and recognition
of compensation expense for all stock-based awards made to employees, directors and consultants based on estimated fair values on the
grant date. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value
of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the
straight-line method. The Company has elected to account for forfeitures of stock-based awards as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements and Financial Instruments</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zdeiGi41SuNj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_862_znF1qK7olRO9">Fair Value Measurements and Financial Instruments</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures the fair value of financial
instruments in accordance with GAAP which defines fair value, establishes a framework for measuring fair value, and expands disclosures
about fair value measurements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">GAAP defines fair value as the exchange price
that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for
the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes a fair value
hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring
fair value. GAAP describes three levels of inputs that may be used to measure fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 1 &#8211; quoted prices
in active markets for identical assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 2 &#8211; quoted prices
for similar assets and liabilities in active markets or inputs that are observable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 3 &#8211; inputs that
are unobservable (for example cash flow modeling inputs based on assumptions).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers the carrying amount of
prepaid assets and all current liabilities to approximate fair value due to the short-term nature of those elements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per Share</a></td>
<td class="text"><p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zWfpQBLGwnH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_866_zO7MsxX3Q3zd">Earnings per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Earnings (loss) per share is computed in accordance
with ASC Topic 260, &#8220;Earnings per Share&#8221; Basic weighted-average number of shares of common stock outstanding for the year
ended December 31, 2025 and December 31, 2024 include the shares of the Company issued and outstanding during such period, on a weighted
average basis. The basic weighted average number of shares of common stock outstanding excludes common stock equivalents such as stock
options and warrants, while diluted weighted average number of shares outstanding includes such stock options and warrants. As of December
31, 2025 there were <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zY1vFKjEfDHj" title="Antidilutive securities excluded from computation of earnings per share">2,814,057</span> common stock warrants and <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zAjoxzE3nv6e" title="Antidilutive securities excluded from computation of earnings per share">4,187,670</span> common stock options that were not included in the computation of diluted
earnings per share, because to do so would have an antidilutive effect. As of December 31, 2024 there were <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zDJUG8wNt7E6" title="Antidilutive securities excluded from computation of earnings per share">2,814,057</span> stock warrants and
<span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z6tprkC9Tt49" title="Antidilutive securities excluded from computation of earnings per share">2,352,670</span> stock options that were not included in the computation of diluted earnings per share, because to do so would have an antidilutive
effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock', window );">Recent accounting pronouncements not yet adopted</a></td>
<td class="text"><p id="xdx_846_ecustom--RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_zBRaUZBi3TX9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_865_zqWhF34cwIFb">Recent accounting pronouncements not yet
adopted</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2023, the FASB issued ASU 2023-09,
<i>Income Taxes (Topic 740) - Improvements to Income Tax Disclosures</i>. The new standard requires a company to expand its existing
income tax disclosures, specifically related to the rate reconciliation and income taxes paid. The standard is effective for the Company
beginning in fiscal year 2025. The Company applied the amendments prospectively for the year ended December 31, 2025, and the impact
of the adoption of the amendments in this update was not material to the Company&#8217;s financial position and results of operations
for the year ended December 31, 2025, since the amendments require only enhancement of existing income tax disclosures in the footnotes
to the Company&#8217;s financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2024, the FASB issued ASU 2024-03,&#160;<i>Income
Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures&#160;</i>(Subtopic 220-40), which requires entities to provide
more detailed disaggregation of expenses in the income statement, focusing on the nature of the expenses rather than their function.
The new disclosures will require entities to separately present expenses for significant line items, including but not limited to, depreciation,
amortization, and employee compensation. Entities will also be required to provide a qualitative description of the amounts remaining
in relevant expense captions that are not separately disaggregated quantitatively, disclose the total amount of selling expenses and,
in annual reporting periods, provide a definition of what constitutes selling expenses. This pronouncement is effective for fiscal years
beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted.
The Company does not expect the adoption of this new guidance to have a material impact on the consolidated financial statements.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_InitialPublicOfferingPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial Public Offering [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_InitialPublicOfferingPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_ProposedMergerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proposed merger [policy text block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_ProposedMergerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recent Accounting Pronouncements Not Yet Adopted [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Lease Expenses</a></td>
<td class="text"><p id="xdx_899_eus-gaap--LeaseCostTableTextBlock_zskfffFPOTjb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The components of lease expense were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B9_zK7BPagaSni4" style="display: none">Schedule of Components of Lease Expenses</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20250101__20251231_zwRyEPX32mg1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zCUrlNHyobJc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Lease Costs</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Operating lease cost</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseCost_maLCzhnC_zazPIYT7LTdk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; width: 60%; text-align: left">Operating lease</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0535">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">55,667</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--VariableLeaseCost_maLCzhnC_zMpYOHkOlHZ2" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Variable lease costs</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0538">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">336,656</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LeaseCost_iT_mtLCzhnC_zK7pGGuKPHIj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0541">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">392,323</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zbF16ohohb73" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B7_zLWTij5Zc7x3" style="display: none">Schedule of Warrant Activity</span>&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Remaining Contractual</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Aggregate Intrinsic</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Warrants</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Exercise Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Term (Years)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Value</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 36%">Outstanding as of December&#160;&#160;31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSgzcXCqO8Bd" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of Warrants Outstanding, Beginning Balance">2,774,057</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaOWzKyPNL4b" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">4.85</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_zyDrtLyYTlU5" title="Weighted Average Remaining Contractual Term (Years), Outstanding Balance">4.5</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">(1)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlO6WbuaHBab" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Aggregate Intrinsic Value, Outstanding Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl0610">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zekvfhw65G1d" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Granted">50,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4VeUTvz9QS6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted">7.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdK1dWmryMj4" title="Weighted Average Remaining Contractual Term (Years), Granted">3.2</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfY5uuixhkXc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised">(10,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWfw2ZLktGL9" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Exercised">3.73</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;&#160;&#160;&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Outstanding as December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKVUmero7Gj7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants Outstanding, Beginning Balance">2,814,057</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsO5r9vgaU38" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">4.97</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDIp_zRAzKSd2xari" title="Weighted Average Remaining Contractual Term (Years), Outstanding Balance">3.49</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">(2)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZVF5Pk3yu4i" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Outstanding Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl0628">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsGhpzl8Y4We" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0630">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbpvVCVaQ5Ea" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0632">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Outstanding as of December 31, 2025</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zf0wLrTBFHVe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants Outstanding, Ending Balance">2,814,057</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsfxDR0OeTV7" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance">4.97</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDIp_z9tUtCU4y52f" title="Weighted Average Remaining Contractual Term (Years), Outstanding Balance">2.45</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">(2)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3XbuYdeo4mj" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Outstanding Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl0640">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="vertical-align: top; width: 0.25in; padding-bottom: 0pt; text-align: left"><span id="xdx_F00_zDaoA1QFIxJ3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="padding-bottom: 0pt; text-align: justify"><span id="xdx_F18_zK8FIGlqJnkb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    warrants herein consist of various contractual terms. The warrants herein consist of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember_zql5MGAc3hig" title="Class of warrants or right number of securities called by warrants or rights">2,439,025</span> warrants issued to Bay Shore Trust
    that have a remaining contractual term of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember_zzBNVlLe1s7g" title="Warrants and rights outstanding term">2.5</span> years as of December 31, 2025, and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zzKKbMRXLy43" title="Class of warrants or right number of securities called by warrants or rights">335,032</span> warrants issued to investors associated
    with the 2023 Private Placement that currently have an indeterminable contractual term. See disclosures below for more information
    on these warrants</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 0pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; padding-bottom: 0pt; text-align: left"><span id="xdx_F0F_zOO4wfwv8DSa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="padding-bottom: 0pt; text-align: justify"><span id="xdx_F1C_zYWuwkJCT5G5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    warrants herein consist of various contractual terms. The warrants herein consist of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zR74nO7EjC5e" title="Warrants issued">2,429,025</span> warrants issued to Bay Shore Trust
    that have a remaining contractual term of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYImeeA0dK1e" title="Warrants remaining contractual term">2.5</span> years as of December 31, 2025; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zhi1RrUuEnck" title="Warrants issued">335,032</span> warrants issued to investors associated with
    the 2023 Private Placement that currently have an indeterminable contractual term, and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantMember_zNmj2VNvS6hi" title="Warrants issued">50,000</span> warrants issued to underwriters as
    part of the IPO with a remaining contractual life of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantMember_zULkKyLPZwji" title="Warrants remaining contractual term">3.2</span> years. See disclosures below for more information on these warrants</span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Key Assumptions Used to Value Stock Options</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zS4fJ3wBJQFf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighted average assumptions for grants are
provided in the following table:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BB_zXrSBk08wuH3" style="display: none">Schedule of Key Assumptions Used to Value Stock Options</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Year ended December 31,</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20250101__20251231_zywcppCibDml" title="Expected volatility, minimum">92.5</span> - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20250101__20251231_zbwf8du1R1F6" title="Expected volatility, maximum">139.0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231_z8hUUw8m1gJa" title="Expected volatility, minimum">88.8</span> - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231_zO12gstweCwk" title="Expected volatility, maximum">90.4</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected term (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__srt--RangeAxis__srt--MinimumMember_ziC3JP46oGs" title="Expected term">5.0</span> - <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__srt--RangeAxis__srt--MaximumMember_zc4OMCC36rE6" title="Expected term">5.4</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zjsn0ym2t798" title="Expected term">5.1</span> - <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zOVvuFZW7rL1" title="Expected term">5.6</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Expected dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20250101__20251231_z2Nja1MEldtl" title="Expected dividend yield">0</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20240101__20241231_zA8eR4LadDb7" title="Expected dividend yield">0</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20250101__20251231_zFsnrmOeG4jl" title="Risk-free interest rate, minimum">4.1</span> - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20250101__20251231_z692LynCcp9i" title="Risk-free interest rate, maximum">4.2</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231_zm7wWKx569h5" title="Risk-free interest rate">3.7</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock', window );">Schedule of Issued Stock Options</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_zaFp6iB3kB62" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2025, the Company
issued stock options under the 2023 Plan as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BD_zdK9D3paRZq9" style="display: none">Schedule of Issued Stock Options</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of stock options</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    Price</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vesting
    period</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    13</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--AwardDateAxis__custom--MayThirteenMember_zlBVXwSDtx2g" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of stock options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardDateAxis__custom--MayThirteenMember_zrBxREo8KkEj" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.75</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: left; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_c20250101__20251231__us-gaap--AwardDateAxis__custom--MayThirteenMember_z74jNDAkPBa2" title="Vesting period">one
    year</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    27</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--AwardDateAxis__custom--MayTwentySevenMember_z8G6KovnsyQc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardDateAxis__custom--MayTwentySevenMember_zNuixU0cFoza" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.10</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_c20250101__20251231__us-gaap--AwardDateAxis__custom--MayTwentySevenMember_zb5YC6ebnGs4" title="Vesting period">immediate</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    15</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--AwardDateAxis__custom--OctoberFifteenMember_z8zUDjKZywYg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardDateAxis__custom--OctoberFifteenMember_z0MUJoaljh9e" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.73</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_c20250101__20251231__us-gaap--AwardDateAxis__custom--OctoberFifteenMember_z9jcuVPMlp67" title="Vesting period">one
    year</span></span></td></tr>
  </table>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zy9gyeG1mzJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&#8217;s stock option activity is as follows:</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><span id="xdx_8B1_zMPMC2XBN3cj" style="display: none">Schedule of Stock Option Activity</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Number of<br/>
 stock options</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Exercise price</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Remaining<br/>
 contractual life <br/>
(years)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Aggregate<br/>
 intrinsic value</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 36%">Balance at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20251231_ze4xV0HqTgN6" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of stock option, Beginning balance">2,352,670</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20251231_zZck69flFVN8" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price, Beginning balance">5.02</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_ziGNoSuEMNHf" title="Weighted average remaining contractual life (years)">9.6</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20250101__20251231_zQ2TfN5EKKXf" title="Aggregate intrinsic value, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl0762">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250101__20251231_z2iyPgtS5G27" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock option, Granted">2,087,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231_zfBB0JIAPDxc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Granted">2.11</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Expired</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_c20250101__20251231_zKt0klDuKVvf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock option, Expired">(72,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231_zT4q1hQBGNE8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Expired">5.02</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20250101__20251231_z9TM7EPjOsYl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock option, Forfeitures">(180,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20250101__20251231_zOZaJmlN7UDd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Forfeitures">5.02</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance at December 31, 2025</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250101__20251231_z6c2PLjdlsgh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock option, Ending balance">4,187,670</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231_zCclC1UlfKx3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Ending balance">3.57</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_zhaK4RzoDfC8" title="Weighted average remaining contractual life (years)">9.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20250101__20251231_znyBlOTnxyDf" title="Aggregate intrinsic value, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl0782">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Vested and exercisable at December 31, 2025</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20250101__20251231_z7XnINVLnQ0k" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock option, Vested and exercisable">4,125,170</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_c20250101__20251231_zN5sX437SXng" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Vested and exercisable">3.60</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231_ztHDm5D4IZO3" title="Weighted average remaining contractual life (years), Vested and exercisable">9.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_c20250101__20251231_zTUp8XCzPB9b" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, Vested and exercisable"><span style="-sec-ix-hidden: xdx2ixbrl0790">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Vested and expected to vest at December 31, 2025</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20250101__20251231_zal0giAgRPxj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock option, Vested and expected to vest">4,187,670</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231_zQpvIvalTXzc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Vested and expected to vest">2.14</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231_zA4ZCS8VW7fa" title="Weighted average remaining contractual life (years), Vested and expected to vest">9.6</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20250101__20251231_zQxM897GxpKh" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, Vested and expected to vest"><span style="-sec-ix-hidden: xdx2ixbrl0798">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=TELO_UnderwriterWarrantMember', window );">Underwriter Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Key Assumptions Used to Value Stock Options</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember_zaEH1wv1i3d7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Key assumptions used to value underwriter warrants in February 2024
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BD_z5zAKzgwTGh4" style="display: none">Schedule of Key Assumptions Used to Value Warrants</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 50%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-size: 10pt">Expected price volatility</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 16%; font-size: 10pt; text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zNEHZOZqCEgc" title="Warrant measurement input">84.78</span></td><td style="width: 1%; font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Risk-free interest rate</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zTufeFAJ6ks1" title="Warrant measurement input">4.14</span></td><td style="font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Fair Market Value of underlying Common Stock</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputFairMarketValueUnderlyingCommonStockMember_zkiSfvatqy75" title="Warrant measurement input">7.01</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Expected term in years</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_znhy7r5V7c14" title="Expected term in years">5</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Dividend yield</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zabaLxhKp6T5" title="Warrant measurement input"><span style="-sec-ix-hidden: xdx2ixbrl0702">-</span></span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of employee stock purchase plan activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718-50/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=TELO_UnderwriterWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=TELO_UnderwriterWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Net Deferred Tax Assets</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zyTHSdHVUPf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify">The significant components of the
Company&#8217;s net deferred tax assets and liabilities consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify"><span id="xdx_8BE_ziJ8CRKjCSBf" style="display: none">Schedule of Net Deferred Tax Assets</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20251231_zvdlN2wv7OK5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20241231_z4fI6gmPOaAd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred tax assets:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGz55t_zwLhxDmaoGRg" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Net operating loss carryforward</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">7,643,465</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">4,427,679</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGz55t_zQ3dH2jHDb89" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Section 174 capitalized research and development</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">700,121</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">995,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_maDTAGz55t_zoh0x94PgLl7" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Goodwill and intangibles</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">23,339</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">28,007</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGz55t_z4oqjyn0ikp6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,856,673</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,680,018</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_maDTAGz55t_z9nf4C0NHVAj" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">Tax credits</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">51,278</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">51,278</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGz55t_maDTANzg2r_z2JYdq0N1oc6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred tax assets, gross</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">11,274,876</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,182,482</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzg2r_zAUxIxWqATCa" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less: valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(11,274,876</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,182,482</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzg2r_maDTALNzcuf_zfxyiGxuzym" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred tax assets, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0843">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0844">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredIncomeTaxLiabilities_iNI_di_msDTALNzcuf_zbksbSThWZP8" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Deferred tax liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0846">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0847">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzcuf_z6K4R2F1LZX4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total net deferred tax asset</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0849">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0850">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Provision for Income Taxes</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zVIEFs8ddJJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify">Provision for (benefit from) income taxes consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BF_zbfAWeBapp8j" style="display: none">Schedule of Provision for  Income Taxes</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20250101__20251231_ztiGjjaoR3v8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zgFgkdt8Rhpl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zMXvmntFXiQa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred tax:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDITEBz7I1_zaQaSXoo1ycg" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Federal</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(463,477</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0858">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDITEBz7I1_z4PzOlw9UAc3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">State</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">463,477</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0861">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_mtDITEBz7I1_maITEBzknf_z1ZkK8ubmzv2" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total deferred tax expense (benefit)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0863">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0864">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzknf_zdEwF8Bg8Pn6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total provision for income taxes</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0866">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0867">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation Effective Income Tax Rate</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z0kmSDp65Qsj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A reconciliation of the statutory U.S. federal income
tax rate to the Company&#8217;s effective income tax rate is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B3_zzTcm5qpDRQ2" style="display: none">Schedule of Reconciliation  Effective Income Tax Rate</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250101__20251231_zlMGFEmExkaf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Amount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Rate</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzgzx_zkJ1UtGDgrQ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Provision for income taxes at U.S. federal statutory rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(2,186,773</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maGOLD_c20250101__20251231_zXnLOtWUO9P" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Provision for income taxes at U.S. federal statutory rate, Percentage">21.00</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzgzx_zsTK6bVo3A14" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">State income taxes, net of federal benefit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">463,477</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maGOLD_c20250101__20251231_zbR9tqDhuNNh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="State income taxes, net of federal benefit, Percentage">(4.45</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzgzx_z2ZE0Vd0HRDg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Other</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">23,616</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maGOLD_c20250101__20251231_zjE9R5GdGww8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other, Percentage">(0.02</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzgzx_zAWzEe8INaF8" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Changes in valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,928,495</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maGOLD_c20250101__20251231_zu09xbp4Ev71" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Changes in valuation allowance, Percentage">(28.12</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_maITEBzgzx_z50HosJpRgBl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">True-ups</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,228,815</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_maGOLD_c20250101__20251231_zYyiPd8PdGhe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="True-ups, Percentage">11.80</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzgzx_ztasadz5Bmb3" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net actual effective rate</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0895">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtGOLD_c20250101__20251231_zNtGJIqSrFWa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net actual effective rate, Percentage">0.21</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of business and summary of significant accounting policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 24, 2025</div></th>
<th class="th"><div>May 20, 2025</div></th>
<th class="th"><div>Feb. 13, 2024</div></th>
<th class="th"><div>Feb. 13, 2024</div></th>
<th class="th"><div>Jul. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 20, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">IPO units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash insured amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash, Uninsured Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,814,057<span></span>
</td>
<td class="nump">2,814,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,187,670<span></span>
</td>
<td class="nump">2,352,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">IPO units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Initial public offering shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherUnderwritingExpense', window );">Underwriting commission and other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_ProceedsFromInitialPublicOfferingNetProceeds', window );">Initial public offering net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_ProceedsFromInitialPublicOfferingNetProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from initial public offering net proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_ProceedsFromInitialPublicOfferingNetProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherUnderwritingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs incurred during the period, such as those relating to general administration and policy maintenance that do not vary with and are not primarily related to the acquisition or renewal of insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherUnderwritingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 7,286,670<span></span>
</td>
<td class="nump">$ 1,266,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Raised amount</a></td>
<td class="nump">9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash in operations</a></td>
<td class="nump">3,688,188<span></span>
</td>
<td class="nump">5,070,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="nump">10,413,205<span></span>
</td>
<td class="nump">16,532,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders equity</a></td>
<td class="nump">$ 5,913,370<span></span>
</td>
<td class="nump">$ 643,037<span></span>
</td>
<td class="nump">$ 3,438,204<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>License agreement, related party (Details Narrative)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Aug. 11, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_LicenseAgreementRelatedPartyDetailsNarrativeLineItems', window );"><strong>LicenseAgreementRelatedPartyDetailsNarrativeLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_PercentageOfRoyaltyPayable', window );">Percentage of royalty payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=TELO_MiralogxLLCMember', window );">MIRALOGX, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_LicenseAgreementRelatedPartyDetailsNarrativeLineItems', window );"><strong>LicenseAgreementRelatedPartyDetailsNarrativeLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_LicenseAgreementRelatedPartyDetailsNarrativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_LicenseAgreementRelatedPartyDetailsNarrativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_PercentageOfRoyaltyPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_PercentageOfRoyaltyPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=TELO_MiralogxLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=TELO_MiralogxLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related parties balances and transactions (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 24, 2025</div></th>
<th class="th"><div>May 27, 2025</div></th>
<th class="th"><div>May 27, 2025</div></th>
<th class="th"><div>May 20, 2025</div></th>
<th class="th"><div>May 19, 2025</div></th>
<th class="th"><div>May 19, 2025</div></th>
<th class="th"><div>Dec. 09, 2024</div></th>
<th class="th"><div>Jul. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Nov. 22, 2024</div></th>
<th class="th"><div>Sep. 24, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 15, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Vested common shares service, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 840,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 840,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Debt Instrument, Repurchase Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent', window );">Payroll taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesOther', window );">Medicare taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Amount due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Costs and Expenses, Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Raised amount in equity financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of restricted shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333,334<span></span>
</td>
<td class="nump">333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardPriceOfCommonStockPercent', window );">Premium share price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Initial payment</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TravelAndEntertainmentExpense', window );">Related party travel costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 370,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=TELO_BayshorefinancingMember', window );">Bayshore Financing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Initial payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=TELO_BayShoreTrustMember', window );">Bay Shore Trust [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Unused line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Fair value of total warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,439,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=TELO_StarwoodTrustMember', window );">Starwood Trust [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate borrowings amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Vested common shares service, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.54<span></span>
</td>
<td class="nump">$ 2.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,218,300<span></span>
</td>
<td class="nump">1,142,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Amount due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,432<span></span>
</td>
<td class="nump">$ 318,234<span></span>
</td>
<td class="nump">$ 93,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TravelAndEntertainmentExpense', window );">Related party travel costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 370,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardPriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award price of common stock percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardPriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TravelAndEntertainmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses incurred for travel and entertainment during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TravelAndEntertainmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=TELO_BayshorefinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=TELO_BayshorefinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=TELO_BayShoreTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=TELO_BayShoreTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=TELO_StarwoodTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=TELO_StarwoodTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Proposed Merger Agreement (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Feb. 04, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Nov. 20, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=TELO_TelomirOneMember', window );">Telomir-1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost', window );">Contingent consideration transaction cost</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=TELO_PhaseOneByTwoMember', window );">Phase 1/2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost', window );">Contingent consideration transaction cost</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Cash or marketable securities</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=TELO_TeliPharmaceuticalsIncMember', window );">TELI Pharmaceuticals, Inc [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Cash or marketable securities</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction cost incurred as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=TELO_TelomirOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=TELO_TelomirOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=TELO_PhaseOneByTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=TELO_PhaseOneByTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=TELO_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=TELO_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=TELO_TeliPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=TELO_TeliPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_LeasesDetailsNarrativeLineItems', window );"><strong>LeasesDetailsNarrativeLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease, cost</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 336,656<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=TELO_TampaFloridaMember', window );">Tampa, Florida [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_LeasesDetailsNarrativeLineItems', window );"><strong>LeasesDetailsNarrativeLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease, cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=TELO_MiralogxLLCMember', window );">MIRALOGX, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_LeasesDetailsNarrativeLineItems', window );"><strong>LeasesDetailsNarrativeLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease, cost</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 320,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_LeasesDetailsNarrativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_LeasesDetailsNarrativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=TELO_TampaFloridaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=TELO_TampaFloridaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=TELO_MiralogxLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=TELO_MiralogxLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Components of Lease Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 55,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">336,656<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 392,323<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrant Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">$ 5.02<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants Outstanding, Beginning Balance</a></td>
<td class="nump">2,814,057<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,774,057<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Beginning Balance</a></td>
<td class="nump">$ 4.97<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4.85<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (Years), Outstanding Balance</a></td>
<td class="text">2 years 5 months 12 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">3 years 5 months 26 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value, Outstanding Beginning Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Warrants, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">50,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted', window );">Weighted Average Remaining Contractual Term (Years), Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Warrants, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(10,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 3.73<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants Outstanding, Ending Balance</a></td>
<td class="nump">2,814,057<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,814,057<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,774,057<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Ending Balance</a></td>
<td class="nump">$ 4.97<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4.97<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4.85<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value, Outstanding Ending Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The
    warrants herein consist of various contractual terms. The warrants herein consist of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zR74nO7EjC5e" title="Warrants issued">2,429,025</span> warrants issued to Bay Shore Trust
    that have a remaining contractual term of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYImeeA0dK1e" title="Warrants remaining contractual term">2.5</span> years as of December 31, 2025; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zhi1RrUuEnck" title="Warrants issued">335,032</span> warrants issued to investors associated with
    the 2023 Private Placement that currently have an indeterminable contractual term, and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantMember_zNmj2VNvS6hi" title="Warrants issued">50,000</span> warrants issued to underwriters as
    part of the IPO with a remaining contractual life of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantMember_zULkKyLPZwji" title="Warrants remaining contractual term">3.2</span> years. See disclosures below for more information on these warrants</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The
    warrants herein consist of various contractual terms. The warrants herein consist of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember_zql5MGAc3hig" title="Class of warrants or right number of securities called by warrants or rights">2,439,025</span> warrants issued to Bay Shore Trust
    that have a remaining contractual term of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember_zzBNVlLe1s7g" title="Warrants and rights outstanding term">2.5</span> years as of December 31, 2025, and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zzKKbMRXLy43" title="Class of warrants or right number of securities called by warrants or rights">335,032</span> warrants issued to investors associated
    with the 2023 Private Placement that currently have an indeterminable contractual term. See disclosures below for more information
    on these warrants</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term 2</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of warrant activity (Details) (Parenthetical)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=TELO_BayShoreTrustWarrantsMember', window );">Bay Shore Trust Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="nump">2,439,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants remaining contractual term</a></td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=TELO_BayShoreTrustWarrantsMember', window );">Bay Shore Trust Warrants [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="nump">2,429,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants remaining contractual term</a></td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=TELO_TwoThousandTwentyThreePrivatePlacementWarrantsMember', window );">2023 Private Placement [Member] | Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="nump">335,032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=TELO_UnderwriterWarrantMember', window );">Underwriter Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants remaining contractual term</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=TELO_BayShoreTrustWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=TELO_BayShoreTrustWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=TELO_TwoThousandTwentyThreePrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=TELO_TwoThousandTwentyThreePrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=TELO_UnderwriterWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=TELO_UnderwriterWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Key Assumptions Used to Value Warrants (Details) - Underwriter Warrant [Member]<br></strong></div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=TELO_UnderwriterWarrantMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">84.78<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=TELO_UnderwriterWarrantMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">4.14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=TELO_UnderwriterWarrantMember', window );">Measurement Input Fair Market Value Underlying Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">7.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=TELO_UnderwriterWarrantMember', window );">Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term in years</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=TELO_UnderwriterWarrantMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=TELO_UnderwriterWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=TELO_UnderwriterWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=TELO_MeasurementInputFairMarketValueUnderlyingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=TELO_MeasurementInputFairMarketValueUnderlyingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Key Assumptions Used to Value Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_ScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems', window );"><strong>ScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">92.50%<span></span>
</td>
<td class="nump">88.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">139.00%<span></span>
</td>
<td class="nump">90.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_ScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems', window );"><strong>ScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_ScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems', window );"><strong>ScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_ScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_ScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Issued Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of stock options</a></td>
<td class="nump">4,187,670<span></span>
</td>
<td class="nump">2,352,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 3.57<span></span>
</td>
<td class="nump">$ 5.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=TELO_MayThirteenMember', window );">May 13 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of stock options</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 2.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod', window );">Vesting period</a></td>
<td class="text">one
    year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=TELO_MayTwentySevenMember', window );">May 27 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of stock options</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod', window );">Vesting period</a></td>
<td class="text">immediate<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=TELO_OctoberFifteenMember', window );">October 15 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of stock options</a></td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 1.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod', window );">Vesting period</a></td>
<td class="text">one
    year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award vesting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=TELO_MayThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=TELO_MayThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=TELO_MayTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=TELO_MayTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=TELO_OctoberFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=TELO_OctoberFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of stock option, Beginning balance</a></td>
<td class="nump">2,352,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Beginning balance</a></td>
<td class="nump">$ 5.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Beginning balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of stock option, Granted</a></td>
<td class="nump">2,087,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">$ 2.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod', window );">Number of stock option, Expired</a></td>
<td class="num">(72,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Expired</a></td>
<td class="nump">$ 5.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of stock option, Forfeitures</a></td>
<td class="num">(180,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeitures</a></td>
<td class="nump">$ 5.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of stock option, Ending balance</a></td>
<td class="nump">4,187,670<span></span>
</td>
<td class="nump">2,352,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Ending balance</a></td>
<td class="nump">$ 3.57<span></span>
</td>
<td class="nump">$ 5.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of stock option, Vested and exercisable</a></td>
<td class="nump">4,125,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Vested and exercisable</a></td>
<td class="nump">$ 3.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life (years), Vested and exercisable</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value, Vested and exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of stock option, Vested and expected to vest</a></td>
<td class="nump">4,187,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Vested and expected to vest</a></td>
<td class="nump">$ 2.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life (years), Vested and expected to vest</a></td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, Vested and expected to vest</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award opttions expired in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 24, 2025</div></th>
<th class="th"><div>May 27, 2025</div></th>
<th class="th"><div>May 27, 2025</div></th>
<th class="th"><div>May 20, 2025</div></th>
<th class="th"><div>May 19, 2025</div></th>
<th class="th"><div>May 19, 2025</div></th>
<th class="th"><div>Feb. 14, 2025</div></th>
<th class="th"><div>Dec. 09, 2024</div></th>
<th class="th"><div>Feb. 13, 2024</div></th>
<th class="th"><div>Feb. 13, 2024</div></th>
<th class="th"><div>Jul. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 22, 2024</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 15, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Issue of shares of capital stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash in ATM, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Additional payment received</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Equity issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 303,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_OfferingCosts', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 863,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 863,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance or sale of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Raised amount in equity financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of resricted shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333,334<span></span>
</td>
<td class="nump">333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Premium share price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issued shares which were fully vested upon grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 840,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">840,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,553,209<span></span>
</td>
<td class="nump">6,832,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair values of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.84<span></span>
</td>
<td class="nump">$ 3.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Grant date fair value of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,800,000<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=TELO_TwoThousandTwentyThreeOmnibusIncentivePlanMember', window );">2023 Omnibus Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock are reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TELO_PlacementAgentMember', window );">Placement Agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash in ATM, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,218,300<span></span>
</td>
<td class="nump">1,142,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.54<span></span>
</td>
<td class="nump">$ 2.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issued shares which were fully vested upon grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issued shares which were fully vested upon grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 840,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Equity issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=TELO_AtTheMarketOfferingAgreementMember', window );">At The Market Offering Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate offering amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=TELO_StarwoodTrustMember', window );">Starwood Trust [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash in ATM, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=TELO_BayShoreTrustMember', window );">Bay Shore Trust [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash in ATM, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,439,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,950,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash in ATM, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Additional payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherUnderwritingExpense', window );">Underwriting commission and other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_ProceedsFromInitialPublicOfferingNetProceeds', window );">Initial public offering net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=TELO_AtTheMarketOfferingMember', window );">At The Market Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,218,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Weighted average price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance or sale of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,553,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_OfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_OfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_ProceedsFromInitialPublicOfferingNetProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from initial public offering net proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_ProceedsFromInitialPublicOfferingNetProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherUnderwritingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs incurred during the period, such as those relating to general administration and policy maintenance that do not vary with and are not primarily related to the acquisition or renewal of insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherUnderwritingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=TELO_TwoThousandTwentyThreeOmnibusIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=TELO_TwoThousandTwentyThreeOmnibusIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=TELO_PlacementAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=TELO_PlacementAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=TELO_AtTheMarketOfferingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=TELO_AtTheMarketOfferingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=TELO_StarwoodTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=TELO_StarwoodTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=TELO_BayShoreTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=TELO_BayShoreTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=TELO_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=TELO_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Net Deferred Tax Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 7,643,465<span></span>
</td>
<td class="nump">$ 4,427,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Section 174 capitalized research and development</a></td>
<td class="nump">700,121<span></span>
</td>
<td class="nump">995,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Goodwill and intangibles</a></td>
<td class="nump">23,339<span></span>
</td>
<td class="nump">28,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">2,856,673<span></span>
</td>
<td class="nump">1,680,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">51,278<span></span>
</td>
<td class="nump">51,278<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets, gross</a></td>
<td class="nump">11,274,876<span></span>
</td>
<td class="nump">7,182,482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(11,274,876)<span></span>
</td>
<td class="num">(7,182,482)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total net deferred tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Provision for Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">$ (463,477)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">463,477<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax expense (benefit)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Reconciliation Effective Income Tax Rate (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Provision for income taxes at U.S. federal statutory rate</a></td>
<td class="num">$ (2,186,773)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Provision for income taxes at U.S. federal statutory rate, Percentage</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">$ 463,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit, Percentage</a></td>
<td class="num">(4.45%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">$ 23,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other, Percentage</a></td>
<td class="num">(0.02%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance</a></td>
<td class="nump">$ 2,928,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance, Percentage</a></td>
<td class="num">(28.12%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">True-ups</a></td>
<td class="num">$ (1,228,815)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">True-ups, Percentage</a></td>
<td class="nump">11.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Net actual effective rate, Percentage</a></td>
<td class="nump">0.21%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying statutory federal (national) tax rate to pretax income (loss) from continuing operation attributable to other reconciling item. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOtherLossCarryforwards', window );">Deferred tax asset</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</a></td>
<td class="nump">$ 30.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOtherLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible loss carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOtherLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>99</ContextCount>
  <ElementCount>248</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>40</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/StatementsOfOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/StatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999014 - Disclosure - Description of business and summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Description of business and summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999015 - Disclosure - Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/GoingConcern</Role>
      <ShortName>Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999016 - Disclosure - License agreement, related party</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/LicenseAgreementRelatedParty</Role>
      <ShortName>License agreement, related party</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999017 - Disclosure - Related parties balances and transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactions</Role>
      <ShortName>Related parties balances and transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999018 - Disclosure - Proposed Merger Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/ProposedMergerAgreement</Role>
      <ShortName>Proposed Merger Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999019 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999020 - Disclosure - Stockholders??? equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999021 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999022 - Disclosure - Description of business and summary of significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Description of business and summary of significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999023 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://telomirpharma.com/role/Leases</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999024 - Disclosure - Stockholders??? equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://telomirpharma.com/role/StockholdersEquity</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999025 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://telomirpharma.com/role/IncomeTaxes</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999026 - Disclosure - Description of business and summary of significant accounting policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Description of business and summary of significant accounting policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999027 - Disclosure - Going Concern (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/GoingConcernDetailsNarrative</Role>
      <ShortName>Going Concern (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://telomirpharma.com/role/GoingConcern</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999028 - Disclosure - License agreement, related party (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative</Role>
      <ShortName>License agreement, related party (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://telomirpharma.com/role/LicenseAgreementRelatedParty</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999029 - Disclosure - Related parties balances and transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative</Role>
      <ShortName>Related parties balances and transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactions</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999030 - Disclosure - Proposed Merger Agreement (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/ProposedMergerAgreementDetailsNarrative</Role>
      <ShortName>Proposed Merger Agreement (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://telomirpharma.com/role/ProposedMergerAgreement</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999031 - Disclosure - Leases (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/LeasesDetailsNarrative</Role>
      <ShortName>Leases (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://telomirpharma.com/role/LeasesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999032 - Disclosure - Schedule of Components of Lease Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/ScheduleOfComponentsOfLeaseExpensesDetails</Role>
      <ShortName>Schedule of Components of Lease Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999033 - Disclosure - Schedule of Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails</Role>
      <ShortName>Schedule of Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999034 - Disclosure - Schedule of warrant activity (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical</Role>
      <ShortName>Schedule of warrant activity (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999035 - Disclosure - Schedule of Key Assumptions Used to Value Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails</Role>
      <ShortName>Schedule of Key Assumptions Used to Value Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999036 - Disclosure - Schedule of Key Assumptions Used to Value Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails</Role>
      <ShortName>Schedule of Key Assumptions Used to Value Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999037 - Disclosure - Schedule of Issued Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/ScheduleOfIssuedStockOptionsDetails</Role>
      <ShortName>Schedule of Issued Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999038 - Disclosure - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/ScheduleOfStockOptionActivityDetails</Role>
      <ShortName>Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999039 - Disclosure - Stockholders??? equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://telomirpharma.com/role/StockholdersEquityTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999040 - Disclosure - Schedule of Net Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails</Role>
      <ShortName>Schedule of Net Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999041 - Disclosure - Schedule of Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Schedule of Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999042 - Disclosure - Schedule of Reconciliation Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Schedule of Reconciliation Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999043 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://telomirpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="form10-k.htm">form10-k.htm</File>
    <File>telo-20251231.xsd</File>
    <File>telo-20251231_cal.xml</File>
    <File>telo-20251231_def.xml</File>
    <File>telo-20251231_lab.xml</File>
    <File>telo-20251231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>fin_001.jpg</File>
    <File>form10-k_001.jpg</File>
    <File>form10-k_002.jpg</File>
    <File>form10-k_003.jpg</File>
    <File>form10-k_004.jpg</File>
    <File>form10-k_005.jpg</File>
    <File>form10-k_006.jpg</File>
    <File>form10-k_007.jpg</File>
    <File>form10-k_008.jpg</File>
    <File>form10-k_009.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="407">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>67
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-k.htm": {
   "nsprefix": "TELO",
   "nsuri": "http://telomirpharma.com/20251231",
   "dts": {
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    },
    "schema": {
     "local": [
      "telo-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "telo-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "telo-20251231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "telo-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "telo-20251231_pre.xml"
     ]
    }
   },
   "keyStandard": 223,
   "keyCustom": 25,
   "axisStandard": 18,
   "axisCustom": 0,
   "memberStandard": 17,
   "memberCustom": 20,
   "hidden": {
    "total": 78,
    "http://fasb.org/us-gaap/2025": 67,
    "http://telomirpharma.com/20251231": 8,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 99,
   "entityCount": 1,
   "segmentCount": 40,
   "elementCount": 495,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 407,
    "http://xbrl.sec.gov/dei/2025": 39,
    "http://xbrl.sec.gov/cyd/2025": 5
   },
   "report": {
    "R1": {
     "role": "http://telomirpharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://telomirpharma.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Balance Sheets",
     "shortName": "Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://telomirpharma.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Balance Sheets (Parenthetical)",
     "shortName": "Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://telomirpharma.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Statements of Operations",
     "shortName": "Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquity",
     "longName": "00000005 - Statement - Statements of Changes in Stockholders' Equity",
     "shortName": "Statements of Changes in Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://telomirpharma.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Statements of Cash Flows",
     "shortName": "Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "TELO:NoInsiderTradingFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "TELO:NoInsiderTradingFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies",
     "longName": "999014 - Disclosure - Description of business and summary of significant accounting policies",
     "shortName": "Description of business and summary of significant accounting policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://telomirpharma.com/role/GoingConcern",
     "longName": "999015 - Disclosure - Going Concern",
     "shortName": "Going Concern",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://telomirpharma.com/role/LicenseAgreementRelatedParty",
     "longName": "999016 - Disclosure - License agreement, related party",
     "shortName": "License agreement, related party",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "TELO:LicenseAgreementRelatedPartyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "TELO:LicenseAgreementRelatedPartyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactions",
     "longName": "999017 - Disclosure - Related parties balances and transactions",
     "shortName": "Related parties balances and transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://telomirpharma.com/role/ProposedMergerAgreement",
     "longName": "999018 - Disclosure - Proposed Merger Agreement",
     "shortName": "Proposed Merger Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "TELO:ProposedMergerAgreementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "TELO:ProposedMergerAgreementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://telomirpharma.com/role/Leases",
     "longName": "999019 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://telomirpharma.com/role/StockholdersEquity",
     "longName": "999020 - Disclosure - Stockholders\u2019 equity",
     "shortName": "Stockholders\u2019 equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://telomirpharma.com/role/IncomeTaxes",
     "longName": "999021 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999022 - Disclosure - Description of business and summary of significant accounting policies (Policies)",
     "shortName": "Description of business and summary of significant accounting policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://telomirpharma.com/role/LeasesTables",
     "longName": "999023 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://telomirpharma.com/role/StockholdersEquityTables",
     "longName": "999024 - Disclosure - Stockholders\u2019 equity (Tables)",
     "shortName": "Stockholders\u2019 equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://telomirpharma.com/role/IncomeTaxesTables",
     "longName": "999025 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999026 - Disclosure - Description of business and summary of significant accounting policies (Details Narrative)",
     "shortName": "Description of business and summary of significant accounting policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2025-07-012025-07-31",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R23": {
     "role": "http://telomirpharma.com/role/GoingConcernDetailsNarrative",
     "longName": "999027 - Disclosure - Going Concern (Details Narrative)",
     "shortName": "Going Concern (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R24": {
     "role": "http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative",
     "longName": "999028 - Disclosure - License agreement, related party (Details Narrative)",
     "shortName": "License agreement, related party (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "AsOf2023-08-11_us-gaap_RelatedPartyMember",
      "name": "TELO:PercentageOfRoyaltyPayable",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "TELO:LicenseAgreementRelatedPartyTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-08-11_us-gaap_RelatedPartyMember",
      "name": "TELO:PercentageOfRoyaltyPayable",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "TELO:LicenseAgreementRelatedPartyTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative",
     "longName": "999029 - Disclosure - Related parties balances and transactions (Details Narrative)",
     "shortName": "Related parties balances and transactions (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2025-05-272025-05-27",
      "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:DebtInstrumentRepurchaseAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R26": {
     "role": "http://telomirpharma.com/role/ProposedMergerAgreementDetailsNarrative",
     "longName": "999030 - Disclosure - Proposed Merger Agreement (Details Narrative)",
     "shortName": "Proposed Merger Agreement (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-02-042026-02-04_custom_TelomirOneMember",
      "name": "us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "TELO:ProposedMergerAgreementDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R27": {
     "role": "http://telomirpharma.com/role/LeasesDetailsNarrative",
     "longName": "999031 - Disclosure - Leases (Details Narrative)",
     "shortName": "Leases (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:VariableLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_TampaFloridaMember",
      "name": "us-gaap:VariableLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R28": {
     "role": "http://telomirpharma.com/role/ScheduleOfComponentsOfLeaseExpensesDetails",
     "longName": "999032 - Disclosure - Schedule of Components of Lease Expenses (Details)",
     "shortName": "Schedule of Components of Lease Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails",
     "longName": "999033 - Disclosure - Schedule of Warrant Activity (Details)",
     "shortName": "Schedule of Warrant Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-12-31_us-gaap_WarrantMember17385953",
      "name": "TELO:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical",
     "longName": "999034 - Disclosure - Schedule of warrant activity (Details) (Parenthetical)",
     "shortName": "Schedule of warrant activity (Details) (Parenthetical)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31_custom_BayShoreTrustWarrantsMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31_custom_BayShoreTrustWarrantsMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails",
     "longName": "999035 - Disclosure - Schedule of Key Assumptions Used to Value Warrants (Details)",
     "shortName": "Schedule of Key Assumptions Used to Value Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputPriceVolatilityMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputPriceVolatilityMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails",
     "longName": "999036 - Disclosure - Schedule of Key Assumptions Used to Value Stock Options (Details)",
     "shortName": "Schedule of Key Assumptions Used to Value Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://telomirpharma.com/role/ScheduleOfIssuedStockOptionsDetails",
     "longName": "999037 - Disclosure - Schedule of Issued Stock Options (Details)",
     "shortName": "Schedule of Issued Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31_custom_MayThirteenMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://telomirpharma.com/role/ScheduleOfStockOptionActivityDetails",
     "longName": "999038 - Disclosure - Schedule of Stock Option Activity (Details)",
     "shortName": "Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative",
     "longName": "999039 - Disclosure - Stockholders\u2019 equity (Details Narrative)",
     "shortName": "Stockholders\u2019 equity (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails",
     "longName": "999040 - Disclosure - Schedule of Net Deferred Tax Assets (Details)",
     "shortName": "Schedule of Net Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails",
     "longName": "999041 - Disclosure - Schedule of Provision for Income Taxes (Details)",
     "shortName": "Schedule of Provision for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails",
     "longName": "999042 - Disclosure - Schedule of Reconciliation Effective Income Tax Rate (Details)",
     "shortName": "Schedule of Reconciliation Effective Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://telomirpharma.com/role/IncomeTaxesDetailsNarrative",
     "longName": "999043 - Disclosure - Income Taxes (Details Narrative)",
     "shortName": "Income Taxes (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:DeferredTaxAssetsOtherLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:DeferredTaxAssetsOtherLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade accounts payable and accrued liabilities",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20"
     ]
    },
    "TELO_AccruedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "AccruedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued compensation - officer",
        "documentation": "Accrued compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedPayrollTaxesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payroll taxes",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails",
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails",
      "http://telomirpharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82",
      "r365",
      "r366",
      "r367",
      "r368",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails",
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails",
      "http://telomirpharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82",
      "r365",
      "r366",
      "r367",
      "r368",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r605",
      "r879"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r763",
      "r764",
      "r765",
      "r766",
      "r824",
      "r881"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r658",
      "r669",
      "r683",
      "r710"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r661",
      "r672",
      "r686",
      "r713"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r698"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r705"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r662",
      "r673",
      "r687",
      "r705",
      "r714",
      "r718",
      "r726"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r250",
      "r259"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of debt issuance costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r179",
      "r753",
      "r832"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive securities excluded from computation of earnings per share",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://telomirpharma.com/role/ProposedMergerAgreementDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://telomirpharma.com/role/ProposedMergerAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r467",
      "r820"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionConsiderationTransferredTransactionCost",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/ProposedMergerAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration transaction cost",
        "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r598",
      "r821",
      "r822",
      "r823"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://telomirpharma.com/role/ProposedMergerAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r467",
      "r820"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r61",
      "r74",
      "r88",
      "r89",
      "r90",
      "r121",
      "r128",
      "r135",
      "r136",
      "r145",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r354",
      "r356",
      "r376",
      "r441",
      "r442",
      "r446",
      "r506",
      "r581",
      "r582",
      "r586",
      "r605",
      "r616",
      "r617",
      "r628",
      "r772",
      "r773",
      "r839"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r77",
      "r88",
      "r89",
      "r90",
      "r145",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r354",
      "r356",
      "r376",
      "r605",
      "r772",
      "r773",
      "r839"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "TELO_AtTheMarketOfferingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "AtTheMarketOfferingAgreementMember",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "At The Market Offering Agreement [Member]",
        "documentation": "At The Market Offering Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TELO_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "At The Market Offering [Member]",
        "documentation": "At The Market Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r640",
      "r642",
      "r665"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r640",
      "r642",
      "r665"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r640",
      "r642",
      "r665"
     ]
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfIssuedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfIssuedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r717"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Overview",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "TELO_BayShoreTrustMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "BayShoreTrustMember",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bay Shore Trust [Member]",
        "documentation": "Bay Shore Trust [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TELO_BayShoreTrustWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "BayShoreTrustWarrantsMember",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bay Shore Trust Warrants [Member]",
        "documentation": "Bay Shore Trust Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TELO_BayshorefinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "BayshorefinancingMember",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bayshore Financing [Member]",
        "documentation": "Bayshore Financing [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://telomirpharma.com/role/ProposedMergerAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r467",
      "r590",
      "r591",
      "r817",
      "r818",
      "r819"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://telomirpharma.com/role/ProposedMergerAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r467",
      "r590",
      "r591",
      "r817",
      "r818",
      "r819"
     ]
    },
    "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of business and summary of significant accounting policies",
        "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets",
      "http://telomirpharma.com/role/GoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r448",
      "r478",
      "r500",
      "r605",
      "r616",
      "r617",
      "r628",
      "r749"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, beginning of year",
        "periodEndLabel": "Cash, end of year",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r42",
      "r87"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r42"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash insured amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashUninsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashUninsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Uninsured Amount",
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r92",
      "r204"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of common stock",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of total warrants issued",
        "verboseLabel": "Warrants issued",
        "terseLabel": "Warrants to purchase common stock",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock are reserved for issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r619",
      "r620",
      "r622",
      "r623",
      "r624",
      "r625",
      "r763",
      "r764",
      "r766",
      "r824",
      "r878",
      "r881"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheetsParenthetical",
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://telomirpharma.com/role/ProposedMergerAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheetsParenthetical",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r492"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r31",
      "r492",
      "r512",
      "r881",
      "r882"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, no par value; 300,000,000 shares authorized, 34,380,971 and 29,762,671 shares issued and outstanding at December 31, 2025 and 2024, respectively.",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r183",
      "r189",
      "r450",
      "r605"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "us-gaap_CostsAndExpensesRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostsAndExpensesRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses, Related Party",
        "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r650",
      "r737"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r650",
      "r737"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r652",
      "r739"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r652",
      "r739"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r654",
      "r741"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r652",
      "r739"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r645",
      "r732"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r646",
      "r733"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r646",
      "r733"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r644",
      "r731"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r647",
      "r734"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r649",
      "r736"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r649",
      "r736"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r650",
      "r737"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r653",
      "r740"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r651",
      "r738"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r648",
      "r735"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate borrowings amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r384",
      "r385",
      "r584",
      "r585",
      "r603"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r178"
     ]
    },
    "us-gaap_DebtInstrumentRepurchaseAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentRepurchaseAmount",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Repurchase Amount",
        "documentation": "Fair value amount of debt instrument that was repurchased."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r757",
      "r761",
      "r811",
      "r812"
     ]
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred financing costs",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r775",
      "r830",
      "r831",
      "r833"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax expense (benefit)",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r66",
      "r757",
      "r761"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r54",
      "r276"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity issuance cost",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "TELO_DeferredOfferingCostsChargedToAdditionalPaidinCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "DeferredOfferingCostsChargedToAdditionalPaidinCapital",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred offering costs charged to additional paid-in capital",
        "documentation": "Deferred offering costs charged to additional paidin capital."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r757",
      "r761",
      "r811",
      "r812"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and intangibles",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, gross",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Section 174 capitalized research and development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total net deferred tax asset",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_DeferredTaxAssetsOtherLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOtherLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax asset",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible loss carryforwards, classified as other."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax credits",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "TELO_DisclosureLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "DisclosureLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "verboseLabel": "Schedule Of Components Of Lease Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "TELO_DisclosureLicenseAgreementRelatedPartyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "DisclosureLicenseAgreementRelatedPartyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement Related Party"
       }
      }
     },
     "auth_ref": []
    },
    "TELO_DisclosureProposedMergerAgreementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "DisclosureProposedMergerAgreementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Proposed Merger Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r640",
      "r642",
      "r665"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r640",
      "r642",
      "r665",
      "r706"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "TELO_DueToOfficer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "DueToOfficer",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due to officer",
        "documentation": "Due to officer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic loss per share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r84",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r111",
      "r113",
      "r115",
      "r116",
      "r117",
      "r120",
      "r181",
      "r249",
      "r296",
      "r352",
      "r371",
      "r372",
      "r440",
      "r456",
      "r577"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted loss per share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r84",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r113",
      "r115",
      "r116",
      "r117",
      "r120",
      "r181",
      "r249",
      "r296",
      "r352",
      "r371",
      "r372",
      "r440",
      "r456",
      "r577"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r119"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net actual effective rate, Percentage",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r594"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for income taxes at U.S. federal statutory rate, Percentage",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r91",
      "r267",
      "r286",
      "r594"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in valuation allowance, Percentage",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r594",
      "r757",
      "r762",
      "r806"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other, Percentage",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r594",
      "r757",
      "r762",
      "r806",
      "r807"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "True-ups, Percentage",
        "documentation": "Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State income taxes, net of federal benefit, Percentage",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r594",
      "r757",
      "r762",
      "r806"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation costs",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://telomirpharma.com/role/LeasesDetailsNarrative",
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails",
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails",
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical",
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r68",
      "r69",
      "r70",
      "r81",
      "r82",
      "r83",
      "r95",
      "r96",
      "r97",
      "r99",
      "r106",
      "r108",
      "r110",
      "r122",
      "r146",
      "r147",
      "r156",
      "r180",
      "r205",
      "r249",
      "r284",
      "r285",
      "r293",
      "r294",
      "r295",
      "r297",
      "r351",
      "r352",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r370",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r386",
      "r388",
      "r392",
      "r455",
      "r460",
      "r461",
      "r462",
      "r476",
      "r535"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative"
     ],
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r292",
      "r376",
      "r746",
      "r747",
      "r748",
      "r813",
      "r814",
      "r815",
      "r816"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r376"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r658",
      "r669",
      "r683",
      "r710"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r655",
      "r666",
      "r680",
      "r707"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements and Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r662",
      "r673",
      "r687",
      "r714"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r662",
      "r673",
      "r687",
      "r714"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r662",
      "r673",
      "r687",
      "r714"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r662",
      "r673",
      "r687",
      "r714"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r662",
      "r673",
      "r687",
      "r714"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expenses",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r515"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IPOMember",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r640",
      "r642",
      "r665"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r91",
      "r263",
      "r267",
      "r271",
      "r272",
      "r273",
      "r274",
      "r280",
      "r287",
      "r289",
      "r290",
      "r291",
      "r445",
      "r466",
      "r472",
      "r594"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails",
      "http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total provision for income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r67",
      "r88",
      "r109",
      "r110",
      "r121",
      "r133",
      "r136",
      "r266",
      "r267",
      "r288",
      "r457",
      "r573",
      "r575",
      "r576",
      "r594"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r264",
      "r265",
      "r274",
      "r275",
      "r279",
      "r283",
      "r469"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r594",
      "r806"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for income taxes at U.S. federal statutory rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r594"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r594",
      "r806",
      "r807"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "True-ups",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying statutory federal (national) tax rate to pretax income (loss) from continuing operation attributable to other reconciling item. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r806",
      "r807"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfReconciliationEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State income taxes, net of federal benefit",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r594",
      "r806"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for income tax",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r86",
      "r281",
      "r282"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Trade accounts payable and accrued liabilities",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "TELO_IncreaseDecreaseInAccruedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "IncreaseDecreaseInAccruedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued compensation - officer",
        "documentation": "Increase decrease in accrued compensation.",
        "label": "IncreaseDecreaseInAccruedCompensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInDueToOtherRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInDueToOtherRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Due to related parties",
        "label": "Increase (Decrease) in Due to Other Related Parties",
        "documentation": "Amount of increase (decrease) in related party payables classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r662",
      "r673",
      "r687",
      "r705",
      "r714",
      "r718",
      "r726"
     ]
    },
    "TELO_InitialPublicOfferingPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "InitialPublicOfferingPolicyTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial public offering",
        "documentation": "Initial Public Offering [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r643",
      "r730"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r643",
      "r730"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r643",
      "r730"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r573",
      "r576",
      "r751"
     ]
    },
    "us-gaap_InterestPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaid",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r131",
      "r136",
      "r581",
      "r750"
     ]
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestorMember",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r835",
      "r836"
     ]
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock for services",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfComponentsOfLeaseExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfComponentsOfLeaseExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r604"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Lease Expenses",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "auth_ref": []
    },
    "TELO_LeasesDetailsNarrativeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "LeasesDetailsNarrativeLineItems",
     "presentation": [
      "http://telomirpharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LeasesDetailsNarrativeLineItems [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "TELO_LeasesDetailsNarrativeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "LeasesDetailsNarrativeTable",
     "presentation": [
      "http://telomirpharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LeasesDetailsNarrativeTable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://telomirpharma.com/role/LeasesDetailsNarrative",
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r19",
      "r20",
      "r21",
      "r24",
      "r25",
      "r26",
      "r29",
      "r88",
      "r89",
      "r90",
      "r145",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r355",
      "r356",
      "r357",
      "r376",
      "r491",
      "r580",
      "r586",
      "r628",
      "r772",
      "r839",
      "r840"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r56",
      "r452",
      "r605",
      "r616",
      "r617",
      "r757",
      "r760",
      "r769",
      "r829"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r73",
      "r88",
      "r89",
      "r90",
      "r145",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r355",
      "r356",
      "r357",
      "r376",
      "r605",
      "r772",
      "r839",
      "r840"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "TELO_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://telomirpharma.com/role/ProposedMergerAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Member]",
        "documentation": "License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TELO_LicenseAgreementRelatedPartyDetailsNarrativeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "LicenseAgreementRelatedPartyDetailsNarrativeLineItems",
     "presentation": [
      "http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LicenseAgreementRelatedPartyDetailsNarrativeLineItems [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "TELO_LicenseAgreementRelatedPartyDetailsNarrativeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "LicenseAgreementRelatedPartyDetailsNarrativeTable",
     "presentation": [
      "http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LicenseAgreementRelatedPartyDetailsNarrativeTable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "TELO_LicenseAgreementRelatedPartyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "LicenseAgreementRelatedPartyTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/LicenseAgreementRelatedParty"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License agreement, related party",
        "documentation": "License Agreement Related Party [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unused line of credit",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r23"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r676",
      "r677"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r676",
      "r678"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r676",
      "r679"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r676",
      "r679"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r676",
      "r679"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r676",
      "r679"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r127",
      "r164",
      "r165",
      "r166",
      "r167",
      "r212",
      "r242",
      "r243",
      "r244",
      "r260",
      "r375",
      "r404",
      "r458",
      "r459",
      "r465",
      "r483",
      "r484",
      "r543",
      "r545",
      "r547",
      "r548",
      "r550",
      "r554",
      "r555",
      "r557",
      "r558",
      "r568",
      "r569",
      "r583",
      "r587",
      "r592",
      "r595",
      "r596",
      "r597",
      "r599",
      "r600",
      "r601",
      "r602",
      "r614",
      "r774",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846"
     ]
    },
    "TELO_MayThirteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "MayThirteenMember",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfIssuedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "May 13 [Member]",
        "documentation": "May 13 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TELO_MayTwentySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "MayTwentySevenMember",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfIssuedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "May 27 [Member]",
        "documentation": "May 27 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r825",
      "r826",
      "r827"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r825",
      "r826",
      "r827"
     ]
    },
    "TELO_MeasurementInputFairMarketValueUnderlyingCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "MeasurementInputFairMarketValueUnderlyingCommonStockMember",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Fair Market Value Underlying Common Stock [Member]",
        "documentation": "Measurement Input Fair Market Value Underlying Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r599",
      "r825",
      "r826",
      "r827"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r825",
      "r826",
      "r827"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r373",
      "r374",
      "r375",
      "r595",
      "r596",
      "r597",
      "r599"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r374",
      "r375",
      "r595",
      "r596",
      "r597",
      "r599"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r127",
      "r164",
      "r165",
      "r166",
      "r167",
      "r212",
      "r242",
      "r243",
      "r244",
      "r260",
      "r375",
      "r404",
      "r458",
      "r459",
      "r465",
      "r483",
      "r484",
      "r543",
      "r545",
      "r547",
      "r548",
      "r550",
      "r554",
      "r555",
      "r557",
      "r558",
      "r568",
      "r569",
      "r583",
      "r587",
      "r592",
      "r595",
      "r596",
      "r597",
      "r599",
      "r600",
      "r601",
      "r614",
      "r774",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846"
     ]
    },
    "TELO_MiralogxLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "MiralogxLLCMember",
     "presentation": [
      "http://telomirpharma.com/role/LeasesDetailsNarrative",
      "http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MIRALOGX, LLC [Member]",
        "documentation": "MIRALOGX, LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from Financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/GoingConcernDetailsNarrative",
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "negatedLabel": "Cash in operations",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r44"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from Operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://telomirpharma.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/GoingConcernDetailsNarrative",
      "http://telomirpharma.com/role/StatementsOfCashFlows",
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://telomirpharma.com/role/StatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss",
        "verboseLabel": "Net Income (Loss)",
        "negatedLabel": "Net Loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r44",
      "r58",
      "r70",
      "r71",
      "r78",
      "r79",
      "r83",
      "r88",
      "r89",
      "r90",
      "r94",
      "r98",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r109",
      "r110",
      "r114",
      "r145",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r181",
      "r184",
      "r186",
      "r190",
      "r249",
      "r296",
      "r352",
      "r372",
      "r376",
      "r454",
      "r513",
      "r533",
      "r534",
      "r573",
      "r575",
      "r576",
      "r626",
      "r772"
     ]
    },
    "TELO_NoInsiderTradingFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "NoInsiderTradingFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No insider trading flag",
        "documentation": "No Insider Trading Flag"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "TELO_OctoberFifteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "OctoberFifteenMember",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfIssuedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "October 15 [Member]",
        "documentation": "October 15 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TELO_OfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "OfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering costs",
        "documentation": "Offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating costs",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating costs:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfComponentsOfLeaseExpensesDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfComponentsOfLeaseExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r604"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due to related parties",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r605"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amount due from related parties",
        "label": "Other Receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r501",
      "r582",
      "r616",
      "r617",
      "r848"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount due from related parties",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "us-gaap_OtherUnderwritingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherUnderwritingExpense",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriting commission and other offering expenses",
        "documentation": "Costs incurred during the period, such as those relating to general administration and policy maintenance that do not vary with and are not primarily related to the acquisition or renewal of insurance contracts."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r660",
      "r671",
      "r685",
      "r712"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r663",
      "r674",
      "r688",
      "r715"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r663",
      "r674",
      "r688",
      "r715"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r692"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/ProposedMergerAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash or marketable securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "TELO_PercentageOfRoyaltyPayable": {
     "xbrltype": "percentItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "PercentageOfRoyaltyPayable",
     "presentation": [
      "http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of royalty payable",
        "documentation": "Percentage of royalty payable."
       }
      }
     },
     "auth_ref": []
    },
    "TELO_PhaseOneByTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "PhaseOneByTwoMember",
     "presentation": [
      "http://telomirpharma.com/role/ProposedMergerAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phase 1/2 [Member]",
        "documentation": "Phase 1/2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TELO_PlacementAgentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "PlacementAgentMember",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent [Member]",
        "documentation": "Placement Agent [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r192"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheetsParenthetical",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r492"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r192"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r492",
      "r512",
      "r881",
      "r882"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, no par value, 100,000,000 shares authorized and none issued or outstanding.",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r183",
      "r188",
      "r449",
      "r605"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r148",
      "r149",
      "r572"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "TELO_ProceedsFromInitialPublicOfferingNetProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "ProceedsFromInitialPublicOfferingNetProceeds",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial public offering net proceeds",
        "documentation": "Proceeds from initial public offering net proceeds."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds",
        "verboseLabel": "Initial payment",
        "terseLabel": "Additional payment received",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from common stock",
        "verboseLabel": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/GoingConcernDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Raised amount",
        "verboseLabel": "Proceeds from issuance or sale of equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r470"
     ]
    },
    "TELO_ProceedsFromRepaymentsOfOfficer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "ProceedsFromRepaymentsOfOfficer",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment from officer",
        "documentation": "Proceeds from repayments of officer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments to related party",
        "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts."
       }
      }
     },
     "auth_ref": []
    },
    "TELO_ProceedsFromSaleOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "ProceedsFromSaleOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from sale of common stock",
        "documentation": "Proceeds from sale of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "TELO_ProceedsFromSaleOfCommonStockRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "ProceedsFromSaleOfCommonStockRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of common stock, related party",
        "documentation": "Proceeds from sale of common stock related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from warrant exercise",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "TELO_ProposedMergerAgreementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "ProposedMergerAgreementDisclosureTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/ProposedMergerAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proposed Merger Agreement",
        "documentation": "Proposed merger agreement disclosure [text block]",
        "label": "ProposedMergerAgreementDisclosureTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "TELO_ProposedMergerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "ProposedMergerPolicyTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proposed merger",
        "documentation": "Proposed merger [policy text block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForOtherCreditLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProvisionForOtherCreditLosses",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit loss expenses - loan due from related party",
        "documentation": "Amount of expense related to credit loss from transactions other than loan and lease transactions."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r57"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r127",
      "r164",
      "r165",
      "r166",
      "r167",
      "r209",
      "r212",
      "r242",
      "r243",
      "r244",
      "r248",
      "r260",
      "r375",
      "r402",
      "r403",
      "r404",
      "r458",
      "r459",
      "r465",
      "r483",
      "r484",
      "r543",
      "r545",
      "r547",
      "r548",
      "r550",
      "r554",
      "r555",
      "r557",
      "r558",
      "r568",
      "r569",
      "r583",
      "r587",
      "r592",
      "r595",
      "r596",
      "r597",
      "r599",
      "r600",
      "r601",
      "r602",
      "r614",
      "r620",
      "r771",
      "r774",
      "r826",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails"
     ],
     "auth_ref": [
      "r127",
      "r164",
      "r165",
      "r166",
      "r167",
      "r209",
      "r212",
      "r242",
      "r243",
      "r244",
      "r248",
      "r260",
      "r375",
      "r402",
      "r403",
      "r404",
      "r458",
      "r459",
      "r465",
      "r483",
      "r484",
      "r543",
      "r545",
      "r547",
      "r548",
      "r550",
      "r554",
      "r555",
      "r557",
      "r558",
      "r568",
      "r569",
      "r583",
      "r587",
      "r592",
      "r595",
      "r596",
      "r597",
      "r599",
      "r600",
      "r601",
      "r602",
      "r614",
      "r620",
      "r771",
      "r774",
      "r826",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846"
     ]
    },
    "TELO_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent accounting pronouncements not yet adopted",
        "documentation": "Recent Accounting Pronouncements Not Yet Adopted [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r655",
      "r666",
      "r680",
      "r707"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative",
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r93",
      "r94",
      "r141",
      "r210",
      "r211",
      "r396",
      "r397",
      "r447",
      "r453",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r511",
      "r542",
      "r880"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative",
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r93",
      "r94",
      "r396",
      "r397",
      "r398",
      "r399",
      "r447",
      "r453",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r511",
      "r542"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r93",
      "r94",
      "r141",
      "r396",
      "r397",
      "r399",
      "r516",
      "r517",
      "r520"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative",
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r93",
      "r94",
      "r141",
      "r210",
      "r211",
      "r396",
      "r397",
      "r447",
      "r453",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r511",
      "r542",
      "r838",
      "r880"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related parties balances and transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r394",
      "r395",
      "r397",
      "r400",
      "r473",
      "r474",
      "r475",
      "r518",
      "r519",
      "r520",
      "r539",
      "r541"
     ]
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfLinesOfCredit",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments under related party line of credit",
        "label": "Repayments of Lines of Credit",
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r757",
      "r758"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r570",
      "r573",
      "r574",
      "r581",
      "r847"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r656",
      "r667",
      "r681",
      "r708"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r657",
      "r668",
      "r682",
      "r709"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r664",
      "r675",
      "r689",
      "r716"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://telomirpharma.com/role/ProposedMergerAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r47",
      "r451",
      "r463",
      "r464",
      "r471",
      "r493",
      "r605"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r69",
      "r70",
      "r95",
      "r96",
      "r97",
      "r99",
      "r106",
      "r108",
      "r110",
      "r146",
      "r147",
      "r156",
      "r180",
      "r249",
      "r284",
      "r285",
      "r293",
      "r294",
      "r295",
      "r297",
      "r351",
      "r352",
      "r359",
      "r361",
      "r362",
      "r364",
      "r370",
      "r386",
      "r388",
      "r460",
      "r462",
      "r476",
      "r881"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r121",
      "r129",
      "r130",
      "r134",
      "r136",
      "r137",
      "r138",
      "r140",
      "r206",
      "r207",
      "r208",
      "r405",
      "r573",
      "r576"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate offering amount",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Raised amount in equity financing",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock shares",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average price",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Provision for Income Taxes",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Net Deferred Tax Assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Reconciliation Effective Income Tax Rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r594",
      "r806"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r292",
      "r376",
      "r746",
      "r747",
      "r748",
      "r813",
      "r814",
      "r815",
      "r816"
     ]
    },
    "TELO_ScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "ScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfKeyAssumptionsUsedToValueStockOptionsLineItems [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "TELO_ScheduleOfKeyAssumptionsUsedToValueStockOptionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "ScheduleOfKeyAssumptionsUsedToValueStockOptionsTable",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfKeyAssumptionsUsedToValueStockOptionsTable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r93",
      "r94",
      "r396",
      "r397",
      "r399",
      "r516",
      "r517",
      "r520"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://telomirpharma.com/role/ProposedMergerAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfIssuedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r216",
      "r217",
      "r218",
      "r219",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r248"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Issued Stock Options",
        "documentation": "Tabular disclosure of employee stock purchase plan activity."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r805"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8",
      "r48"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Key Assumptions Used to Value Stock Options",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrant Activity",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://telomirpharma.com/role/LeasesDetailsNarrative"
     ],
     "auth_ref": [
      "r124",
      "r138",
      "r139",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r441",
      "r442",
      "r443",
      "r444",
      "r480",
      "r481",
      "r482",
      "r544",
      "r546",
      "r549",
      "r551",
      "r554",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r571",
      "r578",
      "r588",
      "r589",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r615",
      "r620",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod": {
     "xbrltype": "stringItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfIssuedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting period",
        "documentation": "Share based compensation arrangement by share based payment award vesting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant date fair value of shares vested",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfIssuedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r216",
      "r217",
      "r218",
      "r219",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r248"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Warrants, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Warrants, Granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Warrants Outstanding, Beginning Balance",
        "periodEndLabel": "Number of Warrants Outstanding, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50"
     ]
    },
    "TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding Beginning Balance",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding Ending Balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the warrants",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue of shares of capital stock",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "TELO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of stock option, Expired",
        "documentation": "Sharebased compensation arrangement by sharebased payment award opttions expired in period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of stock option, Forfeitures",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of stock option, Granted",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant-date fair values of options granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate intrinsic value, Beginning balance",
        "periodEndLabel": "Aggregate intrinsic value, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfIssuedStockOptionsDetails",
      "http://telomirpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of stock options",
        "periodStartLabel": "Number of stock option, Beginning balance",
        "periodEndLabel": "Number of stock option, Ending balance",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r222"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfIssuedStockOptionsDetails",
      "http://telomirpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise price",
        "periodStartLabel": "Weighted average exercise price, Beginning balance",
        "periodEndLabel": "Weighted average exercise price, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r222"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate intrinsic value, Vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of stock option, Vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average exercise price, Vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate intrinsic value, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of stock option, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average exercise price, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245"
     ]
    },
    "TELO_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfStockOptionActivityDetails",
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Exercised",
        "verboseLabel": "Weighted average exercise price, Expired",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Forfeitures",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r220",
      "r239",
      "r240",
      "r241",
      "r242",
      "r245",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial public offering shares",
        "verboseLabel": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding Beginning Balance",
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Term (Years), Outstanding Balance",
        "documentation": "Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term 2"
       }
      }
     },
     "auth_ref": []
    },
    "TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted": {
     "xbrltype": "durationItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Term (Years), Granted",
        "documentation": "Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term granted."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life (years), Vested and exercisable",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life (years), Vested and expected to vest",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardPriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPriceOfCommonStockPercent",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Premium share price percentage",
        "documentation": "Share based compensation arrangement by share based payment award price of common stock percent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Premium share price percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life (years)",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "TELO_StarwoodTrustMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "StarwoodTrustMember",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Starwood Trust [Member]",
        "documentation": "Starwood Trust [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails",
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails",
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical",
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r31",
      "r34",
      "r35",
      "r68",
      "r69",
      "r70",
      "r81",
      "r82",
      "r83",
      "r95",
      "r96",
      "r97",
      "r99",
      "r106",
      "r108",
      "r110",
      "r122",
      "r146",
      "r147",
      "r156",
      "r180",
      "r205",
      "r249",
      "r284",
      "r285",
      "r293",
      "r294",
      "r295",
      "r297",
      "r351",
      "r352",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r370",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r386",
      "r388",
      "r392",
      "r455",
      "r460",
      "r461",
      "r462",
      "r476",
      "r535"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://telomirpharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r124",
      "r138",
      "r139",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r441",
      "r442",
      "r443",
      "r444",
      "r480",
      "r481",
      "r482",
      "r544",
      "r546",
      "r549",
      "r551",
      "r554",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r571",
      "r578",
      "r588",
      "r589",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r615",
      "r620",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r122",
      "r182",
      "r183",
      "r185",
      "r187",
      "r388",
      "r405",
      "r468",
      "r477",
      "r479",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r492",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r502",
      "r503",
      "r504",
      "r505",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r514",
      "r515",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r535",
      "r575",
      "r576",
      "r621",
      "r880"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r122",
      "r141",
      "r182",
      "r183",
      "r185",
      "r187",
      "r388",
      "r405",
      "r468",
      "r477",
      "r479",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r492",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r502",
      "r503",
      "r504",
      "r505",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r514",
      "r515",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r535",
      "r575",
      "r576",
      "r621",
      "r880"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r659",
      "r670",
      "r684",
      "r711"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for services, shares",
        "verboseLabel": "Issued shares which were fully vested upon grant",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for cash in ATM, net, shares",
        "verboseLabel": "IPO units, shares",
        "terseLabel": "Issuance of common stock, net, shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r30",
      "r31",
      "r47",
      "r470",
      "r535",
      "r552"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for cash, Related party, shares",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of restricted shares issued",
        "verboseLabel": "Number of resricted shares issued",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r47"
     ]
    },
    "TELO_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of Warrants, shares",
        "documentation": "Stock issued during period shares warrants exercised."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for services",
        "verboseLabel": "Vested common shares service, value",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for cash in ATM, net",
        "verboseLabel": "Issuance of common stock, value",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r30",
      "r31",
      "r47",
      "r476",
      "r535",
      "r552",
      "r627"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for cash, related party",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "TELO_StockIssuedDuringPeriodValueWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of warrants",
        "documentation": "Stock issued during period value warrants exercised."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets",
      "http://telomirpharma.com/role/GoingConcernDetailsNarrative",
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Stockholders equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r34",
      "r35",
      "r45",
      "r494",
      "r512",
      "r536",
      "r537",
      "r605",
      "r628",
      "r757",
      "r759",
      "r760",
      "r769",
      "r829",
      "r881"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r191",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r358",
      "r369",
      "r538",
      "r540",
      "r553"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://telomirpharma.com/role/ProposedMergerAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r401"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://telomirpharma.com/role/ProposedMergerAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r401"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://telomirpharma.com/role/ProposedMergerAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r401"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/GoingConcern"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Going Concern",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "TELO_TampaFloridaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "TampaFloridaMember",
     "presentation": [
      "http://telomirpharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tampa, Florida [Member]",
        "documentation": "Tampa, Florida [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxesOther",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Medicare taxes",
        "documentation": "Amount of tax expense classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "TELO_TeliPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "TeliPharmaceuticalsIncMember",
     "presentation": [
      "http://telomirpharma.com/role/ProposedMergerAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TELI Pharmaceuticals, Inc [Member]",
        "documentation": "TELI Pharmaceuticals, Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TELO_TelomirOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "TelomirOneMember",
     "presentation": [
      "http://telomirpharma.com/role/ProposedMergerAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Telomir-1 [Member]",
        "documentation": "Telomir-1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r767",
      "r837"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TravelAndEntertainmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TravelAndEntertainmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party travel costs",
        "documentation": "Expenses incurred for travel and entertainment during the period."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "TELO_TwoThousandTwentyThreeOmnibusIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "TwoThousandTwentyThreeOmnibusIncentivePlanMember",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Omnibus Incentive Plan [Member]",
        "documentation": "2023 Omnibus Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TELO_TwoThousandTwentyThreePrivatePlacementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "TwoThousandTwentyThreePrivatePlacementWarrantsMember",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Private Placement [Member]",
        "documentation": "2023 Private Placement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://telomirpharma.com/role/ProposedMergerAgreementDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "TELO_UnderwriterWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20251231",
     "localname": "UnderwriterWarrantMember",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails",
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical",
      "http://telomirpharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriter Warrant [Member]",
        "documentation": "Underwriter Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r123",
      "r125",
      "r126",
      "r127",
      "r441",
      "r443",
      "r579"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfComponentsOfLeaseExpensesDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/LeasesDetailsNarrative",
      "http://telomirpharma.com/role/ScheduleOfComponentsOfLeaseExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable lease, cost",
        "verboseLabel": "Variable lease costs",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r604"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails",
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r619",
      "r622",
      "r623",
      "r624",
      "r625"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant measurement input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r825",
      "r826",
      "r827"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails",
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants remaining contractual term",
        "verboseLabel": "Expected term in years",
        "terseLabel": "Exercise price",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r825",
      "r826",
      "r827"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted weighted average common stock shares outstanding",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r117"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic weighted average common stock shares outstanding",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r117"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-40/tableOfContent"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718-50/tableOfContent"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>68
<FILENAME>0001493152-26-010625-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-26-010625-xbrl.zip
M4$L#!!0    ( (>+<5P23XIT2@,  )0+   *    97@R,RTQ+FAT;=U6VV[;
M.!!]-^!_F!708 M8OK;=UE8-R+'3&G42P19VD4>*HBRV$JF25!/OUW<H6:Z3
MWO;B7:#5@\3+X<R9,T.*WNOP<C5MM[S7"W^.7["/%R[#U6+J]>HOSO;VT][L
M>GX#F_!FM7CI)%*8,0SZA8&0YTS#%;N%M<R)Z-0#'=@PQ1,'%^+2H%EGV)UQ
M2<:W8@R4"</4!/ZJK0GD1&VY<(TLQH#PPT DC9%Y->9,ST2DBXG7"QZX_KMN
M]BZ.&2N^3=&#-SNVZ28DY]EN_#VK%5;S/UE-PIDN[E(><0/#47?@]6;3?T_Y
MF\K<#Z46_W1J_0/7YU)H;(),8"EB5C!\87?-MEPC@,40E%'&*?B4RE(8+K9P
MP57^0^OT!1=O2VUXLG.F?S!(,>YH!W0OC9%@4@9<4*D*J8CA4@#.*Y8@4% [
M52%JT6I N[4QQ+"\TE; A50Y;-Q1!VY33E.(&"4Y Y8DC!K^@548%JF2J!T,
MGW=@V!\^[<"O%SQC<"6[,!J-W.'S)R]>]!_;7(4LDSE7$*1$Y82RTG!*,HQS
M*6C7 F2ID"#2->U6C$1BN"0*'0]^JVP_P\F,5-G<AY=P003E) /=$-??]T0J
MS)Q1ED=,P6A0,P<B8MMX4C42J:R+=HL19(!XZ\_<2M@QHG2C7H$9DC'8 HP_
MM]@!4A0(MXRK!5R#+T2)?-=5F >5!WWWS;>(MUL5\SVIBL/7G';_VU+[G\H9
M@Y8/B_E3[>* K94$]S24*$.M2LI(C%*W6V=9_+Z4D\4=IL?H,U7U; 9TB;D\
MKG@X%/Q/(%M/]V!#,BR&+9R1O)C N<P+(G8="+K^CQ2@,]WXJ]EB_:J)X_HR
M\*]N3AJ',YU)2F!-C$381285C\G);-\_N$YF]L0J'PS]XKKXAV19/(: ;-D$
MT>]+N]70Z 2N"[M7]!A61!MPW?V5SYLO?V\(//@;/K-U$DF%6_,P-LL(?0<#
MI*AEQF/T'OJSU0+.%ZM5X,_GRZM7+YV^4_4W@7_>]/<>]M:HS#)2:"36M"9P
MRV.3VO#[C[YP6_+"=6/C YX']D!MJA?_YO?+.6-)M6+>K#@R_4G]<&ZON6O[
MLA'@%Y5H1#F2LF>UK/4Z?>Y[]E9=7[/M;?PC4$L#!!0    ( (>+<5S+&<[$
MC <  !TO   *    97@S,2TQ+FAT;>U:76_;.!9]'V#^ ]? #EI CN-V,PO$
M'@-.[.X8FVF"U!A@'FF)LKB11)6D['A^_9Y+2K8<.TV*20JGDSPDD<2/>ZES
M[KF78O_7Z6\7@Q]_Z/\Z'H[PE]%/?SJ97HP'_8[_BZ>=ZG'_['+T!_LT_>-B
M_$LK5KD]9=WCPK*IS(1A'\627:N,YX&_$;!/0LNXA8[H>O6U_7HLXWHN\U-&
M38];@Y_RF2EZ_<[5TPS88U;<VC9/Y1RWM)PGMC7HGPW&MXF<2<O>=X^Z_<[9
MX)DF#$5NA7YFK^I)X-;Y^'HZ^3 Y'TXGEQ]?NE__*XV5\:HUF 1LK,6?;)C)
M7"T"=IY($;/QK0A+*Q>"7<:Q#(5F/(_PC$N->7[\0<5L*E*52<VN$HY[H4#S
MD*>8?)*'1P&\T#0!LPFWIT_FQ,ZJ3(=G%V-V/KZX^'0U/)]\_,\OK>.6N[X:
MCD;U=37I4D8VH5F/_]EC,Z4CH=NA2E->&(%UK_[K,3*N;>2?PEO8<KSN3Z\K
M?O>GHWK$YI*F(K8]5LUQ?/3N1.8]5O HDOF\/5/6JLQYT6,+6ALL5MW3J@((
M^W#Y<=I<GG;,,YFN3A]:H!UKNT?]#@U& 6BT:_->D_9BX^E,FG@K$@Y$:;&0
M8BDB0$,:X"HO>8J;A=*6J9Q]4#I#K_9_V4,@ZS7=Q*_KKWE/CW\Q->+^VEHV
M1GD^4Y_NA;T[/ R=<2,B;PE@DJW83:Z6J8CF(O!0JC 4*0R;*PM"YY;+'!!;
ML3*WNA3,6&Y%A@!+X.*(+8BT$O"+>8A;F@%L%DOIV^TTR$4HC.%ZY:U NXS?
M"$S>&-C@7@2+,&]*BD@348-0ZK#,T"S'&# 'L8<M$QDFS)3T:]-_*;2H!B$O
M,FE2P6FU$5ML B]-(4*RLK("@Q<P4D5P&*@ L6:KYH*\TN3Y:/+^I=%$L%CF
MP"!A>H.YP,F[PF/=>"[S&+&86XEQ9!ZF901L =<-; 4@AM3IBA6 )=&*Z):F
M:]YX.RK(FCOS@Y^1I-$#:E&F: "R*(#9S6F<42$W"8M3M30UD[282V,UQVR<
M;GKC86K0X(*I+7(FUTQYY<0WX,2_#H\3TT342*RQ\Y,VGTO5,Q7JJW25HJQJ
M9+P3QK5P^ 4>Y2P5A#,FP)Q9*DU"S:E9!IDAJ:'K2)HP5:9$/Q(@K5(/Y$*K
M4$2X;;PI;P#>2( -GE3CVS#A^5RP(6+[=9G"O^Y[WNZ>O!%O7?_N2>2O_*6D
M(B'W+*))&,7^!KD\SLF@>R;R5NS,%F_-%F,V\O@N[]""<KG3_33JN*Q\\!WF
M^P]G]U\F_4'6"_SMP1%V) R&KG7,94@/\RJ@#"[D)?3OL5THAYL)T,-/5^5E
MJM08 $*RD(;D:9WNB=P-1C7M)C5LRJ06*7>D0^-MS@25A-)#":6#04:E,N+6
M63LS,I)<2_)"^AS2"7=.(Y6&4CH7J*K@09F@4V)E!*RRD%'J67 "2IERDF0X
MZ"S9Y(?HX5/.9KJ,_V:"&D(PT5]$7Z&-3X#_@Q73;^K;TS%G]B+(_&CUVN'T
MXW7O/FK79FSX34T1$Q8R(L9RHW).4L\-V$[U&M&8ZZAF$T@N^4RFTJXH)]TW
M-T491SS'*1\;MIIN<F]OCDLK;BO7BE(7(+9QV7080KB<%:[\FXL<^7$*?N.)
M*"AZ4!/4MY[#B#*R@)Z_LO@ELS@\/!:/%SPM2:TVVPXBCE'6R04@:?:49^L4
M^Q$Z["\W%=N61)$>HR/DT_BZ<*9*^X 9CTD7^+JUH/(W?G@OA<VHNJ;"V@4C
MX=<$1O6\.9CAE7<OF'?1X?%NY(%<\^X.-6AOLRH<W9.]_/L*S:3,5H5AJ0G[
MC0QR=U1O3J:,Q4/Z9H4!#=X,^UPB"\7X;^ZQ)@:=(61W6E?6A^"7VYO-M[\,
MO/6F)=RL$V^20,=\$549.C34K4REX"N6RAN!/VZC]DZGX"\O5N]^MG^_!?!!
M%K GW]6.D_M(%M6L#S:20S+8Y-M&?8@Q#^"VMF:=5^]4J&O[.*I4J[372W>!
M,;-,6BM>=WQ>=WR>AS##M((HE6L2?*!]1MJV#*4 @*L4<;WILA3\AM(]7R2Y
MA,\5>NXC7OT%X1&T:&B?WQKA>DW</3+"(_0V8JTB]U*H*@_1!60%#@.?>!JL
M@"DS(!ZN.X\J'=_[U>4UJ?PNDLH#W)(9YM4W[%@CP ? OG"B!/:X;\X5S0*?
M=<E\H=*%H-0KY_/J^[FN=$QD1:I6 D^7B?+BQ;=(#-)](3FML]I'LO3H;ZH_
M)S3@7OP_8:6!MW[*?N,Z3+P9W7\'[-WQNY^_"-_*R]JF6<K#&];%4KKM[;7<
M?0L'^I-!QW2\A8U#;?W.9/", ?29G=IRY*4Z<<^IPK6^^:.%+]>_-U=^XQ6A
M:NVDMZ'R].USQZV]AW&?^ AI:W/D]1_M-OL@11J=LBM(0@_M/Y=(U&A%>NRR
M< <X3MD%1[G2;M?O8S3YO3;!#[Q^'S^3Z-T))6?;H02S;V)Q,_;>C<W;@6E?
M^-T*T[MA9'I=C[$G,]A>:,HJJ,?>E,.?Y-V:;C?;J3'0[V!UZH5J+&^'UM>O
MX2$> M]@@HZYT_%V?]Z=CL7_'U!+ P04    " "'BW%<K-QC484'   ,,
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MRKL7S+OH\'C7\T"N>/>(&G2V63:.[LI&_GV!9E)EJ\.P,(3]6@6Y;K72K<)
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MMUNA6&8"*:V (:'DD*MI*9ETIH$2>BPISWBN'HZ]]S__BOU_[ S42W(9N4$
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M!*X.XR5C "IN7JE#1PL E2P!8%@Z(@#L]NW$-)WE]^%OF]W96+TAXI1Q"9-
MH(O,S1YH4YV<L0\BD ?Q'[,"LO4B5W\$V]D:UD0]-A;._]QQ<%TA5'*-U=CY
M2WA<M='37,= K9*KZCVS3.#LZ!\]2?ERMKA8M4_28RV;Z<?+T;;C:"_.'TOQ
M.I8^/H#A:5U+$0"^YUCW8:WR&"Q%C5D3*=@7&$EM'49R70+R&'V$.NC#>649
MWSS@\"ID;@HS#N<HY3"Z:8(>D)^$6Y_9Q%ANJH6$2DN'=GQL-5=^[P,FN30B
MZ#<[!];J$")("<C"AIX8IJ*F_,Y7O>?8ZY[':EW:XA?74"1OZ=&'@2SBWQX;
M[7RA\^F@.[Z=W43A;</F+PN E9QK*(X56<%C<56HI^!9S<@@-L3T;>=)O02E
MGU96ES$Y&+H1:E.#!_*;HV)Y1TN)[38\0SBZUG!-DA=AM:AV!YQ7S#3=!U:B
M+#=CY05 B/U+SC%8.7PW[7[Z'[)!]"5J+!V%4%<-XTMVXX3'AR)4RHCB"CK#
M=+# Z.SJDOUF/!^3=G'%OI)SFO^=+;K$&<N[_KK_(!?M*T3*RZW*,UR-/Y2F
MQS] ^2P;E&J,,X5A4:XONPOE;BQJMEJS4C37CS[3<GPD)/'\!61RWGI>G?VY
M[AIPW%BYT4:VV][-)KYJ>.A&6&X%UEGVCR4]Y;DBKP3$Z8\RP2;+]EBC8SBF
ME"$)69KK/NZ$4!R1%;&L+GO*'C4*#C?W"$0[ML@_1%O\BBS3Q<VO'Y]!TV8Y
M<O-D$3C#QN]"\NU+07O>G-),C1=EYVGX;3K%<HI*'.#X"$NV[)KF.#)O](=6
M<]1Q%RL/+W7]4]K)\\(H"X#[A=26U+V?H; QN%_:9!F'YKDI?AC"K^9E:8AZ
M]88H)_)2D5)V.$GH\C\!%];,C6UFC3A7DANO1$X812@B3G;^-8:77*(TUY@(
MJ>56_U#5'[%=UW:_J!C6;%B@[MKJL>B[F9H"8_W+X".8LW@J]:!^/?E)8I#3
MVU&KRHG'@YXD:LTK6D<C@=72NA'G,3_(72#PSRLSYZY75M$UGB*9X^^RKA^=
M_;79P_<B<M07G4K3-0O+,$\)-7Q;U63M_.;\CP;FV8R. 3QQ*C:&= BJ0$.'
M&"Z7*5,E7XK[U)1A/=GLXYHYU'W]G5SRJV(!\#6/A;C6G\^]FG[;W6__[B4B
M;;*RXCT8HV'7!BI@DE!T"_ YF1[%O=%=X^6X=TA5[.JT795?]8LK F"R:TD
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MD'";_#N)YDI\^3)S9Z:T<S7"[H2>1X+A'/<>KP#E<H@X4#UQZD*Y=Z?W.,U
M9M*0](:';6=-^AW8_,E_F46^C'(0C:%09?BBFYK3=54,Z; 9VT-Y81S*6=IW
M\PJ.+MYBX69%T"1J[%.5;AGU:\=>_I4(7Z?"QC@#KJW][HH3 H!D21Z3G!4
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M"?CF^/GMXM&W;_H"AS:*QIU^68\Q+$]J!)2EKY+GO7M<TR(WG\W_7AL5310
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M'E\MFF*5^EQ:Y*KH;<B"+^1+CS*LHLO%,W;^Z#_@.Z0UM_1P]IH0Y8QF2K4
MJ+'L\UJBV7=R_G#SJ\(L58Y5E+\XXE'VY4O*&VA*0URD8^6%&836$  [C@J
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M$8U!NC5;/>_].)LS_^X@6'IUS1/C;\> 86AQ#61*0,5X2?Y/3:7ACFDW&0'
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MXZ  &+"6;^&_P#@\S=OUON>CT5A6DOW#07(RTE3:T.ATCGUVTX7D=5+45&P
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M2O6"U+6M/K:1P7@)K"2?]JCU1FL/[Q]&X0*._'_,R;5!W(KX.8BA+9STA8!
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M">QB)E5 [NSBJQ.*6/X*3$P+Q%;;9^[S$YKWN\XN^N>-C.*SU24PESJ,L4_
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M>GPDL'>UA+N6X$+"L@167TJ+J9^+WU#4][GTUJ\WY*X@LR_7/2O?Y"7_I=
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MN"HW/$X1J8)Z/015W^]R9=!AW[&GB=@ .R!D6LQO R^5+,3*RE]WLJ))(;O
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MZ+W.![.^W-0&N8YMPD14&)]VI9JK'J/OIM%[\V-W %E[;$>ETK7PJJ^.FZY
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MZ%>=,C3KL"%O!DB5-UU\]*B53?Y,0_^%7*+\SZ25\3])\L7!*TM0!J'QQY(
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M>)S)^[[OA8O)8S XYKXGYDBMS%O4I3+&M9S22UYT[+?:!:^+DRFH:/S7)4H
M'[1C<\G!<&8ICV'39%W=_XXY%=OM69.'_#7C]F]CA.A;ZC*/0C11J>S[R!N;
M;:0J/N@I2K. :O#*Y[U'0)J:OQ3U>IY''X(3Z40L[X'<70D/WITDBP$_>8!+
MO;N:3=_XGF8;Z9M^-]303>^,J*A)EDE?BB^TO J#GG#PN="QH7PY.<8BH(;T
M&=AD70,6)LRC8& #5?CX">9.::?$]Z,W6%+F^TLKL(XUB=7ON/WCQ$J G<<!
M#]>&,,B;;=NU:78<[9]A!]J.EI_H.IXLQU%&)W8LQ&R9L_0!S0F,;%@/6LH/
M]@OR49MUGU]L=%]CGY_7<^6Q:A$20WI=C=*XDP!LL VN2'O%^Y\TO,3M#80[
M$16R=#[%.9MUJ*5#"ZX[VE&CIV@SM])^OO7:TH&LBLZTYT69"=+A;F"0I@M[
M*JL$H"5)TLA&:/G]OMI/VK5.J$>83&]JM;8_%O8A ,MXBM1MVH9&D,KS@439
MN&'IYA[;\^-+YX^G.MV'O;I2"2?X'#MW$]UPQ4 <N,HYS%2+YX,^+*%I*FOO
MW_(&VU:JMLK:XOB@3RV!U++-1M@>I!L-\J36,0\9UM?6;)?]^.>Q>242,<O1
M@N+#!WFDF@6MIAZ>,C9ZY>0$DU*F?EZ,@YN>][;I,PB!%;Q26^S*X1SOK35E
M_L0[XEGA&?QB\R:QMMQ8;NO\,N;.U@!:*JNOQCP65JGXAX%0FSO*F;YGO3,6
MMR&9U-I_8Y(][G GBS@3LQ7.VRO(U7*"8&#OLT//4N9;N)A*/D@TK(</PD-;
MT#) UVE\K.HAFI<&UNRF"N6M1G*;<!!BM>SV$A^T4C V+*'YP6>[R\,FQ>=)
M;.A87SDGC%Y(G]H(-GEQZP7%M!R_+(C)!;6GU,K$)ES\L!@9:=3L0Z52\N<>
M%,28AOQ!&A_Y=6>BCV-!G)[K6XX!8VFZAG[,1$31J,)LS='!0 +=O/T3;!>O
MQ^D80R FP!0IFF*,WL%=:4D(K&.#Q%)I9MG=:?](%_P%1Z9Y.(54@D W7$)X
M\TYP[@)FC 29:-7W>-V7WLL!Z& /WM=D\*;$?3Z(&&_$\M=)+0JYJ+FW0#70
MV$F06M%DB5-]15]37MO9/:#@2>HC]JP6P)1I='UX742X17D;W_K*KXKA:&?N
M-:/]8E3N^A]NE)*@-LXA N_Z9BSDQ\:_53W#;SD/N2F\8U3._F&-$JG&#*>4
M0H\,5+JTZT9)<5[SH^::83]2T*97D[?>S%#M F^O(#/*A[1@6+)\$,4=CF %
MI@\C0S@6O93U95<V'X3KM5X*L_7$;;,,ON'^0$\4_9+7BF<$'!'[$KVL*>ZW
M<6O(?W,C#(UNL"RUZ;0"=!\*DLHIO!2BX3TV_20?A/['#N*#K]&?S*?XH#RY
M.17JMZ8)/#=7H#5$_2IM>!?T/F,8K@]BMA1IV7_P0>6DI4VA)WH0M-ZXQ'"J
M<XA1Z,J4J;">0*60$RR:T('<2:>&(G2#>9@XQ:Z&XN&D4(<!G"4?YH?EY>/.
M<E_[D<3"!C#X>R1I3<=]9E*-Y#N0>X<>)32J*2M9,+23,.=>!JY_QAF)[G>4
MULS6FL^,=5I;Z!N>#]J8B<#:)#=0,*^\*"6<1/P&.MY F+'9+*);OQU9LPL7
M@Q>'XONS+VI_+@@8/>M(:AQCVZS$U;KF(G<T0<D\$BHC(.E>S*:V=URG=!J%
M<U'_.F>!#DO K":3(F$;<ZX"?>$PW(,FB'(R2(E\T,(0F*L44_MJ(N<(C9[)
MI9MQQBKU+]"G:4YF:CXUJ-0-?1ES9EHB<P=M=/S7'K7< ;_83N.,\26)U'L6
MGT(F-G83CW"?$"\BY282ZZD'QX$FA\3KIB6AR>.BJGD97E4],P_<A7U&UR76
MT8L1?) "@J;&WNV(GIW#3J,!A>YZM A -6:"X_6,<\GP_*$EOX7#:F]L[T9P
MRN1Q^,B^,"232UY7ZL\U$HV)L-ER45JJJ0BX +?"VE1)^_5->]HOEB:QT(UH
MLC9MLTVR.K;1X%>SR\LC@6:N\K<N/8SM#V@'R:,K5:9A@'+;C_V@?^:#OMU"
M<"4< I>.TX[ILF#<4H,CR,Y&K0_NP=X5Y[GEK</?HZ(E5;*PF]9VI](3'G\J
M_;'@71"8?% ]B27^XWQ9FX]ZFCH7%C7M5%?-K4,'<7YNL<TW2@_4Z13Y7FZG
MN.%?K0<N:>:A](8,)+L13)UM,^U&JF=$-O)[TF'3FN_L/_#^L+TEM?JNC.XF
M2=ZA5Z5ZFK)9^SSZSR&R14C'MSX$0R/^=)YH,],\\0SOJ #P%RH=+<U>+?E?
MY%QT=D&<,!B^EGGO00>Z5B(KJJ^6C/2P:>R;2MDL@/MM;.COI<N9BMUB.BVJ
MA>$Z>]81AWD4ZNY:,9S#+#DJM@_.OG_JX6DOQ8]7G0<#6R-\US7GQW\&HF@K
MT409PC!*O;CA_9SOE$V(;[WSH*VY,G4Q&SZ-_D9@W6>8$>J/B4&90A'K=8&W
MF>*J03Y:19[I,G<##!P\:H_%5CA/%@DRU8CY!"3.8 ?G 9!^1Z-H*>S(O'U^
MG[<LZPCTD3$;_TW^_*G5[_Z=:@8P_4)<5$/>+?%W SGC0VE5 6O[#L=995VT
MBO'!P,?U2T-]K/Q5!01XHX98XR-24FEV&L=ML1YMQ4&[801H\T\3:B.Y+2)'
M,]7\(QQEJ9"V&1]%WN5#PYF74W V&NE0ESZ<M46>,N[MIZV94N05"R"5D4@W
M:I-*N+UQ</*PK8(H[ZWBFO1O!HD^\,1-E8T0&CCAA. ];8V\4[_],4]&:=\Z
MX6=LBT:2PI?!$:@-1NQ$(OG'J>U\$"-&X]=YZ>4HGZ))=G]G=8@O$#;#VRK&
M,'XG"71-HRE#BP]J2C$FH@_,BQY2T+FDO6+)!X'72,K;>JUPJ<N^B9SJK'3
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ML&/SA$@<TR1GP)\>?>S)"0_H[U_&HI(W5J/^?8+#D-=*/-J=#R++-"(8[)N
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M=)\=NO>06;T,Y8/NK3F)L(W"OE1A),-^(B.EKK@OJOG)$T*/3+.+>]JFWC]
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MT?:IE)0Q(*V0$;G)@C@\1@@I"3N&A#;[:A2J!D(^NY[_5??\Y[E/Z=,.FA9
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MI65(OK"9G:3!T?COQN&F\]N,KY5K3X]=#5DMI#"_4'P4!#*)Y(("#XET.4R
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MR\GG4:!H$!Q3E2",W_ON=!TG+<YX%&%\KCK'&6)T76K*C4.8S_XY:/8_G4S
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M'CBA_Q=]?K6L%?Z>$1=IW?X<-::&R8M<97',B@X]I;1J/F339Z@"FF<"-WP
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M61,Q\C2X02XBJE&\7)5K5<,^!+RL.?[?\6'WK?T#+2*),N!=G#T,\@C8#:K
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M6P+@C1$W<L,V4-10"U.IC;2.$H8'1ZO'(LRS&;!! _DCQH@?M,Y.5<J5=?P
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M:7B4_&^B4 &-4GRP$$45> ZU^E7()S02\$.MOZ'J8814R]D .+M#1$!3F;S
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M<"U(@U=8J$)A,?NQ5^=Z3+,@DE+6%9ZLSI,FU58J_M,-H#![,I1U<K)V"$M
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MAW_?;1G:"<O@=E';G1%KM$JQQDYCM_,/$ T<LT,06ZD"KZ=,OI .5-)=*&U
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M7K*LT=876*+X9EPV\F49*'79NZQ07P1_C3C<5W&/(/J..$7/GD!>_M6N,QM
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M&\FD$PTHF%N!D?7%N'3;]U4G9VQXM\2$Z'808Z,>;=OFN>A-V0+.!]1VYS-
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M:"^XQU=P#=EIAI\T*%QD)P49GT"60$#)/S#0,V8:F:S/U]R"@,U+W: F]-
MS+P+!%K.^M3+8)'+NV>N$'5>21)*FI;+X-C3P+5KFPAO!.7L3G<(N(-2(J87
ML]>;9K],C?Z516$(BOQ\X%HW97_TV6\=61A;.A!'QB&=AI<()<8AP*+<E%<Y
MFZ/\"N66+9]PJ)EG@#_@>)$_P&-NN\":.PBT%$OD3*EV3W?)8>URMS92$(%L
M6 W'YQ'LJ(Q75]$RJZJ.?T*)(\]2AWC[957V==S!\4[2<_MP@)@1]0X-B]7A
MB,7G=5*X4$8=6>_LK94ES,K.?,"K-\)PNQ%R;E< EX/TYK#M*)VE&0LKU X,
M^G-\H5:GDT&0$AU.W9"LH5/\*.>N ./K*DBCRH*%370Q\/-',VK!Z[FN^62R
MJ/MY#%KP NCZE%+B;G^+D)0+NXM33+>Z2675U+9P+8\E5;TC6^[XU67U\8.D
M/FNMD ]*KN]J%\^X#4E;V/8^54&481R@&P,(N0@ ;U('<*VJY&++T%P;KR5'
M0C?A(1X6 _F0S3V,W4H'CRM,_L*Y4DF%P!,%=UB^,RD$5;6J$2*=8'2Z9[!Y
MO//>?3J ],&.HMDHIE.:3R?N>H\WQ0[K3F^*W@4OC92TS:,T_W$0W-NI905M
M->$"@(J-;%CIZR&_FXJKZ*!9[<I>L,!(A)AF=@%Q=:"2BG17#TG1WCVMK5D^
MUMP&$^[/5R'/F.H0Y6R5C?()9#F/->Z]RE$VU@L;K!?V::P5\VW(DC2S"H4*
MER,]B^>6JTHSI4$Z/S0[\I3<QD5_VP0@;D"VEG'5".OFNY0VRQ++G,_U'1;3
M&*,D><!E#NZ,MMP3]SZ)HMI\OMOLV$ACC%7/ZX%R,?_YQ6?GGU*";:W1U']^
M_NGYE^DWB&2_K>85*&8^_PQ:"W_ )\>__:* L!3C@JC@\M/MM)U)%S@L 9#,
MPFL^6QWA^;=*0'INKJJD=:? '+ZT?M[!!^GS26Q ^;U53V517>+<0$.*1P3!
MR5'I*,'PU$'.+/Y$<I8JWU!]28)6HL'!,2=DP%1LU3<9V=.$>=FO9DMJ1A\]
M%O>0QU=<DBGI=2>?18"?G+Z3VEL&B9CO*(KGK@BBMAUA P.^+^2KM.D7VJ%C
MA)8F;,,=Z*3/8TT!'D_#USAN"4;":1: MT;Q>+ W5DR\1++0 2(6%.U+EZ6\
M^('TIRTDE:'[6N^B7C.U8QH^2U_4W+2$MG4JSQ ^.[R4LU@G@"*.X_LL-[-H
M=]%JRDL"X(Y@:5:*$)E>KMX2(K#A._;:'1)/2.MXY$'>G$I1T=ZW*ZN]!@%.
MW?'2,N5\A'2"WIWP%6DV-JF%LC8K"N-;5"C(=5#$ K.MJ=+2<"M&//!BX4UQ
M-2@CVC(>C.)?B*UQ5@%4=^!+GD(8\&[\S.<G_,P]XF<^/^%G'O1 !/0Q>9YH
M &A90U==W<68@IR?I4X)UBK]1\Y!==4&318CWY33@_H2[577WA F<&F!(H,$
M0:!<;V9I>^10)K[\NA+&>N6)JQ9!+^EV8MG.N7WB<DC[.M?Z$M$H;;"CDB='
M$GI1<8[0IJROZ2MVK<)5?-EOQXUB56]C>&'!0]EUI>3X+,?>D)?4Z<BUCJS]
M+^W1CA_=Y9*DWY^42\43<Z3A\N"!M:93^.5J"H=!"R;F2'^\[=OVZ$?VZ/F\
MVK*SPAY=(.\YT%DV9;,HR29/GD<W$,2D#D1BE6>V&&(^/KH->EFJ5_EG))>=
MGA*1IXW;!(;?8XN-D4X:N*B>>J.QF<$*H(0G%$0;XU9H&+-%LQ,X@G&,![<&
M6SE34GQJP*SCJ(K9\8X/)N-AFA[.GK+^*D>($A.&B9BP .L)T5OR[,0E-N"7
MU)C@.A(0L%+6,(80M; 4\9+Q'.()BY6*.L1J/0)B'R[=-*&2G+8P3C(S$K%-
M<1 5$PN?U7Q3D,F8;VY&4T%[DIZB9%A3)K&H(RN<KM945 <MNWV1C'GL1PK+
MT>@+T(I'1SPJ\5?1Q4''F%:- ,0?(E*Z9T$"N1R8]=RUSI9E/&+N_^M=5SL,
M1I!Q^(:;H(,>?TMV"=7"58M7,8QMZ1T0R]14WRRUZ'&F7'7M<U4]GYT #^#'
M'ZAJ;I,8448S!DT7QL+(R1UGOKM,,5?;&*)&-1*=3=2FXN#8#]6>)D]6)FM=
MH3G7';:4XDY 2)50Q20X:8VB0[?!,=9#>2_WJ$FEVJW*6H%8KQ/DE^XTI,=&
MNU=*SAB^ZFU<A*NV7<AGT#=,#8/ALC*^/6:!72,1G'H0 1\NI,X%8*X;=2'D
M+HD0!?YH3:0E_CF0)8Y;!+M4HQ%*KRJHMZ"S(MJ>J!8[E&\K5<Y)V0D=E-+E
M<6% Z>;TK0YM074^BX 6Z7NC;AJW,0;-6/AH(D5G1Q@#^+%]J-'J^5>G+5&X
M<,NL:0^0"6VL-821;&'4*Q>?DRS*'?6)X@7E$GD",NVX<7$B" $7+D?*P%=$
M_2W1K*#ZM->- [ <JLLO@/M$*+ :5O$-8UM1C.3([=A )T(Z39GA<D=6%V'M
M5,9DM]D.DJ63!TN6:Q:"0:#KSI&<B'8]<AK(6A#Q2?8->[- N#J20 G(N7&M
M,Y(6!N=PQ)<>*#!"@;%ACF.%@S"*TP7JV L_8]ZZRD.!$C*>;(^U^Q0R!IHX
M9Q,1>HW#4$&CE* )E3'CV-$=ZV.?(=GB;\UPL\\P1'109T-'"ZSY0HV/^W"Q
MV:=4EV3>=44N- QD[T8;A0_>D3[)#QK3!S. DF]+=Z;+.J\)< &6CT3B_BYN
MCSX\8+&*4'::?@(K1->&AL<3Z73T,$+G-8SK!$[^N&3P3"*3ZN,MRIKG>DW?
MF9GLN)OGU+C+QW#1FA7#XU,#!2_?*/:9E$-TEW*8Q;54Y]/[POZ8)$4G55$L
M"6V'8%,H\Q:SW#6+\0&/[MB 28Y[(*940'-Y:-T4ZR[Z61$U(/-_]NFSK[ O
M'GL1R9"]P7K"L,MJWR($*R%[5+<+?1_,75QO1*(]7TRJ ??.&M+D8 Z62/ I
M!('PNR,?^0$<O'V> MRB3Q.1\BK/MDA21!)/:1I1:9*&*UDIO<O)T5<W536,
MTA TRWFGE,;[6:GKMJ*%!NTI3@]/K#N*M_]7&;I94S;HLEZ3,'"BBS,V,#BP
MIB+8[W4EZ=81=1$*B5V,OG'&6L-54-!8I+:DS 5F>RE"-%HDU^B:>T+Q!(A>
M)[-BV83#'H4PA>OPHJZ"<R-8MPNCG4E=6>+G^%C+9',)$ZK8GW34^J\'G,]4
M)/)%H7'12,:158)NJ1@=Y&7";.;J1)?E_.T5: [HVVWW7S150_4?4B-)Y2&Y
M'U,2?CV3$5F9*U[Z'8\X+ ZN.5FD>M\;<2'K__@??_KRJS]-W^;N8[V_[)=T
MLV(H\:S:M"3O[D1Y)0B\JEI4C37\$;0^<R143+G)R5PZ)ZO F="" <[ERPQK
MJ@B+7@$XHNPZ&,?[7,L2:5JD^X5F\^'LY,Z&<?2ROVAL'_ED/*Y50GA(&L;E
M;G'%;11S%@2NF]1K/8_WC6Z\BP9^LLJ357YXJY3L%X:B6K]61)**MU#-1D\[
MY2L5T> #!PL'CD51'M/PZ0&.Y-,[@5>^.(%7[A&\\L7'"UYYIS%]/)'G75W
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MFEXVG_)Q2PPH_'V[ UTJL#2\,)+#<2@.P2Y;L%*TTV@F? (J^]QA\53KP1^
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M9]].6X8<4(G6V)W?];4=)K_H7HD>DM,00W75B= Q%@M];K0 J*"KQ%(+E=N
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MEL@[RX:L& *EK(#M6:_''2*2LR!.9WHY@6 &:''9H6<KL=*WG4%FQ]>HE[R
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M7^J!8W&,K,:.A6BNW#6P9!B#EW)HN[N_WN A5@ROE[7OJ]]3;[H]'!X70B7
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M6VP!XH%1W.,H6..3[SKL=67#,9(<N./F1O5=<"_'41L?8YRVMGL[4C_FC%D
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M6EEJD&G)'Z=V^4>*; ^HN(*;7X@A8.D7 A.W('GS)&,C&HM)N"^?$L>MT43
M //5H%[OZF8BXE?GWAG7^ 8D'-$8@<SK13/W.:.A5<F0GN5C3I%KT93X5+OL
MOU23TBJ1Z TD_ MK9X.2.ZT' =3JRY,W1[^^^OF?L2,&/,=NNHM2*B#RIEDX
M[N,YTME(<L?90M%3:UZ5T<O1;U81+2,$"4VH8P]'GF4^FDU3(<BS;IFD @.
MNB7;V7297X3O.D9KF[RRS'7S8:H&;YP%7 WL53FIA6'9J8P@;EJ-7=BV6W@E
M:1T;7V2'JE58%.%*]2,G7DA.<X];Z9P:>*\!@A^PV?G,K(T=Z1R(D+S2(V?U
M;V:G+]%<ZBQ$O<Y"F@$I>G.%CV#$B+]UK;0;%!G>CQ07[JVY<F^O[2=^[-YJ
MAU@$"$E^?+HD :\7W$1TN8'@I\[.[-7'B05'DQZP=7V4R"BW4J&>WV"$YK<*
M+$2PX:/";F]VK?4U=JZ(VMMYF:A?@*M&=OL0,F2T.IGTP_#VV)? 4+WK##4F
M$+&I.D,\O' Y,['3 N'2#:*75C4#="DFN+G\S<H")PO!.4ES=N4S\>K;T="N
M]7=E$[1/H?P8;M6>089I[EB]BJ)7<EOV] 4GH,Y=]>95 G$?$DV7*NZWDRQJ
M@_VRMR7[S>*#S(EPI-@>=SE;<)D@PQ-U$)? [5IZON'.<B3[':2HHV@6FK<$
M&\EXK?S,$*36#"ODU<M@*]>I0HF96*RQ@(8[&F"UD/1&#+W%^17CO]?>0Y4\
M5@)>P+DO@@SQG_:S)J5@+AQ1MC_G#)Z_,A#T,MFK"""7[/-^2YHT^;?JO^L>
M1;TH,@E>*@K/XQ:*)QEVG5^F$+6@0Z! (9$P.K&:-<4]$<J0&TBKO,\H9Z[*
M'"!JZ]W^&.LKMGRA,N;H&P&%=2\E !Y0%!!O;996GTX)<]:=#.O!=V\#0!GC
M% (FTAA"KO!"X:\ISQ!KMW"^EGU\N6">=GL4:JO"$2IUAI44NN +: -@7"X:
MPK%B.T'2K!0\PH4/"E-[! =&?(W!.B !TNH0888J$.O]4U4,>IO".U^-LA1+
MQ55Y51$B7VOJ09;$-;"93Z#R 0/S&J\;*SI\_74,A@8@1!O8QYM>156X;0^Z
M\)3&(?6\J\H!J5::&![:(+F8YKT>1*?2L5V (9,2BPAQ/N*A8==Q5F0?F*$1
MIJ8=HE@TCRJ'UC0WAM>$6*9N>DWL-6^W#[QI;;])16@:5&6R)4C]"TZC8A<(
MH#\7@$/3N#U,I>*'QY16HX7_H1]PX)Z'+\>]H%B.,B4-S2.+M-+19%Z77LI"
M/XWW-QB#P$-))]HI#B $M>O7XBY9J=(QERB8M]VDS)I&MX7;/@$]@WHYL[^K
MEEG6P;N5E6<8UE[,(6P8*7Y6":.$UP3> 8[O!J*]:Z!+KBXBVM_>%!'=7!'1
M_O8W5T1T5S#/1I.D/ ,-"-9('-B#F%CC2PSYV5P9D@^\G8'>+QW?!7LWZA)!
MXA>D6;(_791L<Q'U7.@,"2VV7&IH?$:!\6G:QB?7+F)=9*<%&O;'28'F%7-M
M>P7G2;WD^GE%P]Q  !.N@B75BJJ[.;>F,YQWB#/P]8T]Z6B.)/HF8>Y0#RQ-
MA%DPC1%7CR/%)7.6P&SL[Z&EX&R1(RV6L3<[7(=66Z=M&%\[*=H@&/VP2KEL
M)9=0D,]S\978WB1?SJM67L*[R*UF+9:,;/G&E!G<QOD<+8PA%$*?5>32G&,%
M*Y&O*=EPX\/GRK2IW0(6NTS;Y(*4P@JY[O4UB*L%T9,KMCCF!$S>Z*Q8F/N3
M.RYU(18J0H)Z:PJ#G6?NUJ//Z-9OV'!9-1,,[2!\U=D+S%.-B> M3@UCK$"1
MMU=Z_?T'OG.2Z[Y;JP%RTKD0QLLZ^&A@NM5$.*]?2UNP(E95O2)5(OO)=)A;
MP22/E+M8W9'04DXF)>UWW,4S):E8A_M/Z@"MNBS%&A(A05LTUVC5"GPV;:>B
M<;4&-@L:J&%TJ179T(Z_40+A#$4D]H$>Q:H6P081!TV=SQ5$D&1G*"A!&:?(
M"B>'G^RF$,X=';)\WM6.2]"0!OJ-(?,] H%"PQ,[W2&$Z'.GT >A](P:B?Q,
M%#NT?56NYQNS7AB=D$GY(GSJH%>A,J-"99ZVB6-AKF8" V0Z0153Q3[4F-14
MG-%D-<4ZP0\[6MB+%BMT(7A*1Q]B,G9IZ2"XCW"QC'^S#]=)3F\-A/0&>X2L
M<Z0*^M2M AZPA_( 13Y&:%.%5X79C?"LQ)=I"<<4+&6<F.D$B3)PLU$=)VJ@
M=O4(6#Y6I:?84D3M+X#%?Y:T84:&2]>==@GE,BI\:F$JDGPJEHIK634KD^CT
M'GTJ EQ."(N@ \<USN@BT^,9#M?/R \>9U1GTLJ"Q2L@\=C8AB1UC3Q&+MO,
M<V[["YR,!@!@47TQT''OTH\4"$>P6O<K/H^M2#8ZT#I"=XD#?=^3#.\80K>,
MP+C8W?[1+D.-EOQ975T 81,)-GZZ\Z-KB)9V(F'&1BP-;S=4I1@/$AX5%>U#
M.E1;X Y<B'SJ0YW0KAF.R?A64:DC?9]=ENI$TE96T%BU(19@M5;YB>ON9>PV
M$QJ&@3 .C]TI%T[L/D@>2@KBU,>9CT;S0?2BPIPOP$M3."PPJX?X\KZWBGTP
MFE18<6:M";MOQMI9]G[F(DA[74VY@AI-2>LSY=6BB7JR*:&8D*9K>X,4I"0>
MWGG/X) 4SVG1V![\.7Y;ZCDAIDX=MVH(% U+..()903"1JIRN#P: *E;E#B!
M<0XX(WBAT^_"$*CI#8%2]9#LTO[VOMNDI!XF5D]MO?I09$O8J-@=-WVCV9&<
M)5(0)AZ9-Q!&RJ PG$F$HD)KFH]<(H-"=.$FS3L2E9#GIE1E697#G#+@=JOS
M!LQSJ#P#S=']<J[%M5M&V7*C*W= ^9S!G[&9-!E-%G-H=US2F['T%1Q%*S3%
M4A$YOLO\;=4OHQ'L$1'1CO,Q K%S\4*]E,+4<0Z@<=$22F/!M<2>SW$%+<-2
M@Q36V-,NYUB^Q^(@%>RQ7:>+#)/QE*=/Y@O)=6-(A2.M=FU'[Z%*?FR$B)3B
M$O8[T>^GW^\,=O<.HB%4DY&MPLDH]@=CN8\Y9WX.(4>79&]UGK#.E/(%NWU;
MOA\$RB.L/6RP.W2$2#+V]8^VMZ,IOSS!1_VR*+-H;ULV#!8+2TLN,LI6MH>_
M[09O?P&O1)0J*_=PM--L2(D-)#6LLVP+%Y]DTU"LCLMJ4SH3R9P_70-C]T1N
M*A9@=*_4QK4N-T.X^%[)>JIX+,9S9Y>,0+! W5U(S^Y^;KOW!0-6DPKB2_@2
M4#>2 /!*!RVXVH$B)?Q4OH9K0H9@J63T"7E_HJ?)91[\&!2>\PH<SR+[,EM,
M0>E;ZE!:N50OO<9-:)+%GW#]:-KGP)V> \R)I 9=HK@D#N[@OC(NK]>?LU.\
MX^K:6E'&U[(\;T U7ZJ(R?&R/EDR53.'@_,B&]8+\"R>Q-"JM<_%_WZ]$\@=
M-@0(,[YZY7Q&5*K<YA!=D88'4E^A6^+S@^Y55N%"EM=NXB#ZO:1G9+ZERMX3
MR?N2LII\E_>]7R 1_!;ZHCPH->=_BR.H"@TXQD)0*QC )* 9ZB#YTA2[MZ1^
M49U"CPS\MUO?J']]S57)[)CIL_F@>[BV5B9VQ:C2ME\'Y2ZJD8:\W&1NNO:\
M_[#FC9=:&>#'*Q;[%$5)\P&K$*%GI)K9@T?6P764R]7#O9A@K:2KQW!7F.MW
MLX\8YX311NEIDT#):C+RV&; _JI?WWY1XR(.7<6&NK5,M%F9G25<JD]18XF*
M7+#*,QSU43%5&KLSS1G0DZPP:V21&5A)^5?KS2! 4/,%[T%?X/EQW,6OK"/B
MDH*7[ V=:%4#Z]>!$F,N.N(K&>[_P;Y&=GYGDYV_P>S\SB8[?]N]'Q(1$A.K
MF29%@7I!].AJ>,^C5%Q R 3-4OL32BDLT0VX.L9C1T% !4K/K48 ]?VV1G&X
M(Z=)BZ4K#^[?@Y8]'X51N1-K?=F1/1@_?+"#8;DW+N46G6[]SR Z[=E327U"
MD"T*@FSMD*QWUXR*$:FT0G=!*94+$-8@Y*PN*K2\J<89XEM9VF534EZ>2VRG
M6%X9]:Z)LOJ+Q'HF:;)T&+7*V,<FMLIY4(2%]4/T(']X,V$/DU89!9<P_A&Y
M\$?T_>Y!._;!<"+V.QP%F4]^A%\\R.UPL, ^",Y [CSM?O:.BJNDB$-I&'B.
M;)=4+P+6\BG40RMWJUN//[\\-AA+JM7G/26FE=1Y@R$:$UI+RD= V[4G$.O3
MIF!>3F=5@TFO=; E4-N2JP @XT'UL*JY@-4Q7(K_*U?JOX%D>JQE4DH_,S+L
M*,A*OQ(_]:)5>)/X4/6501784D.9;[3;.6:#0;9:^I]X<^%!JQEOD(=C.J!K
MI+9?K73(-6Q:2\L1[]PQXY&\I"7V0"[-<CJT3@LK^K?/?WW%.GT0_;?$>2D>
MEH,V\51^02$U1D6<1^BS*TZ@I'&,A,HX=Y&'Y^N2NYI!,.RGQ!2)/N,N^ (4
MP2U> 729L%17!,RN";T0JIJ-KT6#KBZ)MG2Y2"UY&C+,B5P!(3NH:.DZND"$
MQ+E$QQG%PCYO"-7@<RI'J@IP@U31NG\M8D.(-\;C D\P*9;-O.$ BRH@&4<+
MMPRL,%OM&%STS#S3P6Q-4OOS&T?#NGIOK?@T2PK$;* X;N(;]:,^!DA?#@#*
MVKX$Q@9I;5(*[$1#VD%/FOU=[29"(0(!(9&FX&8A^ZJ4Z_U1@ -<JM52&)7!
MM_)<DS],3\?.2&"&LR9ZZBK"AWE**>/FO7Q9%(A^URE<2[1>J)*\PF-?720:
M85QI&@RJYEZEX\0KTS&JE.<,JBFN@!Q2SK"O+&AWD+*JK&I2GEYE^C9-U;-1
M+(TK=\=.=P? E^;%@CHE*YWV:@AECFH@N>$?,W;T6JQ(D3<ZCW\M6]A/ I/M
M A0H99N#*]+(%3D'C%HZNNU8"X=(7#R55?4L*TO&7!$K'&O<UNAV>]9YND(L
M0W5>^ 3Q+4_+_;F+B0A"]@<*F)@<':PY]+\2'Q/EW#A=C7?D!--0[7!<05WB
M]D??'PRLT3S+)&^$Y84.J.T:OY J(R+.H2( $#&#^,X",JYO-HG1Q61=VP'R
MXJJE$CVOTV\**"._M%/?"[SIM@G#O8M:>R=7X$ULGQ1_&KZENCU#JKBP3Z&+
MC[J!J/0=*^9JNV -[HTTX+>,!:Y$QR*LD95@._*:? MRZA+$[-+]B]*U%9.;
M%1;RL;C\>U'-G8^#3B1^>^7KXNZX>@3^&\^&JE$;:H6W<F-=(H>>I=0O"=*#
M_/RA-7G*^01"PA0MU_Y2,_%E ]I-;3I6!7U3?I&LBL\,T;.;@3F2@5Z([:-3
M?+*T?#M+\2U:7K(\GOQ#5D"70G+"7=D>X<2I-\#HGRB\+S@&6?\T,&K//QM$
M/XNB$!N* ]YP>,%4YD8201]LV4 HR00HHMLJPNL=3A1BMX5&\MN51CC4E9>4
M 0<W-RRT%G-K$QMGI'3C%D:GN8#@T%RIY&B!D99LAK_C3@/%, <^ VXS9W,=
M$%O3$/&18'>H7T&O!^5" %%.@@G83$VT-]\PBM<I*$D\(]AJ O?@"_NM/ 7L
MCPM7E)!,J:5!8#ZQ10$KN!D> WC6J+O)(2QT_62XQ/9M$"W"$;2&[A:$;3#Q
M14>L,;B+4L;JW   <1M9^6QR45(+S!X1&9$/X[:^Y[0"@55A $>84[4("Y[[
M#.-4<P.U ?;N:L0<;<N[T%PA_==4&H&%2,DGD3:(8QV(8USYA<8-RYMI"Q"V
MU03RX>54KBB1U:=2O'VL'H*%@1P_(JB%.4[+6B'4\,Z-S2^>'A_%+:<S-D1]
M!^UV)!# 'T:Y26[\@GRMD[F.SZXI>&M*,?9VXEKAV335AQ+W'[0QI_C-X?:C
MP?:3[5VWL;@GWG#F:YRK18)0!-C28)30"^#:.*_PGO:7CPOHENA'0KR9LN"[
MVW^3S^E'9H:./L3<B\*EZ;NAY^CY8@:/V.80KTU*CEC/+654S#VT*/%6IP U
M_8G[ N;VKDT-I\45?A*X 7\BA84:,LT/V8-&14(T'DV&N*^(0U>0%80%J W<
MJE8-@WEAEX!;*'B\D@A@,"R_GK H\_9F-L++R"OD /0@HNK:Y 6L$\,0'IPN
MW)!!)$B22D!T,(S@/D$7&RF_%;/<NR#R7=D%78M%V90+OJ?F=!=)_P?W9.CO
M)]%9/L;@,'X7P1'J)9E;5G/$)OPRI :I&H7DW-4P9%P1$:T&Q9V,J[J8A.E,
M><2."R5>&5^P5()#QBO E:_ZL($/B5A;4AXL5]IJ7U:DJDO5(\B5O?(X&W]>
ML5*=>C!!3-C7DI".2Y4X92TU^A(!S))2W0WZF_P-.ZD?ODS_B2]8T 4*[0(&
M?F50E=!SY=D/^LL:5BH9>KB/^47;@UV\VC^6,;A=_^ *'"YYX(]11RG%W2,0
M?E42U_G$KGM-,5-T5_0E^\6XS%?7]6,6\LM03'_]>=TM 3FQ+@4,8V;O,D#R
M*9BY%_#EV&Z,,<+AOT#W&6K>@(>@:3).^EJ=SLKIBU*8;^3K[LO7<RR_P)%
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M+<7J18<5Y-!;7!5.>/L$ "+V,#4+&H72J'EINO;-F4+W74K)S.IGCL%E4FJ
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M.KK%4^.3UE25O!@6^0B2<'4"_>/0KSE?AO0P*0J\+UI+H_,*RFXPJ2MIRP0
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MAPBQ ^YI[493!^<V;T9%U6#'R9NLF54HT.A\8S?8F"4\@7IE@A.#:B%:3@Y
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MG#%5?0+*X2%^OSW8WM[>@3840C@V]H+B'VEA"#+D_G4>U+"$^)3(!QJ,V)B
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MW;]R9P]#>["]L][BD#U^?+T]UN:'W1TG&0;1G[A4N^G8T+4NTWU;8?.,[S*
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M;2,U&ZGA;"Y5#OG0G,/HQ5HB'X<.:1<V(>.-P'V:P#%.(94,SDA*? )MY*Y
MD"!=),!.'GRZ$:.-&$FM6N6U3S+"D#[6$2* /$0.)%J 57Z29&@G;75&#?T+
M^ =&L'RHJJK#4!;%6'7PBZ"(22\.+J4-6[=JY),4W>0EAK)=S9^O7I12Q!&
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MS.O((T[?GB;-G>F[1']<ZC;5U&UJ&-1W_.2+A1,W@@Z:=$GW*S?8L",N-]G
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M2N$P1T.@*P)Y'/UB0*B#7F!/;6/[;4:M@L75$LEUN7=#4YJ&$QI]KF.CB].
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MV"1B0T>>:-?(@SP"#=X@('<2 :.J?]X:%R0JY7?0,=HQ@O_N6 _!&Z?7,=W
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M!K)+9UGC^>RT+<^:43$3NRJDJ8G/A%T]1HN<;M9O Y(;?JY-,D+N&0(&9[[
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M2UIQIE#[WS+[:?>^F,LA^_B 7T[3R^OC^YN- E/BNPOAP!2AGUUXQ%NAI $
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M-;/=CN6I%\#H.T:3]0@[8/5CIPETW7BWVHW%93Y] 4P8QT?I\$;M=;O, \L
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M5F\\1O%%VMN%;9!?E:,,_>F2N1[0N#4@!Y&FF/3N,_>.&!&0,0\ <D>0X:N
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MXVOI*B_Z@N+]TP^Q'6\DZPPC?L* \<E[T+9NVL 6;0M.CQI!(U"P'M?K19R
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MBM66-$V1=V=^S'Y@>PMC  ]]K)=G>%="RM4P%<PORI[+E-@?K7IVT.J5A^K
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M5)%7: --%8>9"%/D+9(62_A^=7T+K$XTSO/1E^.(.HU8%H=(VZ+GX/NNW;G
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MT"&SE7NQ*8[RSZ)=/HWJV$+H$3BQ :/JQ^>&@?FL\^)DS+F0/7!^ 9?@8JQ
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MFUO;.[M[)Z=GYQ>75]<WM[_T@@) 0_W]^)=ZH3WK]0(&!AH&[I=>4"]<?G5
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MS^Z4BZVFCOE):#TCR0"-R;HA]*C'U%6@)S1E6N[[Q-OXF59SI 6^YAD-S"<
M%&&&K&5J51,<:_4D   G]+W@C\S@A4&L68&"(,H<W? CDZZNYK7N'#;!>EU#
M/=H"\\GI.HGD3X1RL>+DA SSXID!8R\;@N[JDIKU*".T1X^)?AU6FZ#B(I5P
M2;K<\3J'S28ND_&CCPV5E'1?-Y3PQ-NI^/C.])3G>&,T.LX89S4PZ\\YMQIT
MJ%;K EF]1&T.?J9+YG"%CL2G&?)_?P*P)._W2G6BBD)"918N6%)_)/"7FDKA
MU^KY+-!LI=2!G( 0UR_.B.P@)TP E-\?*8VY!==H/U(/=I$Q\;N#(T$<?M*6
M<5+(=O6$W-<Z!6[X-PE1AJE0VFV?6XEV:I,%YC;C:RA;ZN9Z3!8*"XK+LPXR
M+$K6]&!="S2:*T\O)%0E*MLLU#L"Y(2YMW?LY"VNII\ *(Y6+#)OMJ1I.*R;
M3F$OO'/=/\8*(N2)KD8&+3&U!G(D=47W!)I:/2=I"]ZK?'XKTZ9K-AB[WH1C
M<WL770-4?5&]@<SHW%YT7\9YH:S6RRNO"U3:FL4;O:ZP"OW0C94""#,_.NP?
M:!*AWQ-0',9;.F2KB[>.12;!P .3X/?X[#37""A@=A9_S-VFK.QVY).^*Z<3
M;;GW/Y;K2F.TL\G1F2?@+8Y&#NL<L);L\<!7T0L60&.@+R?^)AJ>%6D\:QZU
M9@#N*/-.LXP^5O.OL5+JJK5O29VZ3*A",$XVFH-=7L79D_&HN8S,M[ 7H7C,
ML'0\3NT:[RB3OS.RT_A8HK5<CG=#T#",ARK<5M4QO']4\:7,%=1SU<&!KMZ/
MTCU1F[5:AXR$+L@)<"(;56-;&<'?FZMH4?]Y6,X 5H&.82+E$ ;PR7HH5?M
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MV9T M"R:-<M*:S3X\R3^>1YLB)U W"^JS\M\F1TVE@R@SF$U>9Y%AR@ C*+
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M\=19/@^EXT0*5D/M6ZSZT@HI,L-S]15@@')RS;_MW(KFIT#WG6AV59!)S!H
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M7J#4](,PM3P4#G'8]K[\2"8OD:$;X_U$.A3[I+9AJM5]M]E\YSB("1AO*<J
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MP*W2JWIKQ4-P8?[4J;UVQJK8N.MS'VV!A?M#^6)G!2W;@K(R//;E74HOERM
M>T]=V 6H#P\S;1W$&^"%5P2P+A(L6F2DF5)?'/.%0[A?6"#5.8K20G(U%_;*
M3!9+O0P4)LI-+Q<2+@\VJ88%^QSD7S-0D(]E7"9/^BE45V2WG3OR#&;LU?DJ
M1/FANTTE^":0""7.C*0=C">KT0,O5&)7FJALDQ%>'Q73364LS.),M8!]^F:C
M5=;!W%W=3U'<Z2>W3>P.)T[!!?TYG5YI<U^S+/C5/&(>/2VPQG7#61]T]Z??
M-T[T='"PH/4F8^&J!$;QTOD5-;MN:8X3<@I;*8VZ\-ZEHV,('RG(P8X;&:$!
M[*N_#C@0F[L"3 );XLNL&IS^H?@Q^_8%QQDCG\GIAZ/K.0O)]]^7,U51TD2*
M\C9Y@4PV0=O*E8%V$,X78H' PH*\8AG4KT")%0"BL/I%&DY3'<9&R=M<U[K_
M\PB"%?27R&U=U[&RL;:+?2]+X51DH.#<&K??E"[<K6'_68">N<NZHQN<A;]<
MC4Q1>,"?G."L,-LEZI_Q# Y^:H/3)ZA.J;*,=ET<%,RMJFMTK9GN!UY4)=#=
MREFFG/ B:J>^!***PK6:8]8VEBRX\(-(N[MXZS%V!B#.OO[.2:%'#82?H \O
M#XZT<9\?7P%LLFI&.3KM2M7 QT9"[,G&RXVZC!%-7.].JYY201*4:AC]7)Z<
M&]&.T<P6W*N*RC!:VNH:'[K7N-?]6EP*\3C/AFHDD\H3C#OHK!C>E%LUQ,Z^
M(+A@FT4\[!9Y7HH&27)\;5!+-'VNN!N$%O0_4?%MK&,WF,[17E(<!2:Y?_J.
M (CDULY-=772R-%TTW#>B^(L;L7.EJ,(_+FPVE(.].Z=MQUL6&&^OU7M1,8G
M5B#+YI-'EZ+ 6@G3K[8K8-A1   ]8%N.A^,]SF!-0"B5T P<Z>&3-*&INKH2
M*@_$]MEF+_2D88NT7L3<6U"MD$G9(R;I9HU82?!-\$;0:<(F=-@%DK(Z11[!
M6[50<E8_^;=8G5[]'<@&Q]27)(CF@6?W3]A(+Z*:CRN7W2V\Q#HF4T3]<XLW
M4ZAK?5Z,<*&;>E3XXX>,O9=_*U=.8$E]I S;Q$S\1JE@. (_RJ1::\/\ABA0
M3S?[!%PAW95FL%XV4H'L&Z;T+R(DE]:Y#QSO/N2D] #JXHE_L5Z'^)R$-^EX
M[@UR\Y3E-WR,$;#-C9:TQDEHK#J\(R6NVQWHIL8H5]40J=KDVVO4KN:\G;C5
M\LJ#R3Y_DVPEBAM!INW 8[%:2O+P7'O,;'0+8244\X7SAR6P1\KK"N!V&W+<
M0G$AGMWA46MI?^*\8+#_]4.X+JY9V#R?44^T+/\-C<&QH-["3]V"A:K/E=2>
MB@K8Z_J/NG:9C[EGW]JX<\K Y.U<61<\EX85@1CB[EB>C3HN:Y<[-<FSF8F>
MZZN>Y%-C3(E318?>S<@L0K@]B[,#E1KT.H(&:WD/)#V[-Y&3@B5BD\P.M=.X
MCSR<]2"%-=7FPG%FVJY@E-S=/Z'4):!A[TIZ&T=B,S>\[1DU+VVD;^ ^+6M#
M="WF6(3!9,QT4@(RD<4\!H=O(<SB<75=?^QC%R4.X8VY>,'M2J+]MR;2@_U_
M.)_*;RB^.Y?H<)E]@F*666$?V&RT87_/D$QT:K5\+EA.9FG"@\4=W^=1Z^DP
M(\59)O[8CRT%O,K?ZX&,4LX^BAQM4?;>I]_D@L>C%6.IDWI0^]'HH,TQAN3D
M2J(2@68L1W$0'/(D818"5]S0X^\!T%GC+="7U'Q,E!AOSD!A]T.YY*&QB;C$
M!]Z;NN7B*K[%E$(:$.5/BE8VGPV7:6.%>^#CC<GW:J(<.DM3F9?K[V9<WJN.
MK4$VF[-N[>ZDW(KU<LS"'Y:<E]UIY4K@SVXK2'R2Z6"6RA)Q\N2@1S:Z)/<X
MBF'E#)QM$&\6+(S5US?2NP:0I=K("?!,['S,5LJ/)G(+PS<CJ-059+:99Q3/
MJJ?P/\EI\;B/VGV,8^D%>./$:\Y-G'F9U#+UIB.N,I^DI*]O^A;0TO2$1;O2
M7FVM(@L_E"SL7.9)]F8$L-\2(VJ>"2WK^6R!#&*N(2VP);=>G>&+#YD\S&U
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M_CL]8BW&GE]ZD$UI6RT9MZ+)(>IAG'VR)'#< L8!<C<C:5)LU'S<M:?$OB"
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M7NH=6NN0T5FO2'5V"YQ? :CLTI*TY*#'+Q.DCU=8O'X @P,8;AB.7CQG;11
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MUR>12RKGJLZ0A):A=R'15G/TX;Z2LDL!.5A2123E0_L,4<#&0-^YF#]+F:]
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MBEL;!(O(:?")=736YJI<?<68K5EE+&UALJG\,4^!G^4.ESELB54XNI^./*I
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M(@RE.;4K\R:->L1"3-S58)"APPAUY0)V*(\"/Z$]9,_G6HW#\2H^]7(>R_X
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M?1?D;LK!6,;:*F(9LE$F<?[7\\:"]^GN_HN+D _6RO]5 S1W_9L ?NT8UWX
MR;C(/2XW>4K!J?92SVO\<]!_A0%$=#SV/7C1#"3C5=R!$"+FEM6\?TBAJ3SX
MIT+P3ZM ?."+'QIE?U@])?,_-?;_L)J*]^O+HA\X!6A5\JQ\+&;1.[LEQO _
MA_Q7W0:<!B/M1T/#6KB::>HU<!1 O)?W#_KGZ#SB"+*1(?OZM.4Q/[ ,'6J"
M9[]$ </7X.GIX=C$D-YK4Y V:W38/)P#3_<%RTM?.SI6 <D>'?<C'>573Y9
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MV+B\2G!T9&QA()-AKX5L//BVX'LCP:#4G\J\.HXA\*;HV]8GDX[)SU+>!U3
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M+8P;%X9 NV2DY2HXJ+'_!U!+ P04    " "'BW%<LFK>,NP[   H3@  $
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M012'2:J&<T\3<7]/$S"0QQK#;R8#)\H&F_\N&PB[-_)/X6) '@M^$TX'W6
M6=V#D#C[E4 =Q#0'U%OO"2ZBAEOV- PETH6#F(%@?\<LW+9U;R)]=A?^V1<X
M.E?RETKOH6L,ZQ6&?G#P"IRZQ^WWJ3D;SMOX-S_A<B=BT/<-KNS./58I-C1
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MS^^[(RS(P]F,ZSIW;S_WDN)7>();9[VKPI6G!M4#YE31G1K*Q[Q5 5=EUI0
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M6\A\>8B\B"EC@0SH;AV_@%>I:)%<MDS[HG[&,V:R12?ME$#J<<2LJ*0HS"V
M !RJA.+?@V;;$:3'[*-& !Y_3B( %J($8/9<".YD,^2@_)1;2D 78CMZ+A A
MD$SZSYX<"[5.(]/F![21XB?6N=D*+]V Z>:2&+)P;S&1--@:T\:'W[/T4:C,
M?683</UVJ1$K'W^Q+6B4QZ&SLGGP,0L"8%QZ+?@LC]I+Y7 )=@/]JR2S@L;
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MSE=M\KK K&NW@*;CA5^+%T5TR^('F_'[IN^/=W(</-MZQ2''4/?5]$G&B(W
MLM;]U?Z<Z*4<G\RYMH)6=]?CUHUX_XH.RM825-IG<TT;1[BS<*UIA?U89+V=
ML)Q2VNBP%D7^2^>3CUUY4^\564GG.@I5*[!WXI0\\HQETD<Z:A^T3R96[FR\
MFOW,@/Y\+]MB])-,@_S2!13JJZK\KA?.ELR]QK1K0_T5HAZ[/X1'ULSJ%A@N
MI/,$OX#>J74 8[ZZNG#1+5RS9 3D!'MGHWW&#/)3+ J$(.K'B\YFB\4VY@&(
M!\DU!/+GRWHBJSIC<[BJ=BX=H/F_<&#RTPR>XL">*<*/#U^N#K8B;RJU)@@
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MS.C$L!0SV\TWBB>7FL15-P."9Q8PND:>L&IOC^"9#IY8^M=:T2>MQWP;U@C
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ML(,3\N]:^HSO$\JQBW+PTI>[S=/\6IY:<JTHLFX*M=2]E#3.%;.(H@<A4NR
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M><0[-*KPZ7G'*%4R,LZ0.;/1H:=M"TNJ(IMF!]J7Y0KQ#*,L\(YB,,G )PC
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M/QZ93Y^IZ*F52OE\-DV4^\)@K@D/[.S1;IQ09H+&EDZLO!W2\?[SJX'G6=V
MQT:+VHK\R?(/*AWFC'L3D3.23Y^D731(\T3D,-RZI64>(VMNA[ZP]OR1[20-
M9Y)W0-'Z42P;\$[Y/'FG:76ADJ#FH="<5%+J3=Y7>\>>U-8AZ4&=UI[/@LE#
MPEJ6Q*AWA9ZB1_JR=N,X2@\.CS[+B.&Z<M&66]]=^Q;IS%VAS'C;Q;$HNZ='
M=;)LK&>3::,<SK18=",73SGQVC$+P]R:3EX,S0G[L,AWEB]R09$)!\E),+E8
M9B?2M6GD-/VP,9G^B?30A\TZMSO/TN=CO<,3-G=N>.8]?]Q5;]6X,5-:J>62
M^6E0Y7I912 375%1% 7K0KA/!T7SB>SF>5:U&Y:/5<^=Z %@\A.1GK$E;Z[,
M'SD<ZF055A%SONS*7>GAC.3\X$Q[XX17<4RZYM(78@U"U,Z-BG,<2% H(KDW
M(7QM^5)7(NS%W 3[PU1U:X'Z.0_ 9?>SF!8K%J8?_H:W_/0>?2%9P]ZO17TE
MB+GKD4NF:>H<*N?4.-"""^VTIG(A7$?<6>]6AV?,*1[J-#BB_<:GQKKT%GNR
MF.5!NC$_F=YR@/@MS4S%U:W'LP='C#ZW.TJ<?'Y1,._=2:9 5JUK]AD/BX46
M^6OZPV::;!T-Y'(&0F\Z'?!B^:K55;+A:-RM6AKN@#J=&T4=:17Z3ISK+LEZ
M#J4MF\#'=/VSPSG\5*^\(4J*]('7WP9*I]YQNT.;F\%];UB_]Z+]&2%7SHS!
MQ=JEEU$\W,,U/?0:97__ H392@08=>'?HFYN?S:.^&M-/PB^7!,76Y&\0?QZ
MBLD3@YPHZ-$C7E.?S9X&BRN>G[^/TVTUZ:+':4G\B,-,6N/7(FHC?!>5F6"M
MD O_]#[]7QZ=GG7,A@E54>14J"CM&Y5;C1^F&)/."<:\#W2\>;SD@<Y;>FF;
M6&NU@405[CCN?/& 4"N611,W;2II:/"Y6>VY6*DHQ;G;I91CV;$C*%<&T:*#
MKO6BBU?$,+Q83IO+Y84]-54WU9V+!6RD'[]S,^7*X!0U:_W62!HJE*6/S(?8
ME_07#'D=RIWQY;*>R.#V&T=\2KDKO>N@^-Q8+35^8L2 H_2I<*%@:."9,\M/
M5OJIYK0=WD-0O<6G-[<Z!X?8+9F"7AZ491@/%E.1@6DI RZ)1]#XC'3/1WH5
M%8B>.FG'J-2#N+*;)(E'HEP6S!*^7>RBI(P;7[/,&AFMZ(A[:Y9H5L2E877T
M2_#EZ9EE%]/B]L [5:D7<OR<)3L0U/&2$2W4!5$J?>W\TYOMQ=[*3"3/7PZV
M6J5<&1Q6)M=39H"IB;]FG(OO LV-:'(Y<.OXX 37&R=X91_&'Q?JH23G\+\3
M_6H6YJXIVP)GKEW+3BTTL=00=-0I]9CPFADLIQ$@BWU4(S: \=$O"/2\5#=[
M+>5L1:;5M;?L>OQDH8E>N<)@%_GEHW9,63'*XVF36(6_QFJ QIB44$.^0V=F
M,G4R[6N57(;3VM1:Y0=D??2+0 .[[OE HZQ/HM/.V3,VHU6==1 B+FMTFJ5Q
MB<*A4Y&%[7.02][ ;JS=XKE#6Y_[?9+YR%^.K);</N\^&2Y8\FY\:$1W@KRD
M4M.3XD5LM_I1?X?7CI72'"M]Y6#J#NG R>;8X87?O7^G>44XR;])23;894O%
MWW0R:<:L^#NXYF6O%/(L-_7/I/(?'1[:;NE89V51V(C)\G1:<I _WM:VSGLE
MI^'H6L;3+VR\+VC#O0C 1K^>,G#+V"*HV%&V[O6(FF/^R0EEI1.-E@^KKY_R
M=)+'Y&_^@[L&+>]%B7<-(K[?'=$Q1Q(=J^A[.1-MWO?CAM[>51+VZ;RYHW1.
M'Z+OGMIS(_T,99Y@VR\6%:$L_E02,]FO7U:VO\QD-F^>$[F97!8:&)7L$N%B
M*#1M7/*@(\/%-@5!^9]XUA^/OFXKTXERNX,2<V6?2+#=O3$]8J>O>C/<%B#I
MT;_=Q"%:%%6>(G+LZ1A]_8O<_)=/ M.N,WA* /."^T[EC4=:17E&?O+-;B.!
M*NF14C=*,P%%_RT?O__>SZ.>5RZ,VV/T1,-8\1<CI!*F,%.XOM+AVGU(X?FR
MW6<16HTT:[C^LON&:1'L!Y<-0A G7)7=7DPOG3AA)T#6(4<V831.IOK.K^R:
MXT@$!P&@Q\#28&W;58UC_98O<8H5W9W"RQTCBJDD:R%,?C[]SQ]6EREX<F)\
M-1!?GBTPP40<)W=)W2B6S ]ZA_#)^5_)(@#C4NB970H^ O >@A,*Z,I\WR(;
M8Z20.2N0#\<?@A^ =UR&[HR#368$YE*%- %0 HN,Y0<$@$8^1NL+_):/FH>J
MDC)8<*.?>[KB \%N:)0>SP2O=AQOQ^YK( "^4(S.UVRXT,Z]P?/E,C1"8#MQ
M?Z@F:?U0!!X#1Z<2=Z#?#OD'$T=KX.M,/R?2@=:C^YV7&WK;%L-<79R='3JF
M6SA^+G8"D)P&WZK9^^,)+SR=\8&1WSCQ$4QJQH]M/EX*#T;,?!>6?')/6(&]
M'7ZR,J"/AVU1%3UP<V--E6R'5[N,H[ TWQD#F^J&8 (P*P3911/_+L";+!QR
MB=Z!?EKU?+PXD0$%(@.YWQC@__.5JSEC%?56/A?ZC).9F?B3U#OC2"R-ZD_"
M_<&HV1-_T+4[,#N;F>^!/X2D@W<8_D#_<H4DB+[1WZ"OK.R*0B=X.N #"WZ
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MX9%1Q+?O8[-S\S\6%I>65U:W=W;W]@\.44?'9W+A ?AX?UW_H5Q7<'*=(R#
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M0W/3(@I&,<[4!N%Z&"HL$ 0["RQG"$"_X>QATZ-8@&[5/'U-J"$I(*H;UMR
MQ(6DAE.,S78F+J# 9J>/=F$GZ.EY VE*KY\TU^VG_Z"BAS;_!^P8!Z;T&TS$
MY@_6<!+\C?G49KLH*UBB1._HFPY#!9H+"Y#APG@BSE$LXE@!SP)_,U"4%3FP
MGS#=V_QE5]RYR?-:?D>NG@6"8IGE6TAF.*SRI%ZKA0F:]PF:>#=VIC1.SZ*\
M\QJ9Z)4M=52-7(H!LOQCEMX=[MV.,N(/O%YKKX+:DV\B]P.&W=OBWK,?.+?:
MQMP1X,._=>$H)__!O9QF5>><I(J1?(NJQ.:JBGLKW45!'V'F4[!^7IN3#5A[
MQ 9QWS&A$LX_P%$C^??7H,O44)WY! &TZJ>7WIIF0JTK&D]ZE3<?G8A@ >$?
M)HIY^BWTBC>3;FM<8[OSP;O,>VK6VFI0HQ=Q;3&%&\KV./Q.P6W9LA>RYU:.
MOU[6*^'F??6V5Y;J[8<5>9'[60\=LH:L5Q+S!^,2ZCA'1IW.4ZI*_K\:%]P1
MG-L@S"/H5@'LF ZA!7V+POD<%O'#4? I*507W!J1&VODFTPEPXFBM#KS-1;@
M"9M,+Z)L+/!%8AQ3Q;<#3P&=Q2O_LQ &LOH5PI+>65VMP*L-$525=I/-H>I#
M-0_IUO5_U:7[)N_(IF7.-S]-^47DEA>9K=1!D;]0MVN^WO!5N7>NIFN*'JA-
MK8O)FTX7;2+M]5)J[\WYW.OTU$OOR!L#MX*)2'DQ$QM^1[.[5KOCT(A^NOW7
M)O)S\L^?#E0':C%>$"=U$ZKP+=VP-*[91H31Z,4^62C5*PL>NWN@ FNN>SYU
M+ZTB^-ZYUYKG4@U][=HYSNERI/E<^FMDYZW&Z?*^ETC/Z?VD*RDLS^JH^L'Y
M>*0K<'-PZGA4$5K)FGR1D$F$\LZG0Z)"P%6Y+84.Y=#&[VH_+3T\5Y/ H\0X
M@D</R7*CVE+% GE&J7!*5-_'%5&EBD#CH=+N^[)>JE0)%S0OTB[;<HW-8P&-
M!BE)LK1@#N _&7C\VDRW^FGT!WB9%5V9UN&;"5+]I]#4C%SS:@?;Z+?N3'SI
MK@G*A$90K:&5_"O0_AXZ+@(528+<=G[#_'2HL^A^RECI46MQX+>)RYHU_@F)
MZH,;0M"++^$L%%(<>(&VRF+V(G"AXL$R*^I=]8HRS+@?4;59Q)<P QVYM:JJ
MHL[A3*TGZL[64]"29:O.C6>N-YP:E$#YXI!"T]5RBB?GVVK#X_DYOU<P8)PZ
M45?;8B:MA\H@57$KFZ;AUS(EA0DZNNPF(##]=PF7=C+9/1C*S"OHE:S-+,9\
M/W#37-C6#^CF"J_/T IW+4C2;3=CV1GX9O HVS(\;$,)\]WU&;F=B:U_V%?9
M<U6L.D/65*).F^'F(P=6[=E/LGJE>2V"QWU8/V;C&[B(!J0%<_K\DPW][T=@
ME?)K7.QD-?)Z@07Z1ZM+]+-;(XZNP.MQI?'R\[)TM-SQ>TW4M=G)Y1Y*2'_R
M-5P.8U<?N\>4@@MC)S;'/QJZZCUAE=ZQ>]0_GQCAGGSY>P]H_-H#2X9WD)JO
MZ(308V:!--IQ!T?6<![/T[";>-V<['X"0Q.(- 1X[M3]L&7L@?[*F)XE).;Q
MIX= )#/W]Q\QX[BX6'A5"26=IQ]"O,&B1*^^/.H>Y1KN]2XI>Q=N4Q[(Y6'^
MS >/Q)P*^&&%'[P3 @]*YMP^:1$.=R)6O"\W[>E,Y_GL@\<U\B?B H9PJ'5<
M7.2XC+Q<E*J]O2WA>4!)FE(%[Z^A,[91GNZ69J"W(IQOXKWVVOJ:RX5>V7M;
M[5"9DK(-!2O61]4-%9^2,=H:=\8E)=Q$\/&/^HG\T8\'T'I9L&91#,LV)=T'
MTESF\'L;Z,]A:\EH2/_VKPV1+''3M?ZD%88,;W*9]5*4TRYCL[OQK;GA);G[
M,1-X7W&/$EC]<T?^Z^#'K=0K=86AGAO,8H%K,MN$?A4)_BLSLF9.XA.0RQ.\
M"F#5TO"RH6]"O1^S=:?(J=P>N,9)1BPLV L$KV?[<;UCNA8I]B330-OXLGOP
MCS*;0 RH9F"S\*7C.!3ZGH6+LDGYRV284Y5*T19D,L8#7F.@E/XZ_T).OF!-
M)N:1^T913>:RBVY ?8U@SR6;"RSJ-3NYTVU33/6#KX3I"LQWVH6?Z3'/)X_H
MG3CH([>"AC8PH#M2)I<ZV')M:2M5"&<J^^J<[OIU'8S>?_T\(%J:M)'HVK4B
MW6_R4L*UADD]-PQC+3UCTP]U;(9>Q%9N&R;96.J2>MUP;+_:+1;155H@9I<^
M;2!MQ=BT"_*MOHL/5N."K<=A@=UV\,D/+>>RS$ZWS$[2H"BJ3N;T:MO;#F.5
MC'2E6QR*"[A(:E_MF XS@24JT=/C[ISLG1U<$UR[VH1"W!ZK=G/^B%C1NHLJ
MP;A;3,= E$3S,C2B)P9CA=0NZ7<:?5UQ4!"%T.=9,G$."JYL+6+Z7&<-ON;1
MLT'4G]E:KS-7LA+*M5R^;ZR9F[5NH$#Q2F,SP=U<)RWXUM?_+[45@5"7IRP6
MB*([60-A LM&$GY@V&!?PKSV?Z;"HQ';K*LFD!FS(--X(28[Q2BC!ZZFZ?C%
M];_WWMK9WNNJ!2*B<$_.!Z']-QK6HK' K=T2TC3GI\)1IL$<<([]!Y41P>X2
MN44HD8(]*&5U_<DC>QE=I4"6[.O#QW[\_JO0B@(PE:LM*EV>&C3F4NW,1N$V
M:O_26Z#=2R25C)K\,MH@?$HPOME=8_"6S^"U+Q->MO3GZB1&LJ)':2JEP^V#
MC:5%+GW[0=Y>*]MA1 9'\\V&A%GWM2>LAYAK9@5[9!WU?R*RZ"-*YAIS+(<,
MOOQ^[?OC"P]%CEZ/B4CLX=G_J8^HUZK1DOA5F04;+K+EVX0A#ID&I?DV]A_U
MFT^T2?R;-@9]Q#KF2_)U4$90_#!-=Y#E_A<L,,+7#^D#7Y4 F4_A\JA7SFM*
M<4<_4M3DQC>NOB<417(MN_Z$4<'/^:]*D3:</Y#W590&^ <,='2DU&Y+;7)%
M^+<DI 25$2.0R/*[\>$WS,V>$RA-VQ07=4679FMI#"F:]2OISPG5N;1)@(9
M:C5E0S_\A"57"[XW,=L=(<SHW8JYYNG?TGW=EG@M)IVJOV+ZXN([$CE"YT@I
M!F^JN&KED"@JFE;J5 X EG9IV3))%ZIYS>!P/-O.,HP_<V)<K,?&K=C8?D'!
M+"%1MBIAM2?!F6SU:X9O>.!GPOBYK;EMTG+PV@"4K]&;0SXC\>'P9+QVN)N]
M6%K>:N%AD'5L^R<R\N2W,8J.B2?KO2;*T6E0:;AZYK9TZ'%$('R#!^*XT_J
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MDQ&#=615H->8ZS$M3%=C5+6Y-UDH,AR:G ;EWLWZA8:6BW04IY(1S9%( ,I
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M32;#<9;^G^_^R;5W(+UJ[=A[+$IG"E3# ZQ*CM*;BI_#J61<;<Q6K7@5H%_
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M_MMG\;C66'NN.><:<[SO.\;<\!_P)8! 65Y)'D!"0@)>(/X!\%E %L!$1\=
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M4K@"<2%0AFPC(M(#)HWXWUE?L?5*.30\%?_6#^&HV3,5?]=ERO\98J$Y3'#
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MDN^P,VI<-S5!8WWOO8O&.+&3C* =RJZ"]X]^<69\-V2?3,\YSK:,%42C9ZC
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MO?-G+A%G ;=C"G4N540+OS-L!;83F70S#MX^Z6-KX!//.<U"@_QE#0E*/G[
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M3E_O-+"%R'V.K2Y)732696O?;/#F5KPJM3!Y,J:]RO#DSO6.4CKDX$,7-.B
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M53( [BE^:_C\_)<U!7)V6)UQS/1>^N6@0?(TIU_7D-&.R':VE2HTJ"?QU6L
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MKKR=\.8%)W(O%^K$,W=[]F]8='VL6NK?DT>6X1LJZB#3U99_L63W?[)D*#T
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M=:;1LT<?O)XVAF(56YS.2ZX1BH6 *;Y^,X#8V=L-D[4)[ZWXJ+7FOP?8,T*
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MI7M6M5;^JF\C?Y5AH4;_#U!+ P04    " "'BW%<DV@H,HH>  #4*   $
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MVNR94RGO^.B<?^L83#O?/R9]&O+\NJ<ESS+Y6'ZV#<O928167O[=M.9H=1>
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M>5593(ZG2F 'QW&7A(PZES;"F?M@]]5 !&Y)M?:HC<*WJ?O :@+=>]HC8Q3
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M.<[Z 57-G F.GA?M=L$)PP^Z]' &.U@$>K=M"QFQ+JRZDM^[LW%DNZ.UPT@
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MP*Z?:XI5$8VL*$<5VZ[G(V7@_=WO(3'?T.R<SA:WOE+.W5=9^Z\OWY4]Z"U
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MF=$];*OS+L4L%B4:R@# I P@;+^6>[1G:DD68OU _RK>!C+TXE6L:._$ 0:
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M1-NYEB?ZKL&";PC27#VP>+9"4A28:U6G[F7SLYLQ==D['H>UO(2UG4EE"
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M4'C[2+XS<6*E)X%].9A/>JHP5*:5Q$SPHG &R,C;/"=K?]+A:\^@O1[NNAI
M2<*5'/$4A5 +ANM+=^-P8[3;?][,J0"KO6WF9(Q?]_2<;C:>K2?ML/UC%S+\
M'@ Q-AY\ED;7S+F'(#X/8D&G'H.X+<7VSRBD FX#5)YBJY\W0;R>O0=D1.PN
MNV#/PJ"PUFKJ:[9\_#]!?6$S&$O=4<6_PG$%G+@2\&+SN ?:E*X>"8G=58&1
M,&C8:BCV9_880OX+?=09_;89R[M"?84'VG*#_!.Z6544_Q?;!B^A,,A!\RY+
M+G3+=#Q?QY :E#?"!S?H8)SI\%H/(37_-AO:HM+E[5':7>A%<[]-_>^+X)B*
M"%X[2 H:/^A].^$OC-Y[R?"K70G2177$'36#]816*P<8A]1W#=#-*R9X/8<K
MTELU,%M IT_#9RI81&=ATE "\'IIL3NZJD)T(*D%>LS:?/>N$N>.-;':X8!8
MJ31Q;RG5+,B=9&_9BM[A0L.3<4J3V!]\-#K0&S3K7S8;RRTWXQEZ'+3K4KZ;
MT:@LBCFWBQ#Y% -)M=4;D$T 6E&J064VXN.>O:,;55(Y>I85:WJ<:571DR&;
M9K\K3-B6_,#SC*IR3"MEZQS&.&K/B[8X[F)W<4%ME>06STQ^_M@)%M/2ACY^
M"5TVD&^O$NJS#K%D'*VTVB4L-+$<G^!L?J)I3A/=U0P*BU,5*8  '(3OESW8
MJ&9&]I=/=JN)8A+8C/JX]J,R7&;7PHT>[QT7BZ:PN-4J$<T:5*XG>-3M)V1W
MV3E231GH0 9."%QI<+F0>[FQZN46DZ\!K4.V3T2'>NTS^?,&VMI29A2JVB(Q
M4NBK+#RJ9L>SHD>+NU?B&\*IC$E*58=G<P/YOB*Q[] 9$BT9GE2-T^QA-O.+
M< H*MNSHS&"ZNY.=7ES4]<?>W'U^&J5G=:R'VKD;$Q=UDBKV,-0Y)<5$:K3R
M3K#B3G.<O9#R+8^B(AH*G8!H!5SGIB'=&(\20M>WA<U4FB;Y^BV%K-@&Z>UM
M<G=SR]L?58[ OB(_4T$$-JA.#J-N7;R;=\.TY*>7,HAC\F8]\?C8)7X2,[(,
M<&]C>?G&AI+Y/&*!\AO;+30DK INC0>)U&D]^/MV!*'?;V7 2Y^_0/<U$/(]
M[1AB SW'*@53(UXCY @!]MP!U"E%&6 F:%8U"()0UUG]2W51WY&Z:C?_B1DL
M$?QJ"^E@\GW0J3+H:::6_&]5 A-"UN]E@,J*TN7-8=?=>[U?0MPR';WJG\&W
MI?8]T/-T5&R7T!N4?W8V8LL7MYX>\K!.&['54[A*_:(\\%;N+6*_E-0S].W?
M>D?BE!]^WS%0\SB!2;T'.28\[1[(BASC@4O[AQ#NRC!Y&SI/!)[\*>U:SDGE
MUA9<,LFB.QIP?8Z&D-,W62*.-FY]+H5!4SC6QZ>P T !207M&GP+LE(9S$Z<
MJOK?>JEG,HAVN(C#I&H,:37&0&?0]OR\I"'5KMZ?VJU#6-IMJ0S;BZIR9))Y
MF2'9(^E%@I%J,&)5@JZ!Z$_9UJ 7*%=Z:XN'PF_$B6_Y;0AP#9ZS\Y(GK$>]
M*#=J71.V$\\ :$-?NE'*%?;^&#;RP:.NL.;VF7-(/_[L-&6K']%6L8D0?Q3Q
M\>"6(V?PVQ6?7<[L5[RBO0TE.E%(!?"2P@0E.0:L0[_UK0@G\$X_#!]Y-/IJ
M CG\H.8J0!(UYL?I;,V[+J/E06NWYB6,.8>..K>2Z_?UTUO#Z[-*-=4681:#
MURL?2%]R(GN9T"5J'*H5-5V8*$OD].2%Z>P]HQ>LP?7T6*@G%\ *J^W>"08:
M_[L=Z,.TP#^VH-G!N$2%Q9X?[-[DP4;/F6X'N?O,%^I)YU*=)_]7U1 ;MV)@
MW+@OG!."I6R9]7A!,<X]T)5R<??>]1=45UK"+_PVW3N0*OP\!F&=W@OKE7.7
MOW7=:I3@H5T;H:#M%HTP&W'*]V8^>+^B%JR99[M@$=&5?U'S;-6WH3!FT)10
MZ+6,G2YA&K@\=&+!H/JAAD7-:KX'%!;%KHB,8&VZ'V!Q"OI^"6"N0;L6+D!)
M,XQ<CP,',FP9Z#;>'Y:OG Y>L<!$[X$:=]A''KAQ38XVCLO3(RC(<&F]0C,%
M1N^,CK:60?HD/1#[Y *W6?&?F-Y[.=5';HG?OH<2FY<O,O+4S(.@@W:59IO<
M\:DL#0I;*]P'#9V9GDJBO/-:!Q.%6W))]MW%L^.KKLE@($2N_N;9,<=YVLQA
M[>PYE(/BK-\&#^A9U.+X(N" :\"6G%A013OMSGN1BDO_TT.)$VN:(MF"A*JR
MN,C*;68@PLG8@][&BOCB8S3!/(JP',6>0"MEIQ2@7U57W5@5OC[AD5,=*RG#
MJDBJ3_4.MY6PC?IO4EG-!]2F:-2WCY4P05'!<0<&8KED\XW2C^/;Q@\"QU=S
M*4U3_::7SC \I4M#,++09,ZU9J%+9,)BY;]:IS>RG3X#[A;N54_$B9O^+S3_
M_QR:)QH@C7YMWGKYE6,^01IV>^DZF*5F_$1S_NF4#:NO';FC?W7"=,.M7&6+
M"O=</[+;Q680\Z5*R-'9XF69OD+M?9L,C[JX&"G.PR.\XDW8UN/$&M/*$<^J
MVD;KD61I^T  \N U&@J$;+S(J)6X2BCE_=Y=S#8QLG?VB?V!ADQJ+_Q;4J7(
M3@ =W=%14:Y'Y%?6Z%][-"OY>E@])4\G6RHDVOUZQ>:8U_@5Q6VO54)PMIHF
M=",8@+C_PL[VYG/T.G!=%&3^C"*61PN@W@0?Y-3C'5!P\O[EQ<ET'+'?(&[G
M+PBGG?:/57@NPK!-%^S/.[WGZ$>_XZ\_WU\ >.1W&*LM_HMV=VGZBWW8T/]7
M"Z473)E;SP7HE!98YHWTY&OZL_TS<#3XQZA: 3>E^6=YS:)9UH0&[7DX!/H#
MFB/3(XXW^WL?0^=\X9C[,@?6!H+"%F6EI3+B/ )81IJ!]V+XHQKHVDH[UKH%
MS74\N'M@4W)(?1O" =K.]H?M16(O0.^:5PYN/D WWXI3:KRZI07EOQ+Q+_GO
M>9M1^*WC4@H,X%2.7]V<DRL9<:J0O\7FP<=]GAN=+_CRN7U0H=BJTM(ZEVA;
MUX>2 -#=5P5T]Q .:]IM?#CU?7IJ.&_E%C.'>ELL)*N19NY<+3# /<"$(/9=
MB"_/F*%_/3]7@;Z:9-J4G4J[4-T-1#7NTOV?V*TR?L%Y.E9D;BET<F8F2/4E
MWWED":(NU7A37BU(CO;/M<D],I4U":;!Z*,K49?J06#X2!$I(DL ]^5/+\,8
M^(44S-K$(6]/FX9F%B,.]0(>6=*/-Z?H31]XX8F@$793_]\.Q/^*#L3#0BO=
M\_+\'LJYQLP93(_CW8FCKS=R^Q97V&N[="A6&VZ[_D+73/!9;PU(^.9T)6RJ
MT8,PY\$,O]"B?E[]:X+4&0\CC>HC3+X%4[&7(49INC=.L>AE/11O^S!26K]W
M>]O-<-=#M+ZHB%-0%1XV49HO7^U#C)?7 LY6N71E\MX 6HQ,#[Z0<SJ%>RSG
MMQY&D^MY%.[=.JQHOPR"EZ'P*M&00@  ? "NDV68*1V'>J()?_K2J#4Q:R)V
MN9CP*<\-\S[-&U>@%%G=HG-<HE7$*3P[<TB4J'69&L7*O1K&<61#*=W&;/'.
M6KS3I[O5K%7R^%@:VZ-8.Q75OG"MNB98,#T678XBF-1 MA61"I4N5 7QP<QL
MAX,#@6,K'F*XP-CCKV_\ 0H A20=&P=&:'&GU 0R<RL8B<;J>Z+H6W6^WW2G
M/<H[)B:V4J(D<[_1KJXNHAX*TL-XMV*E+[1'3W?Z6.3[:A93KR4)RVJ[/K=8
M *>#)^DX3_Y[&PL_BN))VC@0-C:'W=I@XM+(KD1HHN>FOP3@7P("'5Z(#_XX
MV*#R'5$63V!%^5LP,@ X A2O,M-Q^",6]Y(EWOEQ'44CN[TF5D-@;2^GKAV+
MEA/I>51;_,$/*:9C'G'4M>\>(+FL$LXOYO>2R%M"GC9 AE/U8CHP;,ZS$7*+
M/+?)->BR=V D&B+E0NB6>.@\A$>P(G(H%*6F/:6S%><T/:4K865#Y2:)^(I'
M/UJ1P)%+3BP,<'3TH0^<F&?QAI)?3I#0BD=U4140JHBW (@M@%-P $[ M6O^
M"[M;O>7+%\<5HR1G#$9<TMM[[]8B7GOR;KFF%-K4.7PH&#G1J-/3LTAX>*)/
M^>V'(_\#495]1Q1G<2J'=!]N RW%Q&4HZ66K 8?]7HN"&H*M%MZSG$^0/7&E
M)B^70G+JMU5>9LEN;E1<1[%9!9[3F&2?PXCI8]ZCO8F6N[49I@G \.C5ZZ"P
M_#&"2^:/P4UDOE)+'^T=K2 G3N4HBJ/+6M8+L5AY2/^#2HLLO:\$[K7B@"*A
MC(@_93Z_^*5Y75$*;SN,^RB@SG!NUC\Q&WFJB#Y(B<ESQC_-YW3+,+; 1M?M
MC?'YG>J:7>&S(-+8-S-9GYEZ*)%E5P^%Q_,]7@:P50UW4=CV/Z)3AC-G2*C9
MEZ-/78T1IT"D1EVL#.FM/JH.,XYP%NT^4\YPQOOAB)_WAVE/FY%Y3AMJ&I2(
M/1KMB]RN3K#D)/LJC-WY?E2A((BPC'R+*_PVO>FE,9"3^_Q5197"<8VT;\8D
M.AH/W H,XY UE0ZDZ@][J4^.K*'F.UI"/J**.6'#7=56MGE]KU]+HU2Z5$%1
M6"N..,N.(D+MWHU4C'QTY4PU_9!?A1\G0,J8RE(_^G 4;[K();>0"&.27X'M
M6Z[.=,NCIUH'>$].W/-_=<DLVIH/0^_R88PSZ_GG86G'A TGMXVU-\F8%NZB
M-52Q0_]1%OQ1&@QX#,K6C5?D\Y5]['<RSM4S8H4+2'BFBLR$MHC''1K)'1IE
M0$D USY[*7VA.<1N/,9+J2:5NJ,>#^)LD,%0L*DT/;W]BJ,8,Y(_O3T%!7K_
M/?!>V.(NXPXLB-#B0YOFUCRIK6"C5!;Q*;/\M@,_3\(3BF6_^D-F5A;'P^;&
M&\<'0R'&O!U5![0ZO+P6(8[?[1BX:BDH7(L<8 ]TQ):L(C! \6^RO% "LM<]
M8.F9-@-M.($<<)#.AM6<#WA/5HU#2W3  ^"/;S1.M:>AS(Q/Z;JGYURYNT'M
M!B6W. 4F%)7M2\I&2&<JMURFADR4JSAIK-QCM.ENI"2$JI6=%S67O";NK@ZN
MSBLX) I.=O7=<0H*.LL_.6?E7A3)H%#:C%BFXSRJN30O]<A1&IGL].,\9F<M
MLJ<,SSM!#EO40%CM?,)B$?[]J"D-V9:N^<;+H[D3PW/-4\S20.Y9JJ%SN=N/
MO4&!K<1]GGY)N4D55S8A/>]BIAY[1I43F1.LK9CN'@UZ][:TYR/I.$)I2X2-
M/1\'5XS(GK_R/4K@59XE1WK-E4S!C7F-)SS)471)I,#=94@PM'04$:([JW5C
M-$-Y!JF[4D$QR&1'84Q^>ZE5-:$0-O]^F3RM6O<N^GCC1:J>,7,H*5LF-6LP
M&JFJTX!0J"L(G2)^.#.%;3\YPB#FC,],=9!S^9%>H0&[ V@:W>=4GV8'W\;I
M!K15-STY"NL.U$A\R)=-W1?IXMKK^)T1T;G?2XH ;G6F^#MOZ9B+O$>#Q0I\
M_$6A [.=6N37>:O7S8P&P\7ZATH3Q=6M82(';/L+'?,<-DEV\\^Z5%6/[$GL
M"LM9HEJ[=/?97"D9M1M2F1BJ:VM'V=&[,\WVUF:DI3U1;#B[M]&H*K/$J=R=
M#L,Q<AOR(\@])BPO6'9C-##YF3%SD(0"X*C>(>A7AT$P&#^@?(!UK5 3-9^'
M5]KE]&]8>\Y2)%43MH7R(Y!VGQ?;%1C[IN_4579^N@?,ZIM&S,,M BS?\N#9
M848S&4]B?<=.@ RAT/KAZ/*4/O>Q6*&C9VOB%TKOY4-?I?RU[.'MX:?QS2BV
M9\*"K >W9BLL]3I/FDC/GM#RH=(]5D.)Q%DRC)("/.+_L(3X^_I@IR@;=(_2
M>E8I:6#LI$J0WY[E/8D],G?4G@%A5ZNOT&:;/41O^2H4KV"8E)?!@5UJ<^?3
MTH=7@H33\M!TZ[H32W<Q\YJQ DC]>'4J:X5%2EGV4H#,1?S^1I6-N3^H67ZG
M/,,W_X:R^//0L+G)+=A]E&J3:Z>A=>>RL?K4 _&8NX?"U#S)]9OVM/R:_IP4
M0:K:#]RD=:::GRVN-*8N9X3M1C;%[FQ)NC]TA6W&O:T.8I=F'269J^J>?OGZ
M,QJVUQN5DH"X-P^GI3I9Q/NA+'![M-^(_NY+P?B^AL;YI_H 'L0?H7" _PO;
M[S2ADZ[I(5&9SZJ9:>U82X)"2"'ICN_[\.1C@>3DU9.W4<JZ6R-SVV(SNBD-
M5CPOL#)?*:Q3?\JGG*+VAA0K?:)J9)RLE.,)8][_4G7S+&N$::AJ#'.7@-C>
M+9T>S]&1NW5+G-C>(*,R=OBKECJ#KMH[% K[\V+>IDGVLQ3X[<'V1.0[&867
M)QWF9"KU)#=IOIKB^G1%9PC1W;WBTPU':B65X0+W0.7#&^&[NFE;^H@]IU"6
M/KMF%AJUF+6 CM@RM!67>?R2ZK$X+"MZ[FEIN>%]#*[^<PN53Y$;ZPH_OU73
M6<><8 XAS[\AW"6#QKMZ<- @DNL%=L<NT^"N.UU\>'&Q&(EMHRB#VSF@H\Y$
M7TX!MV]=5.C#TTAVH_R81'>VAV_$$7N<D?26!:E!TCO/ZNN%?#F'2'*@B)),
MBG@-Q>MOSF&+/GUIL:V+H8$ Q>U,9T[!YN0U?Y"+GA6OL,2ZT$R^'.E.Z6T9
M1@4[\EQ/P^T JBIJ47E;B%O=*WS'22'3*!FVT)C]FZ=TF%>O5U]K^9.DM%-P
M=O^<@N&/%E0R(V?9U%:$Z 2-\".'ZSEJV9::4ESIU1S_Q,IZ$OK8;OM,>#1G
MZW@.-;3@,WI""ZLL F,R9E1,.+("H$</R D@Y!6+"'46YG;Y?K5QBZM6H.&>
M4<HI<O]>0[(>1A'%I%91@N(H0$["56ZE?QFOS-T83:[-:V-32E+)VDF^:+*P
M5E"0SIHD1^.5 \'7N!6TL2F>US>41(S<XKO H">*R8D7R5J.68^=F982;)6\
M*%MH6^!$C@@H+&([_9Q"NC+Z*(B^NBR%TK3,WKT= WCQ\FY(G"YJU))21&V\
MDN0TC.Q&+4Z0/GQ@7FZ:CM0<->LCU:V68-Z.X<-J&P&IPDQB[IZZZ95/?7:O
MQ>E;Z6*Q\#D')EL1<\^FQ+FQ:[\M](,N$<55.^GOI[;Y"H2-Z.VK491^8#!E
MCNP/()75IX-'FSJ$\#_9PGV>]&4T.Y2@-(X9=W<-\4,8O_^\IL1C$OB,G%YQ
M_4&<:=W+MQH-M<%S>Q6?S>44WJV83M0%EUJ1HE>]0L2M<?%=#2<-N:@ M'!<
MB[;?ZC:.5+((L\G(-7%0QD\GF;QX(QO-6FYK)8$5RR" &.#86VW7(.E;T.%J
MC([%HBWCR4:T)MGECB[GORVC\1)X*6KZ$UM0U=GV843[]=PNCAE#;%T1KS?:
MI9C58A<]:P%Z2:?/\'>LFJM/>T#U8@A+OIGGRVC+ ITU^1#ASV1\^/DK Z$/
MZI^]73=#L%^)A;&>J[O\5\T;.DXIUBYT9+G3(F?U(S9_>;[2,<+LA&=5!0CD
M.O)YVA,Z&CHJ.A^[:**1N8?\R2:#XF7'5T(&*Q.1WC6.-UCP\^U$W>SYKV60
MDON3D@Z*L""T-<\@[T]H5::X4N83CGVC][9:6:SL2FE[/J!NB\" 8(*PWI'"
MM:,Y;E<9(H\HKY6JB5<1O5LWFNW(_T'_P>5-=\O2&Y4+Z95I[2G=K:JO,P.$
M@4CF9F$"RMK1CL*8,5W/@5+]XF ?R6^;Q!/Q#_2F%3)6['9ZZ.AF2^EL2H'W
M$7"!LG0"/1I]*(/+Q>4[\7$G4K1Z>GYKKX)GY/898ZQK765;VY]G8D:Z/^GJ
M>].<JF"XHM4\:A?8,:F/'+PO !WF)6>-X"PQZ41P)A4>/@K-H_?7'6%;<R"8
M&\R:U=^J%LY(7<:H>=X!L5<\9:W5=!4T<Z7WN7DM3N,^KO9BU,XE3)2%G-ZT
M*H26QX*M!$]Q.-HQ0P A'8!K*2B4Z="\UOJX,NI XU+ID6'B?0^P+D?+N$I!
M]P.9Q.T3%A>C(M%A;).NOLCR\O4LWLRG4Q>4,OWF>$]S]N5B!QX\F$VR,2GB
M) FU\3"M.;*MUE7'MYIY5Q(2^>CC9WL"/OJP.:[0G-=U7*5FYLZA1)H&UALJ
ML-&JDIJ/DLNXHCPITJCW@+,S[DM3.3CC83@.*D]T2M&7\.=>AO%6&5,APDRW
M^:[F9A^?/$X0?"@A]OBD+1Q8?*F,-+/A8Y"_0\:;2>RE4%@Y\ZSCX&%D=<+J
M"GDDNR(<315A./=[QF"WPF7FT]D@'=:5Z)$9;9,:\ZAW[[I;_/;@4Z9^XAAZ
M(F0Y"V77LZW0PYU V7Z$I&_'E1IC^J=,G"#?A/+%NMHZ:# X?D<'UAC5CWC<
MK]6YM:VU-!<L U=S$NSX?F(5TIH9"N);D0C'O[1EMJ66U-\C+\$6[% 9<4GR
MI9V7W<O0?C="FOF,L0^/C]]657%(41&%E/[L4=Z"#?%.H5RV516GOCQ2A3O7
MU<GG:I;RW/_#WEN&U;5D:Z,3EV A0"! L)4 P=TM! _N[NYN(5@@N"PLN+L'
M=W=W=PL:)$B"W96<T]T[[.[3?>3[SKW/<W_4GRFC:M:P=XRJ&E.AO5KZ:(&C
M%4];PPO>)>=:I;S<7Q)#;<#N,]*+ZG@)[C+TEJT\W5@\A'N@1,@.S'&"4Y&]
MAW-Q-JN]V-F^(ELE7.MMH+B(=@R<]J[@9WGC!>4 %+@2A?MRVBHXC56UISF)
M=R]J& JZ>%-=>&51ZK@4:S!A-@O]7]DAKLSM/E/;'6TH"SYTAC-H<%'(LI.H
MA+?Y$%'7L['"#.5&Q-8;/C*W?8A_86QU=#5BUGO",UULGO5U="C1["6_OL^F
M\8CL0 ;J0-P\$L%&F.TD70!+0RB&JAA.(L\WN;=*J_R,QYV/ R/H3G2\3\.D
M7&"/;1J%"E_-L4RM6@IV7+8]'S[MS ./R\%W-+ CJ\,9#&,EL1&,PEL.CEUE
MG(DW7Q-.%0\6Z83+?)8G]A%:5*RHL6-DW32(5'A_'GW4Y8;ZJ4Z= N=\W3W-
M2WPT7\&HYX4 R#MECB4YS9111?U1X<23O1H&D8O=-+E YB"&!B-1U+!':*(P
M98#%?ZTDAZ+5U[7/">,<-;Z.;!$A3U_AF],ONL-4>A_Q?U4*)RNA D\=.%Z,
M[WRN?6Q65CWMOPVK4J(3J:K&1B'5AURV+$IUR8]L L.D-*ESP@[FT/]XX*0L
M=U0;S&<RL1DXAR-C(WRZ[_V<0TX"DQ%=-M?4K@^DYE\,5SL%9K(&50^VD?//
MR2G< RO\! ?4K4_ DAY\0F63?CD-CCD2IIZV!/(C5N/U>=$4;6!Z)Z82 *4U
MLE+G^-51<9'Z[C;7FX9R2:G]K<J:NMK'\>JY,/DP'.SP7B\G'4.Y1$,-)JU)
MJD(KKOL2S4(<^[C1NRLJ::0ZNI[CR[X82DF+$CY>I+8H >O$Z'IWHZ&OFL7Z
M,?]X64@;5R+Z65M;?+PMS^]57/)-(Z83)QT4DT^F3=\RCB57.Z=:XZ%'YNP(
MJ?: (P2-%84U+ Y$B/9''*S$ !J2F$I3-$:UM=Y%E9=GU#3I-0R5-%N5QNY?
M2;IG= #%;M=A."T_YEOV1HQ@<[VM(RV6^?B^@5Z1R5,/:1ZSN6$TSHL2:I-1
MDV:*B2K+UP?2KK:6CG"'FYEZM:0<K-Z]HI-O%I39 ; $$PXQ/NORR^K:2?"P
MNGJBR1$2CC,3W&E)+QX)HIY *P@>605: 0/IZ8MQ&M"T[I1/I7.YL!ZC\,*[
MV9%C]CMBI-X1XAW<OF%R_\H%]5!.11]63W0QT@%]4V<$^AC+MLR^WF 252B@
MU (US5$!2HZBB-KJA4KL,M)1?&ZD,O)X&7+1IG/K/-(/)05>FJK8(_KIBIY<
M:0:?%3D]?Z0L!*M10<PZBX(* #<$YHSV8'^)ZYJNLQXMUYZBKKF^,7;9/58S
MG93UM%:(X)!?7XNI;W/S3,[E?7OW/7#]6AV.;JUA?>- &0/>WYA]B9J#^\UW
MBWQ</39:J!>MK+25 P-+<FPI%T0'L\DOU0UJ2 5)3Q^)-?K4[4 )K-J'^*83
M5CZ6I![K>";! "^B"-3!P) W(V K*TT5?W,7BE5T-8SL5+HX 0Q2!)-(T79\
M[&P 6#  LE=^3Q:G5#D*\M_;%YXX#W9(X'G-$MH_N/;6AO7<4&/S5 1D"8O)
M".6N]'FFN&JNJHG7WM&D>NSU#P&R)W"FCSY'M??Y:SAQB5JEQQ)R"02=MH]9
ME&X^@P)S?2HRJNEH[]W[$C#D$U"4:AL=<YV6!Z .D5H*JRN'*U:+EJ1[TF0%
MW!W9>KT)8!3W3:UWA7T<"S",IB%O41^6#';I!*U_*3+L13Z-@2W8*=2Q(O8P
M?[[355T]8V\T[SQAF86Q9"8JTP&S 6(;:H ALX>JLN_#U:N[>SDAV1@[O]29
M:EK_4;Y2PC/ND>63X<@RV9$7&D=6N;F 7LZ$;G7#B>3Y42A5CVEM5UY^"$O3
M8AJ&.,$)*4;!()0<KWRL=@2,L\SXP;E0#1N%:O&6ZEHD;J'P1GW9IH$!D8PH
M]Q,EWA&@GHT4]VY4?H#Q$#]HA\M^!F\'J_KB>%Y=R-(24_"WM!YA@?C?.9!2
M<4[E(26(56_X38;;=0GK^&N8C.B> $HNL.H;Y@KOQ51%A[6P8'HR@J02$E=J
M8% /AXD@>1U_O?$XN8G-2DKX8/JEMSXH(?FP9;98OZ99GK8P1PP?L;_70"$9
M2@.&..1KP Y>'_&.QX(YY=?SPGT>;7Z&>>WVSXLW^R!XEPO@RP:*&#[_"X5P
M$ $:TI<BYGV>YU/CBYPYSGV@">:26=P!+G / -6WB@PDC(_CXZNL?GS?&RG#
M'*89  -#W1G[(TJ%\>KG8M0'G_9V'J,>AV4],1CQ0F(=QES33?28C^NO8O/M
M7=<I-EK&:*E9>)Z-RYRJ+4@1EO9>#S02%E:N^G&@"./F<11>1LZY?.X1:ZD4
M/5KS.1:7DZVQ[C\1+<JR:>6"SC(F(S2!$;Z4-LTROV4H*CYG#=5]:J^.YQW"
MZA11E!42%9[H8UKM1N@7$X+1AV6/[[K9H&HH(SYX,'S$5R_FO#M*X%#XS"DJ
M9_>Q&$Y\[OR<"%D\(4VZRM0G+S:,-/O6[<*]'WP7 P)P0STW$L*20VG:5]^Y
M+94M[H'"_9B>H59RJRT=N$F6O$.:-0C2L!17G7E'KUIIF"75T&:DN!#V?8<,
M;TC,TC[7Y:.HL9!$(I>?27:0REW!ER\=Q+X1"B&^$>9A$P?%6:/O.')5AT!N
M1ZG6FPL:PHF#2$1'"T,(>(%!EE3=TE0^::6.<$6L7YG+.S EN!#BQZ#C<2DT
M4N6]$'B\TI#+OE0SF,;.NW==!+LK*7_0*(^)2.\G'(J*(=9)<<G[>EYK2:,3
M.XWD2&DE_8,;Q\(O&[=/1]7'#S &>8\Z$N.Q2+)4J6Q4N_N'#8*M2 7\X]U)
M+(Z;TQP)#%!V FMJ*N.$)ZC35&D<!R2N:YF[JP*>^K ?$3YB3$(GTY%LC4!\
M]71GCI\P2SE79?RYY:MU=F,^"O. 1]^ET%^=',E'CH8$&>8$(I:!4=\(>H#.
M'@7[F_ +1^OXY(G-PT_U@$+3-E/,;G#&VD?HXC 7Q;&&0*8U[E AJ5LC9EWA
M7;$UO"11(A4U"6O32%GJ7OQ!8J0&RH$J*2IX6$]"8"*3_ $8>26?]7V1YIJ*
M2/WZV.4W?G-!?G99E" [CAZRA*V-\DGX7/.</>>G1-;5*/-&=2@ZW\=.FBG]
M68]:\;U;W\%K,-Z4C#KR:'WMGY3;5M^,E87/S!&/['F93(>'Y(7T*#*B,U:#
M,\7[^A706S::&33^@T>TPX,VX\[P2.<15NZ RC'9B[(&66$D/K6$>T"ULJS,
M/$;7YMT(*86.(0UU0W7 # AU;@,,M)$#3^3-E"J6Y_%=:)<GN:! D>&IQC:Y
M5V*[#4E..["VKU=$/D]4':)M=]U\F,+AX9T>M8S?-"&->4L>PF[DM!)98VI$
M#&T"4SSN^.F<-07!1UUB7P_V(FK##2:Y"!'$6(V&B\E.YH.(J?9E&L=62Q"U
M/H!VT_3E!_ 8N&.[/06P$@-TP&*;"9J\W1+N[D[-"5P#5_H,^!V((HZ@Y[:C
M2;2V7J+#"(!6&GP&2+;(-D]!!KH@!$#0E?I/G)O[TSFZ86M+.I+)G./EG,C/
M^\[4^\6BMMMOT-8 F*/AS*VW&+7P K$HN6,%5,'J[KT?E.E%F'5CVD6]_;=(
MHE<O8:%Y$--@ZRIK&D/UZWPX(C4-'I'Z0T7[*^W4$F-X"(D?8.,%PP$&4:,R
MHHK4G0"\&$]AZ,Q7VO-0V4IU5;T:60)GUHQ5^(_R%-<I-*O@-$LH?R;_85QH
M1"B/=?=$#_$IPY$H ]AZ,'^NO7"?-[=^*B/0>=0S6-NWZYO]LU!G:+ZJ.O[$
MR[Q"QXMO":X2"!'Y,C;TV4Y)<-V+^D'YF5=F8T=KDQLU*?VHAYRF$R^[*VM!
M@<B,*8_K%C,I>E XP4NJ),KD4/PW0!H042!&3($'NBC!5SQA.9ZD)O'N/%E@
MFR_1KWJ-+^-%1V?1O^,<NVD=_A6#?=7KS,57SD/O;D&T<G*CHJ(AM#&X2G3'
MYU3W'J ]DK*A1WK%6H%>WV&.7*&[5DM7HC]I=9#0=3/&? 'U.=@AA(%;JI:,
M&$.T^]R"T3>2'^=)1SUM2U8\K5&48F5SLG6LF.$+#4]H+WKNLERK19V0HSY0
M2@!0@,T/H !<<C/8ZS2V+_UVRD1OLCT_WP,F$M428DP^8Q(^XMV+Y/'A,4VU
MQ/@39FIT"P[7L2;9#<F;U94.(8T?([?A6GLUTJC=;!C=E#G2LX\JC.JQ$IRC
M,F8;JVN*7>'?3V/'*[%/M7S$5VF1\G;MTT2'$W"WUM,%X^F7!6!5A1T35<XG
M11R7=X.$B"TCGM3JE[ ]+_ "   -**'J=#N_FYSXMKOFNET+ST'V76X+N^)%
M@2C1I3,^ EP9.GLWDCKOR^F.1',JR[=S\QIO+8\<N:QIM2MXZ<NK#S[0SN('
MD-7 14^Y:R/EI*5H91O%@M]D3)_0S.!<GA1L<V# ?)J3&L_U?YT%+3Q-_ QG
MWBEJO9CWXD+L*VUQ%>@Q,V/O&+[-1WCZ3#A<=CVQ[Q5M[ #JOKJZ.[YHL:5N
MV",7&9"M<(,BE@T DY;/WPHX9?_CH@)EW*JY*RLJZDU@FOX%J9>ITG;8UOK
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M/6+CJ^/4?E7UKRCU#O(CO,-IRL6XL)*2,[T3 $DZH8E*73MJFM@G]ER+;P5
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M'E@ZZI+\9Y3&1NS("*"$[&QS);5^T>E05OV%.G+O-1M<*_FJ5G;B\QX]3A\
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M!<(CHU)0FL#?VPGZNS*:IY;XMJ:>RC1")D-77?OV&60RWEG> ^"F$L^%EKN
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M YG^Z!6'$=B947QK\?QE9J[P-FLO<"S"DOM*+<N.LP*\&9W<4N(+<5R9& _
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MQ;CQ[>A1RBERR9G*-H=@$ZAU9@[G3\7)#ZE1RF+:9]6XK[S<CB1DP$NT2$2
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MWQORA&QL@8[2$<P)F#$EG0?@CFHV]Q[38^O^NN(!6/<07B&=%-YVG!8^&DR
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M'2C;<K%/I3?J/ )5233[(3/)NW;#=[TE/@ZDS3J.7,%+6&V^1M!Z &;DNQ\
MF8SB/H">!$H8CD&0UA/O[8ZB84*%?%$A?]*T0IV=U=WS@\T3JH!:YF@&'\@Q
M$3Q^D/R 8RIKC-/WMXO%*\=FY5M%9N00N;0%$ [KNG$>+LPVA_K+Y?KSEUO3
MF1.<UBDB6HO934+OWY5,GE!&I2UDK,>^W/LIP3KDT0#0EKR_&I8Z-8O@F#0[
M,77371X]W)#;[L1'T@A)9HMN%:2%DE,_%!'2=*&\!:_>?&?FPX?:=NP\E&^=
M7FEQG-#HKLS 8+5.3XP#)XO5,ZR[M$KP *#$0\E.J&$+@ESJ?35(]NNKI??I
M7HGW<LCE Q V@D1A6'@UNZ8XNIHZ91KH$B'KQTBE@^02M7Y?M8P@@H2$JD!\
M()3VR.4OM/3O;O;2KBB_/P!K'-YMIMD/P'!)_0/@1[\$8?\;2_[^OY)_6@4S
MHJ3IH?Z)X]YL=75Q_,!:L(&JGV3R\]0 7C\"N4R(%#6^B?FW8IF_@\G+"KN3
MN?ZY9B3;PZ\'B<ZX,"V#&(?I"2@%,U>L)<^N/Q,D#?SD0HJ7HH=4]L_81]E'
M^#5V+5+RO].W(],ZU779>Z,KJ5P+&3@FF6?$:S6KMC9$S3F[E6^E*B1.IL=!
M(8"J',X=Z4C&=RPL++1P@Q "!=ZR[QK%!S03".%5">STTEB>%26D]&'Q'7W]
M">\:R_;BKM7Y%>6*9/] F/+RZJX_$.;\D/O#(\+@&->6.'@8I_X7A)$N<8OC
MD-WCYQQG+CUDRHQ_*ZN"-5O^&5TZ>L0YVL/\N^.(6\P-,XZ^%>.*G'EO775M
M *ZT91T'^"7O_0.@L,@D%%AR%0N1]'H":9U>NF&;RD['D(/3C]0+.8[O.NS3
MEHVL[,>83JCCZHC"4OHI-4=Y>5[LL2$ C3U9*LT#4%;P .Q05SL[_0>%:NC1
M>,G/R<>?M"MI>S.^M;' :Z7V&5(H+]:FM37T!T].SYH,N5X;\IRUI*/],4OI
MU'\ >E]->._CF4*U@&UA=0G= P"1(<U\I";F>R)GD6<%=C /0 ]49%W@3 B?
ME5@%YOPBNPME?@ ,&5]!*VHS':-_4*Q?7MQSK]_3Q#C <N,M_ UZ(C@^/]=*
M-#S@OGAJX-G)"_6YU*^M^5OAH&#_C#+@?B6Q^Y>-12KJ2$A&/I_S#RG\X<,I
M'V[:/]'-_ZJ=K)F;_*"XU?QU$70160N^Q?HUEQ1Y_N54:/S2\<[SXN 20G=.
M>-I(:UO*258MG755L,5M%UIW'HW72!OELZB06J<(7+LX1@0U9R@B<0F0V9%4
M9#VOQ58@S1;*1M_%K7*0V[3%IX(W4B>+DWSBZW1K:?/Q.;>TI35>EK<I ZKT
MA5'7"QH">!R4UBVK&\<))1%B_0XR# MN(:SC%_E"P3G]>1AL*YUSLYDR!(;\
M\B?LT;[^J2ST*K\I@ FW(XCT5C T#,X/0$9B)!2A>@6.F>_]2IK/5!21.!\
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M4?SE7 &LI?VMC5*QDA>"W)W8N].O>]\MOB]GJ;->-A+73(F8.>XRHFL4.Y%
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M+;Q;F<JW5O.&?4>/):V#FZ_VPBSPAW,6UZ+Z15&W7?Q)S?Y]4G-2F''XCSO
MXG?PG1;,D5XM5IL\)!_C,'U=ESH?-&F*Y*1<]<:M5L!63+*&SZF8!!6ZT31!
M58/TT(U.VE<KUW[<:*;[3\^A&VV?;$[  9/VWT-R_B!XM13=@J_DFWV.Q;@H
MW*(5&_*YM"O8$O0E#W$)WF=FESUBTE%Q5,#0&QW[ 3"WL-S0U9[?NE4V3J,S
MB;6[\W3]&78QY+XC0O3A3XV8:*F66[OV6&?"A7P0)A-X:^F^F-V[X"MUE]
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M]$GT2:&YX)[,DDK55*JV1@P$94UW;J,BGN0K?A]_SIC[XTM;1H?6*4:>+]Q
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MG0EWHW7=;/N'(A7+9*TMX1GBC[/8A(A3$0=D9-:._+AB,"65<G:.+>.Q9]L
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M\2>([RJZ:R^IX9B'_;2)*JN)@!-Q9@S+8D]3^-.N9\@EH,1Y%(U>.Y;HC]]
M+6QBZZSPRW&VHO &HV=.D\:?K91">Y#16.J#G%QY01_I*?U6!=)QL&/]TT2+
M2_>F%HG'7WW2TG1)HUND%J!M89H3G2/T0^/"1!*1!GPL%O5>&5I=<B/$XW9=
MH,J/R',3.\'E"P9*+ZLSEBS-6V'M*A9-M0W-:F3$SS^3#52;57O]?HU7F.[
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M!FY-FX,'P M0:1]N?:N<L:R99"#$B@1%4$BV3B/$DJ=4 !8GO8:SZ7P:?_,
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M&_[2V-SY<>0V\ XNGFB)._8.S(!;3IC6>K70RUL"%NC^L557HYNV[*,L:D8
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MQ"':^O>S&:BI"V+0'K" $I#KL!H@7IF:2NM"L;($^$CI:_&O>\RB>*:M(C#
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MJ9<O\=&+3.'69P#VE:,X[P4?1,C'_P)02P,$%     @ AXMQ7,M\J@X[#@
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M(3RH(LRI5:#F]#8!:T.7_9?@'AX>[NZ]KH(M-"%WS]QEC22*Y&DS\CM_;@C
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MWP'KB=BP(R3;5=4S/79/[T:6'IZ,5BFU4I9[^CHV'!2)3'',)-,@*2GGTU\
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M7274:GGBT2Q-RR"YQ]N,Z.C3%W/-&AG((5FZ,J X(@&FI$8EBRIA3XSX/V5
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M2 5/'D"4]:=<WHDR3Y]Q7C#R5NMC_IPS_8MRR:T2=[N'H0?=W\20RX+I@ P
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MK]!--_C+$1-6=[4>@!6+Z(;M>IHK@2&5+=+12Y2SWDL?_I/6:2<@$_C84P1
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M"H()4DC"&F>])OQ%;-0..P#N\36PZ=)KE\>Y=OJJ%'4\+U&"'<Q-!#D09#&
M4\Y1!F2IU1W3Y:'X[8Z$"[+,R55>Q-6C#)]P\91%.NK8J;FBT1@G&DK9Z("@
MUPB@PF,<[!%-=$?B$*.,H.7#/=J;0)4-UP>]94%'S)2]>V,<KC2RS@Y]37#;
MHU^5( @.F= )Q\![>01SF.NX<9L5_\#MC UK^RT[-0_S(J,3DMF24@<$YT8
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M@%VR]"6\]S1:6,(CM5P(TDKPH:"<?<J2").\0G>;%=A^'3A"W^DIP%BW>H<
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M%_DLC6[BX#%.8I;H963+&&G-3W.8Y+*\#8PR!9#X4_#KV'Z+"]38Y#?Z*JN
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M^)_PSO_3^B6T&H(W<;FIFLJ^Z5@$H9RZ)[-)+ 'OW$K$)L0![TO:4_$ZRK<
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MC29B!8?B6I>W1*YM;HA.QKU+3+E'<-1P\"++"]5#!0I9E^./%FZ7:U)!,..
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M*@B?^K**\CR"79?=Z]&*H=LF#C8*9N5P+$^$SK#N1,><"<!A02V7UX+2?O%
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M4K@YOZP-4*(L9^IV#;,=^L2M143TL4;5R1R9"]95"<\(K]D#R,HZQLF11:G
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M??]'0<#%IDE31."%))7.",)?6@E,0_]A[BUHT.B-,0#M18,/0^HJ\!C?(9B
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M-9RY$C!<E<D4IBHKB^VL4YN6!GS'AD'Y)#I[C@E-5^'FCE">Z-M;:H(]+)K
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M9 ]VS56C32!\>JMB)Y,/?W#-K],E__#IV81C^> '..$=<-'57T[XC%!D0^!
ML$F'"1QF5QY_LS/;?O%>PG6^/DLH39YYTD%OP_ZBVT+;M8)W2-W-*-I@A3YI
MGT=>FLX6Y>LA,WH?+E?9;<Z/B]E><I\<\]R+(IZAJRR7E@4U0T#GAO%.USNZ
M5OI!U$W+N'QAB\XP)>5JM"[\!TM[,#<'M0+G'&Q=T$/G_O@TD@UFEL>RU1I0
M!EUSIYDP<(RDZYBM%DB:\0>VBQSPD*O2-FU B73-0V:/$SJUTH2HU;V_W5ZL
M5A4<(N$8D6!4T/EC2CV1B)^O<&O+O# 6]P!,#\ 8JD%Y<\;A!5-+R1G*)7AF
M9!NV_0Z^$+HD='_]'W#M_?OOZM?>=VU-BL8F^];&R_NH4 ><\M%8'_\N.Q_9
M_4QLPYF-E38J#C@M;K ;&W$@79(UJYK;ZT9]7;BS7A&2BR8$30G5YX?<CU60
MVN[=EP%:<^-J)D1;_%OK9WG*Q$G3J?_//$Q# ;/VAJ:RPFMA3JD@^I5SF63\
M1S;8F.YE JJZP9_!'@%<U=0:YD+5G$3AG5BH^"3/0M^+TNO8U]Y8T5?!#I,'
MVU;U[!2" OK2G[](1/Z9\P7N$_NO.?N4X0ZZJH(;/:3["*=4$/VVN40RT\BF
MJ>((7WK[,W/CRIWSFFBF>^>*XM@#G='$](0X-KAQ\6>+2K2*?FA3%'>DHW0>
MV!3J]7I)O=4EG8-$:7'KQ#O\IGH+W]2GK!MR@UFME=;OZ]BJ.,P"KYYM4KNT
M4Q7&OOK6TNYT+QLX-OY-TY1DX+VKO+0;?:3[Z"?7KG+_RPV*3 LZ57DW:-(9
MG(&/P7>DW'L^BXEI%UHKAGV!4&\?M>VF5,6A4B?SZ[[L8V?;^7.B!55:$OOZ
M'QQ7C:+H [PSC\P/=X0'=ZJ?\$OS9>1\.D]*M](7C_Y&,CZ='4*P-(?HL.K8
MF\L.9%H!A$YG?7 YNM\F5I9%5&UED<GA@,_ZX :QU]@=*.\(HBL']#>$31^0
M-/3??V@\QRBJNI-COI#'G%&^7J[7G:<43NU;BKH:;BR;Y< >;31U2@SV!*+T
MHXU^"\+[QIE#;".<4/1OACJI?J79-BV!UR34[.>0^2VAYMOS?%8Y"D=^C,_T
M4.DN7_-GDBRIMUGQ$V;-*Z3JXJ<U+NAU&>:0UD0%6=:ET3T2JBF.3(4>VR8/
M:D4&<N-YZXUW%24T##R](T]2$"U%FQXIB2=/J27ZSO9GCX:\4XK^JM^S2HIB
M.9- :SCI)E2IKRO;R\/!R"%A_VPAQ-TE2RIUEFTY/]:WG+OF)LEB<FB0_TLT
M.=FUN=^4#A0';MQJUMZ;[V/'V3WQVD9X)^(EH'?(RF)V#Q/T]81K2E6_CB%J
MF$<<+4F #$ZGE\P!P)L]7_T[.%OPU1]/69)Y48TEY.FGO!T\]=FT&N[?')5-
M.M_K)IVRF<FNG8X334\O_)A]GO5R:/F.\W4N B)$2DP^A5.R8E,V6^M<QXPV
M<I.DIHM&=JVXX4*5\]3,=FRA&/Z5(J"\C45L:TIOG/'2MF*L"^DW+MT[>LWO
MP_5 *>Q9.+RK2&_/PCGY+%RYMC"%$=>*84=-V+P&)]40?4<F8FW.S$DDS^I)
M)&^3>+;A90L,#EDQTEF>I9D7!VP'6N0JT@R*HWP=.4ZJ[4I!EBMR)*9:;WXV
M1?*ZS*-9EXVJ+L=L)PBJ*O]">*HD$DS9SMI;DJ.,2@JOUI@"8(]M7<UV;+S<
MM]PVN7HA0-P3/NV((*Y8;+%R+YH3NOZHLV($8; #WGJS:#0BW5@NM%&_.?=P
M!N8K;X?*=+FD9,FXN6:JAXP27X0#5\ R+"/0I,)^7JK/]04RM=BCMXO+Z<]\
MUW#P_(ZRB-Y_$_V*C;-KYQHM0[ZJH!,\-:^@A*3I=5PDEAYBU=NS$.CWC\98
M^0Y"G&MO>W19]*C'/;1UF.VP.%@^Z9-=R?8\:KHX7^\ZYK@S=N6KV._(N3MG
M-ZAQW_Z4TT39!7<JM9W?H6#W+ ?VNWACV>@@]+EOM2=_:/ KW%TU6(YR=\=1
M*5R][. OX^#MW*"+ !:&.]S3A:=U=."*\;XY9WN7RJ8W.'N0Y@B. W41)T-C
M[P2O*R(RP\KB9'_0Q<D^EW&R7B-.=O*[HY;?XF;;/AYEB)+5U7$C= L4$ZM3
M S\"5BI=8Q0#DG/C6G2KV>P@9-VX%+DJE5 ?M:JI\IIH<B0V52J;*4)56\EA
MDC0QJEJ5AKF]?.:QU5-"R9SF:;9[34][C5E; SMX"V!)U<T60/N!CI;FS\E\
ME>0I6V?.GYE>VSDKSO=E3VP]>A=YOEC:@@AIUQ1V4)(E4UWP&HC"G]CJFS[3
M,"/4%,7-RZN+8P<;6%)ATAO=3:MX8RT]VU;_HE\ V+3A\&2C?_ (KB+Z.Q-5
MD4PK UE9-SBRMTP-9ZY<8;F.GTC*FC7=8:F7PYZ!U"95 UVN(/HP]YHOY%D/
M9K#K=W@/2KQ=O_OZKM\-%OE\^M?OI/V[.%.=+0[9D\^]*"+!V;;^S+NE5\"F
M8>1+<S#G(L1O8(_F2:=HV2G%DSD+K2K'.#P"S]BY-36=]&J8C (*B'M9P_Y&
MMM,TS=?%*=U/*0GFB3B9VZFD2>3R>]T!%6MX4FEYPIN>9,E$-+Y+\](UC]A7
M=DSUEM[E+;U+%TIO7#L >TOO\NIVDV_I7=[VEZ?L^<?-XW(2/O\OQ.,+/FXU
MU_$F!SP:K:[A1B_H8=!2JXCNSY>)9AJT='7<X,QDA0!^7/&,U643(<,_)\P>
MPXB-&2:/&; Z]@!H-D,#95I8G!L5[\/TMRM*>, K84AG]VQTL652UP;VD4YG
M.LT #11,4!?DR@MI\9Z<<$Z(^3?:BHNE^R<$]>^8=&@0V[\-I[&KIH[V4Y[2
MWF<3/_?3V?9/65WL")/._5(-B+/<781/84#BH,T8JVL#.TM$;URJ 4+G5.<[
MKZO3[F"AV<KKR-;8!CFGZ3[ULZ,1>%6<)O5QANCJ29181)37R#2G47]H?QHE
MOC I/_%5'4FI+C/;L:)[?K5=4VZX&/2G3NVU&^K!5DMI&N-0-^ING#E=:L],
M9X9O!C]G,KQ%>,^OZJJ?@:S\^960=*S4,(=#$,R5^XZ=@-!-Q<"X'^,EQW(G
MZB".40.87\(X7.?JK3@K4RN"^;"CA/H*F%)=AEF"FU#U7HRH'A=!\V.8497I
M@KZQ:9U,A/O0Q%!7&0!W^_:#MUOLW MSTD0(C"@#YFN%71<Z?:4O:DW=5V&M
M13?%M=:=#*CO.IZ@N1YSYX:YMDE,HU.9^U(^&,QSH&^B/ELYA#D.RHT;YM=W
MCZOZY$<>)(\_C;9^/I6Q4<;4Z[))Z5G\J*M-K01H>Q'7+13 VU=@J*,N-+42
MH!T8GZ2ANKC('%)A1 M%?$_@%$U38Y/(QZ373' 2 ,]$_Z@[$RU:^HH//[L/
M&'M6VB=I-US6Z_$3IW"FVK_6^-?\6@]6C5&PQWGCQIG#VOXI[W?*N''IYJ"0
MZ()-4/K[-K5B7P?#-:71KPGNY3'=M6D4=(,OJ:VI,!_V$N 7;SM?A30C)-8'
MXC?+H<<$RJW@**A>I=U0]Q_8]T1>QP?R! "T613[S@(04Y6. \$Z\[.$?>4J
M7!CM5%X4.]H< *M.Q]/=OS??\ACL?2#UIY!CTOM;I?:U\#*Q\IKL;: 7U?H2
M 'L2/07CM'Q5;?2L7WV_6R7^ZV>29DSWXETY51AQGU_ OO7:OR7V#I&KGLN*
MS[+V%([,=?DGG>NRZK.<3!M/X+SY+M\62X,NEF!.S!$6/FW>QWK(/)KA/R+W
MMG :+>G0>(8ZZ"+(*?-M!+R)WZ;3/%LE-/P7"40NA,J<=Q=YA[=X!2 BRKT"
M7@DG\)GSCP;S=D% [-4:W/Q=0.OU;6N/'WL<93RN?Q+;5SGV""R'_'6,N1T0
M^BQNU.]>0!_.$NO?P<X&,XKYR<%U?R!3'C-*]1IHJ=FG$-@G"/U86_^T#'3B
MT[7?7+YL0C80:T:E3LXAU5?0(@'A:16& ?;T1Z2==6,/2I9R "WNCZ<]+K4B
MYZ0? NG:3Z\2NB!AEE,RPM),^C&@9?[);<ML#[.]^7TJS"\F2Y[GRFWS,_58
M"3!( ZJU)$##_>2VX0Y$D/L3O<.G*[_"'7<BJMIA\VJC>B\.D\O8\9'QE9RP
MV-CJ5W'(\F;!#GJA;:S4@;.0H2!XLTN&$ _685TW#O:9+A+^J[(3\^L-0T_X
M< F@-GO:AR>VC+P9L $NG!5#5[F@QG[:1S7]L/<:ND#CQ!^0L:@MB*I#_R&R
M3PT@([1K.'"NY ABK\0-889DNEQ2X0D<:Y'=022H&2,=?.$#]'H&]_[Q&]$C
M!Y< :M&.'ZSUS,B; 1O@<FJ!WGLL]6F?U?7#WFOH OTOY=0@NK- ;R4CM&LX
M<!KH"&*O>X%>@<25!3I$)/!U 7PSQN2L]\$=YV(HOTNQ2B)&:5K@7E[?O.7/
MGV7ATT'?RK703XUKH95F_N/?__3QPQ__/"&BN?U]T,F^Q;>;H9 Q*7],PR#T
MZ'9&"XF^D&R5!-?Q$[=<\N#M;_,R2V\4WA4S);;K]2MN9$R"#1^]*NY >KN]
MB!7);P"IZPSUW*!TB,Z@- @Y$/A9YZ02ZC/0::I\W<0ZDIRN(M&MMV8_SMGR
M)66C%B/!E*\.4M<UDA6&6V<,H-D@;Z)9,'=]-S,]<5TI@GT#%VYG-2H::@YT
MAV>:S5>D>,)^MF!K:?%VLB9UFZ8\=DBN/=8&A1S9)-_1\(EMANXBSQ?[*Y/Y
MJ\JC.Q!;=P8] KT2E!+_VV7R]#X@8<$-^^% "?O'KS=L:QI=QAE?ZLK7 *Q4
MHY!K$T+_L[Y,Z\KP.@8UQ:>5\S<K<EP"F1098@U,CR4>)K\LO]_^G"3!G.:I
M>G@1-Q-E)=$N>3?@:0[O&M4&FE'/O.W#*J'$#*:T))X3$("F1C?T:7+.VIXM
M*GY(_0Y-4?SUC]-Z_2OY0)#2AE=N1TWCX#:)O<-O*@N&U+0,LF[(#>JU9EQ/
M/VZKXC#3AV0)/5U2HE^L*M;>C8K8-U1;VJ-ABZ' !WT09=-E)N0J!A)^PI/$
M0G6]NTM?S8V>-8;+2X]#92&$0V]-+).G2U'<$3HAIEKC1Z$0MD^+";1.8F%Y
MIEE-4M21:RH*JZHQH%05?>C[18SK1N]*K1ATN3[PM0D8^%(5AP$^I5D%=/:O
M ^#L'[_.^9GV;'$=!_QMV=R+%/,+*ZLHZL@@-."<HM:]DL<*D;)?PFQU3R*!
M>+H*-_/$X'^1*61J!)EF-0=FKDRJ#;,8WSM)ITO3\EM>%"^8K@V(S=6V#@#T
M28:G3>6^;_UR^KC4ZQ_II&I7TK#A<F5:)=?+N<&7S-(4> \[(,V?D_DJR5,O
M#HHGJ>:L.)FMX_ Q3Z]CG_TJ?.)G._HWH^R;@2[-!KOO)#>@ZEC5%AOT<:QX
MC9!] / 0XZ&8&SUCA)&LIG<EOY^C<=;*1%0'3>( .B .\S4WC$=J^+VE_=+I
MC^VDN&=63T,>L"VZQD]QF*7W#S^9]LN&:M!!>KBHD0&[1LTN0 BB#^VMX_N+
M6XCE\[:5IP,Z#!3VG\)^1A 4#=S7C0H3XNBV5/'VP:U"6PG[19E6! -@0*?J
M;G>5QI(M4SWT",PVA,' 0.=,2'>=ICD)+G*Z?P.OD/>6/(L_:8_M8/6Q'Q%I
M-ZI:@8//)9<+<@7=[CKX8.<.[6>ZUY/_^XXF/B%!>L7 X>;DL1W[-5O5A5YT
MES]&H;\[[M<-G^ FL%^W:#F26D+4VB R0I'-89:M"!4/93W3D#])RF^XQJFF
M0ZMK8#]2T8IL$P #15P>V9C,MFY)MBNC.@JQ:@+[/0<[<NSU<V1*E(T=LT5E
M,6TWK-:J8@>6]3:<2B$YZ7GUHA1X9YSG29IIEK&*XNCWD=H0K%5]H/'3!#,O
MU [;X1+DVP^!@R#:YT74\R1F*A$J0+PG/@F?F!W$E1A3S<[ KAGTG/'M=@]M
ML'*)X6-_7;$WO;8F&- *>K;UKOR"D7*)7K&QO2-4" VBLE8#/9*S*VU2!- I
MDBZ::"%V<:9KN9"LU45/G=W?4E**RDFO)4V3!K/67F;8>COH2:,'F6+E:*'W
M<*VOMW;L*D[./M,D;>L8U[2'GF*Y?T^Y$;W3'ATJZPOH]*VN@IZ/N+U37H<!
M?O=NFSGS+J?^RBN3PQ[Y29B./+K.0/- W\3/Q-':3@9EX;2'$MTH6OS^*J$/
MA#XQ%-K./9)VT)/?]C_G*-%ZC08B<IMVMP]5,^A)9?LT#SU6Z//4>>2EZ6Q1
M7K.;T7N>CGGORB!^SD_%2'KN11$)SK:7GK\Z+JL)BNK>--02W'+Z]8:IF]9Q
ME+Y^_\>T_&NJ2<#>LCFH%;CE&NR$G9O,JVVXKDAOHT*S8:@UN.5Q[ G/$PXU
MV:DTC8-"ITKZ=)[B7VTRYIKH5]I;V004D1,F?7<V?!7&W%DK#C)OB6;1H*P
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M!U#^A?\7ST/.?O/_ 5!+ 0(4 Q0    ( (>+<5P23XIT2@,  )0+   *
M          "  0    !E>#(S+3$N:'1M4$L! A0#%     @ AXMQ7,L9SL2,
M!P  '2\   H              ( !<@,  &5X,S$M,2YH=&U02P$"% ,4
M" "'BW%<K-QC484'   ,,   "@              @ $F"P  97@S,2TR+FAT
M;5!+ 0(4 Q0    ( (>+<5QYS8!<9 0  *D2   *              "  =,2
M  !E>#,R+3$N:'1M4$L! A0#%     @ AXMQ7*LUB&IA!   :1,   H
M         ( !7Q<  &5X,S(M,BYH=&U02P$"% ,4    " "'BW%<2IAH;-G1
M  #"]P  "P              @ 'H&P  9FEN7S P,2YJ<&=02P$"% ,4
M" "'BW%<0@C.*[5# @!.2!  #               @ 'J[0  9F]R;3$P+6LN
M:'1M4$L! A0#%     @ AXMQ7+Z%PN$$5@  \&(  !               ( !
MR3$# &9O<FTQ,"UK7S P,2YJ<&=02P$"% ,4    " "'BW%<1,$RZL0\  "[
M4@  $               @ '[AP, 9F]R;3$P+6M?,# R+FIP9U!+ 0(4 Q0
M   ( (>+<5RR:MXR[#L  "A.   0              "  >W$ P!F;W)M,3 M
M:U\P,#,N:G!G4$L! A0#%     @ AXMQ7/9FRV@Y4   \5T  !
M     ( !!P$$ &9O<FTQ,"UK7S P-"YJ<&=02P$"% ,4    " "'BW%<IZ?Y
MG1AO   V>   $               @ %N400 9F]R;3$P+6M?,# U+FIP9U!+
M 0(4 Q0    ( (>+<5R[7;[OCB4  ! T   0              "  ;3 ! !F
M;W)M,3 M:U\P,#8N:G!G4$L! A0#%     @ AXMQ7)-H*#**'@  U"@  !
M             ( !<.8$ &9O<FTQ,"UK7S P-RYJ<&=02P$"% ,4    " "'
MBW%<S\K4$5J>  "&S@  $               @ $H!04 9F]R;3$P+6M?,# X
M+FIP9U!+ 0(4 Q0    ( (>+<5QJU! F7UT  ')\   0              "
M ;"C!0!F;W)M,3 M:U\P,#DN:G!G4$L! A0#%     @ AXMQ7'%1-Q=;#
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M,#(U,3(S,5]L86(N>&UL4$L! A0#%     @ AXMQ7/E(YDC51   4'$$ !4
M             ( !W9\& '1E;&\M,C R-3$R,S%?<')E+GAM;%!+!08
.%0 5  0%  #EY 8    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:TELO="http://telomirpharma.com/20251231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="telo-20251231.xsd" xlink:type="simple"/>
    <context id="From2025-01-01to2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-03-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
        </entity>
        <period>
            <instant>2026-03-12</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2024-02-122024-02-13_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-12</startDate>
            <endDate>2024-02-13</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-13_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-13</instant>
        </period>
    </context>
    <context id="AsOf2025-11-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
        </entity>
        <period>
            <instant>2025-11-20</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_MiralogxLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">TELO:MiralogxLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-08-11_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-11</instant>
        </period>
    </context>
    <context id="From2025-05-262025-05-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
        </entity>
        <period>
            <startDate>2025-05-26</startDate>
            <endDate>2025-05-27</endDate>
        </period>
    </context>
    <context id="From2025-05-272025-05-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
        </entity>
        <period>
            <startDate>2025-05-27</startDate>
            <endDate>2025-05-27</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-05-182025-05-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
        </entity>
        <period>
            <startDate>2025-05-18</startDate>
            <endDate>2025-05-19</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
        </entity>
        <period>
            <instant>2025-05-19</instant>
        </period>
    </context>
    <context id="AsOf2025-05-19_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-19</instant>
        </period>
    </context>
    <context id="From2025-05-202025-05-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
        </entity>
        <period>
            <startDate>2025-05-20</startDate>
            <endDate>2025-05-20</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-07-31_custom_BayshorefinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:BayshorefinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-15_custom_BayShoreTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:BayShoreTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-15</instant>
        </period>
    </context>
    <context id="AsOf2024-09-24_custom_StarwoodTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:StarwoodTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-24</instant>
        </period>
    </context>
    <context id="From2024-12-092024-12-09_custom_StarwoodTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:StarwoodTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-09</startDate>
            <endDate>2024-12-09</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-09_custom_StarwoodTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:StarwoodTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-09</instant>
        </period>
    </context>
    <context id="From2024-12-092024-12-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
        </entity>
        <period>
            <startDate>2024-12-09</startDate>
            <endDate>2024-12-09</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-02-04_custom_TeliPharmaceuticalsIncMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">TELO:TeliPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-04</instant>
        </period>
    </context>
    <context id="From2026-02-042026-02-04_custom_LicenseAgreementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TELO:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-04</startDate>
            <endDate>2026-02-04</endDate>
        </period>
    </context>
    <context id="From2026-02-042026-02-04_custom_TeliPharmaceuticalsIncMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">TELO:TeliPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-04</startDate>
            <endDate>2026-02-04</endDate>
        </period>
    </context>
    <context id="From2026-02-042026-02-04_custom_TelomirOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">TELO:TelomirOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-04</startDate>
            <endDate>2026-02-04</endDate>
        </period>
    </context>
    <context id="From2026-02-042026-02-04_custom_PhaseOneByTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">TELO:PhaseOneByTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-04</startDate>
            <endDate>2026-02-04</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_MiralogxLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:MiralogxLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_MiralogxLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:MiralogxLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TampaFloridaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">TELO:TampaFloridaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-02-132024-02-13_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-13</startDate>
            <endDate>2024-02-13</endDate>
        </period>
    </context>
    <context id="From2025-02-142025-02-14_custom_AtTheMarketOfferingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TELO:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-14</startDate>
            <endDate>2025-02-14</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_AtTheMarketOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">TELO:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_AtTheMarketOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">TELO:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-05-192025-05-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
        </entity>
        <period>
            <startDate>2025-05-19</startDate>
            <endDate>2025-05-19</endDate>
        </period>
    </context>
    <context id="From2025-07-242025-07-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
        </entity>
        <period>
            <startDate>2025-07-24</startDate>
            <endDate>2025-07-24</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-07-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PlacementAgentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TELO:PlacementAgentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-11-22_custom_BayShoreTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:BayShoreTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-22</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_BayShoreTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:BayShoreTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-12-012024-12-31_custom_BayShoreTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:BayShoreTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-29_us-gaap_IPOMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="AsOf2024-02-29_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwoThousandTwentyThreeOmnibusIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TELO:TwoThousandTwentyThreeOmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_CommonStockMember_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_UnderwriterWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">TELO:UnderwriterWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember17385937">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_WarrantMember17385953">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_BayShoreTrustWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TELO:BayShoreTrustWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_TwoThousandTwentyThreePrivatePlacementWarrantsMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TELO:TwoThousandTwentyThreePrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_BayShoreTrustWarrantsMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TELO:BayShoreTrustWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_UnderwriterWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TELO:UnderwriterWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">TELO:UnderwriterWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">TELO:UnderwriterWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="AsOf2024-02-29_custom_UnderwriterWarrantMember_custom_MeasurementInputFairMarketValueUnderlyingCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">TELO:MeasurementInputFairMarketValueUnderlyingCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">TELO:UnderwriterWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">TELO:UnderwriterWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">TELO:UnderwriterWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_MayThirteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">TELO:MayThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_MayThirteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">TELO:MayThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_MayTwentySevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">TELO:MayTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_MayTwentySevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">TELO:MayTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_OctoberFifteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">TELO:OctoberFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_OctoberFifteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">TELO:OctoberFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2025-01-01to2025-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2025-01-01to2025-12-31" id="Fact000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2025-01-01to2025-12-31" id="Fact000005">0001971532</dei:EntityCentralIndexKey>
    <TELO:DueToOfficer
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0096"
      unitRef="USD"
      xsi:nil="true"/>
    <TELO:AccruedCompensation
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0099"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0113"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0114"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0132"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0133"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0163"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0164"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TravelAndEntertainmentExpense
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0172"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0184"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0206"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0213"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0215"
      unitRef="USD"
      xsi:nil="true"/>
    <TELO:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0220"
      unitRef="USD"
      xsi:nil="true"/>
    <TELO:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0222"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0227"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0229"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0232"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0233"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0237"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0244"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0251"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0253"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0258"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0260"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0265"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0272"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0274"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0282"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProvisionForOtherCreditLosses
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0314"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDueToOtherRelatedParties
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <TELO:IncreaseDecreaseInAccruedCompensation
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0341"
      unitRef="USD"
      xsi:nil="true"/>
    <TELO:ProceedsFromRepaymentsOfOfficer
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <TELO:ProceedsFromSaleOfCommonStockRelatedParty
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <TELO:DeferredOfferingCostsChargedToAdditionalPaidinCapital
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0380"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TravelAndEntertainmentExpense
      contextRef="From2025-01-012025-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0509"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:VariableLeaseCost
      contextRef="From2025-01-012025-12-31_custom_MiralogxLLCMember"
      id="xdx2ixbrl0527"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseCost
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0535"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:VariableLeaseCost
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0538"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LeaseCost
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0541"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl0610"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl0628"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember17385953"
      id="xdx2ixbrl0630"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember17385953"
      id="xdx2ixbrl0632"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2025-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl0640"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      id="xdx2ixbrl0702"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0762"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0782"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0790"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0798"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0843"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0844"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0846"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0847"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0849"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0850"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0858"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0861"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0863"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0864"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0866"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0867"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0895"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2025-01-01to2025-12-31" id="Fact000013">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2025-01-01to2025-12-31" id="Fact000014">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2025-01-01to2025-12-31" id="Fact000015">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2025-01-01to2025-12-31" id="Fact000016">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2025-01-01to2025-12-31" id="Fact000017">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2025-01-01to2025-12-31" id="Fact000018">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2025-01-01to2025-12-31" id="Fact000019">001-41952</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2025-01-01to2025-12-31" id="Fact000020">Telomir Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2025-01-01to2025-12-31" id="Fact000021">FL</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2025-01-01to2025-12-31" id="Fact000022">85-3354547</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2025-01-01to2025-12-31" id="Fact000023">100 SE 2nd St</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2025-01-01to2025-12-31" id="Fact000024">Suite 200 #1009</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2025-01-01to2025-12-31" id="Fact000025">Miami</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2025-01-01to2025-12-31" id="Fact000026">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2025-01-01to2025-12-31" id="Fact000027">33131</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2025-01-01to2025-12-31" id="Fact000028">786</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2025-01-01to2025-12-31" id="Fact000029">396-6723</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2025-01-01to2025-12-31" id="Fact000030">Common stock,     no par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2025-01-01to2025-12-31" id="Fact000031">TELO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2025-01-01to2025-12-31" id="Fact000032">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2025-01-01to2025-12-31" id="Fact000033">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2025-01-01to2025-12-31" id="Fact000034">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2025-01-01to2025-12-31" id="Fact000035">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2025-01-01to2025-12-31" id="Fact000036">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2025-01-01to2025-12-31" id="Fact000037">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2025-01-01to2025-12-31" id="Fact000038">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2025-01-01to2025-12-31" id="Fact000039">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2025-01-01to2025-12-31" id="Fact000040">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="From2025-01-01to2025-12-31" id="Fact000042">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2025-01-01to2025-12-31" id="Fact000044">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2025-01-01to2025-12-31" id="Fact000046">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2025-06-30"
      decimals="-5"
      id="Fact000048"
      unitRef="USD">18100000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2026-03-12"
      decimals="INF"
      id="Fact000050"
      unitRef="Shares">34380971</dei:EntityCommonStockSharesOutstanding>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000054">&lt;b&gt;&lt;span id="a_006"&gt;&lt;/span&gt;Item 1C. Cybersecurity.&lt;/b&gt;&#160;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We recognize the importance of assessing, identifying,
and managing material risks associated with cybersecurity threats, as such term is defined in Item 106(a) of Regulation S-K. These risks
include, among other things: operational risks, intellectual property theft, fraud, extortion, harm to employees and violation of data
privacy or security laws.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_z6pWW8gNJ48d"&gt;Identifying and assessing cybersecurity risk
is integrated into our overall risk management systems and processes.&lt;/span&gt; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20250101__20251231_zCY4SzqjJQ56"&gt;Cybersecurity risks related to our business, technical operations,
privacy and compliance issues are identified and addressed through a multi-faceted approach including third party assessments, internal
IT Audit, IT security, governance, risk and compliance reviews. To defend, detect and respond to cybersecurity incidents, we, among other
things: conduct proactive privacy and cybersecurity reviews of systems and applications, audit applicable data, conduct employee training,
monitor emerging laws and regulations related to data protection and information security and implement appropriate changes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_903_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20250101__20251231_zUUz7GzxCRYh"&gt;Our risk management program also assesses third
party risks, and we perform third-party risk management to identify and mitigate risks from third parties such as vendors, suppliers,
and other business partners associated with our use of third-party service providers.&lt;/span&gt; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90C_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20250101__20251231_zoG6IEFrmC26"&gt;Cybersecurity risks are evaluated when determining
the selection and oversight of applicable third-party service providers and potential fourth-party risks when handling and/or processing
our employee, business or customer data.&lt;/span&gt;&lt;/p&gt;

&#160;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="From2025-01-01to2025-12-31" id="Fact000055">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000056">Cybersecurity risks related to our business, technical operations,
privacy and compliance issues are identified and addressed through a multi-faceted approach including third party assessments, internal
IT Audit, IT security, governance, risk and compliance reviews. To defend, detect and respond to cybersecurity incidents, we, among other
things: conduct proactive privacy and cybersecurity reviews of systems and applications, audit applicable data, conduct employee training,
monitor emerging laws and regulations related to data protection and information security and implement appropriate changes.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="From2025-01-01to2025-12-31" id="Fact000057">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="From2025-01-01to2025-12-31" id="Fact000058">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <TELO:NoInsiderTradingFlag contextRef="From2025-01-01to2025-12-31" id="Fact000060">true</TELO:NoInsiderTradingFlag>
    <dei:AuditorFirmId contextRef="From2025-01-01to2025-12-31" id="Fact000062">106</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2025-01-01to2025-12-31" id="Fact000064">SALBERG &amp; COMPANY, P.A.</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2025-01-01to2025-12-31" id="Fact000066">Boca Raton, Florida</dei:AuditorLocation>
    <us-gaap:Cash
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000074"
      unitRef="USD">7286670</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000075"
      unitRef="USD">1266131</us-gaap:Cash>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000077"
      unitRef="USD">54691</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000078"
      unitRef="USD">57874</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000080"
      unitRef="USD">7341361</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000081"
      unitRef="USD">1324005</us-gaap:AssetsCurrent>
    <us-gaap:Assets
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000083"
      unitRef="USD">7341361</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000084"
      unitRef="USD">1324005</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000092"
      unitRef="USD">536769</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000093"
      unitRef="USD">587536</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <TELO:DueToOfficer
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000095"
      unitRef="USD">155518</TELO:DueToOfficer>
    <TELO:AccruedCompensation
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000098"
      unitRef="USD">417470</TELO:AccruedCompensation>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000101"
      unitRef="USD">318234</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000102"
      unitRef="USD">93432</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000104"
      unitRef="USD">1427991</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000105"
      unitRef="USD">680968</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000107"
      unitRef="USD">1427991</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000108"
      unitRef="USD">680968</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000116"
      unitRef="USDPShares">0</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000118"
      unitRef="USDPShares">0</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000120"
      unitRef="Shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000122"
      unitRef="Shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000124"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000126"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000128"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000130"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000135"
      unitRef="USDPShares">0</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000137"
      unitRef="USDPShares">0</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000139"
      unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000141"
      unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000143"
      unitRef="Shares">34380971</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000145"
      unitRef="Shares">34380971</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000147"
      unitRef="Shares">29762671</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000149"
      unitRef="Shares">29762671</us-gaap:CommonStockSharesIssued>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000151"
      unitRef="USD">46923433</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000152"
      unitRef="USD">31239895</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000154"
      unitRef="USD">-41010063</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000155"
      unitRef="USD">-30596858</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000157"
      unitRef="USD">5913370</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000158"
      unitRef="USD">643037</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000160"
      unitRef="USD">7341361</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000161"
      unitRef="USD">1324005</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000169"
      unitRef="USD">8103280</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000170"
      unitRef="USD">9636333</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:TravelAndEntertainmentExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000173"
      unitRef="USD">370500</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000175"
      unitRef="USD">2435569</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000176"
      unitRef="USD">2235341</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000178"
      unitRef="USD">10538849</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000179"
      unitRef="USD">12242174</us-gaap:OperatingExpenses>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000181"
      unitRef="USD">125644</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000182"
      unitRef="USD">48000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000185"
      unitRef="USD">4338542</us-gaap:InterestExpenseNonoperating>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000187"
      unitRef="USD">-10413205</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000188"
      unitRef="USD">-16532716</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000190"
      unitRef="USDPShares">-0.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000192"
      unitRef="USDPShares">-0.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000194"
      unitRef="USDPShares">-0.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000196"
      unitRef="USDPShares">-0.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000198"
      unitRef="Shares">31653094</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000200"
      unitRef="Shares">31653094</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000202"
      unitRef="Shares">29539219</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000204"
      unitRef="Shares">29539219</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000211"
      unitRef="Shares">28609814</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000207"
      unitRef="USD">17502346</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000208"
      unitRef="USD">-14064142</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000209"
      unitRef="USD">3438204</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000218"
      unitRef="Shares">1142857</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000214"
      unitRef="USD">6832973</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000216"
      unitRef="USD">6832973</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <TELO:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000225"
      unitRef="Shares">10000</TELO:StockIssuedDuringPeriodSharesWarrantsExercised>
    <TELO:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000221"
      unitRef="USD">37300</TELO:StockIssuedDuringPeriodValueWarrantsExercised>
    <TELO:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000223"
      unitRef="USD">37300</TELO:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000228"
      unitRef="USD">6867276</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000230"
      unitRef="USD">6867276</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000234"
      unitRef="USD">-16532716</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000235"
      unitRef="USD">-16532716</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000242"
      unitRef="Shares">29762671</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000238"
      unitRef="USD">31239895</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000239"
      unitRef="USD">-30596858</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000240"
      unitRef="USD">643037</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000249"
      unitRef="Shares">29762671</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000245"
      unitRef="USD">31239895</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000246"
      unitRef="USD">-30596858</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000247"
      unitRef="USD">643037</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000256"
      unitRef="Shares">3218300</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000252"
      unitRef="USD">6553209</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000254"
      unitRef="USD">6553209</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000263"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000259"
      unitRef="USD">3000000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000261"
      unitRef="USD">3000000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000270"
      unitRef="Shares">400000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000266"
      unitRef="USD">840000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000268"
      unitRef="USD">840000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000273"
      unitRef="USD">5290329</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000275"
      unitRef="USD">5290329</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000279"
      unitRef="USD">-10413205</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000280"
      unitRef="USD">-10413205</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000287"
      unitRef="Shares">34380971</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000283"
      unitRef="USD">46923433</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000284"
      unitRef="USD">-41010063</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000285"
      unitRef="USD">5913370</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000294"
      unitRef="Shares">34380971</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000290"
      unitRef="USD">46923433</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000291"
      unitRef="USD">-41010063</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000292"
      unitRef="USD">5913370</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000299"
      unitRef="USD">-10413205</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000300"
      unitRef="USD">-16532716</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000305"
      unitRef="USD">5290329</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000306"
      unitRef="USD">6867276</us-gaap:ShareBasedCompensation>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000308"
      unitRef="USD">840000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:ProvisionForOtherCreditLosses
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000312"
      unitRef="USD">130000</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000315"
      unitRef="USD">4338543</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000320"
      unitRef="USD">-3183</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000321"
      unitRef="USD">57160</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000323"
      unitRef="USD">-50767</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000324"
      unitRef="USD">183629</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDueToOtherRelatedParties
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000326"
      unitRef="USD">224802</us-gaap:IncreaseDecreaseInDueToOtherRelatedParties>
    <TELO:IncreaseDecreaseInAccruedCompensation
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000329"
      unitRef="USD">417470</TELO:IncreaseDecreaseInAccruedCompensation>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000332"
      unitRef="USD">-3688188</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000333"
      unitRef="USD">-5070428</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000339"
      unitRef="USD">101000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000342"
      unitRef="USD">-433945</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <TELO:ProceedsFromRepaymentsOfOfficer
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000344"
      unitRef="USD">155518</TELO:ProceedsFromRepaymentsOfOfficer>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000348"
      unitRef="USD">37300</us-gaap:ProceedsFromWarrantExercises>
    <TELO:ProceedsFromSaleOfCommonStockRelatedParty
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000350"
      unitRef="USD">3000000</TELO:ProceedsFromSaleOfCommonStockRelatedParty>
    <TELO:ProceedsFromSaleOfCommonStock
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000353"
      unitRef="USD">6553209</TELO:ProceedsFromSaleOfCommonStock>
    <TELO:ProceedsFromSaleOfCommonStock
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000354"
      unitRef="USD">6832973</TELO:ProceedsFromSaleOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000356"
      unitRef="USD">9708727</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000357"
      unitRef="USD">6335328</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000359"
      unitRef="USD">6020539</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000360"
      unitRef="USD">1264900</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000362"
      unitRef="USD">1266131</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000363"
      unitRef="USD">1231</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000365"
      unitRef="USD">7286670</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000366"
      unitRef="USD">1266131</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <TELO:DeferredOfferingCostsChargedToAdditionalPaidinCapital
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000381"
      unitRef="USD">303281</TELO:DeferredOfferingCostsChargedToAdditionalPaidinCapital>
    <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000383">&lt;p id="xdx_805_eus-gaap--BusinessDescriptionAndAccountingPoliciesTextBlock_zk8HENW6SSVc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 1. &lt;span id="xdx_82B_zhM3PaX6UYEd"&gt;Description of business and summary
of significant accounting policies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zcyNcuoCf5Wk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zEHeuZaF5tl"&gt;Overview&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Telomir Pharmaceuticals, Inc.
(&#x201c;Telomir&#x201d; or the &#x201c;Company&#x201d;) was formed in August 2021 and is a Florida-incorporated pre-clinical stage
biotechnology company developing therapies designed to target the root epigenetic mechanisms underlying cancer, aging, and
degenerative disease. The Company&#x2019;s lead candidate, Telomir-1, has demonstrated activity in preclinical studies involving
modulation of DNA and histone methylation patterns, which may contribute to balanced gene expression, cellular function, and genomic
stability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Telomir-1 is a novel oral small molecule metal
ion regulator designed to extend telomere caps, maintain cellular balance, and combat oxidative stress, a key driver of aging and disease
progression. By modulating essential metal ions such as iron, and copper, Telomir-1 may help protect against age related conditions,
including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson&#x2019;s disease (a genetic disorder leading
to toxic copper buildup in the body), and Age-related Macular Degeneration (AMD), as well as Type 2 diabetes, breast cancer, and Alzheimer&#x2019;s
disease.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As used herein, the Company&#x2019;s common stock,
no par value per share, is referred to as the &#x201c;Common Stock&#x201d; and the Company&#x2019;s preferred stock, no par value per share,
is referred to as the &#x201c;Preferred Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_ecustom--InitialPublicOfferingPolicyTextBlock_zBngH3MgXwqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zOe80Bfe0g8l"&gt;Initial public offering&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 13, 2024, the Company closed its
initial public offering (the &#x201c;IPO&#x201d;) consisting of &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240212__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zXhzjf4GcOrg" title="IPO units, shares"&gt;1,000,000&lt;/span&gt; shares of Common Stock at a price of $&lt;span id="xdx_908_eus-gaap--SharePrice_iI_c20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zXACQWFfZiP9" title="Initial public offering shares"&gt;7.00&lt;/span&gt; per share for approximately
$&lt;span id="xdx_904_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20240212__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zwLJpZMWDhe6" title="Gross proceeds"&gt;7.0&lt;/span&gt; million in gross proceeds. After deducting the underwriting commission and other offering expenses totaling $&lt;span id="xdx_90D_eus-gaap--OtherUnderwritingExpense_pn5n6_c20240212__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z7zUzOHXJlkl" title="Underwriting commission and other offering expenses"&gt;1.2&lt;/span&gt; million, the net
proceeds to the Company were $&lt;span id="xdx_904_ecustom--ProceedsFromInitialPublicOfferingNetProceeds_pn5n6_c20240212__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zACg2SryjJub" title="Initial public offering net proceeds"&gt;5.8&lt;/span&gt; million. The Common Stock began trading on The Nasdaq Capital Market on February 9, 2024 under the
symbol &#x201c;TELO&#x201d; (See Note 7 &#x201c;Common Stock&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--ProposedMergerPolicyTextBlock_zcv5hFANvy8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zDrtsOS9yay7"&gt;Proposed merger&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;The Company and TELI Pharmaceuticals, Inc., a related party private
company incorporated under the laws of Delaware (&#x201c;TELI&#x201d;) have entered into an Agreement and Plan of Merger and Reorganization,
dated November 20, 2025, and as amended on February 4, 2026 (collectively, the &#x201c;Merger Agreement&#x201d;), pursuant to which a wholly
owned subsidiary of Telomir will merge with and into TELI, with TELI surviving as a wholly owned subsidiary of Telomir (the &#x201c;Merger&#x201d;),
subject to shareholder approval. At the effective time of the Merger (the &#x201c;Effective Time&#x201d;), each outstanding share of common
stock of TELI, $&lt;span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251120_zJCp5dWMrgqf" title="Common stock, par value"&gt;0.0001&lt;/span&gt; par value per share (&#x201c;TELI Common Stock&#x201d;), will be converted into the right to receive such number
of Telomir Common Stock as is calculated based on the exchange ratio of the shares for the Merger (the &#x201c;Exchange Ratio&#x201d;).
The Exchange Ratio is calculated using the relative company valuations of each of Telomir and TELI, as determined by a third-party valuation
firm (as further described herein). It is expected that shareholders of TELI will receive one share of Telomir Common Stock for each
share of TELI Common Stock held (the &#x201c;Merger Share Consideration&#x201d;). The Telomir Common Stock issued as the consideration
will not be registered for trading under the Securities Act. The Merger will result in an alignment of U.S. and non-U.S. rights to Telomir-1
within a single public company structure, thereby simplifying global development and partnership efforts. As a result of the Merger,
TELO will own the entire worldwide intellectual property portfolio and development programs related to Telomir-1. See Note 5, &lt;i&gt;Merger
Agreement.&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zAoI6yYkHcLg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zmlQbeYRYKj2"&gt;Revenue recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company currently has no source of revenue.
Miscellaneous income, including interest, is recognized when earned by the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_z8RxvchywP9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zntlUZHp0BVf"&gt;Income taxes&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for income taxes pursuant
to the provision of Accounting Standards Codification (&#x201c;ASC&#x201d;) 740-10, &#x201c;Accounting for Income Taxes&#x201d; (&#x201c;ASC
740-10&#x201d;), which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and
liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary
differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any
net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company follows the provision of&#160;ASC
740-10&#160;related to Accounting for Uncertain Income Tax Positions. When tax returns are filed, there may be uncertainty about the
merits of positions taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of&#160;ASC
740-10, the benefit of a tax position is recognized in the consolidated financial statements in the period during which, based on all
available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the
resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions
that meet the more likely than not recognition threshold are measured at the largest amount of tax benefit that is more than&#160;50&#160;percent
likely of being realized upon settlement with the applicable taxing authority. The portion of the benefit associated with tax positions
taken that exceed the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying
balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The
Company believes its tax positions are all more likely than not to be upheld upon examination. As such, the Company has not recorded
a liability for uncertain tax benefits.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has adopted&#160;ASC 740-10-25, &#x201c;Definition
of Settlement&#x201d;, which provides guidance on how an entity should determine whether a tax position is effectively settled for the
purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion
and examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity
would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based
solely on the basis of its technical merits and the statute of limitations remains open. The federal and state income tax returns of
the Company are subject to examination by the IRS and state taxing authorities, generally for three years after they are filed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_z3CMQ6zURrRb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zIeIdv2Cy7zk"&gt;Research and development expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Research and development costs are expensed in
the period in which they are incurred and include the expenses paid to third parties, such as contract research organizations and consultants,
who conduct research and development activities on behalf of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--UseOfEstimates_zi4qYvdAfKF7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zoZkUJLUcC3k"&gt;Use of estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of financial statements in accordance
with generally accepted accounting principles in the United States of America requires the Company&#x2019;s management to make estimates
and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at
the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results may differ from
such estimates and such differences could be material. Significant estimates during the reporting periods include stock-based compensation
and the deferred tax asset valuation allowance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zhNPo926zCNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zEIO4qLaV7S4"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company considers all highly liquid debt
instruments and other short-term investments with maturities of three months or less, when purchased, to be cash equivalents. The Company
maintains cash and cash equivalent balances at two financial institutions that are insured by the Federal Deposit Insurance Corporation
(&#x201c;FDIC&#x201d;). The Company&#x2019;s accounts at these institutions are insured by the FDIC up to $&lt;span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_c20251231_zhzTq8QqQ3Ih" title="Cash insured amount"&gt;250,000&lt;/span&gt;. On December 31, 2025
and 2024, the Company had cash in excess of FDIC limits of approximately $&lt;span id="xdx_907_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20251231_zYb8zhGQf1Lg" title="Cash, Uninsured Amount"&gt;7.0&lt;/span&gt; million and $&lt;span id="xdx_902_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20241231_z5LbG5jXtJD5" title="Cash, Uninsured Amount"&gt;1.0&lt;/span&gt; million, respectively. To reduce its risk
associated with the failure of such financial institution, the Company evaluates at least annually the rating of the financial institution
in which it holds deposits. Any material loss that the Company may experience in the future could have an adverse effect on its ability
to pay its operational expenses or make other payments and may require the Company to move its cash to other high quality financial institutions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zwFZJoo8kq0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_z0OyzotJZQx9"&gt;Stock-based compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for stock-based compensation
under the provisions of FASB&#160;ASC 718, &#x201c;Compensation - Stock Compensation&#x201d;, which requires the measurement and recognition
of compensation expense for all stock-based awards made to employees, directors and consultants based on estimated fair values on the
grant date. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value
of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the
straight-line method. The Company has elected to account for forfeitures of stock-based awards as they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zdeiGi41SuNj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_znF1qK7olRO9"&gt;Fair Value Measurements and Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company measures the fair value of financial
instruments in accordance with GAAP which defines fair value, establishes a framework for measuring fair value, and expands disclosures
about fair value measurements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;GAAP defines fair value as the exchange price
that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for
the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes a fair value
hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring
fair value. GAAP describes three levels of inputs that may be used to measure fair value:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Level 1 &#x2013; quoted prices
in active markets for identical assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Level 2 &#x2013; quoted prices
for similar assets and liabilities in active markets or inputs that are observable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Level 3 &#x2013; inputs that
are unobservable (for example cash flow modeling inputs based on assumptions).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company considers the carrying amount of
prepaid assets and all current liabilities to approximate fair value due to the short-term nature of those elements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zWfpQBLGwnH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zO7MsxX3Q3zd"&gt;Earnings per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Earnings (loss) per share is computed in accordance
with ASC Topic 260, &#x201c;Earnings per Share&#x201d; Basic weighted-average number of shares of common stock outstanding for the year
ended December 31, 2025 and December 31, 2024 include the shares of the Company issued and outstanding during such period, on a weighted
average basis. The basic weighted average number of shares of common stock outstanding excludes common stock equivalents such as stock
options and warrants, while diluted weighted average number of shares outstanding includes such stock options and warrants. As of December
31, 2025 there were &lt;span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zY1vFKjEfDHj" title="Antidilutive securities excluded from computation of earnings per share"&gt;2,814,057&lt;/span&gt; common stock warrants and &lt;span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zAjoxzE3nv6e" title="Antidilutive securities excluded from computation of earnings per share"&gt;4,187,670&lt;/span&gt; common stock options that were not included in the computation of diluted
earnings per share, because to do so would have an antidilutive effect. As of December 31, 2024 there were &lt;span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zDJUG8wNt7E6" title="Antidilutive securities excluded from computation of earnings per share"&gt;2,814,057&lt;/span&gt; stock warrants and
&lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z6tprkC9Tt49" title="Antidilutive securities excluded from computation of earnings per share"&gt;2,352,670&lt;/span&gt; stock options that were not included in the computation of diluted earnings per share, because to do so would have an antidilutive
effect.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_ecustom--RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_zBRaUZBi3TX9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zqWhF34cwIFb"&gt;Recent accounting pronouncements not yet
adopted&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2023, the FASB issued ASU 2023-09,
&lt;i&gt;Income Taxes (Topic 740) - Improvements to Income Tax Disclosures&lt;/i&gt;. The new standard requires a company to expand its existing
income tax disclosures, specifically related to the rate reconciliation and income taxes paid. The standard is effective for the Company
beginning in fiscal year 2025. The Company applied the amendments prospectively for the year ended December 31, 2025, and the impact
of the adoption of the amendments in this update was not material to the Company&#x2019;s financial position and results of operations
for the year ended December 31, 2025, since the amendments require only enhancement of existing income tax disclosures in the footnotes
to the Company&#x2019;s financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In November 2024, the FASB issued ASU 2024-03,&#160;&lt;i&gt;Income
Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures&#160;&lt;/i&gt;(Subtopic 220-40), which requires entities to provide
more detailed disaggregation of expenses in the income statement, focusing on the nature of the expenses rather than their function.
The new disclosures will require entities to separately present expenses for significant line items, including but not limited to, depreciation,
amortization, and employee compensation. Entities will also be required to provide a qualitative description of the amounts remaining
in relevant expense captions that are not separately disaggregated quantitatively, disclose the total amount of selling expenses and,
in annual reporting periods, provide a definition of what constitutes selling expenses. This pronouncement is effective for fiscal years
beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted.
The Company does not expect the adoption of this new guidance to have a material impact on the consolidated financial statements.&lt;/p&gt;

&lt;p id="xdx_857_zsBX1Un9Bvc4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000385">&lt;p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zcyNcuoCf5Wk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zEHeuZaF5tl"&gt;Overview&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Telomir Pharmaceuticals, Inc.
(&#x201c;Telomir&#x201d; or the &#x201c;Company&#x201d;) was formed in August 2021 and is a Florida-incorporated pre-clinical stage
biotechnology company developing therapies designed to target the root epigenetic mechanisms underlying cancer, aging, and
degenerative disease. The Company&#x2019;s lead candidate, Telomir-1, has demonstrated activity in preclinical studies involving
modulation of DNA and histone methylation patterns, which may contribute to balanced gene expression, cellular function, and genomic
stability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Telomir-1 is a novel oral small molecule metal
ion regulator designed to extend telomere caps, maintain cellular balance, and combat oxidative stress, a key driver of aging and disease
progression. By modulating essential metal ions such as iron, and copper, Telomir-1 may help protect against age related conditions,
including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson&#x2019;s disease (a genetic disorder leading
to toxic copper buildup in the body), and Age-related Macular Degeneration (AMD), as well as Type 2 diabetes, breast cancer, and Alzheimer&#x2019;s
disease.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As used herein, the Company&#x2019;s common stock,
no par value per share, is referred to as the &#x201c;Common Stock&#x201d; and the Company&#x2019;s preferred stock, no par value per share,
is referred to as the &#x201c;Preferred Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <TELO:InitialPublicOfferingPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000387">&lt;p id="xdx_84D_ecustom--InitialPublicOfferingPolicyTextBlock_zBngH3MgXwqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zOe80Bfe0g8l"&gt;Initial public offering&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 13, 2024, the Company closed its
initial public offering (the &#x201c;IPO&#x201d;) consisting of &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240212__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zXhzjf4GcOrg" title="IPO units, shares"&gt;1,000,000&lt;/span&gt; shares of Common Stock at a price of $&lt;span id="xdx_908_eus-gaap--SharePrice_iI_c20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zXACQWFfZiP9" title="Initial public offering shares"&gt;7.00&lt;/span&gt; per share for approximately
$&lt;span id="xdx_904_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20240212__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zwLJpZMWDhe6" title="Gross proceeds"&gt;7.0&lt;/span&gt; million in gross proceeds. After deducting the underwriting commission and other offering expenses totaling $&lt;span id="xdx_90D_eus-gaap--OtherUnderwritingExpense_pn5n6_c20240212__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z7zUzOHXJlkl" title="Underwriting commission and other offering expenses"&gt;1.2&lt;/span&gt; million, the net
proceeds to the Company were $&lt;span id="xdx_904_ecustom--ProceedsFromInitialPublicOfferingNetProceeds_pn5n6_c20240212__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zACg2SryjJub" title="Initial public offering net proceeds"&gt;5.8&lt;/span&gt; million. The Common Stock began trading on The Nasdaq Capital Market on February 9, 2024 under the
symbol &#x201c;TELO&#x201d; (See Note 7 &#x201c;Common Stock&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</TELO:InitialPublicOfferingPolicyTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-02-122024-02-13_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000389"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2024-02-13_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000391"
      unitRef="USDPShares">7.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2024-02-122024-02-13_us-gaap_IPOMember"
      decimals="-5"
      id="Fact000393"
      unitRef="USD">7000000.0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:OtherUnderwritingExpense
      contextRef="From2024-02-122024-02-13_us-gaap_IPOMember"
      decimals="-5"
      id="Fact000395"
      unitRef="USD">1200000</us-gaap:OtherUnderwritingExpense>
    <TELO:ProceedsFromInitialPublicOfferingNetProceeds
      contextRef="From2024-02-122024-02-13_us-gaap_IPOMember"
      decimals="-5"
      id="Fact000397"
      unitRef="USD">5800000</TELO:ProceedsFromInitialPublicOfferingNetProceeds>
    <TELO:ProposedMergerPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000399">&lt;p id="xdx_84E_ecustom--ProposedMergerPolicyTextBlock_zcv5hFANvy8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zDrtsOS9yay7"&gt;Proposed merger&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;The Company and TELI Pharmaceuticals, Inc., a related party private
company incorporated under the laws of Delaware (&#x201c;TELI&#x201d;) have entered into an Agreement and Plan of Merger and Reorganization,
dated November 20, 2025, and as amended on February 4, 2026 (collectively, the &#x201c;Merger Agreement&#x201d;), pursuant to which a wholly
owned subsidiary of Telomir will merge with and into TELI, with TELI surviving as a wholly owned subsidiary of Telomir (the &#x201c;Merger&#x201d;),
subject to shareholder approval. At the effective time of the Merger (the &#x201c;Effective Time&#x201d;), each outstanding share of common
stock of TELI, $&lt;span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251120_zJCp5dWMrgqf" title="Common stock, par value"&gt;0.0001&lt;/span&gt; par value per share (&#x201c;TELI Common Stock&#x201d;), will be converted into the right to receive such number
of Telomir Common Stock as is calculated based on the exchange ratio of the shares for the Merger (the &#x201c;Exchange Ratio&#x201d;).
The Exchange Ratio is calculated using the relative company valuations of each of Telomir and TELI, as determined by a third-party valuation
firm (as further described herein). It is expected that shareholders of TELI will receive one share of Telomir Common Stock for each
share of TELI Common Stock held (the &#x201c;Merger Share Consideration&#x201d;). The Telomir Common Stock issued as the consideration
will not be registered for trading under the Securities Act. The Merger will result in an alignment of U.S. and non-U.S. rights to Telomir-1
within a single public company structure, thereby simplifying global development and partnership efforts. As a result of the Merger,
TELO will own the entire worldwide intellectual property portfolio and development programs related to Telomir-1. See Note 5, &lt;i&gt;Merger
Agreement.&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</TELO:ProposedMergerPolicyTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-11-20"
      decimals="INF"
      id="Fact000401"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000403">&lt;p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zAoI6yYkHcLg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zmlQbeYRYKj2"&gt;Revenue recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company currently has no source of revenue.
Miscellaneous income, including interest, is recognized when earned by the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000405">&lt;p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_z8RxvchywP9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zntlUZHp0BVf"&gt;Income taxes&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for income taxes pursuant
to the provision of Accounting Standards Codification (&#x201c;ASC&#x201d;) 740-10, &#x201c;Accounting for Income Taxes&#x201d; (&#x201c;ASC
740-10&#x201d;), which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and
liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary
differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any
net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company follows the provision of&#160;ASC
740-10&#160;related to Accounting for Uncertain Income Tax Positions. When tax returns are filed, there may be uncertainty about the
merits of positions taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of&#160;ASC
740-10, the benefit of a tax position is recognized in the consolidated financial statements in the period during which, based on all
available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the
resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions
that meet the more likely than not recognition threshold are measured at the largest amount of tax benefit that is more than&#160;50&#160;percent
likely of being realized upon settlement with the applicable taxing authority. The portion of the benefit associated with tax positions
taken that exceed the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying
balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The
Company believes its tax positions are all more likely than not to be upheld upon examination. As such, the Company has not recorded
a liability for uncertain tax benefits.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has adopted&#160;ASC 740-10-25, &#x201c;Definition
of Settlement&#x201d;, which provides guidance on how an entity should determine whether a tax position is effectively settled for the
purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion
and examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity
would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based
solely on the basis of its technical merits and the statute of limitations remains open. The federal and state income tax returns of
the Company are subject to examination by the IRS and state taxing authorities, generally for three years after they are filed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2025-01-01to2025-12-31" id="Fact000407">&lt;p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_z3CMQ6zURrRb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zIeIdv2Cy7zk"&gt;Research and development expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Research and development costs are expensed in
the period in which they are incurred and include the expenses paid to third parties, such as contract research organizations and consultants,
who conduct research and development activities on behalf of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:UseOfEstimates contextRef="From2025-01-01to2025-12-31" id="Fact000409">&lt;p id="xdx_84A_eus-gaap--UseOfEstimates_zi4qYvdAfKF7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zoZkUJLUcC3k"&gt;Use of estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of financial statements in accordance
with generally accepted accounting principles in the United States of America requires the Company&#x2019;s management to make estimates
and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at
the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results may differ from
such estimates and such differences could be material. Significant estimates during the reporting periods include stock-based compensation
and the deferred tax asset valuation allowance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000411">&lt;p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zhNPo926zCNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zEIO4qLaV7S4"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company considers all highly liquid debt
instruments and other short-term investments with maturities of three months or less, when purchased, to be cash equivalents. The Company
maintains cash and cash equivalent balances at two financial institutions that are insured by the Federal Deposit Insurance Corporation
(&#x201c;FDIC&#x201d;). The Company&#x2019;s accounts at these institutions are insured by the FDIC up to $&lt;span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_c20251231_zhzTq8QqQ3Ih" title="Cash insured amount"&gt;250,000&lt;/span&gt;. On December 31, 2025
and 2024, the Company had cash in excess of FDIC limits of approximately $&lt;span id="xdx_907_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20251231_zYb8zhGQf1Lg" title="Cash, Uninsured Amount"&gt;7.0&lt;/span&gt; million and $&lt;span id="xdx_902_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20241231_z5LbG5jXtJD5" title="Cash, Uninsured Amount"&gt;1.0&lt;/span&gt; million, respectively. To reduce its risk
associated with the failure of such financial institution, the Company evaluates at least annually the rating of the financial institution
in which it holds deposits. Any material loss that the Company may experience in the future could have an adverse effect on its ability
to pay its operational expenses or make other payments and may require the Company to move its cash to other high quality financial institutions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000413"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact000415"
      unitRef="USD">7000000.0</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000417"
      unitRef="USD">1000000.0</us-gaap:CashUninsuredAmount>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2025-01-01to2025-12-31" id="Fact000419">&lt;p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zwFZJoo8kq0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_z0OyzotJZQx9"&gt;Stock-based compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for stock-based compensation
under the provisions of FASB&#160;ASC 718, &#x201c;Compensation - Stock Compensation&#x201d;, which requires the measurement and recognition
of compensation expense for all stock-based awards made to employees, directors and consultants based on estimated fair values on the
grant date. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value
of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the
straight-line method. The Company has elected to account for forfeitures of stock-based awards as they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2025-01-01to2025-12-31" id="Fact000421">&lt;p id="xdx_84B_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zdeiGi41SuNj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_znF1qK7olRO9"&gt;Fair Value Measurements and Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company measures the fair value of financial
instruments in accordance with GAAP which defines fair value, establishes a framework for measuring fair value, and expands disclosures
about fair value measurements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;GAAP defines fair value as the exchange price
that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for
the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes a fair value
hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring
fair value. GAAP describes three levels of inputs that may be used to measure fair value:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Level 1 &#x2013; quoted prices
in active markets for identical assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Level 2 &#x2013; quoted prices
for similar assets and liabilities in active markets or inputs that are observable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Level 3 &#x2013; inputs that
are unobservable (for example cash flow modeling inputs based on assumptions).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company considers the carrying amount of
prepaid assets and all current liabilities to approximate fair value due to the short-term nature of those elements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000423">&lt;p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zWfpQBLGwnH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zO7MsxX3Q3zd"&gt;Earnings per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Earnings (loss) per share is computed in accordance
with ASC Topic 260, &#x201c;Earnings per Share&#x201d; Basic weighted-average number of shares of common stock outstanding for the year
ended December 31, 2025 and December 31, 2024 include the shares of the Company issued and outstanding during such period, on a weighted
average basis. The basic weighted average number of shares of common stock outstanding excludes common stock equivalents such as stock
options and warrants, while diluted weighted average number of shares outstanding includes such stock options and warrants. As of December
31, 2025 there were &lt;span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zY1vFKjEfDHj" title="Antidilutive securities excluded from computation of earnings per share"&gt;2,814,057&lt;/span&gt; common stock warrants and &lt;span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zAjoxzE3nv6e" title="Antidilutive securities excluded from computation of earnings per share"&gt;4,187,670&lt;/span&gt; common stock options that were not included in the computation of diluted
earnings per share, because to do so would have an antidilutive effect. As of December 31, 2024 there were &lt;span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zDJUG8wNt7E6" title="Antidilutive securities excluded from computation of earnings per share"&gt;2,814,057&lt;/span&gt; stock warrants and
&lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z6tprkC9Tt49" title="Antidilutive securities excluded from computation of earnings per share"&gt;2,352,670&lt;/span&gt; stock options that were not included in the computation of diluted earnings per share, because to do so would have an antidilutive
effect.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000425"
      unitRef="Shares">2814057</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000427"
      unitRef="Shares">4187670</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000429"
      unitRef="Shares">2814057</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000431"
      unitRef="Shares">2352670</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <TELO:RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000433">&lt;p id="xdx_846_ecustom--RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_zBRaUZBi3TX9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zqWhF34cwIFb"&gt;Recent accounting pronouncements not yet
adopted&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2023, the FASB issued ASU 2023-09,
&lt;i&gt;Income Taxes (Topic 740) - Improvements to Income Tax Disclosures&lt;/i&gt;. The new standard requires a company to expand its existing
income tax disclosures, specifically related to the rate reconciliation and income taxes paid. The standard is effective for the Company
beginning in fiscal year 2025. The Company applied the amendments prospectively for the year ended December 31, 2025, and the impact
of the adoption of the amendments in this update was not material to the Company&#x2019;s financial position and results of operations
for the year ended December 31, 2025, since the amendments require only enhancement of existing income tax disclosures in the footnotes
to the Company&#x2019;s financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In November 2024, the FASB issued ASU 2024-03,&#160;&lt;i&gt;Income
Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures&#160;&lt;/i&gt;(Subtopic 220-40), which requires entities to provide
more detailed disaggregation of expenses in the income statement, focusing on the nature of the expenses rather than their function.
The new disclosures will require entities to separately present expenses for significant line items, including but not limited to, depreciation,
amortization, and employee compensation. Entities will also be required to provide a qualitative description of the amounts remaining
in relevant expense captions that are not separately disaggregated quantitatively, disclose the total amount of selling expenses and,
in annual reporting periods, provide a definition of what constitutes selling expenses. This pronouncement is effective for fiscal years
beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted.
The Company does not expect the adoption of this new guidance to have a material impact on the consolidated financial statements.&lt;/p&gt;

</TELO:RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000435">&lt;p id="xdx_802_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zLT3LOnHb4Dc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 2. &lt;span&gt;&lt;span id="xdx_82B_zKAs4dlBKZTk"&gt;Going Concern&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying financial statements have been
prepared assuming the Company will continue as a going concern which contemplates the realization of assets and settlement of liabilities
and commitments in the normal course of business.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025, the Company had cash of approximately $&lt;span id="xdx_905_eus-gaap--Cash_iI_pn5n6_c20251231_zbwqPtCpZZU4" title="Cash"&gt;7.3&lt;/span&gt; million. The Company raised approximately $&lt;span id="xdx_907_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250101__20251231_zdUdRSVqKBCb" title="Raised amount"&gt;9.6&lt;/span&gt; million in 2025, used
approximately $&lt;span id="xdx_90D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20250101__20251231_zUkOpn2Azphl" title="Cash in operations"&gt;3.7&lt;/span&gt; million of cash in operations during the year ended December 31, 2025, had a net loss of $&lt;span id="xdx_90D_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20250101__20251231_zIMI4waMEKYc" title="Net Loss"&gt;10.4&lt;/span&gt; million in 2025 and
had stockholders&#x2019; equity of approximately $&lt;span id="xdx_903_eus-gaap--StockholdersEquity_iI_pn5n6_c20251231_zMNVUjpEMC28" title="Stockholders equity"&gt;5.9&lt;/span&gt; million at December 31, 2025, versus stockholders&#x2019; equity of approximately
$&lt;span id="xdx_905_eus-gaap--StockholdersEquity_iI_pn5n6_c20241231_zvZDwnTwCI6j" title="Stockholders equity"&gt;0.6&lt;/span&gt; million at December 31, 2024.&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Historically, the Company has been primarily
engaged in developing Telomir-1. During these activities, the Company sustained substantial losses. The Company&#x2019;s ability to fund
ongoing operations and future clinical trials required for FDA approval is dependent on the Company&#x2019;s ability to obtain significant
additional external funding in the near term. Since inception, the Company has financed its operations through related party financings-see
Note 4, an initial public offering &#x2013; see Note 1, and ATM financings. Additional sources of financing may be sought by the Company.
However, there can be no assurance that any fundraising will be achieved on commercially reasonable terms, if at all.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of the date of filing this Annual Report,
the Company will continue to generate losses and have insufficient cash and cash equivalents on hand to support its operations for at
least the 12 months following the date the financial statements are issued. These factors raise substantial doubt about the Company&#x2019;s
ability to continue as a going concern for a period of twelve months from the issuance date of this report. Management cannot provide
assurance that the Company will ultimately achieve profitable operations or become cash flow positive or raise additional debt and/or
equity capital. The Company is seeking to raise capital through additional debt and/or equity financings to fund our operations in the
future. If the Company is unable to raise additional capital or secure additional lending in the near future, management expects that
the Company will need to curtail its operations. These financial statements do not include any adjustments related to the recoverability
and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to
continue as a going concern.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:Cash
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact000437"
      unitRef="USD">7300000</us-gaap:Cash>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2025-01-01to2025-12-31"
      decimals="-5"
      id="Fact000439"
      unitRef="USD">9600000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-01to2025-12-31"
      decimals="-5"
      id="Fact000441"
      unitRef="USD">-3700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="-5"
      id="Fact000443"
      unitRef="USD">-10400000</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact000445"
      unitRef="USD">5900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000447"
      unitRef="USD">600000</us-gaap:StockholdersEquity>
    <TELO:LicenseAgreementRelatedPartyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000449">&lt;p id="xdx_80A_ecustom--LicenseAgreementRelatedPartyTextBlock_zuHDf3ShNRIe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 3. &lt;span id="xdx_821_zX0Qk8kWsmkc"&gt;License agreement, related party&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company licenses the U.S. patent rights for
the use of Telomir-1 in human applications from MIRALOGX, LLC (&#x201c;MIRALOGX&#x201d;), an intellectual property development and holding
company owned by a trust established by the Company&#x2019;s founder&#x2014;a related party to the Company and greater than &lt;span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MiralogxLLCMember_zN1c5biwwgt7" title="Ownership percentage"&gt;10&lt;/span&gt;% shareholder.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 11, 2023, (the &#x201c;Effective Date&#x201d;),
the Company and MIRALOGX entered into an Amended and Restated Exclusive License Agreement, under which the Company has the exclusive
perpetual right and license under the above-described patent rights to make, have made, use, and sell &#x201c;Licensed Products&#x201d;
in the U.S. for human uses and preclinical studies and activities of any kind conducted in furtherance of obtaining regulatory approval
or commercialization for human uses (the &#x201c;MIRALOGX License Agreement&#x201d;). On November 10, 2023, the Company and MIRALOGX entered
into the Amendment No. 1 to the Amended and Restated License Agreement, pursuant to which the field of use relating to the license was
amended to include therapeutic treatments and other medical or health uses in animals, in addition to humans, and related preclinical
studies and activities conducted in furtherance of obtaining regulatory approval for and commercialization of veterinary, in addition
to human, therapeutic treatments and uses (together with the &#x201c;Initial MIRALOGX License Agreement, the &#x201c;MIRALOGX License Agreement&#x201d;).
&#x201c;Licensed Product&#x201d; is defined in the agreement as a drug product containing as an active agent 2,4,6-tris(3,4-dihydro-2H-pyrrol-2-yl)
pyridine or a pharmaceutically acceptable salt, ester, or solvate thereof. The Company also has the right to grant corresponding sublicenses
under the licensed patent rights. The MIRALOGX License Agreement provides for the payment to MIRALOGX of an &lt;span id="xdx_90D_ecustom--PercentageOfRoyaltyPayable_iI_dp_uPure_c20230811__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zmwA0puwMBQ1" title="Percentage of royalty payable"&gt;8&lt;/span&gt;% royalty (payable quarterly)
on the Company&#x2019;s net sales of Licensed Products by the Company or its sublicensees and on non-royalty bearing milestone revenue.
There are no up-front, execution, or milestone payments in the license agreement. Further, no payments have been made to date under the
agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The term of the license from MIRALOGX will continue
through the date of the expiration of the last-to-expire licensed patent or, if later, the date of the expiration of the last strategic
partnership/sublicensing agreement covering the licensed products. The patent rights are expected to extend through 2043, and additional
patent terms may be awarded, including additional patent terms based on the time taken for regulatory review of drug products.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The agreement also provides that Telomir may
bring suit in its own name to enforce patent rights. MIRALOGX will control the prosecution of the patent applications for Telomir-1.
Telomir is required to be kept informed by MIRALOGX of patent prosecution activities and may select identified countries for patent protection.
Telomir is to reimburse MIRALOGX for patent prosecution and maintenance costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</TELO:LicenseAgreementRelatedPartyTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2025-12-31_custom_MiralogxLLCMember"
      decimals="INF"
      id="Fact000451"
      unitRef="Pure">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <TELO:PercentageOfRoyaltyPayable
      contextRef="AsOf2023-08-11_us-gaap_RelatedPartyMember"
      decimals="INF"
      id="Fact000453"
      unitRef="Pure">0.08</TELO:PercentageOfRoyaltyPayable>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000455">&lt;p id="xdx_80C_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zFCAYHHwfmG9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 4. &lt;span id="xdx_82F_z0B6Wg15XUX9"&gt;Related parties balances and transactions&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Due to Officer&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 27, 2025, &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250526__20250527_zxEPbzG6hY5b" title="Issuance of common stock for services, shares"&gt;400,000&lt;/span&gt; fully vested common
shares were granted for services to our Chairman and Chief Executive Officer, Erez Aminov, who is the son-in-law of Jonnie R. Williams
(see below). The shares were valued at $&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250527__20250527_zz3hgQpaTP0f" title="Vested common shares service, value"&gt;840,000&lt;/span&gt; based on the stock quoted trading price at the grant date and were expensed immediately
as compensation expense. In December 2025, Mr. Aminov transferred $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentRepurchaseAmount_iI_c20251231_zijLWuntQxUk" title="Debt Instrument, Repurchase Amount"&gt;155,518&lt;/span&gt; to the Company, for the Company to use to pay certain payroll
withholding taxes Mr. Aminov owed as a result of this RSU grant. These payroll taxes ultimately were not paid in the Company&#x2019;s
payroll processing. Therefore, in January 2026, $&lt;span id="xdx_903_eus-gaap--AccruedPayrollTaxesCurrentAndNoncurrent_iI_c20260131_zWxdXEoGZr1a" title="Payroll taxes"&gt;155,518&lt;/span&gt; was paid back to Mr. Aminov so he can remit this amount directly to the IRS.
The company, however, did remit the employer portion of his Medicare taxes totaling $&lt;span id="xdx_909_eus-gaap--TaxesOther_c20250101__20251231_zknPUSYV97d8" title="Medicare taxes"&gt;12,180&lt;/span&gt; in 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Due from related parties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2023, the
Company provided working capital advances to companies under common control. These advances were due on demand and are non-interest bearing.
Amounts due from related parties as of December 31, 2023 were $&lt;span id="xdx_903_eus-gaap--OtherReceivablesNetCurrent_iI_pn4n6_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zto98vd8Jmj5" title="Amounts due from related parties"&gt;0.13&lt;/span&gt;&#160;million. In 2024, the company under common control was dissolved
and therefore the amount due become uncollectable and was written off and reflected as credit loss expense, which is included in general
and administration expenses. As of December 31, 2024, there was&#160;&lt;span id="xdx_90D_eus-gaap--OtherReceivables_iI_do_c20241231_zvqs9AyY7Eu9" title="Amount due from related parties"&gt;no&lt;/span&gt;&#160;amount due from related parties.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Due to related parties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2024, the
Company received working capital advances from related party companies under common control. These advances are due on demand and are
non-interest bearing. During the year ended December 31, 2025, a related party, MIRALOGX, shipped pharmaceutical chemicals to Telomir&#x2019;s
service provider for ongoing research at a cost of approximately $&lt;span id="xdx_907_eus-gaap--CostsAndExpensesRelatedParty_c20250101__20251231_zq3bixHxPxQ8" title="Costs and Expenses, Related Party"&gt;224,800&lt;/span&gt;. As of December 31, 2025 and 2024, the amounts due to related
parties is $&lt;span id="xdx_906_eus-gaap--OtherReceivablesNetCurrent_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zlX3PKC7d4s3" title="Amount due from related parties"&gt;318,234&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--OtherReceivablesNetCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zH3M4OpdHLYe" title="Amount due from related parties"&gt;93,432&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Investment from Largest Shareholder&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 19, 2025, the Company entered into an
agreement to raise $&lt;span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn6n6_c20250518__20250519_zV85LNB5zcn6" title="Raised amount in equity financing"&gt;3&lt;/span&gt; million in equity financing through a direct investment by The Bayshore Trust, an entity affiliated with the Company&#x2019;s
largest shareholder, Jonnie R. Williams, Sr. The transaction was structured as a straight restricted common stock deal with no warrants.
The Company issued &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20250518__20250519_zF4UueDlZZk2" title="Number of restricted shares issued"&gt;333,334&lt;/span&gt; restricted shares of its common stock, no par value (the &#x201c;Common Stock&#x201d;) at a purchase price of
$&lt;span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20250519_zEGG0u3gJf6g" title="Purchase price per share"&gt;3.00&lt;/span&gt; per share, representing an &lt;span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardPriceOfCommonStockPercent_pid_dp_uPure_c20250518__20250519_zWjL1lsVjamd" title="Premium share price percentage"&gt;18&lt;/span&gt;% premium to the closing share price of the Common Stock of $&lt;span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20250519__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNI76Ln9ibDj" title="Purchase price per share"&gt;2.54&lt;/span&gt; on the date of execution (the &#x201c;Bayshore
Financing&#x201d;). The Company received the initial payment of $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn6n6_c20250520__20250520_zfPI6521hmyb" title="Initial payment"&gt;1&lt;/span&gt; million for the Bayshore Financing on May 20, 2025. In July 2025, an
additional $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn6n6_c20250701__20250731__dei--LegalEntityAxis__custom--BayshorefinancingMember_zXpPCvPz7jLg" title="Initial payment"&gt;2&lt;/span&gt; million was received, for the issuance of &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250701__20250731__dei--LegalEntityAxis__custom--BayshorefinancingMember_zc5JH9hKDeke" title="Issuance of common stock for cash in ATM, net, shares"&gt;666,666&lt;/span&gt; shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Bay Shore Trust Line of Credit &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 15, 2023, the Company entered into a
Promissory Note and Loan Agreement with the Bay Shore Trust, a trust established by the Company&#x2019;s founder, Jonnie R. Williams,
Sr., and under which various of his family members are beneficiaries. Under this Promissory Note and Loan Agreement (the &#x201c;Bay Shore
Note&#x201d;), the Company had the right to borrow up to an aggregate of $&lt;span id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zFFmnsa4vjAf" title="Unused line of credit"&gt;5&lt;/span&gt; million from the Bay Shore Trust at any time up to the second
anniversary of the issuance of the Bay Shore Note or, if earlier, upon the completion of the Company&#x2019;s IPO. As of December 31,
2025 and 2024, the line of credit is no longer available as the IPO was completed in February 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In consideration of the loan facility provided
by the Bay Shore Trust, the Company issued to the Bay Shore Trust a Common Stock purchase warrant on June 15, 2023 giving the Bay Shore
Trust the right to purchase up to &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zrdGKXcSPqfa" title="Fair value of total warrants issued"&gt;2,439,025&lt;/span&gt; shares of Common Stock at an exercise price of $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zl6v0E13OVr5" title="Exercise price"&gt;3.73&lt;/span&gt; per share (See Note 7).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Starwood Trust Line of Credit and Stock
Purchase Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 24, 2024 the Company entered into
an unsecured Promissory Note and Loan Agreement (&#x201c;the Starwood Note&#x201d;) with the Starwood Trust, a separate related party trust
established by the Company&#x2019;s founder, Jonnie R. Williams, Sr. who is the sole owner of Bay Shore Trust as well as our largest shareholder,
and under which various of his family members are beneficiaries. Under the Starwood Note, the Company has the right to borrow up to an
aggregate of $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20240924__dei--LegalEntityAxis__custom--StarwoodTrustMember_ziLnTzY1SvH" title="Aggregate borrowings amount"&gt;5&lt;/span&gt;&#160;million from the Starwood Trust at any time up until September 24, 2026, the second anniversary of the note. The
Company&#x2019;s right to borrow funds under the Starwood Note is subject to the absence of a material adverse change in its assets, operations,
or prospects The Starwood Note contains default provisions in which in the event of the Company misses payment, makes false representations,
fails to comply in any material respect to covenants, files for bankruptcy, or experiences a material adverse change in is assets or
operations than the Company is considered in default and the entire unpaid principal and accrued interest is due immediately. The Starwood
Note, together with accrued interest, is to become due and payable on the second anniversary of the issuance of the note, provides for
prepayment at any time without penalty, and accrues simple interest at a rate equal&#160;&lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240924__dei--LegalEntityAxis__custom--StarwoodTrustMember_zAYufrXDzly9" title="Interest rate"&gt;7&lt;/span&gt;% per annum. As of December 31, 2025 and 2024,
the Company has not borrowed any amounts under the Starwood Note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Further, on December 9, 2024, Starwood Trust
entered into a stock purchase agreement with the Company to purchase &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241209__20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_zUI8d2yFppZk" title="Issuance of common stock, net, shares"&gt;142,857&lt;/span&gt; shares of unregistered common stock at $&lt;span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_zCYpV9BNajWd" title="Share price"&gt;7&lt;/span&gt; a share for a
total of $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20241209__20241209_zzG7EfP120ib" title="Proceeds from common stock"&gt;1.0&lt;/span&gt; million in proceeds to the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;License agreement&lt;/i&gt; - &lt;/b&gt;See Note 3&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Related Party Travel Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 1, 2023 the Company entered into an
Agreement For Shared Lease Costs (the &#x201c;Shared Agreement&#x201d;) with MIRALOGX, LLC, a related party under which we have agreed
to pay our pro rata share of the operating usage costs owing by MIRALOGX under an aircraft lease agreement between MIRALOGX and Supera
Aviation I LLC (&#x201c;Supera Aviation&#x201d;) based on our usage of the leased aircraft each month. No amounts are payable by the Company
under this agreement unless and to the extent the Company chooses to utilize the leased aircraft, and the Company may discontinue the
use of the aircraft and terminate this agreement at any time. Supera Aviation is a company owned by Starwood Trust, a trust established
by Mr. Williams, the Company&#x2019;s founder and largest shareholder. For the year ended December 31, 2025 and December 31, 2024, the
Company incurred &lt;span id="xdx_90C_eus-gaap--TravelAndEntertainmentExpense_dxL_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zm7D8mwFSaHg" title="Related party travel costs::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0509"&gt;nil&lt;/span&gt;&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--TravelAndEntertainmentExpense_pn4n6_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zJQAQorqVN5l" title="Related party travel costs"&gt;0.37&lt;/span&gt; million, respectively, in expenses under the aircraft lease agreement. The aircraft lease was terminated
in April 2024 and no other costs have been incurred under this agreement since the lease termination (See Note 6 Variable lease costs).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Related Party Rental Agreement&lt;/i&gt;&lt;/b&gt;&lt;i&gt;-&lt;/i&gt;
see Note 6 for Variable lease costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2025-05-262025-05-27"
      decimals="INF"
      id="Fact000457"
      unitRef="Shares">400000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-05-272025-05-27"
      decimals="0"
      id="Fact000459"
      unitRef="USD">840000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000461"
      unitRef="USD">155518</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:AccruedPayrollTaxesCurrentAndNoncurrent
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000463"
      unitRef="USD">155518</us-gaap:AccruedPayrollTaxesCurrentAndNoncurrent>
    <us-gaap:TaxesOther
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000465"
      unitRef="USD">12180</us-gaap:TaxesOther>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="-4"
      id="Fact000467"
      unitRef="USD">130000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivables
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000469"
      unitRef="USD">0</us-gaap:OtherReceivables>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000471"
      unitRef="USD">224800</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000473"
      unitRef="USD">318234</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000475"
      unitRef="USD">93432</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="From2025-05-182025-05-19"
      decimals="-6"
      id="Fact000477"
      unitRef="USD">3000000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2025-05-182025-05-19"
      decimals="INF"
      id="Fact000479"
      unitRef="Shares">333334</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2025-05-19"
      decimals="INF"
      id="Fact000481"
      unitRef="USDPShares">3.00</us-gaap:SharesIssuedPricePerShare>
    <TELO:SharebasedCompensationArrangementBySharebasedPaymentAwardPriceOfCommonStockPercent
      contextRef="From2025-05-182025-05-19"
      decimals="INF"
      id="Fact000483"
      unitRef="Pure">0.18</TELO:SharebasedCompensationArrangementBySharebasedPaymentAwardPriceOfCommonStockPercent>
    <us-gaap:SharePrice
      contextRef="AsOf2025-05-19_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000485"
      unitRef="USDPShares">2.54</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2025-05-202025-05-20"
      decimals="-6"
      id="Fact000487"
      unitRef="USD">1000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2025-07-012025-07-31_custom_BayshorefinancingMember"
      decimals="-6"
      id="Fact000489"
      unitRef="USD">2000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-07-012025-07-31_custom_BayshorefinancingMember"
      decimals="INF"
      id="Fact000491"
      unitRef="Shares">666666</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2023-06-15_custom_BayShoreTrustMember"
      decimals="-6"
      id="Fact000493"
      unitRef="USD">5000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-06-15_custom_BayShoreTrustMember"
      decimals="INF"
      id="Fact000495"
      unitRef="Shares">2439025</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-06-15_custom_BayShoreTrustMember"
      decimals="INF"
      id="Fact000497"
      unitRef="USDPShares">3.73</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-09-24_custom_StarwoodTrustMember"
      decimals="-6"
      id="Fact000499"
      unitRef="USD">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-09-24_custom_StarwoodTrustMember"
      decimals="INF"
      id="Fact000501"
      unitRef="Pure">0.07</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-12-092024-12-09_custom_StarwoodTrustMember"
      decimals="INF"
      id="Fact000503"
      unitRef="Shares">142857</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2024-12-09_custom_StarwoodTrustMember"
      decimals="INF"
      id="Fact000505"
      unitRef="USDPShares">7</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-12-092024-12-09"
      decimals="-5"
      id="Fact000507"
      unitRef="USD">1000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:TravelAndEntertainmentExpense
      contextRef="From2024-01-012024-12-31_us-gaap_RelatedPartyMember"
      decimals="-4"
      id="Fact000511"
      unitRef="USD">370000</us-gaap:TravelAndEntertainmentExpense>
    <TELO:ProposedMergerAgreementDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000513">&lt;p id="xdx_802_ecustom--ProposedMergerAgreementDisclosureTextBlock_zHCyNwcpprFi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 5. &lt;span id="xdx_824_z4AiPPcQ1D69"&gt;Proposed Merger Agreement&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company and TELI Pharmaceuticals, Inc., a
related party private company incorporated under the laws of Delaware (&#x201c;TELI&#x201d;) have entered into an Agreement and Plan of
Merger and Reorganization, dated November 20, 2025, and as amended on February 4, 2026 (collectively, the &#x201c;Merger Agreement&#x201d;),
pursuant to which a wholly owned subsidiary of Telomir will merge with and into TELI, with TELI surviving as a wholly owned subsidiary
of Telomir (the &#x201c;Merger&#x201d;), subject to shareholder approval. At the effective time of the Merger (the &#x201c;Effective Time&#x201d;),
each outstanding share of common stock of TELI, $&lt;span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20260204__us-gaap--BusinessAcquisitionAxis__custom--TeliPharmaceuticalsIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zynZBUfk5HZ4" title="Common stock, par value"&gt;0.0001&lt;/span&gt; par value per share (&#x201c;TELI Common Stock&#x201d;), will be converted into
the right to receive such number of Telomir Common Stock as is calculated based on the exchange ratio of the shares for the Merger (the
&#x201c;Exchange Ratio&#x201d;). The Exchange Ratio is calculated using the relative company valuations of each of Telomir and TELI, as
determined by an independent valuation firm. It is expected that shareholders of TELI will receive one share of Telomir Common Stock
for each share of TELI Common Stock held (the &#x201c;Merger Share Consideration&#x201d;). The Telomir Common Stock issued as the consideration
will not be registered for trading under the Securities Act. The Merger will result in an alignment of U.S. and non-U.S. rights to Telomir-1
within a single public company structure, thereby simplifying global development and partnership efforts. As a result of the Merger,
Telomir will own the entire worldwide intellectual property portfolio and development programs related to Telomir-1.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The transaction is expected to be recorded
as an asset acquisition from a related party at acquired cost basis with two assets to be acquired, the license agreement and
$&lt;span id="xdx_903_eus-gaap--PaymentsToAcquireMarketableSecurities_c20260204__20260204__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLImq8MQek" title="Cash or marketable securities"&gt;1,000,000&lt;/span&gt; in cash or marketable securities. TELI is a newly formed legal entity with no revenue, no employees, no facilities, and
no infrastructure. TELI&#x2019;s assets as of the Merger Date will consist exclusively of the $&lt;span id="xdx_90D_eus-gaap--PaymentsToAcquireMarketableSecurities_c20260204__20260204__us-gaap--BusinessAcquisitionAxis__custom--TeliPharmaceuticalsIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zEnGKa9sWeca" title="Cash or marketable securities"&gt;1,000,000&lt;/span&gt; in cash or marketable
securities and the Telo-1 license agreement with MIRALOGX. MIRALOGX is the licensor of the Company&#x2019;s and TELI&#x2019;s rights
to Telomir-1. MIRALOGX is a separate intellectual property development company owned by the Bayshore Trust. The Bayshore Trust, a
related party, is also TELI&#x2019;s largest stockholder. The license agreement grants rights to develop and commercialize the
Telomir-1 compound in the United Arab Amirates, Australia, Canada, China, European Union, Israel, India, Japan, South Korea, Mexico,
Argentina, Taiwan and Uruguay. No other tangible or intangible assets, such as equipment, customer relationships, or developed
technologies, will be transferred. The contingent consideration to Telomir in the transaction consists of two possible payments.
Certain shareholders of TELI will agree to provide $&lt;span id="xdx_900_eus-gaap--AssetAcquisitionConsiderationTransferredTransactionCost_pn6n6_c20260204__20260204__us-gaap--AssetAcquisitionAxis__custom--TelomirOneMember_z8MGnuVeLV19" title="Contingent consideration transaction cost"&gt;2&lt;/span&gt; million upon FDA acceptance of an Investigational New Drug or IND application
for Telomir-1, and $&lt;span id="xdx_905_eus-gaap--AssetAcquisitionConsiderationTransferredTransactionCost_pn6n6_c20260204__20260204__us-gaap--AssetAcquisitionAxis__custom--PhaseOneByTwoMember_z7u2ANPLaGZc" title="Contingent consideration transaction cost"&gt;2&lt;/span&gt; million upon initiation of a Phase 1/2 study.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</TELO:ProposedMergerAgreementDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-02-04_custom_TeliPharmaceuticalsIncMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000515"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="From2026-02-042026-02-04_custom_LicenseAgreementMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact000517"
      unitRef="USD">1000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="From2026-02-042026-02-04_custom_TeliPharmaceuticalsIncMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact000519"
      unitRef="USD">1000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost
      contextRef="From2026-02-042026-02-04_custom_TelomirOneMember"
      decimals="-6"
      id="Fact000521"
      unitRef="USD">2000000</us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost>
    <us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost
      contextRef="From2026-02-042026-02-04_custom_PhaseOneByTwoMember"
      decimals="-6"
      id="Fact000523"
      unitRef="USD">2000000</us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000525">&lt;p id="xdx_806_eus-gaap--LesseeOperatingLeasesTextBlock_zawm3LcwKda7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 6. &lt;span id="xdx_827_zNYFHJwCCwq9"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s former corporate headquarters
was located in Baltimore, Maryland, which included a lease for office space. This lease began in November 2022 and expired in April 2024.
The lease was not renewed. To align with the accounting and administrative staff detailed below, the Company moved all remaining corporate
activities in April 2024 to the shared space in Tampa, Florida referenced below within variable lease costs. In September 2024, the Company
decided to no longer utilize the shared space and moved to a virtual office model. The Company has not had a physical office space since
October 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Variable lease costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Variable lease costs primarily include utilities,
property taxes, and other operating costs that are passed on from the lessor for the former corporate headquarters in Baltimore, Maryland.
Variable lease costs related to the usage of the MIRALOGX airplane include usage expenses, which includes pilot expenses, jet fuel and
general flight expenses that totaled &lt;span id="xdx_90B_eus-gaap--VariableLeaseCost_pn6n6_dxL_c20250101__20251231__dei--LegalEntityAxis__custom--MiralogxLLCMember_zlvaIoQgaSDf" title="Variable lease, cost::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0527"&gt;nil&lt;/span&gt;&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--VariableLeaseCost_pn4n6_c20240101__20241231__dei--LegalEntityAxis__custom--MiralogxLLCMember_za7jS8eni2Ya" title="Variable lease, cost"&gt;0.32&lt;/span&gt; million in 2025 and 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Beginning August 1, 2023, the Company&#x2019;s
accounting and administrative staff began sharing office space with a related party in Tampa, Florida. During the year ended December
31, 2024, this variable least cost related to the Tampa, Florida space totaled $&lt;span id="xdx_90E_eus-gaap--VariableLeaseCost_pn4n6_c20240101__20241231__srt--StatementGeographicalAxis__custom--TampaFloridaMember_zOrri1CkaEWa" title="Variable lease, cost"&gt;0.02&lt;/span&gt; million. The Company did not have lease costs during
the year ended December 31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--LeaseCostTableTextBlock_zskfffFPOTjb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The components of lease expense were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B9_zK7BPagaSni4" style="display: none"&gt;Schedule of Components of Lease Expenses&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250101__20251231_zwRyEPX32mg1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20241231_zCUrlNHyobJc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Lease Costs&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Operating lease cost&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseCost_maLCzhnC_zazPIYT7LTdk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; width: 60%; text-align: left"&gt;Operating lease&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0535"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;55,667&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--VariableLeaseCost_maLCzhnC_zMpYOHkOlHZ2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;Variable lease costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0538"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;336,656&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LeaseCost_iT_mtLCzhnC_zK7pGGuKPHIj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total lease cost&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0541"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;392,323&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A3_ziVK133MZsq" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:VariableLeaseCost
      contextRef="From2024-01-012024-12-31_custom_MiralogxLLCMember"
      decimals="-4"
      id="Fact000529"
      unitRef="USD">320000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="From2024-01-012024-12-31_custom_TampaFloridaMember"
      decimals="-4"
      id="Fact000531"
      unitRef="USD">20000.00</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000533">&lt;p id="xdx_899_eus-gaap--LeaseCostTableTextBlock_zskfffFPOTjb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The components of lease expense were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B9_zK7BPagaSni4" style="display: none"&gt;Schedule of Components of Lease Expenses&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250101__20251231_zwRyEPX32mg1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20241231_zCUrlNHyobJc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Lease Costs&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Operating lease cost&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseCost_maLCzhnC_zazPIYT7LTdk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; width: 60%; text-align: left"&gt;Operating lease&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0535"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;55,667&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--VariableLeaseCost_maLCzhnC_zMpYOHkOlHZ2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;Variable lease costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0538"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;336,656&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LeaseCost_iT_mtLCzhnC_zK7pGGuKPHIj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total lease cost&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0541"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;392,323&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000536"
      unitRef="USD">55667</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000539"
      unitRef="USD">336656</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000542"
      unitRef="USD">392323</us-gaap:LeaseCost>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000544">&lt;p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zpCZYr7cerTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 7. &lt;span id="xdx_82F_zzuTRjiR7yRa"&gt;Stockholders&#x2019; equity&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Capital stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has the authority to issue &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20251231_zyEaGWtevQ5h" title="Issue of shares of capital stock"&gt;400,000,000&lt;/span&gt;
shares of capital stock, consisting of &lt;span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20251231_zXm4V5QyRyj7" title="Common stock, shares authorized"&gt;300,000,000&lt;/span&gt; shares of Common Stock and &lt;span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20251231_zsS9Zuo5gk0i" title="Preferred stock, shares authorized"&gt;100,000,000&lt;/span&gt; shares of undesignated preferred stock, whose
rights and privileges will be defined by the Board of Directors when a series of preferred stock is designated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;2024&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 13, 2024, the Company closed its
initial public offering consisting of&#160;&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zFIkIJZIoWd4" title="IPO units, shares"&gt;1,000,000&lt;/span&gt;&#160;shares at a price of $&lt;span id="xdx_909_eus-gaap--SharePrice_iI_pid_c20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zOrVrnwCQq69" title="Initial public offering shares"&gt;7.00&lt;/span&gt;&#160;per share for approximately $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z1XB749cGgB1" title="Gross proceeds"&gt;7.0&lt;/span&gt;&#160;million
in gross proceeds. After deducting the underwriting commission and other offering expenses totaling $&lt;span id="xdx_906_eus-gaap--OtherUnderwritingExpense_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zVJZFYDF1mT8" title="Underwriting commission and other offering expenses"&gt;1.2&lt;/span&gt;&#160;million, the net proceeds
to the Company were $&lt;span id="xdx_90B_ecustom--ProceedsFromInitialPublicOfferingNetProceeds_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zXKv8Ejxtd77" title="Initial public offering net proceeds"&gt;5.8&lt;/span&gt;&#160;million (the &#x201c;IPO&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 9, 2024, Starwood Trust, a related
party, entered into a stock purchase agreement with the Company to purchase &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241209__20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_ztt5AiAA8fJj" title="Purchase of shares"&gt;142,857&lt;/span&gt; shares of unregistered common stock at $&lt;span id="xdx_90B_eus-gaap--SharePrice_iI_c20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_zBepMB3pLAlb" title="Share price"&gt;7&lt;/span&gt; a share
for a total of $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20241209__20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_zyNk5qPycyWh" title="Proceeds from issuance of common stock"&gt;1.0&lt;/span&gt; million in proceeds to the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2024, deferred
offering costs from December 31, 2023 of $&lt;span id="xdx_902_eus-gaap--DeferredOfferingCosts_c20231231_pp0p0" title="Deferred offering costs"&gt;303,281&lt;/span&gt; and offering costs of $&lt;span id="xdx_90D_ecustom--OfferingCosts_iI_pp0p0_c20241231_zIQahD5ePC2j" title="Offering costs"&gt;863,744&lt;/span&gt; incurred in 2024 were charged against additional paid
in capital.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;2025&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 14, 2025, the Company filed a shelf
registration statement with the SEC to facilitate the issuance of our common stock and entered into an At The Market Offering Agreement
(the &#x201c;ATM Agreement&#x201d;) with Rodman &amp;amp; Renshaw LLC under which the Company may offer and sell shares of its Common Stock,
with an aggregate offering amount to be sold of up to $&lt;span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250214__20250214__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zRnOSWCvYyI" title="Aggregate offering amount"&gt;100,000,000&lt;/span&gt;. During the year ended December 31, 2025, the Company sold a total
of &lt;span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250101__20251231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketOfferingMember_zv2tnUE5EyFc" title="Common stock shares"&gt;3,218,300&lt;/span&gt; shares of its common stock, at a weighted average price of $&lt;span id="xdx_90E_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20251231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketOfferingMember_z4mMUSZ6y28l" title="Weighted average price"&gt;2.12&lt;/span&gt; for total proceeds of $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20250101__20251231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketOfferingMember_zpJYUzirq2O6" title="Proceeds from issuance or sale of equity"&gt;6,553,209&lt;/span&gt;, net of costs of $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250101__20251231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketOfferingMember_zYioGZ9vCGB6" title="Proceeds from issuance of common stock"&gt;72,092&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 19, 2025, the Company entered into an
agreement to raise $&lt;span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn6n6_c20250519__20250519_zQYzFXbfvhM7" title="Raised amount in equity financing"&gt;3&lt;/span&gt;&#160;million in equity financing through a direct investment by The Bayshore Trust, an entity affiliated with the
Company&#x2019;s largest shareholder. The transaction was structured as a straight restricted common stock deal with no warrants. The
Company issued&#160;&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20250519__20250519_z4yEpnShA4E8" title="Number of resricted shares issued"&gt;333,334&lt;/span&gt;&#160;restricted shares of its common stock, no par value at a purchase price of $&lt;span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250519_zJZ7ZW1XIfC9" title="Purchase price per share"&gt;3.00&lt;/span&gt;&#160;per share, representing
an&#160;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20250519__20250519_zcF2MfYPlPP7" title="Premium share price percentage"&gt;18&lt;/span&gt;% premium to the closing share price of the Common Stock of $&lt;span id="xdx_90D_eus-gaap--SharePrice_iI_pid_c20250519__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7DclcrM4CRj" title="Share price"&gt;2.54&lt;/span&gt;&#160;on the date of execution (the &#x201c;Bayshore Financing&#x201d;).
The Company received the initial payment of $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn6n6_c20250520__20250520_z5llPktz0U82" title="Initial payment"&gt;1&lt;/span&gt;&#160;million for the Bayshore Financing on May 20, 2025. In July 2025, an additional $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn6n6_c20250724__20250724_zNdiOKqdS4C4" title="Additional payment received"&gt;2&lt;/span&gt;&#160;million
was received, for the issuance of&#160;&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250701__20250731_zvKZmg3wh0Ra" title="Number of shares issued"&gt;666,667&lt;/span&gt;&#160;shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 27, 2025,&#160;&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250527__20250527_zNKJmeF0jMBa" title="Vested common shares service"&gt;400,000&lt;/span&gt;&#160;fully vested
common shares were granted for services to the Company&#x2019;s CEO. The restricted shares were valued at $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250527__20250527_zKcrYhQZDh75" title="Vested common shares service, value"&gt;840,000&lt;/span&gt;&#160;based on the stock
quoted trading price at the grant date and were expensed immediately as compensation expense.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Warrants &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection with various transactions and the
IPO summarized below, the Company issue stock warrants. Warrant activity for the years ended December 31, 2025 and 2024 is summarized
below:&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zbF16ohohb73" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B7_zLWTij5Zc7x3" style="display: none"&gt;Schedule of Warrant Activity&lt;/span&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Remaining Contractual&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Aggregate Intrinsic&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Term (Years)&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 36%"&gt;Outstanding as of December&#160;&#160;31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSgzcXCqO8Bd" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of Warrants Outstanding, Beginning Balance"&gt;2,774,057&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaOWzKyPNL4b" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;4.85&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_zyDrtLyYTlU5" title="Weighted Average Remaining Contractual Term (Years), Outstanding Balance"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;(1)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlO6WbuaHBab" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Aggregate Intrinsic Value, Outstanding Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0610"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zekvfhw65G1d" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Granted"&gt;50,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4VeUTvz9QS6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;7.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdK1dWmryMj4" title="Weighted Average Remaining Contractual Term (Years), Granted"&gt;3.2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;-&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;Exercised&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfY5uuixhkXc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised"&gt;(10,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWfw2ZLktGL9" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;3.73&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding as December 31, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKVUmero7Gj7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants Outstanding, Beginning Balance"&gt;2,814,057&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsO5r9vgaU38" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;4.97&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDIp_zRAzKSd2xari" title="Weighted Average Remaining Contractual Term (Years), Outstanding Balance"&gt;3.49&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;(2)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZVF5Pk3yu4i" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Outstanding Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0628"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsGhpzl8Y4We" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0630"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;Exercised&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbpvVCVaQ5Ea" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0632"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Outstanding as of December 31, 2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zf0wLrTBFHVe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants Outstanding, Ending Balance"&gt;2,814,057&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsfxDR0OeTV7" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance"&gt;4.97&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDIp_z9tUtCU4y52f" title="Weighted Average Remaining Contractual Term (Years), Outstanding Balance"&gt;2.45&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;(2)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3XbuYdeo4mj" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Outstanding Ending Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0640"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 0.25in; padding-bottom: 0pt; text-align: left"&gt;&lt;span id="xdx_F00_zDaoA1QFIxJ3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0pt; text-align: justify"&gt;&lt;span id="xdx_F18_zK8FIGlqJnkb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    warrants herein consist of various contractual terms. The warrants herein consist of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember_zql5MGAc3hig" title="Class of warrants or right number of securities called by warrants or rights"&gt;2,439,025&lt;/span&gt; warrants issued to Bay Shore Trust
    that have a remaining contractual term of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember_zzBNVlLe1s7g" title="Warrants and rights outstanding term"&gt;2.5&lt;/span&gt; years as of December 31, 2025, and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zzKKbMRXLy43" title="Class of warrants or right number of securities called by warrants or rights"&gt;335,032&lt;/span&gt; warrants issued to investors associated
    with the 2023 Private Placement that currently have an indeterminable contractual term. See disclosures below for more information
    on these warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; padding-bottom: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; padding-bottom: 0pt; text-align: left"&gt;&lt;span id="xdx_F0F_zOO4wfwv8DSa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0pt; text-align: justify"&gt;&lt;span id="xdx_F1C_zYWuwkJCT5G5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    warrants herein consist of various contractual terms. The warrants herein consist of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zR74nO7EjC5e" title="Warrants issued"&gt;2,429,025&lt;/span&gt; warrants issued to Bay Shore Trust
    that have a remaining contractual term of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYImeeA0dK1e" title="Warrants remaining contractual term"&gt;2.5&lt;/span&gt; years as of December 31, 2025; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zhi1RrUuEnck" title="Warrants issued"&gt;335,032&lt;/span&gt; warrants issued to investors associated with
    the 2023 Private Placement that currently have an indeterminable contractual term, and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantMember_zNmj2VNvS6hi" title="Warrants issued"&gt;50,000&lt;/span&gt; warrants issued to underwriters as
    part of the IPO with a remaining contractual life of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantMember_zULkKyLPZwji" title="Warrants remaining contractual term"&gt;3.2&lt;/span&gt; years. See disclosures below for more information on these warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A9_zEa452R8zOSh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Private placement Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2023, the
Company issued to the 2023 Private Placement investors a Common Stock warrant the right to purchase up to &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zvc2ULAczpu8" title="Purchase of common stock"&gt;268,025&lt;/span&gt; shares of common stock
at an exercise price of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zATUyVfStDOd" title="Exercise price"&gt;15.42&lt;/span&gt; per share. The Company also issued to the placement agent a Common Stock warrant the right to purchase
up to &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--PlacementAgentMember_z5IeBiA3nDg7" title="Purchase of common stock"&gt;67,007&lt;/span&gt; shares of common stock at an exercise price of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--PlacementAgentMember_zBJlgu0kOCjj" title="Exercise price"&gt;3.73&lt;/span&gt; per share. Both issuances of warrants are immediately vested and will
be exercisable any time until the day that is one year plus ninety days from the date an Investigational New Drug, or IND, filing is
made with the FDA.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Bay Shore Trust Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In consideration of the line of credit provided
by the Bay Shore Trust, the Company issued to the Bay Shore Trust a common stock purchase warrant on June 15, 2023 giving the Bay Shore
Trust the right to purchase up to&#160;&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zizjv4p1mJ92" title="Shares of common stock"&gt;2,439,025&lt;/span&gt;&#160;shares of common stock at an exercise price of $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zGRQwMMfrJ2i" title="Exercise price"&gt;3.73&lt;/span&gt;&#160;per share. This warrant
will expire &lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zsfm4vhTwd01" title="Exercise price"&gt;five years&lt;/span&gt; after the date of grant.. The fair value of the warrants were estimated on the grant date using the Black-Scholes
valuation model and level 3 inputs based on assumptions for expected volatility, expected dividends, expected term, and the risk-free
interest rate, which resulted in $&lt;span id="xdx_90E_eus-gaap--DeferredFinanceCostsNet_iI_pn4n6_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zKLhU6aA3gub" title="Deferred financing costs"&gt;5.95&lt;/span&gt;&#160;million of deferred financing costs. In 2023 this cost was recorded as deferred financing
costs and additional paid in capital on the balance sheet and was amortized straight-line over the term of the line of credit (which
is 24 months). Associated amortization of deferred finance costs was recorded to interest expense on the statement of operations. The
line of credit expired upon the IPO occurring in February 2024, and as such the remaining deferred financing costs associated with the
warrant was fully amortized to interest expense in 2024. As of December 31, 2024, the warrant is fully amortized (see Note 4).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 22, 2024, Bay Shore Trust transferred
&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241122__dei--LegalEntityAxis__custom--BayShoreTrustMember_zdTH8apfOer9" title="Shares of common stock"&gt;100,000&lt;/span&gt; warrants to an unaffiliated party as part of a gift transfer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2024,&#160;&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__dei--LegalEntityAxis__custom--BayShoreTrustMember_zbBwXnGX684" title="Shares of common stock"&gt;10,000&lt;/span&gt; Common Stock warrants
were exercised at an exercise price of $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__dei--LegalEntityAxis__custom--BayShoreTrustMember_zX0XLRJrEzTj" title="Exercise price"&gt;3.73&lt;/span&gt; per share and the Company issued&#160;&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241201__20241231__dei--LegalEntityAxis__custom--BayShoreTrustMember_zHN2GXRElpSg" title="Issuance of common stock"&gt;10,000&lt;/span&gt;&#160;shares of Common Stock upon such exercise
in exchange for $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20241201__20241231__dei--LegalEntityAxis__custom--BayShoreTrustMember_zO1C5Ee8Gzbc" title="Issuance of common stock, value"&gt;37,300&lt;/span&gt; delivered to the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Underwriter warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection with the IPO in February 2024,
the Company issued&#160;&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240229__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqHCIbWDXnpj" title="Warrants to purchase common stock"&gt;50,000&lt;/span&gt;&#160;warrants to purchase Common Stock to the IPO underwriter (or its designees) at an exercise price
of $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240229__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUysGADoXYcf" title="Exercise price"&gt;7.00&lt;/span&gt;&#160;which are exercisable immediately and expire in the four-and-a-half-year period commencing six months after the commencement
of sales in the IPO. The warrants provide for registration rights (including a one-time demand registration right and piggyback registration
rights that expire 5 years from the commencement of sales of the offering) and customary anti-dilution provisions as permitted under
FINRA Rule 5110(g)(8). The fair value of the warrants were estimated on the grant date using the Black-Scholes valuation model and level
3 inputs based on assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate, which resulted
in $&lt;span id="xdx_900_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20240229__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpx3YmSwkfPc" title="Equity issuance cost"&gt;0.2&lt;/span&gt; million of equity issuance costs. The warrants were considered equity issuance costs and therefore there was no financial statement
impact during the year ended December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember_zaEH1wv1i3d7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Key assumptions used to value underwriter warrants in February 2024
are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_8BD_z5zAKzgwTGh4" style="display: none"&gt;Schedule of Key Assumptions Used to Value Warrants&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 50%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; font-size: 10pt"&gt;Expected price volatility&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zNEHZOZqCEgc" title="Warrant measurement input"&gt;84.78&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zTufeFAJ6ks1" title="Warrant measurement input"&gt;4.14&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Fair Market Value of underlying Common Stock&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputFairMarketValueUnderlyingCommonStockMember_zkiSfvatqy75" title="Warrant measurement input"&gt;7.01&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Expected term in years&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_znhy7r5V7c14" title="Expected term in years"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zabaLxhKp6T5" title="Warrant measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0702"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_z1EAasvFtAHa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;2023 Omnibus Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2023, the Company&#x2019;s Board of
Directors adopted the Company&#x2019;s 2023  Omnibus Incentive Plan, (&#x201c;2023  Plan&#x201d;). The 2023  Plan authorizes
the grant of incentive stock options, within the meaning of Section 422 of the Internal Revenue Code, to the Company&#x2019;s employees
and any of its parent and subsidiary corporations&#x2019; employees, and for the grant of nonstatutory stock options, restricted stock,
restricted stock units, stock appreciation rights, performance units and performance shares to the Company&#x2019;s employees, directors,
and consultants and any of its future subsidiary corporations&#x2019; employees and consultants&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The 2023  Plan provides that &lt;span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusIncentivePlanMember_zWDlk1hkVxN6" title="Common stock are reserved for issuance"&gt;6,500,000&lt;/span&gt;
shares of the Company&#x2019;s Common Stock are reserved for issuance under the 2023  Plan, all of which may be issued pursuant
to the exercise of incentive stock options.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock-based compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Stock options&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The vesting period for stock options granted is generally
immediately to one year. All stock options granted under the 2023 Plan have a maximum contractual term of ten years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The grant-date fair value of each option award
is estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility,
expected dividends, expected term, and the risk-free interest rate. In 2024 expected price volatility is based on the historical volatilities
of a peer group as the Company does not have a multi-year trading history for its shares. Industry peers consist of several public companies
in the biotech industry similar to the Company in size, stage of life cycle and product indications. Starting in 2025 expected price
volatility is based solely on the Company&#x2019;s trading history for its common stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Expected term of options granted is derived using
the &#x201c;simplified method&#x201d; which computes expected term as the average of the sum of the vesting term plus contract term. The
risk-free rate is based on the 5-year U.S. Treasury yield curve in effect at the time of grant. The Company recognizes forfeitures as
they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zS4fJ3wBJQFf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The weighted average assumptions for grants are
provided in the following table:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BB_zXrSBk08wuH3" style="display: none"&gt;Schedule of Key Assumptions Used to Value Stock Options&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20250101__20251231_zywcppCibDml" title="Expected volatility, minimum"&gt;92.5&lt;/span&gt; - &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20250101__20251231_zbwf8du1R1F6" title="Expected volatility, maximum"&gt;139.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231_z8hUUw8m1gJa" title="Expected volatility, minimum"&gt;88.8&lt;/span&gt; - &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231_zO12gstweCwk" title="Expected volatility, maximum"&gt;90.4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__srt--RangeAxis__srt--MinimumMember_ziC3JP46oGs" title="Expected term"&gt;5.0&lt;/span&gt; - &lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__srt--RangeAxis__srt--MaximumMember_zc4OMCC36rE6" title="Expected term"&gt;5.4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zjsn0ym2t798" title="Expected term"&gt;5.1&lt;/span&gt; - &lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zOVvuFZW7rL1" title="Expected term"&gt;5.6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20250101__20251231_z2Nja1MEldtl" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20240101__20241231_zA8eR4LadDb7" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20250101__20251231_zFsnrmOeG4jl" title="Risk-free interest rate, minimum"&gt;4.1&lt;/span&gt; - &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20250101__20251231_z692LynCcp9i" title="Risk-free interest rate, maximum"&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231_zm7wWKx569h5" title="Risk-free interest rate"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A0_zTmXHVtygsOl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_zaFp6iB3kB62" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended December 31, 2025, the Company
issued stock options under the 2023 Plan as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_8BD_zdK9D3paRZq9" style="display: none"&gt;Schedule of Issued Stock Options&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number
    of stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Vesting
    period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-indent: 0pt; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;May
    13&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--AwardDateAxis__custom--MayThirteenMember_zlBVXwSDtx2g" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of stock options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardDateAxis__custom--MayThirteenMember_zrBxREo8KkEj" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.75&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_c20250101__20251231__us-gaap--AwardDateAxis__custom--MayThirteenMember_z74jNDAkPBa2" title="Vesting period"&gt;one
    year&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;May
    27&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--AwardDateAxis__custom--MayTwentySevenMember_z8G6KovnsyQc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardDateAxis__custom--MayTwentySevenMember_zNuixU0cFoza" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.10&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_c20250101__20251231__us-gaap--AwardDateAxis__custom--MayTwentySevenMember_zb5YC6ebnGs4" title="Vesting period"&gt;immediate&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;October
    15&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--AwardDateAxis__custom--OctoberFifteenMember_z8zUDjKZywYg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;37,500&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardDateAxis__custom--OctoberFifteenMember_z0MUJoaljh9e" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.73&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_c20250101__20251231__us-gaap--AwardDateAxis__custom--OctoberFifteenMember_z9jcuVPMlp67" title="Vesting period"&gt;one
    year&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8A5_zn9W7dCunDT9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zy9gyeG1mzJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the Company&#x2019;s stock option activity is as follows:&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"&gt;&lt;span id="xdx_8B1_zMPMC2XBN3cj" style="display: none"&gt;Schedule of Stock Option Activity&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Number of&lt;br/&gt;
 stock options&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Exercise price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Remaining&lt;br/&gt;
 contractual life &lt;br/&gt;
(years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Aggregate&lt;br/&gt;
 intrinsic value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 36%"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20251231_ze4xV0HqTgN6" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of stock option, Beginning balance"&gt;2,352,670&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20251231_zZck69flFVN8" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price, Beginning balance"&gt;5.02&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_ziGNoSuEMNHf" title="Weighted average remaining contractual life (years)"&gt;9.6&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20250101__20251231_zQ2TfN5EKKXf" title="Aggregate intrinsic value, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0762"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250101__20251231_z2iyPgtS5G27" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock option, Granted"&gt;2,087,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231_zfBB0JIAPDxc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Granted"&gt;2.11&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Expired&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_c20250101__20251231_zKt0klDuKVvf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock option, Expired"&gt;(72,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231_zT4q1hQBGNE8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Expired"&gt;5.02&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20250101__20251231_z9TM7EPjOsYl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock option, Forfeitures"&gt;(180,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20250101__20251231_zOZaJmlN7UDd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Forfeitures"&gt;5.02&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Balance at December 31, 2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250101__20251231_z6c2PLjdlsgh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock option, Ending balance"&gt;4,187,670&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231_zCclC1UlfKx3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Ending balance"&gt;3.57&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_zhaK4RzoDfC8" title="Weighted average remaining contractual life (years)"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20250101__20251231_znyBlOTnxyDf" title="Aggregate intrinsic value, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0782"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Vested and exercisable at December 31, 2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20250101__20251231_z7XnINVLnQ0k" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock option, Vested and exercisable"&gt;4,125,170&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_c20250101__20251231_zN5sX437SXng" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Vested and exercisable"&gt;3.60&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231_ztHDm5D4IZO3" title="Weighted average remaining contractual life (years), Vested and exercisable"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_c20250101__20251231_zTUp8XCzPB9b" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, Vested and exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0790"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Vested and expected to vest at December 31, 2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20250101__20251231_zal0giAgRPxj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock option, Vested and expected to vest"&gt;4,187,670&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231_zQpvIvalTXzc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Vested and expected to vest"&gt;2.14&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231_zA4ZCS8VW7fa" title="Weighted average remaining contractual life (years), Vested and expected to vest"&gt;9.6&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20250101__20251231_zQxM897GxpKh" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, Vested and expected to vest"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0798"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AE_zNC8hTkKNP44" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognized approximately $&lt;span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20250101__20251231_zMa96kw0CF7e" title="Stock-based compensation"&gt;5.3&lt;/span&gt; million
and $&lt;span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20240101__20241231_z5I2iuvlKlJ9" title="Stock-based compensation"&gt;6.9&lt;/span&gt; million in stock-based compensation in 2025 and 2024, respectively. The weighted average grant-date fair values of options granted
during the years ended December 31, 2025 and 2024 were $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20250101__20251231_zVirPPE4xA5b" title="Weighted average grant-date fair values of options granted"&gt;1.84&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231_zXTzKxBCPQH8" title="Weighted average grant-date fair values of options granted"&gt;3.80&lt;/span&gt; per share, respectively. The grant date fair value of shares vested
during the years ended December 31, 2025 and 2024 was $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_pn5n6_c20250101__20251231_z9dwPYal4RV" title="Grant date fair value of shares vested"&gt;11.8&lt;/span&gt; million and $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_pn5n6_c20240101__20241231_zsY6mRPM2P5c" title="Grant date fair value of shares vested"&gt;4.0&lt;/span&gt; million, respectively. As of December 31, 2025, there is
$&lt;span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20251231_zHQuLNhvtX81" title="Unrecognized compensation costs"&gt;83,600&lt;/span&gt; of unrecognized compensation cost related to unvested stock options granted under the Company&#x2019;s 2023 Plan that is expected
to be recognized over the next year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Restricted Stock Units (RSUs)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In 2025 the Chairman and CEO was issued RSUs
for &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdCO9dDscqO8" title="Issued shares which were fully vested upon grant"&gt;400,000&lt;/span&gt;&#160;common shares which were fully vested upon grant. These RSUs were valued at $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z85DkXyKZbJe" title="Issuance of common stock for services"&gt;840,000&lt;/span&gt;&#160;based on the stock quoted
trading price at the grant date and were expensed immediately as compensation expense.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000546"
      unitRef="Shares">400000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000548"
      unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000550"
      unitRef="Shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-02-132024-02-13_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000552"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2024-02-13_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000554"
      unitRef="USDPShares">7.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2024-02-132024-02-13_us-gaap_IPOMember"
      decimals="-5"
      id="Fact000556"
      unitRef="USD">7000000.0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:OtherUnderwritingExpense
      contextRef="From2024-02-132024-02-13_us-gaap_IPOMember"
      decimals="-5"
      id="Fact000558"
      unitRef="USD">1200000</us-gaap:OtherUnderwritingExpense>
    <TELO:ProceedsFromInitialPublicOfferingNetProceeds
      contextRef="From2024-02-132024-02-13_us-gaap_IPOMember"
      decimals="-5"
      id="Fact000560"
      unitRef="USD">5800000</TELO:ProceedsFromInitialPublicOfferingNetProceeds>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-12-092024-12-09_custom_StarwoodTrustMember"
      decimals="INF"
      id="Fact000562"
      unitRef="Shares">142857</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2024-12-09_custom_StarwoodTrustMember"
      decimals="INF"
      id="Fact000564"
      unitRef="USDPShares">7</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-12-092024-12-09_custom_StarwoodTrustMember"
      decimals="-5"
      id="Fact000566"
      unitRef="USD">1000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000568"
      unitRef="USD">303281</us-gaap:DeferredOfferingCosts>
    <TELO:OfferingCosts
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000570"
      unitRef="USD">863744</TELO:OfferingCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-02-142025-02-14_custom_AtTheMarketOfferingAgreementMember"
      decimals="0"
      id="Fact000572"
      unitRef="USD">100000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-01-012025-12-31_custom_AtTheMarketOfferingMember"
      decimals="INF"
      id="Fact000574"
      unitRef="Shares">3218300</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-12-31_custom_AtTheMarketOfferingMember"
      decimals="INF"
      id="Fact000576"
      unitRef="USDPShares">2.12</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2025-01-012025-12-31_custom_AtTheMarketOfferingMember"
      decimals="0"
      id="Fact000578"
      unitRef="USD">6553209</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-01-012025-12-31_custom_AtTheMarketOfferingMember"
      decimals="0"
      id="Fact000580"
      unitRef="USD">72092</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="From2025-05-192025-05-19"
      decimals="-6"
      id="Fact000582"
      unitRef="USD">3000000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2025-05-192025-05-19"
      decimals="INF"
      id="Fact000584"
      unitRef="Shares">333334</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2025-05-19"
      decimals="INF"
      id="Fact000586"
      unitRef="USDPShares">3.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="From2025-05-192025-05-19"
      decimals="INF"
      id="Fact000588"
      unitRef="Pure">0.18</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharePrice
      contextRef="AsOf2025-05-19_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000590"
      unitRef="USDPShares">2.54</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2025-05-202025-05-20"
      decimals="-6"
      id="Fact000592"
      unitRef="USD">1000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2025-07-242025-07-24"
      decimals="-6"
      id="Fact000594"
      unitRef="USD">2000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-07-012025-07-31"
      decimals="INF"
      id="Fact000596"
      unitRef="Shares">666667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2025-05-272025-05-27"
      decimals="INF"
      id="Fact000598"
      unitRef="Shares">400000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-05-272025-05-27"
      decimals="0"
      id="Fact000600"
      unitRef="USD">840000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000602">&lt;p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zbF16ohohb73" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B7_zLWTij5Zc7x3" style="display: none"&gt;Schedule of Warrant Activity&lt;/span&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Remaining Contractual&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Aggregate Intrinsic&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Term (Years)&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 36%"&gt;Outstanding as of December&#160;&#160;31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSgzcXCqO8Bd" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of Warrants Outstanding, Beginning Balance"&gt;2,774,057&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaOWzKyPNL4b" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;4.85&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_zyDrtLyYTlU5" title="Weighted Average Remaining Contractual Term (Years), Outstanding Balance"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;(1)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlO6WbuaHBab" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Aggregate Intrinsic Value, Outstanding Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0610"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zekvfhw65G1d" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Granted"&gt;50,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4VeUTvz9QS6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;7.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdK1dWmryMj4" title="Weighted Average Remaining Contractual Term (Years), Granted"&gt;3.2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;-&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;Exercised&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfY5uuixhkXc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised"&gt;(10,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWfw2ZLktGL9" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;3.73&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding as December 31, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKVUmero7Gj7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants Outstanding, Beginning Balance"&gt;2,814,057&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsO5r9vgaU38" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;4.97&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDIp_zRAzKSd2xari" title="Weighted Average Remaining Contractual Term (Years), Outstanding Balance"&gt;3.49&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;(2)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZVF5Pk3yu4i" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Outstanding Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0628"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsGhpzl8Y4We" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0630"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;Exercised&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbpvVCVaQ5Ea" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0632"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Outstanding as of December 31, 2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zf0wLrTBFHVe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants Outstanding, Ending Balance"&gt;2,814,057&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsfxDR0OeTV7" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance"&gt;4.97&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDIp_z9tUtCU4y52f" title="Weighted Average Remaining Contractual Term (Years), Outstanding Balance"&gt;2.45&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;(2)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3XbuYdeo4mj" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Outstanding Ending Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0640"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 0.25in; padding-bottom: 0pt; text-align: left"&gt;&lt;span id="xdx_F00_zDaoA1QFIxJ3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0pt; text-align: justify"&gt;&lt;span id="xdx_F18_zK8FIGlqJnkb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    warrants herein consist of various contractual terms. The warrants herein consist of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember_zql5MGAc3hig" title="Class of warrants or right number of securities called by warrants or rights"&gt;2,439,025&lt;/span&gt; warrants issued to Bay Shore Trust
    that have a remaining contractual term of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember_zzBNVlLe1s7g" title="Warrants and rights outstanding term"&gt;2.5&lt;/span&gt; years as of December 31, 2025, and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zzKKbMRXLy43" title="Class of warrants or right number of securities called by warrants or rights"&gt;335,032&lt;/span&gt; warrants issued to investors associated
    with the 2023 Private Placement that currently have an indeterminable contractual term. See disclosures below for more information
    on these warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; padding-bottom: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; padding-bottom: 0pt; text-align: left"&gt;&lt;span id="xdx_F0F_zOO4wfwv8DSa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0pt; text-align: justify"&gt;&lt;span id="xdx_F1C_zYWuwkJCT5G5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    warrants herein consist of various contractual terms. The warrants herein consist of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zR74nO7EjC5e" title="Warrants issued"&gt;2,429,025&lt;/span&gt; warrants issued to Bay Shore Trust
    that have a remaining contractual term of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYImeeA0dK1e" title="Warrants remaining contractual term"&gt;2.5&lt;/span&gt; years as of December 31, 2025; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zhi1RrUuEnck" title="Warrants issued"&gt;335,032&lt;/span&gt; warrants issued to investors associated with
    the 2023 Private Placement that currently have an indeterminable contractual term, and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantMember_zNmj2VNvS6hi" title="Warrants issued"&gt;50,000&lt;/span&gt; warrants issued to underwriters as
    part of the IPO with a remaining contractual life of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantMember_zULkKyLPZwji" title="Warrants remaining contractual term"&gt;3.2&lt;/span&gt; years. See disclosures below for more information on these warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000604"
      unitRef="Shares">2774057</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <TELO:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000606"
      unitRef="USDPShares">4.85</TELO:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <TELO:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      id="Fact000608">P4Y6M</TELO:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember17385937"
      decimals="INF"
      id="Fact000612"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <TELO:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember17385937"
      decimals="INF"
      id="Fact000614"
      unitRef="USDPShares">7.00</TELO:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <TELO:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember17385937"
      id="Fact000616">P3Y2M12D</TELO:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember17385937"
      decimals="INF"
      id="Fact000618"
      unitRef="Shares">-10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember17385937"
      decimals="INF"
      id="Fact000620"
      unitRef="USDPShares">3.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000622"
      unitRef="Shares">2814057</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <TELO:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000624"
      unitRef="USDPShares">4.97</TELO:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <TELO:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember17385937"
      id="Fact000626">P3Y5M26D</TELO:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000634"
      unitRef="Shares">2814057</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <TELO:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000636"
      unitRef="USDPShares">4.97</TELO:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <TELO:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember17385953"
      id="Fact000638">P2Y5M12D</TELO:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_BayShoreTrustWarrantsMember"
      decimals="INF"
      id="Fact000643"
      unitRef="Shares">2439025</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-12-31_custom_BayShoreTrustWarrantsMember"
      id="Fact000645">P2Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_TwoThousandTwentyThreePrivatePlacementWarrantsMember_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact000647"
      unitRef="Shares">335032</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_BayShoreTrustWarrantsMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000650"
      unitRef="Shares">2429025</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-12-31_custom_BayShoreTrustWarrantsMember_us-gaap_WarrantMember"
      id="Fact000652">P2Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_TwoThousandTwentyThreePrivatePlacementWarrantsMember_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact000654"
      unitRef="Shares">335032</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_UnderwriterWarrantMember"
      decimals="INF"
      id="Fact000656"
      unitRef="Shares">50000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-12-31_custom_UnderwriterWarrantMember"
      id="Fact000658">P3Y2M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2023-12-31_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000660"
      unitRef="Shares">268025</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000662"
      unitRef="USDPShares">15.42</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2023-12-31_custom_PlacementAgentMember"
      decimals="INF"
      id="Fact000664"
      unitRef="Shares">67007</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_PlacementAgentMember"
      decimals="INF"
      id="Fact000666"
      unitRef="USDPShares">3.73</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-06-15_custom_BayShoreTrustMember"
      decimals="INF"
      id="Fact000668"
      unitRef="Shares">2439025</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-06-15_custom_BayShoreTrustMember"
      decimals="INF"
      id="Fact000670"
      unitRef="USDPShares">3.73</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-06-15_custom_BayShoreTrustMember"
      id="Fact000672">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="AsOf2023-06-15_custom_BayShoreTrustMember"
      decimals="-4"
      id="Fact000674"
      unitRef="USD">5950000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-11-22_custom_BayShoreTrustMember"
      decimals="INF"
      id="Fact000676"
      unitRef="Shares">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_BayShoreTrustMember"
      decimals="INF"
      id="Fact000678"
      unitRef="Shares">10000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_BayShoreTrustMember"
      decimals="INF"
      id="Fact000680"
      unitRef="USDPShares">3.73</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-12-012024-12-31_custom_BayShoreTrustMember"
      decimals="INF"
      id="Fact000682"
      unitRef="Shares">10000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-12-012024-12-31_custom_BayShoreTrustMember"
      decimals="INF"
      id="Fact000684"
      unitRef="USD">37300</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-02-29_us-gaap_IPOMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000686"
      unitRef="Shares">50000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-02-29_us-gaap_IPOMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000688"
      unitRef="USDPShares">7.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2024-02-29_us-gaap_WarrantMember"
      decimals="-5"
      id="Fact000690"
      unitRef="USD">200000</us-gaap:DeferredOfferingCosts>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="From2025-01-012025-12-31_custom_UnderwriterWarrantMember"
      id="Fact000692">&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember_zaEH1wv1i3d7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Key assumptions used to value underwriter warrants in February 2024
are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_8BD_z5zAKzgwTGh4" style="display: none"&gt;Schedule of Key Assumptions Used to Value Warrants&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 50%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; font-size: 10pt"&gt;Expected price volatility&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zNEHZOZqCEgc" title="Warrant measurement input"&gt;84.78&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zTufeFAJ6ks1" title="Warrant measurement input"&gt;4.14&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Fair Market Value of underlying Common Stock&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputFairMarketValueUnderlyingCommonStockMember_zkiSfvatqy75" title="Warrant measurement input"&gt;7.01&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Expected term in years&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_znhy7r5V7c14" title="Expected term in years"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zabaLxhKp6T5" title="Warrant measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0702"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact000694"
      unitRef="Pure">84.78</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact000696"
      unitRef="Pure">4.14</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-02-29_custom_UnderwriterWarrantMember_custom_MeasurementInputFairMarketValueUnderlyingCommonStockMember"
      decimals="INF"
      id="Fact000698"
      unitRef="Pure">7.01</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact000700">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeOmnibusIncentivePlanMember"
      decimals="INF"
      id="Fact000704"
      unitRef="Shares">6500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000706">&lt;p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zS4fJ3wBJQFf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The weighted average assumptions for grants are
provided in the following table:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BB_zXrSBk08wuH3" style="display: none"&gt;Schedule of Key Assumptions Used to Value Stock Options&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20250101__20251231_zywcppCibDml" title="Expected volatility, minimum"&gt;92.5&lt;/span&gt; - &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20250101__20251231_zbwf8du1R1F6" title="Expected volatility, maximum"&gt;139.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231_z8hUUw8m1gJa" title="Expected volatility, minimum"&gt;88.8&lt;/span&gt; - &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231_zO12gstweCwk" title="Expected volatility, maximum"&gt;90.4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__srt--RangeAxis__srt--MinimumMember_ziC3JP46oGs" title="Expected term"&gt;5.0&lt;/span&gt; - &lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__srt--RangeAxis__srt--MaximumMember_zc4OMCC36rE6" title="Expected term"&gt;5.4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zjsn0ym2t798" title="Expected term"&gt;5.1&lt;/span&gt; - &lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zOVvuFZW7rL1" title="Expected term"&gt;5.6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20250101__20251231_z2Nja1MEldtl" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20240101__20241231_zA8eR4LadDb7" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20250101__20251231_zFsnrmOeG4jl" title="Risk-free interest rate, minimum"&gt;4.1&lt;/span&gt; - &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20250101__20251231_z692LynCcp9i" title="Risk-free interest rate, maximum"&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231_zm7wWKx569h5" title="Risk-free interest rate"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000708"
      unitRef="Pure">0.925</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000710"
      unitRef="Pure">1.390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000712"
      unitRef="Pure">0.888</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000714"
      unitRef="Pure">0.904</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2025-01-012025-12-31_srt_MinimumMember"
      id="Fact000716">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2025-01-012025-12-31_srt_MaximumMember"
      id="Fact000718">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_srt_MinimumMember"
      id="Fact000720">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_srt_MaximumMember"
      id="Fact000722">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000724"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000726"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000728"
      unitRef="Pure">0.041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000730"
      unitRef="Pure">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000732"
      unitRef="Pure">0.037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000734">&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_zaFp6iB3kB62" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended December 31, 2025, the Company
issued stock options under the 2023 Plan as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_8BD_zdK9D3paRZq9" style="display: none"&gt;Schedule of Issued Stock Options&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number
    of stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Vesting
    period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-indent: 0pt; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;May
    13&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--AwardDateAxis__custom--MayThirteenMember_zlBVXwSDtx2g" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of stock options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardDateAxis__custom--MayThirteenMember_zrBxREo8KkEj" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.75&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_c20250101__20251231__us-gaap--AwardDateAxis__custom--MayThirteenMember_z74jNDAkPBa2" title="Vesting period"&gt;one
    year&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;May
    27&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--AwardDateAxis__custom--MayTwentySevenMember_z8G6KovnsyQc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardDateAxis__custom--MayTwentySevenMember_zNuixU0cFoza" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.10&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_c20250101__20251231__us-gaap--AwardDateAxis__custom--MayTwentySevenMember_zb5YC6ebnGs4" title="Vesting period"&gt;immediate&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;October
    15&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--AwardDateAxis__custom--OctoberFifteenMember_z8zUDjKZywYg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;37,500&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardDateAxis__custom--OctoberFifteenMember_z0MUJoaljh9e" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.73&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_c20250101__20251231__us-gaap--AwardDateAxis__custom--OctoberFifteenMember_z9jcuVPMlp67" title="Vesting period"&gt;one
    year&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-12-31_custom_MayThirteenMember"
      decimals="INF"
      id="Fact000736"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-12-31_custom_MayThirteenMember"
      decimals="INF"
      id="Fact000738"
      unitRef="USDPShares">2.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <TELO:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod
      contextRef="From2025-01-012025-12-31_custom_MayThirteenMember"
      id="Fact000740">one
    year</TELO:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-12-31_custom_MayTwentySevenMember"
      decimals="INF"
      id="Fact000742"
      unitRef="Shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-12-31_custom_MayTwentySevenMember"
      decimals="INF"
      id="Fact000744"
      unitRef="USDPShares">2.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <TELO:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod
      contextRef="From2025-01-012025-12-31_custom_MayTwentySevenMember"
      id="Fact000746">immediate</TELO:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-12-31_custom_OctoberFifteenMember"
      decimals="INF"
      id="Fact000748"
      unitRef="Shares">37500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-12-31_custom_OctoberFifteenMember"
      decimals="INF"
      id="Fact000750"
      unitRef="USDPShares">1.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <TELO:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod
      contextRef="From2025-01-012025-12-31_custom_OctoberFifteenMember"
      id="Fact000752">one
    year</TELO:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000754">&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zy9gyeG1mzJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the Company&#x2019;s stock option activity is as follows:&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"&gt;&lt;span id="xdx_8B1_zMPMC2XBN3cj" style="display: none"&gt;Schedule of Stock Option Activity&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Number of&lt;br/&gt;
 stock options&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Exercise price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Remaining&lt;br/&gt;
 contractual life &lt;br/&gt;
(years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Aggregate&lt;br/&gt;
 intrinsic value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 36%"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20251231_ze4xV0HqTgN6" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of stock option, Beginning balance"&gt;2,352,670&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20251231_zZck69flFVN8" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price, Beginning balance"&gt;5.02&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_ziGNoSuEMNHf" title="Weighted average remaining contractual life (years)"&gt;9.6&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20250101__20251231_zQ2TfN5EKKXf" title="Aggregate intrinsic value, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0762"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250101__20251231_z2iyPgtS5G27" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock option, Granted"&gt;2,087,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231_zfBB0JIAPDxc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Granted"&gt;2.11&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Expired&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_c20250101__20251231_zKt0klDuKVvf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock option, Expired"&gt;(72,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231_zT4q1hQBGNE8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Expired"&gt;5.02&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20250101__20251231_z9TM7EPjOsYl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock option, Forfeitures"&gt;(180,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20250101__20251231_zOZaJmlN7UDd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Forfeitures"&gt;5.02&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Balance at December 31, 2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250101__20251231_z6c2PLjdlsgh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock option, Ending balance"&gt;4,187,670&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231_zCclC1UlfKx3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Ending balance"&gt;3.57&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_zhaK4RzoDfC8" title="Weighted average remaining contractual life (years)"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20250101__20251231_znyBlOTnxyDf" title="Aggregate intrinsic value, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0782"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Vested and exercisable at December 31, 2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20250101__20251231_z7XnINVLnQ0k" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock option, Vested and exercisable"&gt;4,125,170&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_c20250101__20251231_zN5sX437SXng" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Vested and exercisable"&gt;3.60&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231_ztHDm5D4IZO3" title="Weighted average remaining contractual life (years), Vested and exercisable"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_c20250101__20251231_zTUp8XCzPB9b" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, Vested and exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0790"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Vested and expected to vest at December 31, 2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20250101__20251231_zal0giAgRPxj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of stock option, Vested and expected to vest"&gt;4,187,670&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231_zQpvIvalTXzc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Vested and expected to vest"&gt;2.14&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231_zA4ZCS8VW7fa" title="Weighted average remaining contractual life (years), Vested and expected to vest"&gt;9.6&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20250101__20251231_zQxM897GxpKh" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, Vested and expected to vest"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0798"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000756"
      unitRef="Shares">2352670</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000758"
      unitRef="USDPShares">5.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2024-01-012024-12-31" id="Fact000760">P9Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000764"
      unitRef="Shares">2087500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000766"
      unitRef="USDPShares">2.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <TELO:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000768"
      unitRef="Shares">-72500</TELO:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000770"
      unitRef="USDPShares">5.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000772"
      unitRef="Shares">180000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000774"
      unitRef="USDPShares">5.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000776"
      unitRef="Shares">4187670</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000778"
      unitRef="USDPShares">3.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2025-01-01to2025-12-31" id="Fact000780">P9Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000784"
      unitRef="Shares">4125170</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000786"
      unitRef="USDPShares">3.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2025-01-01to2025-12-31" id="Fact000788">P9Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000792"
      unitRef="Shares">4187670</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000794"
      unitRef="USDPShares">2.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2025-01-01to2025-12-31" id="Fact000796">P9Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="-5"
      id="Fact000800"
      unitRef="USD">5300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-5"
      id="Fact000802"
      unitRef="USD">6900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000804"
      unitRef="USDPShares">1.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000806"
      unitRef="USDPShares">3.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="From2025-01-01to2025-12-31"
      decimals="-5"
      id="Fact000808"
      unitRef="USD">11800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="From2024-01-012024-12-31"
      decimals="-5"
      id="Fact000810"
      unitRef="USD">4000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000812"
      unitRef="USD">83600</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000814"
      unitRef="Shares">400000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact000816"
      unitRef="USD">840000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000818">&lt;p id="xdx_803_eus-gaap--IncomeTaxDisclosureTextBlock_zmI1R2AqgVPl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 8 &#x2013; &lt;span id="xdx_82A_zfrBjCgjHwM1"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zyTHSdHVUPf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify"&gt;The significant components of the
Company&#x2019;s net deferred tax assets and liabilities consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify"&gt;&lt;span id="xdx_8BE_ziJ8CRKjCSBf" style="display: none"&gt;Schedule of Net Deferred Tax Assets&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20251231_zvdlN2wv7OK5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20241231_z4fI6gmPOaAd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGz55t_zwLhxDmaoGRg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Net operating loss carryforward&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;7,643,465&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;4,427,679&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGz55t_zQ3dH2jHDb89" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Section 174 capitalized research and development&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;700,121&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;995,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_maDTAGz55t_zoh0x94PgLl7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Goodwill and intangibles&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;23,339&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;28,007&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGz55t_z4oqjyn0ikp6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,856,673&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,680,018&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_maDTAGz55t_z9nf4C0NHVAj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;Tax credits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;51,278&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;51,278&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGz55t_maDTANzg2r_z2JYdq0N1oc6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Deferred tax assets, gross&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;11,274,876&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,182,482&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzg2r_zAUxIxWqATCa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Less: valuation allowance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(11,274,876&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(7,182,482&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzg2r_maDTALNzcuf_zfxyiGxuzym" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0843"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0844"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredIncomeTaxLiabilities_iNI_di_msDTALNzcuf_zbksbSThWZP8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Deferred tax liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0846"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0847"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzcuf_z6K4R2F1LZX4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Total net deferred tax asset&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0849"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0850"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A5_zLeibNXoR1xf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zVIEFs8ddJJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify"&gt;Provision for (benefit from) income taxes consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BF_zbfAWeBapp8j" style="display: none"&gt;Schedule of Provision for  Income Taxes&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20250101__20251231_ztiGjjaoR3v8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20241231_zgFgkdt8Rhpl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zMXvmntFXiQa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Deferred tax:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDITEBz7I1_zaQaSXoo1ycg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;Federal&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;(463,477&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0858"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDITEBz7I1_z4PzOlw9UAc3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;State&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;463,477&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0861"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_mtDITEBz7I1_maITEBzknf_z1ZkK8ubmzv2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Total deferred tax expense (benefit)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0863"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0864"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzknf_zdEwF8Bg8Pn6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Total provision for income taxes&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0866"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0867"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A2_zZpgfiKQUEOj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Beginning in 2022, in accordance with Internal
Revenue Code Section 174, Qualified Research Expenditures are capitalized for tax purposes and amortized over a period of five years.
Accordingly, for income tax purposes, and as of December 31, 2025 and 2024, the Company has recorded a deferred tax asset
totaling approximately $&lt;span id="xdx_90F_eus-gaap--DeferredTaxAssetsOtherLossCarryforwards_iI_pn5n6_c20251231_zbxuSdeLfza9" title="Deferred tax asset"&gt;0.7&lt;/span&gt; million and $&lt;span id="xdx_903_eus-gaap--DeferredTaxAssetsOtherLossCarryforwards_iI_pn5n6_c20241231_zL88S2PKw9Mi" title="Deferred tax asset"&gt;1.0&lt;/span&gt; million, respectively, related to the timing difference between GAAP and Tax recognition
of these expenditures. Under current law, beginning in tax years after December 31, 2024, domestic research and experimental expenditures may again be deducted
currently for U.S. federal income tax purposes; however, the Company continues to carry deferred tax assets related to research costs
capitalized in prior periods that will reverse as amortization deductions are claimed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z0kmSDp65Qsj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A reconciliation of the statutory U.S. federal income
tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B3_zzTcm5qpDRQ2" style="display: none"&gt;Schedule of Reconciliation  Effective Income Tax Rate&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250101__20251231_zlMGFEmExkaf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzgzx_zkJ1UtGDgrQ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Provision for income taxes at U.S. federal statutory rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;(2,186,773&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maGOLD_c20250101__20251231_zXnLOtWUO9P" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Provision for income taxes at U.S. federal statutory rate, Percentage"&gt;21.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzgzx_zsTK6bVo3A14" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;State income taxes, net of federal benefit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;463,477&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maGOLD_c20250101__20251231_zbR9tqDhuNNh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="State income taxes, net of federal benefit, Percentage"&gt;(4.45&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzgzx_z2ZE0Vd0HRDg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Other&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;23,616&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maGOLD_c20250101__20251231_zjE9R5GdGww8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other, Percentage"&gt;(0.02&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzgzx_zAWzEe8INaF8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Changes in valuation allowance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,928,495&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maGOLD_c20250101__20251231_zu09xbp4Ev71" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Changes in valuation allowance, Percentage"&gt;(28.12&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_maITEBzgzx_z50HosJpRgBl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;True-ups&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,228,815&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_maGOLD_c20250101__20251231_zYyiPd8PdGhe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="True-ups, Percentage"&gt;11.80&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzgzx_ztasadz5Bmb3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Net actual effective rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0895"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtGOLD_c20250101__20251231_zNtGJIqSrFWa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net actual effective rate, Percentage"&gt;0.21&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AE_zEDJTTvZtMh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;ASC Topic 740 requires that a deferred tax amount
be reduced by a valuation allowance if, based on the weight of available evidence it is more likely than not (a likelihood of more than
50%) that some portion or all of the deferred tax assets will not be realized. The valuation allowance should be sufficient to reduce
the deferred tax asset to the amount that is more likely than not to be realized. The Company has recorded a full valuation allowance
against its deferred tax assets generated by net operating loss carryforwards as it has determined that such amounts may not be recognizable,
given the historical losses of the Company to date. As of December 31, 2025, the Company has a cumulative federal net operating loss
carryforward of approximately $&lt;span id="xdx_900_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20251231_ziX4kblBaEGd"&gt;30.2&lt;/span&gt;
million. The net operating loss carryforward have no expiry date.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000820">&lt;p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zyTHSdHVUPf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify"&gt;The significant components of the
Company&#x2019;s net deferred tax assets and liabilities consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify"&gt;&lt;span id="xdx_8BE_ziJ8CRKjCSBf" style="display: none"&gt;Schedule of Net Deferred Tax Assets&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20251231_zvdlN2wv7OK5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20241231_z4fI6gmPOaAd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGz55t_zwLhxDmaoGRg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Net operating loss carryforward&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;7,643,465&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;4,427,679&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGz55t_zQ3dH2jHDb89" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Section 174 capitalized research and development&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;700,121&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;995,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_maDTAGz55t_zoh0x94PgLl7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Goodwill and intangibles&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;23,339&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;28,007&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGz55t_z4oqjyn0ikp6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,856,673&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,680,018&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_maDTAGz55t_z9nf4C0NHVAj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;Tax credits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;51,278&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;51,278&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGz55t_maDTANzg2r_z2JYdq0N1oc6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Deferred tax assets, gross&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;11,274,876&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,182,482&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzg2r_zAUxIxWqATCa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Less: valuation allowance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(11,274,876&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(7,182,482&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzg2r_maDTALNzcuf_zfxyiGxuzym" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0843"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0844"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredIncomeTaxLiabilities_iNI_di_msDTALNzcuf_zbksbSThWZP8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Deferred tax liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0846"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0847"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzcuf_z6K4R2F1LZX4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Total net deferred tax asset&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0849"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0850"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000822"
      unitRef="USD">7643465</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000823"
      unitRef="USD">4427679</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000825"
      unitRef="USD">700121</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000826"
      unitRef="USD">995500</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000828"
      unitRef="USD">23339</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000829"
      unitRef="USD">28007</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000831"
      unitRef="USD">2856673</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000832"
      unitRef="USD">1680018</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000834"
      unitRef="USD">51278</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000835"
      unitRef="USD">51278</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000837"
      unitRef="USD">11274876</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000838"
      unitRef="USD">7182482</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000840"
      unitRef="USD">11274876</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000841"
      unitRef="USD">7182482</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000852">&lt;p id="xdx_895_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zVIEFs8ddJJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify"&gt;Provision for (benefit from) income taxes consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BF_zbfAWeBapp8j" style="display: none"&gt;Schedule of Provision for  Income Taxes&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20250101__20251231_ztiGjjaoR3v8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20241231_zgFgkdt8Rhpl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zMXvmntFXiQa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Deferred tax:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDITEBz7I1_zaQaSXoo1ycg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;Federal&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;(463,477&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0858"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDITEBz7I1_z4PzOlw9UAc3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;State&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;463,477&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0861"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_mtDITEBz7I1_maITEBzknf_z1ZkK8ubmzv2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Total deferred tax expense (benefit)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0863"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0864"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzknf_zdEwF8Bg8Pn6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Total provision for income taxes&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0866"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0867"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000857"
      unitRef="USD">-463477</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000860"
      unitRef="USD">463477</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact000869"
      unitRef="USD">700000</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000871"
      unitRef="USD">1000000.0</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000873">&lt;p id="xdx_89A_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z0kmSDp65Qsj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A reconciliation of the statutory U.S. federal income
tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B3_zzTcm5qpDRQ2" style="display: none"&gt;Schedule of Reconciliation  Effective Income Tax Rate&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250101__20251231_zlMGFEmExkaf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzgzx_zkJ1UtGDgrQ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Provision for income taxes at U.S. federal statutory rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;(2,186,773&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maGOLD_c20250101__20251231_zXnLOtWUO9P" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Provision for income taxes at U.S. federal statutory rate, Percentage"&gt;21.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzgzx_zsTK6bVo3A14" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;State income taxes, net of federal benefit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;463,477&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maGOLD_c20250101__20251231_zbR9tqDhuNNh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="State income taxes, net of federal benefit, Percentage"&gt;(4.45&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzgzx_z2ZE0Vd0HRDg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Other&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;23,616&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maGOLD_c20250101__20251231_zjE9R5GdGww8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other, Percentage"&gt;(0.02&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzgzx_zAWzEe8INaF8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Changes in valuation allowance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,928,495&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maGOLD_c20250101__20251231_zu09xbp4Ev71" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Changes in valuation allowance, Percentage"&gt;(28.12&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_maITEBzgzx_z50HosJpRgBl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;True-ups&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,228,815&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_maGOLD_c20250101__20251231_zYyiPd8PdGhe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="True-ups, Percentage"&gt;11.80&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzgzx_ztasadz5Bmb3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Net actual effective rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0895"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtGOLD_c20250101__20251231_zNtGJIqSrFWa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net actual effective rate, Percentage"&gt;0.21&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000875"
      unitRef="USD">-2186773</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000877"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000879"
      unitRef="USD">463477</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000881"
      unitRef="Pure">-0.0445</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000883"
      unitRef="USD">23616</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000885"
      unitRef="Pure">-0.0002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000887"
      unitRef="USD">2928495</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000889"
      unitRef="Pure">-0.2812</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000891"
      unitRef="USD">-1228815</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000893"
      unitRef="Pure">0.1180</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000897"
      unitRef="Pure">0.0021</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact000898"
      unitRef="USD">30200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000608"
          xlink:label="Fact000608"
          xlink:type="locator"/>
        <link:footnote id="Footnote000641" xlink:label="Footnote000641" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
    warrants herein consist of various contractual terms. The warrants herein consist of <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember_zql5MGAc3hig"
  title="Class of warrants or right number of securities called by warrants or rights">2,439,025</xhtml:span> warrants issued to Bay Shore Trust
    that have a remaining contractual term of <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember_zzBNVlLe1s7g"
  title="Warrants and rights outstanding term">2.5</xhtml:span> years as of December 31, 2025, and <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zzKKbMRXLy43"
  title="Class of warrants or right number of securities called by warrants or rights">335,032</xhtml:span> warrants issued to investors associated
    with the 2023 Private Placement that currently have an indeterminable contractual term. See disclosures below for more information
    on these warrants</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000608"
          xlink:to="Footnote000641"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000626"
          xlink:label="Fact000626"
          xlink:type="locator"/>
        <link:footnote id="Footnote000648" xlink:label="Footnote000648" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
    warrants herein consist of various contractual terms. The warrants herein consist of <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zR74nO7EjC5e"
  title="Warrants issued">2,429,025</xhtml:span> warrants issued to Bay Shore Trust
    that have a remaining contractual term of <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYImeeA0dK1e"
  title="Warrants remaining contractual term">2.5</xhtml:span> years as of December 31, 2025; <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zhi1RrUuEnck"
  title="Warrants issued">335,032</xhtml:span> warrants issued to investors associated with
    the 2023 Private Placement that currently have an indeterminable contractual term, and <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantMember_zNmj2VNvS6hi"
  title="Warrants issued">50,000</xhtml:span> warrants issued to underwriters as
    part of the IPO with a remaining contractual life of <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantMember_zULkKyLPZwji"
  title="Warrants remaining contractual term">3.2</xhtml:span> years. See disclosures below for more information on these warrants</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000626"
          xlink:to="Footnote000648"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000638"
          xlink:label="Fact000638"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000638"
          xlink:to="Footnote000648"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
